Clustering O 0 9.140841939370148e-06
of O 0 2.0683221464423696e-06
missense O 0 9.23586412682198e-06
mutations O 0 9.047543159113047e-08
in O 0 1.058895406913507e-07
the O 0 1.9423534467932768e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 1.6538631371076917e-06
in O 0 6.525220896946848e-08
a O 0 8.781047000638864e-08
sporadic B-Disease 0 0.0009194371523335576
T I-Disease 1 0.9999306201934814
- I-Disease 1 0.988804042339325
cell I-Disease 1 0.9954114556312561
leukaemia I-Disease 1 0.9987817406654358
. O 0 1.6040557966334745e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9960535764694214
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 2.779942143149583e-08
is O 0 1.616429989859114e-09
a O 0 1.0416336237994983e-08
recessive B-Disease 0 2.2790297862229636e-06
multi I-Disease 1 0.9994854927062988
- I-Disease 1 0.9999829530715942
system I-Disease 1 0.9999349117279053
disorder I-Disease 1 0.99992835521698
caused O 0 4.010407650412162e-08
by O 0 4.975914680294125e-10
mutations O 0 1.2653139647156308e-09
in O 0 1.6243016931483112e-09
the O 0 5.3761661789053505e-09
ATM O 0 1.1626113973761676e-06
gene O 0 2.8791658834848022e-08
at O 0 4.5792867808813753e-07
11q22 O 0 1.1892469728991273e-06
- O 0 8.025644433473644e-07
q23 O 0 1.21077982839779e-06
( O 0 2.072678029207964e-08
ref O 0 4.479201152207679e-07
. O 0 7.56925544465048e-09
3 O 0 1.759509444809737e-07
) O 0 2.9256383982101397e-08
. O 0 2.2312813996450132e-07

The O 0 7.106361863407074e-07
risk O 0 6.447019586630631e-06
of O 0 5.7480747273075394e-06
cancer B-Disease 0 0.007129282224923372
, O 0 3.1017286516998865e-08
especially O 0 1.5712808476564533e-07
lymphoid B-Disease 0 2.719985059229657e-05
neoplasias I-Disease 0 3.919324080925435e-05
, O 0 4.93962382108748e-09
is O 0 3.3396707621591304e-10
substantially O 0 1.552627715284416e-08
elevated O 0 4.795597305928823e-07
in O 0 4.283820231876234e-08
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.1224057743675075e-05
and O 0 5.4161446882972086e-08
has O 0 6.944998798275037e-09
long O 0 2.334488602429019e-09
been O 0 8.055506262039103e-10
associated O 0 3.919896407467149e-09
with O 0 1.289960582795402e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 0.0009579585748724639

By O 0 5.990084162021958e-08
analysing O 0 1.790367423382122e-05
tumour B-Disease 1 0.9999899864196777
DNA O 0 1.6693065845174715e-06
from O 0 5.801350155820728e-08
patients O 0 6.313852107808771e-09
with O 0 4.751169235817088e-09
sporadic B-Disease 0 4.5045497245155275e-05
T I-Disease 1 0.6385512948036194
- I-Disease 0 0.0006547768134623766
cell I-Disease 0 0.0003659613721538335
prolymphocytic I-Disease 0 0.013326332904398441
leukaemia I-Disease 1 0.9821001887321472
( O 0 2.7012390546587994e-07
T B-Disease 0 2.4806606234051287e-05
- I-Disease 0 4.754227120429277e-06
PLL I-Disease 0 2.212558320024982e-05
) O 0 5.894549293117279e-09
, O 0 1.5078513992961007e-09
a O 0 5.678168601974676e-09
rare O 0 3.9214011593458054e-08
clonal B-Disease 0 4.849511697102571e-06
malignancy I-Disease 0 1.3308673260326032e-05
with O 0 7.567739324088052e-09
similarities O 0 3.0089378100228714e-08
to O 0 4.637781270133701e-09
a O 0 8.701983489345366e-08
mature B-Disease 0 3.4763677376759006e-06
T I-Disease 0 0.0028402938041836023
- I-Disease 0 7.544987511209911e-06
cell I-Disease 0 6.016327461111359e-06
leukaemia I-Disease 0 1.1778744010371156e-05
seen O 0 3.028981510055928e-08
in O 0 9.013899848753226e-09
A B-Disease 1 0.9902744293212891
- I-Disease 0 0.099942646920681
T I-Disease 1 0.9998573064804077
, O 0 2.2812063349419986e-09
we O 0 2.878251248450425e-10
demonstrate O 0 6.115858375288497e-10
a O 0 6.618923464873916e-11
high O 0 5.992443763425115e-10
frequency O 0 3.6361560429298834e-09
of O 0 2.8911772975703798e-09
ATM O 0 8.167118608071178e-07
mutations O 0 1.4931645253568604e-08
in O 0 3.625838829179884e-08
T B-Disease 0 6.704453699057922e-05
- I-Disease 0 3.423863381613046e-05
PLL I-Disease 0 0.0005413542967289686
. O 0 2.406338808214059e-06

In O 0 6.145928637124598e-07
marked O 0 4.1162385855386674e-07
contrast O 0 4.455742441678012e-08
to O 0 2.7138298275275474e-09
the O 0 1.485432399306319e-08
ATM O 0 2.3941154267959064e-06
mutation O 0 3.667905312809694e-09
pattern O 0 5.624953303140501e-08
in O 0 3.8136199975724594e-08
A B-Disease 1 0.9999969005584717
- I-Disease 1 0.999982476234436
T I-Disease 1 0.9999998807907104
, O 0 1.0978638442793454e-08
the O 0 1.3607966975470731e-09
most O 0 1.3158329981166617e-10
frequent O 0 8.143527518988947e-11
nucleotide O 0 6.824268372618292e-10
changes O 0 2.933424891882197e-10
in O 0 3.9895675651990814e-10
this O 0 6.748276382140261e-10
leukaemia B-Disease 0 1.722421256999951e-05
were O 0 1.1877379080260653e-07
missense O 0 4.116452601010678e-06
mutations O 0 1.1133195130241802e-06
. O 0 2.2955512122280197e-06

These O 0 1.3853390612439398e-07
clustered O 0 4.408151426105178e-07
in O 0 7.523126122066515e-09
the O 0 4.989716639869357e-09
region O 0 5.337239539215943e-09
corresponding O 0 2.5290993743709578e-09
to O 0 1.0601008959554292e-09
the O 0 5.917755174777994e-09
kinase O 0 3.656507630012129e-08
domain O 0 4.155245036940869e-08
, O 0 3.3617530981189248e-09
which O 0 3.5415456678400403e-10
is O 0 3.014811178481125e-10
highly O 0 2.1586454845845537e-09
conserved O 0 8.407842422286649e-09
in O 0 1.1518704878810127e-09
ATM O 0 7.839580575819127e-07
- O 0 3.2738107336172106e-08
related O 0 2.5097242062344094e-09
proteins O 0 3.5271327525343565e-10
in O 0 1.9781849491806724e-09
mouse O 0 2.6450861057014663e-08
, O 0 5.139022540845417e-09
yeast O 0 1.439052823570819e-07
and O 0 3.5096348938168376e-08
Drosophila O 0 9.742838074089377e-07
. O 0 6.941147603356512e-07

The O 0 3.7884419157308e-07
resulting O 0 1.869357930672777e-07
amino O 0 3.171831508552714e-07
- O 0 2.0305820669364039e-07
acid O 0 5.5685578814745895e-08
substitutions O 0 7.716665351154006e-08
are O 0 8.814868834861045e-10
predicted O 0 2.036706270303057e-08
to O 0 2.9018401015434847e-09
interfere O 0 2.306775712668241e-07
with O 0 1.7589046663601948e-08
ATP O 0 1.6925028830883093e-05
binding O 0 1.4991564967203885e-07
or O 0 3.9532579876322416e-08
substrate O 0 4.047964807796234e-07
recognition O 0 7.133195936148695e-07
. O 0 1.7125443037002697e-06

Two O 0 1.5842267941934551e-07
of O 0 5.642790483761928e-07
seventeen O 0 1.0567259778326843e-06
mutated O 0 3.630870537563169e-07
T B-Disease 0 9.060890079126693e-06
- I-Disease 0 7.357396611951117e-07
PLL I-Disease 0 3.170859145029681e-06
samples O 0 2.2206496197441083e-08
had O 0 1.0292193763916657e-08
a O 0 2.2657904441558685e-09
previously O 0 2.9700334636117987e-08
reported O 0 7.458535122850662e-08
A B-Disease 1 0.9157012104988098
- I-Disease 0 0.1626654416322708
T I-Disease 1 0.9998230338096619
allele O 0 1.2031346159346867e-06
. O 0 5.139359018357936e-07

In O 0 4.809617166756652e-07
contrast O 0 3.317340144803893e-07
, O 0 6.744560909766051e-09
no O 0 3.307930152018912e-09
mutations O 0 8.997302347601988e-10
were O 0 1.2648988523267235e-09
detected O 0 2.056775905145969e-08
in O 0 1.0840219832886078e-09
the O 0 1.8423170766723729e-09
p53 O 0 3.6131482250567615e-09
gene O 0 6.107165440027984e-09
, O 0 3.4663238945853436e-09
suggesting O 0 2.2475159511259335e-08
that O 0 4.034648171113986e-10
this O 0 3.1447786597027516e-09
tumour B-Disease 1 0.9999948740005493
suppressor O 0 4.13512634622748e-06
is O 0 3.6374325773635974e-09
not O 0 3.7344086156743117e-10
frequently O 0 7.576242966322866e-10
altered O 0 3.428639816505097e-09
in O 0 1.374507285767379e-09
this O 0 3.1196631944396813e-09
leukaemia B-Disease 0 6.21747603872791e-05
. O 0 2.939185890227236e-07

Occasional O 0 2.4274679617519723e-06
missense O 0 3.048057124033221e-06
mutations O 0 4.829564659303287e-08
in O 0 1.305447661081871e-08
ATM O 0 3.5510297493601684e-06
were O 0 3.359601308261517e-08
also O 0 9.796591315947012e-10
found O 0 6.696616594581428e-10
in O 0 1.1821679191115209e-09
tumour B-Disease 1 0.9996849298477173
DNA O 0 9.855411775561151e-08
from O 0 3.3410803013111945e-09
patients O 0 1.2538686755547701e-09
with O 0 1.499957269501806e-09
B B-Disease 0 8.18411645013839e-05
- I-Disease 0 1.863510533439694e-06
cell I-Disease 0 1.5195735613815486e-05
non I-Disease 0 0.0016103512607514858
- I-Disease 1 0.9479051828384399
Hodgkins I-Disease 1 0.9999996423721313
lymphomas I-Disease 0 0.002036666264757514
( O 0 1.1629769147702973e-07
B B-Disease 0 4.661752427637111e-06
- I-Disease 0 8.652448002521851e-08
NHL I-Disease 0 2.681690318695473e-07
) O 0 1.6614895015365505e-09
and O 0 2.2074517769254953e-09
a O 0 3.0557849584056385e-08
B B-Disease 0 0.00010221559932688251
- I-Disease 0 5.392505499912659e-06
NHL I-Disease 0 6.625982496188954e-05
cell O 0 0.00011662682663882151
line O 0 8.256400178652257e-06
. O 0 4.461457763227372e-07

The O 0 2.3111995517410833e-07
evidence O 0 1.6689135406977584e-07
of O 0 1.338949218165908e-08
a O 0 2.259175069241337e-09
significant O 0 2.1196084887264988e-09
proportion O 0 8.262190043240025e-09
of O 0 8.269288542805953e-08
loss O 0 9.7903398454946e-07
- O 0 5.289231808092154e-07
of O 0 1.0624190736052697e-06
- O 0 3.0929592753636825e-07
function O 0 1.5933862584915914e-07
mutations O 0 4.910138073910275e-09
and O 0 8.598428635764321e-10
a O 0 2.3260435799699053e-09
complete O 0 2.522774877888878e-08
absence O 0 1.7285276499023894e-07
of O 0 4.341531223417405e-08
the O 0 6.962586507341939e-09
normal O 0 1.2968929041790034e-08
copy O 0 8.618925129155741e-09
of O 0 3.169479789733032e-09
ATM O 0 1.0412050244212878e-07
in O 0 8.334010703769934e-10
the O 0 4.00438016079363e-10
majority O 0 2.0114446219743343e-10
of O 0 1.930228243907095e-08
mutated O 0 4.217820048779686e-07
tumours B-Disease 1 0.9999972581863403
establishes O 0 2.1153541638341267e-06
somatic O 0 8.876575066096848e-07
inactivation O 0 1.690158342171344e-06
of O 0 1.6148899106838144e-08
this O 0 7.775949328880927e-10
gene O 0 1.0876504141776877e-09
in O 0 5.395188185097766e-10
the O 0 8.969069931197282e-09
pathogenesis O 0 0.00013153653708286583
of O 0 1.6146209418366197e-06
sporadic B-Disease 0 0.013936386443674564
T I-Disease 1 0.9109560251235962
- I-Disease 0 6.655099423369393e-05
PLL I-Disease 0 4.999136945116334e-05
and O 0 1.7918418748763543e-08
suggests O 0 9.785204646561851e-09
that O 0 2.1978256714572098e-10
ATM O 0 2.5942949832824524e-07
acts O 0 5.151213855469905e-08
as O 0 2.7294719373571752e-08
a O 0 2.301052006714599e-07
tumour B-Disease 1 0.9999995231628418
suppressor O 0 0.00023616079124622047
. O 0 4.279118911654223e-06

As O 0 1.8742134955118672e-07
constitutional O 0 6.255728521864512e-07
DNA O 0 1.51147375504479e-07
was O 0 5.4180969044637095e-08
not O 0 1.7970903931630033e-10
available O 0 4.115338902987986e-10
, O 0 4.923743635032451e-10
a O 0 3.015709904019559e-09
putative O 0 5.733969601351419e-07
hereditary O 1 0.996060311794281
predisposition O 0 0.006224622018635273
to O 0 1.1050107787013985e-05
T B-Disease 1 0.9999960660934448
- I-Disease 1 0.7031705379486084
PLL I-Disease 0 0.0005975753883831203
will O 0 8.688014752067375e-09
require O 0 1.8423170766723729e-09
further O 0 1.5506824713185097e-09
investigation O 0 1.0714852116677775e-08
. O 0 2.2416155598392606e-09
. O 0 8.813010765607032e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00028556096367537975
kinase O 0 5.0212051974085625e-06
is O 0 8.464965617349662e-09
involved O 0 8.354449576586376e-09
in O 0 4.6042339385543585e-10
the O 0 8.580669508262417e-10
modulation O 0 2.872271132048354e-08
of O 0 6.568523946981486e-09
the O 0 6.747236991344607e-09
Ca2 O 0 1.9451154287253303e-07
+ O 0 1.3128934597261832e-06
homeostasis O 0 8.45954564283602e-05
in O 0 8.711895702617767e-07
skeletal O 1 0.9990381002426147
muscle O 0 0.024373820051550865
cells O 0 7.682162686251104e-05
. O 0 7.336289399972884e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999544084072113
DM B-Disease 1 1.0
) O 0 6.016637712491502e-07
, O 0 3.181453989142824e-09
the O 0 2.2044308600754903e-09
most O 0 1.4572406392687753e-08
prevalent O 0 0.1111532673239708
muscular B-Disease 1 0.9999902248382568
disorder I-Disease 1 0.9999955892562866
in O 0 1.1815282050520182e-06
adults O 0 4.902317414234858e-07
, O 0 5.748125975202356e-09
is O 0 7.362837561863955e-10
caused O 0 1.1019778867193963e-08
by O 0 3.465200126839818e-09
( O 0 2.6539350272969386e-08
CTG O 0 5.536074240808375e-06
) O 0 4.348540194598627e-09
n O 0 7.736604601404906e-08
- O 0 7.72412800387201e-09
repeat O 0 4.5956554117765336e-09
expansion O 0 4.790506658025606e-09
in O 0 6.184386336371972e-10
a O 0 2.687542410839683e-10
gene O 0 1.7809639873966887e-10
encoding O 0 8.268180806680903e-09
a O 0 4.0372231779883805e-08
protein O 0 5.244823455541336e-07
kinase O 0 1.372583369629865e-06
( O 0 8.362143830709101e-07
DM B-Disease 1 0.9999972581863403
protein O 0 5.009062806493603e-05
kinase O 0 2.8545432542159688e-06
; O 0 4.893004046380156e-08
DMPK O 0 1.874602457974106e-05
) O 0 6.709622635270307e-09
and O 0 1.5317193069463997e-09
involves O 0 1.221832146569568e-08
changes O 0 6.911631711403743e-09
in O 0 1.725828902010562e-08
cytoarchitecture O 0 2.4802177449601004e-06
and O 0 1.1116978981817738e-07
ion O 0 0.001967799849808216
homeostasis O 0 0.24525710940361023
. O 0 1.1310587069601752e-05

To O 0 2.415224003016192e-07
obtain O 0 6.736026421094721e-07
clues O 0 1.5390170347018284e-06
to O 0 6.980350963914361e-09
the O 0 1.477272437711008e-08
normal O 0 1.6679079806181107e-07
biological O 0 1.4796165714869858e-07
role O 0 3.317162722282774e-08
of O 0 5.839071803848128e-08
DMPK O 0 2.2387583157978952e-05
in O 0 3.7728081991872386e-08
cellular O 0 1.5267170283550513e-06
ion O 0 1.3104705431032926e-05
homeostasis O 0 0.00013445565127767622
, O 0 1.877386424098404e-08
we O 0 3.397697678764189e-09
have O 0 2.6740534786462433e-10
compared O 0 1.3697468714823913e-09
the O 0 1.5476655512713933e-09
resting O 0 8.460336431426185e-08
[ O 0 3.7953244991228985e-09
Ca2 O 0 7.778237609556982e-09
+ O 0 1.9229670300546786e-08
] O 0 1.6623111775970756e-08
i O 0 7.157998638263052e-09
, O 0 1.260885285070401e-10
the O 0 9.037475628970171e-11
amplitude O 0 3.3938178933823338e-09
and O 0 9.066761785803124e-10
shape O 0 1.6933071833591384e-08
of O 0 3.718498220450783e-08
depolarization O 0 1.0620001944516844e-07
- O 0 4.941223892274138e-07
induced O 0 1.9735810496968043e-07
Ca2 O 0 1.1092706131421437e-07
+ O 0 3.2929216331467615e-07
transients O 0 9.618407830203068e-07
, O 0 3.0938864803431443e-09
and O 0 4.2178679993121193e-10
the O 0 1.8175674298959166e-09
content O 0 6.234606608757076e-09
of O 0 6.5094933887621664e-09
ATP O 0 3.20873527925869e-06
- O 0 3.485014303805656e-07
driven O 0 6.960065945804672e-08
ion O 0 8.472300692119461e-07
pumps O 0 2.8331510293355677e-07
in O 0 3.3173648716910975e-08
cultured O 0 7.852331691537984e-06
skeletal O 0 0.0004101789672859013
muscle O 0 1.7444999684812501e-06
cells O 0 7.72301120832708e-08
of O 0 9.478524987116543e-08
wild O 0 7.660247547391918e-09
- O 0 4.732321201572631e-09
type O 0 9.612612927867303e-09
and O 0 2.0231154529426476e-09
DMPK O 0 1.7310369003098458e-05
[ O 0 3.7379402328951983e-07
- O 0 1.1649466387098073e-06
/ O 0 1.0764591934275813e-05
- O 0 3.161444283250603e-06
] O 0 1.5151682646319387e-06
knockout O 0 0.03391878679394722
mice O 0 1.4170996109896805e-05
. O 0 5.06878905071062e-07

In O 0 1.0948014050882193e-06
vitro O 0 3.822559392574476e-06
- O 0 9.584857707523042e-07
differentiated O 0 4.2322812987549696e-07
DMPK O 0 0.00011012852337444201
[ O 0 1.2517374443632434e-06
- O 0 3.2749749152571894e-06
/ O 0 5.055260771769099e-06
- O 0 3.3952963462979824e-07
] O 0 3.5655155272706907e-08
myotubes O 0 8.142979623926294e-08
exhibit O 0 2.8386226702536987e-09
a O 0 1.4735851427971625e-09
higher O 0 2.096034457110818e-08
resting O 0 3.8034073668313795e-07
[ O 0 2.029872803177568e-08
Ca2 O 0 1.186157216892525e-08
+ O 0 4.2744179751252886e-08
] O 0 5.377912515314165e-08
i O 0 1.7868247326191522e-08
than O 0 9.008292445322752e-10
do O 0 8.978205956466923e-10
wild O 0 2.485666117379992e-09
- O 0 2.4232649220579106e-09
type O 0 9.811406798121425e-09
myotubes O 0 4.6369880379870665e-08
because O 0 6.706535882194942e-10
of O 0 1.260823334625627e-09
an O 0 2.2665760934792445e-10
altered O 0 2.9046418603684288e-09
open O 0 7.124518308643246e-09
probability O 0 8.429197784209919e-09
of O 0 9.745197537824879e-09
voltage O 0 3.679448354887427e-07
- O 0 1.7415555220168244e-08
dependent O 0 7.298703863511946e-09
l O 0 2.383800357108612e-08
- O 0 5.358670396304888e-09
type O 0 6.44088737900006e-09
Ca2 O 0 7.54289608551062e-09
+ O 0 1.7459857559742886e-08
and O 0 1.3497286843744405e-08
Na O 0 9.04109765542671e-06
+ O 0 5.225736003922066e-07
channels O 0 1.2195990848340443e-06
. O 0 3.072002527915174e-07

The O 0 4.220075425109826e-06
mutant O 0 7.898522198956925e-06
myotubes O 0 7.410389116557781e-06
exhibit O 0 1.3046962976659415e-07
smaller O 0 2.4041055368684283e-08
and O 0 6.289428533534647e-09
slower O 0 1.4463174125012301e-07
Ca2 O 0 2.58022261334645e-08
+ O 0 8.765815628919427e-09
responses O 0 5.862008656265516e-10
upon O 0 2.376304042428501e-09
triggering O 0 9.361324160295226e-09
by O 0 3.923731617394566e-10
acetylcholine O 0 1.0972069475201351e-07
or O 0 8.710929755295638e-09
high O 0 2.5508975909360743e-07
external O 0 1.6199514902837109e-06
K O 0 5.5868731578812e-06
+ O 0 1.7997338090935955e-06
. O 0 5.499384201357316e-07

In O 0 2.8523450623652025e-07
addition O 0 1.285476258772178e-07
, O 0 8.02356847628971e-09
we O 0 3.685957317145494e-09
observed O 0 2.2705060054306614e-09
that O 0 4.650328386257563e-11
these O 0 1.0442365028229261e-10
Ca2 O 0 1.1674469391209641e-08
+ O 0 7.473986585182502e-08
transients O 0 2.2637640029188333e-07
partially O 0 9.255262334306735e-09
result O 0 9.469770523296006e-10
from O 0 2.889422867635716e-10
an O 0 7.501267662579636e-11
influx O 0 7.975122229275655e-10
of O 0 2.398621745669516e-09
extracellular O 0 2.2328986659658767e-08
Ca2 O 0 1.0806142647368233e-08
+ O 0 6.8713963408129075e-09
through O 0 1.0482561485503084e-09
the O 0 3.124439151847014e-09
l O 0 6.769772653569817e-08
- O 0 1.777948455128353e-08
type O 0 1.9420454577812052e-08
Ca2 O 0 7.847518901371586e-08
+ O 0 5.334600814421719e-07
channel O 0 2.4296637093357276e-06
. O 0 5.489255840984697e-07

Neither O 0 2.5165186343656387e-06
the O 0 6.817509046186387e-08
content O 0 3.486163535626474e-08
nor O 0 5.1672506273803265e-09
the O 0 4.2774800368405863e-10
activity O 0 1.1889109696738842e-09
of O 0 5.762891053251451e-09
Na O 0 1.5313337371480884e-06
+ O 0 1.4430629846629017e-07
/ O 0 3.435686153352435e-07
K O 0 1.5795079377767252e-07
+ O 0 7.551479086487234e-08
ATPase O 0 2.4357228767257766e-07
and O 0 2.6674239705926084e-08
sarcoplasmic O 0 1.3444686146613094e-06
reticulum O 0 1.2993982636544388e-06
Ca2 O 0 3.072348135901848e-07
+ O 0 9.848963600234129e-07
- O 0 4.440115901616082e-07
ATPase O 0 2.8841461130468815e-07
are O 0 4.731353087095158e-10
affected O 0 1.0535136096834208e-09
by O 0 1.6251354706398047e-09
DMPK O 0 9.188455442199484e-05
absence O 0 1.2568651982292067e-05
. O 0 2.5027661649801303e-06

In O 0 5.610802986666386e-07
conclusion O 0 3.0264180850281264e-07
, O 0 2.916968533384079e-08
our O 0 1.8458212736049973e-08
data O 0 2.325312919992939e-08
suggest O 0 1.8089428621692605e-08
that O 0 3.436173290349842e-10
DMPK O 0 2.2592164441448404e-06
is O 0 1.4196165354363188e-09
involved O 0 1.2697720652710132e-09
in O 0 3.7448152911956356e-10
modulating O 0 2.571752233393454e-08
the O 0 8.510079307910701e-10
initial O 0 4.330097669313915e-10
events O 0 1.9975242293579498e-10
of O 0 1.674408833807206e-09
excitation O 0 7.410654347950185e-07
- O 0 2.172851736759185e-06
contraction O 0 5.659940143232234e-07
coupling O 0 1.1145306189064286e-06
in O 0 1.8442962357312354e-07
skeletal O 0 0.10168614238500595
muscle O 0 2.8356149414321408e-05
. O 0 5.038484118813358e-07
. O 0 1.8945468127640197e-06

Constitutional O 0 0.00038713865797035396
RB1 O 0 0.01835482008755207
- O 0 8.69400828378275e-05
gene O 0 5.78344042878598e-07
mutations O 0 8.289043051945555e-08
in O 0 1.762592027887422e-08
patients O 0 9.643058795916204e-09
with O 0 1.0971709762941373e-08
isolated O 0 5.643652912112884e-06
unilateral B-Disease 0 1.6500380297657102e-05
retinoblastoma I-Disease 1 0.9972760081291199
. O 0 1.5408411854878068e-05

In O 0 2.703741301957052e-07
most O 0 2.2882799655121744e-08
patients O 0 1.2876426147556685e-08
with O 0 2.52814458256978e-09
isolated O 0 1.5762396969876136e-06
unilateral B-Disease 0 6.946087523829192e-06
retinoblastoma I-Disease 1 0.9998133778572083
, O 0 1.31557513327607e-07
tumor B-Disease 0 2.3337297534453683e-06
development O 0 2.638953411349121e-08
is O 0 1.300394680825434e-09
initiated O 0 2.173891733292521e-09
by O 0 1.741969068991267e-10
somatic O 0 1.4281177129760181e-08
inactivation O 0 1.517972663123146e-07
of O 0 7.039286487042773e-09
both O 0 1.7752265213388796e-09
alleles O 0 2.536882703907395e-09
of O 0 2.4371209050855214e-08
the O 0 1.3964121592380252e-07
RB1 O 0 8.130335481837392e-05
gene O 0 1.980985189220519e-06
. O 0 1.4217994248610921e-06

However O 0 4.937757012157817e-07
, O 0 1.0826277652142835e-08
some O 0 5.157884119810774e-10
of O 0 4.702198186379292e-09
these O 0 1.713508224199245e-09
patients O 0 2.1240612824158234e-08
can O 0 1.2438458263375196e-08
transmit O 0 9.09661321202293e-06
retinoblastoma B-Disease 0 0.002272627782076597
predisposition O 0 4.185266334388871e-06
to O 0 3.998217579237462e-08
their O 0 9.69347979662416e-08
offspring O 0 8.553337806915806e-07
. O 0 9.198445809488476e-07

To O 0 3.953694971414734e-08
determine O 0 8.762626180214284e-08
the O 0 8.28741164582425e-09
frequency O 0 5.383649437362692e-08
and O 0 6.019203468987655e-10
nature O 0 5.800085745022443e-09
of O 0 2.953019517804023e-08
constitutional O 0 5.662230705638649e-06
RB1 O 0 0.00018667768745217472
- O 0 2.2251920199778397e-06
gene O 0 7.869162743645575e-08
mutations O 0 2.1284860096670855e-08
in O 0 7.258693646150505e-09
patients O 0 7.722919193042799e-09
with O 0 8.706694032412088e-09
isolated O 0 3.4759932532324456e-06
unilateral B-Disease 0 3.800531658271211e-06
retinoblastoma I-Disease 0 0.0008280463516712189
, O 0 1.24266010814722e-08
we O 0 4.169127709729992e-09
analyzed O 0 2.6567761324258754e-08
DNA O 0 2.0852558790807052e-08
from O 0 4.474766779338779e-09
peripheral O 0 9.391413868797827e-07
blood O 0 1.4532497516484e-07
and O 0 5.385888357523072e-08
from O 0 1.4212422456694185e-06
tumor B-Disease 0 0.029723286628723145
tissue O 0 0.00041123133269138634
. O 0 6.243145435291808e-06

The O 0 2.32326755167378e-07
analysis O 0 2.2600904969749536e-07
of O 0 1.3773812952422304e-06
tumors B-Disease 1 0.9999996423721313
from O 0 8.660403523208515e-07
54 O 0 2.936591556590429e-07
( O 0 8.282639463175201e-09
71 O 0 5.4314966746460414e-08
% O 0 4.351543569924843e-09
) O 0 2.5741848652671706e-09
of O 0 9.117582777662392e-08
76 O 0 4.709084805654129e-06
informative O 0 6.091346449466073e-07
patients O 0 1.0597339183959775e-07
showed O 0 5.4830621820656233e-08
loss O 0 4.907425577016511e-08
of O 0 2.2730534965376137e-07
constitutional O 0 2.5745044695213437e-05
heterozygosity O 1 0.9145875573158264
( O 0 7.2800248744897544e-06
LOH O 1 0.9993354678153992
) O 0 6.137376828974084e-08
at O 0 1.8831228771887254e-06
intragenic O 0 1.3742750525125302e-05
loci O 0 4.154328507866012e-06
. O 0 2.1500152342923684e-06

Three O 0 5.537777383324283e-07
of O 0 9.280947210754675e-07
13 O 0 4.254297437000787e-06
uninformative O 0 0.001239326549693942
patients O 0 2.0377221972012194e-06
had O 0 3.228463754112454e-07
constitutional O 0 3.425286422498175e-06
deletions O 0 6.5773288042692e-06
. O 0 1.2938115787619608e-06

For O 0 8.829901503304427e-07
39 O 0 1.3412287671599188e-06
randomly O 0 1.0226820279513049e-07
selected O 0 1.1752887303373427e-06
tumors B-Disease 1 0.9999998807907104
, O 0 4.7117799795159954e-07
SSCP O 0 0.00296451966278255
, O 0 2.910417435941781e-07
hetero O 0 4.0597129554953426e-05
- O 0 3.361649874022987e-07
duplex O 0 1.8340284668738605e-06
analysis O 0 8.788481942190174e-09
, O 0 2.994386683052852e-10
sequencing O 0 3.070793619386336e-09
, O 0 8.060332401527148e-10
and O 0 1.1886978068531562e-09
Southern O 0 3.1363700969677666e-08
blot O 0 4.448812873647512e-08
analysis O 0 2.777163832234919e-09
were O 0 1.2245050529102741e-09
used O 0 9.3262109146508e-10
to O 0 9.306930226493648e-10
identify O 0 1.202240724751391e-07
mutations O 0 9.260541560252022e-07
. O 0 1.529730980109889e-06

Mutations O 0 4.5024134465165844e-07
were O 0 8.358597369806375e-08
detected O 0 1.9882388357927994e-07
in O 0 7.146812475156139e-09
21 O 0 7.081560937649556e-08
( O 0 3.3880938055119714e-09
91 O 0 2.1857797349866814e-08
% O 0 4.195628289238584e-09
) O 0 3.2271383343385196e-09
of O 0 2.844318203187868e-07
23 O 1 0.633577287197113
tumors B-Disease 1 1.0
with O 0 0.2451634705066681
LOH O 1 1.0
. O 0 0.00017883007240016013

In O 0 1.5724486956969486e-06
6 O 0 2.7990595299343113e-06
( O 0 3.364769796121436e-08
38 O 0 1.1347825790153365e-07
% O 0 2.610217819665195e-09
) O 0 1.411171957066415e-09
of O 0 1.5434308409112418e-07
16 O 0 0.005988044664263725
tumors B-Disease 1 1.0
without O 0 0.18409845232963562
LOH O 1 0.999998927116394
, O 0 1.0400533767551678e-08
one O 0 3.5753863758536397e-10
mutation O 0 1.9003987272725453e-10
was O 0 7.873919294354437e-09
detected O 0 8.280743202249141e-09
, O 0 2.099577317560275e-10
and O 0 2.8906244065041165e-10
in O 0 1.6484872356059554e-09
9 O 0 5.4378197944515705e-08
( O 0 2.054645786842002e-09
56 O 0 9.926265143178625e-09
% O 0 8.85970463659902e-10
) O 0 9.211686968768618e-10
of O 0 3.079205512790395e-08
the O 0 5.080271421320504e-06
tumors B-Disease 1 1.0
without O 1 0.8678085207939148
LOH O 1 1.0
, O 0 2.1100333924550796e-08
both O 0 1.458725673586514e-08
mutations O 0 1.6575969041809913e-08
were O 0 5.444482553684793e-08
found O 0 8.741792356659062e-08
. O 0 1.355041518991129e-07

Thus O 0 6.985387699387502e-07
, O 0 1.2585751107963006e-08
a O 0 2.699555246010732e-09
total O 0 1.1807099742355831e-09
of O 0 1.5969133571047678e-08
45 O 0 2.5435360484493685e-08
mutations O 0 3.276120486006562e-09
were O 0 4.165773503927994e-09
identified O 0 2.0506572440126547e-08
in O 0 5.9093437698720663e-08
tumors B-Disease 1 1.0
of O 0 0.00016076808969955891
36 O 0 0.0012044457253068686
patients O 0 2.95934769383166e-05
. O 0 4.730492037197109e-06

Thirty O 0 2.3883616449893452e-05
- O 0 1.4485302699540625e-06
nine O 0 3.122593383864114e-08
of O 0 8.117079453029419e-09
the O 0 3.49693052292821e-09
mutations O 0 2.6014603804469516e-09
- O 0 1.7091876358676927e-08
including O 0 3.0563780395453932e-09
34 O 0 8.393505623871533e-08
small O 0 3.65349599462661e-08
mutations O 0 4.151513621764025e-08
, O 0 1.4966088812684575e-08
2 O 0 2.9317450866983563e-07
large O 0 3.008317861485921e-08
structural O 0 7.185135473264381e-05
alterations O 0 1.566942228237167e-05
, O 0 3.500609224715845e-08
and O 0 2.2209249550542154e-08
hypermethylation O 0 0.0043176221661269665
in O 0 1.3021050335737527e-06
3 O 0 0.02101469226181507
tumors O 1 1.0
- O 0 4.496261681197211e-06
were O 0 3.157546402121625e-08
not O 0 4.1786790694331444e-10
detected O 0 2.0052679516879834e-08
in O 0 1.4116235957928325e-10
the O 0 7.217576536433512e-10
corresponding O 0 6.21428384306455e-08
peripheral O 0 2.7263526135357097e-05
blood O 0 1.8003672721533803e-06
DNA O 0 2.095068566632108e-06
. O 0 2.978458724101074e-07

In O 0 5.832693545926304e-07
6 O 0 1.5549177305729245e-06
( O 0 1.1278523892599424e-08
17 O 0 3.797795855575714e-08
% O 0 1.5266063968510935e-09
) O 0 8.457311517773292e-10
of O 0 1.528906246051065e-08
the O 0 6.715425371339734e-08
36 O 0 4.712719032795576e-07
patients O 0 4.7573745831641645e-08
, O 0 1.6015397896751438e-09
a O 0 1.7552475028992376e-09
mutation O 0 8.787472416393882e-10
was O 0 1.180082431773144e-08
detected O 0 1.8512190891328828e-08
in O 0 5.974891137405791e-10
constitutional O 0 1.369891133862211e-08
DNA O 0 2.9419446434530983e-08
, O 0 9.285954227777893e-10
and O 0 2.4476745630330754e-10
1 O 0 7.686679737162194e-09
of O 0 1.484287470709944e-09
these O 0 2.2515039832526895e-10
mutations O 0 9.30765797768629e-10
is O 0 3.516345270515586e-10
known O 0 4.1549319540479246e-10
to O 0 2.0524278110389815e-10
be O 0 1.6414591907931708e-09
associated O 0 1.939705818188031e-08
with O 0 3.597531383903174e-09
reduced O 0 1.5003894304754795e-06
expressivity O 0 5.1642458856804296e-05
. O 0 6.626625008721021e-07

The O 0 7.503058441216126e-07
presence O 0 2.4767970785433135e-07
of O 0 1.8330842976865824e-07
a O 0 2.9194065831461558e-08
constitutional O 0 1.4436906781156722e-07
mutation O 0 5.111397083368274e-09
was O 0 2.9585898175810144e-08
not O 0 3.6525726887504106e-10
associated O 0 1.8621751918246332e-09
with O 0 1.270750310533586e-10
an O 0 5.351425969024604e-10
early O 0 7.77420652298133e-08
age O 0 3.5761411254497943e-07
at O 0 3.440506816332345e-06
treatment O 0 7.928996637929231e-06
. O 0 7.549505198767292e-07

In O 0 1.3602015087599284e-06
1 O 0 9.723894436319824e-06
patient O 0 2.1383939383667894e-06
, O 0 1.0254282756250177e-07
somatic O 0 3.797615136136301e-06
mosaicism O 0 0.0004888831172138453
was O 0 2.847914402082097e-07
demonstrated O 0 5.787466061946134e-09
by O 0 1.1627167978423003e-10
molecular O 0 6.663492868597132e-09
analysis O 0 6.110762451605467e-10
of O 0 2.2602524296644333e-09
DNA O 0 1.2234691482149174e-08
and O 0 3.1620288609701674e-09
RNA O 0 8.50899823490181e-07
from O 0 1.7684185138477915e-07
peripheral O 0 0.0002008905285038054
blood O 0 1.8279888536198996e-05
. O 0 3.079334192079841e-06

In O 0 1.5923442333587445e-06
2 O 0 7.0261758082779124e-06
patients O 0 3.885522659174967e-08
without O 0 4.917045437480283e-09
a O 0 6.235605809479239e-09
detectable O 0 1.3150588529242668e-06
mutation O 0 1.2669229221273781e-08
in O 0 1.4374530010741182e-08
peripheral O 0 3.9045437006279826e-05
blood O 0 3.844341335934587e-06
, O 0 1.0769726799253476e-07
mosaicism O 0 0.003435776336118579
was O 0 9.62627268563665e-07
suggested O 0 4.518113172480298e-08
because O 0 1.2812110261606335e-09
1 O 0 2.6513092166169372e-08
of O 0 3.5271747744758386e-09
the O 0 1.4679586435306646e-08
patients O 0 5.466452535074495e-07
showed O 0 0.00044059992069378495
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 2.2508500308049406e-07
the O 0 2.9158115921745775e-08
other O 0 4.152081789499107e-09
later O 0 7.281840197492784e-08
developed O 0 2.9048547389720625e-07
bilateral B-Disease 0 0.00023177456751000136
retinoblastoma I-Disease 0 0.05073842033743858
. O 0 2.5004999315569876e-06

In O 0 6.565958301507635e-07
conclusion O 0 5.044474846727098e-07
, O 0 2.4100556217376834e-08
our O 0 1.8906211707303555e-08
results O 0 3.725169062107625e-09
emphasize O 0 7.3041910297888535e-09
that O 0 1.1344272049518267e-10
the O 0 1.7383422479255728e-09
manifestation O 0 1.7108858685332962e-07
and O 0 1.4063845199530078e-08
transmissibility O 0 0.00011521163833094761
of O 0 9.465144330533803e-07
retinoblastoma B-Disease 0 9.594456059858203e-06
depend O 0 9.938919909302513e-09
on O 0 1.7696223153507162e-08
the O 0 7.810195823410027e-10
nature O 0 2.182745539869302e-09
of O 0 2.6560504906569804e-09
the O 0 7.848006133848173e-10
first O 0 8.697959574810454e-10
mutation O 0 2.2175448977090895e-10
, O 0 2.2238814956221375e-10
its O 0 1.2084394596101333e-10
time O 0 8.754147962086734e-10
in O 0 2.698292700387128e-10
development O 0 2.4883510807427456e-09
, O 0 3.8043895811412654e-10
and O 0 1.4641317325203573e-10
the O 0 2.932417919598862e-10
number O 0 2.5460672459232114e-10
and O 0 2.6425772681193394e-10
types O 0 9.150122437517894e-09
of O 0 5.934260371986966e-08
cells O 0 2.5965922745285752e-09
that O 0 1.0924880444740381e-10
are O 0 6.127998802840651e-11
affected O 0 6.269399444036594e-10
. O 0 1.659408721543798e-09
. O 0 3.72085331434846e-08

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 0 0.23492367565631866
the I-Disease 0 1.9692617570399307e-05
fifth I-Disease 0 1.3507426956493873e-05
component I-Disease 0 9.530464922136161e-06
of I-Disease 0 3.8432858673331793e-07
complement I-Disease 0 1.1038396223739255e-06
in O 0 5.797975859422877e-07
man O 0 9.911973393172957e-06
. O 0 1.0724911589932162e-06

I O 0 0.006780937314033508
. O 0 6.601234781555831e-05

Clinical O 0 0.000619846279732883
, O 0 2.373880761297187e-06
immunochemical O 0 0.00029400730272755027
, O 0 2.0572197456658614e-07
and O 0 9.960824343124841e-08
family O 0 7.297538218153932e-08
studies O 0 2.1940128647202073e-07
. O 0 3.824043801614607e-07

The O 0 2.1984888576298545e-07
first O 0 7.461395057362097e-08
recognized O 0 1.2102736945962533e-07
human O 0 3.376680410838162e-07
kindred O 0 7.29657185729593e-05
with O 0 3.1450617825612426e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9989853501319885
the I-Disease 0 8.601303125033155e-05
fifth I-Disease 0 1.7440708688809536e-05
component I-Disease 0 7.123268915165681e-06
of I-Disease 0 2.918905693150009e-06
complement I-Disease 0 1.3641307305078954e-05
( O 0 3.916075456800172e-06
C5 O 0 0.0008982113213278353
) O 0 3.9315718680654754e-08
is O 0 1.4943127624178487e-08
described O 0 4.4221010853107146e-07
. O 0 4.289204298402183e-07

The O 0 1.7213354794876068e-06
proband O 0 9.288844012189656e-06
, O 0 1.5465303704331745e-08
a O 0 1.5032375344503635e-08
20 O 0 6.320662748748873e-08
- O 0 2.6864480417998493e-08
year O 0 9.930260169710436e-09
- O 0 5.247460421742289e-07
old O 0 7.267298656188359e-07
black O 0 6.723460899138445e-08
female O 0 2.6719030188360193e-07
with O 0 0.00760105112567544
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9614238739013672
age O 0 0.22005514800548553
11 O 0 4.526861630438361e-06
, O 0 5.598729302391803e-08
lacked O 0 1.6153424439835362e-05
serum O 0 3.863408437609905e-06
hemolytic O 0 3.900740557583049e-05
complement O 0 6.160335033200681e-07
activity O 0 8.571335001761327e-07
, O 0 1.302992469476294e-08
even O 0 1.3382445374077179e-08
during O 0 2.8093583637200936e-07
remission O 0 2.150105274267844e-06
. O 0 3.554014256224036e-07

C5 O 0 0.018163954839110374
was O 0 5.212108590058051e-05
undetectable O 0 0.00020783650688827038
in O 0 6.86669636706938e-08
her O 0 1.0029490127294594e-08
serum O 0 1.7668197571651945e-08
by O 0 4.623109395307523e-10
both O 0 1.8363014220312834e-08
immunodiffusion O 0 2.2841628378955647e-05
and O 0 4.279577865418105e-07
hemolytic O 1 0.985126793384552
assays O 0 3.7775749660795555e-05
. O 0 5.399143446993548e-06

Other O 0 5.7567525857393775e-08
complement O 0 6.208775005234202e-08
components O 0 6.934815246495418e-07
were O 0 5.728054031095553e-09
normal O 0 9.903609488048914e-09
during O 0 6.518078965456198e-09
remission O 0 4.460274638518058e-08
of O 0 7.253630940340372e-08
lupus O 0 3.0269545732153347e-06
, O 0 3.733835285402165e-08
but O 0 5.024175564471989e-08
C1 O 0 0.0021308925934135914
, O 0 6.852852720840019e-07
C4 O 1 0.8096213936805725
, O 0 1.3017756828048732e-07
C2 O 0 2.9965100111439824e-05
, O 0 8.781951521541487e-08
and O 0 1.435301584251647e-07
C3 O 0 0.29641497135162354
levels O 0 0.00016882475756574422
fell O 0 0.024058019742369652
during O 0 8.738349606574047e-06
exacerbations O 0 0.0003485789929982275
. O 0 2.759269364105421e-06

A O 0 6.116957956692204e-05
younger O 0 1.100568533729529e-05
half O 0 3.5621719689515885e-06
- O 0 7.754317266517319e-06
sister O 0 1.3611812619274133e-06
, O 0 6.787809780917087e-08
who O 0 8.264463247087406e-08
had O 0 4.6031672695789894e-07
no O 0 1.407760578331363e-06
underlying O 1 0.9999940395355225
disease O 1 0.9764153361320496
, O 0 8.452961886007415e-09
was O 0 1.753924010472474e-07
also O 0 1.1549460277038293e-09
found O 0 8.9940432879132e-10
to O 0 1.3002210419443827e-09
lack O 0 5.640708309329057e-07
immunochemically O 0 0.00025049105170182884
detectable O 0 0.00693848030641675
C5 O 0 0.014878450892865658
. O 0 4.662735136662377e-06

By O 0 7.671990829294373e-07
hemolytic O 0 0.0020690124947577715
assay O 0 6.470678727055201e-06
, O 0 2.0470859851684509e-07
she O 0 4.0426400005344476e-08
exhibited O 0 2.2405677668757562e-07
1 O 0 3.2227302426690585e-07
- O 0 2.2350546302618568e-08
2 O 0 2.707430546422529e-08
% O 0 1.296748708412565e-09
of O 0 3.6626484067880938e-09
the O 0 7.524818990134463e-09
normal O 0 4.71218442044119e-07
serum O 0 2.4983208390949585e-07
C5 O 0 1.2188618256914197e-06
level O 0 1.0748076562094866e-07
and O 0 1.0576247655436077e-09
normal O 0 1.0658513183159357e-08
concentrations O 0 3.129110126565138e-08
of O 0 3.098616918606467e-09
other O 0 8.501496728818836e-10
complement O 0 6.83146339497398e-08
components O 0 7.549644578830339e-06
. O 0 1.1565755357878515e-06

C5 O 0 0.000808427925221622
levels O 0 1.7866598227556096e-06
of O 0 1.8455558858931909e-07
other O 0 6.899159021855894e-09
family O 0 1.8283392577700397e-09
members O 0 4.909358475302383e-10
were O 0 1.9302972553703057e-09
either O 0 3.1803799593888016e-09
normal O 0 4.622540927812224e-08
or O 0 2.842339252850934e-09
approximately O 0 1.9751988933336406e-09
half O 0 3.0678664053596094e-09
- O 0 2.0584978166482415e-09
normal O 0 3.929635727928371e-09
, O 0 1.3141726595833347e-10
consistent O 0 1.6376314748711707e-09
with O 0 9.725732441623336e-10
autosomal O 0 2.102124341263334e-07
codominant O 0 5.033878096583067e-07
inheritance O 0 3.58462202143528e-08
of O 0 1.6153922643979968e-08
the O 0 2.8614552505246138e-08
gene O 0 1.4076130128160003e-06
determining O 0 0.0015284103574231267
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00013141831732355058

Normal O 0 0.0010195178911089897
hemolytic O 0 0.049320634454488754
titers O 0 0.00010921054490609095
were O 0 2.2221013296075398e-07
restored O 0 2.9957726610518876e-07
to O 0 4.84306683645741e-09
both O 0 7.130448409498058e-08
homozygous O 0 2.443206358293537e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
deficient I-Disease 1 1.0
( O 0 2.9768598324153572e-05
C5D B-Disease 1 1.0
) O 0 5.8978130823561514e-08
sera O 0 1.2684176908805966e-07
by O 0 3.9582337407750856e-10
addition O 0 1.4842703732753648e-09
of O 0 1.7724531176099845e-08
highly O 0 1.4929756844139774e-06
purified O 0 2.723512807278894e-06
human O 0 1.5341344123953604e-06
C5 O 0 0.0014145377790555358
. O 0 2.3202505872177426e-06

In O 0 3.23192637097236e-07
specific O 0 7.355978937084728e-07
C5 O 0 0.00031045949435792863
titrations O 0 1.8340198948862962e-05
, O 0 2.575364987933426e-08
however O 0 7.41115346869492e-09
, O 0 8.670959505963083e-10
it O 0 1.1336916821980125e-10
was O 0 6.23900842100511e-09
noted O 0 1.3377640106781996e-09
that O 0 3.2882120637456325e-11
when O 0 8.285064301283285e-11
limited O 0 8.758452990642596e-11
amounts O 0 1.8921280098282978e-09
of O 0 8.233967285775634e-09
C5 O 0 9.675134151621023e-07
were O 0 4.560526623009764e-09
assayed O 0 3.5637476969441195e-08
in O 0 2.752262306948694e-10
the O 0 2.5341634346531805e-10
presence O 0 6.654523043714278e-10
of O 0 3.2634976943057836e-09
low O 0 1.577542008135424e-07
dilutions O 0 1.1500509344841703e-06
of O 0 5.206251429967779e-08
either O 0 3.786476838740782e-07
C5D B-Disease 1 0.9999982118606567
serum O 0 1.5762667544549913e-06
, O 0 5.72815217481093e-09
curving O 0 1.6432142757594193e-08
rather O 0 2.524588094132696e-09
than O 0 3.95558474863833e-10
linear O 0 9.593526861806367e-09
dose O 0 1.4797124947563134e-07
- O 0 2.52626453089988e-09
response O 0 3.2639191349659313e-10
plots O 0 1.102818392162419e-09
were O 0 4.393792829571197e-10
consistently O 0 1.3936092280175671e-09
obtained O 0 7.325310358297088e-10
, O 0 1.6778352318613798e-10
suggesting O 0 5.75381631229277e-10
some O 0 8.38912411760262e-11
inhibitory O 0 4.708949674636642e-08
effect O 0 2.456381196225266e-07
. O 0 2.33204261235187e-07

Further O 0 5.26965152403136e-07
studies O 0 8.361069347984085e-08
suggested O 0 2.6360053695384522e-08
that O 0 7.329503115549585e-10
low O 0 1.917179588417639e-07
dilutions O 0 5.04479112350964e-06
of O 0 6.783822641409643e-07
C5D B-Disease 1 0.9999969005584717
serum O 0 3.7195201230133534e-07
contain O 0 6.3183454024340335e-09
a O 0 1.5549562748518042e-09
factor O 0 3.0785227700391715e-09
( O 0 5.800680491496735e-10
or O 0 7.58621998553366e-10
factors O 0 8.003927298716462e-09
) O 0 7.945848423673851e-10
interfering O 0 6.079564940364435e-08
at O 0 5.7116704255122386e-08
some O 0 3.1378988296637544e-10
step O 0 6.460573409583503e-09
in O 0 1.1249706721727648e-09
the O 0 9.890527508105151e-09
hemolytic O 0 1.7982318240683526e-05
assay O 0 1.7272865306949825e-06
of O 0 2.240078174509108e-05
C5 O 0 0.1056978777050972
, O 0 1.3339580995364031e-08
rather O 0 3.3520719533441934e-09
than O 0 6.446881917199221e-10
a O 0 9.05011177110282e-09
true O 0 1.876354076557618e-07
C5 O 0 7.121553062461317e-05
inhibitor O 0 2.1584421574516455e-06
or O 0 1.3717455260575662e-07
inactivator O 0 1.304037868976593e-05
. O 0 9.473931186221307e-07

Of O 0 2.231590769952163e-06
clinical O 0 2.750779276539106e-05
interest O 0 2.6409330189380853e-07
are O 0 2.741690430241306e-09
( O 0 8.462055500757515e-10
a O 0 1.199722099443079e-09
) O 0 6.73319178190468e-11
the O 0 3.246497237707757e-10
documentation O 0 7.669432022794354e-08
of O 0 1.2569506679938058e-06
membranous O 1 0.9999998807907104
glomerulonephritis B-Disease 1 1.0
, O 0 0.037961289286613464
vasculitis B-Disease 1 1.0
, O 0 7.215680852823425e-06
and O 0 7.199271931312978e-05
arthritis B-Disease 1 1.0
in O 0 6.736695468134712e-07
an O 0 3.734803755151006e-08
individual O 0 5.2450129572889637e-08
lacking O 1 0.9864476919174194
C5 O 1 0.5037427544593811
( O 0 5.82965409279268e-09
and O 0 8.545033014506487e-10
its O 0 3.3363536933173066e-10
biologic O 0 1.3174472712762508e-07
functions O 0 9.484037555296254e-09
) O 0 6.93247570460187e-10
, O 0 5.744374420579845e-10
and O 0 1.9713184418179708e-09
( O 0 6.181087641721206e-09
b O 0 9.34070882863125e-08
) O 0 1.0585088361381167e-09
a O 0 5.9386504602798595e-09
remarkable O 0 5.769679845002429e-08
propensity O 0 1.1268716662016232e-06
to O 0 3.040811122900777e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.4496519418780736e-08
the O 0 1.2182344910627307e-08
proband O 0 2.120301587638096e-07
, O 0 4.487525628871225e-10
even O 0 8.303304571688486e-11
during O 0 5.910419376142784e-10
periods O 0 4.466785163970144e-09
of O 0 1.4620562538425474e-09
low O 0 4.5106567370112316e-08
- O 0 4.380740659115645e-09
dose O 0 8.097595483036457e-09
or O 0 6.877738933930289e-10
alternate O 0 6.386621009824012e-09
- O 0 4.265800868097358e-08
day O 0 4.9042160554790826e-08
corticosteroid O 0 2.5667874069768004e-05
therapy O 0 3.2334668503608555e-05
. O 0 6.316751068879967e-07

Other O 0 3.695484167565155e-07
observations O 0 2.3871541543485364e-07
indicate O 0 6.183660872238761e-08
that O 0 5.414320658481131e-10
the O 0 1.4925808144994335e-08
C5D B-Disease 1 0.9999210834503174
state O 0 4.10705247588794e-09
is O 0 2.436370272196342e-10
compatible O 0 7.235333221444762e-09
with O 0 7.178038163857536e-10
normal O 0 1.5107056583474332e-07
coagulation O 0 1.7588902778697957e-07
function O 0 3.0175066001447703e-08
and O 0 2.2450257208816993e-09
the O 0 3.0335940426340358e-09
capacity O 0 3.6922287449669966e-08
to O 0 3.541479776103529e-09
mount O 0 1.2162120128778042e-06
a O 0 2.3349267053163203e-07
neutrophilic O 0 0.038622334599494934
leukocytosis O 0 0.004436453338712454
during O 0 9.313260670751333e-05
pyogenic B-Disease 0 0.1113526001572609
infection I-Disease 0 3.3355190680595115e-05
. O 0 1.1247700371086466e-07
. O 0 7.779737529745034e-07

Susceptibility O 0 0.009258106350898743
to O 0 0.00010208031017100438
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.02233312278985977
twins O 0 6.935986220923951e-06
: O 0 1.3476854077154599e-09
the O 0 1.4461477571003911e-09
role O 0 1.3026295597740045e-08
of O 0 2.0625664731710458e-08
genes O 0 1.1659959220367e-08
, O 0 1.0834932950842813e-08
HLA O 0 1.0789088946694392e-06
, O 0 1.2721119269087922e-08
and O 0 4.1773264847222435e-09
the O 0 9.322678806711338e-08
environment O 0 2.170298648707103e-05
. O 0 1.3128283171681687e-06

OBJECTIVE O 0 3.043180186068639e-05
To O 0 4.0941728229881846e-08
determine O 0 3.197942533006426e-08
the O 0 2.132284127043249e-09
relative O 0 1.6438637828741776e-07
effects O 0 1.627396272851911e-06
of O 0 4.730275549036378e-08
genetic O 0 4.324333247041068e-08
and O 0 1.0933390859335645e-09
environmental O 0 1.0220946755623572e-08
factors O 0 5.259185531514277e-09
in O 0 2.923244091235233e-09
susceptibility O 0 1.3935481320004328e-06
to O 0 4.704574166680686e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9743040800094604
AS B-Disease 1 0.9999994039535522
) O 0 3.077400947404385e-07
. O 0 6.169794914967497e-07

METHODS O 0 0.0006120812613517046
Twins O 0 5.5867562878120225e-06
with O 0 2.849397162663081e-08
AS B-Disease 1 0.9987307190895081
were O 0 2.000740551011404e-08
identified O 0 5.195119001655257e-09
from O 0 1.54632007198785e-09
the O 0 3.6108884771124394e-09
Royal O 0 1.7731517800712027e-06
National O 0 8.090742653621419e-07
Hospital O 0 0.0006406853208318353
for O 0 3.878847110172501e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.999998927116394
database O 0 4.1241921280743554e-05
. O 0 1.9371422240510583e-05

Clinical O 0 3.363747600815259e-05
and O 0 9.609205875449334e-08
radiographic O 0 1.0557494533713907e-05
examinations O 0 5.837139269715408e-06
were O 0 3.7643406614051855e-08
performed O 0 3.2635924185342446e-08
to O 0 9.981147019999526e-10
establish O 0 1.2505927315942245e-07
diagnoses O 0 1.8787526641972363e-05
, O 0 2.008897048710878e-08
and O 0 8.75699583957612e-08
disease O 0 0.0010280472924932837
severity O 0 7.3953938226622995e-06
was O 0 1.61481054306023e-07
assessed O 0 1.4829694805484905e-08
using O 0 1.4355562294454671e-09
a O 0 6.860575996192608e-10
combination O 0 6.4308212088803884e-09
of O 0 1.1437183644602555e-08
validated O 0 1.1934434951399453e-07
scoring O 0 6.00725797994528e-07
systems O 0 3.0409346436499618e-05
. O 0 1.3417226227829815e-06

HLA O 0 0.00010941922664642334
typing O 0 1.293957575398963e-05
for O 0 3.75316801637382e-07
HLA O 0 2.1834603103343397e-05
- O 0 7.684324373258278e-06
B27 O 0 2.8774420570698567e-06
, O 0 3.319865271578237e-08
HLA O 0 1.309489675804798e-06
- O 0 8.357153546967311e-07
B60 O 0 6.287638143476215e-07
, O 0 4.279114396155137e-09
and O 0 1.4848630769392912e-08
HLA O 0 7.03588011674583e-05
- O 0 0.0005493353819474578
DR1 O 1 0.9940357208251953
was O 0 9.105156095756683e-08
performed O 0 1.9827751884804456e-08
by O 0 8.097360559844446e-10
polymerase O 0 1.292933120566886e-07
chain O 0 1.1830256774203463e-08
reaction O 0 2.4320151448264937e-10
with O 0 1.9246383653470645e-10
sequence O 0 2.6958606458293843e-09
- O 0 1.9967938413856245e-09
specific O 0 4.6206324877395843e-10
primers O 0 3.7946460196280896e-08
, O 0 6.361354776274197e-10
and O 0 6.354660131435708e-10
zygosity O 0 3.32360997390424e-07
was O 0 3.7924898776964255e-08
assessed O 0 5.4556466011490556e-08
using O 0 4.9235985954965145e-08
microsatellite O 0 4.282449935999466e-06
markers O 0 1.5956003380779293e-06
. O 0 1.2020003623547382e-06

Genetic O 0 2.455423782521393e-06
and O 0 4.071092263302489e-08
environmental O 0 6.130134977411217e-08
variance O 0 9.385191290789408e-09
components O 0 2.703916663904238e-07
were O 0 8.805160156555303e-09
assessed O 0 2.157045386752543e-08
with O 0 4.983798373991988e-10
the O 0 1.8955668146247717e-09
program O 0 4.963972788374349e-09
Mx O 0 4.021675081844478e-08
, O 0 8.982294769088739e-11
using O 0 1.3024790967985922e-10
data O 0 3.986061480887315e-10
from O 0 9.383194915502102e-11
this O 0 1.3132098707069328e-11
and O 0 3.376864760040732e-11
previous O 0 7.155537828928971e-10
studies O 0 3.5834444300775203e-09
of O 0 7.902068333009993e-09
twins O 0 9.70539346667465e-08
with O 0 1.6500106170269646e-08
AS B-Disease 1 0.9999779462814331
. O 0 2.7123023755848408e-06

RESULTS O 0 2.1625239696732024e-06
Six O 0 2.9482959007509635e-07
of O 0 6.659721520918538e-07
8 O 0 7.84237818152178e-06
monozygotic O 0 2.1078038116684183e-05
( O 0 2.6576435629976913e-07
MZ O 0 0.000112577632535249
) O 0 1.4198479902916006e-07
twin O 0 1.6006571286197868e-06
pairs O 0 3.0117513460936607e-07
were O 0 5.561736884374113e-07
disease O 0 4.549075583781814e-06
concordant O 0 5.082928851152246e-07
, O 0 2.748842931055151e-09
compared O 0 9.736502271096015e-09
with O 0 1.6997782070760081e-09
4 O 0 7.443711780297235e-08
of O 0 3.932299108555526e-08
15 O 0 6.432271248968391e-08
B27 O 0 1.079164633210894e-07
- O 0 1.5290755328578598e-08
positive O 0 1.2480562139316476e-09
dizygotic O 0 6.215510666152113e-07
( O 0 2.076318139643263e-08
DZ O 0 7.507420377805829e-06
) O 0 2.2275090216794524e-08
twin O 0 1.5152969012888207e-07
pairs O 0 2.2117347953098943e-08
( O 0 4.014032661814326e-09
27 O 0 4.507319673052734e-08
% O 0 2.827372558300567e-09
) O 0 5.063343633260331e-10
and O 0 1.6803660685127397e-09
4 O 0 4.492282812407211e-08
of O 0 8.523586814135342e-08
32 O 0 1.6766648514021654e-06
DZ O 0 0.0003505525237414986
twin O 0 1.6328094716300257e-06
pairs O 0 6.107086392148631e-08
overall O 0 1.598529166813023e-07
( O 0 6.185675527348167e-09
12 O 0 1.126665516437697e-08
. O 0 4.337487868877332e-10
5 O 0 7.902325016573286e-09
% O 0 2.768627549443181e-09
) O 0 5.275782921643213e-09
. O 0 1.6336475994194188e-07

Nonsignificant O 0 0.00013117057096678764
increases O 0 1.813562420238668e-07
in O 0 5.50968692891729e-09
similarity O 0 2.7909381472568384e-09
with O 0 3.8236602772911965e-10
regard O 0 1.1712564251808999e-08
to O 0 2.5558239968859198e-09
age O 0 2.5206356895068893e-06
at O 0 0.0009195738239213824
disease O 0 0.001452714204788208
onset O 0 4.0884287955123e-06
and O 0 4.228083216872847e-09
all O 0 3.2976870123491153e-09
of O 0 4.691978361393012e-08
the O 0 1.1340620176270022e-07
disease O 0 4.509185771439661e-07
severity O 0 3.7822896814532214e-08
scores O 0 3.2490139467711288e-09
assessed O 0 4.193020153309135e-09
were O 0 1.0139951100995859e-09
noted O 0 1.414929062804049e-09
in O 0 5.49090817258957e-09
disease O 0 9.885239705909044e-06
- O 0 4.99644193041604e-06
concordant O 0 5.36031075171195e-05
MZ O 0 0.017474548891186714
twins O 0 2.4244372980319895e-06
compared O 0 2.781332568702055e-07
with O 0 8.485774571909133e-08
concordant O 0 0.00026638415874913335
DZ O 1 0.9685276746749878
twins O 0 0.00018524835468269885
. O 0 5.247452463663649e-06

HLA O 0 0.0018679428612813354
- O 0 0.00017728068633005023
B27 O 0 1.555908238515258e-05
and O 0 4.828883248819693e-08
B60 O 0 1.559765451020212e-06
were O 0 8.829815989486178e-09
associated O 0 5.695121263471492e-09
with O 0 3.3567282287094713e-10
the O 0 5.641058820060607e-08
disease O 0 3.823762654064922e-06
in O 0 3.2478058020757317e-09
probands O 0 1.1431598068156745e-06
, O 0 5.089932919588591e-10
and O 0 1.3407827625933066e-10
the O 0 8.033104736959729e-10
rate O 0 4.5418392602414315e-08
of O 0 3.712913354547709e-08
disease O 0 6.000627195135166e-07
concordance O 0 2.620740247039066e-08
was O 0 8.524216887906277e-09
significantly O 0 3.1983498072207794e-09
increased O 0 6.2001568323921674e-09
among O 0 5.376043166194222e-09
DZ O 0 1.317245278187329e-05
twin O 0 2.792005204810266e-07
pairs O 0 1.4834730777124605e-08
in O 0 4.959373356427932e-09
which O 0 1.0111965709214132e-09
the O 0 1.022898121760818e-08
co O 0 2.3007739855529508e-06
- O 0 3.4182534136562026e-07
twin O 0 1.31852061713289e-07
was O 0 4.3653290759948504e-08
positive O 0 4.1639128256498736e-10
for O 0 4.05356914701116e-10
both O 0 8.830657982628054e-09
B27 O 0 1.1408443469917984e-06
and O 0 1.7987987632750446e-07
DR1 O 0 0.2770650386810303
. O 0 1.0512719654798275e-06

Additive O 0 1.0478366903043934e-06
genetic O 0 4.1145392515318235e-07
effects O 0 3.05741104966728e-06
were O 0 1.294915641381067e-08
estimated O 0 9.769535180836897e-10
to O 0 2.9904484444287505e-10
contribute O 0 1.9275048224187685e-09
97 O 0 2.6980277567645317e-08
% O 0 1.3838881152139493e-09
of O 0 1.7164130117208742e-09
the O 0 9.328273709030555e-10
population O 0 5.907373895608359e-11
variance O 0 1.590271914153618e-08
. O 0 1.6321432383392676e-07

CONCLUSION O 0 5.7003189795068465e-06
Susceptibility O 0 4.251020527590299e-06
to O 0 5.373380673745487e-08
AS B-Disease 1 0.9983112812042236
is O 0 3.0692316244085305e-08
largely O 0 3.1647271470092164e-08
genetically O 0 5.1710862258858015e-09
determined O 0 5.65626834259092e-09
, O 0 3.1838257030791794e-10
and O 0 1.5592797886210263e-10
the O 0 1.2887549916129615e-09
environmental O 0 1.6651226175667944e-08
trigger O 0 6.72824285175011e-09
for O 0 1.0281770990161476e-09
the O 0 7.037114357899554e-08
disease O 0 2.5225370336556807e-05
is O 0 1.381193737159947e-08
probably O 0 1.568804322005235e-07
ubiquitous O 0 9.802148497328744e-07
. O 0 4.327856686359155e-07

HLA O 0 0.0004014477599412203
- O 0 1.549576518300455e-05
B27 O 0 1.953057562786853e-06
accounts O 0 3.097429202014723e-09
for O 0 1.0159523222696976e-09
a O 0 3.5161120681692637e-09
minority O 0 1.8492771758360504e-09
of O 0 1.2986627773159398e-08
the O 0 3.051079389138067e-08
overall O 0 3.2940997130026517e-07
genetic O 0 2.780733154850168e-07
susceptibility O 0 2.9360370490394416e-07
to O 0 2.6914026562963045e-08
AS B-Disease 1 0.9999876022338867
. O 0 9.368198334414046e-06

Cell O 0 9.127178054768592e-05
cycle O 0 1.8431883290759288e-06
- O 0 1.637857991454439e-07
dependent O 0 3.910585988364801e-08
colocalization O 0 1.3027832892476e-06
of O 0 1.0052149690409351e-07
BARD1 O 0 0.00011778670159401372
and O 0 1.5067481484720702e-08
BRCA1 O 0 1.440741392855216e-08
proteins O 0 1.4271585024872024e-09
in O 0 2.3867698928370373e-09
discrete O 0 2.442209847686172e-07
nuclear O 0 4.395123141875956e-06
domains O 0 2.0448512714210665e-06
. O 0 6.10906738529593e-07

Germ O 1 0.9998593330383301
- O 0 0.00012646769755519927
line O 0 1.8116761566489004e-06
mutations O 0 3.511402368872041e-08
of O 0 2.9241432386584165e-08
the O 0 9.836219305725535e-08
BRCA1 O 0 1.5437444744748063e-07
gene O 0 8.049784838704e-08
predispose O 0 4.894992571280454e-07
women O 0 7.811168600824203e-09
to O 0 3.1179736570408068e-09
early O 0 9.493147081229836e-05
- O 1 0.9995661377906799
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 4.5467623976946925e-07
compromising O 0 6.636416947003454e-05
the O 0 1.9290584418740764e-07
genes O 0 7.017116843144322e-08
presumptive O 0 2.669684363354463e-06
function O 0 2.592481962437887e-07
as O 0 1.874942334723073e-08
a O 0 6.395656271251937e-08
tumor B-Disease 0 1.1251470823481213e-05
suppressor O 0 3.0429362595896237e-05
. O 0 2.963158294733148e-06

Although O 0 2.8615977498702705e-07
the O 0 4.384630258869038e-08
biochemical O 0 7.504468726438063e-07
properties O 0 2.21641744246881e-06
of O 0 1.7375976995026576e-06
BRCA1 O 0 2.6595273538987385e-07
polypeptides O 0 4.815785459300059e-08
are O 0 5.388996471289431e-10
not O 0 1.6906075150924238e-10
understood O 0 3.630473255356037e-09
, O 0 1.4051683427940276e-10
their O 0 6.633735921690587e-11
expression O 0 6.716392442207564e-10
pattern O 0 7.1539312251900355e-09
and O 0 6.895090054470643e-10
subcellular O 0 2.700301138247596e-07
localization O 0 4.0806199308462965e-07
suggest O 0 5.095539989952158e-09
a O 0 1.3915586460910845e-09
role O 0 1.2195271459347623e-08
in O 0 1.2652277447955385e-08
cell O 0 4.097964847460389e-06
- O 0 5.511339509212121e-07
cycle O 0 1.9623914226940542e-07
regulation O 0 1.5052278286020737e-06
. O 0 3.1576399805999245e-07

When O 0 4.8960750973492395e-06
resting O 0 0.0004033175064250827
cells O 0 2.0099918174310005e-07
are O 0 3.016733973737473e-09
induced O 0 4.044128587565865e-08
to O 0 1.1379645004083727e-09
proliferate O 0 4.669310982308161e-08
, O 0 1.1886297501817467e-09
the O 0 1.651256464896278e-09
steady O 0 8.94681093654981e-08
- O 0 2.3411905747394712e-09
state O 0 2.3278844130114607e-10
levels O 0 4.069366621450854e-09
of O 0 1.3249809027726656e-09
BRCA1 O 0 4.672692233143039e-10
increase O 0 1.7149656694748217e-10
in O 0 4.424640098754651e-10
late O 0 3.4590737385542525e-08
G1 O 0 7.2964944308751e-08
and O 0 6.059774348976532e-10
reach O 0 1.8873989038326044e-09
a O 0 5.593056018327047e-10
maximum O 0 4.005749953961413e-09
during O 0 2.2646595709829853e-08
S O 0 8.298992497657309e-07
phase O 0 1.8861099988498609e-06
. O 0 4.46904635964529e-07

Moreover O 0 2.469269247740158e-06
, O 0 8.352286329227354e-08
in O 0 2.3259472570202888e-08
S O 0 9.983551763070864e-07
phase O 0 2.2068145426601404e-06
cells O 0 5.282189263766668e-08
, O 0 7.567971138655594e-09
BRCA1 O 0 1.6188961282637138e-08
polypeptides O 0 2.3186919051454424e-08
are O 0 2.916542840569747e-10
hyperphosphorylated O 0 6.802078900136621e-08
and O 0 1.2812794158989504e-09
accumulate O 0 1.2728206932877129e-08
into O 0 6.778582140043454e-09
discrete O 0 1.7527818840790133e-07
subnuclear O 0 2.9863304007449187e-06
foci O 0 6.049079729564255e-06
termed O 0 7.11070015313453e-07
" O 0 3.146781750729133e-07
BRCA1 O 0 1.0491726243344601e-06
nuclear O 0 1.625380537007004e-05
dots O 0 6.013459369569318e-06
. O 0 7.365090368693927e-07

" O 0 2.219382076873444e-05
BRCA1 O 0 1.1082085620728321e-05
associates O 0 1.5643012375221588e-05
in O 0 8.284854402518249e-08
vivo O 0 7.041907110760803e-07
with O 0 6.225242987767388e-09
a O 0 2.143327577641685e-07
structurally O 0 0.0002403381367912516
related O 0 8.36755680211354e-06
protein O 0 8.543680451111868e-06
termed O 0 9.112867701333016e-06
BARD1 O 0 0.0012011290527880192
. O 0 3.991287485405337e-06

Here O 0 4.2778942770382855e-06
we O 0 1.4538709081080015e-07
show O 0 4.853315260788804e-08
that O 0 6.491895354621136e-10
the O 0 2.6719646495365623e-09
steady O 0 9.6584145126144e-08
- O 0 1.8084451713917815e-09
state O 0 1.5790507790214292e-10
levels O 0 4.872549475010146e-09
of O 0 4.517766605260931e-09
BARD1 O 0 1.5972171922840062e-06
, O 0 7.717173011734246e-10
unlike O 0 8.474201895758426e-10
those O 0 4.168807798965446e-10
of O 0 6.451289280562378e-09
BRCA1 O 0 9.806991663197095e-09
, O 0 1.740890542833995e-09
remain O 0 1.3791956909869896e-08
relatively O 0 4.4775672058960936e-09
constant O 0 1.1608478622804341e-08
during O 0 3.372531409695512e-08
cell O 0 4.833195248465927e-07
cycle O 0 7.873261864688175e-08
progression O 0 6.77134778470645e-07
. O 0 1.7955784414880327e-07

However O 0 2.9073373752908083e-06
, O 0 2.5040409923349216e-07
immunostaining O 0 9.986608347389847e-06
revealed O 0 5.89531623518269e-07
that O 0 5.911505063238565e-09
BARD1 O 0 5.471049735206179e-05
resides O 0 1.694739125923661e-06
within O 0 3.109880708507262e-07
BRCA1 O 0 3.391594134427578e-07
nuclear O 0 4.8385545596829616e-06
dots O 0 2.289225875529155e-07
during O 0 8.43376852799338e-08
S O 0 2.2688604417453462e-07
phase O 0 9.325542293936451e-08
of O 0 7.592912076859193e-09
the O 0 5.401080027667149e-09
cell O 0 1.3114951968873356e-07
cycle O 0 3.4735776477390345e-09
, O 0 2.2586353620734911e-10
but O 0 8.292778963525649e-11
not O 0 1.562495133278219e-10
during O 0 5.81288883694242e-09
the O 0 9.066628336995564e-09
G1 O 0 1.0587122005745186e-06
phase O 0 2.279255795656354e-06
. O 0 3.39364532919717e-07

Nevertheless O 0 3.7501376937143505e-05
, O 0 8.493529435327218e-07
BARD1 O 0 3.195790486643091e-05
polypeptides O 0 2.4512331719961367e-07
are O 0 9.717907589745778e-10
found O 0 1.2895761125619742e-09
exclusively O 0 3.55699580900648e-09
in O 0 4.933680131102847e-10
the O 0 1.3006328236642162e-09
nuclear O 0 5.6340262233334215e-08
fractions O 0 7.05167657599759e-09
of O 0 4.05868494368633e-09
both O 0 3.2772582425621977e-09
G1 O 0 6.173044084789581e-07
- O 0 5.621338772243689e-08
and O 0 5.546020087621173e-09
S O 0 1.754219510985422e-06
- O 0 2.527490892134665e-07
phase O 0 1.78465040789888e-06
cells O 0 1.45407057061675e-07
. O 0 9.851802929006226e-08

Therefore O 0 4.371388513391139e-06
, O 0 1.3015620936585037e-07
progression O 0 6.224734647730656e-07
to O 0 9.202418382869837e-09
S O 0 1.467960828449577e-06
phase O 0 8.84115934240981e-07
is O 0 7.657891543111361e-10
accompanied O 0 1.1374133856989488e-09
by O 0 1.5611269221782464e-11
the O 0 3.4726085895719905e-10
aggregation O 0 3.6993113017302903e-09
of O 0 2.099980100922494e-08
nuclear O 0 5.6672110986255575e-06
BARD1 O 0 9.620053788239602e-06
polypeptides O 0 1.694033215926538e-07
into O 0 1.1181199965903943e-07
BRCA1 O 0 7.352149964390264e-07
nuclear O 0 1.1911927686014678e-05
dots O 0 3.003192432515789e-06
. O 0 5.903305009269388e-07

This O 0 1.4037840401215362e-07
cell O 0 2.058854079223238e-06
cycle O 0 9.88332828910643e-08
- O 0 3.826786709737462e-08
dependent O 0 9.872546335998322e-09
colocalization O 0 5.556949531637656e-07
of O 0 7.747768648869169e-08
BARD1 O 0 0.0001819403696572408
and O 0 2.272790489143972e-08
BRCA1 O 0 1.959742590429414e-08
indicates O 0 1.0117990001390353e-08
a O 0 1.4461202235693804e-09
role O 0 7.395903001139459e-09
for O 0 5.152783089101831e-09
BARD1 O 0 4.605228241416626e-05
in O 0 1.8997289430444653e-07
BRCA1 O 0 2.254412720503751e-06
- O 0 1.3576777746493462e-05
mediated O 0 0.00013507221592590213
tumor B-Disease 0 0.06911196559667587
suppression O 0 0.027500657364726067
. O 0 8.90395949681988e-06

Ethnic O 0 7.363011604866188e-07
differences O 0 2.654264790180605e-06
in O 0 6.915234962434624e-08
the O 0 1.3173855961667869e-07
HFE O 0 1.5132740372791886e-05
codon O 0 4.591749984683702e-07
282 O 0 3.2954299058474135e-06
( O 0 2.9356413051573327e-06
Cys O 0 0.46190500259399414
/ O 0 0.0015209101838991046
Tyr O 0 0.00015808219905011356
) O 0 8.670593274473504e-07
polymorphism O 0 1.3946070794190746e-05
. O 0 5.070624411018798e-06

Recent O 0 1.424793509841038e-07
studies O 0 1.0783127635249912e-07
have O 0 2.509446650478253e-09
shown O 0 3.651350510835982e-08
that O 0 1.605376525048996e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.32856056094169617
HH B-Disease 1 0.9992966651916504
) O 0 8.641760729233283e-08
is O 0 2.7878099828626546e-09
likely O 0 1.95014382420311e-09
to O 0 2.9558003267204924e-10
be O 0 1.9264683182029785e-09
caused O 0 7.308956995188964e-09
by O 0 4.3122952431140504e-10
homozygosity O 0 1.8426453607389703e-07
for O 0 1.690485973426803e-09
a O 0 4.539091769117931e-09
Cys282Tyr O 0 1.6604327868208202e-07
mutation O 0 1.2957795947343698e-09
in O 0 2.0320567450937688e-09
the O 0 3.665571313149485e-08
HFE O 0 1.4849196304567158e-05
gene O 0 3.198526030701032e-07
located O 0 6.928634093128494e-07
4 O 0 2.55508075497346e-06
. O 0 9.521575634607871e-07

5 O 0 9.15553537197411e-05
Mb O 0 0.0005949230981059372
telomeric O 0 0.0001641647977521643
to O 0 3.2302518775395583e-06
HLA O 0 0.001380735426209867
- O 0 0.0001354301202809438
A O 0 1.9974588212789968e-05
. O 0 4.8644546950527e-06

Population O 0 9.831714109509448e-09
studies O 0 2.0891652852128573e-08
of O 0 6.665958895979429e-09
this O 0 4.566251543547395e-10
polymorphism O 0 1.3239280782784135e-08
are O 0 1.0531112093481454e-10
facilitated O 0 1.095765034264673e-09
by O 0 4.7846396983297623e-11
the O 0 9.641177856067884e-10
fact O 0 5.805428915373056e-10
that O 0 4.151990556922058e-11
the O 0 1.2639872482012038e-09
Cys282Tyr O 0 2.409925343727082e-07
mutation O 0 2.4094983785971635e-09
creates O 0 4.329794300872436e-09
a O 0 3.8916252442788846e-09
Rsal O 0 4.782521045854082e-07
restriction O 0 6.251779893773346e-08
site O 0 1.3160683920432348e-07
. O 0 2.3053307529607991e-07

We O 0 4.7134338387877506e-07
have O 0 6.881495817623318e-09
studied O 0 9.64574837780674e-08
the O 0 7.125333656432531e-09
codon O 0 3.474546872439532e-08
282 O 0 2.83686034663333e-07
( O 0 6.125740696916182e-07
Cys O 0 0.04359458386898041
/ O 0 0.00012164159124949947
Tyr O 0 5.859639259142568e-06
) O 0 9.703242653813504e-09
polymorphism O 0 4.1655766835901886e-08
in O 0 1.8731256545834185e-09
different O 0 9.207224427321137e-10
ethnic O 0 1.839288010785367e-08
groups O 0 4.662918495768054e-09
. O 0 1.625387966441849e-07

In O 0 3.511245836307353e-07
agreement O 0 2.2273864885846706e-07
with O 0 5.605104824724094e-09
previous O 0 6.137879893231002e-08
observations O 0 1.0911650605294199e-07
the O 0 2.7703878302531848e-08
Tyr O 0 4.853635005019896e-07
allele O 0 1.779234182208711e-08
appeared O 0 3.8493631393521355e-08
to O 0 3.7789762985518394e-10
be O 0 8.306967891336114e-10
rare O 0 1.7085348691381341e-09
or O 0 2.0930290833831577e-09
absent O 0 5.854349538481074e-08
in O 0 5.181808315768421e-09
Asiatic O 0 6.182481371297399e-08
( O 0 2.060374232337736e-10
Indian O 0 3.9707179211312393e-10
, O 0 1.6944427805309914e-10
Chinese O 0 1.4400977077499988e-09
) O 0 4.757986782344403e-10
populations O 0 2.514227936956104e-09
. O 0 1.0232595570869307e-07

The O 0 2.715092648486461e-07
highest O 0 3.296940747077315e-07
allele O 0 1.1031997537713778e-08
frequency O 0 8.56700665963217e-08
( O 0 2.3230908308136122e-09
7 O 0 1.364868040809597e-08
. O 0 3.7438152578062045e-10
5 O 0 7.347254804557224e-09
% O 0 9.951093282722923e-10
) O 0 4.999450298193153e-10
was O 0 3.459271624706162e-08
found O 0 6.4038685465561684e-09
in O 0 1.7125943330142945e-08
Swedes O 0 5.492510354088154e-06
. O 0 1.39576275159925e-06

Saamis O 0 0.0001706394541542977
( O 0 4.2980528291991504e-07
2 O 0 1.043586394189333e-06
% O 0 1.2108770874874608e-08
) O 0 2.337536164631615e-09
and O 0 7.946944435843761e-09
Mordvinians O 0 3.4967001738550607e-06
( O 0 6.647105088575245e-09
1 O 0 2.7546754211016378e-08
. O 0 3.13483600189457e-10
8 O 0 8.806201101663191e-09
% O 0 6.408263919510659e-10
) O 0 4.2677822387204856e-10
had O 0 1.2361184298370631e-09
significantly O 0 3.250935742826755e-09
lower O 0 2.000263599200025e-08
frequencies O 0 2.800260467950011e-08
of O 0 6.542840935708227e-09
the O 0 1.5584785018063485e-08
Tyr O 0 1.4722423884450109e-06
allele O 0 2.2891188677931495e-07
. O 0 3.939134671782085e-07

Comparisons O 0 6.110011554483208e-07
with O 0 1.2083069655943746e-08
allele O 0 1.3453234082305698e-08
frequencies O 0 4.465867320391226e-08
based O 0 2.6779443107471934e-09
on O 0 6.833963173136226e-09
prevalence O 0 3.836214190755527e-08
estimates O 0 2.5869328901251265e-09
of O 0 1.2886376410392586e-08
HH B-Disease 0 0.0009923467878252268
showed O 0 1.0116312978425412e-06
some O 0 2.817445388103579e-09
disagreements O 0 1.2087475909083878e-07
with O 0 1.6941203995202159e-09
the O 0 8.543146634565346e-09
RFLP O 0 1.1718265113813686e-07
data O 0 1.6609041253445866e-08
, O 0 2.362146256373876e-09
particularly O 0 8.654209793235168e-09
in O 0 1.1390290488577648e-08
Finns O 0 2.7350799882697174e-06
. O 0 8.574752428103238e-07

The O 0 1.6173210042325081e-06
newly O 0 7.878480573708657e-06
described O 0 1.6531566870980896e-06
HFE O 0 4.386451837490313e-05
marker O 0 6.713336802022241e-07
provides O 0 2.3351574895968952e-08
a O 0 3.235569590032128e-09
new O 0 1.806700677953188e-09
approach O 0 4.6289705402102754e-09
to O 0 3.717253449497804e-10
the O 0 1.910827718276664e-09
screening O 0 1.5219583815451188e-08
of O 0 2.2185201231650353e-08
HH B-Disease 0 1.0043359907285776e-05
as O 0 8.112591487474674e-09
well O 0 1.7948509345444563e-09
as O 0 4.232325323538788e-10
studies O 0 3.746274401805749e-09
of O 0 5.95502891442834e-09
the O 0 7.54905649102966e-09
relationship O 0 8.785302441083331e-08
between O 0 1.4506730394714396e-07
the O 0 7.239256660795945e-08
HFE O 0 2.979276905534789e-05
Tyr O 0 1.131970748247113e-06
allele O 0 2.711399282873117e-08
and O 0 4.5040344787139475e-09
different O 0 1.847922987963102e-07
disorders O 1 0.9999936819076538
including O 0 0.0001469663402531296
cancer B-Disease 1 0.9999991655349731

Autosomal B-Disease 1 0.9998138546943665
dominant I-Disease 1 0.9999994039535522
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.622429370880127
associated O 0 9.679620234237518e-07
with O 0 1.1128387988890154e-08
a O 0 2.084210848352086e-07
missense O 0 3.7609177638842084e-07
mutation O 0 6.700734189735158e-09
encoding O 0 2.1635273128595145e-07
Gly23 O 0 1.632636849535629e-05
- O 0 6.017549821990542e-06
- O 0 3.7657700886484236e-06
> O 0 1.7828166392064304e-06
Val O 0 4.927233931084629e-06
in O 0 7.448398520182309e-08
neurophysin O 0 0.00016700623382348567
II O 1 0.9999713897705078
. O 0 3.1589694117428735e-05

Autosomal B-Disease 1 0.9998399019241333
dominant I-Disease 1 0.9999995231628418
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999967813491821
( O 0 1.0077899787575006e-05
ADNDI B-Disease 1 0.9273115992546082
) O 0 4.8300162092118626e-08
is O 0 1.3786144670291378e-08
an O 0 2.9979534588164825e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.1459551751613617
by O 0 2.1257923776829557e-07
progressive O 1 0.999998927116394
degeneration O 1 0.9999997615814209
of O 0 0.00024029416090343148
the O 0 3.567236853996292e-05
magnocellular O 0 0.1940205693244934
neurons O 0 3.959592959290603e-06
of O 0 4.0954699898065883e-07
the O 0 2.608617535315716e-07
hypothalamus O 0 1.1912311492778827e-06
leading O 0 2.0811182821489638e-07
to O 0 5.13504483379279e-09
decreased O 0 2.949468864699156e-07
ability O 0 6.621733383838091e-09
to O 0 1.3297024592517914e-09
produce O 0 3.825996408579613e-09
the O 0 1.6819189596617434e-08
hormone O 0 9.116190824443038e-08
arginine O 0 4.165804057265632e-07
vasopressin O 0 5.4834349612065125e-06
( O 0 2.6333680125389947e-07
AVP O 0 2.431247958156746e-05
) O 0 4.3535717964005016e-07
. O 0 1.4285420775195234e-06

Affected O 0 2.477635803188605e-07
individuals O 0 2.2192638837736922e-09
are O 0 1.8621396646878452e-09
not O 0 2.4261415099147143e-09
symptomatic O 0 2.437972170810099e-07
at O 0 2.0502589848092612e-07
birth O 0 2.0951828716420096e-08
, O 0 9.763239106064248e-10
but O 0 6.11564798802533e-10
usually O 0 1.3373718132925205e-08
develop O 0 9.18712521524867e-06
diabetes B-Disease 1 0.9999687671661377
insipidus I-Disease 0 5.191387390368618e-05
at O 0 1.4686534086649772e-05
1 O 0 1.921081820910331e-05
- O 0 2.6722418624558486e-06
6 O 0 2.955329591713962e-06
yr O 0 1.1484570677566808e-05
of O 0 2.1729978527673666e-07
age O 0 4.676263870351249e-06
. O 0 2.562987901910674e-06

The O 0 4.009838221463724e-07
genetic O 0 1.856867157812303e-07
locus O 0 9.062222972033851e-08
of O 0 1.5039408651773556e-07
the O 0 3.771725687329308e-07
disease O 0 1.4601318980567157e-05
is O 0 6.333294777505216e-09
the O 0 1.1036652836082794e-07
AVP O 0 0.0020858689676970243
- O 0 0.0007252796785905957
neurophysin O 0 0.004198111593723297
II O 1 0.9999995231628418
( O 0 5.125897928337508e-07
NPII O 0 2.858551852114033e-05
) O 0 3.413729299239776e-09
gene O 0 3.1886284723725566e-09
, O 0 1.2290631845601752e-09
and O 0 2.5071404952115017e-09
mutations O 0 3.4976661567043266e-08
that O 0 5.525873536527115e-09
cause O 0 8.579292511967651e-07
ADNDI B-Disease 0 0.03959166258573532
have O 0 7.875991414607597e-09
been O 0 1.6238959066328107e-09
found O 0 1.896271056844867e-10
in O 0 4.172910628152948e-11
both O 0 6.116368522768312e-11
the O 0 4.742854997630275e-10
signal O 0 1.6195476959524058e-08
peptide O 0 1.7457985057589553e-09
of O 0 3.6626133237405156e-09
the O 0 1.728622400776203e-08
prepro O 0 1.6748346752137877e-05
- O 0 8.738441465538926e-06
AVP O 0 9.197993495035917e-05
- O 0 6.414001290977467e-06
NPII O 0 0.000359362835297361
precursor O 0 6.743515314155957e-06
and O 0 3.605329723654904e-08
within O 0 1.590002796092449e-07
NPII O 0 0.00016999342187773436
itself O 0 6.533328473778965e-07
. O 0 3.7853720868952223e-07

An O 0 2.4460419467686734e-07
affected O 0 5.513347787200473e-07
girl O 0 9.141296573034197e-07
who O 0 1.2427122442204563e-08
presented O 0 5.046014450726943e-08
at O 0 2.52448927540172e-07
9 O 0 3.484993271740677e-08
months O 0 1.126961635122825e-09
of O 0 3.205495424651872e-09
age O 0 2.4497740724882533e-08
and O 0 3.166277462440803e-09
her O 0 4.999137992456326e-09
similarly O 0 6.849309119871805e-09
affected O 0 4.002893572163657e-09
younger O 0 3.366194789578003e-08
brother O 0 6.429254284512353e-08
and O 0 9.317911775497123e-09
father O 0 7.583030026125925e-08
were O 0 2.5723311480874145e-08
all O 0 1.3792370578968871e-09
found O 0 5.486215370886782e-10
to O 0 4.3940420746402253e-11
have O 0 7.971726750932717e-11
a O 0 6.689697129580452e-10
novel O 0 1.3030910794853412e-09
missense O 0 6.745242586703171e-09
mutation O 0 3.8403394353458964e-10
( O 0 2.0833506031436855e-09
G1758 O 0 2.2033039215330064e-07
- O 0 2.7821656090054603e-07
- O 0 4.2697976709860086e-07
> O 0 8.864208922432226e-08
T O 0 4.4502471041596436e-08
) O 0 2.420575129225e-10
encoding O 0 1.7205921132301683e-09
the O 0 1.1432205182515531e-09
amino O 0 2.3245445568420564e-09
acid O 0 4.291701660719127e-09
substitution O 0 3.554345795464542e-08
Gly23 O 0 3.8155085348989815e-06
- O 0 1.0535703722780454e-06
- O 0 7.594782118758303e-07
> O 0 8.981910468719434e-07
Val O 0 3.1899826353765093e-06
within O 0 3.9505451354671095e-07
NPII O 0 0.0004484102828428149
. O 0 3.0238211365940515e-06

The O 0 7.380010060842324e-07
mutation O 0 7.589165562649214e-08
was O 0 8.334415468880252e-08
confirmed O 0 3.336775300510908e-09
by O 0 2.4309576573955383e-10
restriction O 0 1.0360894364680462e-08
endonuclease O 0 2.5555482352501713e-07
analysis O 0 1.0566820662916143e-07
. O 0 5.345586373550759e-07

A O 0 0.00012580199108924717
T1 O 0 0.0018314108019694686
- O 0 4.05960122407123e-07
weighted O 0 4.4823032396834606e-08
magnetic O 0 1.0988970444714141e-07
resonance O 0 1.5736621605810797e-07
imaging O 0 2.977176791318925e-06
of O 0 1.6960683524303022e-07
the O 0 9.675577530288137e-07
fathers O 0 2.5961612664104905e-06
pituitary O 0 3.66907988791354e-05
gland O 0 2.2841497411718592e-05
demonstrates O 0 2.3611082724528387e-06
an O 0 1.2248857217400655e-07
attenuated O 0 2.1236954125924967e-05
posterior O 0 9.169812983600423e-05
pituitary O 0 0.012814867310225964
bright O 0 0.00019511058053467423
spot O 0 6.094309355830774e-05
. O 0 5.154603059054352e-06

This O 0 1.0099773106730936e-07
mutation O 0 1.3544537580401084e-07
may O 0 1.9320625099794597e-08
be O 0 1.4276350102093716e-09
valuable O 0 1.037952745974735e-08
for O 0 6.559005560902165e-10
developing O 0 9.48248235488336e-09
models O 0 1.5053636559514416e-08
of O 0 3.830328978438047e-07
dominantly B-Disease 1 0.999823272228241
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 2.0037388992477645e-07
as O 0 7.020354075848445e-09
the O 0 2.863878023617872e-09
early O 0 2.2658650067342023e-08
age O 0 1.1288008039400665e-07
of O 0 2.2659996545826289e-07
onset O 0 0.45706725120544434
of O 0 0.00019827795040328056
symptoms O 1 0.8257657885551453
suggests O 0 1.2562060192067293e-07
that O 0 5.076591369501671e-10
this O 0 2.3531696036194205e-10
mutation O 0 2.7941873259607064e-09
may O 0 3.2358471457882843e-09
be O 0 9.041997151015835e-10
particularly O 0 2.1333133037870766e-09
deleterious O 0 2.786801367449243e-08
to O 0 1.6609983388704563e-09
the O 0 4.8327532198300105e-08
magnocellular O 0 1.0057919098471757e-05
neuron O 0 1.6359829260181868e-06
. O 0 4.4973582191687456e-08
. O 0 2.8278711283746816e-07

Frequent O 0 2.8177078092994634e-06
inactivation O 0 0.00014374015154317021
of O 0 7.544422260252759e-05
PTEN O 1 0.9943442344665527
/ O 0 0.0623544380068779
MMAC1 O 0 0.3064342141151428
in O 0 2.4423386548733106e-06
primary O 1 0.999980092048645
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.001099094282835722

Sporadic B-Disease 1 0.9999985694885254
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 3.84015675081173e-06
the O 0 1.1148830481033656e-07
most O 0 1.0669211292224645e-08
common O 0 1.3589109926215315e-07
male B-Disease 0 4.911770247417735e-06
cancer I-Disease 0 1.9777366105699912e-05
in O 0 2.25261445052638e-08
the O 0 4.7279844039849195e-08
Western O 0 5.423410698313091e-07
world O 0 7.012725511401641e-09
, O 0 1.8480492136596638e-10
yet O 0 3.328840258998156e-10
many O 0 2.4082737540287447e-11
of O 0 5.54138568364948e-10
the O 0 6.424639154012368e-10
major O 0 8.303914889040698e-09
genetic O 0 6.150393527803999e-09
events O 0 6.694317877808942e-10
involved O 0 2.0065293870885625e-09
in O 0 6.395491358723859e-10
the O 0 3.484327271152665e-09
progression O 0 3.5267265729999053e-07
of O 0 1.926866310952846e-08
this O 0 3.2321894050113542e-09
often O 0 2.0292252145281964e-07
fatal O 0 0.00020250001398380846
cancer B-Disease 0 3.56954442395363e-05
remain O 0 6.896200943629083e-07
to O 0 2.001809562557355e-08
be O 0 1.6786954404324206e-07
elucidated O 0 0.00014783085498493165
. O 0 2.1616351659758948e-06

Numerous O 0 1.1957315564359305e-06
cytogenetic O 0 7.254382217070088e-05
and O 0 1.1628981155809015e-07
allelotype O 0 9.84095167950727e-05
studies O 0 5.34769753812725e-07
have O 0 3.4174296725808517e-09
reported O 0 6.975505950634897e-09
frequent O 0 3.7678149489295265e-09
loss O 0 4.95919607601536e-08
of O 0 5.965678724351164e-07
heterozygosity O 0 0.2068244218826294
on O 0 5.4321677453117445e-05
chromosomal O 0 0.005093337967991829
arm O 0 0.00012645311653614044
10q O 0 4.1156275983667e-05
in O 0 9.67808773566503e-07
sporadic B-Disease 1 0.9998067021369934
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0009657411719672382

Deletion O 0 7.4616459642129485e-06
mapping O 0 2.304997451574309e-06
studies O 0 1.0923165660869927e-07
have O 0 1.4352714572396508e-09
unambiguously O 0 3.947659621417188e-08
identified O 0 1.840144214781958e-08
a O 0 8.917861116231052e-09
region O 0 8.674838625211123e-08
of O 0 1.7471143110014964e-07
chromosome O 0 8.000509978955961e-07
10q23 O 0 1.9224083303015504e-07
to O 0 1.440103258865122e-09
be O 0 1.1224351448291259e-09
the O 0 1.9173260756844e-09
minimal O 0 1.0492490787328279e-07
area O 0 3.5139684939622384e-08
of O 0 1.2030986340505478e-07
loss O 0 4.821437869395595e-06
. O 0 3.875264155794866e-06

A O 0 3.835479219560511e-06
new O 0 2.7628323095996166e-07
tumor B-Disease 0 7.95876985648647e-06
suppressor O 0 3.7096119740454014e-06
gene O 0 7.178563805609883e-07
, O 0 6.593555212930369e-07
PTEN O 0 0.001983754336833954
/ O 0 0.0012004747986793518
MMAC1 O 1 0.8147832751274109
, O 0 1.9054462541134853e-07
was O 0 8.326548481818463e-07
isolated O 0 9.903084219331504e-08
recently O 0 2.0840829506596492e-08
at O 0 2.0352421969960233e-08
this O 0 2.1927884508166073e-10
region O 0 9.62088453348997e-09
of O 0 1.791602599610087e-08
chromosome O 0 9.436836734266763e-08
10q23 O 0 1.419547288605827e-07
and O 0 1.1060921067951313e-09
found O 0 7.736833951277333e-10
to O 0 1.529855686577264e-10
be O 0 3.175262830446002e-10
inactivated O 0 5.907086819689766e-09
by O 0 4.927301622270619e-11
mutation O 0 1.0237993786077482e-09
in O 0 3.512432344976446e-09
three O 0 1.6377032352465903e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999638795852661
lines O 0 4.625958899850957e-05
. O 0 9.208267215399246e-07

We O 0 1.4871865232635173e-06
screened O 0 1.3918421245762147e-05
80 O 0 1.5519399312324822e-05
prostate B-Disease 1 0.9997535347938538
tumors I-Disease 1 0.9999995231628418
by O 0 9.995954286523556e-09
microsatellite O 0 9.360271064906556e-07
analysis O 0 2.3202048282655596e-08
and O 0 6.1370935000581994e-09
found O 0 1.956709638761822e-08
chromosome O 0 9.827255098571186e-08
10q23 O 0 8.392849082383691e-08
to O 0 1.3861969350159598e-09
be O 0 2.9465312412213507e-09
deleted O 0 2.667866638716987e-08
in O 0 5.323514074007107e-09
23 O 0 1.4182673169216287e-07
cases O 0 6.136733077255485e-08
. O 0 1.607285327054342e-07

We O 0 1.2455619753382052e-06
then O 0 7.676646873733262e-08
proceeded O 0 3.764469624911726e-08
with O 0 3.7396474805717617e-10
sequence O 0 2.353462535964468e-09
analysis O 0 3.2861775522974312e-09
of O 0 5.345226483655097e-09
the O 0 3.659437908254404e-08
entire O 0 7.4042295636900235e-06
PTEN O 0 0.000439669587649405
/ O 0 2.328604387002997e-05
MMAC1 O 0 4.356795034254901e-05
coding O 0 3.831939920928562e-06
region O 0 1.0716041742853122e-07
and O 0 1.7652120876121558e-09
tested O 0 6.661891926995622e-09
for O 0 8.182127197997602e-10
homozygous O 0 4.701884215307928e-09
deletion O 0 2.038859570063778e-08
with O 0 1.0417284812547223e-09
new O 0 2.3662826365011824e-08
intragenic O 0 2.1280307009874377e-06
markers O 0 6.25285352384708e-08
in O 0 3.010434346251145e-09
these O 0 9.546937684845602e-10
23 O 0 2.0510288578634572e-08
cases O 0 8.970656995010984e-10
with O 0 1.7856315315256666e-09
10q23 O 0 2.384610979788704e-06
loss O 0 1.4197386235537124e-06
of O 0 1.59447081387043e-05
heterozygosity O 1 0.9045076370239258
. O 0 1.925380820466671e-05

The O 0 6.17948643366617e-08
identification O 0 3.2766720892141166e-08
of O 0 3.881648780179603e-08
the O 0 2.4718717739347085e-08
second O 0 1.4814632720572263e-07
mutational O 0 4.0478607843397185e-07
event O 0 2.824872780138321e-08
in O 0 1.158330853456846e-08
10 O 0 2.4520272035033486e-08
( O 0 3.887322463924647e-09
43 O 0 9.777745901828894e-08
% O 0 4.2126663402086706e-07
) O 0 4.336034180596471e-06
tumors B-Disease 1 1.0
establishes O 0 0.18423216044902802
PTEN O 1 0.992324948310852
/ O 0 0.009072523564100266
MMAC1 O 0 0.000625354761723429
as O 0 9.330435091214895e-08
a O 0 1.1327116133941217e-08
main O 0 8.743276680434064e-08
inactivation O 0 5.873272925782658e-07
target O 0 1.793948278816515e-08
of O 0 5.517766865636986e-08
10q O 0 1.2311447790125385e-06
loss O 0 4.4979844915360445e-07
in O 0 3.8283860703813843e-07
sporadic B-Disease 1 0.9998558759689331
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.790454456975567e-06
. O 0 3.1691117783338996e-06

Risk O 0 2.764514647424221e-05
reversals O 0 7.293832823052071e-06
in O 0 1.556013273784629e-08
predictive O 0 1.96731207324774e-07
testing O 0 2.4211922777794825e-07
for O 0 3.920940798707306e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 7.859782635932788e-05

The O 0 7.89112206689424e-08
first O 0 1.2133670068692481e-08
predictive O 0 6.934914864586972e-08
testing O 0 7.721332195842479e-08
for O 0 6.120868874859298e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.596955823719327e-07
HD B-Disease 0 0.00011554986122064292
) O 0 3.2184095388743117e-09
was O 0 5.627149857190261e-09
based O 0 1.3765162620860139e-10
on O 0 3.732578413018217e-10
analysis O 0 4.700393407830461e-10
of O 0 4.037105760801296e-09
linked O 0 4.7057085339474725e-08
polymorphic O 0 2.9028930370600392e-08
DNA O 0 3.162718087423855e-08
markers O 0 1.075514788340115e-08
to O 0 4.081802396083134e-10
estimate O 0 2.2975417124371234e-09
the O 0 1.1141975120310121e-09
likelihood O 0 1.843087815700528e-08
of O 0 1.71860214948083e-08
inheriting O 0 7.957276437764449e-08
the O 0 7.393984535752907e-09
mutation O 0 2.880916394332189e-09
for O 0 1.2133114957180169e-08
HD B-Disease 0 0.0002318342449143529
. O 0 2.097179503834923e-06

Limits O 0 6.318607006505772e-07
to O 0 2.1140740713576633e-08
accuracy O 0 5.254095185591723e-07
included O 0 7.369349219743526e-08
recombination O 0 7.315180283740119e-08
between O 0 4.4765190665430055e-08
the O 0 1.7710338084953037e-08
DNA O 0 7.669446233649069e-08
markers O 0 2.882951832816616e-08
and O 0 2.1172810171776746e-09
the O 0 1.1486196882515287e-08
mutation O 0 9.537370004863988e-09
, O 0 7.25257676137403e-09
pedigree O 0 3.8172807137470954e-08
structure O 0 1.3527807141144876e-07
, O 0 3.119103864079875e-09
and O 0 7.06147085249853e-10
whether O 0 8.062669420993984e-10
DNA O 0 1.9205323997795176e-09
samples O 0 4.3724579512627315e-10
were O 0 2.90244717149335e-10
available O 0 4.713959222968356e-10
from O 0 2.6486188797747445e-09
family O 0 1.7767103344112911e-09
members O 0 4.571979683731797e-09
. O 0 2.4044433644121455e-07

With O 0 3.119397007367297e-08
direct O 0 2.2793196663428716e-08
tests O 0 2.675759169790126e-09
for O 0 1.007258165763858e-09
the O 0 5.30780885910076e-09
HD B-Disease 0 2.3011862140265293e-05
mutation O 0 2.199256776691527e-09
, O 0 4.26706558975809e-10
we O 0 6.796236906581044e-10
have O 0 7.116810613050362e-11
assessed O 0 2.732085224721459e-09
the O 0 2.0683831036816258e-10
accuracy O 0 4.213286608489852e-09
of O 0 4.797764963093698e-10
results O 0 2.3731325238252055e-10
obtained O 0 1.5734116232124506e-09
by O 0 2.7722826811960033e-10
linkage O 0 4.67199257059292e-08
approaches O 0 1.1857863135844582e-08
when O 0 1.454152354085636e-09
requested O 0 3.2297244878520814e-09
to O 0 1.0665320848701754e-09
do O 0 9.757914476438145e-10
so O 0 2.42361519742218e-10
by O 0 6.47193826308623e-11
the O 0 9.375435983116631e-10
test O 0 2.9148423674740798e-09
individuals O 0 1.0606470146612423e-09
. O 0 1.4400536940684106e-07

For O 0 1.3340526550109644e-07
six O 0 1.7946190311590726e-08
such O 0 2.297243728577314e-09
individuals O 0 3.21367238376169e-10
, O 0 1.1015948153669797e-09
there O 0 1.144922601170606e-09
was O 0 1.612652233973222e-08
significant O 0 4.55816984157309e-09
disparity O 0 1.3208867244429712e-07
between O 0 2.2231201768363462e-08
the O 0 2.2663360965680113e-08
tests O 0 6.08305654736796e-08
. O 0 5.944228931298312e-08

Three O 0 1.5850473573664203e-06
went O 0 2.087441998810391e-06
from O 0 3.619916810748691e-08
a O 0 1.412503003450638e-08
decreased O 0 1.209222659781517e-07
risk O 0 4.32077751355564e-09
to O 0 1.4202063136625753e-10
an O 0 1.4612248910861325e-10
increased O 0 9.886170104778103e-09
risk O 0 6.299924137920243e-08
, O 0 1.1126620735879555e-09
while O 0 1.7135147745150903e-09
in O 0 9.301979186915332e-10
another O 0 1.348703704273646e-09
three O 0 5.205213482462057e-10
the O 0 3.137014870091548e-09
risk O 0 6.063665125566331e-08
was O 0 4.482654105686379e-07
decreased O 0 2.757162519628764e-06
. O 0 3.6556713212121394e-07

Knowledge O 0 1.52587890625e-05
of O 0 8.299260798594332e-07
the O 0 6.40592361378367e-08
potential O 0 7.964641213220602e-08
reasons O 0 4.265961361937798e-09
for O 0 2.775478458172387e-10
these O 0 4.308330081581602e-11
changes O 0 5.746664810679647e-10
in O 0 2.0558363345024588e-10
results O 0 2.9324345729442314e-10
and O 0 1.4291436090108078e-10
impact O 0 3.870033182806765e-09
of O 0 2.4446102919739587e-09
these O 0 5.542379888368032e-10
risk O 0 1.6411313197295385e-08
reversals O 0 6.770857652327322e-08
on O 0 4.854565105461006e-08
both O 0 5.44325429174819e-09
patients O 0 6.739442781622529e-09
and O 0 1.595831689016336e-09
the O 0 1.7010016506446846e-08
counseling O 0 3.1614394657708544e-08
team O 0 3.986990737558926e-09
can O 0 8.629876258048341e-10
assist O 0 9.861198968508234e-09
in O 0 1.902855428781436e-09
the O 0 2.1554529272549416e-09
development O 0 5.02877517405409e-09
of O 0 9.416012858309841e-09
strategies O 0 1.3664256393042251e-08
for O 0 7.135761981302835e-10
the O 0 4.055836999583562e-09
prevention O 0 4.5783784230479796e-07
and O 0 9.381070364966604e-10
, O 0 2.722257974596687e-10
where O 0 2.826788803034219e-10
necessary O 0 6.5034124752116895e-09
, O 0 7.711404848009806e-10
management O 0 2.516724073586829e-08
of O 0 1.1125417032076257e-08
a O 0 1.2433358342889278e-08
risk O 0 2.1616045842165477e-08
reversal O 0 2.2858809956005643e-08
in O 0 6.763675175491812e-10
any O 0 5.478132947267511e-10
predictive O 0 1.5022830979205537e-08
testing O 0 8.894605940668043e-09
program O 0 1.1471549932196012e-08
. O 0 4.506844231144669e-09
. O 0 1.214693128304134e-07

A O 0 2.891564918172662e-06
novel O 0 1.3570965506914945e-07
common O 0 5.540789160818349e-08
missense O 0 1.4365353706580208e-07
mutation O 0 2.872247550911311e-09
G301C O 0 9.559155245142392e-08
in O 0 2.236132390365242e-09
the O 0 4.746169679492596e-09
N O 0 1.6223337979681673e-06
- O 0 3.4690876304921403e-07
acetylgalactosamine O 0 2.1165769794606604e-06
- O 0 6.784159154449299e-07
6 O 0 2.3945106022438267e-06
- O 0 9.808601362237823e-07
sulfate O 0 1.7758865169525961e-06
sulfatase O 0 5.1278470891702455e-06
gene O 0 1.1016462764246171e-07
in O 0 1.0469881317476393e-07
mucopolysaccharidosis B-Disease 0 0.00015283506945706904
IVA I-Disease 1 0.9997757077217102
. O 0 5.3986161219654605e-05

Mucopolysaccharidosis B-Disease 1 0.9966111779212952
IVA I-Disease 1 0.9999978542327881
( O 0 0.0010403685737401247
MPS B-Disease 1 0.9999932050704956
IVA I-Disease 1 1.0
) O 0 9.620025309686753e-08
is O 0 4.569486122818489e-09
an O 0 2.3872081200693174e-08
autosomal B-Disease 1 0.9984022974967957
recessive I-Disease 1 0.999997615814209
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.0001629523903829977
by O 0 4.315096902018922e-08
a O 0 2.577011628090986e-06
genetic B-Disease 1 0.9999961853027344
defect I-Disease 1 0.9999908208847046
in O 0 6.195555783961026e-07
N O 0 0.0004303035093471408
- O 0 7.696395186940208e-06
acetylgalactosamine O 0 3.747123992070556e-05
- O 0 4.340258328738855e-06
6 O 0 6.6004781729134265e-06
- O 0 2.7589037472353084e-06
sulfate O 0 1.062102455762215e-05
sulfatase O 0 4.8085861635627225e-05
( O 0 2.314371130296422e-07
GALNS O 0 0.00014322447532322258
) O 0 1.7484643421994406e-07
. O 0 5.755555321229622e-07

In O 0 2.9867638318137324e-07
previous O 0 1.2338288968294364e-07
studies O 0 1.011687444929521e-07
, O 0 3.743674259482077e-09
we O 0 1.067975374802188e-09
have O 0 2.2075559436007808e-10
found O 0 2.65016869560597e-10
two O 0 6.900441329449336e-11
common O 0 1.0676800554776378e-09
mutations O 0 1.0264116223623887e-09
in O 0 2.5139976767007965e-09
Caucasians O 0 2.5598943409477215e-08
and O 0 2.1812180950320226e-09
Japanese O 0 5.026878966418735e-07
, O 0 6.935282570452728e-09
respectively O 0 2.2232524088394712e-07
. O 0 2.1379382530994917e-07

To O 0 9.144609407485405e-07
characterize O 0 1.2496510862547439e-05
the O 0 5.12898850502097e-07
mutational O 0 3.780930273933336e-05
spectrum O 0 3.0422256713791285e-06
in O 0 4.239679718409661e-09
various O 0 3.0524047733848647e-09
ethnic O 0 4.246299756260896e-09
groups O 0 3.6954445059578234e-10
, O 0 4.1379205617531056e-10
mutations O 0 4.122550911755951e-10
in O 0 5.24572829618819e-10
the O 0 5.3722506443421025e-09
GALNS O 0 8.475989488943014e-06
gene O 0 2.994995185190419e-08
in O 0 8.940631346376904e-09
Colombian O 0 1.9028473161597503e-06
MPS B-Disease 1 0.9999920129776001
IVA I-Disease 1 1.0
patients O 0 1.2093502846255433e-05
were O 0 3.7569808597481824e-08
investigated O 0 2.360808224466382e-07
, O 0 6.491251425266853e-10
and O 0 9.370930698082702e-10
genetic O 0 1.2613916133830116e-08
backgrounds O 0 1.2667441318114925e-08
were O 0 2.423625522496309e-09
extensively O 0 2.291331790971185e-09
analyzed O 0 1.0366226765867737e-09
to O 0 1.0097929437069553e-10
identify O 0 2.2980237712744156e-09
racial O 0 3.865415099113534e-09
origin O 0 5.70218372519804e-10
, O 0 2.454973169196961e-10
based O 0 2.3939586424326365e-10
on O 0 2.512861474457395e-09
mitochondrial O 0 3.3396613474678816e-08
DNA O 0 1.836925100917597e-08
( O 0 2.240627905436554e-09
mtDNA O 0 9.840643855341114e-09
) O 0 1.4049635232993296e-08
lineages O 0 2.6837500399778946e-07
. O 0 9.906689228955656e-07

Three O 0 9.8208624876861e-07
novel O 0 1.0642119150361395e-06
missense O 0 3.894058409059653e-06
mutations O 0 1.635672646216335e-07
never O 0 3.817324412125345e-08
identified O 0 6.947887154495902e-09
previously O 0 1.3635931495059594e-08
in O 0 3.775121881766097e-10
other O 0 1.3269274568017408e-10
populations O 0 6.376961458887109e-11
and O 0 2.0295380653845285e-10
found O 0 1.0206135936385863e-09
in O 0 5.225426757959895e-10
16 O 0 5.018129911604774e-09
out O 0 4.1213085721913956e-10
of O 0 1.829522844332132e-08
19 O 0 2.7926552093049395e-07
Colombian O 0 2.1840141926077195e-06
MPS B-Disease 1 0.9438274502754211
IVA I-Disease 1 0.9999995231628418
unrelated O 0 1.3543726709031034e-06
alleles O 0 6.9133063718140875e-09
account O 0 2.102423568572931e-09
for O 0 1.3362881468026444e-08
84 O 0 1.3695929510504357e-06
. O 0 1.7941830492418376e-06

2 O 0 1.9365697880857624e-05
% O 0 1.3050298264261073e-07
of O 0 7.383376043890166e-08
the O 0 9.731229155818255e-09
alleles O 0 3.3546305733267445e-09
in O 0 1.7019030629228382e-09
this O 0 8.901644976688772e-10
study O 0 2.685229105736653e-08
. O 0 1.0540169625983253e-07

The O 0 1.7268023384531261e-06
G301C O 0 6.384031621564645e-06
and O 0 2.810721611012923e-08
S162F O 0 2.579259046342486e-07
mutations O 0 4.8762034410287924e-09
account O 0 3.151539917922719e-09
for O 0 1.1963180668317364e-08
68 O 0 3.6934973195457133e-06
. O 0 2.950491534647881e-06

4 O 0 1.3931500689068343e-05
% O 0 3.9280268993024947e-07
and O 0 2.035452553172945e-07
10 O 0 1.3987969396112021e-06
. O 0 7.173342737587518e-07

5 O 0 2.089405825245194e-06
% O 0 4.3839360586162e-08
of O 0 4.98106587087932e-08
mutations O 0 9.878706741517362e-09
, O 0 4.889736171520553e-09
respectively O 0 6.981471756262181e-08
, O 0 4.131392561390612e-09
whereas O 0 1.1306869218685733e-08
the O 0 1.1569552427204144e-08
remaining O 0 3.1481928886023525e-07
F69V O 0 8.337709914485458e-06
is O 0 2.0600765537892585e-09
limited O 0 4.4637341045650203e-10
to O 0 2.58880722414645e-10
a O 0 4.437759493214344e-09
single O 0 9.406248224763658e-09
allele O 0 1.5007901765784482e-07
. O 0 4.378408675620449e-07

The O 0 1.0543241160121397e-06
skewed O 0 5.633246473735198e-07
prevalence O 0 6.937057719369477e-07
of O 0 2.1489515944494997e-08
G301C O 0 2.534775944695866e-07
in O 0 1.6853348716594496e-09
only O 0 1.072147037817217e-09
Colombian O 0 9.945064327609998e-09
patients O 0 1.9264829731469035e-09
and O 0 8.481801927473498e-10
haplotype O 0 1.9395653083620346e-08
analysis O 0 1.8746768581934248e-09
by O 0 4.3004344529862237e-10
restriction O 0 6.355560522308679e-09
fragment O 0 1.9964483399803612e-08
length O 0 1.440441899092093e-08
polymorphisms O 0 2.1795765192678118e-08
in O 0 2.0759249874657826e-09
the O 0 2.196306958524019e-08
GALNS O 0 1.7551734345033765e-05
gene O 0 3.48470123867628e-08
suggest O 0 2.228010487215215e-08
that O 0 9.852170190782772e-10
G301C O 0 2.701305845675961e-07
originated O 0 5.3222784401896206e-08
from O 0 2.172262814070791e-09
a O 0 4.563110778121882e-09
common O 0 2.1517651660474257e-08
ancestor O 0 9.101629530050559e-07
. O 0 9.144417276729655e-07

Investigation O 0 6.70559666104964e-06
of O 0 1.2149168071573513e-07
the O 0 1.3332992487846695e-08
genetic O 0 1.8582520411314363e-08
background O 0 4.510594120432643e-09
by O 0 1.4882611809596824e-10
means O 0 8.224910530429952e-09
of O 0 2.8878719859903867e-08
mtDNA O 0 2.1306426845058013e-08
lineages O 0 9.672458389786698e-09
indicate O 0 8.585585575815458e-09
that O 0 3.8731179374806857e-10
all O 0 1.5885976978324834e-09
our O 0 1.173438768375945e-08
patients O 0 7.366254273222239e-09
are O 0 1.2079277855736592e-10
probably O 0 1.5785276419322258e-09
of O 0 2.139984633942049e-09
native O 0 1.6861458007610963e-08
American O 0 5.214783413975965e-07
descent O 0 0.0001581596879987046

Low O 0 5.435866569314385e-06
frequency O 0 3.483180989860557e-06
of O 0 5.66555684144987e-07
BRCA1 O 0 6.943795369807049e-07
germline O 0 6.571452217940532e-07
mutations O 0 5.4325712817160365e-09
in O 0 4.195340075341392e-09
45 O 0 2.445516997795494e-07
German O 1 0.9999815225601196
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.1832354377693264e-06
. O 0 2.1029075014666887e-06

In O 0 1.1615126283004429e-07
this O 0 2.277020128005347e-09
study O 0 1.241657332506918e-09
we O 0 4.5996167985506986e-10
investigated O 0 1.0149727280861498e-08
45 O 0 2.8889628467254624e-08
German O 1 0.9673434495925903
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1577521163985693e-08
for O 0 2.4420019784088254e-08
germline O 0 1.5289200518964208e-06
mutations O 0 2.114299846311951e-08
in O 0 6.3849157072581875e-09
the O 0 6.019208598218029e-08
BRCA1 O 0 4.574974070692406e-07
gene O 0 1.0114681572304107e-06
. O 0 1.3742637747782283e-06

We O 0 2.456154106766917e-07
identified O 0 1.559447042609463e-07
four O 0 3.232900169791719e-08
germline O 0 1.210712866850372e-06
mutations O 0 2.8183499978240434e-08
in O 0 1.4253420665966132e-08
three O 0 2.4084042138383666e-07
breast B-Disease 1 0.9999725818634033
cancer I-Disease 0 0.07133762538433075
families O 0 6.869479984850102e-10
and O 0 3.2559557272549e-09
in O 0 1.4873239706503227e-07
one O 0 0.0067396084778010845
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0005432390025816858
. O 0 6.604856217506949e-09
among O 0 5.891960808135366e-10
these O 0 1.4467704811949034e-10
were O 0 4.4158237066938e-09
one O 0 1.2762184642411967e-09
frameshift O 0 3.094360323530054e-08
mutation O 0 1.08893949413158e-09
, O 0 1.1035338198794875e-09
one O 0 1.3055191372401964e-09
nonsense O 0 1.6668488456161867e-07
mutation O 0 4.171609724323844e-09
, O 0 1.6202049701874444e-09
one O 0 7.1081729391409e-10
novel O 0 3.083129973546761e-09
splice O 0 4.4579866909089105e-08
site O 0 1.1199208671541783e-08
mutation O 0 3.2476883404797263e-09
, O 0 3.4984983798835856e-09
and O 0 1.070619060072886e-08
one O 0 1.1089110074635755e-07
missense O 0 1.3002440027776174e-05
mutation O 0 3.5024240787606686e-06
. O 0 3.973536422563484e-06

The O 0 1.1400874200262479e-06
missense O 0 5.871655048395041e-06
mutation O 0 5.708011130423074e-08
was O 0 3.9687765251983365e-07
also O 0 6.066577462604528e-09
found O 0 8.5926297188621e-09
in O 0 1.64933098290021e-08
2 O 0 3.70437624042097e-06
. O 0 9.716466138343094e-07

8 O 0 9.379390576214064e-06
% O 0 1.0385492288378373e-07
of O 0 8.832295605998297e-08
the O 0 7.524159073568626e-09
general O 0 1.8118745614970067e-08
population O 0 2.395378895236888e-10
, O 0 6.523397932944874e-10
suggesting O 0 3.3396534426799462e-09
that O 0 2.7308840952477986e-11
it O 0 6.69094502026013e-11
is O 0 2.615579142162261e-10
not O 0 8.194606659905901e-10
disease O 0 5.750003424509487e-07
associated O 0 3.3365040508215316e-07
. O 0 5.258626742943306e-07

The O 0 4.990152433492767e-07
average O 0 2.2303963476133504e-07
age O 0 5.148424406797858e-07
of O 0 1.0429814665258164e-06
disease O 0 0.0020970830228179693
onset O 0 2.4196044250857085e-05
in O 0 2.4485922622830003e-08
those O 0 5.874906339187191e-09
families O 0 5.146948645062821e-09
harbouring O 0 2.1560106233664555e-06
causative O 0 3.1930233035382116e-06
mutations O 0 2.0330662664491683e-07
was O 0 3.020224312422215e-06
between O 0 2.750386784100556e-06
32 O 0 1.4871644452796318e-05
. O 0 3.893827852152754e-06

3 O 0 4.025840462418273e-05
and O 0 1.0789531188493129e-06
37 O 0 1.9624487322289497e-05
. O 0 3.368152192706475e-06

4 O 0 2.4045328245847486e-05
years O 0 6.357163897519058e-07
, O 0 2.7983276140730595e-08
whereas O 0 3.131683712354061e-08
the O 0 4.0119910948988036e-08
family O 0 2.0547917145563588e-08
harbouring O 0 2.9959549010527553e-06
the O 0 3.9858829126160344e-08
missense O 0 2.649522627962142e-07
mutation O 0 2.670100140989007e-09
had O 0 3.0290843167080084e-09
an O 0 2.0412854739859654e-10
average O 0 4.73238426224043e-09
age O 0 3.833054407209602e-08
of O 0 2.194887542827928e-07
onset O 0 0.00017661777383182198
of O 0 2.0483334083110094e-05
51 O 0 8.943824650486931e-05
. O 0 8.783290468272753e-06

2 O 0 0.0001514830073574558
years O 0 8.122618055494968e-06
. O 0 5.858041276951553e-06

These O 0 3.6650540380378516e-08
findings O 0 4.282219023821199e-08
show O 0 2.2102923935563012e-08
that O 0 1.2630714252281905e-09
BRCA1 O 0 4.10269365147542e-08
is O 0 5.832490490575992e-09
implicated O 0 3.6131361014213326e-08
in O 0 2.4167936540919754e-09
a O 0 8.758523906138294e-10
small O 0 5.044527018327472e-10
fraction O 0 2.4508070239903645e-08
of O 0 2.0990661141695455e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.2844773184260703e-08
suggesting O 0 4.5599808373708584e-08
the O 0 2.3348400990386153e-09
involvement O 0 2.6740664793578617e-08
of O 0 7.365846599327597e-09
another O 0 9.331802885981233e-09
susceptibility O 0 4.063466860770859e-07
gene O 0 1.984588209325011e-07
( O 0 3.58088414031954e-07
s O 0 1.0672430107661057e-05
) O 0 2.22304538510798e-06

Paternal O 0 0.02632075920701027
transmission O 1 0.999991774559021
of O 1 0.9999991655349731
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.999452531337738

We O 0 1.4899475786478433e-07
report O 0 1.0181468113046321e-08
a O 0 1.5475534187459061e-09
rare O 0 1.6475915076696879e-09
case O 0 4.002259856861201e-09
of O 0 4.706633305318064e-08
paternally O 1 0.9999963045120239
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999160766601562
DM B-Disease 1 1.0
) O 0 6.956508968869457e-06
. O 0 2.5561896563885966e-06

The O 0 8.314883643834037e-07
proband O 0 1.2817019523936324e-05
is O 0 1.0985865550594553e-08
a O 0 8.41624903102911e-09
23 O 0 2.8697959564283337e-08
year O 0 9.409155232731337e-09
old O 0 5.097836037748493e-06
, O 0 2.552703563196701e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.9996442794799805
who O 0 0.3467347025871277
suffers O 1 0.9999996423721313
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9532764554023743

He O 0 3.647881158030941e-06
presented O 0 1.8078102357321768e-06
with O 0 5.121129333929275e-07
respiratory O 1 0.9999974966049194
and O 0 1.0769578011604608e-06
feeding O 0 2.7461935587780317e-06
difficulties O 0 1.1061051736760419e-05
at O 0 4.5149958168622106e-05
birth O 0 2.667366061359644e-06
. O 0 1.242776079379837e-06

His O 0 4.662485935114091e-06
two O 0 5.357730060495669e-06
sibs O 1 0.9984232187271118
suffer O 0 0.00022837967844679952
from O 0 6.887210020067869e-06
childhood O 1 0.9513502717018127
onset O 1 0.9999991655349731
DM B-Disease 1 1.0
. O 0 0.0004246491298545152

Their O 0 1.7544508068567666e-07
late O 0 1.1811986041720957e-05
father O 0 3.5644757190311793e-07
had O 0 1.902642132733945e-08
the O 0 3.198984410701655e-09
adult O 0 1.0559483065719633e-08
type O 0 5.367071054251937e-08
of O 0 8.030643243728264e-07
DM B-Disease 1 1.0
, O 0 2.967740009296449e-08
with O 0 6.983360556489515e-09
onset O 0 0.0007997318170964718
around O 0 9.817738089168415e-08
30 O 0 1.2148797168265446e-07
years O 0 6.703331933977097e-08
. O 0 1.7484244096976909e-07

Only O 0 1.9665203865315561e-07
six O 0 1.3918460162187785e-08
other O 0 4.5268985782165316e-10
cases O 0 9.511332832445873e-10
of O 0 5.933306290728524e-09
paternal O 0 8.549589438189287e-06
transmission O 1 0.9999716281890869
of O 1 0.9999880790710449
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 2.1164127247175202e-05
been O 0 1.1155679402463647e-07
reported O 0 2.0723735616456906e-08
recently O 0 5.4445553843152084e-08
. O 0 4.6946546206072526e-08

We O 0 9.013077573172268e-08
review O 0 1.977072905390287e-08
the O 0 4.128155151050805e-09
sex O 0 9.695361846695505e-09
related O 0 7.461164130972975e-09
effects O 0 1.3609329130304104e-07
on O 0 1.9250704497153492e-07
transmission O 0 0.00027744018007069826
of O 0 5.3366500651463866e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.1604173332452774

Decreased O 0 9.418974514119327e-06
fertility O 0 1.5537302715529222e-06
of O 0 5.9333434165864674e-08
males O 0 1.1514317499461413e-08
with O 0 1.0193184962759005e-08
adult O 0 1.0537739399296697e-05
onset O 1 0.9776673913002014
DM B-Disease 1 1.0
and O 0 1.202381696430166e-07
contraction O 0 2.1776574499199342e-07
of O 0 2.640534368936187e-08
the O 0 6.5865393139574735e-09
repeat O 0 6.445323386117252e-09
upon O 0 3.0412006246649526e-09
male O 0 1.1004361866184809e-08
transmission O 0 5.821257431648519e-08
contribute O 0 1.1101839447746897e-09
to O 0 7.032827653574714e-10
the O 0 2.9372668741700636e-09
almost O 0 2.378362840005366e-09
absent O 0 4.089097949133702e-09
occurrence O 0 1.2128573700920242e-09
of O 0 2.2034387647806852e-09
paternal O 0 2.018959719407576e-07
transmission O 0 0.0008955183438956738
of O 0 0.005080265458673239
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.33975133299827576

Also O 0 3.460961863765988e-07
the O 0 1.071448849643275e-07
fathers O 0 5.1264745337675777e-08
of O 0 1.9844248910771967e-08
the O 0 2.6822805310189324e-08
reported O 0 1.6929396906562033e-07
congenitally O 0 5.674209205608349e-06
affected O 0 5.417815085451139e-09
children O 0 1.4707828288607061e-09
showed O 0 7.240468669067468e-09
, O 0 8.672977336310339e-10
on O 0 6.40605524182547e-09
average O 0 9.937896727763018e-09
, O 0 4.7896024923943514e-09
shorter O 0 4.932659862788569e-07
CTG O 0 9.893595233734231e-06
repeat O 0 2.566215755450685e-07
lengths O 0 7.503924734919565e-07
and O 0 3.869088160968204e-09
hence O 0 2.4771813045276758e-08
less O 0 3.6608341247301723e-08
severe O 0 1.2868589465142577e-06
clinical O 0 4.901788543065777e-06
symptoms O 0 4.842496537094121e-07
than O 0 6.863901114151361e-10
the O 0 6.7121566083017115e-09
mothers O 0 8.54334203381768e-09
of O 0 1.9598623168803897e-08
children O 0 2.2622549167294892e-08
with O 0 6.202156328072306e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9563608169555664

We O 0 7.563081112493819e-07
conclude O 0 1.5845365624045371e-06
that O 0 9.591697214261785e-09
paternal O 0 3.0591379527322715e-06
transmission O 0 0.12120014429092407
of O 1 0.5777319669723511
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 2.6569225155981258e-05
rare O 0 1.3377601248976134e-07
and O 0 5.108969691747234e-09
preferentially O 0 1.408945848879739e-08
occurs O 0 5.185120333095483e-09
with O 0 2.796949338801369e-09
onset O 0 0.0001509954163338989
of O 0 6.240464426809922e-05
DM B-Disease 1 1.0
past O 0 9.964300033971085e-07
30 O 0 8.158028208526957e-08
years O 0 2.7921520651119636e-09
in O 0 1.0538351302713522e-09
the O 0 4.378869267185337e-09
father O 0 6.26051530616678e-08
. O 0 2.235459817256924e-08
. O 0 2.9819000246789074e-07

The O 0 3.0542666991095757e-06
RB1 O 0 9.107694495469332e-05
gene O 0 1.743214852467645e-07
mutation O 0 1.605247135216814e-08
in O 0 6.410101338616414e-09
a O 0 1.9504497572597757e-08
child O 0 2.6816317699740466e-07
with O 0 1.0913020105363103e-06
ectopic B-Disease 1 0.9999996423721313
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999998807907104
. O 0 0.0014108145842328668

The O 0 1.5144030840019695e-05
RB1 O 0 0.00021114923583809286
gene O 0 2.6642061357051716e-07
mutation O 0 2.8881473213004938e-08
was O 0 9.952278645641854e-08
investigated O 0 1.4664550462839543e-07
in O 0 3.2195024424197527e-09
a O 0 1.695343065932775e-08
child O 0 3.184063359640277e-07
with O 0 4.108112818812515e-07
ectopic B-Disease 1 0.9998244643211365
intracranial I-Disease 1 0.9999996423721313
retinoblastoma I-Disease 0 0.030438225716352463
using O 0 5.3865154114873803e-08
DNA O 0 2.689185762960733e-08
obtained O 0 1.101108093592984e-08
from O 0 3.059183573128621e-09
both O 0 2.06552197568044e-09
the O 0 3.839969764385387e-08
pineal B-Disease 0 0.0031130663119256496
and I-Disease 0 2.5824931526585715e-06
retinal I-Disease 1 0.9999984502792358
tumours I-Disease 1 1.0
of O 0 0.10881499201059341
the O 0 0.0001084020987036638
patient O 0 0.00033641851041466
. O 0 4.149505912209861e-06

A O 0 1.3336243682715576e-05
nonsense O 0 1.1190709301445168e-05
mutation O 0 7.757913067507616e-08
in O 0 6.478740033344366e-08
exon O 0 3.497550778774894e-06
17 O 0 4.409492930790293e-07
( O 0 1.4486165156313291e-08
codon O 0 4.6189626345949364e-08
556 O 0 8.795160510999267e-08
) O 0 6.176020139747607e-09
of O 0 7.261590440066357e-08
the O 0 3.7796942820023105e-07
RB1 O 0 4.6957535232650116e-05
gene O 0 1.3325484360393602e-07
was O 0 3.221058477720362e-07
found O 0 4.757036542457627e-09
to O 0 3.1893079843747785e-10
be O 0 9.104089704337071e-10
present O 0 4.769564743156707e-09
homozygously O 0 2.454213472447009e-06
in O 0 7.31208071869105e-09
both O 0 1.1432625512952654e-08
the O 0 6.063930868549505e-08
retinal B-Disease 0 9.506371134193614e-05
and I-Disease 0 2.0973786263311922e-07
the I-Disease 0 1.28843630591291e-05
pineal I-Disease 1 0.9997300505638123
tumours I-Disease 1 1.0
. O 0 0.00017613173986319453

The O 0 2.772603409084695e-07
same O 0 4.9826244463702096e-08
mutation O 0 9.490733532402373e-09
was O 0 4.292686384133049e-08
present O 0 1.3776418228417242e-08
heterozygously O 0 4.984792099094193e-07
in O 0 1.6428374216559405e-09
the O 0 1.1580342240691266e-09
DNA O 0 3.879863097466796e-09
from O 0 6.161121612890952e-10
the O 0 6.201041347075886e-10
constitutional O 0 9.344198304006568e-09
cells O 0 7.366348642179332e-10
of O 0 1.9800987516305213e-09
the O 0 9.345192397702817e-10
patient O 0 1.5904479511164027e-08
, O 0 1.2012608685552095e-09
proving O 0 4.054083646565232e-08
it O 0 6.373884753330117e-11
to O 0 1.2334071264330504e-10
be O 0 8.606928503240852e-10
of O 0 1.2373386759634286e-08
germline O 0 5.813484449390671e-07
origin O 0 6.2191688243729e-08
. O 0 2.902891083067516e-07

The O 0 1.0523196181111416e-07
initial O 0 7.068134522114633e-08
mutation O 0 2.5593621444386372e-08
was O 0 1.4444248108702595e-07
shown O 0 1.0298085051374528e-08
to O 0 1.0249893156455414e-09
have O 0 1.3496096462617402e-09
occurred O 0 5.4145122163618e-08
in O 0 6.769818594598576e-10
the O 0 4.915451157216921e-09
paternally O 0 4.1343278667227423e-07
derived O 0 1.260186195395363e-07
RB1 O 0 1.2079623957106378e-05
allele O 0 2.266527872052393e-06
. O 0 3.2370890039601363e-06

The O 0 1.852767042009873e-07
mutation O 0 2.4889979854947342e-08
is O 0 1.8172311433417576e-09
in O 0 5.641935252320707e-10
an O 0 4.897424688010688e-10
area O 0 1.010348693597507e-08
of O 0 1.628018253541086e-08
the O 0 4.44701209190157e-09
gene O 0 1.4388292779443645e-09
that O 0 2.0243189069457657e-10
encodes O 0 5.372104427969759e-10
the O 0 2.0040356041306495e-09
protein O 0 8.045621058272445e-09
- O 0 4.606800718676141e-09
binding O 0 4.46244241558702e-09
region O 0 3.954532346028827e-08
known O 0 9.387429500407052e-09
as O 0 3.4635878609634574e-09
the O 0 1.438967256461865e-08
pocket O 0 0.0353257991373539
region O 0 1.8002232593516965e-07
and O 0 4.750535076425422e-09
has O 0 9.953484703117965e-10
been O 0 8.131564310787098e-10
detected O 0 3.5531038111713542e-09
in O 0 1.4848303142578345e-10
other O 0 1.1899312091223635e-10
cases O 0 7.959120584821733e-10
of O 0 4.396127550876372e-08
retinoblastoma B-Disease 0 0.00012170970876468346
. O 0 7.601870066764604e-08
. O 0 8.77825641509844e-07

Low O 0 4.288425316190114e-06
levels O 0 2.662217184479232e-07
of O 0 2.9100110765512e-08
beta O 0 1.823482449481162e-07
hexosaminidase O 0 3.011874980529683e-07
A O 0 1.515426362175276e-08
in O 0 1.3506397111839874e-09
healthy O 0 4.612445980711755e-09
individuals O 0 1.0451371018627142e-10
with O 0 3.780319168811275e-09
apparent O 0 0.006398471537977457
deficiency O 1 0.9997058510780334
of O 0 1.8905021761383978e-06
this O 0 2.106418328651216e-08
enzyme O 0 4.319123547702475e-07
. O 0 3.31226317484834e-07

Appreciable O 0 8.373946184292436e-05
beta O 0 3.585244121495634e-05
hexosaminidase O 0 7.035477756289765e-05
A O 0 3.4429388051648857e-06
( O 0 4.9228191301153856e-08
hex O 0 8.644676086078107e-07
A O 0 8.530124517847071e-08
) O 0 1.4071028786588613e-09
activity O 0 8.072214008336687e-09
has O 0 6.062341184609465e-10
been O 0 1.044223152391055e-09
detected O 0 4.059012326251832e-08
in O 0 2.7390978374342012e-09
cultured O 0 2.1000537344662007e-06
skin O 0 1.0261340321449097e-05
fibroblasts O 0 1.2989274864594336e-06
and O 0 4.084969305040431e-07
melanoma B-Disease 1 0.9986742734909058
tissue O 0 2.8254708013264462e-05
from O 0 4.361234857697127e-07
healthy O 0 1.435181076203662e-07
individuals O 0 3.163909412240429e-10
previously O 0 5.7138382913990426e-08
reported O 0 8.801264606006498e-09
as O 0 2.8216617931065002e-09
having O 0 1.2391174664116988e-07
deficiency B-Disease 0 0.00010235780064249411
of I-Disease 0 5.356640144782432e-07
hex I-Disease 0 7.572680260636844e-07
A I-Disease 0 2.2110430819566318e-08
activity O 0 4.166472500344298e-09
indistinguishable O 0 8.32597457645079e-09
from O 0 8.956410613158994e-11
that O 0 9.654160283700808e-12
of O 0 9.434092396176652e-10
patients O 0 1.0850299325682045e-08
with O 0 3.3976909890043316e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.463435420300812e-05
TSD B-Disease 1 0.864291787147522
) O 0 6.193074000293564e-07
. O 0 1.3485805538948625e-06

Identification O 0 7.636689360879245e-07
and O 0 1.0158039742691471e-07
quantitation O 0 0.000137295966851525
of O 0 3.1162328468781197e-06
hex O 0 1.3568053873314057e-05
A O 0 8.202947014979145e-07
, O 0 7.435890125861988e-09
amounting O 0 3.88621934632738e-08
to O 0 1.2505850577326783e-08
3 O 0 1.226656081598776e-06
. O 0 3.9822359099161986e-07

5 O 0 1.3834601304552052e-05
% O 0 1.2922726000397233e-06
- O 0 1.3743339877692051e-05
6 O 0 1.0728556844696868e-05
. O 0 1.4723856338605401e-06

9 O 0 4.959043963026488e-06
% O 0 2.5233090283904858e-08
of O 0 1.4027063066635037e-08
total O 0 2.3191240039466265e-09
beta O 0 6.322832746263884e-08
hexosaminidase O 0 1.5570709877010813e-07
activity O 0 6.243722427967668e-09
, O 0 4.585863355721642e-10
has O 0 6.96967414337557e-11
been O 0 6.960879095352368e-11
obtained O 0 1.9680038154668011e-10
by O 0 4.952754317777419e-10
cellulose O 0 2.0489310372795444e-06
acetate O 0 4.3451518649817444e-07
gel O 0 1.357610472041415e-05
electrophoresis O 0 8.040137799980585e-06
, O 0 2.5772058620532334e-07
DEAE O 0 0.0009580522309988737
- O 0 6.056618531147251e-06
cellulose O 0 1.486934706917964e-05
ion O 0 1.39330686579342e-05
- O 0 4.227976830861735e-07
exchange O 0 3.209240048818174e-06
chromatography O 0 6.83782491250895e-05
, O 0 2.8087656644970593e-08
radial O 0 5.201948738431383e-07
immunodiffusion O 0 3.890064363076817e-06
, O 0 2.958087463866832e-08
and O 0 6.745824521203758e-08
radioimmunoassay O 0 6.255837070057169e-05
. O 0 1.9830340534099378e-06

Previous O 0 4.4849211917608045e-06
family O 0 1.8181567895680928e-07
studies O 0 1.1466501348422753e-07
suggested O 0 3.117214220083042e-08
that O 0 1.9414211904766887e-10
these O 0 1.8000370638482366e-10
individuals O 0 1.891030249057124e-10
may O 0 3.731904119064211e-09
be O 0 1.0173135667201905e-09
compound O 0 2.2445600933451715e-08
heterozygotes O 0 1.7365966442639547e-08
for O 0 9.669649525534396e-10
the O 0 3.5420943955699613e-09
common O 0 2.2851049052974304e-08
mutant O 0 2.3335975640748075e-07
TSD B-Disease 0 4.306506525608711e-06
gene O 0 1.0664410687866166e-08
and O 0 1.7652524997302521e-09
a O 0 1.0063099686874466e-08
rare O 0 3.8755160858272575e-08
( O 0 1.9983568577686128e-08
allelic O 0 6.006055173202185e-07
) O 0 4.9025512538491967e-08
mutant O 0 9.504673244009609e-07
gene O 0 1.2279482461963198e-06
. O 0 1.7621570123083075e-06

Thus O 0 1.424170136488101e-06
, O 0 4.2021174095907554e-08
the O 0 2.767593976216176e-08
postulated O 0 4.957560690854734e-07
rate O 0 8.946879148652442e-08
mutant O 0 3.209473220522341e-08
gene O 0 8.422431641008643e-09
appears O 0 4.810513321018561e-09
to O 0 1.609494759691188e-10
code O 0 7.057485706951638e-10
for O 0 5.697041172147976e-10
the O 0 5.904132738265844e-10
expression O 0 1.4122868430277435e-09
of O 0 2.9201456808181092e-09
low O 0 2.2268634936040144e-08
amounts O 0 6.296726695609323e-09
of O 0 2.16316777823522e-08
hex O 0 1.2070996717739035e-06
A O 0 1.1372770813977695e-06
. O 0 7.374860047093534e-07

Heterozygotes O 0 3.49159054167103e-05
for O 0 2.1660748927843088e-07
the O 0 1.2895982592908695e-07
rare O 0 9.66055111462083e-08
mutant O 0 2.4953780553005345e-07
may O 0 7.585138739329977e-09
be O 0 1.5955332610673167e-09
indistinguishable O 0 4.242221862682527e-08
from O 0 2.187309222634326e-09
heterozygotes O 0 2.7532520263662263e-08
for O 0 1.2365547474857408e-09
the O 0 8.773174187126642e-09
common O 0 1.523199131270303e-07
TSD B-Disease 0 0.00017565627058502287
mutant O 0 3.7508780224015936e-06
. O 0 8.123075190269446e-07

However O 0 5.664811055794416e-07
, O 0 2.2529926368974884e-08
direct O 0 3.069319376436397e-08
visualization O 0 1.7607392237550812e-06
and O 0 4.1397321126623865e-08
quantitation O 0 0.0022521107457578182
of O 0 1.3113019122101832e-05
hex O 0 9.485879672865849e-06
A O 0 7.252814526736984e-08
by O 0 2.304624269200417e-10
the O 0 1.38025024742916e-09
methods O 0 2.270918564306612e-08
described O 0 3.3591125436771563e-09
may O 0 6.731281643190812e-10
prevent O 0 2.0541284229125267e-09
false O 0 2.580634594906428e-09
- O 0 7.764407783383831e-09
positive O 0 1.7536813112783989e-09
prenatal O 0 3.894471376497677e-07
diagnosis O 0 3.261275480781478e-07
of O 0 1.3124324027558032e-07
TSD B-Disease 0 0.0027384310960769653
in O 0 1.7107326755194663e-07
fetuses O 0 1.2365887869236758e-07
having O 0 1.324415510595145e-08
the O 0 1.1228297402965381e-08
incomplete O 0 1.695919564781434e-07
hex B-Disease 0 8.65112724568462e-06
A I-Disease 0 7.426406682498055e-06
deficiency I-Disease 0 0.014388244599103928
of O 0 1.0558132998994552e-06
the O 0 1.4555968164131627e-07
type O 0 1.5263850627889042e-06
described O 0 1.6169890315609337e-08
in O 0 9.34515687056603e-10
the O 0 4.804974640393311e-09
four O 0 4.8379455108715774e-08
healthy O 0 6.225554329830629e-07
individuals O 0 3.4258803793818515e-07

The O 0 6.859691893623676e-06
tumor B-Disease 0 0.00011429881124058738
suppressor O 0 1.8461383660905994e-05
gene O 0 1.930289045048994e-06
Smad4 O 0 0.0001429764088243246
/ O 0 2.7499896532390267e-05
Dpc4 O 0 1.0279940397595055e-05
is O 0 2.1669450678274416e-09
required O 0 4.259213426394126e-09
for O 0 4.006842413417644e-09
gastrulation O 0 1.0350820502935676e-06
and O 0 1.2451228492693645e-08
later O 0 4.836699574184422e-08
for O 0 5.429504845722022e-09
anterior O 0 5.06915682763065e-07
development O 0 3.156390846470458e-07
of O 0 3.6194720109961054e-07
the O 0 2.13272898008654e-07
mouse O 0 1.0973781172651798e-06
embryo O 0 3.090358973167895e-07
. O 0 3.529425214310322e-07

Mutations O 0 5.150349693394674e-07
in O 0 5.558243643122296e-08
the O 0 1.659046233726258e-07
SMAD4 O 1 0.7347119450569153
/ O 0 0.0018826357554644346
DPC4 O 0 0.0006199573981575668
tumor B-Disease 0 5.180060725251678e-06
suppressor O 0 6.54387918075372e-07
gene O 0 3.190698549815352e-08
, O 0 6.9631833632399776e-09
a O 0 1.679213568195337e-08
key O 0 7.632291953996173e-07
signal O 0 1.454915491194697e-06
transducer O 0 4.4388460196387314e-07
in O 0 1.7067279145521752e-08
most O 0 3.824085048620418e-09
TGFbeta O 0 1.5798771073605167e-06
- O 0 8.296587594713856e-08
related O 0 5.3723866244581586e-08
pathways O 0 1.1621104967218798e-08
, O 0 3.1380426035454434e-10
are O 0 2.6736238223357134e-11
involved O 0 1.840985003331852e-10
in O 0 1.1163071161890414e-10
50 O 0 1.7728241097358932e-09
% O 0 6.500151084054551e-09
of O 0 1.4817906048847362e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
. O 0 4.541146336123347e-05

Homozygous O 0 0.00010634294449118897
Smad4 O 0 0.0006095145945437253
mutant O 0 5.6302480516023934e-05
mice O 0 1.076058924809331e-05
die O 0 1.127723180616158e-06
before O 0 2.356684944970766e-07
day O 0 2.355956780775159e-07
7 O 0 1.2417725656632683e-06
. O 0 4.774036597154918e-07

5 O 0 3.0524577596224844e-05
of O 0 1.4526788618240971e-05
embryogenesis O 0 0.000483030395116657
. O 0 2.231311191280838e-05

Mutant O 0 2.674893721632543e-06
embryos O 0 1.069770334538589e-07
have O 0 3.0660589622755197e-09
reduced O 0 1.070355626353603e-08
size O 0 7.73269182019476e-09
, O 0 2.007834787320917e-09
fail O 0 9.550622515064333e-09
to O 0 1.1023556512057553e-09
gastrulate O 0 6.052075605111895e-07
or O 0 6.779047545535377e-09
express O 0 1.5625435390020925e-09
a O 0 2.6998949742562672e-09
mesodermal O 0 7.254945444401528e-08
marker O 0 6.1470537104924e-08
, O 0 2.252836805993752e-09
and O 0 3.2457065923807704e-09
show O 0 1.4263964942529128e-07
abnormal O 0 2.043090944425785e-06
visceral O 0 7.96909171185689e-06
endoderm O 0 0.00010791322711156681
development O 0 2.0855600268987473e-06
. O 0 1.2312481203480274e-06

Growth B-Disease 1 0.9999969005584717
retardation I-Disease 1 1.0
of O 0 1.407072431902634e-05
the O 0 1.213322775583947e-06
Smad4 O 0 0.001672622049227357
- O 0 7.192898920038715e-06
deficient O 0 1.158094164566137e-06
embryos O 0 5.456601392950233e-09
results O 0 8.753213709411511e-10
from O 0 7.353728737058418e-10
reduced O 0 1.5159466570935365e-08
cell O 0 7.775422261602216e-08
proliferation O 0 6.029228671877718e-08
rather O 0 1.38732902943417e-09
than O 0 4.583476376218698e-10
increased O 0 2.5263430458721814e-08
apoptosis O 0 7.565309942947351e-07
. O 0 1.7434791743653477e-07

Aggregation O 0 7.564913744317892e-07
of O 0 2.835058978689631e-07
mutant O 0 8.56881797517417e-07
Smad4 O 0 1.081008213077439e-05
ES O 0 1.6963997495622607e-06
cells O 0 9.057381511468066e-09
with O 0 1.2724389319984653e-09
wild O 0 1.0119822313470195e-08
- O 0 3.743804555256247e-08
type O 0 2.4075433202597196e-07
tetraploid O 0 1.9257181520515587e-06
morulae O 0 3.146192466374487e-05
rescues O 0 2.937156295956811e-06
the O 0 3.1941272027324885e-07
gastrulation B-Disease 0 0.00018404322327114642
defect I-Disease 0 5.9845166106242687e-05
. O 0 3.252660690122866e-06

These O 0 5.534610281188179e-08
results O 0 5.097914979046436e-08
indicate O 0 3.845657303713779e-08
that O 0 3.788453550868098e-09
Smad4 O 0 6.99526708558551e-07
is O 0 1.1944295552623885e-09
initially O 0 1.982608077710779e-09
required O 0 4.3963244156230985e-10
for O 0 3.0690003316458103e-10
the O 0 9.473221096456541e-10
differentiation O 0 1.5496750549459648e-08
of O 0 1.7251377215643515e-08
the O 0 2.8808301522076363e-08
visceral O 0 1.4775311001358205e-06
endoderm O 0 2.1916594050708227e-06
and O 0 3.5460423486455284e-09
that O 0 3.922152880253549e-10
the O 0 5.305268668820418e-09
gastrulation B-Disease 0 1.1031587519028108e-06
defect I-Disease 0 1.4333127751342545e-07
in O 0 3.553889849072789e-09
the O 0 1.1938015909152e-08
epiblast O 0 6.326931725197937e-06
is O 0 1.4880064957978334e-09
secondary O 0 7.538569946063944e-08
and O 0 8.017098096502195e-09
non O 0 4.767566679220181e-06
- O 0 8.509545295964926e-06
cell O 0 2.6012987291323952e-05
autonomous O 0 2.0172478798485827e-06
. O 0 1.6923212342589977e-06

Rescued O 0 0.0005707909585908055
embryos O 0 1.241954760189401e-05
show O 0 4.2702640712377615e-06
severe O 0 3.0505429094773717e-05
anterior O 0 0.000167321995832026
truncations O 1 0.8961387872695923
, O 0 2.8139785968051e-07
indicating O 0 2.062911335087847e-07
a O 0 1.0821570306518424e-08
second O 0 6.798107854422142e-09
important O 0 3.1560154489795877e-09
role O 0 1.2478807320803753e-08
for O 0 8.298230547154617e-09
Smad4 O 0 1.2710790542769246e-05
in O 0 6.427635668160292e-08
anterior O 0 1.3284049600770231e-05
patterning O 0 0.000665886327624321
during O 0 0.0001417122402926907
embryogenesis O 0 0.00017321416817139834
. O 0 2.9795141927024815e-06

Prevalence O 0 3.685326737468131e-05
of O 0 1.8638019128047745e-06
p16 O 0 2.7338569452695083e-06
and O 0 8.609826807060017e-08
CDK4 O 0 0.00018515299598220736
germline O 0 4.118879587622359e-06
mutations O 0 2.8804674201410307e-08
in O 0 4.437245593180705e-08
48 O 0 1.3525189388019498e-05
melanoma B-Disease 1 0.9999972581863403
- O 0 0.015472999773919582
prone O 0 0.00016867190424818546
families O 0 3.909964796378063e-09
in O 0 7.275731661593454e-08
France O 0 2.0664983821916394e-06
. O 0 9.051216807165474e-07

The O 0 2.5319543510704534e-06
French O 0 0.0007310078362934291
Familial B-Disease 1 0.999398946762085
Melanoma I-Disease 1 0.9999994039535522
Study O 0 3.9244050640263595e-06
Group O 0 9.214195983986428e-07
. O 0 1.0193689377047122e-06

Germline O 0 0.00023822326329536736
mutations O 0 1.2173934464954073e-06
in O 0 7.101552057520166e-08
the O 0 9.573624026870675e-08
p16 O 0 1.5906730368442368e-06
and O 0 8.458691524992901e-08
CDK4 O 0 0.0006523000774905086
genes O 0 3.0340121526251096e-08
have O 0 4.1449585430619607e-10
been O 0 2.5513563484125257e-10
reported O 0 1.9906894188626012e-10
in O 0 5.065330793696532e-11
a O 0 3.9770844950659523e-10
subset O 0 2.034481560997392e-08
of O 0 2.871080653221725e-07
melanoma B-Disease 0 0.04373365268111229
pedigrees O 0 3.147208076370589e-07
, O 0 1.6756293019781765e-09
but O 0 1.8521249811609408e-10
their O 0 1.5550177812073684e-10
prevalence O 0 2.249034025680885e-08
is O 0 7.071387919665995e-11
not O 0 1.0730548394288775e-10
well O 0 9.173428683340035e-10
known O 0 1.340569255603441e-08
. O 0 1.773297668705709e-07

We O 0 3.4657776382118755e-07
searched O 0 3.7878169223404257e-07
for O 0 2.7754269993351954e-09
such O 0 4.054351965265823e-09
germline O 0 8.7332404064e-07
mutations O 0 1.5795706076460192e-08
in O 0 2.2655713749486495e-08
48 O 0 1.2904622508358443e-06
French O 1 0.8103986978530884
melanoma B-Disease 1 1.0
- O 0 0.1735054850578308
prone O 0 5.281203630147502e-05
families O 0 1.3135669219010992e-09
selected O 0 4.019671706601002e-09
according O 0 6.480909142680957e-10
to O 0 1.9037074694416845e-10
two O 0 3.95042748513319e-10
major O 0 6.196775981237579e-09
criteria O 0 3.264931081048417e-08
families O 0 1.545862188256919e-10
with O 0 4.293509159314368e-10
at O 0 1.7755026249233197e-07
least O 0 1.3619573246970162e-09
three O 0 9.039462511850616e-10
affected O 0 4.921640872623811e-10
members O 0 3.792428038273954e-10
( O 0 4.811134823867746e-10
n O 0 2.488243211473673e-08
= O 0 2.7135930835697764e-08
20 O 0 1.7608817515224473e-08
) O 0 4.802168662720874e-10
or O 0 9.124637712076833e-10
families O 0 4.9524866846395454e-11
with O 0 2.1590643162205936e-10
two O 0 9.361390551632098e-10
affected O 0 1.0552008156139436e-09
members O 0 2.5230370570561433e-10
, O 0 2.970738377516824e-10
one O 0 1.3526858799739472e-10
of O 0 8.735300260909185e-10
them O 0 1.2747120026190828e-10
affected O 0 2.1355472945572274e-10
before O 0 7.048647221452597e-10
the O 0 1.1007290218190136e-10
age O 0 1.8528749645696507e-09
of O 0 3.1663618393906745e-09
50 O 0 5.086247867325255e-09
( O 0 8.94219698288623e-10
n O 0 2.7832633975322096e-08
= O 0 2.3739859855709255e-08
28 O 0 4.490055616201971e-08
) O 0 1.2544690841664874e-09
, O 0 1.0666113547941336e-09
and O 0 6.123094253851491e-10
one O 0 3.505904455636255e-10
additional O 0 3.2273843597607765e-09
minor O 0 5.400541454037011e-07
criterion O 0 0.0002559234562795609
. O 0 3.498611704344512e-06

Sixteen O 0 7.548348548880313e-06
different O 0 5.047289732829086e-07
p16 O 0 5.750832315243315e-06
germline O 0 6.995353032834828e-06
mutations O 0 1.3019669609093398e-07
were O 0 2.562449097354147e-08
found O 0 7.848204752747279e-09
in O 0 3.1319329352186287e-09
21 O 0 2.3099604007370544e-08
families O 0 3.211062249430796e-10
, O 0 1.4626421185326421e-09
while O 0 1.5493794691678886e-08
one O 0 8.552244246118335e-09
germline O 0 4.1925025584532705e-07
mutation O 0 1.0327885213712307e-08
, O 0 6.112269357316791e-09
Arg24His O 0 2.023853767241235e-06
, O 0 1.1122234688798471e-08
was O 0 8.095962300558313e-08
detected O 0 5.34512700767209e-08
in O 0 1.5871711722681425e-09
the O 0 1.4298838557635918e-08
CDK4 O 0 5.0702707085292786e-05
gene O 0 1.0848890497072716e-06
. O 0 9.873150474959402e-07

The O 0 2.9194853823355515e-07
frequency O 0 9.820328159548808e-07
of O 0 1.7730607737576065e-07
p16 O 0 2.034274615425602e-07
gene O 0 6.439241140299146e-09
mutation O 0 1.7176640110250219e-09
in O 0 5.288656179658346e-10
our O 0 9.852884064187606e-10
sample O 0 7.881938990372817e-10
( O 0 5.489219634391418e-10
44 O 0 5.66399860346678e-09
% O 0 2.4868376247155766e-09
) O 0 1.1773659824854121e-09
is O 0 9.460509042824583e-10
among O 0 2.703449131225e-10
the O 0 1.897375589976491e-09
highest O 0 4.928954311367306e-08
rates O 0 1.5480619453001054e-08
yet O 0 1.2583200037497022e-09
reported O 0 2.050276837195497e-09
and O 0 4.403205577929725e-10
the O 0 3.357831124262134e-09
CDK4 O 0 1.3278627193358261e-06
mutation O 0 8.498254322475418e-10
is O 0 9.719867272162119e-11
the O 0 2.089721173881287e-10
second O 0 9.409509837965402e-10
mutation O 0 4.400745878818668e-10
detected O 0 6.404259789150046e-09
in O 0 3.067841536363858e-10
this O 0 2.565351264749438e-10
gene O 0 1.4164581507714047e-08
worldwide O 0 3.814267657276105e-08
. O 0 3.1548498213851417e-07

In O 0 9.90383682619722e-07
summary O 0 4.882199391431641e-06
, O 0 2.4216628702333765e-08
our O 0 8.4954221435396e-09
results O 0 3.933377179521358e-09
show O 0 5.563225435878394e-09
frequent O 0 1.7265391338838754e-09
involvement O 0 1.510457181552738e-08
of O 0 5.894121635208194e-09
the O 0 1.6432172955660462e-08
p16 O 0 2.688778693027416e-07
gene O 0 6.19606908003334e-08
in O 0 3.1630921881742324e-08
familial B-Disease 0 0.0006438252166844904
melanoma I-Disease 1 0.9974687099456787
and O 0 5.974565908672957e-08
confirm O 0 9.013130153334714e-08
the O 0 1.1693701118531408e-08
role O 0 1.0985534260044005e-07
of O 0 7.058501694245933e-08
the O 0 7.163382775843274e-08
CDK4 O 0 3.0007933673914522e-05
gene O 0 2.5287004490337495e-08
as O 0 1.7315064937406532e-08
a O 0 2.3211150335100683e-07
melanoma B-Disease 1 0.9928146600723267
- O 0 5.754893209086731e-05
predisposing O 0 2.0004135876661167e-05
gene O 0 7.417626193273463e-07
. O 0 2.5060404595933505e-07
. O 0 2.297018454555655e-06

Progression O 0 0.00036457894020713866
of O 0 2.648885129019618e-05
somatic O 0 0.0001053361120284535
CTG O 0 0.0005011482280679047
repeat O 0 7.318348025364685e-07
length O 0 5.125526314486706e-08
heterogeneity O 0 1.0608340517137549e-07
in O 0 1.6267852620543977e-09
the O 0 2.8940241314501236e-09
blood O 0 1.293150120318387e-07
cells O 0 1.119927219406236e-06
of O 0 0.05584602430462837
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9242165684700012
. O 0 1.6437885278719477e-05

The O 0 1.3423493783193408e-07
genetic O 0 2.808450290103792e-07
basis O 0 1.01342229754664e-05
of O 1 0.9999943971633911
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9905709028244019
DM B-Disease 1 1.0
) O 0 8.084018787712921e-08
is O 0 1.6636267918812564e-09
the O 0 1.2700385187969232e-09
expansion O 0 3.613425647586155e-08
of O 0 4.067653947004146e-08
an O 0 2.8389974815468122e-08
unstable O 0 0.0007202131091617048
CTG O 0 0.00016456081357318908
repeat O 0 2.579544400305167e-07
in O 0 8.505685933357654e-09
the O 0 2.4377715845957937e-08
34 O 0 1.6694626481239538e-07
UTR O 0 1.2457957382139284e-05
of O 0 1.242296860937131e-07
the O 0 5.52563335531886e-07
DM B-Disease 1 0.9999926090240479
protein O 0 1.8623841242515482e-06
kinase O 0 1.6393393309499515e-07
gene O 0 3.874000853443249e-08
on O 0 3.0198503964129486e-07
chromosome O 0 7.7471768236137e-06
19 O 0 8.35518858366413e-06
. O 0 2.9900293156970292e-06

One O 0 1.592780165537988e-07
of O 0 1.1034505575935327e-07
the O 0 2.664794962470296e-08
principal O 0 1.5484509958696435e-06
features O 0 3.969798001435265e-08
of O 0 1.251812307145883e-07
the O 0 9.160880267700122e-07
DM B-Disease 1 1.0
mutation O 0 2.577527347114028e-08
is O 0 2.2313180192412574e-09
an O 0 1.4926683222782344e-09
extraordinarily O 0 3.707963855958951e-07
high O 0 3.94663260294692e-07
level O 0 3.6652122616942506e-06
of O 0 5.805971454719838e-07
somatic O 0 3.7906638681306504e-06
mosaicism O 0 9.597300959285349e-05
, O 0 4.641232731472655e-09
due O 0 9.093368724677475e-09
to O 0 2.9672050927409543e-10
an O 0 4.390676433541074e-10
extremely O 0 1.1893878770763422e-08
high O 0 3.8727968387775036e-08
degree O 0 2.632659743539989e-07
of O 0 5.78720396049448e-08
somatic O 0 6.338608500300325e-07
instability O 0 4.490287039971008e-07
both O 0 2.4495392381140846e-09
within O 0 4.953795595952215e-09
and O 0 4.5269246684576103e-10
between O 0 3.178234919687384e-08
different O 0 2.676704724535739e-08
tissues O 0 1.342212840427237e-06
. O 0 4.693405912803428e-07

This O 0 1.7778181700123241e-06
instability O 0 0.00012125874491175637
appears O 0 3.933949983547791e-07
to O 0 3.1802707134431785e-09
be O 0 2.3405966054212968e-09
biased O 0 7.659751055655306e-09
towards O 0 2.4010982091482447e-09
further O 0 7.639320287466944e-10
expansion O 0 5.675093284196464e-09
and O 0 3.154485284095898e-10
continuous O 0 3.733021891605404e-09
throughout O 0 1.033781393822153e-09
the O 0 5.216444498579165e-10
life O 0 1.1050166337511769e-09
of O 0 9.608318585208053e-10
an O 0 1.0445970477501731e-10
individual O 0 3.341575904869387e-10
, O 0 1.6071183273069778e-09
features O 0 6.617314696200083e-09
that O 0 5.708222783340489e-10
could O 0 1.2559222550834193e-09
be O 0 3.3559663381588223e-10
associated O 0 4.3873613075895435e-10
with O 0 1.2256914927455398e-10
the O 0 5.140806891290595e-09
progressive O 0 1.3187461718189297e-06
nature O 0 7.42850758683744e-08
of O 0 1.7272341779062117e-07
the O 0 1.1804041832874645e-06
disease O 0 0.0003509919624775648
. O 0 5.906532010158116e-07

Although O 0 1.043150987811714e-07
increasing O 0 5.055011342847138e-08
measured O 0 1.2237356372679642e-07
allele O 0 3.944001747413495e-08
size O 0 4.506571471551979e-08
between O 0 1.2929046988574555e-07
patients O 0 2.0807386036381104e-08
clearly O 0 1.508295177643504e-08
correlates O 0 6.600687108004877e-09
with O 0 1.7273880936752306e-10
an O 0 2.6723914747783795e-10
increased O 0 8.266130890888235e-09
severity O 0 1.1461072517704451e-06
of O 0 2.473914548772882e-07
symptoms O 0 5.191154741623905e-07
and O 0 4.712394918726659e-10
an O 0 1.1382504661039405e-10
earlier O 0 2.8967193088647036e-09
age O 0 1.3814045907167838e-08
of O 0 3.3693808632051514e-08
onset O 0 1.3090487982481136e-06
, O 0 1.6330401475528333e-09
this O 0 1.3560959299940833e-10
correlation O 0 3.5674048159961558e-09
is O 0 2.1650024828456793e-10
not O 0 1.572786761938616e-10
precise O 0 7.341231178514818e-09
and O 0 1.1457986781593377e-09
measured O 0 1.7279599973107906e-08
allele O 0 2.798891785005253e-09
length O 0 2.8952331643239404e-09
cannot O 0 7.949017000186132e-10
be O 0 1.0072460920884652e-10
used O 0 1.0628822127989324e-10
as O 0 1.4812907844774514e-11
an O 0 1.0415287556020392e-11
accurate O 0 1.1286012124855915e-08
predictor O 0 3.157862806801859e-07
of O 0 1.8814695579294494e-08
age O 0 1.254031531061628e-06
of O 0 6.0131264945084695e-06
onset O 1 0.6073386669158936
. O 0 8.0082891145139e-06

In O 0 2.573374615622015e-07
order O 0 4.254181718010841e-08
to O 0 3.793370506599558e-09
further O 0 1.3256109099302193e-08
characterize O 0 5.805124487778812e-07
the O 0 1.1300771518563124e-07
dynamics O 0 0.00013786900672130287
of O 0 0.00037658546352759004
DM B-Disease 1 1.0
CTG O 1 0.9986761212348938
repeat O 0 4.417174568516202e-05
somatic O 0 3.119340181001462e-05
instability O 0 2.2387624994735233e-05
, O 0 3.249771651780975e-08
we O 0 5.566303418191865e-09
have O 0 4.5441050922079285e-10
studied O 0 5.1651745991421194e-08
repeat O 0 4.015671795087883e-09
length O 0 5.199894403951077e-10
changes O 0 8.915454485780572e-11
over O 0 1.1686979162206512e-10
time O 0 9.9851449331112e-10
in O 0 1.0522870574902754e-08
111 O 0 0.0068229567259550095
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.521316203768947e-07
with O 0 4.4523504882931775e-09
varying O 0 1.7279820951898728e-07
clinical O 0 3.216679488105001e-06
severity O 0 3.0770474950259086e-06
and O 0 3.139476234537142e-08
CTG O 0 1.2028239325445611e-05
repeat O 0 3.731542719265235e-08
size O 0 1.7303205535057486e-09
over O 0 6.245577388597212e-10
time O 0 8.229378289925648e-10
intervals O 0 3.6608813758221004e-09
of O 0 1.7339844005093141e-09
1 O 0 5.715102702197328e-08
- O 0 4.618451754367925e-08
7 O 0 7.034510929315729e-08
years O 0 5.7116704255122386e-08
. O 0 1.5394266483781394e-07

We O 0 8.807723475001694e-07
have O 0 7.546579361417116e-09
found O 0 4.311738077689142e-09
a O 0 9.901904851616905e-10
direct O 0 3.146524818475882e-09
progression O 0 5.971433125750991e-08
of O 0 1.79091248497798e-08
the O 0 1.0177351406071011e-08
size O 0 1.1711177805295847e-08
heterogeneity O 0 5.4027104567921924e-08
over O 0 4.560813504639327e-09
time O 0 6.042903510916631e-09
related O 0 5.3865947258202596e-09
to O 0 1.577564634480666e-09
initial O 0 2.94256192745479e-08
CTG O 0 6.01753845330677e-06
repeat O 0 6.667055174602865e-08
size O 0 1.256814297079245e-08
and O 0 1.4254527558321684e-09
the O 0 2.5919955071174172e-09
time O 0 4.616582671701508e-09
interval O 0 1.9551503527281966e-08
and O 0 9.70629243646215e-10
always O 0 2.4396076270249978e-09
biased O 0 1.8258127232329002e-09
towards O 0 3.283852967328471e-09
further O 0 1.0446857601209558e-08
expansion O 0 2.884382865886437e-07
. O 0 4.169261842434935e-07

Attempts O 0 5.237870368546282e-07
to O 0 2.522404507487863e-08
mathematically O 0 7.22318077350792e-07
model O 0 6.186444778677469e-08
the O 0 5.283681048240396e-08
dynamics O 0 5.764769230154343e-05
have O 0 2.4262631015403713e-08
proved O 0 7.984389185367036e-07
only O 0 2.1684296580559703e-09
partially O 0 2.557600531361004e-08
successful O 0 9.427442826392962e-09
suggesting O 0 5.540332193021413e-09
that O 0 3.781144494729993e-11
individual O 0 1.4082962226935614e-11
specific O 0 2.2212616468397783e-10
genetic O 0 8.267045714660526e-09
and O 0 4.413684973059162e-09
/ O 0 7.109927651072212e-07
or O 0 8.63039062437565e-09
environmental O 0 1.5773787609418832e-08
factors O 0 6.564440546696915e-09
also O 0 5.765229960097429e-10
play O 0 6.8364793825992365e-09
a O 0 3.888694255493874e-09
role O 0 4.5739007248357666e-08
in O 0 5.815564207978241e-08
somatic O 0 4.222994448355166e-06
mosaicism O 0 0.00010509009734960273
. O 0 1.5747070847282885e-07
. O 0 1.141535449278308e-06

Aspartylglucosaminuria B-Disease 1 0.9991324543952942
among O 0 4.096884254067845e-07
Palestinian O 0 1.6931655864027562e-06
Arabs O 0 3.329540959384758e-06
. O 0 1.6702683751645964e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9986507296562195
AGU B-Disease 1 1.0
) O 0 4.976157015335048e-07
is O 0 2.4867109260640063e-08
a O 0 2.1559470653187418e-08
rare O 0 1.2123731494284584e-06
disorder B-Disease 1 0.9999939203262329
of I-Disease 1 0.9833773374557495
glycoprotein I-Disease 1 0.9999927282333374
metabolism I-Disease 1 0.9997316002845764
caused O 0 5.565371452576073e-07
by O 0 1.5280892107227828e-09
the O 0 1.1204106442619377e-07
deficiency B-Disease 1 0.981086790561676
of I-Disease 0 8.953500582720153e-06
the I-Disease 0 2.9329296467039967e-06
lysosomal I-Disease 0 0.2900669574737549
enzyme I-Disease 0 7.491925657632237e-07
aspartylglucosaminidase I-Disease 0 5.0401402404531837e-05
( O 0 2.2017388801032212e-07
AGA O 0 3.771995034185238e-05
) O 0 3.125484226984554e-07
. O 0 1.4583412166757626e-06

AGU B-Disease 1 1.0
is O 0 1.506242188042961e-05
inherited O 0 0.012181760743260384
as O 0 5.459382919070777e-07
an O 0 2.4176389956664934e-07
autosomal O 1 0.8811757564544678
recessive O 0 0.28593215346336365
trait O 0 1.7701137039694004e-05
and O 0 7.825785530712892e-08
occurs O 0 3.017276384298384e-08
with O 0 7.587131478636877e-10
a O 0 3.9048972944044635e-09
high O 0 1.398424558374245e-07
frequency O 0 1.4757890198779933e-07
in O 0 1.985999142917194e-09
Finland O 0 2.093541162651036e-08
because O 0 1.3381750152419158e-09
of O 0 1.574364105749737e-08
a O 0 5.8177722195296155e-08
founder O 0 1.023922891363327e-06
effect O 0 1.1262400221312419e-06
. O 0 1.2546369134724955e-06

While O 0 1.5574198641843395e-06
very O 0 2.142614334843529e-07
few O 0 9.285501789690898e-08
patients O 0 1.413727233057216e-07
with O 0 3.991102062173013e-07
AGU B-Disease 1 1.0
have O 0 2.524685882576705e-08
been O 0 7.640431398669989e-09
reported O 0 9.662717292968637e-10
from O 0 1.730352666706736e-10
non O 0 6.621708514842339e-09
- O 0 8.467322842875546e-09
Finnish O 0 1.2139154250689899e-06
origin O 0 1.7107790739601114e-08
, O 0 2.654682917935247e-09
we O 0 4.569486122818489e-09
diagnosed O 0 9.070149076251255e-07
the O 0 1.5574979528309996e-08
disorder O 0 4.536644701147452e-05
in O 0 6.340171943008954e-09
8 O 0 3.9600497103720045e-08
patients O 0 1.8992729611255754e-09
originating O 0 1.1485117301646142e-09
from O 0 1.0644367609558003e-09
3 O 0 2.1973040276179745e-08
unrelated O 0 1.821510942079385e-08
families O 0 4.852299118063286e-11
, O 0 6.877421548923124e-11
all O 0 2.163614253036794e-11
Palestinian O 0 1.7843651001214766e-09
Arabs O 0 2.0122017385659774e-09
from O 0 6.732424617794663e-10
the O 0 5.30610555493638e-10
region O 0 3.72624953115519e-09
of O 0 1.0402477990112402e-08
Jerusalem O 0 8.944342653194326e-07
. O 0 6.441258619815926e-07

The O 0 1.1904066923307255e-06
clinical O 0 0.0007205501897260547
diagnosis O 1 0.9994813799858093
of O 1 0.9987503290176392
AGU B-Disease 1 1.0
is O 0 1.1296251614112407e-06
often O 0 5.3429021207307414e-09
difficult O 0 2.059720038971591e-08
, O 0 4.5831879957880517e-10
in O 0 1.516902575771084e-10
particular O 0 4.938839892609792e-10
early O 0 3.2640516955950716e-09
in O 0 2.1121895898978948e-10
the O 0 7.099135168608939e-10
course O 0 2.1713400855105647e-08
of O 0 8.257716288539996e-09
the O 0 2.9353307340329593e-08
disease O 0 3.955540250899503e-07
, O 0 3.3926964015940086e-10
and O 0 2.550042677018638e-10
most O 0 2.0123577804120885e-10
of O 0 2.2619055073391792e-08
the O 0 9.0916728368029e-08
patients O 0 2.4713136781429057e-07
are O 0 3.0264160066906243e-09
diagnosed O 0 2.592823307168146e-07
after O 0 7.522924505565243e-09
the O 0 2.4532984532754654e-09
age O 0 2.2333287219566955e-08
of O 0 7.642752564152033e-08
5 O 0 2.317664353768123e-07
years O 0 7.626022124895826e-08
. O 0 5.142447321304644e-07

However O 0 2.899683977375389e-06
, O 0 1.2015827621780772e-07
since O 0 3.271925663739239e-08
these O 0 4.622591642799989e-09
patients O 0 4.386368157582865e-09
excrete O 0 4.034944467434798e-08
early O 0 4.310455548051095e-09
large O 0 5.910903988493033e-10
amounts O 0 1.9392314420940693e-09
of O 0 5.0106794269311195e-09
aspartylglucosamine O 0 1.6102985966881533e-07
in O 0 1.4865993991364235e-09
urine O 0 2.767022611038783e-09
, O 0 2.2100879459863165e-10
biochemical O 0 1.6153952842046237e-08
screening O 0 8.489963398972122e-09
is O 0 3.954830352093097e-10
easy O 0 1.4477982146487989e-09
by O 0 2.4164881207155986e-10
urine O 0 2.091932671532959e-08
chromatography O 0 8.14259510661941e-06
. O 0 9.677739853941603e-08
. O 0 6.5346989686077e-07

Detection O 0 1.851943670772016e-05
of O 0 5.73888200960937e-07
heterozygous O 0 1.6660098367538012e-07
carriers O 0 4.417771748421728e-08
of O 0 1.236679594285306e-07
the O 0 8.171377885446418e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 9.059352123585995e-06
ATM O 0 0.00033714284654706717
) O 0 2.171191049171739e-08
gene O 0 9.574697479308725e-09
by O 0 3.492830913387479e-09
G2 O 0 8.420873200520873e-05
phase O 0 0.0001679923152551055
chromosomal O 0 0.0006971445982344449
radiosensitivity O 0 0.0001568634033901617
of O 0 6.152969945105724e-06
peripheral O 1 0.8789900541305542
blood O 0 5.881905963178724e-05
lymphocytes O 0 1.4003711839905009e-05
. O 0 2.163198359994567e-06

In O 0 0.0015609388938173652
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9993307590484619
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.7238820027596375e-07
patients O 0 5.372089617594611e-08
, O 0 1.4967337369498068e-09
mutations O 0 1.1146863432287546e-09
in O 0 1.305504149229364e-09
a O 0 2.1420918372427877e-09
single O 0 1.3896117589951018e-09
gene O 0 7.46159134479285e-09
, O 0 2.283870426111889e-09
ATM O 0 2.514520247132168e-06
, O 0 7.059424156352634e-10
result O 0 6.584023326539068e-10
in O 0 1.8968111525907716e-09
an O 0 1.692594366886624e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 9.634363777877297e-07
embraces O 0 5.375988507694274e-07
a O 0 1.793483050960276e-08
variety O 0 2.1425341500957984e-08
of O 0 3.094791267699293e-08
clinical O 0 3.2598418897578085e-07
features O 0 3.46854776012151e-08
and O 0 1.312763497907099e-08
manifests O 0 2.2598922555516765e-07
extreme O 0 7.346374104599818e-07
radiosensitivity O 0 5.558706106967293e-06
and O 0 8.430451892138535e-09
a O 0 1.527652848665184e-08
strong O 0 1.7383797512593446e-08
pre O 0 1.3655545444635209e-05
- O 0 1.6718014421712724e-06
disposition O 0 3.9947144614416175e-06
to O 0 1.1193148452548485e-07
malignancy B-Disease 0 0.04593386873602867
. O 0 2.2592853383684997e-06

Heterozygotes O 0 9.22940034797648e-06
for O 0 1.1182052617186855e-07
the O 0 5.326431917751506e-08
ATM O 0 7.34027844373486e-06
gene O 0 1.5707916745100192e-08
have O 0 2.9644725563215957e-10
no O 0 4.427476718582568e-10
clinical O 0 4.455859681229413e-09
expression O 0 2.609132909725531e-09
of O 0 6.111625907578855e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 4.9662574497233436e-08
may O 0 2.926910980249886e-08
be O 0 1.1248490139337264e-08
cancer B-Disease 0 4.6921840635150147e-07
prone O 0 4.1037107934016603e-08
with O 0 6.956728526574807e-10
a O 0 1.444224473345912e-08
moderate O 0 1.5720063117896643e-07
increase O 0 4.463719172065339e-09
in O 0 4.883817350531672e-09
in O 0 1.5432211952770558e-08
vitro O 0 5.847675765835447e-07
radiosensitivity O 0 3.89410297430004e-06
. O 0 4.232188359765132e-07

We O 0 4.3563088070186495e-07
performed O 0 1.0013616247306345e-06
a O 0 7.445174787790165e-08
blind O 0 5.411434926827496e-07
chromosomal O 0 1.6875925439308048e-06
analysis O 0 7.798890067078901e-08
on O 0 4.6739666004214087e-07
G2 O 0 1.3062469406577293e-05
- O 0 9.230003428228883e-08
phase O 0 9.243692034033302e-08
lymphocytes O 0 7.774440646812764e-09
from O 0 6.876798241961524e-09
7 O 0 6.8661066165987e-08
unrelated O 0 4.148708683260338e-07
A B-Disease 1 0.9998661279678345
- I-Disease 1 0.9999473094940186
T I-Disease 1 0.9999998807907104
patients O 0 5.605962201116199e-07
, O 0 7.859005002330832e-09
13 O 0 3.9128316586811707e-08
obligate O 0 2.3544541249975737e-07
A B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999837875366211
T I-Disease 1 0.9999996423721313
heterozygotes O 0 6.61914236843586e-06
( O 0 5.620692355989831e-09
parents O 0 1.9449052091058405e-10
of O 0 5.989929663385851e-10
the O 0 2.196029136314337e-09
patients O 0 3.0391016370145962e-09
) O 0 1.6405976577260617e-10
, O 0 3.0775818005146505e-10
and O 0 6.327954826801374e-10
14 O 0 1.5251897522716718e-08
normal O 0 3.018663363718588e-08
controls O 0 4.1901042635572594e-08
following O 0 3.116071400910414e-09
X O 0 1.6498492527716735e-07
- O 0 3.322874420064181e-08
irradiation O 0 3.630419698197329e-08
with O 0 2.5705246819995864e-09
1 O 0 3.95035300471136e-07
Gy O 0 6.25306256551994e-07
in O 0 8.385864225246564e-10
order O 0 2.1073688627470943e-10
to O 0 2.1444862552399968e-10
evaluate O 0 7.591029138609429e-09
this O 0 1.0542975381611086e-09
cytogenetic O 0 4.3101167079839797e-07
method O 0 2.426272338595936e-08
as O 0 2.6529973773392612e-09
a O 0 9.312417503792858e-10
tool O 0 1.7178582112364893e-08
for O 0 5.340098363504353e-10
detection O 0 2.735014845711703e-07
of O 0 4.207952315482544e-07
ATM O 0 0.0005322638317011297
carriers O 0 4.430287390277954e-06
. O 0 1.1449819794506766e-06

Both O 0 7.1624444899498485e-06
A B-Disease 1 0.999998927116394
- I-Disease 1 0.999997615814209
T I-Disease 1 0.9999997615814209
homozygotes O 0 7.566735439468175e-05
and O 0 3.20862874048089e-08
heterozygotes O 0 1.873489736681222e-07
showed O 0 5.0051105482396e-09
significantly O 0 7.9492590288055e-10
increased O 0 4.0065120665566667e-10
levels O 0 4.9995576567596345e-09
of O 0 1.00121733126457e-08
radiation O 0 0.053798526525497437
- O 0 6.0088846112194005e-06
induced O 0 5.120980858919211e-06
chromatid O 0 9.415747626917437e-05
damage O 0 9.990437774831662e-07
relative O 0 2.6600068281368294e-07
to O 0 2.7076509923062986e-09
that O 0 9.633126518693302e-10
of O 0 3.944091986340936e-08
normal O 0 1.0266783192491857e-06
controls O 0 4.427550720720319e-06
. O 0 5.273623173707165e-07

These O 0 8.222545488933974e-08
results O 0 5.810973746633863e-08
show O 0 5.503608946355598e-08
that O 0 9.511278431517667e-10
the O 0 1.6475670605586856e-08
G2 O 0 1.5516616258537397e-05
- O 0 2.9276631607899617e-07
phase O 0 1.4652991922048386e-06
chromosomal O 0 5.713663426831772e-07
radiosensitivity O 0 7.827799777260225e-07
assay O 0 3.572608875401784e-08
can O 0 8.078370195008233e-10
be O 0 3.2183158915621846e-10
used O 0 2.687162714565261e-10
for O 0 1.179559089292681e-10
the O 0 3.6525865665382184e-10
detection O 0 4.3081973899461445e-07
of O 0 3.625424369602115e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999984502792358
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.00013334129471331835
. O 0 1.8337659639655612e-06

In O 0 6.41132658074639e-07
combination O 0 1.6107529745568172e-06
with O 0 7.014025982243766e-08
molecular O 0 3.5572975320974365e-05
genetic O 0 5.410640255831822e-07
analyses O 0 1.1161107238422119e-07
, O 0 1.7418936293367437e-09
this O 0 2.440742330467316e-10
test O 0 1.2419296702148586e-09
may O 0 4.033817169180054e-10
be O 0 4.647251333755875e-11
of O 0 2.1733102817389494e-10
value O 0 5.6515425672643e-10
in O 0 1.3734897941208857e-10
studies O 0 5.59813584377622e-10
of O 0 7.51752771144254e-10
familial B-Disease 0 7.175525951197415e-08
and I-Disease 0 2.9602661655303564e-08
sporadic I-Disease 0 4.213753345538862e-05
cancers I-Disease 0 0.0009403196745552123
aimed O 0 2.0793369515104132e-07
at O 0 1.179257154149127e-07
determination O 0 1.462958110209911e-08
of O 0 9.444972803862584e-09
the O 0 2.184857406106744e-09
potential O 0 8.990410194087417e-09
involvement O 0 1.3401653120581614e-08
of O 0 2.2390569398567095e-08
ATM O 0 1.1943721801799256e-05
mutations O 0 5.554248261319117e-08
in O 0 2.2623368067797855e-08
tumor B-Disease 0 8.984019586932845e-06
risk O 0 2.8646340410887206e-07
or O 0 1.5584785018063485e-08
development O 0 8.343624813278439e-08
. O 0 3.8108499467170986e-08
. O 0 3.9971737919586303e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999945163726807
telangiectasia I-Disease 1 0.999998927116394
: O 0 8.473838164491099e-08
identification O 0 4.284228793949296e-08
and O 0 1.5707429801281592e-09
detection O 0 2.236593445559265e-06
of O 0 8.729127785045421e-07
founder O 0 5.0885413656942546e-05
- O 0 1.1868721685459604e-06
effect O 0 4.3502018343133386e-07
mutations O 0 1.1268632249539223e-08
in O 0 2.753324013227143e-09
the O 0 5.454541263105739e-09
ATM O 0 1.8332553963773535e-06
gene O 0 4.779627804651909e-09
in O 0 1.6206037622978897e-09
ethnic O 0 8.150682795360353e-09
populations O 0 2.2070656413575307e-08
. O 0 3.530030880938284e-07

To O 0 3.3402475452248837e-08
facilitate O 0 9.627991914840095e-08
the O 0 8.802876649838254e-09
evaluation O 0 5.730187524477515e-08
of O 0 8.604901324815728e-08
ATM O 0 1.2431599316187203e-05
heterozygotes O 0 6.011304094499792e-07
for O 0 6.330058255343829e-09
susceptibility O 0 1.490973744466828e-07
to O 0 3.3189138104461335e-09
other O 0 3.951923588374484e-08
diseases O 0 0.39563482999801636
, O 0 2.582328573197401e-09
such O 0 5.34489030812324e-09
as O 0 7.939498573250603e-06
breast B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9993579983711243
, O 0 1.3431957768261782e-07
we O 0 2.8693250442302087e-08
have O 0 1.8597261508546126e-09
attempted O 0 1.4371405399060677e-08
to O 0 1.5393362973181723e-10
define O 0 7.650931443947684e-09
the O 0 3.042680107867568e-09
most O 0 2.465507797921873e-10
common O 0 3.421510852419374e-10
mutations O 0 5.977327660611209e-11
and O 0 3.526458292046897e-11
their O 0 8.862523215302787e-11
frequencies O 0 9.787859767129703e-08
in O 0 1.6105781242004014e-07
ataxia B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999380111694336
telangiectasia I-Disease 1 1.0
( O 0 0.00018540100427344441
A B-Disease 1 1.0
- I-Disease 1 0.9999881982803345
T I-Disease 1 0.9999983310699463
) O 0 6.169099719954829e-08
homozygotes O 0 7.271909225892159e-07
from O 0 1.2827179318719573e-08
10 O 0 1.4239345702549144e-08
ethnic O 0 2.4236022078127917e-09
populations O 0 1.6492052168359805e-08
. O 0 8.902162562662852e-08

Both O 0 5.327015628608933e-07
genomic O 0 1.0497020639377297e-06
mutations O 0 6.283100617565651e-08
and O 0 3.138199478058823e-09
their O 0 9.73475189347539e-10
effects O 0 8.864308824740874e-07
on O 0 1.4569313577794674e-07
cDNA O 0 1.798378548301116e-07
were O 0 1.6467565089328673e-08
characterized O 0 9.43068343417508e-08
. O 0 1.6437964234228275e-07

Protein O 0 9.54619281401392e-06
- O 0 5.758827796853438e-07
truncation O 0 8.93454796369042e-07
testing O 0 7.680264957343752e-08
of O 0 2.503147378263293e-08
the O 0 1.1102650354644084e-08
entire O 0 6.19096596210511e-08
ATM O 0 4.4666217036137823e-07
cDNA O 0 4.472106951425303e-08
detected O 0 2.355183426061558e-08
92 O 0 4.2280209555656256e-08
( O 0 3.961853956013783e-09
66 O 0 4.319815261055737e-08
% O 0 4.06007849562684e-09
) O 0 1.3666804354883766e-09
truncating O 0 1.0439830333552891e-07
mutations O 0 6.013480380318015e-09
in O 0 7.055362072350135e-09
140 O 0 2.3266794713094896e-08
mutant O 0 1.134974212391171e-07
alleles O 0 6.57890808497541e-08
screened O 0 3.376462700543925e-06
. O 0 1.3630412922793766e-06

The O 0 2.128247842847486e-06
haplotyping O 0 0.0002106085594277829
of O 0 1.354762844130164e-06
patients O 0 8.953485064466804e-08
with O 0 4.3948760186651725e-09
identical O 0 1.8711541827087785e-07
mutations O 0 8.972902421078288e-09
indicates O 0 8.394254180643657e-09
that O 0 1.250531345142747e-10
almost O 0 4.507951789634035e-10
all O 0 4.3196193150185636e-11
of O 0 2.7871385754885125e-10
these O 0 4.3160780505147045e-11
represent O 0 3.3991673364930364e-10
common O 0 6.942107999563518e-10
ancestry O 0 3.181118701789387e-10
and O 0 1.2452616715563636e-10
that O 0 1.2493321654982736e-10
very O 0 1.2632159762659967e-09
few O 0 1.6632587529485932e-09
spontaneously O 0 4.118342289416432e-08
recurring O 0 7.680658313802269e-07
ATM O 0 5.705843068426475e-05
mutations O 0 8.3417455698509e-07
exist O 0 9.824666449276265e-07
. O 0 9.796074209589278e-07

Assays O 0 5.912747838010546e-07
requiring O 0 7.076322106058797e-08
minimal O 0 2.5983183604694204e-07
amounts O 0 1.8867233109176595e-08
of O 0 4.374261397543933e-09
genomic O 0 1.6472528230337957e-08
DNA O 0 1.043204367334738e-08
were O 0 1.5626866467499667e-09
designed O 0 2.1039079367568547e-09
to O 0 1.1374778896566795e-10
allow O 0 1.0409340056583005e-09
rapid O 0 4.4708958313322e-08
screening O 0 1.68871761019318e-08
for O 0 1.7466578183800152e-09
common O 0 1.4019867933257046e-08
ethnic O 0 6.786009976167406e-08
mutations O 0 6.214983159225085e-07
. O 0 7.277264444383036e-07

These O 0 8.190238531824434e-08
rapid O 0 5.730197472075815e-07
assays O 0 1.4773885936847364e-07
detected O 0 3.8963730020213916e-08
mutations O 0 1.703491125937262e-09
in O 0 2.264286980135921e-09
76 O 0 2.5852276763771442e-08
% O 0 5.294745086814601e-09
of O 0 9.4679911910589e-08
Costa O 0 1.2482590818763128e-06
Rican O 0 1.8997611732629593e-06
patients O 0 1.4642930068475835e-07
( O 0 1.580594433114868e-09
3 O 0 4.9741331054065085e-09
) O 0 1.222353052110492e-10
, O 0 1.5070569792108301e-10
50 O 0 5.730280139282229e-10
% O 0 3.347112864648949e-10
of O 0 7.457521711273785e-09
Norwegian O 0 2.595693104012753e-06
patients O 0 3.460565167756613e-08
( O 0 9.46213329910961e-10
1 O 0 7.648567112994442e-09
) O 0 5.41211901683436e-11
, O 0 7.372122357018895e-11
25 O 0 6.268084384863926e-10
% O 0 2.4342519666653573e-10
of O 0 4.447538337615242e-09
Polish O 0 3.4336895623710006e-05
patients O 0 1.3540727650251938e-07
( O 0 1.052553488811725e-09
4 O 0 4.036451617395187e-09
) O 0 7.004163221635551e-11
, O 0 1.1641770880643776e-10
and O 0 1.3287332345512937e-10
14 O 0 6.97466795429591e-09
% O 0 1.9446391164024135e-09
of O 0 8.0581102679389e-08
Italian O 0 0.0010967656271532178
patients O 0 7.687546599299822e-07
( O 0 7.738948148983127e-09
1 O 0 5.485635057311811e-08
) O 0 3.8399436408376175e-10
, O 0 2.4287100108821846e-10
as O 0 2.1119640758460179e-10
well O 0 4.702034317460857e-10
as O 0 1.068122035263741e-09
in O 0 2.3441484309216776e-09
patients O 0 7.721063788324045e-09
of O 0 7.846022498370075e-08
Amish O 0 2.9034968065388966e-06
/ O 0 4.98045710628503e-06
Mennonite O 0 8.141572038766753e-07
and O 0 6.828385856749719e-09
Irish O 0 3.3041141023204545e-07
English O 0 5.933020474913064e-07
backgrounds O 0 7.202057190625055e-07
. O 0 5.637497793031798e-07

Additional O 0 1.926475334812494e-07
mutations O 0 3.4952318372916125e-08
were O 0 7.474838525922678e-09
observed O 0 6.890084947031028e-09
in O 0 1.0277221296206562e-09
Japanese O 0 5.7810041198536055e-08
, O 0 2.494700002131367e-09
Utah O 0 1.4676567161586718e-07
Mormon O 0 1.714032293875789e-08
, O 0 9.207049567194758e-10
and O 0 2.5618611676492264e-09
African O 0 1.455194222899081e-07
American O 0 1.1578667908906937e-06
patients O 0 3.0386477192223538e-06
. O 0 1.6620598444205825e-06

These O 0 4.5796799241770714e-08
assays O 0 5.9065264679247775e-08
should O 0 1.7364931714780596e-09
facilitate O 0 3.676275284192343e-09
screening O 0 1.9339355006309233e-08
for O 0 2.0446776716198656e-08
A B-Disease 1 0.9999819993972778
- I-Disease 1 0.9998623132705688
T I-Disease 1 0.9999932050704956
heterozygotes O 0 9.026529141920037e-07
in O 0 1.736340848879081e-09
the O 0 7.118375333625693e-10
populations O 0 3.590982511347818e-10
studied O 0 6.316070511047656e-08
. O 0 4.244461671021327e-09
. O 0 7.784206701444418e-08

The O 0 2.4283421225845814e-05
von B-Disease 1 0.9995642304420471
Hippel I-Disease 1 0.9998014569282532
- I-Disease 1 0.9994107484817505
Lindau I-Disease 1 0.9571360349655151
tumor I-Disease 0 3.419138374738395e-05
suppressor O 0 1.8799378267431166e-06
gene O 0 2.005508825675406e-08
is O 0 6.065857260928453e-10
required O 0 5.220547993900482e-09
for O 0 9.76376579586713e-09
cell O 0 1.2133643849665532e-06
cycle O 0 3.417281391193683e-08
exit O 0 2.3729899822910738e-08
upon O 0 3.7048703660502724e-08
serum O 0 3.081138970628672e-07
withdrawal O 0 5.156010729479021e-07
. O 0 6.697171670566604e-07

The O 0 2.538072862989793e-07
inactivation O 0 7.320955774048343e-06
of O 0 1.5056241409183713e-07
the O 0 2.787548964988673e-07
von B-Disease 1 0.997721254825592
Hippel I-Disease 1 0.9997904896736145
- I-Disease 1 0.9999682903289795
Lindau I-Disease 1 0.9999208450317383
( I-Disease 0 1.1620511941146106e-05
VHL I-Disease 0 0.08521398156881332
) I-Disease 0 1.4845792293272098e-06
tumor I-Disease 0 0.00039119136636145413
suppressor O 0 0.0001035262321238406
gene O 0 2.504824578863918e-06
predisposes O 0 3.478277903923299e-06
affected O 0 3.695074823895084e-08
individuals O 0 6.526733042910848e-10
to O 0 3.977693729950715e-09
the O 0 8.865247309586266e-07
human O 1 0.9996792078018188
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 6.456104983953992e-08
is O 0 2.0460342309291946e-09
associated O 0 5.403264502490401e-09
with O 0 9.536606171423045e-09
sporadic B-Disease 1 0.9999899864196777
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.058201342821121216
RCC B-Disease 1 0.999997615814209
) O 0 4.7267894842661917e-07
and O 0 4.610258201864781e-07
brain B-Disease 1 0.9989811778068542
hemangioblastomas I-Disease 0 0.008038170635700226
. O 0 2.9630821245518746e-06

VHL O 0 0.004955699667334557
- O 0 4.7526707930956036e-05
negative O 0 1.3079968539386755e-06
786 O 0 9.692001185612753e-05
- O 0 0.000535953207872808
0 O 0 2.935319344032905e-06
RCC B-Disease 0 0.03234009072184563
cells O 0 9.349550111892313e-08
are O 0 4.257166619225927e-09
tumorigenic O 0 2.3407953904097667e-06
in O 0 6.258007800852283e-08
nude O 0 1.3419116839941125e-05
mice O 0 2.9101758514116227e-07
which O 0 1.175620156779189e-09
is O 0 2.95649948967025e-10
suppressed O 0 1.10636211303472e-09
by O 0 4.901945169222266e-11
the O 0 1.98456029387728e-09
reintroduction O 0 5.44433724769533e-08
of O 0 8.917695737409304e-08
VHL B-Disease 0 0.00032700266456231475
. O 0 3.2717939575377386e-06

Remarkably O 0 7.685327727813274e-05
, O 0 1.3184999758664162e-08
this O 0 3.294943762277569e-10
occurs O 0 8.149980135208068e-10
without O 0 2.5655860769191463e-10
affecting O 0 2.477070493167588e-10
the O 0 1.3515744079484193e-10
growth O 0 6.280411191106339e-10
rate O 0 2.8414610664384554e-09
and O 0 5.050804774420214e-10
cell O 0 3.282064042764432e-08
cycle O 0 1.5079434367848421e-09
profile O 0 6.818738906844146e-10
of O 0 6.591198142835708e-10
these O 0 2.507473950696948e-10
cells O 0 1.3836610746054134e-09
in O 0 1.2937446669525343e-09
culture O 0 6.601382551707502e-08
. O 0 6.421312548354763e-08

The O 0 3.999708042101702e-06
786 O 0 7.442716014338657e-05
- O 0 7.335963164223358e-05
0 O 0 9.03119541817432e-07
cell O 0 2.6251786948705558e-06
line O 0 1.8502331045056053e-07
, O 0 2.53452725473835e-09
like O 0 3.096212397579734e-09
many O 0 2.4390216513126006e-09
cancer B-Disease 0 1.8665858760869014e-06
cells O 0 1.9132135875565837e-08
, O 0 1.638068902742873e-09
fails O 0 3.955133998090332e-09
to O 0 8.973241039100799e-10
exit O 0 5.81292489698626e-08
the O 0 3.1733044636439445e-08
cell O 0 3.5402328535383276e-07
cycle O 0 1.0658634863602856e-08
upon O 0 8.246603400152708e-09
serum O 0 1.347407732055217e-07
withdrawal O 0 1.1926778142878902e-07
. O 0 4.20811318235792e-07

Here O 0 4.034924586449051e-06
, O 0 3.429537542842809e-08
it O 0 1.7147834263653294e-09
is O 0 5.052057105991992e-10
shown O 0 8.392408434865217e-10
that O 0 5.704834521447211e-11
reintroduction O 0 3.90256671423117e-09
of O 0 2.490440298430485e-09
the O 0 5.55275159186408e-09
wild O 0 2.8874644897314283e-08
- O 0 2.0206374529152527e-07
type O 0 5.229709358900436e-07
VHL B-Disease 0 2.999660500790924e-05
gene O 0 6.588150114339442e-08
restores O 0 1.1798206855928584e-07
the O 0 5.411164849533634e-09
ability O 0 2.4228503647805155e-08
of O 0 1.2433675919965026e-06
VHL O 1 0.9967854022979736
- O 0 0.01571359671652317
negative O 0 7.02198849467095e-06
RCC B-Disease 1 0.9999995231628418
cancer I-Disease 0 0.007159483153373003
cells O 0 1.95290663640435e-08
to O 0 4.42663461441839e-09
exit O 0 1.974650274405576e-07
the O 0 6.125763718500821e-08
cell O 0 9.98037194221979e-07
cycle O 0 1.643812908014297e-08
and O 0 1.8564798587306086e-09
enter O 0 2.752764771685179e-07
G0 O 0 0.00013694817607756704
/ O 0 5.273208444123156e-06
quiescence O 0 3.6078931771044154e-06
in O 0 4.1902403324911575e-08
low O 0 1.6664801023580367e-06
serum O 0 2.7453188522486016e-06
. O 0 4.988539217265497e-07

Both O 0 5.659256203216501e-06
VHL O 0 0.0035444851964712143
- O 0 3.4293132102902746e-06
positive O 0 1.8359020970137863e-08
and O 0 4.27394510893464e-08
VHL O 0 0.16037233173847198
- O 0 1.7773347281035967e-05
negative O 0 3.152958072405454e-07
RCC B-Disease 1 0.7693848013877869
cells O 0 4.43138432615342e-08
exit O 0 3.775946666451091e-08
the O 0 7.796417733629823e-09
cell O 0 1.4814223447956465e-07
cycle O 0 3.0494429203997697e-09
by O 0 4.969009648192468e-10
contact O 0 2.5100851530623913e-07
inhibition O 0 2.6305870051146485e-06
. O 0 9.691775630926713e-07

The O 0 3.996962277597049e-06
cyclin O 0 4.3194377212785184e-05
- O 0 2.244835513920407e-06
dependent O 0 2.83710932080794e-07
kinase O 0 8.646638320897182e-07
inhibitor O 0 3.759020898996823e-07
, O 0 1.6935558733166545e-08
p27 O 0 2.5709168767207302e-06
, O 0 1.1905453511928954e-08
accumulates O 0 5.044782369623135e-08
upon O 0 8.364494874513184e-09
serum O 0 5.065744446142162e-08
withdrawal O 0 1.3505990992257466e-08
, O 0 1.6766203980722594e-09
only O 0 1.7529480644817852e-10
in O 0 2.0312342086103996e-10
the O 0 9.269195966332688e-10
presence O 0 1.1698096713530504e-08
of O 0 2.7391993739911413e-07
VHL B-Disease 0 0.00011410694423830137
, O 0 1.340308486419417e-08
as O 0 2.133887067046203e-09
a O 0 1.5697426691829719e-09
result O 0 8.172161281017054e-10
of O 0 2.8557722853150835e-09
the O 0 1.3056934422550626e-09
stabilization O 0 1.7666150142758852e-07
of O 0 1.1916999653749372e-07
the O 0 2.5784351009860984e-07
protein O 0 1.954742174348212e-06
. O 0 4.0883639940147987e-07

We O 0 2.7865706897500786e-07
propose O 0 8.46506651441814e-08
that O 0 4.564866817879931e-10
the O 0 2.7994684348442433e-09
loss O 0 1.245225575985387e-07
of O 0 6.706784461130155e-07
wild O 0 4.875359991274308e-07
- O 0 1.1010492926288862e-06
type O 0 1.357458131678868e-06
VHL B-Disease 0 1.4802567420701962e-05
gene O 0 7.264219892277879e-09
results O 0 3.5418985522284174e-09
in O 0 1.2936952620279385e-09
a O 0 1.1395456800400439e-09
specific O 0 3.101632506385954e-09
cellular O 0 1.9764261196542066e-06
defect O 0 2.311906968088806e-07
in O 0 1.527617854435448e-08
serum O 0 3.7337824210226245e-07
- O 0 1.0648520287759311e-07
dependent O 0 6.289346998755718e-08
growth O 0 6.263763907554676e-08
control O 0 2.5167371404677397e-06
, O 0 4.207689308088902e-09
which O 0 9.218593666204811e-10
may O 0 1.1346317663196714e-08
initiate O 0 1.0143809703322404e-07
tumor B-Disease 0 9.770391443453263e-06
formation O 0 9.556677468935959e-06
. O 0 7.14578345650807e-06

This O 0 5.88787720801065e-08
is O 0 9.876068851610853e-09
corrected O 0 3.5166838330269456e-08
by O 0 2.399347942549923e-10
the O 0 1.561345830403127e-09
reintroduction O 0 3.6411549331205606e-08
of O 0 2.540219945501576e-08
wild O 0 5.851703832604471e-08
- O 0 1.4695211802973063e-06
type O 0 0.00014423289394471794
VHL B-Disease 1 0.9995710253715515
, O 0 2.503028781575267e-06
implicating O 1 0.8833893537521362
VHL B-Disease 1 0.6810315251350403
as O 0 2.091773438905875e-07
the O 0 4.3246213721204185e-08
first O 0 3.599042841528899e-08
tumor B-Disease 0 2.2423407699534437e-06
suppressor O 0 6.501840061901021e-07
involved O 0 3.499901524151028e-08
in O 0 3.462015785160588e-09
the O 0 8.718726185463765e-09
regulation O 0 3.529856087425287e-07
of O 0 1.8552033509422472e-07
cell O 0 7.306684892682824e-06
cycle O 0 6.234585470110687e-08
exit O 0 2.775380636421687e-08
, O 0 1.671332960917482e-09
which O 0 3.7748051906483227e-10
is O 0 3.238970203156555e-10
consistent O 0 2.2588693138203553e-09
with O 0 4.527623831407368e-10
its O 0 1.5941280517850487e-09
gatekeeper O 0 2.7808206937152136e-07
function O 0 1.0630722613313992e-07
in O 0 2.023973166842552e-08
the O 0 7.358926978895397e-08
kidney O 0 0.00024976753047667444
. O 0 1.3271116472424183e-07
. O 0 1.42502892686025e-06

Piebaldism B-Disease 1 1.0
with O 0 0.16916558146476746
deafness B-Disease 1 1.0
: O 0 3.7870802316319896e-07
molecular O 0 5.219709464654443e-07
evidence O 0 1.993160836377683e-08
for O 0 6.747800096462697e-10
an O 0 2.533502518886621e-09
expanded O 0 1.492661795055028e-05
syndrome O 1 0.9999805688858032
. O 0 7.267413820954971e-06

In O 0 7.990795438672649e-07
a O 0 3.7290067211870337e-07
South O 0 5.635127422465303e-07
African O 0 2.5020190719260427e-07
girl O 0 5.330568342287734e-07
of O 0 4.499731005580543e-07
Xhosa O 0 0.00106918066740036
stock O 0 3.0185404398253013e-07
with O 0 9.399128586551342e-09
severe O 0 7.124215335352346e-05
piebaldism B-Disease 0 0.04821864143013954
and O 0 6.6330258050584234e-06
profound O 1 0.999998927116394
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 9.765709546627477e-05
identified O 0 8.817295906737854e-07
a O 0 1.2058941400994172e-08
novel O 0 7.925026856980821e-09
missense O 0 4.3928082504862687e-08
substitution O 0 5.00346182263911e-08
at O 0 1.9374934367988317e-07
a O 0 2.104342300413009e-08
highly O 0 4.027924305205488e-08
conserved O 0 5.078456410956278e-08
residue O 0 8.163460307741843e-08
in O 0 3.4219169720017817e-09
the O 0 5.023847116092384e-09
intracellular O 0 6.759309201243013e-08
kinase O 0 6.333889501775047e-08
domain O 0 6.342581571061601e-08
of O 0 4.322733104800136e-08
the O 0 1.9981936816293455e-07
KIT O 0 0.0037897001020610332
proto O 0 0.007618015632033348
- O 0 9.525427594780922e-05
oncogene O 0 6.569960532942787e-05
, O 0 3.274870152836229e-07
R796G O 0 1.72647341969423e-05
. O 0 1.8701333601711667e-06

Though O 0 6.492882221209584e-06
auditory B-Disease 0 0.004539795219898224
anomalies I-Disease 0 0.0005059513496235013
have O 0 1.1527721888171527e-08
been O 0 8.323212341565522e-09
observed O 0 1.074854427685068e-08
in O 0 6.30715968341633e-09
mice O 0 2.583098535069439e-08
with O 0 3.881994725674076e-09
dominant O 0 0.052542794495821
white O 0 4.30844520451501e-05
spotting O 1 0.8698647618293762
( O 0 3.992198571722838e-07
W O 0 0.00012717126810457557
) O 0 1.558989159988755e-09
due O 0 2.5836058625827718e-08
to O 0 8.274049889678281e-09
KIT O 1 0.8383812308311462
mutations O 0 2.092330760206096e-05
, O 0 1.9877748854923993e-05
deafness B-Disease 1 1.0
is O 0 1.8717680916324753e-07
not O 0 3.963395833750383e-09
typical O 0 1.3871728299363895e-07
in O 0 5.700152794219093e-09
human O 0 5.570363725837524e-08
piebaldism B-Disease 0 8.740583325561602e-06
. O 0 7.70116685089306e-07

Thus O 0 1.0103941576744546e-06
, O 0 1.411431149733744e-08
the O 0 4.043525070329679e-09
occurrence O 0 2.5134627890111005e-07
of O 0 0.00024054103414528072
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.0813437206234084e-06
this O 0 8.738037848843305e-09
patient O 0 2.3146133898421795e-08
extends O 0 1.963273321692327e-09
considerably O 0 1.0577060116645498e-08
the O 0 4.963118249712295e-10
phenotypic O 0 6.511296390954158e-08
range O 0 4.081136850686562e-08
of O 0 2.5949796977897677e-08
piebaldism B-Disease 0 5.085537395643769e-07
due O 0 2.6395827745773204e-08
to O 0 3.6805059000499796e-09
KIT O 0 4.758890099765267e-06
gene O 0 2.390976838739789e-08
mutation O 0 5.262095204017214e-09
in O 0 4.298550404513435e-09
humans O 0 2.1872434530223472e-08
and O 0 6.2182889948303455e-09
tightens O 0 5.4230699930712944e-08
the O 0 8.015110353198907e-09
clinical O 0 3.228513207886863e-07
similarity O 0 8.121388361814752e-08
between O 0 8.472833883388375e-07
piebaldism B-Disease 0 8.748890650167596e-06
and O 0 4.406081277608109e-09
the O 0 7.282625058557812e-10
various O 0 1.5458216928720958e-09
forms O 0 3.515718205449048e-08
of O 0 1.1811861440946814e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999854564666748
. O 0 5.542585768125718e-07
. O 0 1.9744782093766844e-06

Cycloheximide O 0 0.00010458056931383908
facilitates O 0 1.1669435480143875e-06
the O 0 1.7902738846942157e-08
identification O 0 6.165735300101005e-08
of O 0 8.16793033209251e-08
aberrant O 0 2.2015373701833596e-07
transcripts O 0 1.3690028026758227e-06
resulting O 0 3.811547699683615e-08
from O 0 1.2552283656930285e-08
a O 0 6.553106501883121e-09
novel O 0 7.16389925159433e-09
splice O 0 1.0953772999755529e-07
- O 0 1.5978242728920122e-08
site O 0 3.5092850847462387e-09
mutation O 0 1.5070004133477255e-09
in O 0 4.229543382194834e-09
COL17A1 O 0 2.6756368242786266e-05
in O 0 1.6317333262350076e-08
a O 0 1.6043625095107927e-08
patient O 0 4.7068127173588437e-08
with O 0 1.84861530527769e-08
generalized O 0 0.3712793290615082
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999996423721313
bullosa I-Disease 1 0.9996700286865234
. O 0 3.132074198219925e-05

Patients O 0 4.319380877859658e-06
with O 0 4.04754786131889e-07
generalized O 1 0.9766675233840942
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998700618743896
often O 0 1.355247007950311e-07
show O 0 4.7733895058854614e-08
decreased O 0 7.348575792320844e-08
expression O 0 9.853190263697797e-09
of O 0 4.153367072490255e-08
type O 0 1.0056050086859614e-05
XVII O 1 0.7913889288902283
collagen O 0 1.8889411876443774e-05
, O 0 1.3010645716349245e-07
a O 0 1.4612506049616059e-07
transmembrane O 0 4.30017252028847e-07
hemidesmosomal O 0 1.8485942518964293e-06
protein O 0 8.095467762814224e-08
encoded O 0 2.758613781850272e-08
by O 0 1.6365456545486268e-08
COL17A1 O 0 0.00012507008796092123
. O 0 2.8542547170218313e-06

This O 0 5.6849550844617625e-08
report O 0 4.749250948066219e-08
documents O 0 4.948887522004952e-08
a O 0 1.480894784577913e-08
novel O 0 1.4271537729371175e-08
splice O 0 2.903868789871922e-07
- O 0 5.021358617796068e-08
site O 0 1.029070251234998e-08
mutation O 0 2.9603495210750452e-09
in O 0 3.9430219089808816e-09
COL17A1 O 0 3.8518021028721705e-05
in O 0 2.469275273142557e-08
a O 0 3.577729756898407e-08
patient O 0 7.576134208875374e-08
with O 0 1.9024426478608802e-08
generalized O 0 0.09926343709230423
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9989921450614929
, O 0 7.076740615730159e-08
and O 0 7.121230716222726e-09
applies O 0 1.7102571803206956e-08
a O 0 2.25373075757318e-09
new O 0 5.983843420764856e-10
methodology O 0 5.509876110920686e-09
to O 0 6.436929322894969e-10
define O 0 6.473428726394559e-08
and O 0 1.1232410557227013e-08
characterize O 0 4.195662484107743e-07
the O 0 2.280941835408612e-08
resulting O 0 4.936113739972825e-08
mRNA O 0 2.6058873459078313e-07
splice O 0 5.706464207833051e-07
variants O 0 5.463737124955514e-07
. O 0 5.120186870044563e-07

Mutational O 0 8.885592978913337e-05
analysis O 0 9.69760094449157e-07
of O 0 1.6224158798650024e-06
COL17A1 O 0 0.0002605091140139848
identified O 0 7.481202146664145e-07
a O 0 1.4082048949148884e-07
maternally O 0 2.003692316066008e-06
inherited O 0 1.2433436495484784e-05
G O 0 1.9985371181974187e-05
- O 0 8.611926318735641e-07
to O 0 7.375690813660185e-08
- O 0 3.8139787648105994e-05
T O 0 2.142229823220987e-05
transversion O 0 3.4287900234630797e-06
at O 0 2.885015248921263e-07
the O 0 8.538227014298627e-09
- O 0 1.4409171633644746e-08
1 O 0 1.7248810380010582e-08
position O 0 1.5785825979719448e-08
of O 0 8.601652012885097e-08
exon O 0 2.185147650379804e-06
32 O 0 1.9040635379496962e-06
. O 0 1.4468514564214274e-06

This O 0 5.6252002167411774e-08
acceptor O 0 8.67472351728793e-08
splice O 0 2.159241148547153e-06
- O 0 4.0440562543153646e-07
site O 0 5.831893190588744e-08
mutation O 0 4.344726800553644e-09
led O 0 8.352713187775862e-09
to O 0 8.482319846514486e-10
the O 0 1.7397761453707972e-08
formation O 0 2.761680889307172e-06
of O 0 2.1296284558047773e-06
aberrant O 0 4.194710356841824e-07
transcripts O 0 1.6242271385635831e-06
present O 0 5.461643581838871e-08
at O 0 3.8322068007801136e-07
extremely O 0 2.236419760492936e-07
low O 0 4.6586805524384545e-07
levels O 0 9.044055104823201e-07
. O 0 1.6965083204922848e-07

Based O 0 6.313215976661013e-07
on O 0 1.901336617038396e-07
our O 0 8.699092113317874e-09
recent O 0 1.0314985532389187e-09
finding O 0 3.057246900084465e-09
that O 0 3.881815147099843e-10
cycloheximide O 0 3.967569455198827e-07
stabilized O 0 9.932072316587437e-06
mutant O 0 2.80805920738203e-07
COL17A1 O 0 4.55746067018481e-06
transcripts O 0 4.7661072244409297e-07
in O 0 3.1391036436900777e-09
keratinocytes O 0 1.7526689433111642e-08
homozygous O 0 1.1125692367386364e-08
for O 0 1.304274688251894e-09
a O 0 1.3509597884819868e-08
frameshift O 0 1.974362220380499e-07
mutation O 0 6.028179733164052e-09
, O 0 1.3937181408962829e-09
the O 0 1.985605235788057e-09
effects O 0 1.5494924809900112e-06
of O 0 1.192598091392938e-07
the O 0 4.2407013012280004e-08
splice O 0 1.4887473298585974e-07
- O 0 1.0503120151383882e-08
site O 0 8.942281914947614e-10
mutation O 0 6.93813409502475e-11
on O 0 3.875321841206869e-09
splicing O 0 2.3427507045425955e-08
of O 0 1.7673826846476004e-08
COL17A1 O 0 5.195297944737831e-06
transcripts O 0 3.732525613031612e-07
were O 0 4.598426084356788e-09
determined O 0 3.507063306429359e-09
using O 0 2.655482944646792e-09
reverse O 0 5.1025256908587835e-08
transcriptase O 0 3.0167851150508795e-07
polymerase O 0 3.1031169100970146e-07
chain O 0 4.8183764533860085e-08
reaction O 0 2.5588335894610736e-09
of O 0 9.271445833292091e-09
total O 0 4.260602537442537e-09
RNA O 0 1.463999979023356e-07
from O 0 1.5209195680654375e-08
keratinocytes O 0 6.375024952376407e-08
incubated O 0 1.921634833479402e-07
for O 0 1.6798958668573505e-08
2 O 0 1.4060794910619734e-06
. O 0 3.224473346108425e-07

5 O 0 7.757106686767656e-06
h O 0 2.0210588900226867e-06
in O 0 3.271401638471616e-08
the O 0 6.782436390295743e-09
presence O 0 2.5425030969472573e-08
or O 0 1.905947399905017e-08
absence O 0 2.313550311328072e-07
of O 0 3.5139089504809817e-07
10 O 0 5.073310944680998e-07
microg O 0 3.2234845548373414e-06
cycloheximide O 0 3.173170171066886e-06
per O 0 3.6707635331367783e-07
ml O 0 1.6732783478801139e-06
. O 0 4.085253522134735e-07

Using O 0 2.3345036481714487e-07
this O 0 4.223086325083614e-09
approach O 0 7.036899773993355e-08
, O 0 3.828398043026482e-09
an O 0 5.235375244438956e-09
abnormally O 0 7.888065169936453e-07
spliced O 0 4.5632131673301046e-07
transcript O 0 9.226885140378727e-07
was O 0 6.764133075876089e-08
identified O 0 2.5248965140889368e-09
that O 0 1.0056489668786028e-10
contains O 0 1.1776528363593997e-10
an O 0 1.0539673300780095e-10
extra O 0 4.23183532660687e-09
264 O 0 1.1574915248502293e-08
bases O 0 9.678696066828252e-09
upstream O 0 1.0319206467102049e-07
from O 0 2.6130985375516502e-08
exon O 0 8.690685717738234e-07
32 O 0 1.4383503810222464e-07
, O 0 4.936252295806298e-09
resulting O 0 1.9190391498113968e-08
in O 0 1.2033391172394658e-08
a O 0 2.7911205791042448e-08
premature O 0 5.517050993830708e-08
termination O 0 1.3978126389702084e-07
codon O 0 3.428089883072971e-07
27 O 0 1.9829340089927427e-06
bp O 0 2.005979240493616e-06
downstream O 0 5.042800808041648e-07
from O 0 8.376951399213795e-08
the O 0 1.573509109675797e-07
cryptic O 0 4.48924356533098e-06
splice O 0 5.4577767514274456e-06
site O 0 1.795004550331214e-06
. O 0 1.571045686432626e-06

Three O 0 2.951412909624196e-07
other O 0 1.0612788869934775e-08
splice O 0 1.7263036511394603e-07
variants O 0 3.865416786652531e-08
, O 0 2.3310002816856468e-09
including O 0 1.1624401441423515e-09
one O 0 5.959980842185075e-10
derived O 0 1.4618833921176133e-09
from O 0 3.101336742972194e-09
the O 0 6.925038764649116e-09
skipping O 0 1.6677664405051473e-07
of O 0 1.1695991730675814e-07
exon O 0 1.5554486481050844e-06
32 O 0 2.0560410973757826e-07
, O 0 1.04660431432535e-08
were O 0 2.1676822115068717e-08
also O 0 7.054797190875206e-09
identified O 0 1.7988639910981874e-07
. O 0 3.365855434367404e-07

These O 0 1.587919058465559e-07
results O 0 5.014745241282981e-08
indicate O 0 3.283021854372237e-08
the O 0 6.993517764897206e-09
usefulness O 0 1.1411214728695995e-07
of O 0 1.8881056718100808e-08
cycloheximide O 0 3.5583826729634893e-07
treatment O 0 2.3090926504210074e-08
in O 0 6.42062125688625e-10
evaluating O 0 6.098772598051028e-09
the O 0 7.163389881270632e-10
abnormal O 0 4.235347628167574e-09
processing O 0 2.4133905540679734e-08
of O 0 4.794757479942291e-09
mRNA O 0 6.224483151129334e-09
due O 0 1.4290550964801696e-08
to O 0 3.4080820388027178e-09
splice O 0 1.8113050259671581e-07
- O 0 6.065423008294601e-08
site O 0 9.584564253373173e-09
mutations O 0 2.4556112698803645e-09
, O 0 2.9271551849063826e-09
because O 0 5.194029206734285e-09
( O 0 1.4047063068289845e-08
i O 0 1.5002920861206803e-07
) O 0 4.502977990483714e-09
aberrant O 0 3.499407341678307e-08
splicing O 0 1.250841989985929e-07
often O 0 3.320091757075261e-09
generates O 0 2.1870003585888753e-09
a O 0 1.5327129565534392e-09
premature O 0 5.357965182639646e-09
termination O 0 9.90160664571249e-09
codon O 0 1.9794613947965445e-08
, O 0 7.866292506264472e-09
( O 0 4.7566461880421684e-09
ii O 0 8.952663847594522e-06
) O 0 5.97922600320544e-09
transcripts O 0 2.485587629053043e-07
with O 0 9.848192483730145e-09
premature O 0 1.5772786809975514e-07
termination O 0 4.3722117482047906e-08
codons O 0 2.6626812754670937e-08
can O 0 2.487440031728738e-09
occur O 0 5.792291979389574e-09
at O 0 5.26639567510756e-08
low O 0 8.38566478478242e-08
or O 0 1.264223503660844e-09
undetectable O 0 1.6341556374754873e-07
levels O 0 9.554338653572358e-09
due O 0 6.99389124392269e-09
to O 0 1.0478983236694717e-09
nonsense O 0 1.359220789254323e-07
- O 0 1.6267613034415263e-08
mediated O 0 2.4278463683913287e-08
mRNA O 0 1.1255142595700818e-08
decay O 0 2.855093725884217e-07
, O 0 1.693203022234968e-09
and O 0 5.876876207899784e-10
( O 0 7.867939633143806e-10
iii O 0 7.805488166923169e-07
) O 0 2.5556520788505566e-10
the O 0 7.437715443536774e-10
levels O 0 1.5395638541804146e-08
of O 0 2.150861488914302e-09
these O 0 8.115894761795417e-11
transcripts O 0 1.106738345413305e-08
can O 0 8.837287845953057e-11
be O 0 1.014770420471045e-10
increased O 0 4.800538855320724e-10
by O 0 8.747672031184095e-10
cycloheximide O 0 2.3371082988887792e-06
. O 0 4.356105591796222e-07

A O 0 5.26311487192288e-06
deletion O 0 4.1156831684929784e-06
mutation O 0 5.132628899673364e-08
in O 0 1.9003898898972693e-08
COL17A1 O 0 1.9094142771791667e-05
in O 0 1.4144603710519732e-08
five O 0 1.6158882232275573e-08
Austrian O 0 5.453903213492595e-07
families O 0 1.0132198413614901e-09
with O 0 1.3166678414222588e-08
generalized O 0 0.015176351182162762
atrophic B-Disease 1 1.0
benign I-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 0.9999963045120239
bullosa I-Disease 0 0.08903994411230087
represents O 0 2.103859344515513e-07
propagation O 0 3.795037741838314e-07
of O 0 8.54680095585536e-08
an O 0 1.9839367482177295e-08
ancestral O 0 2.0107579530304065e-06
allele O 0 3.2167347399081336e-06
. O 0 2.1949515485175652e-06

Patients O 0 3.816214302787557e-06
with O 0 3.1542842293674767e-07
generalized O 1 0.9082264304161072
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999791383743286
, O 0 2.7072013608631096e-07
a O 0 2.149640287996135e-08
usually O 0 5.994230445338644e-09
nonlethal O 0 2.6052882162730384e-07
form O 0 2.9601475048934844e-08
of O 0 9.486892849963624e-06
junctional B-Disease 1 0.999998927116394
epidermolysis I-Disease 1 0.9999955892562866
bullosa I-Disease 1 0.9806792736053467
, O 0 6.253402062839086e-08
have O 0 4.088832383786212e-09
generalized O 0 3.703072763983073e-07
blistering B-Disease 0 8.669139788253233e-06
, O 0 4.501410330703948e-06
nail B-Disease 1 1.0
dystrophy I-Disease 1 0.999996542930603
, O 0 1.4404700777959079e-05
patchy B-Disease 1 0.9999887943267822
alopecia I-Disease 1 1.0
, O 0 7.153495062084403e-06
and O 0 0.0030814867932349443
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9808337092399597

Skin B-Disease 1 0.9999648332595825
fragility I-Disease 1 0.9674774408340454
in O 0 1.9399487882765243e-07
most O 0 2.7987958617359254e-09
cases O 0 8.799866946240797e-10
is O 0 7.530468609795449e-11
due O 0 7.674545998703763e-10
to O 0 1.8204669716137545e-10
mutations O 0 4.444160872640879e-10
in O 0 3.6664207780923164e-10
the O 0 7.984025662821637e-10
gene O 0 3.0527542715930167e-09
encoding O 0 9.118921440176564e-08
type O 0 1.6638148736092262e-05
XVII O 1 0.9943720102310181
collagen O 0 0.002064039697870612
( O 0 4.033027835248504e-06
COL17A1 O 0 0.0012910529039800167
) O 0 1.1859059441121644e-06
. O 0 2.3105831132852472e-06

Recently O 0 6.621945431106724e-06
, O 0 7.989655159690301e-08
we O 0 1.805440774660383e-08
reported O 0 1.3249234598333715e-08
five O 0 1.5157580746105737e-09
Austrian O 0 1.4530461101003311e-07
families O 0 1.6982767969686563e-10
with O 0 3.913262602850409e-09
generalized O 0 0.00032156499219127
atrophic B-Disease 1 0.9999998807907104
benign I-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999892711639404
who O 0 9.166595305032388e-07
share O 0 4.420536470206571e-08
the O 0 3.4920866198717704e-08
same O 0 1.0141603468127869e-07
COL17A1 O 0 0.00011682661715894938
mutation O 0 2.3430997941886744e-07
. O 0 2.604125768357335e-07

Affected O 0 2.651790396157594e-07
individuals O 0 8.102447601743279e-09
in O 0 1.1260338439456063e-08
three O 0 2.526062248264793e-09
families O 0 1.2013839922886405e-10
are O 0 3.7986305073678395e-11
homozygous O 0 4.4748157956853163e-10
for O 0 4.174751655483533e-10
4003delTC O 0 4.371728579144474e-08
, O 0 1.3292942302456368e-09
whereas O 0 4.3464174481755435e-09
those O 0 4.374426376685392e-10
in O 0 1.094386470334996e-09
two O 0 1.1616267947545111e-09
others O 0 1.4609161658185599e-09
are O 0 4.823998978054078e-10
compound O 0 1.5917277096377802e-07
heterozygotes O 0 3.937398560083238e-06
. O 0 6.798732101742644e-07

To O 0 8.353210745326578e-08
determine O 0 1.158576523607735e-07
if O 0 4.396728758848667e-09
the O 0 1.0710842213157434e-09
occurrence O 0 4.866104408307592e-09
of O 0 3.0130078432222263e-09
4003delTC O 0 4.5634958922846636e-08
in O 0 6.843403066447706e-10
these O 0 2.1785062642720732e-10
unrelated O 0 4.5342893884026125e-09
families O 0 3.3897322448961376e-11
signifies O 0 4.749753368393783e-10
propagation O 0 9.419911073393905e-09
of O 0 3.756420507983194e-09
an O 0 1.4391531300006477e-09
ancestral O 0 4.266337683134225e-08
allele O 0 2.994926617816418e-08
or O 0 9.50111100905815e-09
a O 0 3.348444366224612e-08
mutational O 0 2.5644374090916244e-06
hot O 0 3.5748423670156626e-06
spot O 0 5.192392791286693e-07
, O 0 5.548876913508138e-09
haplotypes O 0 3.315347285592907e-08
were O 0 2.1228045987697897e-09
determined O 0 4.6882453474950125e-09
for O 0 7.970286097780388e-10
polymorphisms O 0 2.3026053952435177e-08
both O 0 8.397937456550153e-09
within O 0 1.4664115610685258e-07
and O 0 1.068167705398082e-07
flanking O 0 0.0011882144026458263
COL17A1 O 1 0.9952848553657532
. O 0 7.677417670493014e-06

Five O 0 4.31920761911897e-06
intragenic O 0 2.0878902432741597e-05
polymorphisms O 0 3.367357805927895e-07
were O 0 2.1959801088655695e-08
chosen O 0 1.8987629246680626e-08
based O 0 7.862408502035123e-09
on O 0 3.5760038485932455e-08
their O 0 2.2820124456757185e-08
informativeness O 0 2.1840809495188296e-05
. O 0 6.422777119041712e-07

One O 0 1.1832494806185423e-07
of O 0 6.81225813536912e-08
these O 0 8.417240793257008e-10
, O 0 9.191993832757817e-10
not O 0 1.5691492549763097e-10
previously O 0 5.297806193738097e-09
reported O 0 2.820241373768795e-09
, O 0 8.101963544504542e-10
was O 0 4.945509246567781e-08
2988 O 0 3.0029320896574063e-07
A O 0 7.772635512992565e-08
or O 0 1.2789654668665662e-08
C O 0 2.005745727728936e-06
that O 0 6.662549401070805e-10
introduces O 0 3.884927934905136e-09
a O 0 6.895695681130576e-10
new O 0 2.1164321684086218e-10
restriction O 0 1.1834222490847424e-09
site O 0 2.5570772166361166e-09
for O 0 2.802182486050242e-09
Eco0109 O 0 1.147916464105947e-06
I O 0 1.6451276678708382e-05
. O 0 2.405505711067235e-06

All O 0 6.887893988505311e-08
the O 0 7.679386015979617e-08
4003delTC O 0 3.0883376211932045e-07
alleles O 0 1.9184390964710474e-08
showed O 0 2.652897634902729e-08
the O 0 1.778330815938034e-09
same O 0 2.079610927907538e-09
haplotype O 0 2.2733759763582384e-08
for O 0 1.673920335676371e-09
these O 0 9.139128898105753e-10
five O 0 1.2417077144277755e-08
polymorphic O 0 3.1201798833535577e-07
markers O 0 1.1339176353430958e-06
. O 0 2.0079564819752704e-06

Fourteen O 0 1.2710815099126194e-05
microsatellite O 0 1.3286786270327866e-05
polymorphisms O 0 4.0259968159261916e-07
were O 0 2.205723070858312e-08
selected O 0 7.502105603407472e-09
based O 0 2.547360766769202e-09
on O 0 1.1177911041215793e-08
their O 0 1.516602399220801e-09
high O 0 5.27725546817237e-07
heterozygosity O 0 1.257929056919238e-06
and O 0 2.0285946256137777e-09
their O 0 7.222810127771595e-10
location O 0 1.2296500706554525e-08
within O 0 4.888076166054134e-09
10q23 O 0 1.3726510417200188e-07
- O 0 7.323207995568737e-08
q25 O 0 6.21237575160194e-07
near O 0 1.2804734978999477e-06
COL17A1 O 0 0.00012422264262568206
. O 0 2.4272967493743636e-06

Three O 0 1.017467184283305e-06
families O 0 2.0532912259341174e-08
shared O 0 1.4935824310668977e-07
microsatellite O 0 5.8896907830785494e-06
polymorphisms O 0 4.236238737576059e-07
covering O 0 2.197938556491863e-06
at O 0 3.9924070733832195e-06
most O 0 2.56899195250071e-08
19 O 0 1.504379696370961e-07
cM O 0 2.2536423216479307e-07
, O 0 8.25305512819341e-09
whereas O 0 1.5459256985650427e-08
the O 0 9.483512641850211e-09
others O 0 8.575487875361887e-09
shared O 0 5.635162558803586e-09
smaller O 0 3.707830265042844e-09
regions O 0 2.4437338819183196e-09
consistent O 0 7.881912900131738e-09
with O 0 1.1597449667277715e-09
cross O 0 4.3735713717296676e-08
- O 0 2.8874753255081487e-08
over O 0 1.9167263332064977e-09
events O 0 4.2117503928906785e-10
during O 0 1.5751352444581812e-09
passage O 0 9.736905726143164e-10
of O 0 5.58284529716957e-10
this O 0 7.03605715357547e-11
mutation O 0 2.5245486257041705e-10
through O 0 8.080774382968059e-10
several O 0 1.7080198366770105e-09
generations O 0 1.0801963412632176e-07
. O 0 3.5208626059102244e-07

These O 0 4.170752632148833e-08
results O 0 1.7712533662006535e-08
indicate O 0 1.3888574734721715e-08
that O 0 4.774140527352699e-10
4003delTC O 0 2.5951379711841582e-08
occurs O 0 1.0432038566321467e-09
on O 0 2.618830263756422e-09
a O 0 4.3318160170002784e-10
single O 0 3.172272444729174e-10
ancestral O 0 5.089770382937786e-09
allele O 0 6.012620179518535e-09
. O 0 8.00899790931453e-09
. O 0 1.0047281051583923e-07

The O 0 2.3577465526614105e-06
haptoglobin O 0 0.00010885570372920483
- O 0 7.916340223346197e-07
gene O 0 2.3908990343102232e-08
deletion O 0 1.8446357330503815e-07
responsible O 0 5.979011774570608e-08
for O 0 6.229141291669293e-08
anhaptoglobinemia B-Disease 0 0.00037399999564513564
. O 0 4.666894255933585e-06

We O 0 6.169100856823206e-07
have O 0 2.765692785899887e-09
found O 0 6.1851179733452e-10
an O 0 1.1022353169076737e-10
allelic O 0 3.506603718506085e-08
deletion O 0 1.46809640000356e-07
of O 0 2.5116369783972914e-07
the O 0 1.2512649618656724e-06
haptoglobin O 0 0.000357701675966382
( O 0 1.1966631063842215e-07
Hp O 0 2.1051538112715207e-07
) O 0 1.5057591840061946e-09
gene O 0 1.7875876334727536e-09
from O 0 2.7164035465432335e-09
an O 0 5.873827535474163e-10
individual O 0 1.0762386537521706e-09
with O 0 8.987293398377005e-08
anhaptoglobinemia B-Disease 0 0.05951885133981705
. O 0 5.192999651626451e-06

The O 0 4.112599526706617e-06
Hp O 0 3.387095830476028e-06
gene O 0 4.81036899202536e-08
cluster O 0 2.947060728786255e-08
consists O 0 2.256346931517328e-08
of O 0 2.2262645060777686e-08
coding O 0 2.267686795676127e-06
regions O 0 3.7256114637784776e-08
of O 0 1.2189833853426535e-07
the O 0 9.584531568407328e-08
alpha O 0 2.7595799565460766e-06
chain O 0 8.023434361348336e-08
and O 0 1.888508016634205e-09
beta O 0 1.1513377984329054e-07
chain O 0 3.4244258984017506e-08
of O 0 9.595466643474992e-09
the O 0 3.7419198406496434e-08
haptoglobin O 0 5.282862275635125e-06
gene O 0 9.684497825901417e-08
( O 0 1.65296842880025e-08
Hp O 0 1.854976972026634e-07
) O 0 2.004937993405065e-09
and O 0 1.5045590329165748e-09
of O 0 1.8992373895798664e-08
the O 0 4.9620251019177886e-08
alpha O 0 1.506794660599553e-06
chain O 0 2.6935492059010357e-08
and O 0 1.1600193028371564e-09
beta O 0 1.6351391707303264e-07
chain O 0 2.967615309046323e-08
of O 0 6.061696478099066e-09
the O 0 2.82005991891765e-08
haptoglobin O 0 4.862979949393775e-06
- O 0 1.4642958490185265e-07
related O 0 5.737394914717697e-08
gene O 0 2.7426541038266805e-08
( O 0 1.5772826600368717e-08
Hpr O 0 5.518608077181852e-07
) O 0 3.496163802907404e-09
, O 0 4.079702797810114e-09
in O 0 9.148341639786395e-09
tandem O 0 1.8260454908158863e-06
from O 0 6.11943420381067e-08
the O 0 1.8124298151178664e-07
5 O 0 1.5417317626997828e-06
side O 0 1.9283168057881994e-06
. O 0 1.5430998701049248e-06

Southern O 0 1.47255359479459e-05
blot O 0 9.654648238210939e-06
and O 0 2.8907981786119308e-08
PCR O 0 6.019461693540507e-07
analyses O 0 1.0700355801418482e-07
have O 0 2.29977326071662e-09
indicated O 0 6.513729111645716e-09
that O 0 7.768651694162187e-11
the O 0 1.5833453992364355e-10
individual O 0 3.736009765442638e-11
with O 0 4.413573395645187e-10
anhaptoglobinemia B-Disease 0 4.534429933755746e-07
was O 0 2.3198110099542646e-08
homozygous O 0 1.3183810709804789e-09
for O 0 3.760848854561516e-10
the O 0 1.639056446123277e-09
gene O 0 3.74920494650155e-09
deletion O 0 6.871844959732698e-08
and O 0 2.014655553495004e-09
that O 0 2.932831755231291e-10
the O 0 1.0578508069514214e-09
gene O 0 8.878989765648271e-10
deletion O 0 2.725003511727664e-08
was O 0 5.5868564885486194e-08
included O 0 3.513919821784839e-09
at O 0 4.9500954446557444e-08
least O 0 7.609711749623216e-10
from O 0 1.1804149879779402e-09
the O 0 4.795086994136e-09
promoter O 0 4.470615749596618e-06
region O 0 3.424449630529125e-07
of O 0 1.6159210645128042e-06
Hp O 0 1.3949629646958783e-06
to O 0 7.203472307537595e-08
Hpr O 0 6.919508905411931e-06
alpha O 0 1.0518635917833308e-06
but O 0 6.6274954413358955e-09
not O 0 1.949373995557835e-09
to O 0 4.75048089754182e-09
Hpr O 0 1.1823093473140034e-06
beta O 0 1.221443881149753e-06
( O 0 9.521777855070468e-08
Hpdel O 0 4.823387826036196e-06
) O 0 6.077211622823597e-08
. O 0 3.6847154660790693e-07

In O 0 4.1722452692738443e-07
addition O 0 7.24700655041488e-08
, O 0 9.678105428179151e-09
we O 0 4.453548196892143e-09
found O 0 2.4470363513273696e-09
seven O 0 7.222933362527328e-10
individuals O 0 5.345383857768837e-11
with O 0 1.0265603922476885e-09
hypohaptoglobinemia B-Disease 0 3.283377509433194e-06
in O 0 9.105761478167551e-09
three O 0 1.4451937424553307e-09
families O 0 4.542976064780824e-11
, O 0 7.616038355529042e-11
and O 0 1.0718398391063033e-10
the O 0 1.473371646909527e-09
genotypes O 0 2.8901862236807574e-08
of O 0 2.0690244184606854e-08
six O 0 3.2205096367476926e-09
of O 0 5.897720090075609e-09
the O 0 8.635891113328853e-09
seven O 0 5.764132726682192e-09
individuals O 0 1.160791254783966e-10
were O 0 4.7781787415601684e-09
found O 0 1.983621711332262e-09
to O 0 7.187902495431331e-10
be O 0 2.8873873958445984e-08
Hp2 O 0 3.2557789381826296e-05
/ O 0 7.472975994460285e-05
Hpdel O 0 7.624186400789768e-05
. O 0 1.7672025478532305e-06

The O 0 9.775142189027974e-07
phenotypes O 0 1.9282138055132236e-06
and O 0 3.954381355697478e-08
genotypes O 0 5.645223382089171e-07
in O 0 1.2712314756413434e-08
one O 0 1.1104740460510243e-09
of O 0 4.147254095698827e-09
these O 0 3.375089097090722e-10
three O 0 1.7734801405211442e-09
families O 0 2.951642541493271e-10
showed O 0 1.26576837899961e-08
the O 0 3.0058211475392227e-09
father O 0 6.640060057350183e-09
to O 0 1.1347783823723034e-09
be O 0 1.2394172799190528e-08
hypohaptoglobinemic B-Disease 0 9.474645139562199e-07
( O 0 1.3674659626872199e-08
Hp2 O 0 4.701339548773831e-07
) O 0 2.9839775095297227e-09
and O 0 1.3599955828169641e-08
Hp2 O 0 1.829856773838401e-05
/ O 0 6.765887974324869e-06
Hpdel O 0 7.97702250565635e-06
, O 0 9.840493753188184e-09
the O 0 1.015360062694981e-08
mother O 0 1.271668015334626e-08
to O 0 1.5128697183897089e-09
be O 0 1.2927635850701336e-08
Hp2 O 0 1.4421676723941346e-06
- O 0 1.0375315184774081e-07
1 O 0 1.0675525885517345e-07
and O 0 8.111570082292019e-09
Hp1 O 0 6.283870789047796e-06
/ O 0 1.19130163511727e-06
Hp2 O 0 1.342511041002581e-06
, O 0 2.7735587160293562e-09
one O 0 4.2732642424603284e-10
of O 0 2.8533222451443407e-09
the O 0 2.835186529992484e-09
two O 0 3.3485063610783072e-09
children O 0 3.9130665374642604e-10
to O 0 2.3210079691526886e-10
be O 0 4.31343272211393e-09
hypohaptoglobinemic B-Disease 0 1.2052431657139095e-06
( O 0 4.446876644692566e-09
Hp2 O 0 4.771446242557431e-07
) O 0 3.0991194055474125e-09
and O 0 6.075818514972298e-09
Hp2 O 0 1.5422172509715892e-05
/ O 0 7.223398370115319e-06
Hpdel O 0 8.30134013085626e-06
, O 0 6.4118741427421355e-09
and O 0 6.358903958947337e-10
the O 0 4.591081737004288e-09
other O 0 1.9839925258224866e-09
child O 0 6.503536376101238e-09
to O 0 4.542207165947332e-10
be O 0 8.248302485469594e-09
Hp1 O 0 2.222799594164826e-06
and O 0 2.7284205117439342e-08
Hp1 O 0 3.1746556487632915e-05
/ O 0 9.402183422935195e-06
Hpdel O 0 6.149097771412926e-06
, O 0 4.187346025474881e-09
showing O 0 6.0441482929718404e-09
an O 0 5.385790702305826e-10
anomalous O 0 7.773804782118532e-07
inheritance O 0 1.075734189726063e-06
of O 0 2.698182470339816e-06
Hp O 0 1.9878930288541596e-06
phenotypes O 0 2.078367344893195e-07
in O 0 4.97445551417286e-09
the O 0 7.965412329724586e-09
child O 0 1.4294176509110912e-08
with O 0 2.8184361511307543e-08
Hp1 O 0 0.0003009185893461108
. O 0 3.197710157110123e-06

The O 0 6.172623670863686e-06
Hp2 O 0 0.000566408212762326
/ O 0 5.6826454965630546e-05
Hpdel O 0 8.46017701405799e-06
individuals O 0 2.5308510842592113e-09
had O 0 1.6385477863423148e-08
an O 0 6.677574049263058e-10
extremely O 0 1.9358989078455124e-08
low O 0 8.591650413336538e-08
level O 0 8.215238835873606e-07
of O 0 1.4960586725010216e-07
Hp O 0 2.342485316830789e-07
( O 0 2.6774489292336057e-09
mean O 0 7.57108953308716e-09
+ O 0 1.9018619568100803e-08
/ O 0 8.798684092425901e-08
- O 0 3.0106253490203017e-08
SD O 0 4.5428055273077916e-07
= O 0 4.956274324285914e-08
0 O 0 8.582604849038944e-09
. O 0 1.0841253450522004e-09
049 O 0 9.210464213538216e-08
+ O 0 4.0594304806518267e-08
/ O 0 3.3039785307664715e-07
- O 0 1.7590815559742623e-07
0 O 0 3.817761395907837e-08
. O 0 3.17561577034553e-09
043 O 0 1.2435561984602828e-06
mg O 0 1.5530341670455527e-06
/ O 0 1.8446674232563964e-07
ml O 0 6.995173862378579e-08
; O 0 1.7200048052501415e-09
n O 0 5.64881084130775e-08
= O 0 1.3876393367695528e-08
6 O 0 1.5572306111266698e-08
) O 0 2.3165144802383963e-10
, O 0 1.4099525713628935e-10
compared O 0 5.2399984351581e-10
with O 0 1.923060460873316e-10
the O 0 6.238877414688204e-09
level O 0 6.415889401978347e-07
( O 0 2.5843289730431707e-09
1 O 0 1.0765121238875963e-08
. O 0 2.865504777904704e-10
64 O 0 1.0218568213815615e-08
+ O 0 2.2030153701280142e-08
/ O 0 1.0050673893147177e-07
- O 0 2.2593701132223032e-08
1 O 0 2.2971923030468133e-08
. O 0 6.385874606884556e-10
07 O 0 4.739857573099471e-08
mg O 0 1.9692548391958553e-07
/ O 0 5.9503545202233e-08
ml O 0 2.988535641179624e-08
) O 0 7.003926327797672e-10
obtained O 0 1.2068558596922685e-08
from O 0 2.053757341968776e-08
52 O 0 2.3699034557012055e-07
healthy O 0 1.9022617436803557e-07
volunteers O 0 5.521999213442541e-08
having O 0 6.394277818344563e-08
phenotype O 0 3.568971607137428e-08
Hp2 O 0 1.1328227174089989e-06
, O 0 3.2906872782234586e-09
whereas O 0 9.18022458051837e-09
the O 0 7.949839897491984e-09
serum O 0 9.216545038270851e-08
Hp O 0 2.898942597084897e-08
level O 0 1.503572093497496e-07
of O 0 9.053581884188588e-09
an O 0 4.5265877157696366e-10
individual O 0 2.38239317162936e-10
with O 0 3.648786606191834e-09
Hp1 O 0 1.934698229888454e-05
/ O 0 6.057508016965585e-06
Hpdel O 0 9.023533493746072e-06
was O 0 1.4618975683333701e-06
0 O 0 3.4535139548097504e-07
. O 0 2.7751565312428284e-07

50 O 0 1.0194106835115235e-05
mg O 0 4.030972922919318e-05
/ O 0 8.720110599824693e-06
ml O 0 8.48876709369506e-07
, O 0 9.02573571437415e-09
which O 0 1.1639156305420784e-09
was O 0 3.241946444632049e-08
approximately O 0 3.5036935575050165e-09
half O 0 9.759552055399467e-10
the O 0 6.960192422411637e-10
level O 0 2.0381526155688334e-07
of O 0 4.03674569326995e-08
Hp O 0 5.810086989299634e-08
in O 0 3.288058492145751e-09
control O 0 2.2232524088394712e-07
sera O 0 2.1966340568724263e-07
from O 0 6.012987441295081e-09
the O 0 6.579783828897234e-09
Hp1 O 0 1.8766243670143012e-07
phenotype O 0 3.501489098667321e-09
( O 0 9.92966930901673e-10
1 O 0 7.730007745010425e-09
. O 0 4.377464779548035e-10
26 O 0 8.433121756468154e-09
+ O 0 1.0670962780068294e-08
/ O 0 1.755245904178082e-07
- O 0 5.8282008552623665e-08
0 O 0 1.1523392018375489e-08
. O 0 2.1980826048206836e-09
33 O 0 2.5863405994641653e-07
mg O 0 1.0829984375959611e-06
/ O 0 3.5476651305543783e-07
ml O 0 1.0593054611263142e-07
; O 0 3.384890145952113e-09
n O 0 1.0183821785858527e-07
= O 0 4.735068515060448e-08
9 O 0 4.792255126062628e-08
) O 0 7.739135998718893e-10
, O 0 6.291585030737679e-10
showing O 0 6.294829102415633e-09
a O 0 6.502060667656906e-09
gene O 0 1.9344593482628625e-08
- O 0 1.0867327659980219e-07
dosage O 0 1.04681794255157e-06
effect O 0 1.3339653150978847e-06
. O 0 6.098287030908978e-07

The O 0 4.325009399508417e-07
other O 0 3.450303154295398e-08
allele O 0 6.017050679929525e-08
( O 0 1.3801878750996366e-08
Hp2 O 0 8.398531576858659e-07
) O 0 2.1653669968202394e-09
of O 0 1.181492326196576e-08
individuals O 0 7.354233888534623e-10
with O 0 2.7470727914646886e-08
Hp2 O 0 0.26320797204971313
/ O 0 0.0006220384384505451
Hpdel O 0 8.280011388706043e-05
was O 0 7.307830856007058e-07
found O 0 2.2544701661075806e-09
to O 0 1.6231828381396696e-10
have O 0 1.5151878363095506e-10
, O 0 9.847881538016523e-11
in O 0 1.6173419548071166e-10
all O 0 7.79271203121823e-10
exons O 0 2.4846341872830635e-08
, O 0 4.5248008118115024e-10
no O 0 6.258730200769946e-10
mutation O 0 2.973068458089756e-10
, O 0 1.2268189242270466e-10
by O 0 2.5170096562554534e-10
DNA O 0 9.4780730819366e-08
sequencing O 0 3.3164954515996214e-07
. O 0 4.1581915866117924e-07

On O 0 1.8693880292630638e-06
the O 0 3.747534194076252e-08
basis O 0 5.895473620398661e-08
of O 0 9.838053927069268e-09
the O 0 1.4384615720786087e-09
present O 0 1.0521500337645762e-09
study O 0 8.596346412481637e-10
, O 0 9.193602823476255e-11
the O 0 2.174495999929249e-10
mechanism O 0 4.736233805147094e-08
of O 0 4.66829561673876e-08
anhaptoglobinemia B-Disease 0 5.839895607095968e-07
and O 0 4.5722214903065606e-10
the O 0 9.34399779772832e-10
mechanism O 0 9.53839176531801e-08
of O 0 2.6572374522970676e-08
anomalous O 0 9.407756351720309e-07
inheritance O 0 4.6956668597886164e-07
of O 0 4.6429218514276727e-07
Hp O 0 1.3121498341206461e-06
phenotypes O 0 2.1902290825437376e-07
were O 0 3.3954510314515574e-08
well O 0 3.205918730486701e-08
explained O 0 5.81813253575092e-07
. O 0 3.9409530927514425e-07

However O 0 9.049413165485021e-07
, O 0 2.8172161492534542e-08
the O 0 7.384386879749627e-09
mechanism O 0 5.816118573420681e-07
of O 0 1.640831612803595e-07
hypohaptoglobinemia B-Disease 0 5.586243423749693e-05
remains O 0 5.765972673543729e-06
unknown O 0 1.4670995369669981e-05

ATM O 0 0.0002759121125563979
mutations O 0 7.701497111156641e-07
and O 0 3.891945965506238e-08
phenotypes O 0 4.608188191923546e-06
in O 0 1.5821018678252585e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 6.806439500905981e-08
in O 0 1.745732802760358e-08
the O 0 1.7840596555629418e-08
British O 0 1.298290612794517e-07
Isles O 0 9.534736022942525e-08
: O 0 6.707610578082779e-10
expression O 0 2.1466235455847027e-09
of O 0 9.666814904107923e-09
mutant O 0 3.0269717399278306e-08
ATM O 0 8.509403528478288e-07
and O 0 1.4113550328431756e-09
the O 0 3.119294378350901e-09
risk O 0 8.606723156390217e-08
of O 0 2.3775305635354016e-06
leukemia B-Disease 1 1.0
, O 1 0.896521270275116
lymphoma B-Disease 1 1.0
, O 0 0.00019553741731215268
and O 0 0.004536807537078857
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 0.000426947750383988

We O 0 2.2015687761722802e-07
report O 0 7.329031603831027e-09
the O 0 2.0337396211544956e-09
spectrum O 0 4.511801066087173e-08
of O 0 1.2633178947396573e-08
59 O 0 6.582234135521503e-08
ATM O 0 1.2119766097384854e-06
mutations O 0 1.0703515407328723e-08
observed O 0 6.695677257084753e-08
in O 0 6.526864240186114e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9944924116134644
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.649725202758418e-08
patients O 0 3.2600386834502615e-09
in O 0 4.73949102186566e-10
the O 0 6.514287775871708e-09
British O 0 2.4632404915791994e-07
Isles O 0 8.94766117198742e-07
. O 0 2.907432303800306e-07

Of O 0 1.2719715414277744e-05
51 O 0 1.3434841093840078e-05
ATM O 0 7.336593262152746e-05
mutations O 0 4.128795083602199e-08
identified O 0 3.2132589922184707e-08
in O 0 8.554985164721529e-09
families O 0 3.068379994530801e-10
native O 0 1.7319746747901377e-09
to O 0 6.815435993345886e-10
the O 0 8.235978121717835e-09
British O 0 1.4672986026198487e-07
Isles O 0 2.212680527691191e-07
, O 0 4.813138332337985e-09
11 O 0 3.1170358738563664e-08
were O 0 3.9449947308867195e-08
founder O 0 2.6443228762218496e-07
mutations O 0 4.408199583139094e-09
, O 0 5.8562230620395894e-09
and O 0 6.580135103462226e-09
2 O 0 3.830909918178804e-07
of O 0 5.955350701469797e-08
these O 0 6.323372936378746e-09
11 O 0 9.554542401701838e-08
conferred O 0 2.4427666289739136e-07
a O 0 1.1631127172506694e-08
milder O 0 4.0302449377804805e-08
clinical O 0 5.179350992534637e-08
phenotype O 0 3.1958495849693236e-09
with O 0 9.023804481422815e-10
respect O 0 2.676505594934042e-08
to O 0 4.441301371116424e-08
both O 0 1.5586319932481274e-05
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 0.9999997615814209
and O 0 7.534475571446819e-06
cellular O 0 0.0008371947915293276
features O 0 6.94558366376441e-06
. O 0 2.452248281770153e-06

We O 0 1.9502104464663716e-07
report O 0 1.8271583357432064e-08
, O 0 1.0939399386344917e-09
in O 0 9.311706405945586e-10
two O 0 6.57233334422358e-09
A B-Disease 1 0.9908522963523865
- I-Disease 1 0.7889280319213867
T I-Disease 1 0.9999382495880127
families O 0 2.0348094043054488e-10
, O 0 1.8017821956650693e-10
an O 0 3.5986413848831944e-10
ATM O 0 3.9363331438835303e-07
mutation O 0 3.36425465263801e-09
( O 0 5.0712518628870384e-09
7271T O 0 2.160170851084331e-07
- O 0 2.751934857769811e-07
- O 0 3.42924408869294e-07
> O 0 1.9373530335542455e-07
G O 0 6.980479270168871e-07
) O 0 1.6046586281959208e-09
that O 0 3.403039794402929e-10
may O 0 5.789229651220751e-10
be O 0 9.09622169253943e-11
associated O 0 1.5322970670084146e-10
with O 0 1.2624006007211364e-11
an O 0 2.0126140337639598e-11
increased O 0 2.950096167353422e-09
risk O 0 3.023463435170015e-08
of O 0 3.019403891357797e-07
breast B-Disease 1 0.9371904730796814
cancer I-Disease 0 6.505178589577554e-06
in O 0 7.915297750571426e-09
both O 0 2.469261239923526e-08
homozygotes O 0 6.948048394406214e-07
and O 0 4.326319302805359e-09
heterozygotes O 0 9.51936272031162e-08
( O 0 3.39544303784578e-09
relative O 0 1.37018702162095e-07
risk O 0 6.404213337418696e-08
12 O 0 1.5987327017796815e-08
. O 0 1.2184383502145124e-09
7 O 0 3.1903820030265706e-08
; O 0 1.6653856071968676e-09
P O 0 1.9301492102385964e-06
= O 0 9.410989321168017e-08
. O 0 5.799201119316422e-09
0025 O 0 4.39606054669639e-07
) O 0 9.878776685567914e-10
, O 0 3.215977761872324e-10
although O 0 6.011287023710565e-10
there O 0 4.250033103225803e-10
is O 0 2.383847841347375e-10
a O 0 1.7569825594421218e-09
less O 0 5.224296018013774e-08
severe O 0 6.679399666609243e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999585151672363
T I-Disease 1 0.9999186992645264
phenotype O 0 8.992520506012625e-09
in O 0 3.0613764301357094e-10
terms O 0 8.438926224485499e-10
of O 0 9.5970720259686e-10
the O 0 5.508843936574692e-10
degree O 0 6.608348712688894e-07
of O 0 1.3822868822899181e-06
cerebellar B-Disease 1 0.9999960660934448
degeneration I-Disease 1 0.9999942779541016
. O 0 2.669412970135454e-05

This O 0 7.743026486650706e-08
mutation O 0 4.8930505869293484e-08
( O 0 2.7686237302759764e-08
7271T O 0 2.1664975520252483e-06
- O 0 6.843956725788303e-07
- O 0 3.735929965387186e-07
> O 0 6.262724383532259e-08
G O 0 6.212719938503142e-08
) O 0 2.1924873028211778e-10
also O 0 6.323837287158796e-11
allows O 0 4.891522256689207e-11
expression O 0 2.465907478210738e-10
of O 0 1.7731623946914965e-09
full O 0 5.638108202532521e-09
- O 0 1.2091875944975072e-08
length O 0 2.429971557305066e-09
ATM O 0 2.7276200853521004e-07
protein O 0 5.287287052624379e-09
at O 0 4.428965638680893e-09
a O 0 2.791426534365371e-10
level O 0 1.5029709032887695e-08
comparable O 0 3.256858249756078e-08
with O 0 2.1080280576679655e-10
that O 0 4.235410078212709e-10
in O 0 2.857832193114973e-09
unaffected O 0 8.967089115685667e-08
individuals O 0 3.95339183612009e-09
. O 0 2.835756731656147e-07

In O 0 1.235826090351111e-07
addition O 0 3.978666995863023e-08
, O 0 3.183657337757495e-09
we O 0 1.0890391921591913e-09
have O 0 2.502762719291951e-10
studied O 0 1.6322522355949332e-07
18 O 0 5.095188271297957e-07
A B-Disease 1 0.99998939037323
- I-Disease 1 0.9999935626983643
T I-Disease 1 0.9999997615814209
patients O 0 6.828076948295347e-08
, O 0 4.027174982379478e-10
in O 0 5.181223228234444e-10
15 O 0 2.9454634287162662e-09
families O 0 4.186598984157186e-11
, O 0 4.794517560746669e-10
who O 0 2.4166550982585022e-09
developed O 0 0.0001515828334959224
leukemia B-Disease 1 1.0
, O 0 0.12890653312206268
lymphoma B-Disease 1 1.0
, O 0 3.179615305271e-05
preleukemic O 0 0.3331661522388458
T O 0 0.1830430030822754
- O 0 1.2571913430292625e-05
cell O 0 1.964519833563827e-05
proliferation O 0 0.000588257098570466
, O 0 4.1111299253770994e-08
or O 0 6.963378109503537e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.0601821638119873e-07
mostly O 0 6.808722474715978e-09
in O 0 1.2581765851393811e-08
childhood O 0 1.7755714907252695e-06
. O 0 2.9825966407770466e-07

A O 0 4.042551154270768e-06
wide O 0 2.2109804831416113e-07
variety O 0 9.767046549313818e-08
of O 0 4.78903885436921e-08
ATM O 0 8.384267857763916e-06
mutation O 0 1.2741760535561752e-08
types O 0 1.2371404345401515e-08
, O 0 7.226255149817007e-10
including O 0 2.0547474832710577e-09
missense O 0 1.6736903774017264e-07
mutations O 0 1.5093540639554703e-08
and O 0 3.267622616931476e-08
in O 0 1.3636768869673688e-07
- O 0 3.824827672360698e-06
frame O 0 0.0007952626328915358
deletions O 0 6.322874810393841e-07
, O 0 5.739711816943327e-09
were O 0 5.952621950910952e-09
seen O 0 1.2115331848860933e-08
in O 0 8.995312272830347e-10
these O 0 1.9496082526160308e-09
patients O 0 9.471133921579167e-08
. O 0 1.9200136591734918e-07

We O 0 3.512156467877503e-07
also O 0 1.0787773341291995e-08
show O 0 6.0572125093472096e-09
that O 0 8.753509028736062e-11
25 O 0 1.6419789972133003e-09
% O 0 4.724436952763256e-10
of O 0 6.643365857428307e-09
all O 0 2.7628262344592258e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999964237213135
T I-Disease 1 0.9999994039535522
patients O 0 3.609871157550515e-08
carried O 0 2.232109608257815e-09
in O 0 1.9232302417293567e-09
- O 0 3.749514476680815e-08
frame O 0 3.854962358218472e-07
deletions O 0 4.286778931827939e-08
or O 0 2.4012230426251335e-08
missense O 0 2.847713460596424e-07
mutations O 0 8.368021831017813e-09
, O 0 7.301471094400824e-10
many O 0 8.700543757678147e-11
of O 0 1.3268985910031006e-08
which O 0 9.9135455400301e-10
were O 0 2.7580651096315023e-09
also O 0 1.1124642179671795e-10
associated O 0 8.761526920642027e-11
with O 0 3.9206998758700706e-11
expression O 0 3.003379767108072e-09
of O 0 3.095930622976084e-08
mutant O 0 3.676638584693137e-07
ATM O 0 2.7847087039845064e-05
protein O 0 1.941156824614154e-06
. O 0 4.77061348647112e-07

The O 0 9.188922831526725e-07
DMPK O 0 0.0001894126762636006
gene O 0 7.387093887700757e-07
of O 0 4.461587195692118e-06
severely O 1 0.999997615814209
affected O 1 0.9999994039535522
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9970993995666504
is O 0 1.5915363746898947e-06
hypermethylated O 0 7.311951776500791e-05
proximal O 0 4.056415036757244e-06
to O 0 1.2007758343202113e-08
the O 0 4.628593330835429e-08
largely O 0 1.5999872005068028e-07
expanded O 0 3.660516938452929e-07
CTG O 0 5.6247416068799794e-05
repeat O 0 3.836148607661016e-06
. O 0 1.6432006759714568e-06

Using O 0 5.506495881490991e-07
methylation O 0 1.340409085059946e-06
- O 0 2.2993826576112042e-07
sensitive O 0 3.481758596990403e-07
restriction O 0 1.758971812648724e-08
enzymes O 0 1.1482254258510238e-08
, O 0 1.0233269787107702e-09
we O 0 7.585135297638601e-10
characterized O 0 2.944862353970734e-09
the O 0 2.1290167406817773e-09
methylation O 0 4.4531766718591825e-08
pattern O 0 8.899174730458981e-08
on O 0 8.518401983792501e-08
the O 0 1.9160401265594373e-08
5 O 0 3.484235833184357e-08
side O 0 3.499901524151028e-08
of O 0 2.4044632951358835e-08
the O 0 4.243969797812497e-08
CTG O 0 1.1495825674501248e-05
repeat O 0 6.840904376304024e-08
in O 0 1.692044060419562e-09
the O 0 3.8984526717911194e-09
DMPK O 0 1.5846302403588197e-06
gene O 0 7.954010783350896e-09
of O 0 1.6599159380348283e-08
normal O 0 8.48708552325661e-08
individuals O 0 3.663205572213002e-10
and O 0 2.382094743680341e-09
of O 0 2.762676842849032e-07
patients O 0 4.321960204833886e-06
affected O 0 6.097193363530096e-07
with O 1 0.5223732590675354
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.008312603469676e-07
showing O 0 6.333539204206318e-08
expansions O 0 3.126050174273587e-08
of O 0 1.2698598617078005e-08
the O 0 1.1324654103361809e-08
repetitive O 0 2.4749062959017465e-06
sequence O 0 1.1802472243971351e-07
. O 0 3.1611503459316737e-07

The O 0 9.132425589086779e-07
gene O 0 1.5101768724434805e-07
segment O 0 1.5158042288021534e-07
analyzed O 0 4.295282707289516e-08
corresponds O 0 9.395704658743398e-09
to O 0 9.693397196031128e-10
the O 0 5.833480809513958e-09
genomic O 0 5.834301646245876e-07
SacI O 0 2.3951952243805863e-05
- O 0 3.986248486853583e-07
HindIII O 0 1.308570858782332e-06
fragment O 0 1.265834157493373e-07
carrying O 0 1.00315219242475e-07
exons O 0 5.602477699540032e-07
11 O 0 9.225441885973851e-07
- O 0 8.085929152912286e-07
15 O 0 1.0043485190180945e-06
. O 0 8.413907721660507e-07

There O 0 7.597708986395446e-07
is O 0 3.525656566694124e-08
constitutive O 0 8.467591783301032e-07
methylation O 0 7.391674330392561e-07
in O 0 1.4175466844790208e-07
intron O 0 1.2549728126032278e-05
12 O 0 8.949012197945194e-08
at O 0 3.225416733698694e-08
restriction O 0 2.081106620366313e-09
sites O 0 7.672570356831443e-10
of O 0 2.683353761412377e-09
SacII O 0 3.4696236639319977e-07
and O 0 5.757737842060351e-09
HhaI O 0 9.470733175476198e-07
, O 0 3.4078484478783366e-09
localized O 0 4.480628135183906e-08
1 O 0 8.381235261367692e-08
, O 0 2.1053769838630387e-09
159 O 0 7.812881896995805e-09
- O 0 2.1426281193726027e-08
1 O 0 6.757414183766741e-08
, O 0 3.5089366967611113e-09
232 O 0 9.851892635026616e-09
bp O 0 1.0086585433555229e-07
upstream O 0 7.528784351507056e-08
of O 0 4.5869182230262595e-08
the O 0 9.908790588042393e-08
CTG O 0 6.307899457169697e-05
repeat O 0 1.6873450192633754e-07
, O 0 3.839528250892954e-09
whereas O 0 6.0112097521880514e-09
most O 0 9.422153057769833e-10
, O 0 2.2171346703014905e-10
if O 0 1.289708340124207e-10
not O 0 4.9088878795178204e-11
all O 0 8.573435017478204e-11
, O 0 8.476590263040151e-11
of O 0 2.2042488667661786e-10
the O 0 1.4748385845919643e-10
other O 0 3.2240588671017534e-11
sites O 0 1.8600160300863422e-10
of O 0 1.281973749378551e-09
SacII O 0 1.9931272277062817e-07
, O 0 3.9292231690524204e-09
HhaI O 0 4.794750907421985e-07
, O 0 1.902804358522303e-09
and O 0 1.2092700174548554e-09
HpaII O 0 4.288099546556623e-07
in O 0 1.2242808988816023e-09
this O 0 1.2756896927701433e-10
region O 0 2.992344372287903e-09
are O 0 3.4330091547296604e-10
unmethylated O 0 8.175380372676955e-08
, O 0 4.701801170625686e-10
in O 0 6.445087241679914e-10
normal O 0 2.4331310299885445e-08
individuals O 0 1.4336894171851355e-10
and O 0 3.12045889128143e-10
most O 0 6.966833221433433e-10
of O 0 1.504100843874312e-08
the O 0 9.553905044867861e-08
patients O 0 3.5615127558230597e-07
. O 0 2.3724292930182855e-07

In O 0 1.6033018823691236e-07
a O 0 2.45228921613716e-08
number O 0 4.8275730080149515e-09
of O 0 1.975867292003386e-07
young O 0 3.4737590226541215e-07
and O 0 3.030799859971012e-07
severely O 0 0.06840525567531586
affected O 0 1.3192766346037388e-07
patients O 0 3.374641721620719e-08
, O 0 9.546300416829467e-10
however O 0 9.148825586002829e-10
, O 0 2.5908225564919007e-10
complete O 0 1.772387903109518e-09
methylation O 0 7.021170755905359e-09
of O 0 3.0344156076722584e-09
these O 0 1.4690942906625537e-10
restriction O 0 7.284042258248746e-10
sites O 0 6.24999829668127e-10
was O 0 7.239639998601888e-09
found O 0 8.978942034332249e-10
in O 0 3.598998044029855e-10
the O 0 1.8744765739597824e-09
mutated O 0 1.0563189434265041e-08
allele O 0 7.434091742197779e-08
. O 0 1.808350020837679e-07

In O 0 2.1335387145882123e-07
most O 0 4.820212229361687e-09
of O 0 1.1475729699839121e-08
these O 0 4.26193358382676e-10
patients O 0 1.6071427522135195e-09
, O 0 2.574880864081308e-10
the O 0 2.2554291767562518e-09
onset O 0 2.1419602489913814e-05
of O 0 4.1301822761852236e-07
the O 0 2.382619641139172e-05
disease O 1 0.9999979734420776
was O 1 0.993627667427063
congenital O 1 1.0
. O 0 0.0015758617082610726

Preliminary O 0 3.4670806599024218e-06
in O 0 4.075622257460054e-07
vivo O 0 1.2007002624159213e-05
footprinting O 0 3.465113331913017e-05
data O 0 3.4908219959106646e-07
gave O 0 3.316966257216336e-08
evidence O 0 3.783602764428906e-08
for O 0 4.877552139959107e-09
protein O 0 8.451949895516009e-08
- O 0 3.309831342335201e-08
DNA O 0 1.8797871703668534e-08
contact O 0 3.318966079746133e-08
in O 0 3.6233065436874767e-09
normal O 0 4.85052069620906e-08
genes O 0 1.3010124089163355e-09
at O 0 1.859244669333293e-08
an O 0 6.578688704905744e-10
Sp1 O 0 1.3782732821709942e-07
consensus O 0 2.505554874687732e-08
binding O 0 7.60550733502896e-09
site O 0 2.00297431973695e-08
upstream O 0 5.4208985744708116e-08
of O 0 4.1982399778817125e-08
the O 0 9.804413991787442e-08
CTG O 0 6.138497701613232e-05
repeat O 0 1.6804557390059927e-07
and O 0 2.9570705883941173e-09
for O 0 6.622134507416888e-10
a O 0 7.8346351628511e-10
significant O 0 1.7133808816183205e-09
reduction O 0 2.2968329460582027e-08
of O 0 6.586790668450249e-09
this O 0 1.812982541871122e-10
interaction O 0 5.710686590276737e-09
in O 0 1.304926611211954e-09
cells O 0 4.87792195524861e-10
with O 0 3.1274424716620786e-10
a O 0 1.0566051145133315e-08
hypermethylated O 0 1.2781797522620764e-06
DMPK O 0 9.160215086012613e-06
gene O 0 7.223312081805489e-08
. O 0 3.0494966551941616e-08
. O 0 4.4938769860891625e-07

The O 0 9.690115984994918e-05
hemochromatosis B-Disease 1 1.0
gene O 0 8.922380629883264e-07
product O 0 1.770024908864798e-07
complexes O 0 2.3581146990636626e-07
with O 0 4.285583443675023e-09
the O 0 8.062323075819222e-08
transferrin O 0 1.8764540072879754e-06
receptor O 0 3.883952004457569e-08
and O 0 8.088751002333083e-09
lowers O 0 5.1575650417134966e-08
its O 0 4.539323361640868e-10
affinity O 0 1.075461408817091e-08
for O 0 4.163025035808232e-09
ligand O 0 1.3740158522068668e-07
binding O 0 3.6810243386753427e-07
. O 0 8.768876682552218e-07

We O 0 2.3565639821754303e-06
recently O 0 8.700678222339775e-07
reported O 0 1.958602879881255e-08
the O 0 4.409284493078758e-09
positional O 0 1.6045438542278134e-06
cloning O 0 4.461406533096124e-08
of O 0 5.810250502946701e-09
a O 0 7.773342858286014e-09
candidate O 0 3.5352726968085335e-08
gene O 0 2.3028783857625967e-07
for O 0 6.459777523559751e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999982118606567
HFE O 1 0.9999895095825195
. O 0 0.00010345399641664699

The O 0 4.257144610164687e-07
gene O 0 7.532174350899368e-08
product O 0 3.131193793137754e-08
, O 0 2.3199691057129712e-09
a O 0 4.324000713040732e-09
member O 0 6.939967267527436e-09
of O 0 5.6736350728670004e-08
the O 0 6.477492320300371e-08
major O 0 2.1196494799369248e-06
histocompatibility O 0 0.004782896488904953
complex O 0 0.00015047009219415486
class O 0 3.5639487805383396e-07
I O 0 4.3360673771530855e-06
- O 0 1.420980311195308e-07
like O 0 5.656419332922269e-09
family O 0 2.0543009515705535e-09
, O 0 1.2667966675650177e-09
was O 0 2.8314861566514082e-08
found O 0 1.2718492925500868e-09
to O 0 3.60774743413117e-10
have O 0 5.245218148708375e-10
a O 0 2.435237789200073e-09
mutation O 0 8.248503546859354e-10
, O 0 5.525115032156691e-09
Cys O 0 9.015258910949342e-06
- O 0 1.0318857448510244e-06
282 O 0 7.133045869522903e-07
- O 0 2.7632324872683967e-06
- O 0 1.5168279787758365e-06
> O 0 3.077092571857065e-07
Tyr O 0 6.32347166629188e-07
( O 0 4.080325410882324e-09
C282Y O 0 4.1830372055073894e-08
) O 0 5.033004013554887e-10
, O 0 4.56230775380817e-10
in O 0 6.067604751969213e-10
85 O 0 8.68340954696123e-09
% O 0 1.5409680642619605e-08
of O 0 2.132794207909683e-07
patient O 0 7.372775144176558e-06
chromosomes O 0 9.717332432046533e-06
. O 0 2.3620586944161914e-06

This O 0 4.79423896138087e-08
mutation O 0 2.775327700987873e-08
eliminates O 0 1.0524941984613179e-07
the O 0 7.696186798966664e-09
ability O 0 2.155075584653332e-08
of O 0 1.0641778658282419e-07
HFE O 0 1.3490716810338199e-05
to O 0 2.8138380514519667e-08
associate O 0 1.6761340475568431e-06
with O 0 3.799918957270165e-08
beta2 O 0 0.0002345214452361688
- O 0 2.2676114895148203e-05
microglobulin O 0 2.637886609591078e-05
( O 0 3.00699234401236e-08
beta2m O 0 7.441717002620862e-07
) O 0 1.1100230734584215e-09
and O 0 2.145518207541386e-09
prevents O 0 2.4827061295695785e-08
cell O 0 4.201046067464631e-06
- O 0 2.1117169524131896e-07
surface O 0 2.2611607164435554e-06
expression O 0 8.665410859975964e-07
. O 0 6.023562377777125e-07

A O 0 7.946877303766087e-06
second O 0 5.072541853223811e-07
mutation O 0 1.3593913550380421e-08
that O 0 1.015185269181984e-09
has O 0 6.104926009165013e-10
no O 0 6.827914345031161e-10
effect O 0 1.1844119462978142e-08
on O 0 5.9343733482819516e-08
beta2m O 0 1.1172154472660623e-06
association O 0 1.140109429087488e-08
, O 0 2.5270356918127845e-09
H63D O 0 2.349764145037625e-06
, O 0 1.6989225581909295e-09
was O 0 1.3688829625380095e-08
found O 0 5.122735569074166e-10
in O 0 3.1381741649738615e-10
eight O 0 9.964540303997182e-10
out O 0 3.639859524895428e-10
of O 0 1.3373105289815612e-08
nine O 0 8.383473470985336e-08
patients O 0 1.4289569527647927e-08
heterozygous O 0 5.169429329043851e-09
for O 0 3.141193971600842e-09
the O 0 5.669426883514461e-08
C282Y O 0 4.974689545633737e-06
mutant O 0 2.1708410713472404e-06
. O 0 6.982523927945294e-07

In O 0 8.463710088335574e-08
this O 0 1.4444662133072939e-09
report O 0 2.526134412761394e-09
, O 0 6.067708557822016e-10
we O 0 5.770708355612442e-10
demonstrate O 0 7.6510042745781e-09
in O 0 4.1598342548354594e-09
cultured O 0 1.179909574489102e-07
293 O 0 8.503661774739157e-08
cells O 0 7.593479978140749e-08
overexpressing O 0 1.8968355561810313e-06
wild O 0 3.034208972962915e-08
- O 0 4.534023645419438e-08
type O 0 1.5478381953926146e-07
or O 0 1.0756854607052446e-07
mutant O 0 9.665617426435347e-07
HFE O 0 9.564144420437515e-06
proteins O 0 1.3470384807590108e-08
that O 0 4.073558157458024e-10
both O 0 1.3246219676688042e-09
the O 0 4.7463326602326106e-09
wild O 0 1.0001218520017119e-08
- O 0 2.3853056418943197e-08
type O 0 6.500241056528466e-08
and O 0 3.0011598539658735e-08
H63D O 0 0.0013266802998259664
HFE O 0 5.069661347079091e-05
proteins O 0 2.3879550781202852e-08
form O 0 1.4041544815768248e-08
stable O 0 1.089112402041792e-06
complexes O 0 6.91000039410028e-08
with O 0 4.3730268295405494e-09
the O 0 3.487972932703087e-08
transferrin O 0 1.547227270748408e-06
receptor O 0 1.4554052540916018e-07
( O 0 4.2907053909857495e-08
TfR O 0 3.722000883499277e-06
) O 0 8.873157497646389e-08
. O 0 7.401846460197703e-07

The O 0 2.5707672648422886e-06
C282Y O 0 2.5538831323501654e-05
mutation O 0 1.320937030868663e-07
nearly O 0 4.14246486002412e-08
completely O 0 5.550986159619242e-08
prevents O 0 3.383024749226138e-09
the O 0 4.598697866953216e-09
association O 0 3.6588079233013104e-09
of O 0 8.19642398397491e-09
the O 0 3.6493034372142574e-08
mutant O 0 6.987866072449833e-07
HFE O 0 4.0196719055529684e-05
protein O 0 1.6938214741912816e-07
with O 0 8.259354089545923e-09
the O 0 3.710224234509951e-07
TfR O 0 0.00014992986689321697
. O 0 1.522542675047589e-06

Studies O 0 1.3042401860730024e-06
on O 0 6.103744567553804e-07
cell O 0 1.6801334368210519e-06
- O 0 9.41671700616098e-08
associated O 0 3.245355273406858e-08
transferrin O 0 3.6143978832114954e-07
at O 0 6.420486329261621e-07
37 O 0 1.0371753944582451e-07
degrees O 0 1.518095814390108e-06
C O 0 1.7372066167808953e-06
suggest O 0 2.798080656063462e-09
that O 0 1.0599952166012727e-10
the O 0 6.115394413086506e-09
overexpressed O 0 8.691498010193754e-07
wild O 0 6.518142470213206e-08
- O 0 1.6192055340980005e-07
type O 0 4.033679488202324e-07
HFE O 0 2.301625136169605e-05
protein O 0 5.252070778283269e-08
decreases O 0 1.1779416553281408e-08
the O 0 7.083891251369323e-10
affinity O 0 7.665538426238072e-09
of O 0 1.4597554276463143e-08
the O 0 6.03198841986341e-08
TfR O 0 9.134027095569763e-06
for O 0 1.3386662089942547e-07
transferrin O 0 1.2233743291290011e-05
. O 0 1.9191784303984605e-06

The O 0 1.24094367492944e-05
overexpressed O 0 0.00313887489028275
H63D O 0 0.01136756967753172
protein O 0 1.413297354702081e-06
does O 0 2.6386852702842134e-09
not O 0 1.8629060793973196e-10
have O 0 1.4960043620559915e-11
this O 0 6.432209799511757e-12
effect O 0 1.0290265306522883e-09
, O 0 1.2917517056010297e-10
providing O 0 5.188303675573991e-10
the O 0 1.460330467661919e-10
first O 0 2.0687145052544764e-10
direct O 0 2.929734232992587e-10
evidence O 0 4.26508051099006e-10
for O 0 9.076533968865874e-11
a O 0 5.010485359946415e-10
functional O 0 8.907988302553349e-08
consequence O 0 8.655171512828019e-08
of O 0 4.031205946830596e-08
the O 0 9.608362461221986e-08
H63D O 0 7.01646858942695e-05
mutation O 0 1.980196486783825e-07
. O 0 3.7521689932873414e-07

Addition O 0 8.868722147781227e-07
of O 0 2.583670720923692e-06
soluble O 0 4.379050005809404e-05
wild O 0 1.1762530220948975e-06
- O 0 5.625769972539274e-06
type O 0 0.00010933788144029677
HFE O 1 0.9997369647026062
/ O 1 0.9934359788894653
beta2m O 0 0.0015420876443386078
heterodimers O 0 6.989463145146146e-05
to O 0 4.729445279849642e-08
cultured O 0 2.3643440272280714e-06
cells O 0 2.3383176284141882e-08
also O 0 1.208304012401129e-09
decreased O 0 1.6352819542930774e-08
the O 0 6.843376976206628e-10
apparent O 0 4.379996809689146e-09
affinity O 0 7.006869751080558e-09
of O 0 1.1727362192459623e-08
the O 0 1.1093377771942414e-08
TfR O 0 1.0545277717710633e-07
for O 0 4.812208964644071e-10
its O 0 1.363674867471687e-10
ligand O 0 1.0137731543125028e-08
under O 0 3.723664931953863e-08
steady O 0 1.0237461083306698e-06
- O 0 8.343811863653627e-09
state O 0 3.486239907868338e-10
conditions O 0 5.595256702406459e-09
, O 0 3.2447144970859654e-10
both O 0 2.339899107806076e-10
in O 0 1.3019929578916845e-09
293 O 0 5.060623475827697e-09
cells O 0 2.8682511921118703e-09
and O 0 1.958246897970639e-09
in O 0 2.0919525667295602e-08
HeLa O 0 3.5198424939153483e-06
cells O 0 6.890719106422694e-08
. O 0 1.198395693791099e-07

Furthermore O 0 1.360915121040307e-06
, O 0 1.0742092371174294e-07
at O 0 6.871018740639556e-07
4 O 0 1.886513416593516e-07
degrees O 0 2.4066760033747414e-06
C O 0 2.356791128477198e-06
, O 0 3.709365259396691e-09
the O 0 4.186690993890352e-09
added O 0 8.531116435506192e-08
soluble O 0 1.8016024228018068e-07
complex O 0 4.935831157126813e-07
of O 0 4.5599551867780974e-07
HFE O 0 0.0005632255924865603
/ O 0 1.4880128219374456e-05
beta2m O 0 1.6543758647458162e-06
inhibited O 0 4.918408080811787e-08
binding O 0 2.1073146783123775e-08
of O 0 6.183896772427033e-08
transferrin O 0 9.729996008900343e-07
to O 0 4.1200237888006086e-08
HeLa O 0 7.737283340247814e-06
cell O 0 7.865754128033586e-07
TfR O 0 5.67598306133732e-07
in O 0 2.5415369808712285e-09
a O 0 3.300682172024949e-09
concentration O 0 2.8787706014554715e-06
- O 0 2.3238459334606887e-07
dependent O 0 4.635484529558198e-08
manner O 0 2.592195187389734e-07
. O 0 2.573936512817454e-07

Scatchard O 0 0.00025388150243088603
plots O 0 1.61616776495066e-06
of O 0 1.2119103587338032e-07
these O 0 3.0744740087129685e-09
data O 0 2.3593063502858058e-08
indicate O 0 9.436509351701261e-09
that O 0 4.6000467324169847e-10
the O 0 1.0691539209517487e-08
added O 0 7.147414748942538e-08
heterodimer O 0 9.516512733398486e-08
substantially O 0 2.6781906470318972e-08
reduced O 0 3.774569101722136e-09
the O 0 7.150749437023762e-10
affinity O 0 8.04054334224702e-09
of O 0 5.93770188572762e-08
TfR O 0 5.086636974738212e-06
for O 0 2.0325389016306872e-07
transferrin O 0 3.2844032830325887e-05
. O 0 2.135593831553706e-06

These O 0 3.8988112294191524e-08
results O 0 4.783688822840304e-08
establish O 0 8.362249559468182e-08
a O 0 1.9317234034588182e-08
molecular O 0 2.1021517113695154e-06
link O 0 1.577633724991756e-06
between O 0 1.7522130519864731e-06
HFE O 0 0.0009773749625310302
and O 0 6.872316760109243e-08
a O 0 6.719089640228049e-08
key O 0 3.0905612220522016e-06
protein O 0 1.7781594863208738e-07
involved O 0 5.4606228871989515e-08
in O 0 2.2197900406695226e-08
iron O 0 0.0048088189214468
transport O 0 1.9189130853192182e-06
, O 0 1.3024954448326298e-08
the O 0 3.203003373641877e-08
TfR O 0 8.781071301200427e-06
, O 0 2.846657798372121e-09
and O 0 7.489676656646793e-10
raise O 0 1.7075183489367873e-09
the O 0 1.3025095446650425e-09
possibility O 0 1.3134272336401409e-08
that O 0 1.1361855206670768e-10
alterations O 0 6.390763918062703e-09
in O 0 3.7963363008763906e-10
this O 0 7.03880911889776e-11
regulatory O 0 4.097258354818223e-08
mechanism O 0 9.71805206972931e-07
may O 0 1.972007623862737e-08
play O 0 3.1867394056916964e-08
a O 0 2.5826831784314663e-09
role O 0 1.0194273869501558e-08
in O 0 4.131195829870649e-09
the O 0 5.136614333878242e-08
pathogenesis O 1 0.9830479621887207
of O 0 0.14291228353977203
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0008148732013069093
. O 0 1.3469786608766299e-05

Genomic O 0 3.5559605748858303e-06
organization O 0 1.5300825850772526e-07
of O 0 3.672430182177777e-07
the O 0 1.0400315204606159e-06
UBE3A O 1 0.9867569208145142
/ O 0 0.45617443323135376
E6 O 0 0.0003076471039094031
- O 0 1.0510590982448775e-05
AP O 0 1.5343275663326494e-05
gene O 0 5.4936975857344805e-08
and O 0 9.0944789477021e-09
related O 0 6.557759775205341e-07
pseudogenes O 0 9.562311788613442e-06
. O 0 7.975294806783495e-07

The O 0 4.8600313675706275e-06
UBE3A O 0 8.018405787879601e-05
gene O 0 1.824832338570559e-07
encodes O 0 7.952557723456266e-08
the O 0 1.2749740108120022e-07
E6 O 0 3.2307234505424276e-05
- O 0 1.7464642951381393e-05
AP O 0 8.490718028042465e-05
ubiquitin O 0 4.220812115818262e-06
- O 0 8.713640227142605e-07
protein O 0 9.238386411425381e-08
ligase O 0 6.868333457532572e-08
and O 0 7.64244312279061e-09
has O 0 2.333161885914592e-09
recently O 0 7.956711733925204e-09
been O 0 1.0941652028861881e-09
shown O 0 1.1226316404266967e-10
to O 0 1.0197622260510464e-11
be O 0 9.796624622637751e-11
mutated O 0 8.882889979133779e-09
in O 0 3.3522215403536393e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0004456404712982476
who O 0 1.0440985676041237e-07
lack O 0 7.58573378334404e-07
15q11 O 0 4.536715096037369e-06
- O 0 1.1358571327946265e-06
q13 O 0 1.2547684491437394e-06
deletions O 0 3.0689599839206494e-07
or O 0 1.1392675247634543e-07
chromosome O 0 7.098584319464862e-06
15 O 0 3.1534229947283166e-06
paternal O 0 3.8043704989831895e-05
uniparental B-Disease 0 0.03671525418758392
disomy I-Disease 0 0.0018793117487803102
. O 0 1.1584340427361894e-05

Previous O 0 8.144529601850081e-06
UBE3A O 0 0.0001370754325762391
cDNA O 0 3.8138423406053334e-06
analysis O 0 2.5658218305579794e-07
has O 0 8.498906467480083e-09
shown O 0 4.131810449337081e-09
a O 0 1.5302533684646846e-09
coding O 0 7.184934247561614e-08
region O 0 2.1541879391406837e-08
of O 0 2.3646494540230378e-08
approximately O 0 2.1267124949986282e-08
2 O 0 7.140641287151084e-07
. O 0 1.4580365359506686e-07

6 O 0 4.97464498039335e-05
kb O 0 4.827680822927505e-05
and O 0 2.626425725793524e-07
a O 0 3.205194900601782e-07
3 O 0 1.2132278470744495e-06
- O 0 6.690889335914108e-07
untranslated O 0 0.00011492898920550942
region O 0 8.423060080531286e-07
( O 0 1.902819946053569e-08
UTR O 0 4.417116542754229e-06
) O 0 5.432985616948827e-09
of O 0 1.2058140441695286e-07
< O 0 9.356432997265074e-07
50 O 0 1.9670700623919402e-07
bp O 0 2.861374071017053e-07
, O 0 3.032980755435233e-09
whereas O 0 9.726664806919416e-09
Northern O 0 6.130506768897703e-09
analysis O 0 1.4239825985029597e-09
has O 0 2.7753460640767003e-10
indicated O 0 6.657340789750776e-10
mRNA O 0 1.0598744104584057e-09
sizes O 0 2.7814894831834636e-09
of O 0 8.818538788091246e-09
5 O 0 1.4193362574133062e-07
- O 0 1.8742224483503378e-07
8 O 0 6.790600082240417e-07
kb O 0 3.085035132244229e-05
. O 0 3.4344714094913797e-06

We O 0 4.3487750644999323e-07
have O 0 5.0254573835673e-09
analyzed O 0 2.131943510619294e-08
additional O 0 4.583189827656042e-09
cDNA O 0 6.695064058703792e-08
clones O 0 1.2102028712490664e-08
and O 0 3.4159289286073147e-10
provide O 0 3.917278446063932e-10
evidence O 0 1.2965558626731877e-09
for O 0 1.223916107351286e-10
an O 0 2.2463267357331063e-10
additional O 0 6.236010374749412e-09
0 O 0 1.3500201134775125e-07
. O 0 1.5177411682998354e-07

5 O 0 1.9807661374215968e-05
kb O 0 5.174973193788901e-05
of O 0 5.253471044852631e-06
5 O 0 6.402694907592377e-06
- O 0 2.1285118236846756e-06
UTR O 0 3.169960473314859e-05
and O 0 5.853054219073783e-08
> O 0 3.0193839961611957e-07
2 O 0 3.5315633795107715e-07
kb O 0 4.36936261394294e-06
of O 0 7.974047662173689e-07
3 O 0 2.821975613187533e-05
- O 0 3.069932427024469e-05
UTR O 0 0.0011734371073544025
. O 0 3.859704065689584e-06

We O 0 4.853764608014899e-07
have O 0 6.613756209361554e-09
established O 0 6.6781251639724815e-09
the O 0 2.1519199755459795e-09
genomic O 0 2.7726873241817884e-08
organization O 0 3.8216936282253755e-09
of O 0 4.1678575257719785e-08
UBE3A O 0 6.287707492447225e-06
and O 0 4.139035336692132e-09
the O 0 3.2841036556874315e-09
sequence O 0 1.2177326702556002e-08
of O 0 1.953799539933243e-07
intron O 0 6.05696186539717e-05
- O 0 7.10435415385291e-06
exon O 0 9.634854905016255e-06
borders O 0 5.025196401220455e-07
. O 0 8.172524985639029e-07

We O 0 9.65434082900174e-07
have O 0 1.1599977867149391e-08
also O 0 6.498886317984898e-09
mapped O 0 9.188878102861509e-09
two O 0 3.248865176885829e-09
highly O 0 1.867882026829193e-08
homologous O 0 2.5049191165749107e-08
processed O 0 5.141142978004609e-08
pseudogenes O 0 7.021856163191842e-08
, O 0 2.303324642127791e-09
UBE3AP1 O 0 1.0893585340454592e-06
and O 0 7.589350481396195e-09
UBE3AP2 O 0 1.0918434782070108e-05
, O 0 3.1430638092189156e-09
to O 0 1.260217485921089e-09
chromosomes O 0 2.4751836136260863e-08
2 O 0 4.398727782017886e-08
and O 0 1.9167483156223852e-09
21 O 0 1.6886723130937753e-08
, O 0 1.213590894444394e-09
respectively O 0 1.2899459278514769e-08
, O 0 1.4136154469213125e-09
and O 0 3.9901842940892607e-10
determined O 0 7.451351535792128e-09
their O 0 2.3616733013653857e-09
genomic O 0 1.5518126872393623e-07
organization O 0 4.2270531963595204e-08
. O 0 2.943275489997177e-07

These O 0 3.9237580296003216e-08
results O 0 1.2189736331436052e-08
will O 0 1.0357807944672004e-09
form O 0 6.900905957785142e-10
the O 0 2.766034623569169e-10
basis O 0 9.652567634077514e-10
for O 0 1.7729687162848506e-10
studies O 0 6.592292267626476e-10
of O 0 1.5894039417929662e-09
mutation O 0 4.6021877975199743e-10
and O 0 2.3413468941413385e-09
imprinting O 0 1.163354454547516e-06
of O 0 2.9332877602428198e-06
UBE3A O 0 0.25848451256752014
. O 0 1.66619192896178e-05

Mutation O 0 8.421365578215045e-07
spectrum O 0 2.4311934794241097e-06
and O 0 2.210225069632088e-08
genotype O 0 5.659983344230568e-07
- O 0 2.264521867800795e-07
phenotype O 0 1.3976028334639068e-08
analyses O 0 1.5586598678396513e-08
in O 0 1.1313772141363643e-08
Cowden B-Disease 1 0.9034443497657776
disease I-Disease 0 6.36059048702009e-05
and O 0 2.090696540335557e-07
Bannayan B-Disease 1 0.9999920129776001
- I-Disease 1 0.9999998807907104
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.308004347170936e-07
two O 0 1.5363275451818481e-06
hamartoma B-Disease 1 0.999982476234436
syndromes I-Disease 1 0.8817877173423767
with O 0 0.00010549422586336732
germline O 1 0.9999626874923706
PTEN O 1 0.9975195527076721
mutation O 0 2.6710937163443305e-05
. O 0 6.0240486163820606e-06

The O 0 3.6009791074320674e-05
tumour B-Disease 1 0.9999995231628418
suppressor O 0 0.0003868586500175297
gene O 0 7.140981324482709e-06
PTEN O 0 7.192011980805546e-05
, O 0 5.2104041969869286e-08
which O 0 5.062901653474228e-09
maps O 0 1.1422625334489567e-07
to O 0 7.507217958391266e-08
10q23 O 0 2.6785188310896046e-05
. O 0 2.3491636511607794e-06

3 O 0 3.187911488566897e-06
and O 0 2.889497352498438e-08
encodes O 0 1.0893223212349312e-08
a O 0 3.383560320813217e-09
403 O 0 1.867410892586463e-09
amino O 0 3.794123237810254e-09
acid O 0 1.8903289600302742e-08
dual O 0 2.906534177782305e-07
specificity O 0 5.669523943652166e-07
phosphatase O 0 0.00016580669034738094
( O 0 1.0928813765076484e-07
protein O 0 4.1895449953699426e-07
tyrosine O 0 4.0043391891231295e-07
phosphatase O 0 3.7826330299139954e-06
; O 0 1.862449572342939e-08
PTPase O 0 3.2935827221081126e-06
) O 0 1.5584934232037995e-08
, O 0 7.877764218733319e-09
was O 0 2.352995096543964e-07
shown O 0 1.817859640595998e-08
recently O 0 1.5883834691976517e-08
to O 0 6.773770988566241e-10
play O 0 9.334262074389699e-08
a O 0 5.05845187959153e-09
broad O 0 2.126396125845531e-08
role O 0 6.829066023783525e-08
in O 0 3.2595615095942776e-08
human O 0 4.30453809485698e-07
malignancy B-Disease 0 0.0008693761192262173
. O 0 2.0667466742452234e-06

Somatic O 0 0.0017407384002581239
PTEN O 0 0.0010074994061142206
deletions O 0 4.39043105870951e-06
and O 0 3.5702107936685934e-08
mutations O 0 3.4155025474547074e-08
were O 0 7.452829464682509e-09
observed O 0 1.1559913026815138e-08
in O 0 3.369456491597589e-09
sporadic B-Disease 0 1.5851586795179173e-05
breast I-Disease 1 0.6006525754928589
, I-Disease 0 5.7350632687303e-07
brain I-Disease 1 0.9999986886978149
, I-Disease 0 2.968112130474765e-05
prostate I-Disease 1 1.0
and I-Disease 1 0.9999934434890747
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999977350234985
lines O 0 1.1849318980239332e-05
and O 0 1.1725483695101957e-08
in O 0 2.7630988608251528e-09
several O 0 5.096910449253755e-09
primary O 0 3.196024408680387e-06
tumours B-Disease 1 0.9999995231628418
such O 0 3.937762826922153e-08
as O 0 0.00011281158367637545
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999998807907104
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9952735304832458

In O 0 9.150681421488116e-07
addition O 0 5.263548814582464e-07
, O 0 1.0534883898571934e-07
PTEN O 0 1.7249361917492934e-05
was O 0 2.1270822969654546e-07
identified O 0 5.992035312374355e-09
as O 0 6.331769553113986e-10
the O 0 1.4373371381992683e-09
susceptibility O 0 2.9144381130663533e-08
gene O 0 2.850863323189401e-09
for O 0 8.769778681028129e-09
two O 0 1.3341841622604989e-06
hamartoma B-Disease 1 0.9999998807907104
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999676942825317
( O 0 1.2523339876224782e-07
CD B-Disease 0 7.907597137091216e-06
; O 0 1.7543145602871846e-08
MIM O 0 7.841406841180287e-06
158350 O 0 3.251688269756414e-07
) O 0 9.465960237875493e-10
and O 0 2.6817166265402648e-09
Bannayan B-Disease 0 2.6758256353787147e-05
- I-Disease 0 2.2104135496192612e-05
Zonana I-Disease 0 0.002325806301087141
( I-Disease 0 6.36653112451313e-08
BZS I-Disease 0 1.8436878235661425e-05
) I-Disease 0 6.832034049608637e-09
or I-Disease 0 1.8948629332271594e-08
Ruvalcaba I-Disease 0 4.575947968987748e-06
- I-Disease 0 5.303862508299062e-06
Riley I-Disease 0 0.00017979127005673945
- I-Disease 1 0.9627664089202881
Smith I-Disease 1 0.9998924732208252
syndrome I-Disease 1 0.9999995231628418
( O 0 6.071886673453264e-06
MIM O 0 0.420780748128891
153480 O 0 0.00014697923325002193
) O 0 3.665893757442973e-07
. O 0 1.0281597724315361e-06

Constitutive O 0 2.742028664215468e-05
DNA O 0 2.121004399668891e-06
from O 0 1.57322403993021e-07
37 O 0 2.9207191687419254e-07
CD B-Disease 0 1.1267825357208494e-06
families O 0 1.4595040731535391e-09
and O 0 4.2213303963478666e-09
seven O 0 7.90502667769033e-08
BZS B-Disease 0 8.119804988382384e-05
families O 0 2.4181951996382622e-09
was O 0 6.4215576855986e-08
screened O 0 7.151942327254801e-08
for O 0 2.876766913573192e-08
germline O 0 4.854008511756547e-05
PTEN O 0 0.00035550520988181233
mutations O 0 2.289475560246501e-06
. O 0 2.9222198918432696e-06

PTEN O 0 0.00019919584156014025
mutations O 0 2.0615838991489e-07
were O 0 3.471526355269816e-08
identified O 0 9.99564875314718e-09
in O 0 2.351075334416919e-09
30 O 0 1.7103843674703967e-08
of O 0 3.7279217934838016e-08
37 O 0 3.235966801184986e-07
( O 0 1.1230482321877844e-08
81 O 0 1.72971169831726e-07
% O 0 9.455535021629657e-09
) O 0 3.4650151636839155e-09
CD B-Disease 0 3.407772624086647e-07
families O 0 7.809838331596097e-10
, O 0 7.13057835000086e-10
including O 0 2.3854955788493726e-09
missense O 0 2.6773719241646177e-07
and O 0 2.3174628438482614e-08
nonsense O 0 4.126782187086064e-06
point O 0 2.4337589366041357e-06
mutations O 0 2.5826352612057235e-08
, O 0 4.097217232157391e-09
deletions O 0 3.966573558500386e-08
, O 0 5.8228311061725435e-09
insertions O 0 1.301411884924164e-07
, O 0 8.980470589392553e-09
a O 0 2.8216309289064156e-08
deletion O 0 4.619941591954557e-06
/ O 0 2.2898553652339615e-05
insertion O 0 2.0630327526305337e-06
and O 0 4.336102676916198e-07
splice O 0 1.4355386156239547e-05
site O 0 7.894913096606615e-07
mutations O 0 1.1252072908973787e-06
. O 0 2.098431878039264e-06

These O 0 8.01404382855253e-08
mutations O 0 4.961504984635212e-08
were O 0 1.4289242677989478e-08
scattered O 0 5.557731608263339e-09
over O 0 2.479813243638773e-09
the O 0 2.5462822961230813e-09
entire O 0 1.2539936200539614e-08
length O 0 1.033815433260088e-08
of O 0 4.766693351143658e-08
PTEN O 0 1.0958219718304463e-06
, O 0 1.4410785897922551e-09
with O 0 2.993244541116269e-10
the O 0 1.6737766728169845e-09
exception O 0 2.2916946118556325e-09
of O 0 4.125974673030441e-09
the O 0 1.904318480683287e-09
first O 0 6.687570053287573e-09
, O 0 2.3991386655097813e-09
fourth O 0 3.144582549907682e-08
and O 0 8.661079853311549e-09
last O 0 2.0948138512721926e-07
exons O 0 3.3137273476313567e-06
. O 0 1.8102219883076032e-06

A O 0 3.7264944694470614e-05
hot O 0 4.230611375533044e-05
spot O 0 1.9662688828248065e-06
for O 0 5.262780433668013e-08
PTEN O 0 6.407233286154224e-06
mutation O 0 7.104936194934908e-09
in O 0 5.356166621339753e-09
CD B-Disease 0 3.222342854769522e-07
was O 0 5.958440851827618e-08
identified O 0 4.26207380499477e-09
in O 0 5.215283316317709e-09
exon O 0 1.9486932956169767e-07
5 O 0 7.849866534570538e-09
that O 0 1.4166513795377256e-10
contains O 0 1.337687516311803e-09
the O 0 3.508896728732225e-09
PTPase O 0 5.493880053109024e-07
core O 0 7.481772854589508e-07
motif O 0 5.148541859512079e-08
, O 0 6.842737487744444e-10
with O 0 2.2308148384109217e-10
13 O 0 2.6104284955863477e-08
of O 0 7.507704680165261e-08
30 O 0 2.129280289864255e-07
( O 0 9.142288703856138e-09
43 O 0 6.136873764717166e-08
% O 0 5.660628854542438e-09
) O 0 3.514576629726207e-09
CD B-Disease 0 4.86031865420955e-07
mutations O 0 9.665948041970296e-09
identified O 0 8.646422244851237e-09
in O 0 2.8462885381941305e-09
this O 0 1.047670927789568e-08
exon O 0 6.96698589308653e-06
. O 0 1.328523921984015e-06

Seven O 0 2.1502589788724435e-06
of O 0 8.054835234361235e-07
30 O 0 3.6392702895682305e-07
( O 0 6.386255524404305e-09
23 O 0 5.4186244824450114e-08
% O 0 2.6030684274758187e-09
) O 0 6.154520781898043e-10
were O 0 2.864304127214723e-09
within O 0 3.2426374918514966e-09
the O 0 7.1925416733620295e-09
core O 0 5.346601028577425e-07
motif O 0 2.983296099046129e-08
, O 0 2.570229584719641e-10
the O 0 6.71883992886535e-10
majority O 0 5.92959292777806e-10
( O 0 5.967670246853629e-10
five O 0 1.0800903504915027e-09
of O 0 9.224138786123603e-09
seven O 0 3.7155896137619493e-09
) O 0 2.161759105057115e-10
of O 0 4.04364053352424e-09
which O 0 7.681649205615315e-10
were O 0 1.8827222447725944e-08
missense O 0 3.9410923591276514e-07
mutations O 0 1.508105107461688e-08
, O 0 7.271026003508041e-09
possibly O 0 4.595858982270329e-08
pointing O 0 5.7130211672529185e-08
to O 0 1.7468044788415682e-09
the O 0 3.443996199337107e-09
functional O 0 2.821018370013917e-07
significance O 0 1.1340090821931881e-07
of O 0 3.171785678546257e-08
this O 0 3.2905242974834437e-09
region O 0 4.160726234658796e-07
. O 0 5.916595569033234e-07

Germline O 0 0.004869492258876562
PTEN O 0 0.0004226919845677912
mutations O 0 2.765505371371546e-07
were O 0 2.6159758803601108e-08
identified O 0 1.2734933996227937e-08
in O 0 1.4323262575999252e-09
four O 0 1.1080283357500775e-09
of O 0 1.6469638097760253e-08
seven O 0 3.049206043215236e-08
( O 0 7.3900365826773395e-09
57 O 0 1.7010869157729758e-07
% O 0 1.1904698027365157e-07
) O 0 2.1068429134629696e-07
BZS B-Disease 0 0.0008249831735156476
families O 0 6.046582967655922e-08
studied O 0 2.389742439845577e-05
. O 0 2.1949936126475222e-06

Interestingly O 0 2.4460294298478402e-05
, O 0 1.938118145972112e-07
none O 0 3.029085604566717e-08
of O 0 8.885381319601038e-09
these O 0 3.8849556904807514e-10
mutations O 0 2.24740759335873e-09
was O 0 1.3685279576236553e-08
observed O 0 5.996986018885764e-09
in O 0 9.014410884411461e-10
the O 0 1.179155439956503e-08
PTPase O 0 8.274578249256592e-06
core O 0 1.4605272554035764e-05
motif O 0 3.5707194001588505e-06
. O 0 8.547467018615862e-07

It O 0 9.351886376407492e-08
is O 0 2.2939477872796488e-08
also O 0 5.344655829020439e-09
worthy O 0 3.498586664818504e-08
of O 0 1.6926549051277107e-08
note O 0 1.3879596139076966e-08
that O 0 2.6596685964719313e-10
a O 0 1.2774483693078764e-09
single O 0 8.655609007313103e-10
nonsense O 0 7.723836148443297e-08
point O 0 2.8983508926216928e-08
mutation O 0 5.400191405158239e-10
, O 0 4.955040822096635e-10
R233X O 0 3.7396652885490766e-08
, O 0 9.181795879165122e-10
was O 0 1.1767895990999477e-08
observed O 0 3.908801726737465e-09
in O 0 9.141848389404572e-10
the O 0 2.2606017058279804e-09
germline O 0 2.8960300824110163e-08
DNA O 0 1.0974849473655013e-08
from O 0 2.9318152350299442e-09
two O 0 1.6691094062437628e-09
unrelated O 0 4.038624723534667e-08
CD B-Disease 0 7.532618724326312e-07
families O 0 1.7513949179814858e-09
and O 0 1.1183477255372054e-08
one O 0 1.837561569573154e-07
BZS B-Disease 0 0.04812104254961014
family O 0 1.260946191905532e-06
. O 0 1.741972937452374e-06

Genotype O 0 3.890798689099029e-05
- O 0 6.797824880777625e-06
phenotype O 0 1.5811794185083272e-07
studies O 0 2.4702643486307352e-08
were O 0 1.434149576873267e-09
not O 0 1.1781066400207152e-10
performed O 0 3.415930649453003e-09
on O 0 5.094130894889304e-09
this O 0 2.0519501375826366e-10
small O 0 1.3588411507114984e-09
group O 0 4.289427035786275e-09
of O 0 3.759633955269237e-07
BZS B-Disease 0 0.1395971029996872
families O 0 9.623861529917122e-08
. O 0 6.540635126839334e-07

However O 0 8.823899406706914e-07
, O 0 1.0036900022214468e-07
genotype O 0 3.9558986486554204e-07
- O 0 1.1062724070143304e-07
phenotype O 0 8.024915842952396e-09
analysis O 0 1.3076031812886413e-08
inthe O 0 5.288611646392383e-07
group O 0 9.377049359216016e-09
of O 0 9.212185858586963e-08
CD B-Disease 0 2.6850815629586577e-05
families O 0 4.889455951229138e-09
revealed O 0 4.28017763454136e-08
two O 0 5.04123798261702e-10
possible O 0 1.0018280649504163e-09
associations O 0 1.9594041666959328e-10
worthy O 0 6.5349707867312645e-09
of O 0 4.255242380679647e-09
follow O 0 3.2069384925392797e-09
- O 0 8.832931719382486e-09
up O 0 1.9044674726131916e-09
in O 0 1.8915904398397743e-09
independent O 0 5.564891658593751e-09
analyses O 0 6.782762795864983e-08
. O 0 1.7892263315388846e-07

The O 0 6.751687351425062e-07
first O 0 1.1308696201695057e-07
was O 0 1.5407381681598054e-07
an O 0 1.1004440692019557e-09
association O 0 1.566500484884159e-09
noted O 0 3.476546828196092e-09
in O 0 4.3221104473190053e-10
the O 0 5.736447428184022e-10
group O 0 1.4417383953357898e-09
of O 0 2.0449897775165482e-08
CD B-Disease 0 2.8583664970938116e-05
families O 0 6.899001370186397e-09
with O 0 7.394748422484554e-07
breast B-Disease 1 1.0
disease I-Disease 1 0.9999964237213135
. O 0 3.729324816958979e-05

A O 0 2.8147135253675515e-06
correlation O 0 9.5016548584681e-07
was O 0 3.820318568159564e-07
observed O 0 2.2939435240232342e-08
between O 0 5.141669756625333e-09
the O 0 2.56666421449836e-09
presence O 0 3.147991023411123e-08
/ O 0 3.7311801293071767e-07
absence O 0 1.1629845886318435e-07
of O 0 1.0526548521738732e-07
a O 0 1.388034291949225e-07
PTEN O 0 2.9431564598780824e-06
mutation O 0 1.1916966302649712e-09
and O 0 4.0876924067845266e-10
the O 0 1.5349627124905396e-09
type O 0 2.979833766403317e-07
of O 0 1.6138342289195862e-06
breast O 1 0.9000301957130432
involvement O 0 0.001811107387766242
( O 0 1.181945208372781e-06
unaffected O 0 2.588342067610938e-05
versus O 0 0.2579343318939209
benign O 1 0.905524730682373
versus O 1 0.9788379669189453
malignant O 1 0.9965006113052368
) O 0 4.4623001826948894e-07
. O 0 1.4612202221542248e-06

Specifically O 0 1.6362170072170557e-06
and O 0 4.645964679639292e-08
more O 0 2.8719737699134384e-09
directly O 0 1.1335674621193448e-08
, O 0 1.014031858481701e-09
an O 0 1.034777596942149e-09
association O 0 7.705983406935957e-09
was O 0 2.5583378260307654e-07
also O 0 1.5527750196753232e-09
observed O 0 2.228315310048856e-09
between O 0 1.0495464497495277e-09
the O 0 2.97621149947247e-10
presence O 0 1.4234123879575122e-09
of O 0 6.276246633518667e-09
a O 0 3.141830617892083e-08
PTEN O 0 9.269986185245216e-05
mutation O 0 4.801376576324401e-07
and O 0 4.015975264337612e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
. O 0 6.961524923099205e-05

Secondly O 0 6.270571611821651e-05
, O 0 6.380742547662521e-07
there O 0 1.1430645230348091e-07
appeared O 0 1.445240513930912e-07
to O 0 1.3729404280127255e-09
be O 0 1.739071997519659e-09
an O 0 2.533695919737511e-09
interdependent O 0 2.7226194561080774e-06
association O 0 1.497657535765029e-07
between O 0 7.071498089317174e-07
mutations O 0 1.1354472917446401e-07
upstream O 0 2.0300865344324848e-07
and O 0 5.745802056367211e-09
within O 0 3.1938828470856606e-08
the O 0 1.3436872947636402e-08
PTPase O 0 7.448763881257037e-06
core O 0 7.29939301891136e-06
motif O 0 1.980088910613631e-07
, O 0 2.2435058255609874e-09
the O 0 1.5727245061825101e-09
core O 0 1.7469143642756535e-07
motif O 0 1.8448252703251455e-08
containing O 0 8.574158050222991e-10
the O 0 3.042098517536118e-10
majority O 0 2.6165619670948104e-10
of O 0 1.6276487713184906e-08
missense O 0 2.222745649760327e-07
mutations O 0 6.6562013678606036e-09
, O 0 1.132527405189876e-09
and O 0 5.837885730386461e-10
the O 0 2.513863561759422e-09
involvement O 0 8.54056025900718e-08
of O 0 1.5025266364432355e-08
all O 0 1.5655983176543486e-09
major O 0 2.4296906531162676e-07
organ O 1 0.9999226331710815
systems O 1 0.999997615814209
( O 0 8.614114449301269e-06
central O 0 0.002638185163959861
nervous O 0 0.0007238386897370219
system O 0 0.0006265515112318099
, O 0 2.1719342839787714e-06
thyroid O 1 1.0
, O 0 0.004339729901403189
breast O 1 1.0
, O 0 0.24776360392570496
skin O 1 1.0
and O 1 0.9999942779541016
gastrointestinal O 1 1.0
tract O 1 0.9999990463256836
) O 0 4.785639248439111e-05
. O 0 1.670951496635098e-05

However O 0 6.100212317505793e-07
, O 0 2.2683991574012907e-08
these O 0 8.741334323048022e-10
observations O 0 1.1989357950881185e-08
would O 0 1.6936615443441383e-09
need O 0 1.7349569558788858e-09
to O 0 1.6869870778091212e-10
be O 0 2.687983169380459e-10
confirmed O 0 5.270479608299183e-10
by O 0 3.6174199052885214e-11
studying O 0 6.658576356954882e-09
a O 0 3.8445019390209723e-10
larger O 0 2.4516599861357236e-10
number O 0 1.4849210749900976e-10
of O 0 5.399905855796305e-09
CD B-Disease 0 1.4654094684374286e-06
families O 0 7.789550338088702e-09
. O 0 1.0602150979366343e-07

Molecular O 1 0.9473206996917725
defects O 1 0.9989645481109619
leading O 0 8.40268603496952e-06
to O 0 6.44301536567582e-08
human O 0 1.109050003833545e-06
complement B-Disease 0 0.0008522397838532925
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.80776048259213e-08
an O 0 2.8065791912723626e-09
African O 0 9.542249301830452e-08
- O 0 5.101236411064747e-07
American O 0 2.2314154080049775e-07
family O 0 2.9942788160042255e-07
. O 0 5.105597438159748e-07

Complement B-Disease 0 0.0009428705670870841
component I-Disease 1 0.999997615814209
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.08065431858995e-06
C6D B-Disease 0 0.000718129042070359
) O 0 8.825155362046644e-08
was O 0 2.0030333871545736e-06
diagnosed O 0 2.687560936465161e-06
in O 0 6.247081518750974e-09
a O 0 3.7039216138623487e-09
16 O 0 1.3469742654592665e-08
- O 0 5.050845519605218e-09
year O 0 1.4420712401985725e-09
- O 0 1.4164122319471062e-08
old O 0 5.5623583961050826e-08
African O 0 1.1735798111089935e-08
- O 0 3.176210938704571e-08
American O 0 5.859194907031906e-09
male O 0 7.285439096449409e-08
with O 0 2.770224682535627e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.544979896716541e-06

The O 0 4.430794433574192e-06
patients O 0 3.500927959976252e-06
father O 0 1.131964268097363e-06
and O 0 1.8968920301176695e-07
two O 0 3.024658212780196e-07
brothers O 0 2.6087565856869332e-05
also O 0 1.742523210168656e-07
had O 0 1.4662762168882182e-06
C6D B-Disease 0 0.028699418529868126
, O 0 2.549771727089478e-09
but O 0 4.019562183099623e-10
gave O 0 1.4636913903132154e-09
no O 0 8.727206735059667e-10
history O 0 6.995118706498715e-09
of O 0 3.4583618457872944e-07
meningitis B-Disease 1 0.9999885559082031
or O 0 2.746988947421869e-08
other O 0 2.911160201790608e-08
neisserial B-Disease 0 0.00034792162477970123
infection I-Disease 0 0.0002761478826869279
. O 0 1.8106295556208352e-06

By O 0 3.981134000241582e-08
using O 0 1.3479680660566373e-07
exon O 0 6.740769435964467e-07
- O 0 1.981006114704087e-08
specific O 0 1.2464551613078356e-09
polymerase O 0 1.0634575886570019e-07
chain O 0 1.1117250231507114e-08
reaction O 0 1.4466636777399344e-09
( O 0 1.2491183642993064e-09
PCR O 0 2.0631921060498826e-08
) O 0 1.5101511152693092e-09
/ O 0 4.3227579737958877e-08
single O 0 8.848833665808797e-09
- O 0 9.114000931731425e-08
strand O 0 2.5732436625958144e-08
conformation O 0 7.679470392929488e-09
polymorphism O 0 6.621405201912012e-09
as O 0 9.647064258544447e-10
a O 0 5.00785801715864e-10
screening O 0 2.1352957180198473e-09
step O 0 2.097729101535606e-09
and O 0 1.4881250398612877e-10
nucleotide O 0 1.992722875598929e-09
sequencing O 0 4.622644489415961e-09
of O 0 8.633997516938052e-09
target O 0 2.918899788539875e-08
exons O 0 1.0599583077919306e-07
, O 0 3.739321297047127e-09
we O 0 1.5961907351424998e-09
determined O 0 6.600624491426288e-09
that O 0 2.4720955837942427e-10
the O 0 1.6276915371093992e-09
proband O 0 1.978637271804473e-07
was O 0 5.663147817358549e-08
a O 0 2.508149909985491e-09
compound O 0 3.269717296916497e-08
heterozygote O 0 9.547747481519764e-08
for O 0 8.550661512174429e-09
two O 0 1.0550247253604539e-07
C6 O 0 0.013263062573969364
gene O 0 1.5446885299752466e-06
mutations O 0 1.319892362516839e-06
. O 0 6.720114242853015e-07

The O 0 1.4721820207341807e-06
first O 0 2.638599312376755e-07
, O 0 4.93298912829232e-08
1195delC O 0 4.800763235834893e-07
located O 0 7.652321443174515e-08
in O 0 2.0086019958398538e-08
exon O 0 1.5999124798327102e-06
7 O 0 6.782955779272015e-07
, O 0 1.2524948189707175e-08
is O 0 1.5273665665560543e-09
a O 0 1.3154222155975503e-09
novel O 0 1.651180858708301e-09
mutation O 0 5.102199218676162e-10
, O 0 4.122660823835389e-10
while O 0 9.35004185187438e-10
the O 0 2.2458093162924797e-09
second O 0 1.399566151860654e-08
, O 0 2.0789285848366035e-09
1936delG O 0 2.4427659894854514e-08
in O 0 4.861540059408753e-09
exon O 0 2.401445726718521e-07
12 O 0 6.032632882124744e-08
, O 0 3.3715521485788713e-09
has O 0 1.0551103324374367e-09
been O 0 1.5448755608105103e-09
described O 0 4.110257467715428e-09
before O 0 4.962117383655595e-09
to O 0 5.052490648083108e-10
cause O 0 1.608348831894091e-08
C6D B-Disease 0 2.5799527065828443e-06
in O 0 2.251960395938113e-09
an O 0 6.965252263846367e-10
unrelated O 0 9.050701521573501e-08
African O 0 4.9023828552208215e-08
- O 0 8.295511833011915e-08
American O 0 1.4582832719156613e-08
individual O 0 8.129475759233173e-09
. O 0 8.216570677177515e-07

Both O 0 2.381458159561589e-07
mutations O 0 5.9294631427064814e-08
result O 0 2.4857101266206882e-08
in O 0 2.2085478335043263e-08
premature O 0 1.596295930994529e-07
termination O 0 1.2934485482674063e-07
codons O 0 1.849128921094234e-07
and O 0 1.0119692461785235e-07
C6 O 0 0.0001155604186351411
null O 0 1.5146486475714482e-05
alleles O 0 1.1060250244554481e-06
. O 0 2.027640221058391e-06

Allele O 0 1.5392753311971319e-06
- O 0 1.5052464164000412e-07
specific O 0 7.955588188224283e-09
PCR O 0 1.0913212378227399e-07
indicated O 0 1.5679898268672332e-08
that O 0 2.7448912587324514e-10
the O 0 8.809796447906137e-09
probands O 0 1.5628743312845472e-06
two O 0 1.869197241433085e-08
brothers O 0 2.641240257617028e-07
also O 0 5.3804334321228e-09
inherited O 0 2.556935214670375e-07
the O 0 8.815848495657974e-09
1195delC O 0 9.064643791134586e-08
mutation O 0 5.462721386351177e-10
from O 0 1.2090993761759705e-09
their O 0 4.899704530991755e-10
heterozygous O 0 7.070990015733969e-09
mother O 0 2.0250148224931763e-09
and O 0 2.5193150343660875e-10
the O 0 1.5076645487610563e-09
1936delG O 0 3.303543039123724e-08
mutation O 0 7.102832766392453e-10
from O 0 2.5021866800756243e-09
their O 0 1.756071177361207e-09
homozygous O 0 7.263751911068539e-08
father O 0 8.296066056345808e-08
. O 0 5.826400695241318e-08
. O 0 6.584902507711377e-07

PAX6 O 0 0.008683288469910622
mutations O 0 1.87099303730065e-05
reviewed O 0 4.595409336616285e-05
. O 0 9.119796231971122e-06

Mutations O 0 1.621401224838337e-06
in O 0 2.772799518879765e-07
PAX6 O 0 4.302442539483309e-05
are O 0 1.3836353396357026e-08
responsible O 0 5.946928283151465e-08
for O 0 1.3440460300273571e-08
human O 0 6.994119985392899e-07
aniridia B-Disease 1 1.0
and O 0 1.1392555876454935e-07
have O 0 1.6165533356371498e-09
also O 0 6.346956293867834e-10
been O 0 2.0226438579573625e-10
found O 0 1.3109582863712888e-10
in O 0 1.1041670355815825e-10
patients O 0 1.9747418977811293e-10
with O 0 2.140049915055897e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 7.610714419570286e-06
with O 1 0.9983306527137756
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.9389181137084961
with O 0 0.3770505487918854
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 1.2112949434595066e-06
and O 0 7.849300942552873e-08
with O 0 2.9833925054845167e-06
isolated B-Disease 1 0.9999964237213135
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.37264910340309143

No O 0 1.008285153147881e-06
locus O 0 3.7132187458155386e-07
other O 0 1.6674936986760258e-08
than O 0 6.911711203372306e-09
chromosome O 0 4.0279709878632275e-07
11p13 O 0 8.890367553249234e-07
has O 0 3.5961800204376004e-09
been O 0 3.0053510791105964e-09
implicated O 0 3.451850361102515e-08
in O 0 1.4383553903485335e-08
aniridia B-Disease 1 0.9999988079071045
, O 0 3.998706077368297e-08
and O 0 3.451356533901162e-08
PAX6 O 0 0.0001254637900274247
is O 0 1.2654377101739556e-08
clearly O 0 1.04606554529596e-08
the O 0 2.18495732617896e-09
major O 0 1.5805410313873836e-08
, O 0 8.635606119078432e-10
if O 0 2.7094887444789606e-10
not O 0 1.2022825790491964e-10
only O 0 3.5915714846623814e-10
, O 0 1.98027994002814e-09
gene O 0 1.721554987454965e-08
responsible O 0 2.750486771674332e-07
. O 0 6.165683430481295e-07

Twenty O 0 1.821009755076375e-05
- O 0 1.928044639498694e-06
eight O 0 6.09341483936987e-08
percent O 0 1.858868792226076e-08
of O 0 1.4937713288531995e-08
identified O 0 1.0815384143825213e-07
PAX6 O 0 8.261205039161723e-06
mutations O 0 1.2034308660702209e-08
are O 0 4.4999386439315e-09
C O 0 2.5083361833821982e-05
- O 0 1.0570696531431167e-06
T O 0 7.498409217987501e-07
changes O 0 1.3036512314101856e-08
at O 0 2.4578176294198784e-07
CpG O 0 1.0596348687386126e-07
dinucleotides O 0 3.57159763098025e-07
, O 0 2.689517719645096e-09
20 O 0 4.194556257886006e-09
% O 0 3.25126869871184e-10
are O 0 9.47090392222627e-11
splicing O 0 1.08903552842321e-08
errors O 0 6.508937389071434e-08
, O 0 1.9460304478968737e-09
and O 0 7.593212170142749e-10
more O 0 1.3589751546305706e-10
than O 0 1.8253276667934415e-10
30 O 0 2.0695047897589802e-09
% O 0 4.385721508182172e-10
are O 0 3.8828074089281017e-10
deletion O 0 2.2681005518165875e-08
or O 0 1.1658579879281206e-08
insertion O 0 2.781693240194727e-07
events O 0 2.1116544246524427e-07
. O 0 8.084510909611708e-07

There O 0 1.7604774029678083e-06
is O 0 4.060661495941531e-08
a O 0 4.206961179420432e-08
noticeably O 0 9.534142009215429e-07
elevated O 0 4.641124462523294e-07
level O 0 3.755760076273873e-07
of O 0 1.9221053193518856e-08
mutation O 0 8.375921622949534e-10
in O 0 4.52948095697181e-10
the O 0 1.4140280057972632e-09
paired O 0 6.45599129711627e-09
domain O 0 1.3621893835136234e-08
compared O 0 2.609331861691544e-09
with O 0 1.3714217261817652e-10
the O 0 5.772340383458641e-09
rest O 0 2.8211465163963112e-08
of O 0 1.3926533704022859e-08
the O 0 1.940197869032545e-08
gene O 0 9.269080436524746e-08
. O 0 1.6972416005955893e-07

Increased O 0 3.258884362367098e-07
mutation O 0 2.457256975674227e-08
in O 0 6.541692521011555e-09
the O 0 1.561912732483961e-08
homeodomain O 0 1.3317104503585142e-06
is O 0 3.0600002531855353e-09
accounted O 0 7.79183917387627e-09
for O 0 5.140980974260856e-10
by O 0 6.516434059022913e-10
the O 0 2.845709268228802e-08
hypermutable O 0 4.879601874563377e-06
CpG O 0 1.4320339687401429e-06
dinucleotide O 0 3.0678381790494313e-06
in O 0 3.78993014749085e-08
codon O 0 2.069342741606306e-07
240 O 0 8.000174602784682e-07
. O 0 1.067979837898747e-06

Very O 0 2.007313014473766e-06
nearly O 0 5.701634364640995e-08
all O 0 3.05939362732488e-09
mutations O 0 6.1549707552899235e-09
appear O 0 1.9992146604863592e-08
to O 0 8.215044200454713e-10
cause O 0 1.939365468217602e-08
loss O 0 6.172665933945609e-08
of O 0 8.673747231568996e-08
function O 0 1.28293734746876e-07
of O 0 2.574844160108114e-08
the O 0 5.331572072719837e-09
mutant O 0 4.116957885713646e-09
allele O 0 1.0802139183141435e-09
, O 0 3.5760003291862574e-10
and O 0 1.7896882587020713e-10
more O 0 4.979842579966309e-11
than O 0 1.8809938329145126e-10
80 O 0 1.961626416857598e-09
% O 0 9.481680995904185e-10
of O 0 1.2510455782432928e-08
exonic O 0 4.5143144689063774e-07
substitutions O 0 3.2494678947614375e-08
result O 0 1.071362643045859e-08
in O 0 8.191422651293578e-09
nonsense O 0 7.305433769033698e-07
codons O 0 5.111205041430367e-07
. O 0 4.1691149021971796e-07

In O 0 5.641961706714937e-07
a O 0 4.3532146776215086e-08
gene O 0 4.688567312172154e-09
with O 0 5.51222789635375e-10
such O 0 3.132888837242831e-09
extraordinarily O 0 2.1809640315950674e-07
high O 0 5.078204523556451e-08
sequence O 0 1.686016437574267e-09
conservation O 0 7.082000541558386e-10
throughout O 0 2.7583793582586225e-10
evolution O 0 2.140082555612821e-09
, O 0 1.9927216821091776e-10
there O 0 4.49471238006538e-10
are O 0 6.991433543213077e-10
presumed O 0 1.9784975791026227e-07
undiscovered O 0 5.61733941140119e-05
missense O 0 7.667324553040089e-07
mutations O 0 1.3333019133199286e-08
, O 0 2.2692592249740073e-09
these O 0 5.697997629283691e-10
are O 0 2.787670372317308e-10
hypothesized O 0 4.1922127991256275e-09
to O 0 2.7882712805293863e-10
exist O 0 1.089933299169843e-08
in O 0 4.981557832905992e-09
as O 0 2.5227027578011985e-08
- O 0 8.649841021224347e-08
yet O 0 1.0504361824814623e-08
unidentified O 0 2.3122531445096683e-07
phenotypes O 0 1.0380164638945644e-07
. O 0 3.9403776241897503e-08
. O 0 2.842205901743e-07

Genetic O 0 1.718055864330381e-05
heterogeneity O 0 1.4565922356268857e-05
and O 0 1.3707136758966953e-07
penetrance O 0 6.058998678781791e-06
analysis O 0 8.144844088064929e-08
of O 0 7.447603422860993e-08
the O 0 9.669344791518597e-08
BRCA1 O 0 3.592737130020396e-07
and O 0 5.608070097196105e-08
BRCA2 O 0 2.0925038768382365e-07
genes O 0 1.1097277052840582e-07
in O 0 4.028562443636474e-07
breast B-Disease 1 0.9999315738677979
cancer I-Disease 1 0.9925121068954468
families O 0 1.2834146900786436e-07
. O 0 3.3661485758784693e-06

The O 0 0.0010450576664879918
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.021521497517824173
Consortium O 0 2.0634635802707635e-05
. O 0 2.164739953514072e-06

The O 0 1.9810104845419119e-07
contribution O 0 1.7275206687372702e-07
of O 0 5.91781429193361e-07
BRCA1 O 0 7.971720492605527e-07
and O 0 6.666597585081036e-08
BRCA2 O 0 1.53991561546718e-06
to O 0 3.520799054967938e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.02537950687110424
assessed O 0 4.030645186503534e-07
by O 0 1.0065340783071974e-09
linkage O 0 9.555544977501995e-08
and O 0 4.5438189322233313e-10
mutation O 0 3.37553984763872e-10
analysis O 0 1.2470782184692553e-09
in O 0 9.5967789270901e-10
237 O 0 5.976341643787464e-09
families O 0 2.588046998930338e-10
, O 0 4.1969869246649694e-10
each O 0 8.224634862052937e-11
with O 0 2.1216620127439967e-10
at O 0 4.3983000352909585e-08
least O 0 2.4205384918651873e-10
four O 0 4.0872710771466814e-10
cases O 0 1.9392460970379943e-09
of O 0 3.1970651548363094e-07
breast B-Disease 1 0.9994329810142517
cancer I-Disease 0 0.0001509834692114964
, O 0 1.6020836879349076e-09
collected O 0 7.525274292596862e-10
by O 0 4.218511651110646e-10
the O 0 1.452230435461388e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0007520219078287482
Consortium O 0 4.3080262912553735e-06
. O 0 6.0729826145689e-07

Families O 0 4.3563126439494226e-08
were O 0 1.4128533010193678e-08
included O 0 2.9013196289895404e-09
without O 0 1.9489019287277642e-09
regard O 0 2.521845177128057e-09
to O 0 1.3096786155575302e-10
the O 0 4.395410702073832e-10
occurrence O 0 2.993601810885593e-08
of O 0 2.817396307364106e-06
ovarian B-Disease 1 0.9999984502792358
or I-Disease 0 2.1229094272712246e-05
other I-Disease 0 4.566074494505301e-06
cancers I-Disease 1 0.9999899864196777
. O 0 1.045712997438386e-05

Overall O 0 4.955280019203201e-05
, O 0 7.093806743796449e-06
disease O 0 0.0028449012897908688
was O 0 2.631568122524186e-06
linked O 0 1.5027808331069537e-07
to O 0 2.1489667823004766e-09
BRCA1 O 0 6.8159984323301614e-09
in O 0 2.043565539011638e-09
an O 0 7.244084221369462e-10
estimated O 0 4.371192297014659e-09
52 O 0 2.2654978337754983e-08
% O 0 5.7826330390753355e-09
of O 0 5.990003870692817e-08
families O 0 9.37820821000912e-10
, O 0 7.372406574113199e-10
to O 0 5.24267740331652e-10
BRCA2 O 0 5.8262195068436995e-09
in O 0 1.3660654829550367e-09
32 O 0 1.4929709024613658e-08
% O 0 2.7919180300983726e-09
of O 0 2.7359925880432456e-08
families O 0 9.07340536038248e-10
, O 0 4.621645843805311e-10
and O 0 2.0360052532808481e-10
to O 0 2.2793567033829731e-10
neither O 0 3.610158394451446e-09
gene O 0 5.298854133251041e-10
in O 0 1.7242223204760876e-09
16 O 0 9.474399931264088e-09
% O 0 1.4624020883147182e-09
( O 0 1.2187777453931403e-09
95 O 0 2.810608989989305e-08
% O 0 1.0192542809761562e-08
confidence O 0 6.195277819642797e-07
interval O 0 1.5290250985344755e-06
[ O 0 1.4668565029296587e-07
CI O 0 2.028704693657346e-05
] O 0 2.795850093662011e-07
6 O 0 1.2349106270903576e-07
% O 0 6.279168296430271e-09
- O 0 2.405279708739272e-08
28 O 0 3.214650590166457e-08
% O 0 4.658224916909148e-09
) O 0 1.5669038289090054e-09
, O 0 2.1806025873871704e-09
suggesting O 0 1.728566445535762e-08
other O 0 8.16197776032368e-09
predisposition O 0 3.2492255286342697e-06
genes O 0 4.8170994659813e-07
. O 0 8.788232435108512e-07

The O 0 3.413370279758965e-07
majority O 0 5.744599462786937e-08
( O 0 1.843432251291688e-08
81 O 0 8.364833092855406e-08
% O 0 3.739321297047127e-09
) O 0 9.507868936609043e-10
of O 0 4.8558433718426386e-08
the O 0 4.173532943241298e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.034932305467919e-08
were O 0 2.2663622090135505e-08
due O 0 3.6930526192691104e-08
to O 0 2.9550351055007695e-09
BRCA1 O 0 5.071600472916771e-09
, O 0 2.627790207654357e-10
with O 0 1.2195537635317777e-10
most O 0 1.168896868186664e-09
others O 0 2.519638275799707e-09
( O 0 1.0142775508370505e-09
14 O 0 9.709500758958711e-09
% O 0 1.753728162690038e-09
) O 0 6.299450405755636e-10
due O 0 3.6265650038558306e-08
to O 0 5.0524089800774163e-08
BRCA2 O 0 1.551111381559167e-06
. O 0 1.6441365460195811e-06

Conversely O 0 1.0044940609077457e-05
, O 0 3.4439715079770394e-08
the O 0 4.697339406334322e-09
majority O 0 1.3874879023489939e-09
of O 0 8.312630583873215e-09
families O 0 1.376621316939719e-10
with O 0 4.806218756314706e-10
male B-Disease 0 3.654827764876245e-07
and I-Disease 0 1.0886783456953708e-06
female I-Disease 1 0.9991401433944702
breast I-Disease 1 1.0
cancer I-Disease 1 0.9997287392616272
were O 0 4.235052983858623e-06
due O 0 6.812538231315557e-06
to O 0 4.971782985307982e-08
BRCA2 O 0 9.967780556507932e-08
( O 0 1.6891329224222318e-08
76 O 0 2.0985910964554932e-07
% O 0 6.940631891438898e-08
) O 0 9.485307828072109e-08
. O 0 3.437006910189666e-07

The O 0 2.0604923065548064e-06
largest O 0 4.4649138430941093e-07
proportion O 0 1.0664068383903214e-07
( O 0 8.723150202172292e-09
67 O 0 8.612914115246895e-08
% O 0 6.463408475099186e-09
) O 0 2.4683086685683975e-09
of O 0 2.92934618784102e-08
families O 0 2.5351401533590945e-10
due O 0 1.692603213143684e-08
to O 0 5.851887863173033e-10
other O 0 1.5755858839838766e-09
genes O 0 1.3045383662202426e-09
was O 0 3.3331637894207233e-08
found O 0 1.7402929097798392e-09
in O 0 6.866676671712924e-10
families O 0 2.5166339498450263e-11
with O 0 1.5158323207753455e-10
four O 0 4.241297535401145e-09
or O 0 1.9137345041997378e-09
five O 0 7.872713592149694e-10
cases O 0 9.191433170130381e-10
of O 0 4.9632369325536274e-08
female O 0 0.04055934399366379
breast B-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9961322546005249
only O 0 8.890511367098952e-07
. O 0 6.755797585356049e-06

These O 0 4.3749814437887835e-08
estimates O 0 5.5440136037532284e-08
were O 0 9.10537867326866e-09
not O 0 4.314565926755165e-10
substantially O 0 5.306260320026013e-09
affected O 0 6.59136190073184e-10
either O 0 4.953641941085607e-10
by O 0 6.83630235753796e-11
changing O 0 7.668067958377378e-09
the O 0 2.4940054466071615e-09
assumed O 0 4.152590804551437e-08
penetrance O 0 3.670146497825044e-08
model O 0 3.94424048977271e-09
for O 0 3.4636737922255634e-09
BRCA1 O 0 6.472364422194232e-09
or O 0 1.0029294061908445e-09
by O 0 2.0821659674208348e-10
including O 0 7.314731043095435e-09
or O 0 9.220923402608605e-08
excluding O 0 5.461442469822941e-06
BRCA1 O 0 1.0287492386851227e-06
mutation O 0 8.767424475308871e-08
data O 0 1.0821095202118158e-06
. O 0 9.177687161354697e-07

Among O 0 1.6429579829946306e-07
those O 0 1.887284817314594e-08
families O 0 9.210807672133114e-10
with O 0 2.0177136406118734e-08
disease O 0 5.1288992835907266e-05
due O 0 7.287695780178183e-07
to O 0 3.1888124141232765e-08
BRCA1 O 0 9.276667611857192e-08
that O 0 2.6763766758364227e-09
were O 0 5.914189582512108e-09
tested O 0 1.7582831857154702e-09
by O 0 3.985960519981013e-11
one O 0 1.0943818073982925e-10
of O 0 3.4053515562959547e-10
the O 0 2.3453147757201975e-10
standard O 0 6.246617001437471e-09
screening O 0 5.736972563674669e-10
methods O 0 1.4461202235693804e-09
, O 0 5.2418749896254724e-11
mutations O 0 4.753829274672938e-11
were O 0 4.172482637176955e-10
detected O 0 2.5494120148294996e-09
in O 0 1.4128680170255592e-10
the O 0 1.7387460915507802e-10
coding O 0 1.3034049395344027e-08
sequence O 0 1.7359897963586945e-09
or O 0 7.366222631866037e-10
splice O 0 4.136786024844241e-09
sites O 0 1.2238046132040381e-09
in O 0 2.645704211268196e-10
an O 0 1.1378467612566112e-10
estimated O 0 1.0140821515847165e-09
63 O 0 2.5813795545559515e-08
% O 0 7.536338664237974e-09
( O 0 6.5209140309718805e-09
95 O 0 1.7177738698137546e-07
% O 0 4.057796942902314e-08
CI O 0 7.304675091290846e-05
51 O 0 8.062966685429274e-07
% O 0 1.1980436909198033e-07
- O 0 5.024094207328744e-07
77 O 0 4.4560744072441594e-07
% O 0 1.6696363047685736e-07
) O 0 1.6477579833917844e-07
. O 0 1.1866254681081045e-06

The O 0 6.701234838146775e-07
estimated O 0 7.059780671170302e-08
sensitivity O 0 9.710503690030237e-08
was O 0 4.722837587678441e-08
identical O 0 1.138967697933424e-09
for O 0 1.6617643372462965e-10
direct O 0 1.1457003123993559e-09
sequencing O 0 3.5980185497663797e-09
and O 0 9.960625657612354e-10
other O 0 5.548570047864132e-09
techniques O 0 9.269314432458486e-06
. O 0 9.698923122414271e-07

The O 0 1.8347963077758322e-06
penetrance O 0 6.255198240978643e-05
of O 0 8.319108019350097e-06
BRCA2 O 0 1.914334461616818e-06
was O 0 5.698997256331495e-07
estimated O 0 8.694745368131862e-09
by O 0 1.256684312167522e-09
maximizing O 0 2.4190526914935617e-07
the O 0 3.323837560742504e-08
LOD O 0 5.6290344218723476e-05
score O 0 3.0091561598055705e-07
in O 0 2.8375847449524372e-08
BRCA2 O 0 1.0788929927230129e-07
- O 0 7.402256585464784e-08
mutation O 0 1.29670429949158e-09
families O 0 1.4765273725902972e-10
, O 0 4.330031888599706e-10
over O 0 2.7069075869690096e-09
all O 0 2.413103938891936e-09
possible O 0 2.8120409112375455e-08
penetrance O 0 1.6110770957311615e-06
functions O 0 1.383677044941578e-06
. O 0 1.1302458915452007e-06

The O 0 6.538601127203947e-08
estimated O 0 2.010944122332603e-08
cumulative O 0 2.2964482582210621e-07
risk O 0 4.426637190135807e-07
of O 0 6.021213039275608e-07
breast B-Disease 0 0.00013778700667899102
cancer I-Disease 0 8.50080596137559e-07
reached O 0 5.128205771143257e-07
28 O 0 2.1400657601589046e-07
% O 0 5.092945620788214e-09
( O 0 1.5820181831216473e-09
95 O 0 3.560038308592084e-08
% O 0 1.0984398279845209e-08
CI O 0 2.1858793843421154e-05
9 O 0 2.6253061946590606e-07
% O 0 1.1581982484187847e-08
- O 0 1.2419207884306616e-08
44 O 0 2.8943112351242917e-09
% O 0 3.359777178690848e-10
) O 0 4.7341401632206015e-11
by O 0 7.900115978065614e-11
age O 0 4.2484873397086176e-09
50 O 0 1.7177820277325395e-09
years O 0 1.1191686466460737e-09
and O 0 3.068303944253614e-10
84 O 0 4.324578029013537e-09
% O 0 1.0162062302754293e-09
( O 0 5.907636047020048e-10
95 O 0 2.282500055628134e-08
% O 0 9.665320988005988e-09
CI O 0 8.825474651530385e-06
43 O 0 9.940553979959077e-08
% O 0 4.65818938977236e-09
- O 0 5.299089611554564e-09
95 O 0 7.2952524021729914e-09
% O 0 5.257126955982017e-10
) O 0 9.242938359133035e-11
by O 0 2.1504745206790687e-10
age O 0 8.805533724398629e-08
70 O 0 2.1694715712783363e-07
years O 0 3.9212372371366655e-07
. O 0 7.156758670134877e-07

The O 0 1.758618168423709e-06
corresponding O 1 0.9989990592002869
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0035027211997658014
were O 0 2.21001801037346e-06
0 O 0 1.5998849676179816e-06
. O 0 3.519690778830409e-07

4 O 0 5.043174951424589e-06
% O 0 1.2684503758464416e-07
( O 0 2.64535362504148e-08
95 O 0 1.9148552610204206e-07
% O 0 5.115085954798815e-08
CI O 0 3.465979534666985e-05
0 O 0 6.473280222962785e-08
% O 0 7.252769940180315e-09
- O 0 1.0620321511112252e-08
1 O 0 7.478575092534356e-09
% O 0 1.203301069896412e-10
) O 0 1.955117664986794e-11
by O 0 2.955843902974209e-11
age O 0 3.615450605565229e-09
50 O 0 3.4292217954146054e-09
years O 0 7.70364272373314e-10
and O 0 4.874703973811734e-10
27 O 0 1.0217243051613423e-08
% O 0 7.330956952600332e-10
( O 0 7.393980427927715e-10
95 O 0 1.2572506591368438e-08
% O 0 5.670884206665505e-09
CI O 0 5.336399226507638e-06
0 O 0 2.9173635951451615e-08
% O 0 3.1585747350959537e-09
- O 0 6.6129235420930854e-09
47 O 0 9.803624578808012e-09
% O 0 7.403520574378319e-10
) O 0 1.269166161055324e-10
by O 0 4.797810482237708e-10
age O 0 1.742533299875504e-07
70 O 0 4.0831307046573784e-07
years O 0 4.459415947621892e-07
. O 0 8.394816291001916e-07

The O 0 4.5953029825795966e-07
lifetime O 0 2.186740402976284e-06
risk O 0 1.6039033653214574e-05
of O 0 0.00023810815764591098
breast B-Disease 1 0.9999982118606567
cancer I-Disease 0 0.24935974180698395
appears O 0 8.139346618918353e-08
similar O 0 7.110762534345838e-10
to O 0 5.228477095720052e-10
the O 0 7.736351115283924e-09
risk O 0 1.7710414113025763e-07
in O 0 1.4175122409199048e-08
BRCA1 O 0 1.1591618331863174e-08
carriers O 0 1.2396867532515898e-08
, O 0 1.318682829598572e-09
but O 0 2.0726365068668429e-10
there O 0 4.0543887691590896e-10
was O 0 6.311732914099366e-09
some O 0 1.1173657832319606e-10
suggestion O 0 2.4262802877927925e-09
of O 0 2.7346398479011214e-09
a O 0 2.4893669348102776e-09
lower O 0 1.2477539712563157e-07
risk O 0 3.0487001367873745e-08
in O 0 2.981258129253206e-09
BRCA2 O 0 4.361099037453187e-09
carriers O 0 3.925335612109393e-09
< O 0 6.100997040903167e-08
50 O 0 5.596590746392849e-09
years O 0 4.369583361807372e-09
of O 0 2.8418419617537438e-08
age O 0 1.5481793980143266e-06
. O 0 1.770422841218533e-06

Eye B-Disease 1 0.9971304535865784
movement I-Disease 0 6.992429553065449e-05
abnormalities I-Disease 0 0.0026593233924359083
correlate O 0 4.982263703823264e-07
with O 0 2.0979383563712872e-08
genotype O 0 1.0952078810078092e-05
in O 0 3.775011236939463e-07
autosomal O 1 0.9955428242683411
dominant O 1 0.9999986886978149
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 0.9999998807907104
type I-Disease 1 0.9999970197677612
I I-Disease 1 0.9999920129776001
. O 0 7.93755825725384e-05

We O 0 1.16201499622548e-06
compared O 0 1.4967479273764184e-06
horizontal O 0 1.6064705050666817e-05
eye O 0 9.743859118316323e-05
movements O 0 5.57750183816097e-07
( O 0 1.998940213354672e-08
visually O 0 6.592335921595804e-08
guided O 0 1.19808976251079e-06
saccades O 0 4.240933776600286e-06
, O 0 1.58239927827708e-08
antisaccades O 0 1.3275006267576828e-06
, O 0 4.153301702558565e-09
and O 0 3.6340621623054403e-09
smooth O 0 9.764323749550385e-07
pursuit O 0 1.5217703719372366e-07
) O 0 7.549859071254161e-10
in O 0 1.4032649486850346e-09
control O 0 1.123850097428658e-07
subjects O 0 6.010936886013951e-07
( O 0 5.231043598286078e-09
n O 0 1.0997106159038594e-07
= O 0 6.510452266184075e-08
14 O 0 5.4291351858637427e-08
) O 0 1.954500561396344e-09
and O 0 3.000059090041418e-09
patients O 0 1.8377651622714097e-09
with O 0 1.579409242280505e-10
three O 0 1.7692771692168208e-09
forms O 0 9.694478109167903e-08
of O 0 2.685396611923352e-05
autosomal O 1 0.9318885207176208
dominant O 1 0.9996956586837769
cerebellar B-Disease 1 0.9999778270721436
ataxias I-Disease 0 0.06736945360898972
type I-Disease 0 0.0009905386250466108
I I-Disease 0 0.03946971893310547
spinocerebellar B-Disease 0 0.01769067533314228
ataxias I-Disease 0 1.8001226635533385e-05
1 I-Disease 0 8.581313863942341e-07
and I-Disease 0 2.2356813289547972e-08
2 I-Disease 0 2.9138305990272784e-07
( O 0 5.856402029991159e-09
SCA1 B-Disease 0 1.6900053196877707e-06
, O 0 7.2240258219835596e-09
n O 0 3.7721747503383085e-08
= O 0 3.149270000335491e-08
11 O 0 2.239428553707512e-08
; O 0 1.6892481857766484e-09
SCA2 B-Disease 0 6.346634791043471e-07
, O 0 3.755861843757202e-09
n O 0 2.2585687986520497e-08
= O 0 1.55709400928572e-08
10 O 0 8.37289082511461e-09
) O 0 1.7584543821058674e-09
and O 0 2.060777326562402e-08
SCA3 B-Disease 1 0.9999998807907104
/ O 0 0.011669707484543324
Machado B-Disease 0 9.624072117730975e-05
- I-Disease 0 0.0003702345711644739
Joseph I-Disease 1 0.6379984617233276
disease I-Disease 0 0.06548210978507996
( O 0 2.217509660340511e-07
MJD B-Disease 1 0.9999995231628418
) O 0 4.224949279318935e-08
( O 0 1.172651131753355e-08
n O 0 3.044534082619066e-07
= O 0 3.161361235015647e-07
16 O 0 2.8247552563698264e-07
) O 0 5.0704812792901066e-08
. O 0 3.498053899875231e-07

In O 0 3.2383488814957673e-06
SCA1 B-Disease 0 8.294473082059994e-05
, O 0 5.100385180867306e-08
saccade O 0 6.390486078089452e-07
amplitude O 0 1.9412237861615722e-07
was O 0 8.926169670075979e-08
significantly O 0 8.62254267985918e-09
increased O 0 4.535924080784071e-09
, O 0 6.770438099046316e-10
resulting O 0 5.927266677474563e-09
in O 0 1.0908775216478261e-08
hypermetria B-Disease 0 7.080060186126502e-06
. O 0 7.688984737797e-07

The O 0 2.407123702141689e-06
smooth O 0 2.5192077373503707e-05
pursuit O 0 4.024436748295557e-06
gain O 0 4.1961457100114785e-06
was O 0 2.867684088414535e-06
decreased O 0 5.562778369494481e-06
. O 0 4.965017410540895e-07

In O 0 4.370079750515288e-06
SCA2 B-Disease 0 0.0003022461023647338
, O 0 2.4463102477056964e-07
saccade O 0 3.0510148008033866e-06
velocity O 0 1.0319231478206348e-06
was O 0 8.516823868376378e-07
markedly O 0 2.8384454253682634e-06
decreased O 0 3.169571073158295e-06
. O 0 5.077139348941273e-07

The O 0 6.828479399700882e-07
percentage O 0 1.4903298506396823e-06
of O 0 2.02525015424726e-07
errors O 0 4.737209565064404e-06
in O 0 8.567039344598015e-08
antisaccades O 0 8.018445441848598e-06
was O 0 1.7612352110063512e-07
greatly O 0 1.071474997615951e-08
increased O 0 2.110547514533323e-09
and O 0 2.8398178253397077e-10
was O 0 3.5868907843905617e-09
significantly O 0 9.272785872482814e-10
correlated O 0 2.495171180783018e-09
with O 0 5.649279377628602e-10
age O 0 6.262569058890222e-07
at O 0 0.00017711121472530067
disease O 0 0.027121273800730705
onset O 0 0.00013322714949026704
. O 0 1.92028619494522e-06

In O 0 1.7105693927987886e-07
addition O 0 6.074650826803918e-08
, O 0 1.4303231488099755e-08
a O 0 8.138379747890667e-09
correlation O 0 4.112071039230614e-08
between O 0 1.9091478975497012e-07
smooth O 0 1.8040531358565204e-05
pursuit O 0 1.1816657661256613e-06
gain O 0 9.692259084204125e-08
and O 0 1.9145267593501103e-09
the O 0 5.703532091061447e-10
number O 0 3.013576721500044e-09
of O 0 1.2696546036750078e-07
trinucleotide O 0 2.622165447974112e-05
repeats O 0 2.0203715678235312e-07
was O 0 3.766714939956728e-07
found O 0 6.031056898336828e-08
. O 0 1.1629912677335597e-07

In O 0 1.7497033695690334e-05
SCA3 B-Disease 1 0.9999998807907104
, O 0 5.86101987209986e-06
gaze B-Disease 0 0.0013541082153096795
- I-Disease 0 4.1475650505162776e-05
evoked I-Disease 0 1.395284925820306e-06
nystagmus I-Disease 0 3.736931603270932e-06
was O 0 2.299957344575887e-07
often O 0 2.634033879900244e-09
present O 0 1.8508369281633463e-09
as O 0 3.901948986140269e-09
was O 0 3.763931388789388e-08
saccade O 0 1.6664260726884095e-07
hypometria O 0 4.347323852016416e-07
and O 0 9.625895636133919e-09
smooth O 0 3.177903636242263e-06
pursuit O 0 1.2122020507376874e-06
gain O 0 8.320341748913052e-07
was O 0 7.687341962991923e-07
markedly O 0 1.68435440173198e-06
decreased O 0 2.812523916873033e-06
. O 0 4.0013694047047466e-07

Three O 0 3.494179452445678e-07
major O 0 3.88705785780985e-07
criteria O 0 3.938868076147628e-07
, O 0 6.513085537562802e-08
saccade O 0 1.544246515550185e-06
amplitude O 0 4.803199544767267e-07
, O 0 3.332706199898894e-08
saccade O 0 9.256868338525237e-07
velocity O 0 3.8355011611201917e-07
, O 0 1.174907904299971e-08
and O 0 9.38697675145761e-10
presence O 0 1.6184669604513147e-08
of O 0 5.472127782013558e-07
gaze B-Disease 0 0.04800369217991829
- I-Disease 0 1.6691104974597692e-05
evoked I-Disease 0 3.645178594524623e-07
nystagmus I-Disease 0 3.6015845239489863e-07
, O 0 2.5057733665789783e-09
permitted O 0 5.822586857107126e-09
the O 0 2.3833808260320666e-09
correct O 0 1.473108213190244e-08
assignment O 0 1.2145269678853765e-08
of O 0 6.84742840206809e-09
90 O 0 1.4967460160164592e-08
% O 0 3.0912086224077484e-09
of O 0 2.009188193596856e-08
the O 0 4.1535731298836254e-08
SCA1 B-Disease 0 1.0523138371354435e-05
, O 0 2.856022973674044e-09
90 O 0 6.933140284104411e-09
% O 0 4.1944100970248144e-10
of O 0 2.054308723131726e-09
the O 0 5.5334039572585425e-09
SCA2 B-Disease 0 3.2197424388868967e-06
, O 0 1.4315887364446667e-09
and O 0 6.699708010593497e-10
93 O 0 8.819430519224625e-09
% O 0 1.805601779203414e-09
of O 0 9.655316546286485e-09
the O 0 4.545982079662281e-08
patients O 0 2.4513727936437135e-08
with O 0 2.6409120224002436e-08
SCA3 B-Disease 1 0.9999998807907104
to O 0 8.169608989305743e-09
their O 0 3.6900231759062763e-09
genetically O 0 1.2938958349195673e-08
confirmed O 0 6.9867982510629645e-09
patient O 0 1.572524510606854e-08
group O 0 1.6595005369879345e-09
and O 0 2.869487758516698e-09
, O 0 4.032373102091924e-09
therefore O 0 1.856972886571384e-08
, O 0 2.044318048177729e-09
may O 0 2.5468651632110095e-09
help O 0 4.454024260525102e-09
orient O 0 2.9234546673251316e-05
diagnoses O 0 1.7169776356240618e-06
of O 0 3.511590875859838e-07
SCA1 B-Disease 0 0.007023897022008896
, O 0 7.102866561581322e-08
SCA2 B-Disease 0 7.898122566984966e-05
, O 0 1.4828564154356627e-08
and O 0 1.59042663483433e-08
SCA3 B-Disease 1 0.9999995231628418
at O 0 1.4684620737170917e-06
early O 0 9.11841766537691e-08
clinical O 0 1.1915805941953295e-07
stages O 0 1.479035347529134e-07
of O 0 1.4037185280812992e-07
the O 0 4.540072495728964e-07
diseases O 0 0.29903271794319153
. O 0 3.3648724695467536e-08
. O 0 2.6540774911154585e-07

Genetic O 0 1.5814191556273727e-06
basis O 0 1.7859738932202163e-07
and O 0 5.551968218497905e-09
molecular O 0 1.1699567039613612e-06
mechanism O 0 2.4499933715560474e-05
for O 0 1.012643588182982e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999334812164307

Ventricular B-Disease 1 0.9999972581863403
fibrillation I-Disease 1 0.9999994039535522
causes O 0 5.716659870813601e-05
more O 0 2.53915430903362e-08
than O 0 1.202728761029448e-08
300 O 0 9.612392659619218e-09
, O 0 1.5405442477245401e-09
000 O 0 1.0350702517314403e-08
sudden O 0 1.0509271675118725e-08
deaths O 0 5.140706194062261e-10
each O 0 1.0914882886403632e-10
year O 0 3.1200422800914396e-10
in O 0 5.854299267582519e-10
the O 0 5.621721754778264e-09
USA O 0 1.1319453108171729e-07
alone O 0 1.4753794630451011e-07
. O 0 1.9173934617811028e-07

In O 0 7.236563988044509e-07
approximately O 0 9.970023739924727e-08
5 O 0 1.340224713430871e-07
- O 0 3.8960681791877505e-08
12 O 0 8.93901219711779e-09
% O 0 8.959935571262179e-10
of O 0 2.3260879888908903e-09
these O 0 1.787116149509771e-10
cases O 0 2.895756412435446e-10
, O 0 4.174534676271158e-11
there O 0 9.253063593117616e-11
are O 0 4.505078254890549e-11
no O 0 1.6220725873594688e-09
demonstrable O 0 3.0416717891057488e-06
cardiac O 0 0.16967123746871948
or O 0 9.391727644469938e-07
non O 1 0.9451576471328735
- O 1 0.9991279244422913
cardiac O 1 0.9999873638153076
causes O 0 1.6128436186590989e-07
to O 0 2.8648177163859145e-09
account O 0 1.1843978020564805e-09
for O 0 2.24410512394968e-09
the O 0 1.2310862551601076e-08
episode O 0 2.3560909667708074e-08
, O 0 1.5942214215414197e-10
which O 0 3.042561341759509e-11
is O 0 1.7415397249309628e-11
therefore O 0 1.261787480055787e-10
classified O 0 3.5024643185721516e-09
as O 0 2.9711893390071964e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999920129776001
IVF B-Disease 1 1.0
) O 0 1.7250608834729064e-06
. O 0 1.3350102108233841e-06

A O 0 1.339774030384433e-06
distinct O 0 1.2630184187401028e-07
group O 0 9.120069677237552e-08
of O 0 0.00021163518249522895
IVF B-Disease 1 1.0
patients O 0 1.7755781982486951e-06
has O 0 3.604509801746758e-09
been O 0 2.0768280428740127e-09
found O 0 1.708377467268818e-10
to O 0 2.0948881518378926e-11
present O 0 6.30730079276276e-10
with O 0 1.8504416887665798e-09
a O 0 4.921983176586764e-08
characteristic O 0 4.283626367396209e-06
electrocardiographic O 0 7.104385440470651e-05
pattern O 0 1.2600263289641589e-05
. O 0 5.883487119717756e-07

Because O 0 7.338587693084264e-07
of O 0 3.875945537856751e-07
the O 0 2.853617608877812e-08
small O 0 2.7720408191100887e-09
size O 0 1.2185365605432708e-08
of O 0 2.3802790849458688e-08
most O 0 2.0369927966612522e-09
pedigrees O 0 1.2314221642384382e-08
and O 0 4.98159291595357e-10
the O 0 1.5714501921948454e-09
high O 0 6.882692105136812e-07
incidence O 0 2.8063882382411975e-06
of O 0 8.066922418947797e-08
sudden B-Disease 0 2.5124944613708067e-07
death I-Disease 0 6.22502938085745e-09
, O 0 2.608942506476808e-10
however O 0 1.7574072752601921e-10
, O 0 4.481544302326057e-11
molecular O 0 6.397349761044779e-09
genetic O 0 3.3605094262867397e-09
studies O 0 1.0540206041298461e-08
of O 0 5.383571988204494e-07
IVF B-Disease 1 0.9999933242797852
have O 0 2.6138995412594568e-09
not O 0 8.599052025992648e-10
yet O 0 1.7839023591648129e-09
been O 0 1.4366573486412904e-09
done O 0 1.2135729754447766e-08
. O 0 4.049964275054663e-08

Because O 0 0.0007233532378450036
IVF B-Disease 1 1.0
causes O 0 0.039496466517448425
cardiac O 1 0.9999997615814209
rhythm O 1 1.0
disturbance O 1 0.9999967813491821
, O 0 3.409794544495526e-07
we O 0 2.2800458410188185e-08
investigated O 0 2.2066284088850807e-07
whether O 0 3.630710665447623e-08
malfunction O 0 0.000725496094673872
of O 0 8.081151747774129e-08
ion O 0 5.8122077462030575e-05
channels O 0 1.499308564234525e-05
could O 0 4.4142847599459856e-08
cause O 0 1.7162403054271635e-08
the O 0 3.3326028603397617e-09
disorder O 0 2.110136705368859e-07
by O 0 1.6622461740389838e-10
studying O 0 2.9283070190899707e-08
mutations O 0 7.614850972004206e-10
in O 0 6.358540360906773e-10
the O 0 1.2220371381488349e-08
cardiac O 0 0.00024254992604255676
sodium O 0 4.139364136790391e-06
channel O 0 4.157677722105291e-06
gene O 0 7.747220820419898e-07
SCN5A O 0 0.0001438824983779341
. O 0 2.73012847173959e-06

We O 0 7.220288011922094e-07
have O 0 1.5704204159305846e-08
now O 0 5.5783351271543324e-09
identified O 0 6.160984167280503e-09
a O 0 5.782170298118672e-09
missense O 0 1.4393575042959128e-07
mutation O 0 6.098272109511527e-09
, O 0 4.924657126537113e-09
a O 0 2.319762337776865e-08
splice O 0 7.335705163313833e-07
- O 0 2.120240765179915e-07
donor O 0 1.497119939131153e-08
mutation O 0 1.3937110132644648e-08
, O 0 5.779512868286929e-09
and O 0 5.144779713361913e-09
a O 0 4.585317014971224e-08
frameshift O 0 3.5377388485358097e-07
mutation O 0 1.5752523729872792e-09
in O 0 8.966449249747654e-10
the O 0 1.41918332641211e-09
coding O 0 2.0912111153847945e-07
region O 0 3.728256103840977e-08
of O 0 4.9978631011526886e-08
SCN5A O 0 2.4420158297289163e-05
in O 0 3.625942213147937e-08
three O 0 1.421061739392826e-07
IVF B-Disease 1 0.9988409876823425
families O 0 2.389649900180757e-08
. O 0 2.7742646580009023e-07

We O 0 3.618867765453615e-07
show O 0 6.219394776962872e-08
that O 0 1.1112601949747614e-09
sodium O 0 7.298007975720111e-09
channels O 0 1.9425039354814544e-09
with O 0 3.117270608310463e-10
the O 0 8.68003180443111e-09
missense O 0 1.711285761984982e-07
mutation O 0 3.304600371123456e-09
recover O 0 1.222416443624752e-07
from O 0 2.2915338959705878e-08
inactivation O 0 1.974135329874116e-06
more O 0 1.65729252543656e-09
rapidly O 0 1.606760413608299e-08
than O 0 3.724840713648092e-10
normal O 0 4.5236121515301875e-09
and O 0 1.1586477610681101e-10
that O 0 8.946593466063746e-11
the O 0 3.017723848586229e-09
frameshift O 0 9.310861770472911e-08
mutation O 0 2.6481692394497713e-09
causes O 0 1.6363950194886456e-09
the O 0 7.001899504643916e-09
sodium O 0 2.2515235897913044e-08
channel O 0 2.0872773731639427e-08
to O 0 4.845124856878158e-10
be O 0 1.8518291344804538e-09
non O 0 1.2813711691705976e-07
- O 0 2.233742577573139e-07
functional O 0 3.5591226605902193e-06
. O 0 1.4404330386241782e-06

Our O 0 7.589438837385387e-07
results O 0 3.9018317465888686e-08
indicate O 0 3.2003104166733465e-08
that O 0 5.831797822430929e-10
mutations O 0 1.7061477786128876e-09
in O 0 4.881395732070359e-09
cardiac O 0 1.1869856280100066e-05
ion O 0 3.345483492012136e-05
- O 0 4.7179044486256316e-05
channel O 0 9.809274388317135e-07
genes O 0 1.0166752995033335e-09
contribute O 0 5.835903982287505e-10
to O 0 1.1652499798397997e-10
the O 0 8.99994578862362e-10
risk O 0 2.5197115505193324e-08
of O 0 5.615273579451241e-08
developing O 0 2.8328522603260353e-05
IVF B-Disease 1 0.9997069239616394
. O 0 2.439292678957372e-08
. O 0 1.3137646703853534e-07

Molecular O 0 9.828648035181686e-05
heterogeneity O 0 4.309801443014294e-05
in O 0 1.9271512883278774e-06
mucopolysaccharidosis B-Disease 0 0.0002850009477697313
IVA I-Disease 1 0.7897131443023682
in O 0 2.4198396886276896e-07
Australia O 0 2.4487837535502877e-08
and O 0 2.706236346128321e-09
Northern O 0 4.828137178947145e-08
Ireland O 0 7.860506912038545e-08
: O 0 2.465889936686949e-09
nine O 0 1.1133844068922372e-08
novel O 0 6.602361768415221e-09
mutations O 0 2.0314832038792474e-09
including O 0 3.814935034540667e-09
T312S O 0 4.0395579503638146e-07
, O 0 5.447450490692063e-09
a O 0 4.350896531946091e-09
common O 0 4.245651830103725e-09
allele O 0 4.514527862653495e-09
that O 0 1.050175169048373e-09
confers O 0 1.2151924977388262e-07
a O 0 6.336982494303811e-08
mild O 0 1.8828068277798593e-06
phenotype O 0 6.075867418076086e-07
. O 0 4.459441242943285e-07

Mucopolysaccharidosis B-Disease 1 0.9473345875740051
IVA I-Disease 1 0.9999991655349731
( O 0 0.0019620603416115046
MPS B-Disease 1 0.9999889135360718
IVA I-Disease 1 1.0
) O 0 1.7761597348453506e-07
is O 0 1.0112896298153373e-08
an O 0 1.9295546493935944e-08
autosomal B-Disease 1 0.999484658241272
recessive I-Disease 1 0.9999982118606567
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.00018583766359370202
by O 0 4.41022010022607e-08
a O 0 3.4746378787531285e-06
genetic B-Disease 1 0.9999959468841553
defect I-Disease 1 0.999988317489624
in O 0 1.2570213812068687e-06
N O 0 0.0008792827720753849
- O 0 9.61816476774402e-06
acetylgalactosamine O 0 4.9273090553469956e-05
- O 0 3.656721446532174e-06
6 O 0 8.939764484239276e-06
- O 0 3.7595407320623053e-06
sulfate O 0 1.2903569768241141e-05
sulfatase O 0 5.926424273638986e-05
( O 0 3.228901164220588e-07
GALNS O 0 0.00013305273023433983
) O 0 1.0048143650465136e-07
. O 0 4.006126914646302e-07

Previous O 0 3.856878265651176e-07
studies O 0 3.2458976306770637e-07
of O 0 1.8570602833278826e-07
patients O 0 4.667369779554065e-08
from O 0 1.4376449364306154e-08
a O 0 1.8730871076400035e-08
British O 0 3.352355690822151e-07
- O 0 5.106410867483646e-07
Irish O 0 3.939348687254096e-07
population O 0 4.105350781546946e-10
showed O 0 1.0816205708863436e-08
that O 0 9.441307458057935e-11
the O 0 1.4078115340154795e-09
I113F O 0 4.287531396585109e-08
mutation O 0 1.7482033876081715e-10
is O 0 4.314218080003762e-11
the O 0 1.2494204282287313e-10
most O 0 3.0663190736524015e-11
common O 0 2.644372221194402e-10
single O 0 4.3112424741309496e-10
mutation O 0 1.5356947935529774e-09
among O 0 5.899655430852135e-09
MPS B-Disease 1 0.9996870756149292
IVA I-Disease 1 1.0
patients O 0 3.780472252401523e-05
and O 0 5.097808042364704e-08
produces O 0 3.5218793215108235e-08
a O 0 2.201016258140953e-08
severe O 0 7.0979749580146745e-06
clinical O 0 1.5209681805572473e-05
phenotype O 0 2.8583269795490196e-06
. O 0 1.7835377548180986e-06

We O 0 4.685856538344524e-07
studied O 0 3.49758738593664e-06
mutations O 0 2.628003414884006e-08
in O 0 4.943846665383944e-09
the O 0 6.7761525279763646e-09
GALNS O 0 1.101494490285404e-06
gene O 0 8.921400507233557e-09
from O 0 4.683383458825574e-09
23 O 0 2.962858758337461e-08
additional O 0 3.1816799861417167e-08
MPS B-Disease 1 0.8901118636131287
IVA I-Disease 1 1.0
patients O 0 2.3663380943617085e-06
( O 0 4.038299472597373e-09
15 O 0 1.0975790942779895e-08
from O 0 1.651426662085953e-09
Australia O 0 7.160098070002618e-10
, O 0 2.2093966933756093e-10
8 O 0 3.896608813391822e-09
from O 0 1.214392142401266e-09
Northern O 0 1.0523011795271486e-08
Ireland O 0 1.3698493894764852e-08
) O 0 3.584672836343117e-10
, O 0 1.5463545721683403e-10
with O 0 9.348004315068437e-11
various O 0 1.1144191347511878e-08
clinical O 0 3.879720225086203e-06
phenotypes O 0 9.935927209880902e-07
( O 0 4.99248002938657e-08
severe O 0 1.910721039166674e-06
, O 0 4.989983093395267e-09
16 O 0 9.15427733616525e-09
cases O 0 4.3998726884098005e-10
; O 0 1.3880588345394074e-10
intermediate O 0 5.919541479215695e-08
, O 0 9.572118653267125e-10
4 O 0 8.101086912404298e-09
cases O 0 1.0029331809491282e-09
; O 0 5.47552114760208e-10
mild O 0 5.155597548878177e-08
, O 0 1.3873713289314082e-09
3 O 0 2.322276770883036e-08
cases O 0 3.0537734563296226e-09
) O 0 3.520292723990792e-09
. O 0 4.326486191530421e-08

We O 0 1.0283833944413345e-06
found O 0 1.0756095747410654e-07
two O 0 2.2641488683916577e-09
common O 0 3.2864722054881668e-09
mutations O 0 7.428189174873978e-10
that O 0 5.756765897313443e-11
together O 0 7.542029223372992e-10
accounted O 0 8.721653621535097e-09
for O 0 2.4147293053999874e-09
32 O 0 1.5410416054351117e-08
% O 0 2.694102718692193e-09
of O 0 1.3842055501811501e-08
the O 0 1.7861809809005535e-08
44 O 0 4.8840433919394854e-08
unrelated O 0 2.5551527116363104e-08
alleles O 0 8.787354732753272e-10
in O 0 2.0783457177486753e-09
these O 0 5.08256237097271e-09
patients O 0 1.2259960158189642e-07
. O 0 3.0527039029948355e-07

One O 0 5.626293955174333e-07
is O 0 3.1053456694962733e-08
the O 0 2.5213847010263635e-08
T312S O 0 9.779458878256264e-07
mutation O 0 1.0188131227550912e-08
, O 0 1.4056221742109187e-09
a O 0 1.594103626878507e-09
novel O 0 1.875878563595279e-09
mutation O 0 8.946735019499386e-10
found O 0 1.4730148212294125e-09
exclusively O 0 1.657568482471561e-08
in O 0 1.629907409039788e-08
milder O 0 1.361233216812252e-06
patients O 0 5.145979571352655e-07
. O 0 3.6719816876029654e-07

The O 0 6.588614382962987e-07
other O 0 2.7360707477441792e-08
is O 0 4.291194510841478e-09
the O 0 2.6480024839514726e-09
previously O 0 2.595860948417794e-08
described O 0 2.2540843858109838e-08
I113F O 0 6.368303928638852e-08
that O 0 4.3486625411759405e-10
produces O 0 1.5362161542853414e-09
a O 0 1.0054696630845683e-08
severe O 0 9.388897979079047e-07
phenotype O 0 6.09055121003621e-07
. O 0 5.810762786495616e-07

The O 0 5.616847715828044e-07
I113F O 0 2.2705648916598875e-06
and O 0 2.004158972113146e-08
T312S O 0 2.449879730193061e-07
mutations O 0 2.329915593790588e-09
accounted O 0 1.2920586378584176e-08
for O 0 4.523732943795267e-09
8 O 0 5.4646655200940586e-08
( O 0 2.0322119542726114e-09
18 O 0 2.4811392052015435e-08
% O 0 1.9505901338590093e-09
) O 0 9.889618013403378e-10
and O 0 3.950210825109934e-09
6 O 0 1.0851255893840062e-07
( O 0 1.9879622392693364e-09
14 O 0 8.61567084342596e-09
% O 0 1.084764500447477e-09
) O 0 5.051025708802115e-10
of O 0 1.2568095009157787e-08
44 O 0 6.215090309069637e-08
unrelated O 0 8.194926692794979e-08
alleles O 0 1.3231884921083292e-08
, O 0 1.317300846181979e-08
respectively O 0 7.443853178301651e-07
. O 0 5.957514304100187e-07

The O 0 6.717231144648395e-07
relatively O 0 7.927218916847778e-07
high O 0 1.6753190266172169e-06
residual O 0 9.554663847666234e-06
GALNS O 0 7.246230961754918e-05
activity O 0 1.0836942010428174e-07
seen O 0 1.2374661295666556e-08
when O 0 7.192181294968236e-10
the O 0 2.318726100014601e-09
T312S O 0 5.2575330755644245e-08
mutant O 0 1.10656950269572e-08
cDNA O 0 3.374757895358016e-08
is O 0 1.934229665323528e-09
overexpressed O 0 1.8867491746732412e-07
in O 0 3.6325513708135304e-09
mutant O 0 4.6847887347212236e-08
cells O 0 3.46846662502287e-09
provides O 0 6.599135682350266e-10
an O 0 1.0900818442349802e-10
explanation O 0 1.0198973887654006e-09
for O 0 5.996685925602208e-10
the O 0 6.692738363511808e-09
mild O 0 2.6408221742713067e-07
phenotype O 0 1.6224726451241622e-08
in O 0 3.292702777102363e-09
patients O 0 9.540439549482471e-10
with O 0 5.467850616724945e-10
this O 0 2.552944522449252e-09
mutation O 0 7.087371045599866e-08
. O 0 3.1382737120111415e-07

The O 0 1.3820638855577272e-07
distribution O 0 2.2047599301799892e-08
and O 0 4.197851510845396e-10
relative O 0 1.027050622326442e-08
frequencies O 0 2.7946793323962993e-08
of O 0 3.153283634205195e-09
the O 0 1.940348770546052e-09
I113F O 0 5.00953518667302e-08
and O 0 5.646176859386287e-10
T312S O 0 4.0455631733493647e-08
mutations O 0 1.0467077204978636e-09
in O 0 8.165492726419643e-10
Australia O 0 1.0777032599662562e-09
corresponded O 0 1.5156597088505919e-09
to O 0 1.201459626232193e-10
those O 0 8.951150237690442e-11
observed O 0 2.3745461152913094e-09
in O 0 6.441461253281489e-10
Northern O 0 3.5830411970749765e-09
Ireland O 0 4.572084488785322e-09
and O 0 3.028944040028847e-10
are O 0 6.837515276192363e-11
unique O 0 1.7051286771430085e-10
to O 0 9.007943696515142e-11
these O 0 5.324686525032263e-11
two O 0 2.9558452907529897e-10
populations O 0 6.11211470324946e-10
, O 0 2.7132643354299546e-10
suggesting O 0 1.020603934698272e-09
that O 0 3.4541834670331895e-11
both O 0 2.7663249468901085e-10
mutations O 0 3.348210875220303e-10
were O 0 1.1904539576335083e-09
probably O 0 1.2467666898885454e-09
introduced O 0 2.932350751105872e-10
to O 0 5.1964418879002494e-11
Australia O 0 7.071428165250637e-11
by O 0 8.021923403322972e-11
Irish O 0 2.3961765904800814e-08
migrants O 0 1.5722896318237645e-09
during O 0 1.1325993476418716e-08
the O 0 8.135493168026642e-09
19th O 0 4.963407604918757e-07
century O 0 8.11483687357395e-07
. O 0 3.793836356180691e-07

Haplotype O 0 1.3065136045042891e-05
analysis O 0 5.428756253422762e-07
using O 0 2.501873552773759e-07
6 O 0 8.951689665082085e-07
RFLPs O 0 3.5470291095407447e-06
provides O 0 1.6730593799252347e-08
additional O 0 2.0083901208778343e-09
data O 0 9.486696761484836e-09
that O 0 1.738951621588214e-10
the O 0 2.479472849259423e-09
I113F O 0 1.1134655863997978e-07
mutation O 0 3.6883487375405366e-09
originated O 0 2.0030430647466346e-08
from O 0 1.5720796886498078e-09
a O 0 8.346964008865143e-09
common O 0 2.8605329660535972e-08
ancestor O 0 5.948004968558962e-07
. O 0 7.609485805915028e-07

The O 0 8.457818125862104e-07
other O 0 5.6489181332608496e-08
9 O 0 1.5282509480130102e-07
novel O 0 7.599591178575338e-09
mutations O 0 1.7782867400839564e-09
identified O 0 1.3217146266342183e-09
in O 0 3.416202598582885e-10
these O 0 3.973187612249518e-10
23 O 0 4.9944038238436406e-08
patients O 0 4.057214564312517e-09
were O 0 2.8209889979535774e-09
each O 0 1.3684534061475517e-10
limited O 0 4.758540228522179e-10
to O 0 1.5850225298930098e-10
a O 0 6.724112378009295e-09
single O 0 1.5102179062864707e-08
family O 0 6.216298942263165e-08
. O 0 2.0814221102227748e-07

These O 0 6.762894599887659e-08
data O 0 1.0394826688298053e-07
provide O 0 3.2658638016158648e-09
further O 0 2.4735775649986635e-09
evidence O 0 5.215949450132484e-09
for O 0 4.6560374999948806e-10
extensive O 0 1.796389526020903e-08
allelic O 0 2.2360018192557618e-07
heterogeneity O 0 1.406794353897567e-06
in O 0 2.8334966373222414e-07
MPS B-Disease 1 0.6122933030128479
IVA I-Disease 1 0.9999998807907104
in O 0 1.7204068569753872e-07
British O 0 8.522396797161491e-07
- O 0 5.504741693584947e-07
Irish O 0 1.3669829002083134e-07
patients O 0 9.643071896547895e-10
and O 0 1.2706025120934328e-10
provide O 0 4.184485535851934e-10
evidence O 0 6.47106812579068e-09
for O 0 3.278306792697805e-10
their O 0 3.1772318109801745e-10
transmission O 0 1.2707903174202784e-08
to O 0 1.218879441822196e-10
Australia O 0 6.653732426142867e-11
by O 0 2.8630776569005256e-11
British O 0 7.071717877948913e-09
- O 0 1.3391227682291174e-08
Irish O 0 4.743728609923892e-08
migrants O 0 4.788351049000994e-09
. O 0 3.4778933066803575e-09
. O 0 8.151355501695434e-08

Identification O 0 1.1517917073433637e-06
of O 0 8.733548497730226e-07
constitutional O 0 5.968518235022202e-05
WT1 O 0 0.0042096516117453575
mutations O 0 2.2372027785877435e-07
, O 0 6.189062595751693e-09
in O 0 6.308820577061169e-09
patients O 0 2.555957046013191e-08
with O 0 2.308753366264682e-08
isolated O 0 0.23875220119953156
diffuse B-Disease 1 0.9999997615814209
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.1413866591046826e-07
and O 0 3.797931746873928e-09
analysis O 0 2.1069407551976838e-08
of O 0 1.876173598702735e-07
genotype O 0 2.991392648254987e-06
/ O 0 4.116900072403951e-06
phenotype O 0 1.7558845044618465e-08
correlations O 0 2.2389416542978324e-08
by O 0 3.02061292645206e-10
use O 0 2.268172982766714e-09
of O 0 1.4410327153768776e-08
a O 0 3.9143547070352724e-08
computerized O 0 4.422140591486823e-06
mutation O 0 4.209931248055909e-08
database O 0 3.3648441899458703e-07
. O 0 9.753221092978492e-07

Constitutional O 0 1.1010683010681532e-05
mutations O 0 4.0176507809519535e-07
of O 0 2.980793851747876e-07
the O 0 3.132090284907463e-07
WT1 O 0 1.0121897503267974e-05
gene O 0 3.030969963901953e-08
, O 0 5.406481040637345e-09
encoding O 0 9.758872465681634e-08
a O 0 2.2502061369777948e-07
zinc O 0 0.035837553441524506
- O 0 2.1502082745428197e-05
finger O 0 4.163919584243558e-06
transcription O 0 2.0087261418666458e-06
factor O 0 2.4762633188402106e-07
involved O 0 1.6239516753557837e-07
in O 0 2.570477874996868e-07
renal O 1 0.9999985694885254
and O 0 1.777168654371053e-05
gonadal O 1 0.9999992847442627
development O 0 0.003611766966059804
, O 0 3.853175556400856e-08
are O 0 5.834189797937483e-10
found O 0 2.0230384034647386e-09
in O 0 6.421453924154719e-10
most O 0 9.32012800269888e-10
patients O 0 5.747204934181127e-09
with O 0 5.3181583581363157e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.064876990625635e-05
DDS B-Disease 1 1.0
) O 0 6.52116511901113e-08
, O 0 7.926552747505866e-09
or O 0 3.3215155781363137e-07
diffuse B-Disease 1 0.9999951124191284
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.004153949208557606
DMS B-Disease 1 0.9996594190597534
) O 0 1.5006420994723157e-08
associated O 0 2.2868663407393797e-08
with O 0 1.9808247486707842e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 7.381892828561831e-06
/ O 1 0.9940635561943054
or O 0 0.00016409388626925647
Wilms B-Disease 1 0.9999997615814209
tumor I-Disease 1 0.9849875569343567
( O 0 3.2447787816636264e-06
WT B-Disease 1 0.9998931884765625
) O 0 5.427068572316784e-07
. O 0 1.0963279919451452e-06

Most O 0 3.478035068837926e-07
mutations O 0 5.742813300457783e-07
in O 0 1.0659712188498816e-06
DDS B-Disease 1 1.0
patients O 0 2.2319643903756514e-05
lie O 0 1.0811421816470101e-05
in O 0 1.1362879348553179e-07
exon O 0 2.3154516384238377e-06
8 O 0 6.912906087563897e-07
or O 0 6.026078125387357e-08
exon O 0 1.513726942903304e-06
9 O 0 4.027363900149794e-07
, O 0 1.1876423400281055e-08
encoding O 0 4.164719769050862e-07
zinc O 0 0.0005298078758642077
finger O 0 0.0009770971955731511
2 O 0 0.0001426135713700205
or O 0 2.7432615752331913e-06
zinc O 1 0.8157444000244141
finger O 0 0.0005539165576919913
3 O 0 1.5729600590930204e-06
, O 0 4.375713569260142e-09
respectively O 0 2.385378650160419e-08
, O 0 1.3755511174551316e-09
with O 0 7.559224912689899e-10
a O 0 3.430937667303624e-08
hot O 0 2.254249466204783e-06
spot O 0 2.9532034773183113e-07
( O 0 5.037279926511928e-09
R394W O 0 1.2598184184753336e-07
) O 0 1.7089324400032524e-09
in O 0 1.733257803948618e-08
exon O 0 4.366492703411495e-06
9 O 0 3.9460819607484154e-06
. O 0 2.003275767492596e-06

We O 0 1.4789378610657877e-07
analyzed O 0 1.3788476849185827e-07
a O 0 7.123037271128396e-09
series O 0 2.745007776638886e-09
of O 0 9.331055039751845e-09
24 O 0 1.2644972002817667e-07
patients O 0 1.523657466862005e-08
, O 0 2.7642690358931077e-09
10 O 0 2.610338789565958e-08
with O 0 1.1992057125098654e-08
isolated B-Disease 0 2.4826247681630775e-05
DMS I-Disease 1 0.9999672174453735
( O 0 1.0454381254021428e-06
IDMS B-Disease 0 0.00021043914603069425
) O 0 3.512474222588935e-08
, O 0 7.928579570659622e-09
10 O 0 1.3971230394815848e-08
with O 0 9.776921494619728e-09
DDS B-Disease 1 1.0
, O 0 9.423994384860634e-08
and O 0 1.4365485689893376e-08
4 O 0 2.587450751434517e-07
with O 0 5.653294365970396e-08
urogenital B-Disease 1 0.9999347925186157
abnormalities I-Disease 1 0.9999998807907104
and O 0 0.19817934930324554
/ O 1 0.9999983310699463
or O 1 0.70428067445755
WT B-Disease 1 1.0
. O 0 3.485854540485889e-05

We O 0 1.0316809948562877e-06
report O 0 2.565026875345211e-07
WT1 O 0 1.67358921316918e-05
heterozygous O 0 1.0958558505080873e-07
mutations O 0 1.7709458788317534e-08
in O 0 1.0450365017788954e-08
16 O 0 3.6410062875802396e-07
patients O 0 8.028899856071803e-08
, O 0 8.504420279109581e-09
4 O 0 2.2563476420600637e-07
of O 0 1.7233953997219942e-07
whom O 0 1.9360582825811434e-07
presented O 0 5.607363391391118e-07
with O 0 4.30852594490716e-07
IDMS B-Disease 1 0.9738335609436035
. O 0 2.115339520969428e-05

One O 0 6.190234103087278e-07
male O 0 2.9618570351885865e-07
and O 0 2.5202499642773546e-08
two O 0 2.710471846967266e-07
female O 0 0.0013603242114186287
IDMS B-Disease 1 0.9999934434890747
patients O 0 6.288050644798204e-05
with O 0 4.276018444215879e-06
WT1 O 1 0.9999923706054688
mutations O 0 0.0003456773702055216
underwent O 0 0.1491643488407135
normal O 0 0.00020982444402761757
puberty O 0 0.0007277029217220843
. O 0 4.6869345169398e-06

Two O 0 2.22105995817401e-06
mutations O 0 2.1794514850626e-06
associated O 0 2.193965883634519e-06
with O 0 2.838134776084189e-07
IDMS B-Disease 0 0.19267980754375458
are O 0 5.747643694320459e-09
different O 0 6.972602495380897e-10
from O 0 1.3888593608513133e-09
those O 0 8.00201516160115e-10
described O 0 5.7968264854935114e-08
in O 0 1.283685122643874e-07
DDS B-Disease 1 1.0
patients O 0 4.873558646067977e-05
. O 0 2.5385791104781674e-06

No O 0 5.255531050352147e-06
WT1 O 0 0.00019072822760790586
mutations O 0 1.7327595003280294e-07
were O 0 3.6352908239223325e-08
detected O 0 4.349812172677048e-07
in O 0 1.6391877855070902e-09
the O 0 2.9630269349212313e-09
six O 0 1.2390485082391933e-08
other O 0 2.332264337212564e-08
IDMS B-Disease 1 0.99965500831604
patients O 0 1.0531684893066995e-06
, O 0 5.617777354416376e-09
suggesting O 0 3.4969321660582864e-08
genetic O 0 4.4230077378415444e-08
heterogeneity O 0 2.987595451031666e-07
of O 0 4.666462132263405e-07
this O 0 3.638947418949101e-07
disease O 0 0.17168590426445007
. O 0 1.452553078706842e-06

We O 0 1.5114593452381087e-06
analyzed O 0 1.1965690646320581e-05
genotype O 0 1.5021595572761726e-05
/ O 0 1.2336232430243399e-05
phenotype O 0 2.10027081948283e-07
correlations O 0 9.97159986582119e-07
, O 0 8.631165115957629e-09
on O 0 1.393769366586639e-08
the O 0 9.013276791591807e-10
basis O 0 9.160809000263725e-09
of O 0 2.4174573454160964e-09
the O 0 1.023205964401086e-09
constitution O 0 8.611394930468919e-10
of O 0 5.032075200972486e-09
a O 0 1.11532498792144e-08
WT1 O 0 5.029549470236816e-07
mutation O 0 2.101830265388571e-09
database O 0 1.3945565591200193e-08
of O 0 1.6282457693250763e-07
84 O 0 5.256783697404899e-05
germ O 1 0.9999986886978149
- O 0 0.013024382293224335
line O 0 9.889935427054297e-06
mutations O 0 1.899179480346902e-08
, O 0 1.2853256237121968e-09
to O 0 4.092052807713742e-10
compare O 0 6.337717461946113e-09
the O 0 2.8045885613892096e-09
distribution O 0 8.377075921828236e-09
and O 0 5.754858256601381e-10
type O 0 3.1441867776038634e-08
of O 0 1.797626936195229e-08
mutations O 0 4.164129041583919e-09
, O 0 5.681935477674926e-10
according O 0 3.7679570574766785e-10
to O 0 4.155027155672286e-10
the O 0 3.3950804390059375e-09
different O 0 3.9917409822010086e-08
symptoms O 0 1.5026295841380488e-05
. O 0 5.903823421249399e-07

This O 0 2.392738167600328e-07
demonstrated O 0 1.6869424825927126e-06
( O 0 2.6931997965107257e-08
1 O 0 7.71812267430505e-08
) O 0 7.163212245586692e-10
the O 0 2.8425832798717465e-09
association O 0 4.131463171574978e-09
between O 0 1.359160695102446e-08
mutations O 0 7.634749721319167e-09
in O 0 1.1897100193891674e-08
exons O 0 6.23820142209297e-08
8 O 0 1.2568627028031187e-07
and O 0 7.303996074625729e-09
9 O 0 4.167071665506228e-07
and O 0 1.3078081906314765e-07
DMS B-Disease 1 0.5700600743293762
; O 0 6.785311512658154e-08
( O 0 4.337376324770048e-08
2 O 0 1.0881385605898686e-06
) O 0 7.300040572033595e-09
among O 0 4.578445622627214e-09
patients O 0 2.4373671081434622e-08
with O 0 3.3765477525093957e-08
DMS B-Disease 1 0.9999268054962158
, O 0 1.9695454156476444e-08
a O 0 2.0774382214483467e-09
higher O 0 4.49979253858146e-09
frequency O 0 1.6833757499057356e-08
of O 0 5.747632148001003e-09
exon O 0 7.599536644420368e-08
8 O 0 2.2968066559769795e-08
mutations O 0 2.336929760815565e-09
among O 0 5.65502533689255e-10
46 O 0 4.482320292709119e-08
, O 0 4.418344801138119e-08
XY O 0 0.0005064278375357389
patients O 0 1.4165790673814627e-07
with O 0 3.909278678548844e-09
female O 0 6.65051871351352e-08
phenotype O 0 1.2834275864292977e-08
than O 0 9.969749470428724e-10
among O 0 8.406859652865251e-10
46 O 0 5.1595524297454176e-08
, O 0 2.3907851698368177e-08
XY O 0 0.002646293956786394
patients O 0 1.868976511332221e-07
with O 0 4.699759248438795e-09
sexual O 0 5.084543772682082e-07
ambiguity O 0 1.9763648140269652e-07
or O 0 2.7252687218037863e-08
male O 0 1.410960148717777e-08
phenotype O 0 4.031342371035862e-09
; O 0 3.8842148941675703e-10
and O 0 2.257688924700574e-09
( O 0 2.8017601572116746e-09
3 O 0 1.131049298663811e-08
) O 0 1.5623520532859203e-10
statistically O 0 6.218392467616241e-10
significant O 0 3.531494818798109e-10
evidence O 0 1.1652394604766414e-09
that O 0 5.852722473331795e-11
mutations O 0 6.803071994632148e-10
in O 0 2.149442401844226e-09
exons O 0 7.242833532927762e-08
8 O 0 5.1978872761537787e-08
and O 0 2.5398165792722693e-09
9 O 0 7.278063662852219e-08
preferentially O 0 1.2725366538290928e-08
affect O 0 8.770848936023867e-09
amino O 0 1.2215571665308289e-08
acids O 0 4.520920970918496e-09
with O 0 7.796320533604018e-11
different O 0 5.797074487112752e-10
functions O 0 8.196583678454772e-08
. O 0 1.3223204753387563e-08
. O 0 1.4151531502193393e-07

The O 0 2.6989905563823413e-06
185delAG O 0 1.2341738511167932e-05
BRCA1 O 0 3.3146363875857787e-07
mutation O 0 9.771291331617249e-09
originated O 0 4.967950939516186e-09
before O 0 2.9106370647014046e-09
the O 0 2.846059221628394e-10
dispersion O 0 1.2837312546309931e-08
of O 0 3.4166216522635295e-09
Jews O 0 1.7244525807313948e-09
in O 0 1.530214704947852e-10
the O 0 3.3837135871017665e-10
diaspora O 0 1.0057185084733078e-09
and O 0 6.457526735559327e-10
is O 0 2.93735508138937e-10
not O 0 1.2437116614361088e-10
limited O 0 1.4547794080499443e-09
to O 0 8.467404555290159e-09
Ashkenazim O 0 3.1684612622484565e-05
. O 0 1.9275703380117193e-06

The O 0 8.2224494235561e-07
185delAG O 0 2.557757625254453e-06
mutation O 0 7.115856703876489e-08
in O 0 1.8744060525932582e-08
BRCA1 O 0 3.5235121487176e-08
is O 0 7.47800044109681e-10
detected O 0 3.323882324934857e-08
in O 0 6.437285149374361e-10
Ashkenazi O 0 6.974430988293534e-08
Jews O 0 1.942333627269477e-09
both O 0 1.2626450995867344e-09
in O 0 3.0514343052345794e-08
familial B-Disease 1 0.9978705644607544
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.313259210495744e-05
in O 0 6.103720551209335e-08
the O 0 1.3928473485691484e-08
general O 0 3.721229901998413e-08
population O 0 3.0920697113856477e-09
. O 0 1.36502606551403e-07

All O 0 4.0529207012696133e-07
tested O 0 1.4018899037182564e-06
Ashkenazi O 0 1.0543975577093079e-06
mutation O 0 1.607808997050597e-08
carriers O 0 1.0743542944169349e-08
share O 0 2.271285826083158e-09
the O 0 1.6867369723172487e-09
same O 0 2.4309219082141453e-09
allelic O 0 1.3613950500257488e-07
pattern O 0 1.9893519720426411e-07
at O 0 4.437017366853979e-07
the O 0 8.795764472324663e-08
BRCA1 O 0 4.3570818775151565e-07
locus O 0 6.315023028946598e-07
. O 0 1.1815913012469537e-06

Our O 0 1.4557635950041004e-06
previous O 0 2.3521695879935578e-07
study O 0 2.3968166118493173e-08
showed O 0 1.929911697118314e-08
that O 0 1.1831734203493482e-10
this O 0 1.9541268603262552e-10
Ashkenazi O 0 2.7466118268648643e-08
mutation O 0 1.9625021607794224e-09
also O 0 5.786712220512413e-10
occurs O 0 5.233805611126741e-10
in O 0 5.145572301579193e-10
Iraqi O 0 3.968775885709874e-08
Jews O 0 5.0406825380377995e-09
with O 0 5.954060577906262e-10
a O 0 2.2483981343413006e-09
similar O 0 4.3833399132608974e-09
allelic O 0 4.526484360667382e-07
pattern O 0 5.642958512908081e-06
. O 0 1.5270053381755133e-06

We O 0 4.276358538390923e-07
extended O 0 6.602641633435269e-08
our O 0 9.651100363328169e-09
analysis O 0 1.8872332585573304e-09
to O 0 2.2558713230758087e-10
other O 0 4.800456143705389e-10
non O 0 1.3402591036992817e-07
- O 0 1.0987315590682556e-07
Ashkenazi O 0 6.437524291413865e-08
subsets O 0 5.930198199166625e-08
354 O 0 1.2082562506066097e-08
of O 0 4.5334247467110345e-09
Moroccan O 0 1.0806723338419033e-07
origin O 0 3.1382594301021527e-09
, O 0 1.161691076667637e-09
200 O 0 2.620474059966682e-09
Yemenites O 0 2.1423262808184518e-07
and O 0 4.015993315675814e-09
150 O 0 8.812939711333456e-09
Iranian O 0 1.3235334961336775e-07
Jews O 0 5.296556082612369e-08
. O 0 1.4595779873616266e-07

Heteroduplex O 0 1.71759875229327e-05
analysis O 0 1.196603705011512e-07
complemented O 0 2.535519882940207e-08
by O 0 6.648306349887889e-10
direct O 0 2.204321614129867e-09
DNA O 0 4.076373461003868e-09
sequencing O 0 5.900994359819833e-09
of O 0 8.343414847900021e-09
abnormally O 0 3.138847759487362e-08
migrating O 0 1.7765272586345304e-09
bands O 0 4.36751115273637e-08
were O 0 3.381994062578997e-08
employed O 0 8.254576187027851e-07
. O 0 2.929590152689343e-07

Four O 0 4.15773513395834e-07
of O 0 2.3657958081457764e-07
Moroccan O 0 7.367021908066818e-07
origin O 0 1.568016827491192e-08
( O 0 1.3605865323285116e-09
1 O 0 6.868251745117959e-09
. O 0 1.3721465630389673e-10
1 O 0 7.14994818906689e-09
% O 0 3.204564391623421e-10
) O 0 1.6162195193292206e-10
and O 0 3.392308378646902e-10
none O 0 4.606678150054222e-09
of O 0 6.034817534583681e-09
the O 0 1.3286333810924589e-08
Yemenites O 0 1.6774934010754805e-06
or O 0 1.3902726969661217e-08
Iranians O 0 4.896757133110441e-08
was O 0 3.084142718989824e-08
a O 0 3.38710504088624e-09
carrier O 0 1.1325085758073783e-08
of O 0 6.448237943601498e-09
the O 0 9.682777246666774e-09
185delAG O 0 3.7757419590889185e-07
mutation O 0 2.0952269252916267e-08
. O 0 9.821015112265741e-08

BRCA1 O 0 1.6982849047053605e-05
allelic O 0 6.2118701862345915e-06
patterns O 0 6.50899949050654e-07
were O 0 6.508490457690641e-08
determined O 0 4.207547021906066e-08
for O 0 1.8228446529988673e-09
four O 0 2.028617940297295e-09
of O 0 5.497772459506223e-09
these O 0 1.3533311971070106e-10
individuals O 0 1.2065962812224384e-11
and O 0 1.237370483853084e-10
for O 0 4.332493530601056e-10
12 O 0 5.883675768814101e-09
additional O 0 1.5374327366757257e-09
non O 0 9.527718702884158e-08
- O 0 4.5909615664641024e-08
Ashkenazi O 0 3.461106601321262e-08
185delAG O 0 2.485255023998434e-08
mutation O 0 9.05093500147558e-10
carriers O 0 4.727864766351786e-09
who O 0 1.0283050855264264e-08
had O 0 2.208447767770849e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.02003430761396885

Six O 0 4.375601292849751e-06
non O 0 5.292552668834105e-05
- O 0 1.9890796465915628e-05
Ashkenazi O 0 1.7093640281018452e-06
individuals O 0 2.513537378234787e-09
shared O 0 3.061940390125528e-08
the O 0 7.562819703821333e-09
common O 0 1.3909119189747798e-08
Ashkenazi O 0 4.417797470068763e-07
haplotype O 0 4.0496172459825175e-07
, O 0 1.0734448885330039e-08
four O 0 1.1391421139705926e-08
had O 0 2.8713838418070736e-08
a O 0 3.6159331084917312e-09
closely O 0 4.1556313945534384e-09
related O 0 1.9263444173134303e-08
pattern O 0 1.6834199811910366e-07
, O 0 1.5074574921669637e-09
and O 0 2.2420429957037413e-09
the O 0 3.5064097403392225e-08
rest O 0 1.7572138233390433e-07
( O 0 6.186549050823942e-09
n O 0 1.627848291718692e-07
= O 0 6.693315413031087e-08
6 O 0 6.769398908090807e-08
) O 0 1.267166371832218e-09
displayed O 0 4.55579929337091e-08
a O 0 7.1694215009188156e-09
distinct O 0 1.4570710860084546e-08
BRCA1 O 0 2.0668163358550373e-07
allelic O 0 3.0570438411814393e-06
pattern O 0 8.7554590209038e-06
. O 0 1.5280221532520954e-06

We O 0 1.0187333145950106e-06
conclude O 0 1.323299102296005e-06
that O 0 5.058461649554147e-09
the O 0 1.5771140837728126e-08
185delAG O 0 2.6686228693506564e-07
BRCA1 O 0 3.1538867517610925e-08
mutation O 0 1.5623945470721878e-09
occurs O 0 8.313181254493429e-10
in O 0 3.1452812576659994e-10
some O 0 2.131225751433874e-10
non O 0 7.849300942552873e-08
- O 0 1.9552086882868025e-07
Ashkenazi O 0 1.4765210210043733e-07
populations O 0 1.5708627731925162e-09
at O 0 2.4672367260336614e-08
rates O 0 1.2807011451343442e-08
comparable O 0 7.035903859531345e-09
with O 0 2.3221903566739144e-10
that O 0 4.568281308792166e-10
of O 0 1.5376805606592825e-07
Ashkenazim O 0 4.343494583736174e-05
. O 0 1.522271077192272e-06

The O 0 2.671971799372841e-07
majority O 0 1.7240653349404056e-08
of O 0 5.813268444399e-08
Jewish O 0 3.9959001441047803e-08
185delAG O 0 2.658033793068171e-07
mutation O 0 7.003395197102691e-09
carriers O 0 2.4424104960729665e-09
have O 0 2.8338606461453253e-10
a O 0 1.2131188276143234e-09
common O 0 4.770001282849989e-09
allelic O 0 1.3078917504572019e-07
pattern O 0 3.3430492862862593e-07
, O 0 4.042260304260026e-09
supporting O 0 1.1558876522599348e-08
the O 0 1.4187239827379017e-08
founder O 0 1.4416352200896654e-07
effect O 0 6.925107953748011e-08
notion O 0 8.417922714443193e-08
, O 0 1.966702800615394e-09
but O 0 5.739423936113042e-10
dating O 0 9.134411449451818e-09
the O 0 6.926871853885075e-10
mutations O 0 3.7272068764693245e-10
origin O 0 4.658916030741977e-10
to O 0 1.7996491796790082e-10
an O 0 3.060173781044284e-10
earlier O 0 5.206467257323766e-09
date O 0 2.8259828255272623e-08
than O 0 2.6933835162168407e-09
currently O 0 1.345018052489877e-08
estimated O 0 2.401713139477124e-08
. O 0 1.6099716049211565e-07

However O 0 1.548390400785138e-06
, O 0 3.2563363561166625e-08
the O 0 4.25757251676373e-09
different O 0 1.6340589992225318e-09
allelic O 0 2.1687745288545557e-07
pattern O 0 4.1255998439737596e-07
at O 0 5.050964091424248e-07
the O 0 3.0776789117226144e-08
BRCA1 O 0 2.3378538216434208e-08
locus O 0 1.0595738508811792e-08
even O 0 1.2866231413610763e-09
in O 0 3.0759622626774785e-10
some O 0 1.5279368048570774e-10
Jewish O 0 1.4807980397435472e-09
mutation O 0 1.1971688085310461e-09
carriers O 0 3.05197400685131e-09
, O 0 1.6555897763836924e-09
might O 0 1.5075407588938106e-09
suggest O 0 1.4323452424136462e-09
that O 0 5.630225799468924e-11
the O 0 7.114628886029095e-10
mutation O 0 5.060408758694734e-10
arose O 0 4.493266203553503e-09
independently O 0 4.9285002745591555e-09
. O 0 9.027405489803186e-09
. O 0 2.002917653953773e-07

Crystal O 1 0.9872357249259949
structure O 0 0.00017158969421871006
of O 0 7.310836372198537e-05
the O 0 0.004009706899523735
hemochromatosis B-Disease 1 1.0
protein O 0 0.0002908183087129146
HFE O 0 0.0004343542386777699
and O 0 5.416629633714365e-08
characterization O 0 3.435112887473224e-07
of O 0 7.135182755746428e-08
its O 0 5.080837528481652e-09
interaction O 0 1.952829080664742e-07
with O 0 5.296606531146608e-08
transferrin O 0 1.886773679871112e-05
receptor O 0 2.2307631297735497e-06
. O 0 1.4625919675381738e-06

HFE O 0 0.0037242909893393517
is O 0 9.927003929988132e-07
an O 0 3.193173938598193e-07
MHC O 0 0.00016553307068534195
- O 0 0.00035286875208839774
related O 0 1.099209111998789e-05
protein O 0 1.8720393768489885e-07
that O 0 5.463816066253457e-10
is O 0 2.7184232642696315e-10
mutated O 0 1.995575482638401e-09
in O 0 1.0147516160685655e-09
the O 0 4.227126026989936e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9997299313545227

HFE O 0 0.001040427596308291
binds O 0 4.563819402392255e-06
to O 0 4.6897102379261923e-07
transferrin O 0 1.513441475253785e-05
receptor O 0 7.105677468643989e-07
( O 0 8.793281836005917e-08
TfR O 0 1.9052259858653997e-06
) O 0 3.979788054664368e-09
and O 0 1.6937714564235762e-09
reduces O 0 1.3338715909583243e-08
its O 0 9.495472186316078e-10
affinity O 0 1.0875659484099742e-08
for O 0 2.0277717283079255e-08
iron O 1 0.9320372343063354
- O 0 1.641640551497403e-06
loaded O 0 1.6092025134639698e-07
transferrin O 0 9.51285301198368e-07
, O 0 2.5655447544181698e-08
implicating O 0 2.2213578631635755e-05
HFE O 0 0.07403309643268585
in O 0 7.663189535378478e-06
iron O 1 0.9999978542327881
metabolism O 1 0.9774291515350342
. O 0 8.491410881106276e-06

The O 0 1.8216853277408518e-05
2 O 0 0.00013796251732856035
. O 0 8.350441930815578e-06

6 O 0 0.0003194678283762187
A O 0 0.00013089207641314715
crystal O 1 0.9982408285140991
structure O 0 0.00022683781571686268
of O 0 6.952867261134088e-05
HFE O 0 0.363479346036911
reveals O 0 2.8924648631800665e-07
the O 0 6.440113331507291e-09
locations O 0 1.4660111347097882e-08
of O 0 1.8853636447602184e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 1.2332529877312481e-06
and O 0 1.7759953152562957e-07
a O 0 4.6083061988611007e-07
patch O 0 0.07455790042877197
of O 0 0.08356703817844391
histidines O 1 0.7130077481269836
that O 0 7.0144112740422315e-09
could O 0 3.2381071157772112e-09
be O 0 5.413453574298899e-10
involved O 0 1.131592486380839e-09
in O 0 1.044055841781244e-09
pH O 0 3.0102719392743893e-06
- O 0 1.2267988722669543e-06
dependent O 0 2.7556512804949307e-07
interactions O 0 2.242896925963578e-06
. O 0 1.0363581850469927e-06

We O 0 9.237591029886971e-07
also O 0 6.397730345497621e-08
demonstrate O 0 3.5512016438588034e-08
that O 0 7.239902899414119e-09
soluble O 0 5.427946234703995e-06
TfR O 0 2.2256515876506455e-05
and O 0 6.915340122759517e-08
HFE O 0 7.015552546363324e-05
bind O 0 2.434986470234435e-07
tightly O 0 1.1400406947359443e-06
at O 0 1.074215347784957e-07
the O 0 3.148583838097352e-09
basic O 0 5.81274726130232e-08
pH O 0 2.3429456064150145e-07
of O 0 1.721318554359641e-08
the O 0 1.0312159126613096e-08
cell O 0 1.3114826913351862e-07
surface O 0 1.4773718248761725e-07
, O 0 1.5084699045431194e-09
but O 0 1.425123075105006e-10
not O 0 1.5689068100233072e-10
at O 0 6.67682575894446e-09
the O 0 8.05996325237146e-10
acidic O 0 1.6622699661184015e-08
pH O 0 1.0559643897067872e-06
of O 0 5.670897280651843e-07
intracellular O 0 1.653523759159725e-05
vesicles O 0 3.2871168514247984e-05
. O 0 4.881891982222442e-06

TfR O 0 0.004345818422734737
HFE O 0 0.0009513982222415507
stoichiometry O 0 1.7707838196656667e-05
( O 0 6.729785582137993e-07
2 O 0 1.4808094874751987e-06
1 O 0 3.7576197087219043e-07
) O 0 9.284257806996266e-09
differs O 0 5.7655764607034143e-08
from O 0 5.481054543565733e-08
TfR O 0 3.0148082714731572e-06
transferrin O 0 5.781973300145182e-07
stoichiometry O 0 6.452669367718045e-07
( O 0 5.779438438935358e-08
2 O 0 4.695505708696146e-07
2 O 0 1.8453131644946552e-07
) O 0 3.1290370294811964e-09
, O 0 1.6340621078470008e-09
implying O 0 3.4944700466610357e-09
a O 0 6.12449591042008e-10
different O 0 1.1819148437730576e-10
mode O 0 2.1135337036071178e-08
of O 0 1.3939441823040966e-09
binding O 0 1.4191887665049308e-09
for O 0 3.4896878720047653e-09
HFE O 0 7.1642548391537275e-06
and O 0 3.2372444280781565e-08
transferrin O 0 8.309303325404471e-07
to O 0 1.6213991926861127e-08
TfR O 0 6.964819931454258e-06
, O 0 8.356712655199772e-09
consistent O 0 9.782815446612858e-09
with O 0 5.484123710708388e-10
our O 0 8.375669935389851e-09
demonstration O 0 2.219785777413108e-08
that O 0 7.894516707018795e-10
HFE O 0 1.7428736782676424e-06
, O 0 7.873453000684094e-09
transferrin O 0 3.97416982877985e-07
, O 0 6.6972583034896616e-09
and O 0 9.97319649087558e-09
TfR O 0 2.1625712633976946e-06
form O 0 3.765094191976459e-08
a O 0 4.050504998076576e-08
ternary O 0 2.8984895834582858e-06
complex O 0 8.354620513273403e-05
. O 0 1.9055204347750987e-06

Identification O 0 8.699607860762626e-07
of O 0 3.730810362867487e-07
three O 0 1.660929349611706e-08
novel O 0 7.465833284925338e-09
mutations O 0 1.4401581038825384e-09
and O 0 2.967612544590992e-10
a O 0 1.1723643167371733e-09
high O 0 2.3014901984197422e-08
frequency O 0 6.273448605043086e-08
of O 0 7.736041141015448e-09
the O 0 5.469126040935635e-09
Arg778Leu O 0 2.3661230841298675e-07
mutation O 0 1.1983454228925439e-09
in O 0 6.544110253692281e-10
Korean O 0 6.52369692488719e-07
patients O 0 7.972601245853639e-09
with O 0 8.744057033993613e-09
Wilson B-Disease 0 0.004064812324941158
disease I-Disease 1 0.521312952041626
. O 0 2.2072081264923327e-06

Four O 0 9.406634831066185e-07
mutations O 0 3.175829874635383e-07
- O 0 1.2639983424378443e-06
- O 0 7.699829893681454e-07
R778L O 0 1.6547244285902707e-06
, O 0 1.0938882688549256e-08
A874V O 0 2.3291865147712087e-07
, O 0 3.313904040069815e-09
L1083F O 0 4.410741638594118e-08
, O 0 7.085242947901804e-10
and O 0 8.864437517352997e-10
2304delC O 0 6.572862787379563e-08
- O 0 2.9176362659200095e-08
- O 0 7.830098347483272e-09
in O 0 1.0075579259805068e-09
the O 0 8.818656915821066e-09
copper O 0 9.147765922534745e-06
- O 0 3.498246314848075e-08
transporting O 0 2.1881280787283686e-08
enzyme O 0 1.5706951295157978e-09
, O 0 1.7923810213815727e-09
P O 0 3.1510180633631535e-06
- O 0 1.2878371080660145e-07
type O 0 2.0577731163484714e-07
ATPase O 0 4.7434662064915756e-07
( O 0 2.561290912694858e-08
ATP7B O 0 3.998899501311826e-06
) O 0 1.9357502267780546e-09
, O 0 2.2623088125062196e-10
were O 0 3.6603975406279687e-10
identified O 0 9.186385541148923e-10
in O 0 1.2537634264120356e-09
Korean O 0 5.112041435495485e-06
Patients O 0 5.97293663417986e-08
with O 0 2.66594391007402e-08
Wilson B-Disease 0 0.004923919215798378
disease I-Disease 0 0.05017117038369179
. O 0 1.1817840004368918e-06

Arg778Leu O 0 0.0012023241724818945
, O 0 3.65102380328608e-07
the O 0 3.725355668393604e-08
most O 0 3.2349400935771655e-09
frequently O 0 3.0675737505703182e-09
reported O 0 8.707753407222185e-10
mutation O 0 2.0375241771564134e-10
of O 0 4.647953966152585e-10
this O 0 3.57560300812132e-11
enzyme O 0 3.055053432454713e-10
, O 0 5.158287130768713e-10
was O 0 2.013592315108781e-08
found O 0 2.4071233895028854e-09
in O 0 1.1671547062164223e-09
six O 0 2.7377085043411853e-09
of O 0 2.5612861165313916e-08
eight O 0 5.259629531906285e-08
unrelated O 0 1.7716494937758398e-07
patients O 0 6.613604774940995e-09
studied O 0 5.5798064835244077e-08
, O 0 1.5603805747499422e-10
an O 0 6.616234643486152e-11
allele O 0 2.5408875004018228e-09
frequency O 0 1.4717004148678825e-07
of O 0 1.2875472066298244e-07
37 O 0 2.8720796763082035e-06
. O 0 1.0230248790321639e-06

5 O 0 1.2010495083814021e-05
% O 0 3.304303106688167e-07
, O 0 2.5941778503124624e-08
which O 0 1.6182808426634665e-09
is O 0 3.315489272015526e-10
considerably O 0 2.914848140633808e-09
higher O 0 4.12085476853008e-09
than O 0 1.2274929683808722e-10
those O 0 7.133676288573199e-11
in O 0 1.1389584414489562e-10
other O 0 2.5599941610998656e-10
Asian O 0 1.342165756312852e-08
populations O 0 7.284601810653157e-09
. O 0 5.332368147037414e-08

The O 0 2.933098528501432e-07
novel O 0 2.6109363560067322e-08
single O 0 4.618105897691294e-09
nucleotide O 0 5.737504338299004e-08
deletion O 0 1.4983189089434745e-07
, O 0 4.322425972702604e-09
2304delC O 0 2.0162369196441432e-07
, O 0 4.34708047336585e-09
was O 0 5.975967809490612e-08
found O 0 6.923387640966894e-09
in O 0 3.201816811682079e-09
one O 0 5.8763189869637245e-09
patient O 0 8.735856340535975e-07
. O 0 1.1333943348290632e-06

Since O 0 4.3688277173714596e-07
a O 0 6.763062287973298e-08
mutation O 0 5.5177005187090344e-09
at O 0 1.4586066754418425e-07
cDNA O 0 2.943168908586813e-07
nucleotide O 0 4.4414710487217235e-07
2302 O 0 4.135566268814728e-05
( O 0 3.188283415056503e-08
2302insC O 0 5.203829118727299e-07
) O 0 1.0567945629702535e-08
had O 0 4.727938929249831e-08
been O 0 5.632153854406852e-09
previously O 0 2.1688236984118703e-08
described O 0 3.1937474886944983e-09
, O 0 3.148108163042451e-10
this O 0 3.389900513073307e-11
region O 0 1.9238795001541575e-09
of O 0 2.9408659951712934e-09
the O 0 1.2344039568290555e-08
ATP7B O 0 5.954368316452019e-05
gene O 0 2.9178533367257842e-08
may O 0 4.764836525339433e-09
be O 0 1.308156361012891e-09
susceptible O 0 5.747336384587243e-09
to O 0 1.243275926654519e-09
gene O 0 9.361521051687305e-07
rearrangements O 0 0.0021520948503166437
causing O 0 0.01417521107941866
Wilson B-Disease 0 0.40090814232826233
disease I-Disease 1 0.5024606585502625
. O 0 3.5410469081398332e-06

Disruption O 0 2.4225966626545414e-05
of O 0 3.8464241924884846e-07
splicing O 0 1.8682121094570903e-07
regulated O 0 5.935222446851185e-08
by O 0 9.750230622884715e-10
a O 0 1.6601914509806193e-08
CUG O 0 1.0933200428553391e-05
- O 0 3.4280995464541775e-07
binding O 0 1.8153014025301673e-07
protein O 0 2.7490508728078566e-05
in O 0 9.214045348926447e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00024085633049253374

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995943903923035
DM B-Disease 1 1.0
) O 0 1.8514082285037148e-06
is O 0 5.484442766601205e-08
caused O 0 2.8270987328937736e-08
by O 0 1.330897503315498e-09
a O 0 5.0361393277853495e-08
CTG O 0 1.2871613762399647e-05
expansion O 0 2.1062461996734783e-07
in O 0 5.6236095780093365e-09
the O 0 1.2242441727039477e-08
3 O 0 1.1078010686560447e-07
untranslated O 0 6.626936283282703e-06
region O 0 3.049456154258223e-08
of O 0 3.5995714853243044e-08
the O 0 5.451079800877778e-07
DM B-Disease 1 1.0
gene O 0 4.54979181085946e-06
. O 0 1.9530148165358696e-06

One O 0 2.8460192424972774e-07
model O 0 6.702385348944517e-07
of O 0 3.167476097587496e-05
DM B-Disease 1 1.0
pathogenesis O 1 0.9999445676803589
suggests O 0 3.5147601806784223e-07
that O 0 3.6759806310016074e-09
RNAs O 0 2.0484688434407872e-07
from O 0 2.478214966572523e-09
the O 0 1.482544531583585e-09
expanded O 0 5.7997762148431775e-09
allele O 0 2.0565786851278745e-09
create O 0 1.8465914353171797e-09
a O 0 2.201170357096771e-09
gain O 0 6.377079841968225e-08
- O 0 4.06567579602779e-08
of O 0 6.727039192355733e-08
- O 0 2.5763672084622158e-08
function O 0 7.2217662960838425e-09
mutation O 0 1.2005157978833836e-10
by O 0 6.410167535664257e-11
the O 0 5.800105395969979e-10
inappropriate O 0 1.302868124497536e-08
binding O 0 6.242245831344917e-09
of O 0 2.3790352798869208e-08
proteins O 0 1.4784077295715292e-09
to O 0 1.890504641721691e-09
the O 0 6.765526450180914e-08
CUG O 0 0.0002460089745000005
repeats O 0 2.5219628696504515e-06
. O 0 6.408899366761034e-07

Data O 0 4.3258778532617725e-06
presented O 0 1.2009702459181426e-06
here O 0 5.401556535389318e-08
indicate O 0 1.0293057961519025e-08
that O 0 4.0986375404727937e-10
the O 0 2.337732230017764e-09
conserved O 0 1.6518629308848176e-07
heterogeneous O 0 1.1976007954217494e-06
nuclear O 0 8.921043445297983e-06
ribonucleoprotein O 0 3.5575176298152655e-06
, O 0 8.93780160993174e-09
CUG O 0 1.829817847465165e-06
- O 0 5.033853867075777e-08
binding O 0 1.589671505541901e-08
protein O 0 5.641456723992633e-08
( O 0 1.4337619091975284e-08
CUG O 0 2.9355402148212306e-05
- O 0 2.1694872884836514e-06
BP O 0 4.109791916562244e-06
) O 0 1.004561056561215e-08
, O 0 1.0945582218369054e-08
may O 0 2.7323471485374284e-08
mediate O 0 4.7193978502946266e-07
the O 0 4.037015912672359e-07
trans O 0 3.570392436813563e-06
- O 0 3.501782259718311e-07
dominant O 0 5.244033332019171e-07
effect O 0 1.0861484867064064e-07
of O 0 7.344091557115462e-08
the O 0 4.598165048719238e-08
RNA O 0 1.66107099630608e-06
. O 0 2.9689269354093994e-07

CUG O 1 0.9446229338645935
- O 0 0.0013433266431093216
BP O 0 8.017602522158995e-05
was O 0 6.578230227205495e-07
found O 0 2.086237405052316e-09
to O 0 3.2831187768422865e-10
bind O 0 2.0594008720564716e-09
to O 0 8.305446885792378e-10
the O 0 3.347377841578236e-08
human O 0 2.4355142613785574e-06
cardiac O 1 0.9999270439147949
troponin O 1 0.6406818628311157
T O 0 0.000240312481764704
( O 0 3.446573870746761e-08
cTNT O 0 2.344474410165276e-07
) O 0 2.5939883574466194e-09
pre O 0 2.900254116866563e-07
- O 0 8.850153676576156e-08
messenger O 0 8.882111046659702e-09
RNA O 0 1.7687854736436748e-08
and O 0 4.156548993883291e-10
regulate O 0 1.947370931176806e-09
its O 0 4.703953893070434e-10
alternative O 0 2.1250945891893025e-08
splicing O 0 5.459471594804199e-07
. O 0 2.3099126167380746e-07

Splicing O 0 1.226441963808611e-05
of O 0 1.3254891655378742e-06
cTNT O 0 5.63915709790308e-05
was O 0 1.881259049696382e-05
disrupted O 0 6.799773109378293e-05
in O 0 3.1372489956993377e-06
DM B-Disease 1 1.0
striated O 0 0.06717542558908463
muscle O 0 2.744121229625307e-05
and O 0 1.0766132163553266e-07
in O 0 3.8502960819641885e-08
normal O 0 3.328425179915939e-07
cells O 0 3.5695555400394596e-09
expressing O 0 2.355105888085518e-09
transcripts O 0 2.606656934744933e-08
that O 0 3.2211039391327745e-10
contain O 0 2.044338565099224e-08
CUG O 0 1.2495889677666128e-05
repeats O 0 9.093369044421706e-07
. O 0 2.4305066403940145e-07

Altered O 0 9.644834335631458e-07
expression O 0 9.902215225565669e-08
of O 0 1.2097336821170757e-07
genes O 0 2.037390167686226e-08
regulated O 0 1.4402253611933702e-07
posttranscriptionally O 0 4.4303197910267045e-07
by O 0 1.0318966126021678e-08
CUG O 0 0.016169598326086998
- O 0 4.104738400201313e-05
BP O 0 1.285044436372118e-05
therefore O 0 1.0494812840988743e-07
may O 0 1.0773789860252236e-08
contribute O 0 1.1219263740258612e-08
to O 0 1.1834075053229753e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9998735189437866
. O 0 3.6445948126129224e-07
. O 0 7.875196388340555e-07

Identification O 0 1.7187387584272074e-06
of O 0 2.570163815107662e-07
a O 0 3.273736126629956e-08
novel O 0 1.694854923073308e-08
nonsense O 0 7.671743418313781e-08
mutation O 0 1.8824413139384433e-09
and O 0 6.532711593898455e-10
a O 0 5.286389548331272e-09
missense O 0 4.4168029234015194e-08
substitution O 0 2.1346290068890994e-08
in O 0 4.259343100443402e-09
the O 0 2.006101773588398e-08
vasopressin O 0 1.610533331586339e-06
- O 0 9.600098564988002e-07
neurophysin O 0 4.515685304795625e-06
II O 1 0.8345316648483276
gene O 0 1.091247980866683e-08
in O 0 2.350752481561358e-09
two O 0 8.857710676046793e-10
Spanish O 0 5.324979213128245e-08
kindreds O 0 1.056271571542311e-06
with O 0 6.088151849326096e-08
familial B-Disease 1 0.9999626874923706
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999215602874756
. O 0 5.535980380955152e-05

Familial B-Disease 1 0.9999988079071045
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
( O 0 0.0009906211635097861
FNDI B-Disease 1 1.0
) O 0 6.848266309589235e-08
is O 0 3.625761024750318e-09
an O 0 1.0595799793122751e-08
autosomal B-Disease 1 0.999996542930603
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 8.386525587411597e-05
by O 0 1.4482677102023445e-07
deficiency O 1 0.9998931884765625
in O 0 6.530549967465049e-07
the O 0 7.718438610027079e-06
antidiuretic O 0 6.101996041252278e-05
hormone O 0 5.759460691479035e-06
arginine O 0 2.491663963155588e-06
vasopressin O 0 3.6543995065585477e-06
( O 0 1.2977929486623907e-07
AVP O 0 2.455290314173908e-06
) O 0 3.908533052765506e-09
encoded O 0 5.009590076099357e-09
by O 0 1.5288996735307592e-09
the O 0 5.4737412824579224e-08
AVP O 0 8.43484012875706e-05
- O 0 4.006220115115866e-05
neurophysin O 0 0.0005055965739302337
II O 1 0.9999990463256836
( O 0 2.3493923890782753e-06
AVP O 0 6.211230356711894e-05
- O 0 3.5027846934099216e-06
NPII O 0 1.526449341326952e-05
) O 0 6.242388383981279e-09
gene O 0 1.538102267772956e-08
on O 0 1.735173782435595e-07
chromosome O 0 3.7531822272285353e-06
20p13 O 0 2.0084768038941547e-05
. O 0 2.000505674004671e-06

In O 0 1.005968783829303e-07
this O 0 1.2902502399825266e-09
study O 0 3.3197495863390714e-09
, O 0 6.859267598358088e-10
we O 0 4.2805650690702635e-10
analyzed O 0 8.157666542274455e-09
two O 0 3.0751645674342853e-10
families O 0 4.7994282159624646e-11
with O 0 6.813109520997784e-10
FNDI B-Disease 1 0.8460719585418701
using O 0 6.909259386844724e-09
direct O 0 2.6695297083989544e-09
automated O 0 4.536237696584067e-08
fluorescent O 0 7.779483723879821e-09
, O 0 8.649057026133278e-10
solid O 0 4.227883820817624e-08
phase O 0 1.7665021800894465e-07
, O 0 1.5751171478228798e-09
single O 0 1.343953059951275e-09
- O 0 8.728459732765259e-09
stranded O 0 2.182733105371426e-09
DNA O 0 7.076491059798684e-10
sequencing O 0 6.063219926133456e-10
of O 0 4.542313636335393e-09
PCR O 0 7.524248246681964e-08
- O 0 3.3914517416633316e-07
amplified O 0 8.561694926356722e-07
AVP O 0 6.572241545654833e-05
- O 0 1.4231533896236215e-05
NPII O 0 0.00015726748097222298
DNA O 0 2.528686991354334e-06
. O 0 4.6769719119765796e-07

In O 0 3.1482676376981544e-07
one O 0 1.3124906494965671e-08
of O 0 3.83595057940056e-08
the O 0 1.1784045739204885e-08
families O 0 4.330989733514201e-10
, O 0 4.4540982013785424e-10
affected O 0 1.2029453821948977e-10
individuals O 0 3.264814113501657e-11
presented O 0 7.835117443732997e-09
a O 0 1.76833936382792e-09
novel O 0 2.519191300009993e-09
nonsense O 0 1.4799799608056219e-08
mutation O 0 5.140912140433329e-10
in O 0 1.6489244414330528e-09
exon O 0 1.0150796470043133e-07
3 O 0 3.4280073890613494e-08
of O 0 8.365676151811385e-09
the O 0 2.9733362438832955e-09
gene O 0 1.6544470238244458e-09
, O 0 6.229646243305353e-10
consisting O 0 3.1181282000858346e-09
in O 0 1.8010684055269621e-09
a O 0 9.45218125991687e-09
G O 0 4.5554952521342784e-07
to O 0 3.491354050311202e-08
T O 0 1.6134194083861075e-05
transition O 0 1.350469665339915e-05
at O 0 4.646842626243597e-06
nucleotide O 0 2.3528424719643226e-07
2101 O 0 1.8418211311654886e-06
, O 0 6.655033857327908e-09
which O 0 7.58405005463203e-10
produces O 0 2.942833754460139e-10
a O 0 6.409095476556104e-10
stop O 0 1.80919035308591e-09
signal O 0 2.410924615503518e-08
in O 0 2.6945397024746853e-09
codon O 0 9.719617111159096e-09
82 O 0 2.422282534553233e-07
( O 0 3.7108531358853725e-08
Glu O 0 1.3580766790255439e-05
) O 0 5.4017213813040144e-08
of O 0 2.425760158075718e-06
NPII O 0 0.2592609226703644
. O 0 9.560223588778172e-06

The O 0 1.6138467344717355e-06
premature O 0 1.265282776330423e-06
termination O 0 3.0099423042884155e-07
eliminates O 0 4.924613108414633e-07
part O 0 1.627226708933449e-08
of O 0 1.417147199589408e-08
the O 0 3.226887557161717e-08
C O 0 4.315797923482023e-05
- O 0 1.999625283133355e-07
terminal O 0 3.714713159297389e-07
domain O 0 2.6390289065147954e-08
of O 0 2.935616194577051e-08
NPII O 0 6.445021881518187e-06
, O 0 4.084062865672422e-09
including O 0 1.3141783217207603e-09
a O 0 4.9961070835990995e-09
cysteine O 0 1.1835131985549197e-08
residue O 0 1.1864179327858437e-07
in O 0 3.6732052954846495e-09
position O 0 1.627766010869891e-07
85 O 0 1.1298056534769785e-07
, O 0 4.6886747817609375e-09
which O 0 7.558273451557795e-10
could O 0 2.5774078427076574e-09
be O 0 7.193250994852463e-10
involved O 0 1.3155777578433003e-09
in O 0 3.9150077624228174e-10
the O 0 1.7204805358161934e-09
correct O 0 8.099854653664806e-08
folding O 0 8.927061685426452e-07
of O 0 1.3940929477485042e-07
the O 0 6.132760859145492e-07
prohormone O 0 0.0011136226821690798
. O 0 4.078638085047714e-06

In O 0 5.139957011124352e-07
the O 0 1.3738612381075654e-07
second O 0 2.358614210606902e-07
family O 0 7.0574617261343064e-09
, O 0 1.2503674762243122e-09
a O 0 3.614464727519362e-09
G279A O 0 4.094281891298124e-08
substitution O 0 1.8981584304356147e-08
at O 0 1.1129262844633558e-07
position O 0 2.0613676099401346e-07
- O 0 8.667660722494475e-08
1 O 0 7.59278435680244e-08
of O 0 1.9824122787781562e-08
the O 0 1.0909690928428972e-08
signal O 0 2.0977226711238472e-07
peptide O 0 1.7494659942940416e-08
was O 0 8.884212476800712e-09
observed O 0 1.5610303050195284e-09
in O 0 3.5966582490054577e-10
all O 0 9.454483862469942e-10
affected O 0 2.576493463024576e-09
individuals O 0 2.4149779953575035e-09
. O 0 2.595292016849271e-07

This O 0 4.5424630457091553e-07
missense O 0 7.138189630495617e-06
mutation O 0 1.682097661159787e-07
, O 0 1.721502229656835e-08
which O 0 9.536678113875041e-09
replaces O 0 2.0138199033681303e-05
Ala O 0 3.516740252962336e-05
with O 0 2.95304886321901e-07
Thr O 0 0.013436147011816502
, O 0 3.159076555903084e-08
is O 0 2.572584811844081e-09
frequent O 0 6.197993229761778e-09
among O 0 2.1009254780324227e-08
FNDI B-Disease 1 1.0
patients O 0 1.034540036926046e-05
and O 0 9.040488180289685e-08
is O 0 2.1948663331272655e-08
thought O 0 8.696073194869314e-09
to O 0 3.6580247164685886e-10
reduce O 0 1.1397463417495146e-08
the O 0 7.016230707534987e-09
efficiency O 0 1.1559443180431117e-07
of O 0 2.190792436351785e-08
cleavage O 0 2.646393326699581e-08
by O 0 1.7038225275101126e-09
signal O 0 1.1487837809909252e-06
peptidases O 0 3.150519205519231e-06
. O 0 3.853197583225665e-08
. O 0 4.574974070692406e-07

Genetic O 0 3.6574188015947584e-06
heterogeneity O 0 1.3629785826196894e-05
of O 0 2.8905154977110215e-05
Saethre B-Disease 1 0.9999810457229614
- I-Disease 1 0.9999955892562866
Chotzen I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999994039535522
, O 0 5.248405798852218e-08
due O 0 6.757883852515079e-07
to O 0 2.669225551699128e-08
TWIST O 0 1.653303115745075e-05
and O 0 1.8143893498745456e-07
FGFR O 0 0.03846398741006851
mutations O 0 1.3294466043589637e-06
. O 0 1.313409370595764e-06

Thirty O 0 0.0002868286392185837
- O 0 5.323698132997379e-05
two O 0 6.727732682065835e-08
unrelated O 0 1.2673816627284396e-06
patients O 0 3.2731599652890964e-09
with O 0 2.1989159104673917e-10
features O 0 4.514615881134887e-08
of O 0 1.423480398443644e-06
Saethre B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999992847442627
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.7153481241271038e-08
a O 0 5.6517205138106874e-08
common O 0 2.9094176170474384e-06
autosomal B-Disease 0 0.0015195119194686413
dominant I-Disease 0 0.08861921727657318
condition I-Disease 1 0.6185818314552307
of O 1 0.9471792578697205
craniosynostosis B-Disease 1 0.9999998807907104
and O 0 0.00108206772711128
limb B-Disease 1 0.9999548196792603
anomalies I-Disease 1 0.9998422861099243
, O 0 2.465113482230663e-07
were O 0 3.994856356825949e-08
screened O 0 4.0491919151008915e-08
for O 0 2.8458109202489368e-09
mutations O 0 7.327494166986526e-09
in O 0 5.487160059658436e-09
TWIST O 0 1.476933789490431e-06
, O 0 2.0520774413057552e-08
FGFR2 O 0 2.4879145712475292e-05
, O 0 2.396944509541754e-08
and O 0 6.12361361618241e-08
FGFR3 O 0 0.006497777532786131
. O 0 3.836777977994643e-06

Nine O 0 2.219806219727616e-06
novel O 0 2.810462547131465e-07
and O 0 8.624977176907578e-09
three O 0 1.3237362317397583e-08
recurrent O 0 1.1203811709492584e-06
TWIST O 0 3.5856453450833214e-06
mutations O 0 7.028486237459219e-09
were O 0 3.4135272386492943e-09
found O 0 1.5015947374408256e-09
in O 0 1.247789649383435e-09
12 O 0 5.804670877296303e-08
families O 0 4.819679322309867e-09
. O 0 2.6617681214702316e-07

Seven O 0 1.2711608405879815e-06
families O 0 6.354954340537233e-09
were O 0 1.5800708297319943e-08
found O 0 2.590601511087698e-09
to O 0 2.7880212027930895e-10
have O 0 2.105496471616064e-10
the O 0 1.6849555084519352e-09
FGFR3 O 0 1.7203064999193884e-06
P250R O 0 2.6735666125432545e-08
mutation O 0 2.691071254723454e-10
, O 0 1.0632512231767421e-10
and O 0 6.167821114955174e-11
one O 0 1.2695849926913638e-10
individual O 0 1.3219560168753475e-10
was O 0 4.44788810227692e-08
found O 0 5.370209277266724e-10
to O 0 1.0768910763125916e-10
have O 0 1.0314075982176263e-10
an O 0 3.6809955084038393e-10
FGFR2 O 0 3.820890469796723e-06
VV269 O 0 1.3862896821592585e-06
- O 0 4.328352076754527e-07
270 O 0 2.270927978997861e-07
deletion O 0 2.9156894925108645e-06
. O 0 1.0127578207175247e-06

To O 0 1.0367917013809347e-07
date O 0 6.939241075087921e-07
, O 0 1.0036398379043021e-08
our O 0 3.8249603484530326e-09
detection O 0 3.8732768103955095e-08
rate O 0 6.12681327893938e-09
for O 0 8.128587247746566e-10
TWIST O 0 9.51447916008874e-08
or O 0 6.666136975752579e-09
FGFR O 0 3.657195520645473e-06
mutations O 0 4.209174342406641e-09
is O 0 1.0673765205027053e-09
68 O 0 2.0868952788077877e-08
% O 0 4.897343419685285e-09
in O 0 2.477539284839736e-09
our O 0 5.4482221401030984e-08
Saethre B-Disease 1 0.8389288187026978
- I-Disease 1 0.9984384179115295
Chotzen I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.9999983310699463
patients O 0 1.7180441602704377e-07
, O 0 2.258567555202262e-09
including O 0 3.543466187139188e-09
our O 0 6.243415384687978e-08
five O 0 1.4378278478943685e-07
patients O 0 7.755515696317161e-08
elsewhere O 0 2.689647438103293e-08
reported O 0 5.405748737530303e-09
with O 0 5.088838683775521e-09
TWIST O 0 1.2634194717975333e-05
mutations O 0 2.743159939200268e-07
. O 0 4.019433106350334e-07

More O 0 1.613603757277815e-07
than O 0 1.6546781722581727e-08
35 O 0 4.735592540328071e-08
different O 0 5.20432230644019e-09
TWIST O 0 3.238130830141017e-07
mutations O 0 2.1991644061358784e-09
are O 0 1.5768206185207134e-10
now O 0 1.164795038199884e-09
known O 0 8.569172038619399e-10
in O 0 6.139759811674139e-10
the O 0 3.824289329656949e-09
literature O 0 6.817067088604745e-08
. O 0 6.890245884960677e-08

The O 0 6.559530447702855e-07
most O 0 1.0165343233836666e-08
common O 0 5.729058560888234e-09
phenotypic O 0 1.7513750094622083e-07
features O 0 3.909415013936268e-08
, O 0 2.0815948964525433e-09
present O 0 3.71829789180822e-09
in O 0 1.6213056452940577e-09
more O 0 1.4807351178536265e-10
than O 0 1.1435383195923521e-10
a O 0 8.110482840884004e-10
third O 0 4.1914929305164605e-09
of O 0 3.662908554247224e-08
our O 0 2.0198083205968942e-08
patients O 0 5.710686590276737e-09
with O 0 7.369060917028492e-10
TWIST O 0 1.159645989901037e-06
mutations O 0 4.5894537059609775e-09
, O 0 1.482923561724192e-09
are O 0 4.5003056836634414e-10
coronal B-Disease 0 4.997796736461169e-07
synostosis I-Disease 0 1.5579576029267628e-06
, O 0 1.8917031496812342e-08
brachycephaly B-Disease 0 2.4914975256251637e-06
, O 0 3.187608399457531e-08
low B-Disease 0 5.6883498473325744e-05
frontal I-Disease 1 0.9999345541000366
hairline I-Disease 1 0.9999998807907104
, O 0 1.7923150153364986e-05
facial B-Disease 1 0.9999843835830688
asymmetry I-Disease 1 0.9999802112579346
, O 0 6.732162091793725e-06
ptosis B-Disease 0 0.03673219308257103
, O 0 6.610813443330699e-07
hypertelorism B-Disease 0 0.006977780722081661
, O 0 1.3828589828790427e-07
broad B-Disease 0 6.855121227999916e-06
great I-Disease 0 0.00020337500609457493
toes I-Disease 0 0.0006453761016018689
, O 0 3.6109174317289217e-08
and O 0 5.62949331595064e-08
clinodactyly B-Disease 0 0.0002067733003059402
. O 0 3.151372766296845e-06

Significant O 0 2.9733830615441548e-06
intra O 0 0.0001860816264525056
- O 0 1.274113128602039e-05
and O 0 2.3540920324194303e-08
interfamilial O 0 3.740454303624574e-06
phenotypic O 0 2.7809423954749946e-06
variability O 0 2.9598199944302905e-06
is O 0 9.512221010865574e-10
present O 0 7.853726002871042e-10
for O 0 3.2299709573635482e-09
either O 0 1.2534118809526262e-07
TWIST O 0 4.4321550376480445e-06
mutations O 0 3.4759388256588863e-08
or O 0 7.896196052570303e-08
FGFR O 0 0.00011264528438914567
mutations O 0 5.309239554662781e-07
. O 0 4.4434708001972467e-07

The O 0 3.699610147123167e-07
overlap O 0 8.682873726684193e-07
in O 0 3.258200109712561e-08
clinical O 0 6.249377975109383e-07
features O 0 5.819892123781756e-08
and O 0 4.768527794851707e-09
the O 0 9.060232564195303e-09
presence O 0 2.1401000083187682e-08
, O 0 1.597073917558589e-09
in O 0 6.400446284082761e-10
the O 0 3.048830632401689e-10
same O 0 3.1175914627645795e-10
genes O 0 2.2631028995245828e-10
, O 0 1.0372135789138426e-10
of O 0 8.31584578975253e-10
mutations O 0 2.8086286074646694e-10
for O 0 8.925599703779596e-10
more O 0 5.638836619858978e-10
than O 0 5.080253440148397e-10
one O 0 1.2106223801211513e-09
craniosynostotic B-Disease 0 2.7307666528031405e-07
condition I-Disease 0 1.567996577023223e-07
- O 0 2.2287670375931157e-08
such O 0 1.6374878120117842e-09
as O 0 1.4660447078540528e-08
Saethre B-Disease 0 3.751872327484307e-06
- I-Disease 0 5.185153781894769e-07
Chotzen I-Disease 0 2.447271754135727e-06
, I-Disease 0 1.904039770295185e-08
Crouzon I-Disease 0 5.159216016181745e-06
, I-Disease 0 3.3208152672159486e-08
and I-Disease 0 2.35348878163677e-07
Pfeiffer I-Disease 1 0.98511803150177
syndromes I-Disease 0 0.002545310650020838
- O 0 1.7693391782813706e-06
support O 0 3.2560134144432595e-08
the O 0 1.0634474278958805e-07
hypothesis O 0 2.3344940203173792e-08
that O 0 5.460554786118621e-10
TWIST O 0 1.2832127538331406e-07
and O 0 3.3477083327682067e-09
FGFRs O 0 4.512764917308232e-07
are O 0 1.8921127165061336e-10
components O 0 1.989909392818845e-08
of O 0 3.289771122183538e-09
the O 0 1.4025959282903955e-09
same O 0 1.6927896862029002e-09
molecular O 0 3.398528747311502e-08
pathway O 0 4.329158365123931e-09
involved O 0 1.2446140784660997e-09
in O 0 4.939150755056687e-10
the O 0 1.0140047690399001e-09
modulation O 0 1.0411846460556262e-06
of O 0 3.800843387580244e-06
craniofacial O 1 0.9999997615814209
and O 0 0.001648415345698595
limb O 1 0.999916672706604
development O 0 0.0019966994877904654
in O 0 2.6481764052732615e-06
humans O 0 1.2478757298595156e-06
. O 0 3.737975262652071e-08
. O 0 4.434754146132036e-07

Mutation O 0 1.7133220353571232e-07
analysis O 0 8.242503213296004e-08
of O 0 3.395244618786819e-07
UBE3A O 1 0.9997387528419495
in O 1 0.7344280481338501
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9363828301429749
. O 0 3.9552342059323564e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.4060291647911072
AS B-Disease 1 1.0
) O 0 1.963810376537367e-07
is O 0 1.745892674875904e-08
caused O 0 5.010175030406572e-08
by O 0 4.03893096745378e-09
chromosome O 0 1.6743287005738239e-06
15q11 O 0 4.111085672775516e-06
- O 0 3.715712466600962e-07
q13 O 0 3.9430173615073727e-07
deletions O 0 5.495751409512195e-08
of O 0 1.7587336031965606e-08
maternal O 0 4.0314983351663614e-08
origin O 0 1.0944371631183003e-08
, O 0 2.718093083942108e-09
by O 0 3.80811604472342e-09
paternal O 0 9.944772500602994e-06
uniparental B-Disease 1 0.9038362503051758
disomy I-Disease 1 0.9878491759300232
( O 0 1.6190144378924742e-05
UPD B-Disease 1 0.9999904632568359
) O 0 8.363748804640636e-08
15 O 0 6.974298116801947e-08
, O 0 2.5991688801241253e-09
by O 0 3.2159550578114704e-09
imprinting O 0 0.0004506148397922516
defects O 1 0.9410538077354431
, O 0 5.655257240277933e-08
and O 0 7.354770570344726e-09
by O 0 3.1340126049883565e-09
mutations O 0 6.505101879383801e-08
in O 0 1.7942289431971403e-08
the O 0 4.0287429214913573e-07
UBE3A O 0 0.0012769140303134918
gene O 0 5.399565907282522e-06
. O 0 4.0484615055902395e-06

UBE3A O 0 0.0006061545573174953
encodes O 0 2.063304236799013e-06
a O 0 1.324379695688549e-06
ubiquitin O 0 6.271298389037838e-06
- O 0 3.2105961054185173e-06
protein O 0 2.980387421303021e-07
ligase O 0 1.530114701608909e-07
and O 0 7.577836136363203e-09
shows O 0 2.518059716294374e-07
brain O 0 0.00015513050311710685
- O 0 4.250791505455709e-07
specific O 0 6.05004402132181e-08
imprinting O 0 1.6476024029543623e-05
. O 0 2.8993852083658567e-06

Here O 0 3.2518789794266922e-06
we O 0 1.8269845725171763e-07
describe O 0 1.4532209888784564e-06
UBE3A O 0 9.912333189276978e-05
coding O 0 6.117844895925373e-05
- O 0 4.0709514905756805e-06
region O 0 9.528390876312187e-08
mutations O 0 7.727870787732627e-09
detected O 0 2.505999141533266e-08
by O 0 4.2695652568980336e-10
SSCP O 0 1.3497513009497197e-06
analysis O 0 1.553468997883556e-08
in O 0 4.1288323870958266e-09
13 O 0 9.094742381421383e-08
AS B-Disease 0 0.2090078890323639
individuals O 0 4.005940912321648e-09
or O 0 1.10260067742729e-07
families O 0 1.158357321173753e-08
. O 0 3.411733473512868e-07

Two O 0 3.20686410759663e-07
identical O 0 9.146022534878284e-07
de O 0 8.145112587953918e-06
novo O 0 5.62677860216354e-06
5 O 0 2.2013139187038178e-06
- O 0 6.923627893229423e-07
bp O 0 3.0057685762585606e-07
duplications O 0 4.293562483326241e-07
in O 0 1.9057148747947394e-08
exon O 0 2.2814915610069875e-06
16 O 0 1.7073244862331194e-07
were O 0 6.128007612460351e-08
found O 0 1.0275152817484923e-07
. O 0 2.952412216927769e-07

Among O 0 1.2801325510736206e-07
the O 0 4.954544863267074e-08
other O 0 2.6504936023741266e-09
11 O 0 6.40137720608891e-09
unique O 0 1.826589435260928e-09
mutations O 0 2.0217885143836156e-09
, O 0 1.7161184695524412e-09
8 O 0 1.5550520870988294e-08
were O 0 6.0112212985075075e-09
small O 0 2.1062687149964177e-09
deletions O 0 9.770023901012337e-09
or O 0 1.1902661078977417e-08
insertions O 0 1.8411311941690656e-07
predicted O 0 2.289778251451935e-07
to O 0 8.132809981020728e-09
cause O 0 3.1804032118998293e-07
frameshifts O 0 9.344767931906972e-06
, O 0 2.1931505500560888e-08
1 O 0 1.3508314111732034e-07
was O 0 4.0803740830597235e-08
a O 0 1.6322866391860202e-09
mutation O 0 2.4693244671247783e-10
to O 0 3.2077260292417975e-10
a O 0 5.326693308660424e-09
stop O 0 7.233332599554387e-09
codon O 0 7.617615871424732e-09
, O 0 4.8815729236650895e-09
1 O 0 4.939815312354767e-08
was O 0 3.598308495611491e-08
a O 0 8.941433371489893e-09
missense O 0 4.192014912973718e-08
mutation O 0 1.4267230730169445e-09
, O 0 1.1493839213727597e-09
and O 0 4.145553678114311e-09
1 O 0 4.872064778282947e-07
was O 0 5.476795195136219e-07
predicted O 0 5.6680217852544956e-08
to O 0 7.740878493756043e-10
cause O 0 4.953890186953913e-09
insertion O 0 2.8267159279948828e-08
of O 0 6.81587124518046e-08
an O 0 8.997237621599652e-09
isoleucine O 0 3.01171644423448e-06
in O 0 2.2754278461434296e-08
the O 0 3.138883641895518e-08
hect O 0 6.585053142771358e-07
domain O 0 3.615149068991741e-08
of O 0 4.3602611299320415e-08
the O 0 1.6515825507212867e-07
UBE3A O 0 5.207000867812894e-05
protein O 0 1.7910836902501615e-07
, O 0 1.8996786366187735e-09
which O 0 1.898474988326626e-10
functions O 0 2.7973030114480935e-08
in O 0 1.9353709745928427e-08
E2 O 0 2.5709878173074685e-06
binding O 0 3.3646863073499844e-08
and O 0 1.8835592641153198e-08
ubiquitin O 0 1.525507514088531e-06
transfer O 0 5.2787831918976735e-06
. O 0 1.8442045757183223e-06

Eight O 0 5.840441872351221e-07
of O 0 8.090991343578935e-08
the O 0 1.102612756653798e-08
cases O 0 6.9151395720723485e-09
were O 0 6.138111796616386e-09
familial O 0 8.052394662172446e-08
, O 0 4.826781196953789e-09
and O 0 4.383465590507285e-09
five O 0 1.7064643031972082e-08
were O 0 4.636527961565662e-08
sporadic O 0 2.1130676941538695e-06
. O 0 3.073830896482832e-07

In O 0 9.824046856010682e-07
two O 0 5.676059444681414e-08
familial O 0 4.296447968954453e-06
cases O 0 1.0874668987526093e-07
and O 0 8.834128095713822e-09
one O 0 3.858962038805203e-09
sporadic O 0 8.563540063732944e-07
case O 0 6.440324540335496e-08
, O 0 5.311910911132145e-09
mosaicism O 0 3.986821866419632e-06
for O 0 2.7406041880340126e-08
UBE3A O 0 8.129032357828692e-05
mutations O 0 4.806214448649371e-08
was O 0 1.2488622758155543e-07
detected O 0 7.473444441075117e-08
in O 0 1.7538219765356189e-09
the O 0 5.349694021106188e-09
mother O 0 1.9944044638009473e-08
of O 0 7.576510085982591e-08
three O 0 1.3693927769509173e-07
AS B-Disease 1 0.9999998807907104
sons O 0 8.251126018876676e-06
, O 0 4.290408917029254e-09
in O 0 2.334020976491047e-09
the O 0 1.119527937021303e-08
maternal O 0 7.425029480145895e-07
grandfather O 0 1.2299958598305238e-06
of O 0 3.8523236867149535e-07
two O 0 9.296239511513704e-08
AS B-Disease 1 0.9999911785125732
first O 0 2.845449671440292e-07
cousins O 0 1.8960872694151476e-07
, O 0 3.0495475034086894e-09
and O 0 1.8575175841917257e-09
in O 0 6.276162700658006e-09
the O 0 2.215724848042555e-08
mother O 0 1.933610960236365e-08
of O 0 8.342224333546255e-08
an O 0 3.491986788617396e-08
AS B-Disease 1 0.9999998807907104
daughter O 0 0.0012061690213158727
. O 0 6.212409061845392e-06

The O 0 1.9001964801645954e-07
frequencies O 0 1.9329920064592443e-07
with O 0 1.5338739167702897e-09
which O 0 2.9378818822145547e-10
we O 0 3.6357034050027437e-10
detected O 0 3.932386860583392e-09
mutations O 0 2.5279409121559127e-10
were O 0 2.9477338348016247e-09
5 O 0 6.3746941059150686e-09
( O 0 7.618861097569152e-10
14 O 0 9.756337071564758e-09
% O 0 1.5502004124812174e-09
) O 0 5.301260541656916e-10
of O 0 9.425932034901052e-09
35 O 0 3.7483701476048736e-08
in O 0 2.1561352703258763e-09
sporadic O 0 4.620954285883272e-08
cases O 0 9.191748473469374e-10
and O 0 1.0629901403547137e-09
8 O 0 4.723757029978515e-08
( O 0 1.424368401004017e-09
80 O 0 5.623909782315195e-09
% O 0 1.3330010428802552e-09
) O 0 5.270449632277519e-10
of O 0 8.948702223676719e-09
10 O 0 2.124231457401038e-08
in O 0 4.684009180522253e-09
familial O 0 2.406638941465644e-07
cases O 0 4.117682550486279e-08
. O 0 1.5826165267185388e-08
. O 0 1.5551816545666952e-07

The O 0 0.00013336226402316242
hemochromatosis B-Disease 1 0.9999995231628418
845 O 0 4.5415014028549194e-05
G O 0 4.6037086576689035e-05
- O 0 2.5728027139848564e-06
- O 0 3.13592209977287e-07
> O 0 2.9415740954163994e-08
A O 0 1.040216002223815e-08
and O 0 1.1827949730758291e-09
187 O 0 4.226825556230551e-09
C O 0 1.0727059134296724e-06
- O 0 1.6094097077257175e-07
- O 0 8.395090844715014e-08
> O 0 4.1182325105637574e-08
G O 0 9.345877316491169e-08
mutations O 0 1.2129799387139428e-09
: O 0 3.674807957931847e-10
prevalence O 0 1.0395892147130326e-08
in O 0 1.37365296914993e-09
non O 0 7.136598014767515e-07
- O 0 1.7133659184764838e-06
Caucasian O 0 8.792625294518075e-07
populations O 0 5.024932292485573e-08
. O 0 1.9395103834085603e-07

Hemochromatosis B-Disease 1 0.9999980926513672
, O 0 6.160884822747903e-06
the O 0 0.0002325276000192389
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999998807907104
, O 0 2.410438582955976e-06
leads O 0 4.4942853492102586e-06
, O 0 1.0615525525281555e-07
if O 0 8.314788715324539e-07
untreated O 1 0.9992096424102783
, O 0 1.6466465524445084e-08
to O 0 5.991957863216157e-08
progressive O 1 0.9999985694885254
iron B-Disease 1 1.0
overload I-Disease 1 0.9999998807907104
and O 0 0.0009899078868329525
premature B-Disease 0 0.0008102433639578521
death I-Disease 0 8.670967872603796e-06
. O 0 2.1541177375183906e-06

The O 0 0.0008119703852571547
hemochromatosis B-Disease 1 1.0
gene O 0 3.1301748094847426e-05
, O 0 8.735090091249731e-07
HFE O 0 0.059401318430900574
, O 0 4.3225352897025004e-07
recently O 0 3.741692182757106e-07
has O 0 1.775842806139849e-09
been O 0 7.828390713449096e-10
identified O 0 8.706689813564594e-10
, O 0 2.0055947180797062e-10
and O 0 1.7408796626483536e-10
characterization O 0 2.3304322027684066e-08
of O 0 1.9708981113808477e-08
this O 0 7.882179353657648e-10
gene O 0 5.546506809395169e-09
has O 0 1.1845017189315854e-09
shown O 0 4.038944456663529e-10
that O 0 1.2861285821064161e-11
it O 0 8.32561363600659e-12
contains O 0 3.424263997353627e-11
two O 0 2.3958347458719054e-11
mutations O 0 4.828470609452573e-11
that O 0 1.0967068399259094e-11
result O 0 1.4385320712406724e-10
in O 0 1.7445327127330046e-10
amino O 0 9.363640973703014e-10
acid O 0 4.921718144146325e-09
substitutions O 0 1.937221227876762e-08
- O 0 1.502303170752839e-08
cDNA O 0 1.9199472234276982e-08
nucleotides O 0 3.3126970055974425e-09
845 O 0 5.6679780868762464e-08
G O 0 1.9546456542229862e-07
- O 0 8.00846677861955e-08
- O 0 4.424999033858512e-08
> O 0 3.8772903110384505e-08
A O 0 3.629880040989519e-08
( O 0 8.692984110325597e-10
C282Y O 0 1.086500223124176e-08
) O 0 1.7570017663004478e-10
and O 0 3.993481101360885e-10
187 O 0 2.2051287462687696e-09
C O 0 3.379205963938148e-07
- O 0 9.844176673823313e-08
- O 0 1.7024891008077248e-07
> O 0 3.072321987929172e-07
G O 0 3.5545808714232408e-06
( O 0 4.394786401462625e-08
H63D O 0 2.934375879704021e-05
) O 0 1.455323257459895e-07
. O 0 6.158261385280639e-07

Although O 0 0.0002827216812875122
hemochromatosis B-Disease 1 1.0
is O 0 1.587257401070019e-07
common O 0 6.84535450545809e-08
in O 0 2.334008719628855e-08
Caucasians O 0 1.502795186070216e-07
, O 0 4.013588572604476e-09
affecting O 0 1.6248943524033166e-08
> O 0 5.599904184805382e-08
= O 0 1.1605028049643806e-07
1 O 0 2.5157024197142164e-07
/ O 0 4.732784120164979e-08
300 O 0 2.3643369484460663e-09
individuals O 0 9.014802099249764e-11
of O 0 2.277289246066516e-09
northern O 0 1.6467965879840563e-09
European O 0 3.2443077113697427e-09
origin O 0 5.066901564987347e-09
, O 0 2.9347452246142325e-10
it O 0 3.822885064064252e-11
has O 0 2.85713154524192e-11
not O 0 2.198935825092896e-11
been O 0 4.296153016669635e-11
recognized O 0 5.93579074781303e-11
in O 0 1.2395105775109272e-10
other O 0 3.754198063532499e-10
populations O 0 2.0418318147363834e-09
. O 0 6.867730917292647e-08

The O 0 2.5045258666978043e-07
present O 0 7.859023298806278e-08
study O 0 1.427807205800491e-08
used O 0 3.699339279350511e-09
PCR O 0 1.8566257864449653e-08
and O 0 1.6437902150556738e-09
restriction O 0 1.1865713744896311e-08
- O 0 1.462667853502353e-08
enzyme O 0 1.7555722431339404e-09
digestion O 0 7.97238808303291e-09
to O 0 3.145293192563514e-10
analyze O 0 1.3246858721061017e-08
the O 0 1.7368111393523122e-09
frequency O 0 3.466589859613123e-08
of O 0 8.98139607130588e-09
the O 0 9.347870921772028e-09
845 O 0 1.0485248935765412e-07
G O 0 4.963980018146685e-07
- O 0 1.252035559673459e-07
- O 0 4.9866176965451814e-08
> O 0 1.402992655386015e-08
A O 0 1.62716453644407e-08
and O 0 1.3441711077533114e-09
187 O 0 3.6762122235245442e-09
C O 0 5.004955596632499e-07
- O 0 8.656690653197074e-08
- O 0 6.226932214303815e-08
> O 0 2.4889883931678014e-08
G O 0 8.787145588939893e-08
mutations O 0 2.790060182888965e-09
in O 0 2.454777492388871e-09
HLA O 0 9.668274714158542e-08
- O 0 2.2799893528713255e-08
typed O 0 6.25941432019772e-09
samples O 0 1.3249201735732186e-09
from O 0 1.1508032304874405e-09
non O 0 8.470977519436929e-08
- O 0 1.886965037556365e-07
Caucasian O 0 1.1860706194966042e-07
populations O 0 9.97300131366785e-10
, O 0 2.064508564103562e-10
comprising O 0 6.126669727102296e-10
Australian O 0 1.4034155171316343e-08
Aboriginal O 0 2.141169908043139e-08
, O 0 9.764113961807652e-10
Chinese O 0 9.359645503081993e-09
, O 0 3.1783424780940095e-09
and O 0 1.062447463340277e-08
Pacific O 0 3.564962298696628e-06
Islanders O 0 1.3099969692120794e-05
. O 0 6.434332817661925e-07

Results O 0 4.131238142690563e-07
showed O 0 1.970904435211196e-07
that O 0 1.3092745776432935e-09
the O 0 8.315500288347266e-09
845 O 0 1.2201697074942786e-07
G O 0 2.0280210719647584e-06
- O 0 5.474763611346134e-07
- O 0 9.898608510638951e-08
> O 0 2.3318817099493572e-08
A O 0 5.6184736862974205e-09
mutation O 0 3.5503919249002536e-10
was O 0 2.9848881144545203e-09
present O 0 1.7386166117905333e-10
in O 0 5.316344933725681e-11
these O 0 2.309186175608602e-11
populations O 0 3.494106740054015e-11
( O 0 2.5425380550947452e-11
allele O 0 1.2961695605717694e-10
frequency O 0 5.249203738344477e-09
0 O 0 1.7320407330601029e-09
. O 0 1.761273071831937e-10
32 O 0 3.080049992831846e-09
% O 0 8.281213492722372e-10
) O 0 5.559531723875466e-10
, O 0 9.88627957276833e-10
and O 0 1.913949887466515e-09
, O 0 1.6656112045154714e-09
furthermore O 0 1.0876137324089541e-08
, O 0 7.556917869244728e-10
it O 0 1.848207836774307e-10
was O 0 1.9998974920554247e-08
always O 0 2.685412114900032e-09
seen O 0 1.4242977908196508e-09
in O 0 1.2338330357408722e-10
conjunction O 0 1.6214601883390856e-09
with O 0 2.5345854304248405e-09
HLA O 0 3.0228638934204355e-06
haplotypes O 0 8.23183370357583e-07
common O 0 8.758699721056473e-08
in O 0 2.0039259140958166e-08
Caucasians O 0 8.734975409652179e-08
, O 0 1.783065362026548e-09
suggesting O 0 7.643055077721783e-09
that O 0 8.917890870208112e-10
845 O 0 4.489944060992457e-08
G O 0 2.492624162186985e-06
- O 0 1.7027452940965304e-06
- O 0 2.0605473309842637e-06
> O 0 7.150543410716637e-07
A O 0 2.517223833820026e-07
may O 0 7.890215591999095e-09
have O 0 1.889948475497505e-10
been O 0 1.335025701099113e-10
introduced O 0 1.0078148732217684e-10
into O 0 2.9682391960994536e-11
these O 0 2.636095768754343e-12
populations O 0 3.1975032430825445e-12
by O 0 6.125638191134541e-11
Caucasian O 0 4.7544716608172166e-08
admixture O 0 1.969359345821431e-06
. O 0 1.1776729706980404e-06

187 O 0 4.312387773097726e-06
C O 0 3.381140049896203e-05
- O 0 3.5059063066000817e-06
- O 0 5.968951199974981e-07
> O 0 1.5408190279231349e-07
G O 0 2.0667592082190822e-07
was O 0 1.671716454154648e-08
present O 0 4.76868933230179e-10
at O 0 4.3555461459732214e-09
an O 0 4.3306407071508346e-11
allele O 0 3.74059644370206e-10
frequency O 0 5.58549224649596e-08
of O 0 5.959213922324125e-08
2 O 0 2.2051694941183086e-06
. O 0 5.63160824640363e-07

68 O 0 1.3284847227623686e-05
% O 0 2.827525804605102e-07
in O 0 2.3654703085185247e-08
the O 0 1.0850464526868109e-08
two O 0 2.0423147617520954e-09
populations O 0 2.83728956995688e-10
analyzed O 0 2.9235061038690446e-09
( O 0 4.5750739308125787e-10
Australian O 0 9.15780429266988e-09
Aboriginal O 0 1.7043305433617206e-08
and O 0 2.2953734468700304e-09
Chinese O 0 7.686859504474342e-08
) O 0 3.4971389339943926e-08
. O 0 2.987219716032996e-07

In O 0 1.272873362268001e-07
the O 0 1.517372893999891e-08
Australian O 0 2.8883292202408484e-08
Aboriginal O 0 8.97923690956759e-09
samples O 0 2.1165380559295954e-09
, O 0 4.577404566497023e-10
187 O 0 3.318698649223961e-09
C O 0 9.192070251629048e-07
- O 0 2.2773085106564395e-07
- O 0 1.7293702114784537e-07
> O 0 7.59336415967482e-08
G O 0 9.343023066321621e-07
was O 0 1.2403660321069765e-07
found O 0 1.329263810134762e-09
to O 0 1.8769798215689804e-10
be O 0 4.919913365597495e-10
associated O 0 9.515820131866803e-09
with O 0 6.052870205053296e-09
HLA O 0 5.023657649871893e-05
haplotypes O 0 1.6669584965711692e-06
common O 0 7.462419659987063e-08
in O 0 2.3946597593749175e-08
Caucasians O 0 2.4911358309509524e-07
, O 0 2.8250219941128307e-09
suggesting O 0 5.9090026205410595e-09
that O 0 9.409611978483667e-11
it O 0 6.735799418233768e-11
was O 0 1.0685377027641607e-09
introduced O 0 5.041103090519528e-10
by O 0 1.1044934411508223e-10
recent O 0 3.3230185270127777e-09
admixture O 0 6.773685754524195e-07
. O 0 8.112383511615917e-07

In O 0 2.3579258368044975e-07
the O 0 3.051573926882156e-08
Chinese O 0 1.4758474442544411e-08
samples O 0 1.0980287790118837e-09
analyzed O 0 2.938746357372679e-09
, O 0 4.397314179449552e-10
187 O 0 3.568908724105313e-09
C O 0 4.592065181441285e-07
- O 0 2.1135282679551892e-07
- O 0 1.7043799971361295e-07
> O 0 8.766454584474559e-08
G O 0 8.60555587678391e-07
was O 0 1.375465927822006e-07
present O 0 1.702608543041606e-08
in O 0 1.929363335761991e-08
association O 0 4.951518750573314e-09
with O 0 1.1826009060911247e-09
a O 0 1.284211226248999e-08
wide O 0 2.0604666417511908e-08
variety O 0 2.4083369964955637e-08
of O 0 1.4447238072534674e-07
HLA O 0 5.811200480820844e-06
haplotypes O 0 1.1890190307894954e-06
, O 0 1.1481378514588414e-08
showing O 0 2.370406804175218e-08
this O 0 1.358656381844625e-10
mutation O 0 2.204984667075749e-10
to O 0 1.0449797277489736e-10
be O 0 3.0542496309848843e-10
widespread O 0 9.100061260092218e-10
and O 0 9.740453998929866e-10
likely O 0 1.657036619029384e-09
to O 0 3.993587682771249e-10
predate O 0 6.327429247221517e-08
the O 0 2.374473728750104e-09
more O 0 3.5901193129461717e-10
genetically O 0 5.01186203649695e-10
restricted O 0 5.457264640185144e-10
845 O 0 1.1627933282909453e-08
G O 0 1.0029845043391106e-06
- O 0 7.617051096531213e-07
- O 0 6.49772402994131e-07
> O 0 4.4719877223542426e-07
A O 0 3.1752088602843287e-07
mutation O 0 1.0012998075126234e-07
. O 0 1.7822986819737707e-07

Genotype O 0 7.136659405659884e-05
- O 0 1.8755859855446033e-05
phenotype O 0 9.301824093199684e-07
correlations O 0 2.380409750912804e-05
in O 0 6.139687229733681e-06
attenuated B-Disease 1 0.9960363507270813
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.9999891519546509
. O 0 8.73899189173244e-05

Germ O 1 0.9999868869781494
- O 0 0.00042383422260172665
line O 0 1.578699198034883e-06
mutations O 0 1.6586501061510717e-08
of O 0 2.188929570934306e-08
the O 0 3.502759682305623e-08
tumor B-Disease 0 2.5369687136844732e-05
suppressor O 0 5.279206106933998e-06
APC O 0 3.7452551282513014e-07
are O 0 3.5094187555984035e-09
implicated O 0 7.087201652211661e-07
in O 0 5.126435667079932e-07
attenuated B-Disease 1 0.9999550580978394
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.0014943293062970042
AAPC B-Disease 1 0.9999998807907104
) O 0 3.054858410678207e-08
, O 0 9.755960483914805e-10
a O 0 1.5746005610495217e-09
variant O 0 4.7391435487043054e-07
of O 0 0.00028955398011021316
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0005513557116501033
FAP B-Disease 0 6.529175880132243e-05
) O 0 2.1721082248404855e-06
. O 0 5.17991293236264e-06

AAPC B-Disease 1 0.9999855756759644
is O 0 3.7882830383750843e-07
recognized O 0 1.9752109281512276e-08
by O 0 5.185632478976743e-10
the O 0 2.4952901966912577e-09
occurrence O 0 1.499978274921432e-08
of O 0 7.305754934350261e-08
< O 0 5.374413376557641e-06
100 O 0 4.469519296890212e-07
colonic B-Disease 0 9.535779099678621e-05
adenomas I-Disease 0 1.9689801774802618e-05
and O 0 7.919329192418445e-09
a O 0 7.068481799876736e-09
later O 0 1.1095159635488017e-07
onset O 0 0.09277786314487457
of O 1 0.9998495578765869
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.1178315162396757e-06
age O 0 1.63146000886627e-06
> O 0 4.6382129426092433e-07
40 O 0 5.917125633914111e-08
years O 0 2.328579462584912e-08
) O 0 1.93716207519401e-08
. O 0 2.538840249144414e-07

The O 0 5.370183089326019e-07
aim O 0 7.059981612655974e-07
of O 0 5.764081123516007e-08
this O 0 6.348360725993984e-10
study O 0 3.1696731905839215e-09
was O 0 5.132420710651786e-09
to O 0 4.126027852713321e-10
assess O 0 6.940962293811026e-08
genotype O 0 7.248125939440797e-07
- O 0 1.018747866510239e-06
phenotype O 0 1.2020663575640356e-07
correlations O 0 5.955939741397742e-06
in O 0 1.6503998949701781e-06
AAPC B-Disease 1 0.9999995231628418
families O 0 6.144850317468808e-07
. O 0 2.1269938770274166e-06

By O 0 2.56906616868946e-07
protein O 0 7.969121043061023e-07
- O 0 5.27942006556259e-07
truncation O 0 1.5883204014244257e-06
test O 0 2.563505745456496e-07
( O 0 8.872595991249455e-09
PTT O 0 2.468583488735021e-07
) O 0 6.83163969839029e-10
assay O 0 7.293722070755848e-09
, O 0 2.929119724548457e-10
the O 0 5.64430280292072e-10
entire O 0 1.1107479380711993e-08
coding O 0 2.1528781246615836e-07
region O 0 1.5992359436722836e-08
of O 0 1.1506984698428369e-08
the O 0 1.0540086137211802e-08
APC B-Disease 0 2.9019908254213078e-08
gene O 0 4.2242866982178384e-09
was O 0 4.38251497314468e-08
screened O 0 1.623518919302569e-08
in O 0 6.620947123892051e-10
affected O 0 6.273323527317132e-10
individuals O 0 4.784632690046919e-10
from O 0 1.1741175853785535e-07
11 O 0 5.160061482456513e-05
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 0.0003319928073324263
, O 0 4.985457380257685e-08
and O 0 3.2380083059280196e-09
their O 0 2.448903968499394e-09
phenotypic O 0 2.5662893676781096e-06
differences O 0 2.768555532384198e-06
were O 0 4.907023480882344e-07
examined O 0 2.4399128051300067e-06
. O 0 5.606935928881285e-07

Five O 0 4.0093700590659864e-06
novel O 0 6.2415738284471445e-06
germ O 1 0.9733994007110596
- O 0 3.752598786377348e-05
line O 0 4.661436832975596e-06
APC B-Disease 0 6.005562340760662e-07
mutations O 0 2.3454958864022046e-08
were O 0 1.1650843845245618e-08
identified O 0 1.6792968793311047e-08
in O 0 1.8835448756249207e-08
seven O 0 5.240148652774224e-07
kindreds O 0 4.312687087804079e-05
. O 0 1.934612555487547e-06

Mutations O 0 1.8457353689882439e-06
were O 0 2.146027355820479e-07
located O 0 7.733757456662715e-08
in O 0 2.2431894119989693e-09
three O 0 3.255438696392332e-10
different O 0 1.7725189371819994e-10
regions O 0 1.878757593942737e-09
of O 0 1.5343633918973865e-08
the O 0 1.524916370954088e-08
APC B-Disease 0 4.094648886621144e-08
gene O 0 1.5185889878921444e-08
( O 0 7.676102420361985e-09
1 O 0 6.798460105983395e-08
) O 0 1.1587941717294825e-09
at O 0 3.4716851615712585e-08
the O 0 1.168217522717896e-08
5 O 0 4.416230225956497e-08
end O 0 6.248013306731082e-08
spanning O 0 4.6068430492596235e-07
exons O 0 9.211694163013817e-08
4 O 0 4.3662947035727484e-08
and O 0 2.35945352144995e-09
5 O 0 4.193126557083815e-08
, O 0 2.8071895918913015e-09
( O 0 1.5087633364885278e-09
2 O 0 2.6521588480932223e-08
) O 0 1.3952555777407838e-09
within O 0 1.718323616728412e-08
exon O 0 3.243920048134896e-07
9 O 0 9.957367552715368e-08
, O 0 5.323473661889011e-09
and O 0 4.031873057641633e-09
( O 0 4.638276873691893e-09
3 O 0 9.123566258040228e-08
) O 0 2.7143007841345934e-09
at O 0 1.383530445764336e-07
the O 0 2.1318987464269412e-08
3 O 0 2.6841902922569716e-07
distal O 0 3.732909874543111e-07
end O 0 1.858424383271995e-07
of O 0 1.2251322800693742e-07
the O 0 6.32050571880427e-08
gene O 0 2.1124722593413026e-07
. O 0 4.080841904396948e-07

Variability O 0 5.625020639854483e-05
in O 0 4.186660973459766e-08
the O 0 1.5659395558031974e-08
number O 0 4.030268030419393e-08
of O 0 0.10196138918399811
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.09764369577169418
most O 0 1.5425737132090944e-08
apparent O 0 6.727193380129393e-08
in O 0 2.0218271501448726e-09
individuals O 0 7.92568302654395e-11
with O 0 5.883785125782026e-10
mutations O 0 9.876238493689016e-09
in O 0 3.086226030291073e-08
region O 0 1.913256113539319e-07
1 O 0 2.553163767515798e-06
, O 0 9.647437515525326e-09
and O 0 4.002292186555678e-08
upper O 1 0.9999642372131348
- O 1 0.9997561573982239
gastrointestinal O 1 0.9996167421340942
manifestations O 0 0.0748215764760971
were O 0 8.594442419962434e-07
more O 0 3.0061537703574004e-09
severe O 0 2.1266055227897596e-07
in O 0 4.90713292222722e-09
them O 0 8.327912581762575e-09
. O 0 2.035347819173694e-07

In O 0 1.9131175577058457e-07
individuals O 0 1.4896250899454344e-09
with O 0 2.2822201906080863e-09
mutations O 0 1.0137209294214244e-08
in O 0 7.261629075827614e-09
either O 0 4.935002806405464e-08
region O 0 3.152708529796655e-07
2 O 0 2.466891544372629e-07
or O 0 8.244181337602186e-09
region O 0 5.869331332064576e-08
3 O 0 3.750794874690655e-08
, O 0 3.8925956902247094e-10
the O 0 5.180215145728084e-10
average O 0 1.2182059805354584e-09
number O 0 1.5931795882551114e-09
of O 0 1.2460606058084522e-07
adenomas B-Disease 0 2.721728742471896e-05
tended O 0 1.0548858142556128e-07
to O 0 4.997441127585489e-09
be O 0 7.466545604017938e-09
lower O 0 1.14089516500826e-07
than O 0 4.677453424584144e-10
those O 0 1.4791487479293153e-10
in O 0 6.48342837750171e-11
individuals O 0 8.016596067528248e-12
with O 0 1.206527794339607e-10
mutations O 0 1.3172475332723366e-09
in O 0 1.4533343417610922e-09
region O 0 3.790855629404177e-08
1 O 0 7.843523519568407e-08
, O 0 6.44444775321773e-10
although O 0 1.5289054466904872e-09
age O 0 4.169455891656071e-08
at O 0 3.8517944744853594e-07
diagnosis O 0 1.7485723446952761e-06
was O 0 2.49790161888086e-07
similar O 0 6.207448421946538e-08
. O 0 4.640588997517625e-07

In O 0 4.682140570366755e-06
all O 0 7.92041919339681e-06
AAPC B-Disease 1 0.9999986886978149
kindreds O 0 0.0001722130400594324
, O 0 1.1329972693374657e-07
a O 0 6.149152653733836e-08
predominance O 0 3.660119546111673e-06
of O 0 9.291537935496308e-06
right O 1 0.9964172840118408
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999349117279053
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9983049631118774
sparing O 0 4.39648965766537e-06
was O 0 1.7220891095348634e-06
observed O 0 6.944378583284561e-07
. O 0 3.861372306346311e-07

No O 0 0.00014029016892891377
desmoid B-Disease 1 0.9999018907546997
tumors I-Disease 1 1.0
were O 0 1.0301325801265193e-06
found O 0 3.0175005605315164e-08
in O 0 3.979469198611696e-09
these O 0 7.05226810282511e-09
kindreds O 0 7.701145477767568e-06
. O 0 3.1184754334390163e-07

Our O 0 3.5342247883818345e-07
data O 0 2.8474204327721964e-07
suggest O 0 3.967890549461117e-08
that O 0 5.983592510361291e-10
, O 0 3.1241051967612066e-09
in O 0 5.269469838253826e-08
AAPC B-Disease 1 0.9999996423721313
families O 0 2.8095357151869393e-09
, O 0 4.5239037516076053e-10
the O 0 8.829103559371276e-10
location O 0 1.1470455696382942e-08
of O 0 7.497298781800055e-09
the O 0 1.801326909856016e-08
APC B-Disease 0 6.111077937021037e-07
mutation O 0 5.008694259345248e-08
may O 0 1.783848624370421e-08
partially O 0 5.295646587910596e-08
predict O 0 3.0789941263265064e-08
specific O 0 4.666050212875916e-09
phenotypic O 0 2.5122217266471125e-06
expression O 0 9.12187658741459e-07
. O 0 1.1845676226585056e-06

This O 0 9.415388291245108e-08
should O 0 3.8474109231856346e-08
help O 0 4.6711972068180785e-09
in O 0 7.568053961293231e-10
the O 0 2.1815094175536842e-09
design O 0 6.218291304094237e-08
of O 0 2.810298305178094e-08
tailored O 0 7.667121337817662e-08
clinical O 0 1.02565070392302e-06
- O 0 2.1385987736266543e-07
management O 0 1.7870779345230403e-07
protocols O 0 1.5458158486580942e-06
in O 0 3.336597220737758e-09
this O 0 2.494318085410896e-10
subset O 0 3.137082060788998e-08
of O 0 7.781802224826606e-08
FAP B-Disease 0 6.895700721543108e-07
patients O 0 1.382808818561898e-07
. O 0 5.2171660769317896e-08
. O 0 6.746209919583634e-07

Wilms B-Disease 1 0.9998125433921814
' I-Disease 0 6.223029049579054e-05
tumor I-Disease 0 5.4064981668489054e-05
1 O 0 3.732383447641041e-06
and O 0 1.2020801420931093e-07
Dax O 1 0.9972111582756042
- O 0 2.230086693089106e-06
1 O 0 1.8674175805699633e-07
modulate O 0 8.125850570195325e-08
the O 0 1.4074633014615756e-08
orphan O 0 1.0198594679877715e-07
nuclear O 0 5.132638989380212e-07
receptor O 0 2.2304979196974273e-08
SF O 0 5.422451522463234e-06
- O 0 1.4764252398435929e-07
1 O 0 3.826728089961762e-08
in O 0 6.221109183357498e-10
sex O 0 4.043525070329679e-09
- O 0 1.0223377699958291e-09
specific O 0 1.73299166683627e-10
gene O 0 4.647344731267822e-09
expression O 0 2.8775955840387724e-08
. O 0 1.5403327324747806e-07

Products O 0 2.9455209187290166e-06
of O 0 1.0654416655597743e-06
steroidogenic O 0 3.1363844755105674e-05
factor O 0 5.711767698812764e-07
1 O 0 1.2813310377168818e-06
( O 0 4.690287269681903e-08
SF O 0 2.3393373339786194e-05
- O 0 6.258950975279731e-07
1 O 0 4.576300796088617e-07
) O 0 7.532888979255858e-09
and O 0 6.164442112321922e-08
Wilms B-Disease 1 0.996712327003479
tumor I-Disease 0 0.0016450084513053298
1 O 0 1.7269770978600718e-05
( O 0 6.698973464835944e-08
WT1 O 0 1.972641030079103e-06
) O 0 3.804035753063317e-09
genes O 0 1.2829814988180033e-09
are O 0 1.3082779304340875e-10
essential O 0 3.760442179867596e-09
for O 0 1.0574675579633208e-09
mammalian O 0 2.973696098251821e-07
gonadogenesis O 0 5.291860247780278e-07
prior O 0 5.332998753715401e-08
to O 0 5.428956395547857e-09
sexual O 0 2.8819877684327366e-07
differentiation O 0 4.688154604082229e-06
. O 0 1.7901768387673656e-06

In O 0 5.657230985889328e-07
males O 0 1.4277151194619364e-07
, O 0 2.0076565476756514e-07
SF O 0 0.0010980080114677548
- O 0 2.511368847990525e-06
1 O 0 3.970658042362629e-07
participates O 0 6.229756710496304e-09
in O 0 6.28689489357015e-10
sexual O 0 1.8940129464795064e-09
development O 0 3.0961636032778017e-10
by O 0 5.5316150965323274e-11
regulating O 0 1.8272105606342848e-08
expression O 0 2.116320008127559e-09
of O 0 6.895264803574719e-09
the O 0 1.1093801433048611e-08
polypeptide O 0 7.580628107461962e-07
hormone O 0 2.289771714458766e-07
Mullerian O 0 1.6417970982729457e-06
inhibiting O 0 2.568897059518349e-07
substance O 0 8.906209586712066e-06
( O 0 1.5755739468659158e-07
MIS O 0 6.428949563996866e-05
) O 0 2.6552572762739146e-07
. O 0 6.801955123592052e-07

Here O 0 2.9327618449315196e-06
, O 0 8.13540381727762e-08
we O 0 2.1100776237403807e-08
show O 0 6.377736383456067e-08
that O 0 9.54257384222501e-09
WT1 O 0 4.32965716754552e-05
- O 0 1.2944315130880568e-05
KTS O 0 0.0008462866535410285
isoforms O 0 9.475937190472905e-07
associate O 0 3.273994479968678e-06
and O 0 2.790311626199582e-08
synergize O 0 6.523965566884726e-06
with O 0 2.319765002312124e-07
SF O 1 0.9277300238609314
- O 0 1.0101492989633698e-05
1 O 0 4.81152540032781e-07
to O 0 4.125951136302319e-09
promote O 0 1.2838235363688e-07
MIS O 0 3.7843285099370405e-05
expression O 0 4.6429440203610284e-07
. O 0 1.004635805657017e-06

In O 0 8.100408876998699e-07
contrast O 0 1.684521407696593e-06
, O 0 3.811657336427743e-07
WT1 O 0 0.0003542899212334305
missense O 0 8.781063115748111e-06
mutations O 0 1.9137178242090158e-07
, O 0 9.344198304006568e-09
associated O 0 4.385433172160447e-08
with O 0 2.1981046316454922e-08
male B-Disease 0 0.00020279677119106054
pseudohermaphroditism I-Disease 1 1.0
in O 0 4.347746289568022e-05
Denys B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999977350234985
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.6933138858330494e-07
fail O 0 1.3270094996187254e-06
to O 0 6.3368133851327e-08
synergize O 0 3.942355397157371e-05
with O 0 1.662120098444575e-06
SF O 1 0.9999868869781494
- O 0 0.02396959625184536
1 O 0 5.801785664516501e-05
. O 0 1.296827008445689e-06

Additionally O 0 3.7375623378466116e-06
, O 0 5.748063358623767e-08
the O 0 3.2458629561915586e-08
X O 0 1.446546502847923e-05
- O 0 3.1959571060724556e-06
linked O 0 3.052765009670111e-07
, O 0 1.6079123588141897e-09
candidate O 0 2.283992550644598e-09
dosage O 0 1.2447362962575426e-07
- O 0 1.6393636670386513e-08
sensitive O 0 1.8974638749114092e-07
sex O 0 2.88659443015149e-08
- O 0 1.0109269865665738e-08
reversal O 0 1.040343011737832e-08
gene O 0 3.2271627592450614e-09
, O 0 1.0143689443964377e-08
Dax O 0 0.3586149215698242
- O 0 4.458379862626316e-06
1 O 0 1.304894567510928e-06
, O 0 1.2873135446511697e-08
antagonizes O 0 5.416102339950157e-07
synergy O 0 1.820441411837237e-06
between O 0 3.013928790096543e-06
SF O 0 0.05289565771818161
- O 0 6.277413831412559e-06
1 O 0 8.341936563738273e-07
and O 0 2.8919400207882973e-08
WT1 O 0 4.647862169804284e-06
, O 0 3.4566978168726337e-09
most O 0 1.0546414852541375e-09
likely O 0 1.696564999598138e-09
through O 0 3.5630576267209335e-10
a O 0 9.945437806635482e-10
direct O 0 8.731019796037742e-10
interaction O 0 1.2857700681934148e-08
with O 0 4.427920075045222e-08
SF O 0 0.17552727460861206
- O 0 1.8493245079298504e-05
1 O 0 1.104705279431073e-05
. O 0 6.795257831981871e-07

We O 0 1.4592036450267187e-06
propose O 0 2.696075625863159e-06
that O 0 9.698990766082716e-08
WT1 O 0 7.025367085589096e-05
and O 0 1.0311596270184964e-06
Dax O 1 0.998782217502594
- O 0 2.1240759451757185e-05
1 O 0 1.1682731155815418e-06
functionally O 0 1.4517178215101012e-07
oppose O 0 6.361563720247432e-09
each O 0 2.3282618888398332e-10
other O 0 1.7380562267188537e-10
in O 0 8.885021052229547e-10
testis O 0 1.1740738159460307e-07
development O 0 6.589228274123116e-09
by O 0 2.0770658526458874e-09
modulating O 0 2.7605196919466835e-06
SF O 0 0.04028942063450813
- O 0 2.6923044060822576e-05
1 O 0 2.1805053620482795e-05
- O 0 6.748430223524338e-07
mediated O 0 1.1507794397402904e-06
transactivation O 0 1.4444207408814691e-05
. O 0 1.2680355609973049e-07
. O 0 4.957792043569498e-07

A O 0 2.68549570137111e-06
mouse O 0 1.9924640071167232e-07
model O 0 7.917535072010651e-08
for O 0 7.028381219242874e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999996423721313
- O 1 0.999992847442627
centre O 1 0.9987661838531494
mutations O 0 6.052403932699235e-06
. O 0 1.987358245969517e-06

Imprinting O 0 1.990358578041196e-05
in O 0 1.6241236266978376e-07
the O 0 1.0882760648200929e-07
15q11 O 0 3.032849008377525e-06
- O 0 3.377752761934971e-07
q13 O 0 2.5258424329877016e-07
region O 0 1.4983655205469404e-08
involves O 0 4.249800067412934e-09
an O 0 9.006917989218266e-10
imprinting O 0 8.619748541605077e-07
centre O 0 4.0231880120700225e-05
( O 0 6.500599880610025e-08
IC O 0 6.440118795580929e-06
) O 0 1.3352308592118334e-08
, O 0 3.2143789852057125e-09
mapping O 0 6.285605280709206e-08
in O 0 3.641000168030928e-09
part O 0 5.447304829431232e-09
to O 0 2.5610404907894235e-09
the O 0 6.613569780711259e-08
promoter O 0 1.90361406566808e-05
and O 0 3.7718582035495274e-08
first O 0 1.4784428969960572e-07
exon O 0 6.445919098041486e-06
of O 0 2.1718763036915334e-06
SNRPN O 0 0.0145681481808424
. O 0 9.52256959863007e-06

Deletion O 0 1.754564254952129e-05
of O 0 1.0467001629876904e-06
this O 0 2.3955459838020943e-08
IC O 0 1.8911363440565765e-05
abolishes O 0 1.1931764447581372e-06
local O 0 2.2419415657282116e-08
paternally O 0 7.0954328634798e-08
derived O 0 1.891413692334254e-09
gene O 0 1.58110713410764e-09
expression O 0 7.871482354815384e-10
and O 0 2.1205537326096646e-10
results O 0 2.9465647699566944e-09
in O 0 3.300523871985206e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999995231628418
PWS B-Disease 1 1.0
) O 0 3.697446663863957e-05
. O 0 5.83597602599184e-06

We O 0 3.4187618780379125e-07
have O 0 4.208708936914718e-09
created O 0 4.370867223713049e-09
two O 0 1.1637157903976458e-09
deletion O 0 1.6957481818735687e-07
mutations O 0 4.8969624799610756e-08
in O 0 4.336044412411866e-08
mice O 0 3.6702664374388405e-07
to O 0 2.011205069152311e-08
understand O 0 9.450856305193156e-05
PWS B-Disease 1 1.0
and O 0 5.9480399272615614e-08
the O 0 1.4378369606049546e-08
mechanism O 0 4.903336616735032e-07
of O 0 2.9204533902316143e-08
this O 0 5.4996389664552225e-09
IC O 0 2.728974686760921e-05
. O 0 6.329420898509852e-07

Mice O 0 6.554502760991454e-05
harbouring O 0 2.1776811991003342e-05
an O 0 3.85421223825233e-08
intragenic O 0 1.169039387605153e-05
deletion O 0 8.540915814592154e-07
in O 0 4.1431288622106877e-08
Snrpn O 0 6.814754215156427e-06
are O 0 6.0456701866939966e-09
phenotypically O 0 2.052872105196002e-06
normal O 0 2.1640803993250302e-07
, O 0 1.6393754131982519e-09
suggesting O 0 3.3851610403701216e-09
that O 0 1.0161669422581454e-10
mutations O 0 5.507541089855295e-10
of O 0 4.27910640254936e-09
SNRPN O 0 6.824281626904849e-06
are O 0 4.35194019710039e-10
not O 0 2.4553944988348064e-10
sufficient O 0 1.406760130606699e-08
to O 0 1.33495072773826e-08
induce O 0 1.8231488866149448e-05
PWS B-Disease 1 0.9999994039535522
. O 0 4.9332797061651945e-05

Mice O 0 9.863420928013511e-06
with O 0 2.467288595653372e-08
a O 0 4.3311430886205926e-08
larger O 0 1.947327277207478e-08
deletion O 0 4.184841202459211e-07
involving O 0 1.149068253880614e-07
both O 0 3.0903610337418286e-08
Snrpn O 0 7.568755336251343e-06
and O 0 3.1890195373307506e-08
the O 0 4.0617118202135316e-07
putative O 0 4.221056224196218e-05
PWS O 1 0.9999997615814209
- O 0 7.928555714897811e-05
IC O 0 3.29415597661864e-05
lack O 0 1.2585395836595126e-07
expression O 0 6.601442947840042e-09
of O 0 7.543470736948166e-09
the O 0 9.3504395337618e-09
imprinted O 0 1.1230272889406478e-07
genes O 0 4.439742795625534e-08
Zfp127 O 0 2.487119900251855e-06
( O 0 2.012501987280757e-08
mouse O 0 4.578055268211756e-08
homologue O 0 4.08419793984649e-07
of O 0 2.3640816948500287e-07
ZNF127 O 0 0.00048360167420469224
) O 0 1.9563277930956247e-07
, O 0 2.702277299704292e-07
Ndn O 0 7.607701263623312e-05
and O 0 2.1912632064413629e-07
Ipw O 0 6.86554194544442e-05
, O 0 8.14945906313369e-08
and O 0 1.506834301778781e-08
manifest O 0 3.3280824141002086e-07
several O 0 7.234119081545032e-09
phenotypes O 0 1.1345319990141434e-06
common O 0 2.786871107218758e-07
to O 0 3.5569410101743415e-06
PWS B-Disease 1 1.0
infants O 1 0.9992351531982422
. O 0 2.4970373488031328e-05

These O 0 2.2257848897311305e-08
data O 0 6.784379991131573e-08
demonstrate O 0 5.2265082928215634e-08
that O 0 6.1501320702817e-10
both O 0 1.4009381432700252e-09
the O 0 3.2975360220177663e-09
position O 0 6.768675575585803e-08
of O 0 2.9440551330139897e-08
the O 0 1.4668417591678917e-08
IC O 0 1.0903531801886857e-06
and O 0 1.3117716912702804e-09
its O 0 2.811549604242458e-10
role O 0 6.724881984609965e-09
in O 0 3.126637004857713e-10
the O 0 5.120000534653002e-10
coordinate O 0 2.000216881015149e-09
expression O 0 2.0756203422678254e-09
of O 0 9.701947689677581e-09
genes O 0 2.1315358367246517e-09
is O 0 5.555143012259123e-10
conserved O 0 1.560310636250506e-08
between O 0 4.4469803839319866e-08
mouse O 0 9.05529518036019e-08
and O 0 1.0244562531624979e-08
human O 0 3.124470282500624e-08
, O 0 3.979165885681368e-09
and O 0 1.4968649653113175e-09
indicate O 0 1.525748416497663e-08
that O 0 5.679627879118243e-10
the O 0 4.853303536833664e-09
mouse O 0 7.083003517038833e-09
is O 0 1.8152038205876408e-10
a O 0 2.436249257886658e-10
suitable O 0 3.3241087660229596e-09
model O 0 2.1259651816762926e-09
system O 0 1.3143544919103078e-08
in O 0 1.0972939223918843e-09
which O 0 1.1867262728060268e-10
to O 0 1.0721669385649335e-10
investigate O 0 2.7373796562812913e-09
the O 0 2.238513374663853e-09
molecular O 0 1.461992127360645e-07
mechanisms O 0 1.257719191016804e-06
of O 0 1.0788806292794106e-07
imprinting O 0 5.513410883395409e-07
in O 0 2.7186011219981765e-09
this O 0 5.387228996234228e-10
region O 0 3.889458088934816e-09
of O 0 2.5326329922137347e-09
the O 0 4.132512110288644e-09
genome O 0 3.0558591213036834e-09
. O 0 3.934232939428739e-09
. O 0 9.958393576425806e-08

Mutations O 0 1.8107106143361307e-06
of O 0 3.0930479510971054e-07
the O 0 9.384800847556107e-08
ATM O 0 6.111740276537603e-06
gene O 0 3.7541013853115146e-08
detected O 0 1.564120850616746e-07
in O 0 1.1267600186215532e-08
Japanese O 0 0.020478269085288048
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00042272175778634846
: O 0 9.407145284967555e-09
possible O 0 6.767035642951669e-08
preponderance O 0 6.844297331554117e-06
of O 0 7.201329310646543e-08
the O 0 6.53023803920405e-08
two O 0 6.614843783836477e-08
founder O 0 1.2932243862451287e-06
mutations O 0 6.341711156210295e-08
4612del165 O 0 2.0387174117786344e-06
and O 0 1.520480736871832e-07
7883del5 O 0 2.179806870117318e-05
. O 0 2.851446879503783e-06

The O 0 2.799000867526047e-06
ATM O 0 0.0011140502756461501
( O 0 1.0160835699934978e-05
A O 1 0.9999899864196777
- O 1 0.9999147653579712
T O 1 0.9999864101409912
, O 0 1.4566653661063356e-08
mutated O 0 6.023869403293247e-09
) O 0 5.085643572932952e-10
gene O 0 2.587322800451375e-09
on O 0 2.076433069930772e-08
human O 0 6.6143137189556e-08
chromosome O 0 2.600162815724616e-06
11q22 O 0 1.3670946827915031e-05
. O 0 1.5782748050696682e-06

3 O 0 3.725755595951341e-05
has O 0 7.085033359999215e-08
recently O 0 5.8140557257502223e-08
been O 0 1.4267285131097651e-09
identified O 0 3.127132164326696e-10
as O 0 7.509011468176396e-11
the O 0 9.445359078208426e-11
gene O 0 1.5024706478961036e-10
responsible O 0 1.0874284805950651e-09
for O 0 4.3290654394567696e-10
the O 0 2.4090720529557075e-08
human O 0 0.0002602310851216316
recessive B-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9584219455718994
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 8.065719612204703e-07
. O 0 6.214675067894859e-07

In O 0 8.210822954879404e-08
order O 0 6.490215476162575e-09
to O 0 4.607958736801976e-10
define O 0 1.2274239402643161e-08
the O 0 2.5266500003340298e-09
types O 0 2.3112147573556285e-07
of O 0 3.4365518786216853e-06
disease O 0 0.24862907826900482
- O 0 1.7957460158868344e-06
causing O 0 4.02585868641836e-07
ATM O 0 1.1425524462538306e-05
mutations O 0 7.655164502295975e-09
in O 0 3.919103708227567e-09
Japanese O 0 2.496123215678381e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999985694885254
T I-Disease 1 0.9999998807907104
patients O 0 1.5839549405427533e-07
as O 0 5.221245213959946e-09
well O 0 1.7485145553663983e-09
as O 0 1.073649169569535e-09
to O 0 3.995057895611609e-10
look O 0 1.9700365783137386e-09
for O 0 7.101288446165199e-10
possible O 0 1.0029987507209626e-08
mutational O 0 5.455162295220362e-07
hotspots O 0 3.7899451399425743e-07
, O 0 5.5529847386992515e-09
reverse O 0 6.768584626115626e-08
- O 0 5.223518684260853e-08
transcribed O 0 2.2065268723281406e-08
RNA O 0 1.3050991398699807e-08
derived O 0 8.008092522437948e-10
from O 0 6.931629714657106e-10
ten O 0 5.210361475604941e-09
patients O 0 8.272246776463987e-10
belonging O 0 2.8388607020701784e-09
to O 0 9.848976079140925e-10
eight O 0 2.559762357634554e-08
unrelated O 0 5.048584625910735e-07
Japanese O 0 2.043539825535845e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9998291730880737
T I-Disease 1 0.9999845027923584
families O 0 4.5133716208844987e-10
was O 0 4.483652116249459e-09
analyzed O 0 9.611305085144295e-10
for O 0 5.4906412749744504e-11
mutations O 0 8.718151894848702e-11
by O 0 2.991901865145863e-11
the O 0 8.357266545466757e-10
restriction O 0 2.5793749358626883e-09
endonuclease O 0 2.808728005732064e-08
fingerprinting O 0 3.0132395067994366e-07
method O 0 2.1549651307850581e-07
. O 0 4.6143838972056983e-07

As O 0 2.442818413328496e-06
has O 0 2.442258129065067e-08
been O 0 2.5610942255838154e-09
reported O 0 6.695314302973543e-10
by O 0 4.654889668165296e-11
others O 0 4.971275613385728e-10
, O 0 3.804933867979088e-10
mutations O 0 6.329596291543282e-10
that O 0 1.497298257602253e-10
lead O 0 1.4833684502946198e-08
to O 0 9.904553621709056e-09
exon O 0 8.514391083735973e-06
skipping O 0 1.0910522405538359e-06
or O 0 5.080956100300682e-08
premature O 0 1.8229277998216276e-07
protein O 0 1.0963847785205871e-07
truncation O 0 2.665268254986586e-07
were O 0 3.348546329107194e-08
also O 0 8.3175306642147e-09
predominant O 0 1.7583687395017478e-07
in O 0 8.860756572914852e-09
our O 0 4.3069480426538576e-08
mutants O 0 7.891202358223381e-07
. O 0 2.624998103328835e-07

Six O 0 1.4802093062371569e-07
different O 0 7.067457286069612e-09
mutations O 0 8.037338794508742e-09
were O 0 3.987493002455267e-09
identified O 0 3.3534659493739127e-09
on O 0 9.176600812565994e-09
12 O 0 1.4223492605935917e-08
of O 0 5.946788839139572e-09
the O 0 9.616867302497667e-09
16 O 0 1.220286094394396e-07
alleles O 0 1.6112041478777428e-08
examined O 0 1.5075981991685694e-06
. O 0 6.15273165749386e-07

Four O 0 7.163211535043956e-07
were O 0 1.1345759531877775e-07
deletions O 0 3.3182641345774755e-07
involving O 0 1.9754752145217935e-07
a O 0 2.3829636930372544e-08
loss O 0 1.766554191817704e-07
of O 0 4.259634067693696e-07
a O 0 5.18670582039249e-08
single O 0 1.6356720422550097e-08
exon O 0 5.886276426281256e-07
exon O 0 3.3633588714110374e-07
7 O 0 1.1836219471206277e-07
, O 0 9.507056475399622e-09
exon O 0 4.3180324382774415e-07
16 O 0 2.325291319493772e-07
, O 0 3.9267078477678297e-08
exon O 0 2.6345837795815896e-06
33 O 0 1.7616446257306961e-06
or O 0 4.1292369701295684e-07
exon O 0 4.40886287833564e-05
35 O 0 1.6494732335559092e-05
. O 0 3.17712488140387e-06

The O 0 1.0437078117320198e-06
others O 0 7.83408964366572e-08
were O 0 2.527981912692212e-08
minute O 0 1.671008753589831e-08
deletions O 0 5.41324940428467e-09
, O 0 9.660580113646233e-10
4649delA O 0 1.844814612184109e-08
in O 0 4.725781987957589e-09
exon O 0 1.5100430061920633e-07
33 O 0 3.4634307866099334e-08
and O 0 4.98114882674372e-09
7883del5 O 0 4.2618199813659885e-07
in O 0 5.0537387608073914e-08
exon O 0 5.983945811749436e-06
55 O 0 2.078899797197664e-06
. O 0 2.036339083133498e-06

The O 0 1.0023725280916551e-06
mutations O 0 2.7760910370489e-07
4612del165 O 0 7.260634333761118e-07
and O 0 1.1340475225551927e-08
7883del5 O 0 4.5325364794734924e-07
were O 0 7.222703324316626e-09
found O 0 4.2522305121472925e-10
in O 0 7.944253588298977e-11
more O 0 1.738121625793898e-11
than O 0 4.561069924524652e-11
two O 0 1.1253671605704341e-10
unrelated O 0 5.6172413387400866e-09
families O 0 4.9677279650994777e-11
; O 0 7.819717096069212e-11
44 O 0 2.6220841053969934e-09
% O 0 1.693726270346474e-09
( O 0 1.868971644114481e-09
7 O 0 4.8564359644842625e-08
of O 0 4.949897558503835e-08
16 O 0 4.636510197997268e-08
) O 0 6.257226958794604e-10
of O 0 5.363056665430577e-09
the O 0 7.753530262277764e-09
mutant O 0 9.877274109726386e-09
alleles O 0 2.047513936176415e-09
had O 0 1.0064020727895695e-08
one O 0 9.175493698165837e-10
of O 0 4.705499545565317e-09
the O 0 8.285420349807282e-09
two O 0 1.3743402860200149e-08
mutations O 0 7.930578505010999e-08
. O 0 4.827907105209306e-07

The O 0 2.37648328038631e-06
4612del165 O 0 1.002232966129668e-05
mutations O 0 1.109473686256024e-07
in O 0 5.126863378279722e-09
three O 0 6.433197863309204e-10
different O 0 4.5585329955244447e-10
families O 0 1.2707987440130353e-10
were O 0 9.072730344783508e-10
all O 0 2.250881425691631e-10
ascribed O 0 4.257312724575968e-09
to O 0 3.8088404652469876e-10
the O 0 5.852995865751609e-09
same O 0 2.4410008236941394e-08
T O 0 1.319420334766619e-06
- O 0 1.0336935929444735e-07
- O 0 2.1873020727980474e-08
> O 0 5.47121281613272e-09
A O 0 2.4232418294189983e-09
substitution O 0 8.588168509682248e-10
at O 0 9.11020858751499e-09
the O 0 2.065750459578908e-09
splice O 0 2.5369370604266805e-08
donor O 0 5.921142243181521e-09
site O 0 2.431479551034954e-08
in O 0 3.821666183512207e-08
intron O 0 7.603885023854673e-05
33 O 0 2.6069012164953165e-05
. O 0 1.0555883818597067e-05

Microsatellite O 0 0.0007881235796958208
genotyping O 0 7.690847996855155e-05
around O 0 2.4776710461082985e-07
the O 0 5.923144286157367e-08
ATM O 0 6.748231044184649e-06
locus O 0 8.554564345786275e-08
also O 0 6.366200455687476e-09
indicated O 0 6.3624621127189585e-09
that O 0 1.8826162850871242e-10
a O 0 1.3052352532127998e-09
common O 0 6.964047116753136e-09
haplotype O 0 1.6487922493979568e-07
was O 0 8.942340912199143e-08
shared O 0 3.1460267724270352e-09
by O 0 2.0499825448272446e-10
the O 0 8.689767794223258e-10
mutant O 0 5.486835874535245e-09
alleles O 0 2.162296341978731e-09
in O 0 2.6894511062636184e-09
both O 0 2.3399460147288664e-08
mutations O 0 3.776271455535607e-07
. O 0 1.128825033447356e-06

This O 0 1.589993559036884e-07
suggests O 0 1.8451916616868402e-07
that O 0 7.08664849025098e-10
these O 0 2.9034660786741995e-10
two O 0 1.6475442121688388e-09
founder O 0 3.1197842531582864e-07
mutations O 0 8.285609531810678e-09
may O 0 5.2362643110370755e-09
be O 0 6.947407094060054e-10
predominant O 0 1.3369612084090932e-08
among O 0 1.7677651009684325e-10
Japanese O 0 2.6111155904118277e-08
ATM O 0 1.5787263691890985e-06
mutant O 0 8.679423046942247e-08
alleles O 0 4.838527090100797e-08
. O 0 2.751095280473237e-07

W474C O 0 4.905956666334532e-05
amino O 0 1.1906042800546857e-06
acid O 0 1.7770271654171665e-07
substitution O 0 4.297388755958309e-08
affects O 0 3.881595045385211e-09
early O 0 4.372042727851522e-09
processing O 0 2.0069361283958642e-08
of O 0 1.6655731238657268e-09
the O 0 1.7157583132032528e-09
alpha O 0 4.798566166641649e-08
- O 0 6.389252682481583e-09
subunit O 0 7.1996235639915085e-09
of O 0 1.1005012900966449e-08
beta O 0 3.8405414670705795e-07
- O 0 1.020231081838574e-07
hexosaminidase O 0 1.6878021824595635e-07
A O 0 1.2322233011730077e-08
and O 0 5.704859362687387e-10
is O 0 3.489599442740854e-10
associated O 0 8.481806368365596e-09
with O 0 2.995520986814881e-08
subacute O 1 0.9960152506828308
G B-Disease 1 0.93892902135849
( I-Disease 0 1.6820509927129024e-06
M2 I-Disease 0 0.0037598533090204
) I-Disease 0 1.5844730683056696e-07
gangliosidosis I-Disease 0 1.2369548130664043e-05
. O 0 5.631753197121725e-07

Mutations O 0 1.4283350537880324e-06
in O 0 1.106683882312609e-07
the O 0 7.52591304831185e-08
HEXA O 0 4.355242708697915e-06
gene O 0 7.311578453794709e-09
, O 0 9.51566936358006e-10
encoding O 0 4.051746937960843e-09
the O 0 3.5422160760134602e-09
alpha O 0 4.839865397343601e-08
- O 0 1.2154632855754244e-08
subunit O 0 8.875336909852649e-09
of O 0 2.3906439494680853e-08
beta O 0 5.679881951436982e-07
- O 0 3.955751708417665e-07
hexosaminidase O 0 1.6687368997736485e-06
A O 0 4.0934119738267327e-07
( O 0 5.4376716462911645e-09
Hex O 0 1.3986446845137834e-07
A O 0 5.936819036378438e-08
) O 0 7.79648789972498e-10
, O 0 3.4099009726951124e-10
that O 0 9.039578807712445e-11
abolish O 0 2.754843642094329e-08
Hex O 0 7.312809202630888e-08
A O 0 9.589867566717203e-09
enzyme O 0 1.2691190320879286e-08
activity O 0 1.957225492787984e-07
cause O 0 0.16388528048992157
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.2142570085416082e-05
TSD B-Disease 0 0.26667606830596924
) O 0 6.589054635242064e-08
, O 0 1.9032301068477864e-08
the O 0 4.557928789949983e-08
fatal O 0 1.3625885912915692e-05
infantile B-Disease 0 7.700154128542636e-06
form I-Disease 0 6.844087465651683e-07
of I-Disease 0 0.0005501777632161975
G I-Disease 1 0.6724165678024292
( I-Disease 0 4.3104165570184705e-07
M2 I-Disease 0 6.007364936522208e-05
) I-Disease 0 1.3330883064099908e-08
gangliosidosis I-Disease 0 8.987582873487554e-07
, I-Disease 0 6.459365931021921e-09
Type I-Disease 0 2.3811175253740657e-07
1 I-Disease 0 2.456798938510474e-06
. O 0 4.946726335219864e-07

Less O 0 1.0199843927694019e-05
severe O 0 0.00043543375795707107
, O 0 1.536156105430564e-06
subacute O 1 0.9070836305618286
( O 0 2.9469820219674148e-06
juvenile O 1 0.9902423024177551
- O 0 3.956905857194215e-05
onset O 0 0.22170382738113403
) O 0 1.4480066568012262e-07
and O 0 1.9148128558299504e-06
chronic O 1 1.0
( O 0 1.0793351975735277e-05
adult O 0 0.0006987618398852646
- O 0 8.255408829427324e-06
onset O 0 8.252399129560217e-05
) O 0 4.661673269623634e-09
variants O 0 2.4800320019835453e-08
are O 0 4.4144993216477246e-10
characterized O 0 2.5842108453133505e-09
by O 0 1.5447980394878158e-10
a O 0 2.88828916339412e-09
broad O 0 2.7537666369426006e-08
spectrum O 0 4.269203373041819e-07
of O 0 2.141214672235492e-08
clinical O 0 3.5775357787315443e-07
manifestations O 0 2.179001512558898e-07
and O 0 4.2324406201998954e-09
are O 0 4.5623599342903276e-10
associated O 0 2.6190949409254927e-09
with O 0 9.431179170960036e-10
residual O 0 4.6134077820170205e-06
levels O 0 1.5950282659105142e-06
of O 0 1.456332654470316e-07
Hex O 0 1.0369385563535616e-06
A O 0 6.397181095962878e-08
enzyme O 0 1.8008561752935748e-08
activity O 0 1.3104950369324797e-07
. O 0 1.6628938226403989e-07

We O 0 4.7603469965906697e-07
identified O 0 4.0040944782049337e-07
a O 0 1.1856804604803983e-07
1422 O 0 1.1625666047621053e-05
G O 0 1.052978404914029e-05
- O 0 5.19213745064917e-06
- O 0 2.090191173920175e-06
> O 0 3.345055006320763e-07
C O 0 5.2292734835646115e-06
( O 0 5.9397375906655725e-09
amino O 0 1.2106553981539037e-08
acid O 0 1.089118661923294e-08
W474C O 0 2.600147297471267e-08
) O 0 2.5792359914511565e-10
substitution O 0 1.9395272055078294e-09
in O 0 4.0672851198131355e-10
the O 0 5.275911374447162e-10
first O 0 9.256669319945843e-10
position O 0 9.7613073180014e-09
of O 0 4.117949714554925e-08
exon O 0 4.4441406998885213e-07
13 O 0 8.896526537682803e-08
of O 0 7.352851838504648e-08
HEXA O 0 4.7511435695923865e-05
of O 0 1.6046863038354786e-07
a O 0 4.127385722085819e-08
non O 0 1.2522209544840734e-06
- O 0 2.2640362828951766e-07
Jewish O 0 5.887484277877775e-08
proband O 0 1.254592280020006e-05
who O 0 5.553093629373507e-08
manifested O 0 1.9324207300996932e-07
a O 0 5.99793850142305e-08
subacute O 0 1.8172089767176658e-05
variant O 0 6.292994498835469e-07
of O 0 4.4272887862462085e-06
G B-Disease 0 0.0063106524758040905
( I-Disease 0 1.088291128326091e-06
M2 I-Disease 0 0.0006920528248883784
) I-Disease 0 4.020548374228383e-07
gangliosidosis I-Disease 0 2.3411583242705092e-05
. O 0 1.7455183751735603e-06

On O 0 5.981840331514832e-06
the O 0 3.8548927250303677e-07
second O 0 8.713948318472831e-07
maternally O 0 1.9953308765252586e-06
inherited O 0 1.4032341368874768e-06
allele O 0 3.757568833862024e-08
, O 0 2.4752626615054396e-09
we O 0 4.82609729957062e-10
identified O 0 1.897570989228825e-09
the O 0 5.866161334466824e-09
common O 0 2.2697811346006347e-06
infantile O 1 0.999479353427887
disease O 1 0.9987902045249939
- O 0 2.863556073862128e-05
causing O 0 3.833037771983072e-05
4 O 0 4.6611101424787194e-05
- O 0 1.359385692012438e-06
bp O 0 1.868730663545648e-07
insertion O 0 5.3882004635852354e-08
, O 0 1.2856081532675034e-08
+ O 0 2.7697282689587155e-07
TATC O 0 2.9554415959864855e-05
1278 O 0 2.3743838028167374e-05
, O 0 3.587884478406522e-08
in O 0 5.379543566164102e-08
exon O 0 1.0097813174070325e-05
11 O 0 4.68623693450354e-06
. O 0 4.238600467942888e-06

Pulse O 0 0.0012435154058039188
- O 0 7.063726116030011e-06
chase O 0 1.543531027436984e-07
analysis O 0 8.311028310004076e-09
using O 0 1.640946578618241e-08
proband O 0 5.783705319117871e-07
fibroblasts O 0 4.6607333104020654e-08
revealed O 0 2.49648639538691e-08
that O 0 1.7065991675391246e-10
the O 0 6.110343342413671e-10
W474C O 0 1.0869894317977469e-08
- O 0 1.2785257297309727e-09
containing O 0 3.568478290638666e-10
alpha O 0 1.0548210305216799e-08
- O 0 2.6938817843102925e-09
subunit O 0 1.2778778923916434e-08
precursor O 0 5.17704954461351e-08
was O 0 2.7575932648460366e-08
normally O 0 2.608525839775666e-09
synthesized O 0 1.553634909612356e-08
, O 0 6.886691772400866e-10
but O 0 1.859019327365985e-10
not O 0 5.584440201933383e-11
phosphorylated O 0 2.7263589164050472e-09
or O 0 1.0510128323204526e-09
secreted O 0 1.2060982212958038e-09
, O 0 2.946321797647755e-10
and O 0 9.684970603274223e-10
the O 0 7.694293202575864e-09
mature O 0 1.144644201644951e-07
lysosomal O 0 5.477403647091705e-06
alpha O 0 1.6363792383344844e-06
- O 0 1.0109795312018832e-07
subunit O 0 1.2535517157630238e-07
was O 0 3.336806173592777e-07
not O 0 2.0616814921936566e-08
detected O 0 1.703448674561514e-06
. O 0 2.966640124668629e-07

When O 0 3.188852701896394e-07
the O 0 1.5234111572226539e-07
W474C O 0 1.1070740129071055e-06
- O 0 4.2097145325215024e-08
containing O 0 7.778148791715012e-09
alpha O 0 5.7375480366772535e-08
- O 0 2.349857375349984e-08
subunit O 0 5.254054613601511e-08
was O 0 2.8719350098072027e-07
transiently O 0 4.369061059605883e-07
co O 0 2.623556554226525e-07
- O 0 9.660179323134344e-09
expressed O 0 7.376894095578734e-10
with O 0 2.3936572168814507e-10
the O 0 1.3318930403016793e-09
beta O 0 2.4226284978112744e-08
- O 0 2.9384661370812637e-09
subunit O 0 1.7801293772379267e-09
to O 0 3.322554176232728e-10
produce O 0 1.4344531118481996e-09
Hex O 0 9.748249141239285e-08
A O 0 6.678153141592702e-08
( O 0 3.575415519208036e-09
alphabeta O 0 9.712800164152213e-08
) O 0 2.9989264405116955e-09
in O 0 1.6373512323752948e-08
COS O 0 0.00010810521780513227
- O 0 3.0178027827787446e-06
7 O 0 4.0395579503638146e-07
cells O 0 9.979379989033532e-09
, O 0 1.3668525200571935e-09
the O 0 2.4811188659157324e-09
mature O 0 1.6176830541780873e-08
alpha O 0 1.21057723845297e-07
- O 0 9.401226463978674e-09
subunit O 0 5.802875069349511e-09
was O 0 1.4777486789796512e-08
present O 0 9.621264895898207e-10
, O 0 2.4935378761803406e-10
but O 0 6.089804355235984e-11
its O 0 3.664670997216568e-11
level O 0 4.2848498083003506e-08
was O 0 1.7483852587929505e-08
much O 0 1.4821882610149828e-09
lower O 0 2.93200530521176e-09
than O 0 7.989672812236392e-11
that O 0 1.79560238205978e-11
from O 0 1.4250742252919224e-10
normal O 0 2.9979998483753434e-09
alpha O 0 2.546526367552815e-08
- O 0 6.26732266084673e-09
subunit O 0 7.171473193068323e-09
transfections O 0 4.9631896814616994e-08
, O 0 2.651888153515358e-10
although O 0 7.025248438541354e-11
higher O 0 1.4533954040274466e-09
than O 0 4.378639464897027e-11
in O 0 1.3895423700560627e-10
those O 0 1.8556893521815e-10
cells O 0 4.5797796111024525e-10
transfected O 0 3.312577101510783e-09
with O 0 7.715299926713826e-11
an O 0 1.751257056037403e-10
alpha O 0 8.765702119717389e-08
- O 0 3.3974139057590946e-08
subunit O 0 4.8588354673029244e-08
associated O 0 1.2272488447706564e-07
with O 0 2.703424399896903e-07
infantile O 1 0.8168745636940002
TSD B-Disease 1 0.9881228804588318
. O 0 2.886352922359947e-05

Furthermore O 0 3.0707242331118323e-06
, O 0 6.018921538952782e-08
the O 0 1.0244953330129647e-08
precursor O 0 1.2508574798175687e-07
level O 0 2.3416968986111897e-07
of O 0 2.1496155966360675e-08
the O 0 1.479867073328478e-08
W474C O 0 1.260300308558726e-07
alpha O 0 1.1376031494592098e-07
- O 0 1.1513504816207387e-08
subunit O 0 1.4873829279338224e-08
was O 0 4.929142249920915e-08
found O 0 6.967643684241409e-10
to O 0 2.5770427458660095e-10
accumulate O 0 1.4996034636283184e-08
in O 0 6.26733165365323e-10
comparison O 0 1.9438011200634264e-09
to O 0 5.908390998676794e-10
the O 0 8.72345040647815e-09
normal O 0 1.6948007441897062e-07
alpha O 0 5.364211119740503e-07
- O 0 5.70246143638542e-08
subunit O 0 8.193629241759481e-08
precursor O 0 5.707041168534488e-07
levels O 0 5.279741799313342e-07
. O 0 1.6630413313123427e-07

We O 0 1.0758245707620517e-06
conclude O 0 1.383057110615482e-06
that O 0 3.788525937409304e-09
the O 0 2.3106919044835195e-08
1422 O 0 9.249577487935312e-06
G O 0 1.1502932466100901e-05
- O 0 3.619997414716636e-06
- O 0 1.0138455763808452e-06
> O 0 2.727817616232642e-07
C O 0 2.7684288852469763e-06
mutation O 0 2.3078190469760784e-09
is O 0 2.009270527736362e-10
the O 0 8.820451591340372e-10
cause O 0 7.630498899402482e-09
of O 0 1.1739552263634323e-07
Hex B-Disease 0 2.6616220566211268e-05
A I-Disease 0 8.842535316944122e-05
enzyme I-Disease 1 0.9999935626983643
deficiency I-Disease 1 1.0
in O 0 1.5167773881330504e-07
the O 0 2.897975832638622e-07
proband O 0 6.193970330059528e-05
. O 0 9.797942084333044e-07

The O 0 9.935396292348742e-07
resulting O 0 3.6191889307701786e-07
W474C O 0 1.6552043007322936e-06
substitution O 0 2.650177179930324e-07
clearly O 0 1.1282465806061737e-07
interferes O 0 8.328869682827644e-08
with O 0 5.183103279904344e-09
alpha O 0 2.5974264872274944e-07
- O 0 1.4989371521778594e-08
subunit O 0 1.4200640663375452e-08
processing O 0 8.726816247417446e-08
, O 0 3.393744729685011e-10
but O 0 1.163391188940821e-10
because O 0 6.212165504226874e-11
the O 0 3.1406410805345786e-10
base O 0 2.3015285233185523e-09
substitution O 0 7.783788724680107e-09
falls O 0 7.691552639244037e-08
at O 0 3.19542472482226e-08
the O 0 2.472426707811337e-09
first O 0 2.2702331126112085e-09
position O 0 3.293608941135062e-08
of O 0 6.01566227942385e-08
exon O 0 4.930801651426009e-07
13 O 0 8.578076915455313e-08
, O 0 4.4132808518781985e-09
aberrant O 0 4.516984475344543e-08
splicing O 0 3.1808613698558474e-07
may O 0 6.21160580749347e-08
also O 0 3.4245810631716722e-09
contribute O 0 4.52855042354372e-09
to O 0 1.6452840867486884e-08
Hex B-Disease 0 6.858200504211709e-05
A I-Disease 0 6.214489258127287e-05
deficiency I-Disease 0 0.014964197762310505
in O 0 2.2347689920820812e-08
this O 0 3.0537967710131397e-09
proband O 0 9.832277783061727e-07
. O 0 1.3964569944846517e-08
. O 0 1.2988898845378571e-07

Two O 0 4.0451169525113073e-07
frequent O 0 5.69654105220252e-07
missense O 0 1.0231058695353568e-05
mutations O 0 2.587181597846211e-06
in O 0 7.785581146890763e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0005357922054827213

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.7955045450435136e-06
an O 0 2.5697629098431207e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9991907477378845
by O 0 1.7453857026339392e-07
early O 1 0.9997329115867615
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999984502792358
goiter B-Disease 1 1.0
. O 1 0.998995840549469

A O 0 8.090996743703727e-06
century O 0 2.050475359283155e-06
after O 0 2.5066638542625697e-08
its O 0 4.971057454561389e-10
recognition O 0 9.858641014659497e-09
as O 0 3.233227019450169e-08
a O 0 2.394201317201805e-07
syndrome O 0 3.825725343631348e-06
by O 0 2.088650363774036e-09
Vaughan O 0 1.8041830571746686e-06
Pendred O 0 2.649415546329692e-05
, O 0 4.1410824991316986e-08
the O 0 2.870283708489296e-07
disease O 0 0.0009275519987568259
gene O 0 1.2918903280478844e-07
( O 0 1.0981678855159771e-07
PDS O 0 8.555453860026319e-06
) O 0 1.6666795943365287e-08
was O 0 2.8956085884601634e-07
mapped O 0 2.1609450229220784e-08
to O 0 9.36741528789753e-09
chromosome O 0 2.771123035927303e-06
7q22 O 0 1.4335577361634932e-05
- O 0 5.61139904675656e-06
q31 O 0 1.5963223631842993e-05
. O 0 1.0121021887243842e-06

1 O 0 1.335612432740163e-05
and O 0 2.406804071597435e-07
, O 0 3.375684798356815e-08
recently O 0 6.584921408148148e-08
, O 0 2.592227765774169e-09
found O 0 6.374156202859638e-10
to O 0 2.2187547632501747e-10
encode O 0 2.747418470505636e-08
a O 0 1.1315611203599474e-07
putative O 0 8.321600944327656e-06
sulfate O 0 0.0014899001689627767
transporter O 0 0.024820249527692795
. O 0 1.6141490050358698e-05

We O 0 1.9031327269658505e-07
performed O 0 1.224906753805044e-07
mutation O 0 4.326352165406888e-09
analysis O 0 6.124218909775436e-09
of O 0 1.318864661925545e-08
the O 0 5.211546749706031e-08
PDS B-Disease 0 1.4494655260932632e-05
gene O 0 6.046110456736642e-08
in O 0 2.5477071119439643e-08
patients O 0 2.9211108198978764e-08
from O 0 2.5906327749680713e-08
14 O 0 2.9071330232000037e-07
Pendred B-Disease 0 2.714085212573991e-06
families O 0 6.906238914083929e-10
originating O 0 1.0697495333999996e-08
from O 0 9.588033700325127e-10
seven O 0 7.426573800373149e-10
countries O 0 4.9621123182630456e-11
and O 0 2.781328778400649e-10
identified O 0 1.0949403161930604e-08
all O 0 8.59135163011615e-09
mutations O 0 3.289123924332671e-07
. O 0 5.401926728154649e-07

The O 0 5.687666089215782e-07
mutations O 0 4.6578630730209625e-08
include O 0 9.614647744626836e-09
three O 0 4.751966820037978e-09
single O 0 5.819833504006056e-09
base O 0 1.5668217656639172e-07
deletions O 0 1.5450480361778318e-07
, O 0 8.684304830808287e-09
one O 0 4.043941626008518e-09
splice O 0 1.1084224382784669e-07
site O 0 4.697771771589032e-08
mutation O 0 1.2655970493824498e-08
and O 0 2.4963769718056028e-08
10 O 0 1.4804338661633665e-06
missense O 0 1.4959124200686347e-05
mutations O 0 6.878014119138243e-06
. O 0 4.695520146924537e-06

One O 0 1.2833672826673137e-06
missense O 0 3.453935960351373e-06
mutation O 0 6.624603088312142e-08
( O 0 2.5840543926847204e-08
L236P O 0 1.0939800176856807e-06
) O 0 1.2337895149983069e-08
was O 0 1.1643707154007643e-07
found O 0 3.958907868195638e-09
in O 0 7.16190107219461e-10
a O 0 2.2439767821680334e-09
homozygous O 0 9.01916230588995e-09
state O 0 3.263597392333395e-09
in O 0 2.8580826594293285e-09
two O 0 4.872326542226801e-09
consanguineous O 0 1.246113356501155e-06
families O 0 3.3480193617485554e-10
and O 0 6.107418459855296e-10
in O 0 1.0591266752513206e-09
a O 0 1.4281115179315407e-09
heterozygous O 0 6.363138349563258e-10
state O 0 1.2562810514094025e-10
in O 0 1.1610813005491494e-10
five O 0 1.407204075487556e-10
additional O 0 1.232114521521055e-09
non O 0 8.797607051747036e-07
- O 0 7.722060217929538e-06
consanguineous O 0 2.6356836315244436e-05
families O 0 3.586899310903391e-08
. O 0 3.122561338386731e-07

Another O 0 5.222261734161293e-06
missense O 0 5.68906079934095e-06
mutation O 0 5.472634612146976e-08
( O 0 1.5171645273426293e-08
T416P O 0 3.9781440364095033e-07
) O 0 5.061105756709594e-09
was O 0 6.36496437778078e-08
found O 0 1.4371671630541982e-09
in O 0 6.31905305858993e-10
a O 0 7.653583877775816e-10
homozygous O 0 8.458924671828072e-10
state O 0 6.899879001487363e-10
in O 0 1.6270087499492547e-09
one O 0 1.1226878315895306e-09
family O 0 4.809364018143469e-10
and O 0 3.077992860589518e-10
in O 0 1.4636523104627486e-09
a O 0 1.319185982673332e-09
heterozygous O 0 1.0358538471422207e-09
state O 0 7.809064506147934e-10
in O 0 2.2990935821809444e-09
four O 0 9.893338592803502e-09
families O 0 4.9123585199595254e-09
. O 0 1.3492864070485666e-07

Pendred B-Disease 0 0.000490281730890274
patients O 0 8.669469480082626e-07
in O 0 3.028750583666806e-08
three O 0 1.9795256989141308e-08
non O 0 3.6686742532765493e-06
- O 0 1.930179314513225e-05
consanguineous O 0 1.1986557183263358e-05
families O 0 8.55165160906779e-10
were O 0 2.7629776244708637e-09
shown O 0 1.489943279864292e-09
to O 0 1.690375339702399e-10
be O 0 1.125704751636647e-09
compound O 0 3.417757099555274e-08
heterozygotes O 0 4.87649458591477e-08
for O 0 4.820332133448346e-09
L236P O 0 4.868149403591815e-07
and O 0 2.9412262847472448e-08
T416P O 0 3.829368324659299e-06
. O 0 5.933014790571178e-07

In O 0 3.438836131408607e-07
total O 0 5.199840558134383e-08
, O 0 3.054439190464109e-08
one O 0 2.9393965039758996e-09
or O 0 1.2689924666631214e-09
both O 0 9.748426510469699e-10
of O 0 3.2493612245332315e-09
these O 0 2.3443308405646235e-10
mutations O 0 4.4111747588004846e-10
were O 0 1.2249652403539812e-09
found O 0 6.353811921044894e-10
in O 0 6.425386334107941e-10
nine O 0 4.011950771598549e-09
of O 0 1.0072739975441891e-08
the O 0 2.0417937562910993e-08
14 O 0 8.051811306586387e-08
families O 0 1.311774244783237e-09
analyzed O 0 1.3110400232108077e-07
. O 0 3.720811605489871e-07

The O 0 1.3749372840266005e-07
identification O 0 1.7519278117106296e-07
of O 0 1.6308223393934895e-07
two O 0 7.26287865404629e-08
frequent O 0 5.483746576828707e-07
PDS B-Disease 0 3.999570253654383e-05
mutations O 0 2.8701736098923902e-08
will O 0 2.375302621260289e-09
facilitate O 0 1.6098464783453892e-08
the O 0 9.86153736448614e-09
molecular O 0 5.334476099960739e-06
diagnosis O 0 0.00018597183225210756
of O 0 0.00039741743239574134
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00030668164254166186

Insertional O 0 6.455420952988788e-05
mutation O 0 1.7656867612458882e-07
by O 0 1.5912306139398424e-08
transposable O 0 0.00018803444982040673
element O 0 1.4420011211768724e-05
, O 0 1.982985793347325e-07
L1 O 0 0.0001025901801767759
, O 0 2.4945444820900775e-08
in O 0 1.7943794006214375e-08
the O 0 1.6265494195977226e-07
DMD B-Disease 1 0.9999744892120361
gene O 0 3.536607806609027e-08
results O 0 6.337209867979254e-09
in O 0 2.0834788116985692e-08
X B-Disease 1 0.9992231130599976
- I-Disease 1 0.9998745918273926
linked I-Disease 1 0.9990859031677246
dilated I-Disease 1 0.9997382760047913
cardiomyopathy I-Disease 1 1.0
. O 0 0.43868932127952576

X B-Disease 1 0.999992847442627
- I-Disease 1 0.9999997615814209
linked I-Disease 1 0.999990701675415
dilated I-Disease 1 0.9999953508377075
cardiomyopathy I-Disease 1 1.0
( O 0 0.006381632294505835
XLDCM B-Disease 1 0.999881386756897
) O 0 4.686066645831488e-08
is O 0 3.457304220688684e-09
a O 0 3.106078505510368e-09
clinical O 0 1.603103072511658e-07
phenotype O 0 3.8863383622356196e-08
of O 0 4.502263379890792e-07
dystrophinopathy B-Disease 0 7.25353165762499e-05
which O 0 2.2790274112338693e-09
is O 0 4.651191376492392e-10
characterized O 0 1.092230195176569e-09
by O 0 6.079756698085248e-10
preferential O 0 1.5416758287756238e-06
myocardial B-Disease 1 0.9971217513084412
involvement I-Disease 0 1.4466141919911024e-06
without O 0 2.499664475408281e-08
any O 0 3.652985691715571e-09
overt O 0 9.117303534367238e-08
clinical O 0 5.395635298555135e-07
signs O 0 1.1122605201308033e-06
of O 0 0.011814016848802567
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9821013808250427

To O 0 7.13714314315439e-08
date O 0 3.6161461025585595e-07
, O 0 3.7476683978354686e-09
several O 0 8.544250307274126e-10
mutations O 0 4.419632215757474e-09
in O 0 1.1057319504459429e-08
the O 0 0.0008188424981199205
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9610990285873413
, O 0 0.06331820040941238
DMD O 1 1.0
, O 0 4.6958820121290046e-07
have O 0 2.3487984890380176e-09
been O 0 1.8635466503269527e-09
identified O 0 2.1777968317593377e-09
in O 0 1.4757285393685038e-09
patients O 0 4.862421132401096e-09
with O 0 5.380854428693738e-09
XLDCM B-Disease 1 0.9718195199966431
, O 0 7.20652026942048e-09
but O 0 3.764537848116589e-10
a O 0 5.524774526755039e-10
pathogenic O 0 6.280150177673249e-09
correlation O 0 5.853900031382864e-09
of O 0 2.8290176867784567e-09
these O 0 1.1983430914241922e-09
cardiospecific O 0 6.889502515150525e-07
mutations O 0 3.183476948720454e-08
in O 0 2.875505167310166e-08
DMD O 1 0.9998669624328613
with O 0 1.281773887029658e-08
the O 0 2.822843043759349e-07
XLDCM B-Disease 0 0.002057141624391079
phenotype O 0 1.2079432565315074e-07
has O 0 5.501915811834124e-09
remained O 0 1.4357190991631796e-07
to O 0 8.043745114427736e-10
be O 0 1.0193612176578881e-08
elucidated O 0 1.4210228982847184e-05
. O 0 6.559110943271662e-07

We O 0 5.12884184900031e-07
report O 0 2.2275729705256708e-08
here O 0 1.597134868802641e-09
the O 0 4.383680640707155e-10
identification O 0 2.0707604519998313e-09
of O 0 3.766794876014501e-09
a O 0 2.6045683387820873e-09
unique O 0 1.218452894136135e-08
de O 0 1.9860358406731393e-06
novo O 0 2.5585823095752858e-06
L1 O 0 1.324842196481768e-05
insertion O 0 1.2848870483139763e-06
in O 0 6.554459730523376e-08
the O 0 1.3521822950224305e-07
muscle O 0 2.3912380129331723e-06
exon O 0 9.882628546620253e-06
1 O 0 1.9578467345127137e-06
in O 0 1.1460335969104563e-07
DMD O 1 0.9999876022338867
in O 0 2.5310841422765407e-08
three O 0 2.0749206797177067e-08
XLDCM B-Disease 0 0.00013703425065614283
patients O 0 5.145449577526051e-08
from O 0 8.527192285612273e-09
two O 0 8.700983045173416e-09
unrelated O 0 3.004473114742723e-07
Japanese O 0 7.557846402050927e-07
families O 0 9.832801239895161e-09
. O 0 1.6298537275361014e-07

The O 0 3.635568930349109e-07
insertion O 0 1.532173541818338e-06
was O 0 1.4026160215507844e-06
a O 0 4.788390128851461e-08
5 O 0 4.7020300542044424e-08
- O 0 9.498338116031846e-09
truncated O 0 9.36161015374637e-09
form O 0 3.1551183887756906e-09
of O 0 3.7080514658782704e-08
human O 0 3.0536586592688764e-08
L1 O 0 3.0219298423617147e-06
inversely O 0 4.759466492032516e-07
integrated O 0 5.289801947583328e-07
in O 0 4.934407105139371e-09
the O 0 4.813900389422088e-09
5 O 0 4.5205613474763595e-08
- O 0 3.800955639121639e-08
untranslated O 0 5.261845217319205e-06
region O 0 3.1436890424174635e-08
in O 0 3.720142416341332e-09
the O 0 2.141623234308554e-08
muscle O 0 4.074087200933718e-07
exon O 0 3.974821538577089e-06
1 O 0 5.452150730889116e-07
, O 0 2.7934414781327632e-09
which O 0 1.8911675003785433e-10
affected O 0 2.6416097087533785e-10
the O 0 7.062710416505524e-10
transcription O 0 8.948446428291845e-09
or O 0 9.884959517592051e-10
the O 0 1.8195793760611423e-09
stability O 0 9.45723115819419e-07
of O 0 1.6235814825904527e-07
the O 0 3.100516110521312e-08
muscle O 0 2.4102901008404842e-08
form O 0 1.2784143521571423e-08
of O 0 3.7631278360095166e-07
dystrophin O 0 1.0891643569266307e-06
transcripts O 0 1.3882130645015422e-07
but O 0 1.9964577213649193e-10
not O 0 5.127141419758452e-11
that O 0 2.5337417927651096e-11
of O 0 1.5272499931384687e-09
the O 0 2.8808301522076363e-08
brain O 0 0.021154921501874924
or O 0 3.1971811154107854e-07
Purkinje O 0 0.00014210153312887996
cell O 0 4.896560312772635e-06
form O 0 2.698269518930374e-08
, O 0 5.018752080587774e-09
probably O 0 9.258545929924367e-09
due O 0 4.578611711991698e-09
to O 0 5.133005132051949e-10
its O 0 1.0342286055342598e-10
unique O 0 6.531590268643583e-10
site O 0 2.013180511184487e-09
of O 0 5.134888070301713e-09
integration O 0 6.462448709498858e-07
. O 0 1.1347332247169106e-06

We O 0 9.286755471293873e-07
speculate O 0 2.9819338465131295e-07
that O 0 4.825121968643487e-10
this O 0 8.711303900454936e-11
insertion O 0 1.5791549401455995e-08
of O 0 6.156708476368067e-09
an O 0 3.597428577251094e-09
L1 O 0 9.108696758630686e-06
sequence O 0 1.1381869313709103e-07
in O 0 2.1724675036693952e-07
DMD O 1 0.9999972581863403
is O 0 5.4922493220033175e-09
responsible O 0 7.690976744356703e-09
for O 0 4.2615025397374495e-10
some O 0 1.5582213297449243e-10
of O 0 1.52130741337686e-09
the O 0 6.116931405841797e-10
population O 0 3.4265180970383113e-11
of O 0 3.505418399996074e-09
Japanese O 0 3.2371767133554386e-07
patients O 0 7.265563706226885e-09
with O 0 7.421735226387227e-09
XLDCM B-Disease 0 0.0001440013584215194
. O 0 5.2363674285516026e-08
. O 0 3.2065310051621054e-07

Severe O 0 0.0008344730013050139
early O 0 0.03156595677137375
- O 1 0.9999892711639404
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.2919382154941559
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9999690055847168
red O 1 0.9997772574424744
hair O 1 0.9999381303787231
pigmentation O 1 0.9923651814460754
caused O 0 6.481449418060947e-06
by O 0 5.0310895005623024e-08
POMC O 1 0.5797055959701538
mutations O 0 5.314305440151657e-07
in O 0 5.073518849485481e-08
humans O 0 6.954624609534221e-07
. O 0 2.86699275875435e-07

Sequential O 0 5.358102953323396e-06
cleavage O 0 2.372226390434662e-06
of O 0 3.1597366501046054e-07
the O 0 5.052794449511566e-08
precursor O 0 4.840165388486639e-07
protein O 0 4.4542726840290925e-08
pre O 0 1.448127022740664e-06
- O 0 7.959961294545792e-07
pro O 0 9.801534361031372e-06
- O 0 6.1207811086205766e-06
opiomelanocortin O 0 1.089584384317277e-05
( O 0 3.716654362051486e-08
POMC O 0 1.8372669501331984e-06
) O 0 3.2077827061272046e-09
generates O 0 3.325922648400592e-09
the O 0 4.211109683183167e-09
melanocortin O 0 1.7627218085181084e-06
peptides O 0 1.9585057131621397e-08
adrenocorticotrophin O 0 1.3151365010344307e-06
( O 0 1.5445198897623413e-08
ACTH O 0 3.08691824102425e-07
) O 0 5.9180482736564954e-09
, O 0 1.854180453619847e-08
melanocyte O 0 3.534248662617756e-06
- O 0 2.3639290702703875e-06
stimulating O 0 1.4210713743523229e-06
hormones O 0 2.0997261174215964e-07
( O 0 6.043929356991384e-09
MSH O 0 5.995136120873212e-07
) O 0 3.7883002290683976e-10
alpha O 0 1.0560490260047573e-08
, O 0 2.8724106426736284e-10
beta O 0 2.8014555120137175e-09
and O 0 2.2175110359068384e-10
gamma O 0 1.4597164366136894e-08
as O 0 4.089735772261349e-10
well O 0 1.6394996471547074e-10
as O 0 2.2142060407404074e-10
the O 0 4.6072207160463563e-10
opioid O 0 9.727855143637498e-08
- O 0 8.831369058270866e-08
receptor O 0 1.0270074568552445e-08
ligand O 0 1.3037187329700828e-07
beta O 0 6.4990395003405865e-06
- O 0 4.373940555524314e-06
endorphin O 0 1.7050728274625726e-05
. O 0 6.273651820265513e-07

While O 0 1.0908670446951874e-06
a O 0 3.796774805664427e-08
few O 0 3.6577263440307206e-09
cases O 0 4.4115302522129696e-09
of O 0 9.141037793369833e-08
isolated O 0 8.516843809047714e-05
ACTH B-Disease 1 0.9638893008232117
deficiency I-Disease 1 0.9995290040969849
have O 0 2.8457145972993203e-08
been O 0 1.9874551782095295e-08
reported O 0 1.6696004578875545e-08
( O 0 4.671758535579329e-09
OMIM O 0 1.9454266748653026e-06
201400 O 0 7.343586503338884e-07
) O 0 5.015842852174046e-09
, O 0 4.3669254878864194e-09
an O 0 3.1882528617188655e-08
inherited O 1 0.9999814033508301
POMC O 1 0.9999991655349731
defect O 1 0.9624179601669312
has O 0 1.2625476131233881e-07
not O 0 5.206904241106258e-09
been O 0 3.887618671427617e-09
described O 0 1.0476189693520155e-08
so O 0 1.7721276668325459e-09
far O 0 2.294788004064685e-08
. O 0 6.834487464857375e-08

Recent O 0 6.537578656207188e-07
studies O 0 2.0858415439306555e-07
in O 0 1.0487226198563349e-08
animal O 0 6.238448868600699e-09
models O 0 9.687560975635279e-09
elucidated O 0 5.915443921367114e-07
a O 0 5.878964426386801e-09
central O 0 1.8853132388585436e-08
role O 0 2.809210464249645e-08
of O 0 1.965761100564123e-07
alpha O 0 1.3479399058269337e-05
- O 0 1.9436984075582586e-06
MSH O 0 4.425895895110443e-06
in O 0 2.83023737779331e-09
the O 0 1.1220755435914498e-09
regulation O 0 1.2837899632245353e-08
of O 0 1.875084532088067e-09
food O 0 6.283250586491818e-10
intake O 0 1.8607754226351858e-10
by O 0 4.3799152672774344e-12
activation O 0 1.609329891572031e-09
of O 0 1.700473006849279e-08
the O 0 5.1383391763693e-08
brain O 0 3.3451196941314265e-05
melanocortin O 0 2.064569889626e-05
- O 0 4.457285740500083e-07
4 O 0 3.207809413652285e-07
- O 0 4.645371021183564e-08
receptor O 0 3.952916660665551e-09
( O 0 8.227027947782517e-09
MC4 O 0 7.069535058690235e-06
- O 0 7.056104323055479e-07
R O 0 3.4737663554551546e-06
; O 0 6.063107349518759e-09
refs O 0 8.588633022554859e-07
3 O 0 1.2687867467775504e-07
- O 0 2.1211221223893517e-08
5 O 0 4.94652541149776e-09
) O 0 1.3120163289137565e-10
and O 0 1.3975906543173267e-10
the O 0 1.408472227737434e-09
linkage O 0 2.166320882679429e-07
of O 0 2.1043970832579362e-07
human O 0 5.4169267968973145e-06
obesity B-Disease 1 0.9999991655349731
to O 0 1.4214027288517173e-08
chromosome O 0 7.778239137223864e-07
2 O 0 7.422055432471097e-07
in O 0 2.0832402469750377e-08
close O 0 1.4794754576996638e-07
proximity O 0 1.2368671775675466e-07
to O 0 5.481888276648306e-09
the O 0 1.2240076330272132e-07
POMC O 0 3.564377402653918e-05
locus O 0 2.1811595729559485e-07
, O 0 1.3390462072493392e-08
led O 0 1.3184697778001464e-08
to O 0 5.999420404911859e-10
the O 0 2.579414459802365e-09
proposal O 0 4.0384846577978806e-09
of O 0 4.736023573315151e-09
an O 0 3.5518703533909957e-09
association O 0 1.5938278252747295e-08
of O 0 6.048781528988911e-07
POMC O 0 0.04239259660243988
with O 0 4.5441700535775453e-07
human O 0 0.2759592533111572
obesity B-Disease 1 1.0
. O 0 9.310005225415807e-06

The O 0 3.82040610702461e-07
dual O 0 7.477414101231261e-07
role O 0 5.886327016924042e-07
of O 0 1.1156492973896093e-06
alpha O 0 4.4857610191684216e-05
- O 0 8.977835932455491e-06
MSH O 0 3.027181992365513e-05
in O 0 1.2952020789214203e-08
regulating O 0 6.704795509904216e-07
food O 0 5.76471919089272e-08
intake O 0 9.876166728872704e-08
and O 0 1.3158770073573578e-08
influencing O 0 1.6657137166475877e-05
hair O 0 0.00011769812408601865
pigmentation O 0 7.640228432137519e-05
predicts O 0 2.4339092874470225e-07
that O 0 1.1907081987061474e-09
the O 0 3.831137629362047e-09
phenotype O 0 4.5452512864585515e-09
associated O 0 4.536556019729687e-09
with O 0 1.2792306103293072e-09
a O 0 6.69299637934273e-08
defect O 0 1.232907152370899e-06
in O 0 1.1522319454115859e-07
POMC O 0 8.650310337543488e-05
function O 0 1.000346969703969e-06
would O 0 5.4491366086040216e-08
include O 0 1.5000504163253936e-06
obesity B-Disease 1 1.0
, O 0 4.8319421352971403e-08
alteration O 0 8.287814125651494e-06
in O 0 9.673002523413743e-07
pigmentation O 1 0.9492310285568237
and O 0 0.0002948193287011236
ACTH B-Disease 1 0.9999587535858154
deficiency I-Disease 1 0.9999929666519165
. O 0 2.7242316718911752e-05

The O 0 1.1353654372214805e-06
observation O 0 0.0001076267144526355
of O 0 4.284555643607746e-07
these O 0 1.9753390034793483e-08
symptoms O 0 2.661569851625245e-06
in O 0 9.919016719095453e-09
two O 0 5.091858046313291e-09
probands O 0 1.1347527788529987e-06
prompted O 0 7.002260105082314e-09
us O 0 1.2286600625799338e-09
to O 0 2.6426680288516025e-10
search O 0 5.537648561926289e-09
for O 0 1.9496231296045607e-09
mutations O 0 9.978390558273986e-09
within O 0 5.260973878762343e-08
their O 0 5.0145441576887606e-08
POMC O 0 0.0005006087012588978
genes O 0 1.3235325013738475e-06
. O 0 7.456997082044836e-07

Patient O 0 5.590752334683202e-05
1 O 0 1.4213169379218016e-05
was O 0 2.3345758108916925e-06
found O 0 1.2004689686762049e-08
to O 0 9.814509205341437e-10
be O 0 2.7751516640250884e-09
a O 0 2.9325704087312943e-09
compound O 0 3.829700290225446e-08
heterozygote O 0 9.277004409113943e-08
for O 0 1.1721899007000047e-09
two O 0 7.109501320989864e-10
mutations O 0 2.109348251622123e-09
in O 0 1.8052169536986185e-08
exon O 0 9.787520411919104e-07
3 O 0 2.3769361234826647e-07
( O 0 1.6294505300606943e-08
G7013T O 0 2.0290316626869753e-07
, O 0 6.540420205425335e-09
C7133delta O 0 2.0796045419047005e-07
) O 0 1.0497946956178339e-09
which O 0 2.617101257929022e-10
interfere O 0 5.119328960745406e-09
with O 0 1.340220295853456e-10
appropriate O 0 7.84506148931996e-09
synthesis O 0 6.221399928563187e-08
of O 0 8.980577348438601e-08
ACTH O 0 1.9475114640954416e-06
and O 0 7.297148840734735e-08
alpha O 0 0.00012710096780210733
- O 0 0.0001105932387872599
MSH O 0 0.0015189767582342029
. O 0 1.9963624708907446e-06

Patient O 0 1.0446425221743993e-05
2 O 0 1.719243641673529e-06
was O 0 8.46776302410035e-08
homozygous O 0 3.035886209090677e-09
for O 0 7.04501845749661e-10
a O 0 2.353139239019697e-09
mutation O 0 7.431986692729708e-10
in O 0 8.592645706073654e-09
exon O 0 8.270611147054296e-07
2 O 0 7.198843263722665e-07
( O 0 1.2055997089532866e-08
C3804A O 0 1.1523945886438014e-07
) O 0 2.3335446908134827e-09
which O 0 4.427242572546675e-09
abolishes O 0 1.4573317912436323e-06
POMC O 0 0.00010364012996433303
translation O 0 7.537580586358672e-06
. O 0 5.012382644054014e-06

These O 0 6.419011100433636e-08
findings O 0 8.611814195091938e-08
represent O 0 5.28230748031433e-09
the O 0 2.1181372211742655e-09
first O 0 9.369465203690197e-10
examples O 0 5.5678324173413785e-09
of O 0 2.1293955043688584e-08
a O 0 3.1341849648924835e-07
genetic B-Disease 1 0.9999988079071045
defect I-Disease 1 0.9999889135360718
within O 0 1.7418400375390775e-06
the O 0 5.578427249020024e-07
POMC O 0 3.4993707231478766e-05
gene O 0 1.755720369089886e-08
and O 0 3.081189747788926e-09
define O 0 1.240791931422791e-07
a O 0 4.451104729241706e-08
new O 0 1.1306188980597653e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9945741295814514
resulting O 0 5.669362224125507e-08
in O 0 5.2732276323297356e-09
early O 0 4.940295639244141e-06
- O 0 0.3840586543083191
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.5812320709228516
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9999830722808838
red O 1 0.9935271739959717
hair O 1 0.9934911131858826
pigmentation O 0 0.0073639084585011005
. O 0 1.3441017188142723e-07
. O 0 5.830196414535749e-07

A O 0 2.124391130564618e-06
European O 0 1.4454144547926262e-06
multicenter O 0 2.5307585019618273e-05
study O 0 1.7003341667987115e-07
of O 0 4.361968422017526e-06
phenylalanine B-Disease 1 0.9999996423721313
hydroxylase I-Disease 1 0.9999984502792358
deficiency I-Disease 1 1.0
: O 0 2.162073116096508e-07
classification O 0 1.4489476143353386e-06
of O 0 1.9738417904591188e-06
105 O 0 2.0072727693332126e-06
mutations O 0 6.464841106890162e-08
and O 0 8.99890295613659e-09
a O 0 8.984410548862343e-09
general O 0 2.003895183122495e-08
system O 0 3.8660733281403736e-08
for O 0 4.185205959572613e-09
genotype O 0 9.00457237662522e-08
- O 0 3.2440926389654123e-08
based O 0 5.187662743821875e-09
prediction O 0 2.7307771688356297e-07
of O 0 4.2349219597781484e-07
metabolic O 0 0.13161325454711914
phenotype O 0 7.768959221721161e-06
. O 0 2.8813633434765507e-06

Phenylketonuria B-Disease 1 0.9739714860916138
( O 0 1.4394689969776664e-05
PKU B-Disease 0 0.0036036132369190454
) O 0 4.107564279820508e-07
and O 0 7.305949338842765e-07
mild B-Disease 1 0.9998451471328735
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.2652091681957245
MHP B-Disease 1 1.0
) O 0 2.737906470429152e-07
are O 0 2.3682376948386263e-08
allelic B-Disease 0 0.00981985405087471
disorders I-Disease 1 0.9999945163726807
caused O 0 2.199346624820464e-07
by O 0 1.2785672520720937e-09
mutations O 0 3.94231536304801e-09
in O 0 9.691788482868446e-10
the O 0 4.0177936533325465e-09
gene O 0 9.934902678310209e-09
encoding O 0 2.788279971355223e-07
phenylalanine O 0 1.1056264156650286e-05
hydroxylase O 0 0.0002474887587595731
( O 0 5.518384114111541e-06
PAH O 1 0.9957893490791321
) O 0 4.6925247261242475e-06
. O 0 7.513257969549159e-06

Previous O 0 9.786922419152688e-07
studies O 0 4.5645106183656026e-07
have O 0 1.867111576459024e-09
suggested O 0 5.8488329734984745e-09
that O 0 6.435060123655134e-11
the O 0 8.054154010395109e-10
highly O 0 1.538386840138628e-08
variable O 0 2.7957008796875016e-07
metabolic O 0 0.0006430275971069932
phenotypes O 0 9.712959581520408e-06
of O 0 0.0012380406260490417
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999914169311523
correlate O 0 0.00021974396076984704
with O 0 0.00013627990847453475
PAH O 1 0.9999997615814209
genotypes O 0 0.04052380472421646
. O 0 2.696503361221403e-05

We O 0 2.087184327592695e-07
identified O 0 5.6696539019185366e-08
both O 0 8.556388486624655e-09
causative O 0 7.14207203600381e-07
mutations O 0 6.361263160670205e-08
in O 0 3.535730996873099e-08
686 O 0 1.5939651802909793e-06
patients O 0 1.9214131441458449e-07
from O 0 3.101095913393692e-08
seven O 0 4.3967986584902974e-08
European O 0 3.1330642968896427e-07
centers O 0 1.3734776302953833e-06
. O 0 6.071256848372286e-07

On O 0 4.981760071132157e-07
the O 0 1.5191684354931567e-08
basis O 0 2.1437154273939996e-08
of O 0 4.133449582610638e-09
the O 0 1.82279247251671e-09
phenotypic O 0 3.006327915500151e-07
characteristics O 0 1.3123960229677323e-07
of O 0 2.2817779665729176e-07
297 O 0 5.921082788518106e-07
functionally O 0 6.720884357491741e-06
hemizygous O 0 9.72069665294839e-06
patients O 0 3.253666847058412e-08
, O 0 3.025359962549601e-09
105 O 0 3.132424453156091e-08
of O 0 1.4348370491745754e-08
the O 0 5.288578019957413e-09
mutations O 0 2.829120271385932e-09
were O 0 3.3568194890420955e-09
assigned O 0 1.0999577249037884e-08
to O 0 4.1834000152896067e-10
one O 0 6.63014754209712e-10
of O 0 5.03496488946098e-09
four O 0 1.6661069190959665e-09
arbitrary O 0 1.3784960728457918e-08
phenotype O 0 4.846118883961026e-08
categories O 0 2.065277442397928e-07
. O 0 6.064289550522517e-07

We O 0 5.530831685973681e-07
proposed O 0 2.137685299885561e-07
and O 0 1.609938671265354e-08
tested O 0 1.3526899600435627e-08
a O 0 6.354078374570804e-10
simple O 0 5.585614748504497e-10
model O 0 5.373108624695533e-10
for O 0 2.6646396200646905e-10
correlation O 0 7.379163502463371e-09
between O 0 3.4007399563051877e-08
genotype O 0 7.17703159125449e-08
and O 0 5.353225862592126e-09
phenotypic O 0 8.277460210592835e-07
outcome O 0 1.6242271385635831e-06
. O 0 9.584199460732634e-07

The O 0 3.987065610999707e-07
observed O 0 2.840054662556213e-07
phenotype O 0 6.621319670330195e-08
matched O 0 4.61024924902631e-08
the O 0 8.963973563425043e-09
predicted O 0 5.8595109209136353e-08
phenotype O 0 3.273584736618318e-09
in O 0 1.8090178244278832e-09
79 O 0 1.3575206736504697e-08
% O 0 2.8183109179735766e-09
of O 0 9.60326573817838e-09
the O 0 5.317688955841504e-09
cases O 0 2.0433237324368747e-09
, O 0 1.3804760112812176e-10
and O 0 8.750187380224261e-11
in O 0 4.006733278494323e-10
only O 0 3.4398323078832505e-10
5 O 0 2.5936619518773796e-09
of O 0 6.998054580265034e-09
184 O 0 1.3574222634815669e-08
patients O 0 7.3094450492305896e-09
was O 0 4.014777843508455e-08
the O 0 3.880662458044526e-09
observed O 0 1.2050433539911865e-08
phenotype O 0 1.9164192455178863e-09
more O 0 1.5389135799015463e-10
than O 0 1.612696781672085e-10
one O 0 1.22850479788994e-10
category O 0 2.626839412656068e-09
away O 0 1.3107537277790016e-09
from O 0 4.3442852093455997e-10
that O 0 2.3003907112517652e-10
expected O 0 3.633280698522867e-08
. O 0 1.5095103833573376e-07

Among O 0 2.567366550465522e-07
the O 0 4.955348131829851e-08
seven O 0 3.223442845978752e-08
contributing O 0 2.8077264957460102e-08
centers O 0 6.683196662748969e-09
, O 0 2.809191212982398e-10
the O 0 4.994932245594441e-10
proportion O 0 6.855033429786772e-09
of O 0 4.884704907226478e-08
patients O 0 9.233292352917033e-09
for O 0 3.537658610497374e-09
whom O 0 7.745283525650848e-09
the O 0 4.690284605146644e-09
observed O 0 1.2620799516582792e-08
phenotype O 0 1.0878516976120522e-09
did O 0 8.009207741466184e-10
not O 0 8.345236307549797e-11
match O 0 1.0124978189196554e-08
the O 0 2.054959313824156e-09
predicted O 0 9.372543630092878e-09
phenotype O 0 9.176403525934518e-10
was O 0 1.246667480359065e-08
4 O 0 1.208924782503118e-08
% O 0 2.569995327661445e-09
- O 0 2.363932338766972e-08
23 O 0 6.470441604733423e-08
% O 0 1.991082498875585e-08
( O 0 2.1342057010542703e-08
P O 0 9.234401659341529e-06
< O 0 4.658942600599403e-07
. O 0 5.449435125370883e-09
0001 O 0 4.927779173158342e-06
) O 0 5.2008495288191625e-09
, O 0 1.2600156473752122e-09
suggesting O 0 4.476021775445815e-09
that O 0 1.1702369628885378e-10
differences O 0 6.334599511603756e-09
in O 0 5.050110885029824e-10
methods O 0 4.850092327757238e-09
used O 0 3.9023934084170264e-10
for O 0 1.8152107594815448e-10
mutation O 0 6.41868669326584e-10
detection O 0 1.5961587962465273e-07
or O 0 8.254787076111825e-09
phenotype O 0 1.4141043003235154e-08
classification O 0 6.715130496104393e-08
may O 0 4.304408829369777e-09
account O 0 3.693964856221754e-10
for O 0 2.8610322444500014e-10
a O 0 3.6550676374424995e-10
considerable O 0 1.675491856367728e-09
proportion O 0 2.7185804718499185e-09
of O 0 3.291605210620219e-08
genotype O 0 2.1069906779302983e-06
- O 0 4.814656222151825e-06
phenotype O 0 4.248631171321904e-07
inconsistencies O 0 3.341042656757054e-06
. O 0 1.3188769116823096e-06

Our O 0 7.397711669909768e-07
data O 0 3.905894061517756e-07
indicate O 0 4.883186477400159e-08
that O 0 2.8319653289088365e-09
the O 0 1.029441705213685e-07
PAH O 1 0.9961003065109253
- O 0 2.202536052209325e-06
mutation O 0 3.0840709985824333e-09
genotype O 0 1.587950215764522e-08
is O 0 1.9493023861727465e-10
the O 0 2.9405503032542413e-10
main O 0 7.466033125069771e-09
determinant O 0 1.1305083802426452e-07
of O 0 9.689930635659039e-08
metabolic O 0 0.00038857641629874706
phenotype O 0 5.079095899418462e-08
in O 0 9.374241827231344e-09
most O 0 1.1486328332921403e-08
patients O 0 3.6439311656977225e-07
with O 0 6.068281800253317e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.8032593131065369

In O 0 2.457700531977025e-07
the O 0 1.9183548971568598e-08
present O 0 1.676745853274042e-08
study O 0 4.465183778279425e-09
, O 0 2.777141294707519e-10
the O 0 3.698956696496225e-10
classification O 0 2.660645570529141e-08
of O 0 3.312490548523783e-07
105 O 0 6.0098802350694314e-05
PAH O 1 0.9998979568481445
mutations O 0 2.70091419452001e-07
may O 0 2.553530364934886e-08
allow O 0 2.6534678898570974e-09
the O 0 6.578579014870911e-09
prediction O 0 7.965339676729855e-08
of O 0 1.1386164899818141e-08
the O 0 8.050441202556158e-09
biochemical O 0 1.5553462162642973e-07
phenotype O 0 7.499429521828915e-09
in O 0 5.9464255741659144e-09
> O 0 3.987981500586102e-08
10 O 0 1.2540080085443606e-08
, O 0 1.6999693874808486e-09
000 O 0 9.378892329436894e-09
genotypes O 0 7.450060479641252e-08
, O 0 4.84653206456187e-09
which O 0 5.753102438887936e-10
may O 0 1.7773881255678248e-09
be O 0 2.806443966107963e-10
useful O 0 1.830467777352851e-09
for O 0 2.7828359061565777e-10
the O 0 2.339114901772632e-09
management O 0 1.9991389876850008e-07
of O 0 4.873509737990389e-07
hyperphenylalaninemia B-Disease 1 0.9999994039535522
in O 0 6.112406367719814e-07
newborns O 0 1.389357635162014e-06
. O 0 5.7600522040957e-07

Somatic O 0 0.00028889579698443413
instability O 0 0.00010094764729728922
of O 0 2.855597131201648e-06
the O 0 2.0874997517239535e-06
CTG O 0 0.0014127660542726517
repeat O 0 1.2102152595616644e-06
in O 0 7.212175034965185e-08
mice O 0 1.3732704928770545e-07
transgenic O 0 6.7739449605142e-08
for O 0 3.081097332824356e-08
the O 0 0.018953077495098114
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.003108093747869134
is O 0 6.078614234183988e-08
age O 0 1.2827416639993316e-07
dependent O 0 1.678176175801127e-08
but O 0 3.537872772518824e-10
not O 0 8.122708755609054e-11
correlated O 0 1.3638993268116906e-09
to O 0 1.4229664668796715e-10
the O 0 5.137315017833544e-10
relative O 0 3.341024878977805e-08
intertissue O 0 1.8896662368206307e-07
transcription O 0 1.4900923872573912e-07
levels O 0 2.4236760509666055e-07
and O 0 5.03262498341428e-08
proliferative O 0 0.00045259081525728106
capacities O 0 0.00015269435243681073
. O 0 3.691806796268793e-06

A O 0 6.0889058659086004e-05
( O 0 7.283339868990879e-07
CTG O 0 4.140609598834999e-05
) O 0 2.233013596253386e-08
nexpansion O 0 8.070983312791213e-07
in O 0 9.461488481576907e-09
the O 0 1.4506985834827901e-08
3 O 0 7.473557275261555e-07
- O 0 3.0610880230597104e-07
untranslated O 0 6.955287972232327e-05
region O 0 1.2670529940805864e-06
( O 0 4.145761067775311e-08
UTR O 0 1.3090153515804559e-05
) O 0 1.4722655095056325e-08
of O 0 1.1373189323649058e-07
the O 0 1.526140522400965e-06
DM O 1 0.9999998807907104
protein O 0 6.6978118411498144e-06
kinase O 0 3.0090095037849096e-07
gene O 0 5.9165614629819174e-08
( O 0 1.3757880168441261e-08
DMPK O 0 4.910496045340551e-06
) O 0 2.512837715684668e-09
is O 0 6.27892571269939e-10
responsible O 0 2.3717138475376487e-08
for O 0 9.847798310147482e-07
causing O 1 1.0
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9987975358963013
DM B-Disease 1 1.0
) O 0 1.2454868738132063e-05
. O 0 3.4535473787400406e-06

Major O 0 8.425868873018771e-05
instability O 0 0.012897024862468243
, O 0 3.768852252505894e-08
with O 0 3.351714239485659e-09
very O 0 1.0083581081232751e-08
large O 0 1.6157033044805758e-08
expansions O 0 4.220028770873796e-08
between O 0 7.52851221363926e-08
generations O 0 1.3050766689559623e-08
and O 0 8.443353793907704e-10
high O 0 1.537198990320121e-08
levels O 0 2.597644055413184e-08
of O 0 3.4210707156034914e-08
somatic O 0 1.086790348381328e-06
mosaicism O 0 1.2667832379520405e-05
, O 0 2.0916441911822403e-09
is O 0 3.489040445447955e-10
observed O 0 6.713885447595658e-09
in O 0 1.0744608758272989e-08
patients O 0 1.565674523362759e-07
. O 0 4.1107699644271634e-07

There O 0 1.2314136483837501e-06
is O 0 5.6318022245704924e-08
a O 0 1.7725005463375965e-08
good O 0 1.681511463402785e-08
correlation O 0 2.7066612062753848e-08
between O 0 7.039275118359001e-08
repeat O 0 1.1378688924423841e-07
size O 0 5.876590236653101e-08
( O 0 5.5679922894569245e-09
at O 0 4.5433644402237405e-08
least O 0 5.938624592083386e-10
in O 0 7.05378477849905e-10
leucocytes O 0 1.1447620806848136e-07
) O 0 7.658870204707569e-10
, O 0 5.551594739472421e-10
clinical O 0 2.2295960633300638e-08
severity O 0 1.437626337974507e-07
and O 0 4.08744504909464e-09
age O 0 2.2300199020719447e-07
of O 0 5.67018389574514e-07
onset O 0 0.007250005844980478
. O 0 2.3317809336731443e-06

The O 0 2.2624702978646383e-05
trinucleotide O 1 0.9835872054100037
repeat O 0 7.289706991286948e-05
instability O 0 0.00017085892613977194
mechanisms O 0 0.00010665949230315164
involved O 0 8.666650046507129e-07
in O 0 2.3192053788534395e-07
DM B-Disease 1 1.0
and O 0 1.0681555551173005e-07
other O 0 1.0465848276908218e-07
human O 0 0.03779959678649902
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.8355557901704742e-08
unknown O 0 1.8953149947265047e-06
. O 0 3.493859423997492e-07

We O 0 3.723544921285793e-07
studied O 0 8.160312063409947e-06
somatic O 0 1.1901092875632457e-06
instability O 0 3.2269528560391336e-07
by O 0 2.0900212671648433e-09
measuring O 0 1.368281664326787e-05
the O 0 4.881179620497278e-07
CTG O 0 0.00011135664681205526
repeat O 0 2.0945901724189753e-07
length O 0 2.5418678717414878e-08
at O 0 2.6026876653872932e-08
several O 0 3.3369645935366066e-10
ages O 0 3.0916977866723983e-09
in O 0 1.091473786352104e-10
various O 0 6.681663555774264e-10
tissues O 0 2.029683265902804e-08
of O 0 9.597776085001897e-08
transgenic O 0 1.2108786506814795e-07
mice O 0 2.149705835563509e-08
carrying O 0 7.233925902738747e-09
a O 0 1.2098567481189093e-08
( O 0 5.897967891854705e-09
CTG O 0 3.401133881197893e-06
) O 0 6.75004319106165e-09
55expansion O 0 2.170193766914963e-07
surrounded O 0 7.626603348853678e-08
by O 0 1.3972049073274206e-09
45 O 0 3.798092862439262e-08
kb O 0 2.401984602329321e-06
of O 0 1.4065821574149595e-07
the O 0 1.0190681365429555e-07
human O 0 4.0032202264228545e-07
DM B-Disease 1 0.9999990463256836
region O 0 1.6583297224315174e-07
, O 0 4.4450426672781873e-10
using O 0 1.5615603254914845e-09
small O 0 3.135154580391486e-09
- O 0 4.239552708895644e-08
pool O 0 4.635135439912119e-07
PCR O 0 3.97259753981416e-07
. O 0 1.9418459373810038e-07

These O 0 4.00310966597317e-07
mice O 0 7.23603250207816e-07
have O 0 1.9569477149872228e-09
been O 0 1.3687857514099733e-09
shown O 0 2.9609012464071327e-10
to O 0 7.137487129105224e-11
reproduce O 0 2.926251019275128e-09
the O 0 2.8863067491613492e-09
intergenerational O 0 6.859260537339651e-08
and O 0 7.706908888849284e-09
somatic O 0 6.741939841958811e-07
instability O 0 7.94608126852836e-07
of O 0 1.672131588748016e-07
the O 0 3.8882367903170234e-07
55 O 0 3.1219944958138512e-06
CTG O 0 0.00011922532576136291
repeat O 0 4.722684820990253e-07
suggesting O 0 4.174914991494916e-08
that O 0 5.059211938274188e-10
surrounding O 0 6.673769981091482e-09
sequences O 0 4.940924558383131e-09
and O 0 1.1116226827923015e-09
the O 0 5.050190488020689e-09
chromatin O 0 4.18831064052938e-07
environment O 0 6.115105577464419e-08
are O 0 5.048078621783247e-10
involved O 0 4.432312294966323e-09
in O 0 2.2383639386447385e-09
instability O 0 1.5758022300360608e-06
mechanisms O 0 2.4904069505282678e-05
. O 0 1.7472571016696747e-06

As O 0 1.1946301015086647e-07
observed O 0 2.5479256038352105e-08
in O 0 1.4407955939432782e-09
some O 0 1.2077643052332832e-10
of O 0 3.213012078617794e-09
the O 0 7.83060549736092e-09
tissues O 0 3.8791441170360486e-07
of O 0 1.7689795640762895e-05
DM B-Disease 1 1.0
patients O 0 3.018764346052194e-06
, O 0 3.843624085675401e-09
there O 0 1.6655731238657268e-09
is O 0 4.999011204986914e-10
a O 0 1.0884535495137015e-09
tendency O 0 1.0959866347803882e-09
for O 0 1.105303293336135e-09
repeat O 0 2.4767704331907225e-08
length O 0 1.2581430119951165e-08
and O 0 8.106156634823947e-09
somatic O 0 1.52678694576025e-07
mosaicism O 0 7.875331675677444e-07
to O 0 6.452343659368864e-10
increase O 0 7.660784229202022e-10
with O 0 5.24267740331652e-10
the O 0 1.229284229964378e-08
age O 0 2.695916805350862e-07
of O 0 9.66844098115871e-08
the O 0 7.446324445936625e-08
mouse O 0 6.497066920019279e-07
. O 0 2.0444035442324093e-07

Furthermore O 0 3.923754320567241e-06
, O 0 3.394965375491665e-08
we O 0 7.1598282858076345e-09
observed O 0 1.443288244473706e-08
no O 0 1.6757507603770705e-09
correlation O 0 5.548940418265147e-09
between O 0 2.477222649233113e-09
the O 0 2.0886941065612064e-09
somatic O 0 2.303457513619378e-08
mutation O 0 1.8776038501755465e-09
rate O 0 4.418384769167005e-09
and O 0 9.803657885498751e-10
tissue O 0 3.723452550730144e-07
proliferation O 0 2.1165094949537888e-05
capacity O 0 2.3825014068279415e-06
. O 0 2.9925402600383677e-07

The O 0 8.435182508037542e-07
somatic O 0 3.1363636026071617e-06
mutation O 0 6.759992743354815e-08
rates O 0 4.088476046604228e-08
in O 0 4.669573616666867e-10
different O 0 2.513929342473631e-10
tissues O 0 6.424421883366449e-09
were O 0 2.739045656952044e-09
also O 0 8.96430638053225e-11
not O 0 1.8359029574366303e-11
correlated O 0 4.2556380641656233e-10
to O 0 2.0681424628410383e-10
the O 0 4.2536765221257156e-09
relative O 0 4.0642989915795624e-06
inter O 1 0.9040818214416504
- O 0 1.331400540038885e-06
tissue O 0 1.331049759301095e-07
difference O 0 3.61247458613434e-08
in O 0 4.064927283664588e-10
transcriptional O 0 3.0492568470208425e-09
levels O 0 6.86194034926757e-09
of O 0 1.943793570546859e-09
the O 0 1.6284026349566716e-09
three O 0 3.6079419452050843e-09
genes O 0 3.0263123118601243e-09
( O 0 4.653163188095277e-09
DMAHP O 0 2.205688815593021e-06
, O 0 1.437628593947693e-08
DMPK O 0 6.953656793484697e-06
and O 0 1.1169620783846312e-08
59 O 0 1.3207129256898043e-07
) O 0 1.875742672297065e-09
surrounding O 0 3.60443550562195e-08
the O 0 2.273930910234867e-08
repeat O 0 1.628397825470529e-07
. O 0 1.8402529278205293e-08
. O 0 1.5576263479033514e-07

A O 0 3.1355621104012243e-06
novel O 0 3.1511393672190025e-07
missense O 0 1.5176005945249926e-06
mutation O 0 2.2767604690443477e-08
in O 0 1.1395637322664243e-08
patients O 0 7.001007418239169e-08
from O 0 1.3498539885858918e-07
a O 0 1.4857944279356161e-06
retinoblastoma B-Disease 0 0.17840400338172913
pedigree O 0 3.378598194103688e-06
showing O 0 2.410398565189098e-07
only O 0 7.814654701121526e-09
mild O 0 1.6697381965968816e-07
expression O 0 2.026638767915756e-08
of O 0 1.0422859020309261e-07
the O 0 1.6847080530624226e-07
tumor B-Disease 0 1.5967836588970385e-05
phenotype O 0 4.2176310444119736e-07
. O 0 7.397626404781477e-07

We O 0 3.0704762821187614e-07
have O 0 4.559943977966441e-09
used O 0 3.5699911915543225e-09
single O 0 1.6613025399792036e-09
strand O 0 4.785803753293294e-09
conformation O 0 2.0231927244651615e-09
polymorphism O 0 2.9147979585530948e-09
analysis O 0 9.222058672264666e-10
to O 0 3.4190644759846123e-10
study O 0 2.2146211531293147e-09
the O 0 1.1593431992196201e-08
27 O 0 4.609659924881271e-07
exons O 0 2.7712977157534624e-07
of O 0 7.016340930476872e-08
the O 0 1.1204555505628377e-07
RB1 O 0 1.7683692021819297e-06
gene O 0 5.774388966983679e-09
in O 0 1.2568569518478512e-09
individuals O 0 2.2098688157168311e-10
from O 0 2.4885517646566768e-08
a O 0 1.0161624430793381e-07
family O 0 2.6966128885419494e-08
showing O 0 1.4503325473924633e-07
mild O 0 3.1264767130778637e-07
expression O 0 4.072559889323202e-08
of O 0 2.2489446394047263e-07
the O 0 2.54320951853515e-07
retinoblastoma B-Disease 0 0.0006953245028853416
phenotype O 0 2.206355702583096e-06
. O 0 1.411126390848949e-06

In O 0 2.87279789290551e-07
this O 0 6.5016885208990516e-09
family O 0 1.4572850481897603e-08
affected O 0 2.7605282504339357e-09
individuals O 0 4.5199016751595877e-10
developed O 0 1.0796932201628806e-06
unilateral B-Disease 0 5.0994709454244e-05
tumors I-Disease 1 1.0
and O 0 1.2373808431220823e-06
, O 0 7.1707750848304386e-09
as O 0 1.7940364749335913e-09
a O 0 8.11569811354218e-10
result O 0 1.9195141032213314e-09
of O 0 2.6785686557673216e-08
linkage O 0 9.371045450734528e-08
analysis O 0 1.4244669443996827e-08
, O 0 1.6607828445813766e-09
unaffected O 0 1.5748476300814218e-08
mutation O 0 6.797689078297253e-10
carriers O 0 1.1876100103336285e-09
were O 0 2.050378533624553e-09
also O 0 6.60167864818817e-10
identified O 0 2.4568667100766106e-09
within O 0 4.711696366399565e-09
the O 0 4.4250832331727e-08
pedigree O 0 1.024465973387123e-06
. O 0 5.780661354037875e-07

A O 0 1.4369069276654045e-06
single O 0 5.4273439076268915e-08
band O 0 2.859353003259457e-07
shift O 0 1.1107271546961783e-07
using O 0 2.0655742005715183e-08
SSCP O 0 5.128057182446355e-06
was O 0 1.226111834284893e-07
identified O 0 1.732230003881341e-08
in O 0 8.562820674740124e-09
exon O 0 2.381283223940045e-07
21 O 0 2.6801631136663673e-08
which O 0 3.9017383768324976e-10
resulted O 0 5.645597767056643e-09
in O 0 3.321181107907023e-09
a O 0 1.2752433775631289e-08
missense O 0 5.486765175533037e-08
mutation O 0 3.293550765448572e-09
converting O 0 2.403748453616572e-07
a O 0 1.9216402336041938e-07
cys O 0 0.00022826607164461166
- O 0 1.7585391105967574e-05
- O 0 1.1427628123783506e-05
> O 0 7.610705097249593e-07
arg O 0 2.4812158017084585e-07
at O 0 4.0575574189460895e-07
nucleotide O 0 1.5035966782761534e-07
position O 0 3.950021323362307e-07
28 O 0 2.668839158559422e-07
in O 0 2.4223881567309036e-08
the O 0 1.35857675331863e-07
exon O 0 2.3299773602047935e-05
. O 0 2.6151085421588505e-06

The O 0 4.862103537561779e-07
mutation O 0 1.0376641768061745e-07
destroyed O 0 1.002411750050669e-06
an O 0 1.565011054083243e-08
NdeI O 0 2.065804665107862e-06
restriction O 0 1.581584996301899e-07
enzyme O 0 1.1908240793445657e-07
site O 0 4.707760012934159e-07
. O 0 6.041350388841238e-07

Analysis O 0 8.335144912052783e-07
of O 0 3.311328384825174e-07
all O 0 4.604888204085e-08
family O 0 1.3704504198130962e-08
members O 0 1.4119796443168298e-09
demonstrated O 0 3.2773768143812276e-09
that O 0 6.839041832851223e-11
the O 0 2.4957949040782523e-09
missense O 0 9.611221685190685e-08
mutation O 0 1.6263641100522364e-08
co O 0 1.9031685951631516e-06
- O 0 2.4195705918828025e-06
segregated O 0 2.8235153877176344e-06
with O 0 8.130253803528831e-08
patients O 0 2.4341758035006933e-05
with O 0 9.108962694881484e-05
tumors B-Disease 1 1.0
or O 1 0.9999508857727051
who O 0 1.2359124411887024e-05
, O 0 1.3991551028880167e-08
as O 0 3.351394495254567e-09
a O 0 1.0842763353835494e-09
result O 0 1.8396799639219807e-09
of O 0 2.9580705884768577e-08
linkage O 0 2.5759158006621874e-07
analysis O 0 2.2041039215991987e-08
had O 0 1.6671567237835916e-08
been O 0 2.096153250974453e-09
predicted O 0 3.5502989437219412e-09
to O 0 1.393563320295499e-10
carry O 0 1.2234265822641532e-09
the O 0 9.902098696557005e-09
predisposing O 0 1.5547961993434e-06
mutation O 0 2.967701107081666e-07
. O 0 1.0652496484908625e-06

These O 0 1.1931635413020558e-07
observations O 0 1.1326638968967018e-06
point O 0 1.0533271961321589e-06
to O 0 2.8094553350399565e-09
another O 0 1.2356783152256412e-08
region O 0 2.1699159802324175e-08
of O 0 3.174236695713262e-08
the O 0 8.089895686680393e-08
RB1 O 0 1.3945526006864384e-05
gene O 0 5.2718327481215965e-08
where O 0 1.0719615417542627e-08
mutations O 0 2.4306110457672503e-09
only O 0 2.0991289262362045e-10
modify O 0 2.1847907927252663e-09
the O 0 9.211615914495042e-10
function O 0 1.3705001578045994e-08
of O 0 1.1037364799904026e-08
the O 0 3.57701845921099e-09
gene O 0 2.357330330937657e-09
and O 0 8.050621280730752e-10
raise O 0 2.92082513730918e-09
important O 0 1.8100050347413799e-09
questions O 0 4.5810923943179205e-09
for O 0 9.620402252608073e-10
genetic O 0 3.657847003069037e-08
counseling O 0 7.500920418124224e-08
in O 0 2.6517679163617913e-09
families O 0 1.0916215847922572e-10
with O 0 1.3932018039231053e-10
these O 0 9.965528402489099e-10
distinctive O 0 5.9408513664038765e-08
phenotypes O 0 1.998902661171087e-07
. O 0 4.1088643598641283e-08
. O 0 3.485529589397629e-07

Maternal B-Disease 0 0.0004154980997554958
disomy I-Disease 0 0.003908981569111347
and O 0 0.0003014285466633737
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.11443495750427246
with O 0 7.426828005918651e-07
gamete O 0 0.00019238922686781734
complementation O 0 2.4656648747622967e-05
in O 0 2.19479936447442e-08
a O 0 1.2941501204011274e-08
case O 0 2.1134491490215623e-08
of O 0 9.546618429112641e-08
familial O 0 1.4292835430751438e-06
translocation O 0 3.4388829135423293e-06
( O 0 1.0864965815926553e-07
3 O 0 2.1576528297373443e-07
; O 0 2.7206656927347694e-09
15 O 0 2.5508430923082415e-08
) O 0 1.963827767070825e-09
( O 0 3.2909133196312723e-09
p25 O 0 2.2255773046708782e-07
; O 0 5.0933053330481926e-09
q11 O 0 3.527409546677518e-07
. O 0 6.866863078158758e-09
2 O 0 2.405195402843674e-07
) O 0 2.1095505786661306e-08
. O 0 2.6195965574515867e-07

Maternal B-Disease 0 0.021840820088982582
uniparental I-Disease 1 0.9964157342910767
disomy I-Disease 1 0.9579996466636658
( I-Disease 0 2.6350653570261784e-05
UPD I-Disease 1 0.9999638795852661
) I-Disease 0 7.620482023185104e-08
for I-Disease 0 3.4481388411222724e-08
chromosome I-Disease 0 2.429804339953989e-07
15 I-Disease 0 4.880560666720157e-08
is O 0 1.0930346627802123e-09
responsible O 0 2.395818876621547e-09
for O 0 9.025318825628403e-10
an O 0 4.618006810286346e-10
estimated O 0 2.55148413508266e-09
30 O 0 6.484375258963837e-09
% O 0 5.759712151665042e-10
of O 0 1.1232190733068137e-09
cases O 0 3.3233100715790442e-09
of O 0 5.003899786970578e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999150037765503
PWS B-Disease 1 1.0
) O 0 7.734531209280249e-06
. O 0 2.602187123557087e-06

We O 0 2.1913133707585075e-07
report O 0 1.454641296305681e-08
on O 0 5.239201517071024e-09
an O 0 2.45306330803885e-10
unusual O 0 2.68042787965328e-09
case O 0 2.744222626915871e-09
of O 0 4.889670446317496e-09
maternal B-Disease 0 2.4760200290074863e-07
disomy I-Disease 0 3.1670363114244537e-06
15 I-Disease 0 2.0207993145504588e-07
in O 0 9.642271692200666e-08
PWS B-Disease 1 0.999983549118042
that O 0 2.0070267670035946e-09
is O 0 5.282647652649075e-10
most O 0 1.3033464585365806e-10
consistent O 0 1.2545097183291887e-09
with O 0 3.0239333259629575e-10
adjacent O 0 9.940441003664091e-08
- O 0 1.6727952356632159e-07
1 O 0 3.24593173672838e-07
segregation O 0 1.685352515323757e-07
of O 0 1.57645256848582e-08
a O 0 2.921757413787418e-08
paternal O 0 7.661565604166753e-08
t O 0 1.0836549080295299e-07
( O 0 4.069444337062578e-09
3 O 0 1.820489714532414e-08
; O 0 5.230033073289064e-10
15 O 0 7.067295637597226e-09
) O 0 7.995348272338276e-10
( O 0 1.7896140125372995e-09
p25 O 0 9.769171072093741e-08
; O 0 1.2943172089663335e-09
q11 O 0 6.505933924927376e-08
. O 0 1.541667127291646e-09
2 O 0 1.7261120532907626e-08
) O 0 1.9591762934201284e-10
with O 0 2.4565563472300767e-10
simultaneous O 0 3.608851883996067e-08
maternal O 0 9.127898579208704e-07
meiotic O 0 1.0480533092049882e-05
nondisjunction O 0 6.710125035169767e-06
for O 0 1.765459529678992e-07
chromosome O 0 8.308674296131358e-06
15 O 0 4.789440936292522e-06
. O 0 3.4441902698745253e-06

The O 0 2.4091471004794585e-06
patient O 0 6.540112735820003e-06
( O 0 5.760794863363117e-08
J O 0 1.946766815308365e-06
. O 0 3.3019540435219596e-09
B O 0 1.034954237866259e-07
. O 0 1.6782895906342077e-10
) O 0 6.081087716713895e-11
, O 0 1.729814763651305e-10
a O 0 1.6829192484024702e-09
17 O 0 2.4562448075471366e-08
- O 0 3.040488749661563e-08
year O 0 2.601491466691641e-08
- O 0 9.295403629039356e-07
old O 0 2.8039939934387803e-06
white O 0 7.471719953855427e-08
male O 0 8.566892262251713e-08
with O 0 1.8089329500980966e-07
PWS B-Disease 1 1.0
, O 0 1.5558269694793125e-07
was O 0 5.621048444481858e-07
found O 0 1.781916281196061e-09
to O 0 1.8620713304606795e-10
have O 0 5.103912292803159e-10
47 O 0 1.6472151642688004e-08
chromosomes O 0 4.327078251264993e-09
with O 0 2.225019724022559e-09
a O 0 5.8322374485442197e-08
supernumerary O 0 9.049801519722678e-06
, O 0 2.9206093543621137e-08
paternal O 0 7.644209176760342e-07
der O 0 0.0011753729777410626
( O 0 2.309422875157452e-08
15 O 0 1.1966375446093025e-08
) O 0 2.745022265049357e-10
consisting O 0 2.16631290683722e-09
of O 0 8.18211631781196e-09
the O 0 3.43528547830374e-08
short O 0 7.468414509048671e-08
arm O 0 6.437850288421032e-07
and O 0 1.1281664491491483e-08
the O 0 2.2033374591501342e-07
proximal O 0 0.00022322387667372823
long O 0 2.4247933652077336e-06
arm O 0 7.823508894944098e-06
of O 0 1.6952515125012724e-06
chromosome O 0 5.309945208864519e-06
15 O 0 1.142133328357886e-06
, O 0 2.761256290284564e-08
and O 0 1.6479057762808225e-07
distal O 0 0.2413303703069687
chromosome O 0 0.4994223415851593
arm O 1 0.9973835349082947
3p O 1 0.99933260679245
. O 0 8.951350901043043e-05

The O 0 1.19815513244248e-05
t O 0 6.09500011705677e-06
( O 0 3.5317274438284585e-08
3 O 0 9.155432678653597e-08
; O 0 1.056427278989247e-09
15 O 0 1.400490123870668e-08
) O 0 5.161348015647604e-10
was O 0 6.305271416096048e-09
present O 0 6.603794733273105e-10
in O 0 3.9808945029307097e-10
the O 0 4.112301887904124e-10
balanced O 0 1.1268282973375676e-09
state O 0 1.581772907099932e-10
in O 0 1.631420415426632e-10
the O 0 9.731150329983507e-10
patients O 0 8.247893923396532e-09
father O 0 1.6762120580438022e-08
and O 0 1.116346570739779e-08
a O 0 3.004080610935489e-07
sister O 0 1.4567604011972435e-05
. O 0 1.7991658296523383e-06

Fluorescent O 0 6.763881629012758e-06
in O 0 1.2548242978027702e-07
situ O 0 2.1941605155006982e-06
hybridization O 0 6.52820872915072e-08
analysis O 0 2.16082156612174e-08
demonstrated O 0 1.7910286587152768e-08
that O 0 9.94263116282923e-10
the O 0 5.6431247230648296e-08
PWS B-Disease 1 0.9999921321868896
critical O 0 6.361663054121891e-07
region O 0 8.894610203924458e-08
resided O 0 1.521046328889497e-07
on O 0 5.394634960964595e-09
the O 0 1.964546969546177e-09
derivative O 0 8.60555786630357e-08
chromosome O 0 1.0363665836621294e-07
3 O 0 7.348378971983038e-08
and O 0 2.6974860123374356e-09
that O 0 3.350274224711569e-10
there O 0 7.993167794317912e-10
was O 0 1.5735505343172917e-08
no O 0 1.015940664927939e-09
deletion O 0 2.1592477139620314e-08
of O 0 2.5103094714040708e-08
the O 0 2.83300522596619e-07
PWS B-Disease 1 0.9999995231628418
region O 0 6.673594725725707e-07
on O 0 6.357551285418594e-08
the O 0 1.1796660537299886e-08
normal O 0 5.530579372248212e-08
pair O 0 5.346309706055763e-08
of O 0 4.334581049647568e-08
15s O 0 2.819662086039898e-06
present O 0 2.0676483813986124e-07
in O 0 3.3871722848743957e-07
J O 0 0.00034674545167945325
. O 0 3.3231581255677156e-06

B O 0 0.00722281401976943
. O 0 6.34535972494632e-05

Methylation O 0 4.420428922458086e-06
analysis O 0 5.170946337784699e-07
at O 0 2.2950785023567732e-06
exon O 0 2.4877649593690876e-06
alpha O 0 5.918660690440447e-07
of O 0 7.310033822705009e-08
the O 0 2.7506956712386454e-08
small O 0 6.670641994332982e-08
nuclear O 0 2.015233985730447e-05
ribonucleoprotein O 0 4.495588200370548e-06
- O 0 8.402587781120019e-08
associated O 0 5.79052716886963e-08
polypeptide O 0 3.702137121308624e-07
N O 0 2.829418690453167e-06
( O 0 1.3274908283733566e-08
SNRPN O 0 2.232133510915446e-06
) O 0 3.798467762550217e-09
gene O 0 1.063231991338398e-08
showed O 0 1.7918077688250378e-08
a O 0 4.5982417873347e-09
pattern O 0 5.927676482997413e-08
characteristic O 0 1.3778105767414672e-07
of O 0 7.293141379705048e-08
only O 0 2.5404462977718367e-09
the O 0 7.8689943450172e-09
maternal O 0 1.380375351800467e-07
chromosome O 0 3.644219361831347e-07
15 O 0 2.9373785537245567e-07
in O 0 8.393937633854875e-08
J O 0 0.00021342511172406375
. O 0 2.719292979236343e-06

B O 0 0.008018219843506813
. O 0 6.026149640092626e-05

Maternal B-Disease 0 0.00023955183860380203
disomy I-Disease 0 0.00023293634876608849
was O 0 2.2111246380518423e-06
confirmed O 0 3.4528511605458334e-08
by O 0 1.5177483714268192e-09
polymerase O 0 2.2144284628211608e-07
chain O 0 1.3711694890616855e-08
reaction O 0 1.4825359828662954e-09
analysis O 0 1.0820621731966185e-08
of O 0 3.004212345558699e-08
microsatellite O 0 4.840451310883509e-07
repeats O 0 7.684074176950162e-08
at O 0 8.039703658369035e-08
the O 0 9.754253404992141e-09
gamma O 0 3.565509416603163e-07
- O 0 8.544991914050115e-08
aminobutyric O 0 1.4270291615048336e-07
acid O 0 2.29257004491501e-08
receptor O 0 1.3228301121159802e-08
beta3 O 0 2.1029705976616242e-07
subunit O 0 1.7223668180577079e-07
( O 0 2.00709688868983e-08
GABRB3 O 0 5.048015736974776e-06
) O 0 6.144228592575018e-08
locus O 0 7.407248290292046e-07
. O 0 8.560437549931521e-07

A O 0 4.991733658243902e-05
niece O 0 4.250470738043077e-05
( O 0 1.018327822066567e-07
B O 0 1.2396783404255984e-06
. O 0 5.045877049525416e-09
B O 0 1.0641839764957695e-07
. O 0 4.0240574761263304e-10
) O 0 1.6460860452482962e-10
with O 0 5.227998589596439e-10
45 O 0 1.4244561086229623e-08
chromosomes O 0 1.307378738601983e-08
and O 0 2.973897794689151e-09
the O 0 3.6893619270728095e-09
derivative O 0 8.435796416961239e-08
3 O 0 3.404926118832918e-08
but O 0 5.207954623109856e-10
without O 0 2.1692154739128e-09
the O 0 8.479055679799785e-09
der O 0 3.694412225740962e-05
( O 0 8.173880239326081e-09
15 O 0 2.7587347517510352e-08
) O 0 1.4601334585861991e-09
demonstrated O 0 9.774199227763347e-09
a O 0 4.560257060859385e-09
phenotype O 0 3.889606858820116e-09
consistent O 0 7.03233515864099e-09
with O 0 2.6045271495078737e-10
that O 0 1.1336852290266819e-10
reported O 0 1.7379510053316949e-09
for O 0 1.4036984907761507e-09
haploinsufficiency O 0 1.842049641709309e-06
of O 0 2.548453608142154e-07
distal O 0 8.752828580327332e-05
3 O 0 4.306630216888152e-05
p O 0 0.00014983468281570822
. O 0 2.8355316317174584e-06

Uniparental B-Disease 1 0.9999972581863403
disomy I-Disease 1 0.9994575381278992
associated O 0 2.2901022020960227e-06
with O 0 5.892056620382391e-08
unbalanced O 0 1.798324410628993e-05
segregation O 0 1.8996715880348347e-05
of O 0 3.74997654262188e-07
non O 0 1.4834053217782639e-05
- O 0 1.3743458112003282e-05
Robertsonian O 0 4.154915950493887e-05
translocations O 0 1.008339040708961e-06
has O 0 2.8079178981954556e-09
been O 0 9.502592046573e-10
reported O 0 7.330034357266868e-10
previously O 0 3.3087501627449e-09
but O 0 2.0194135252893375e-10
has O 0 8.308263105272218e-11
not O 0 1.322823656169092e-10
, O 0 7.687537412204293e-11
to O 0 1.318010839357342e-10
our O 0 2.53223197965724e-09
knowledge O 0 1.0596389188322064e-07
, O 0 7.732643969582398e-10
been O 0 1.4272040493867877e-10
observed O 0 5.297803307158233e-10
in O 0 1.7590169598680205e-10
a O 0 1.1500790320084775e-09
case O 0 1.1330746119142532e-08
of O 0 2.672904599876347e-07
PWS B-Disease 1 0.9999994039535522
. O 0 9.455821782466955e-06

Furthermore O 0 2.7017254979000427e-05
, O 0 1.7443107935832813e-07
our O 0 1.6182477580173327e-08
findings O 0 3.3339127014642145e-09
are O 0 5.780730061299977e-11
best O 0 2.0290193136762724e-10
interpreted O 0 1.0863381305625808e-09
as O 0 1.6108101519307638e-09
true O 0 1.5192552993426034e-08
gamete O 0 1.1440170055720955e-06
complementation O 0 2.51647065852012e-06
resulting O 0 9.624466912327989e-08
in O 0 2.3566714446587866e-07
maternal B-Disease 0 0.00012295682972762734
UPD I-Disease 1 0.9999990463256836
15 I-Disease 0 0.000464802811620757
and O 0 0.0002733031287789345
PWS B-Disease 1 0.9999998807907104

Schwartz B-Disease 1 0.9891968369483948
- I-Disease 1 0.9997968077659607
Jampel I-Disease 1 0.9999808073043823
syndrome I-Disease 1 0.9999889135360718
type I-Disease 0 0.00036868115421384573
2 I-Disease 0 3.704258051584475e-05
and O 0 1.7144711250693945e-07
Stuve B-Disease 1 0.9999133348464966
- I-Disease 1 0.9999935626983643
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999839067459106
: O 0 1.4503473089177987e-08
a O 0 1.4863619668403771e-08
case O 0 1.1464572402530848e-08
for O 0 1.2223162482172256e-09
" O 0 1.7775857230617476e-08
lumping O 0 1.940877751849257e-07
" O 0 1.4985404561684845e-07
. O 0 1.7393720952441072e-07

Recent O 0 5.608294983971973e-08
studies O 0 8.742392765270779e-08
demonstrated O 0 2.5006754000855835e-08
the O 0 6.45160902479347e-09
existence O 0 6.399973884185783e-09
of O 0 8.845897347953269e-09
a O 0 1.1139601241438868e-08
genetically O 0 4.5380184054977235e-09
distinct O 0 1.1532730326280216e-09
, O 0 3.236252932303785e-10
usually O 0 2.615728744714829e-10
lethal O 0 1.1676511979530346e-09
form O 0 1.6773744893061604e-10
of O 0 2.888250527632863e-09
the O 0 3.3556432299519656e-08
Schwartz B-Disease 0 0.005834891460835934
- I-Disease 0 0.12103637307882309
Jampel I-Disease 1 0.9998488426208496
syndrome I-Disease 1 0.9999579191207886
( O 0 8.728011948733183e-07
SJS B-Disease 1 0.9971152544021606
) O 0 2.0349885687664937e-07
of O 0 2.52535810432164e-05
myotonia B-Disease 1 0.9999992847442627
and O 1 0.8018373250961304
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.2170950867584907e-05
which O 0 1.0746539658157417e-07
we O 0 1.4213490828751674e-07
called O 0 1.4401801990970853e-06
SJS B-Disease 1 0.9960696697235107
type I-Disease 0 0.00013948397827334702
2 I-Disease 0 8.153253293130547e-05
. O 0 1.7855594478533021e-06

This O 0 1.5104188832992804e-06
disorder O 1 0.9994311928749084
is O 0 1.5663628971651633e-07
reminiscent O 0 3.5697688872460276e-05
of O 0 6.511135666187329e-07
another O 0 4.381887919180372e-08
rare O 0 4.7170580330657685e-08
condition O 0 4.5574722662422573e-07
, O 0 3.0116173999061857e-09
the O 0 4.8234888083698024e-08
Stuve B-Disease 1 0.9995137453079224
- I-Disease 1 0.9999982118606567
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.51534924650332e-06
SWS B-Disease 0 0.0013215411454439163
) O 0 1.7908851290826533e-08
, O 0 2.3063579934756717e-09
which O 0 2.7399066349076406e-10
comprises O 0 1.0328929711533874e-08
campomelia B-Disease 0 2.3694724404776935e-06
at O 0 1.0827288861037232e-06
birth O 0 3.43460811791374e-07
with O 0 6.893110366945621e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.0020681798923760653
contractures B-Disease 1 0.9999834299087524
, O 0 8.882265660759003e-07
and O 0 1.2691727135916153e-07
early B-Disease 0 6.941068022570107e-06
death I-Disease 0 2.385921334280283e-06
. O 0 7.195836815299117e-07

To O 0 5.62391271330398e-08
test O 0 3.4416999028508144e-08
for O 0 1.6907890643125256e-09
possible O 0 3.925240221747117e-08
nosologic O 0 3.524212388583692e-06
identity O 0 6.889956694067223e-08
between O 0 2.6654868179321056e-07
these O 0 2.7700126636887035e-08
disorders O 1 0.8326793313026428
, O 0 3.9792569239693876e-09
we O 0 6.671959651427528e-10
reviewed O 0 2.2567632207426414e-09
the O 0 1.6132505054056168e-10
literature O 0 3.278813054397034e-10
and O 0 2.92946465696442e-11
obtained O 0 4.626682093000767e-10
a O 0 1.9419287011768205e-10
follow O 0 2.4965551848055156e-10
- O 0 2.0177897130935207e-09
up O 0 1.3010992283568612e-09
of O 0 3.4738227849828718e-09
the O 0 1.251875603180963e-09
only O 0 4.472614500983241e-10
two O 0 8.895161274224961e-10
surviving O 0 2.2622813844463963e-07
patients O 0 1.8291633097078375e-08
, O 0 4.302914469178631e-09
one O 0 4.617462856515431e-09
with O 0 4.187028324054154e-08
SJS B-Disease 1 0.984993577003479
type I-Disease 0 1.788002555258572e-05
2 I-Disease 0 3.7215288557490567e-06
at O 0 4.160876869718777e-07
age O 0 1.7352978431972588e-07
10 O 0 3.033584050626814e-08
years O 0 3.873548148902728e-09
and O 0 1.6154991788752682e-09
another O 0 2.85142909284275e-09
with O 0 7.488737630012565e-09
SWS B-Disease 0 1.3655076145369094e-05
at O 0 2.771926801869995e-06
age O 0 1.1182750085936277e-06
7 O 0 1.1455346111688414e-06
years O 0 2.295789158779371e-07
. O 0 4.2668671085266396e-07

Patients O 0 1.3249837138573639e-05
reported O 0 4.4398069576345733e-07
as O 0 5.0176154786640836e-08
having O 0 4.062401330884313e-07
either O 0 4.4466331019066274e-05
neonatal O 1 1.0
SJS B-Disease 1 0.9999998807907104
or O 0 3.985046350862831e-05
SWS B-Disease 0 0.0002624229236971587
presented O 0 1.7012101238833566e-07
a O 0 8.089167558011923e-09
combination O 0 3.197308728886128e-08
of O 0 3.352156952018959e-08
a O 0 3.959234007311352e-08
severe O 0 4.591899596562143e-06
, O 0 1.0198011324291656e-07
prenatal O 1 0.9922768473625183
- O 1 0.9999432563781738
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.007979966700077057
with O 1 0.52467280626297
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999305009841919
respiratory O 1 1.0
and O 0 0.0033751490991562605
feeding O 0 0.0011591241927817464
difficulties O 0 0.15172408521175385
, O 0 1.337283066504824e-07
tendency O 0 1.0588409082856742e-07
to O 0 4.4622403549965384e-08
hyperthermia B-Disease 1 0.9999865293502808
, O 0 2.823149003461367e-08
and O 0 7.957378755918398e-09
frequent O 0 2.9479661378672972e-08
death O 0 1.119825228101945e-07
in O 0 6.512513550660515e-08
infancy O 0 3.1429929094883846e-06
) O 0 9.986573790143893e-10
with O 0 6.573521171837626e-10
a O 0 7.593592421528683e-09
distinct O 0 4.061343261696493e-08
campomelic B-Disease 1 0.886438250541687
- I-Disease 1 0.9947773218154907
metaphyseal I-Disease 1 0.9997591376304626
skeletal I-Disease 1 0.9999997615814209
dysplasia I-Disease 1 0.9999998807907104
. O 0 0.0017057930817827582

The O 0 2.3242226632191887e-07
similarity O 0 3.634383460848767e-07
of O 0 4.582628605476202e-07
the O 0 1.8411137148177659e-07
clinical O 0 3.993876362073934e-06
and O 0 2.5841629280876077e-08
radiographic O 0 1.878973125712946e-05
findings O 0 4.333803715894646e-08
is O 0 1.8020613890001869e-09
so O 0 4.68877991988137e-10
extensive O 0 5.024729077263146e-09
that O 0 1.991672937684541e-10
these O 0 4.093639649482839e-09
disorders O 0 0.07020969688892365
appear O 0 7.60316112291548e-08
to O 0 9.300116232680011e-10
be O 0 1.4489032196252083e-09
a O 0 2.328689241437587e-09
single O 0 4.108251072665325e-09
entity O 0 4.1439517417529714e-07
. O 0 1.9265705759607954e-06

The O 0 8.518367167198448e-07
follow O 0 1.6693465454409306e-07
- O 0 2.3143446981066518e-07
up O 0 2.2801545540573898e-08
observation O 0 8.451431767753093e-07
of O 0 7.371314225679271e-09
an O 0 6.350952541644972e-10
identical O 0 7.48034345576798e-09
and O 0 6.907608374184804e-10
unique O 0 5.851120477018412e-09
pattern O 0 1.0141947086594882e-06
of O 0 0.00010941233631456271
progressive O 1 0.9999996423721313
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
in O 0 3.0616301955888048e-06
the O 0 3.0297846933535766e-06
two O 0 5.907089644097141e-07
patients O 0 4.4287651235208614e-07
( O 0 7.633672360896071e-09
one O 0 4.232327377451384e-09
with O 0 2.899152562463314e-08
SJS B-Disease 1 0.9999487400054932
type I-Disease 0 0.0006977770826779306
2 I-Disease 0 7.643190656381194e-06
, O 0 4.910766016053003e-09
one O 0 1.1603202842991323e-09
with O 0 1.4631869049708257e-08
SWS B-Disease 0 0.0005835504271090031
) O 0 8.329504908033414e-08
surviving O 0 7.170379831222817e-06
beyond O 0 1.6413041521445848e-05
infancy O 0 4.937441190122627e-06
adds O 0 1.655574699555018e-08
to O 0 6.62306876009211e-10
the O 0 9.640956921685984e-10
evidence O 0 5.175131434498326e-09
in O 0 2.4677332399747343e-10
favor O 0 3.3693150491842516e-09
of O 0 9.203928286183327e-09
identity O 0 1.441800208112909e-07
. O 0 3.155277283894975e-07

The O 0 4.93228355935571e-07
hypothesis O 0 7.250490625665407e-07
that O 0 5.700808358710674e-08
SWS B-Disease 0 0.00012704861001111567
and O 0 8.234235906456888e-07
SJS B-Disease 1 0.9998288154602051
type I-Disease 0 0.00026808559778146446
2 I-Disease 0 3.0863109259371413e-06
are O 0 7.057256445897053e-10
the O 0 1.2626185652564459e-09
same O 0 3.5013304255926414e-08
disorder O 0 5.973847692075651e-06
should O 0 4.344577142489925e-09
be O 0 1.5010562792738824e-09
testable O 0 3.6739760123083443e-09
by O 0 8.980855642493069e-11
molecular O 0 3.7719878775988036e-08
methods O 0 7.211638575199686e-08
. O 0 1.304449526173812e-08
. O 0 1.542208281080093e-07

A O 0 4.589317086356459e-06
mouse O 0 2.2159389345688396e-07
model O 0 4.984734403024049e-08
of O 0 2.807513226343872e-07
severe O 1 0.9999244213104248
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 3.1196912459563464e-05
defects O 1 0.9971730709075928
in O 0 4.803832325706026e-06
hemostasis O 1 0.999964714050293
and O 0 0.0025694340001791716
thrombosis B-Disease 1 0.9999897480010986
. O 0 0.0002644760243128985

von B-Disease 1 0.9991063475608826
Willebrand I-Disease 1 0.9998295307159424
factor I-Disease 0 0.0006995011353865266
( I-Disease 0 4.582465408020653e-05
vWf I-Disease 1 0.5818861722946167
) I-Disease 0 0.001546661020256579
deficiency I-Disease 1 0.9999998807907104
causes O 1 0.9923630952835083
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.00012929578952025622
humans O 0 5.858187796548009e-05
. O 0 1.0602793736325111e-06

We O 0 2.989733332015021e-07
generated O 0 3.628703026947733e-08
a O 0 1.2068374743989807e-08
mouse O 0 4.744866277661686e-09
model O 0 1.6515148137941082e-09
for O 0 2.778444418982673e-10
this O 0 3.7132497077152493e-10
disease O 0 3.159183359358053e-09
by O 0 3.8290589449152534e-11
using O 0 2.8659763451344134e-09
gene O 0 2.3192667342186724e-08
targeting O 0 8.942392071276117e-08
. O 0 2.581348326202715e-07

vWf B-Disease 1 0.8800660967826843
- I-Disease 1 0.9998970031738281
deficient I-Disease 1 0.9993047714233398
mice O 0 2.1902633307036012e-05
appeared O 0 2.3489079126193246e-07
normal O 0 1.0092917079873587e-07
at O 0 7.876746366264342e-08
birth O 0 6.742477687282644e-09
; O 0 3.411865789892943e-10
they O 0 4.169460054992413e-10
were O 0 6.757746362495709e-09
viable O 0 1.536033096272149e-07
and O 0 2.2232857332937783e-08
fertile O 0 9.599585837349878e-07
. O 0 5.687134603249433e-07

Neither O 0 0.00031492908601649106
vWf O 0 0.0012194935698062181
nor O 0 0.00016776066331658512
vWf O 0 0.0003777772653847933
propolypeptide O 0 0.00033559303847141564
( O 0 2.0013644643768203e-06
von B-Disease 0 0.0010324897011741996
Willebrand I-Disease 0 0.00044388481182977557
antigen O 0 9.308337780566944e-07
II O 1 0.8291206955909729
) O 0 2.960249290140382e-08
were O 0 1.08196305248498e-08
detectable O 0 2.8655713890657353e-07
in O 0 1.9018140395843375e-09
plasma O 0 1.077602973964531e-06
, O 0 4.412809229137338e-09
platelets O 0 5.927359580937264e-08
, O 0 3.998978481689619e-09
or O 0 3.88749299418123e-09
endothelial O 0 2.854428871046366e-08
cells O 0 4.463600156157099e-09
of O 0 4.821426369261417e-09
the O 0 1.829114459894754e-08
homozygous O 0 3.332830544877652e-07
mutant O 0 1.846407940320205e-06
mice O 0 1.1769442380682449e-06
. O 0 3.2163990226763417e-07

The O 0 1.1867634839290986e-06
mutant O 0 3.069286321988329e-05
mice O 0 1.458183669456048e-05
exhibited O 0 1.1007407010765746e-05
defects O 0 0.001937534543685615
in O 0 3.771779688577226e-07
hemostasis O 0 0.0021957617718726397
with O 0 7.495986409367106e-08
a O 0 1.2381765372992959e-06
highly O 0 0.1182037889957428
prolonged O 1 0.9994990825653076
bleeding O 1 0.9996663331985474
time O 0 6.581631168955937e-07
and O 0 1.1184334880454117e-07
spontaneous O 0 3.6330771990833455e-07
bleeding O 0 1.1302218808850739e-05
events O 0 5.931665825187338e-09
in O 0 3.6844813866565573e-09
approximately O 0 4.668311071043263e-09
10 O 0 7.082976427597032e-09
% O 0 5.459984908640081e-09
of O 0 9.351386864864253e-08
neonates O 0 4.157134753768332e-06
. O 0 1.6354557601516717e-06

As O 0 3.203841174581612e-07
in O 0 2.62598920386381e-08
the O 0 7.268907609159214e-08
human O 0 1.1608851764322026e-06
disease O 0 2.94894425678649e-06
, O 0 1.5499993510914578e-09
the O 0 4.540520404106019e-09
factor O 0 1.6184669604513147e-08
VIII O 0 9.54959887167206e-06
level O 0 1.4719166756549384e-06
in O 0 1.0039327591471192e-08
these O 0 1.9028334463655483e-09
mice O 0 9.876991668988921e-09
was O 0 7.084881126218079e-09
reduced O 0 5.638947531139138e-09
strongly O 0 8.62770355158915e-10
as O 0 2.3069376964279797e-10
a O 0 3.3121014264558823e-10
result O 0 6.792271189937082e-10
of O 0 1.8314805227959141e-09
the O 0 3.3640108476618025e-09
lack O 0 2.1714892994850743e-08
of O 0 9.061372985286198e-09
protection O 0 4.0012846369563704e-08
provided O 0 9.180872062586332e-09
by O 0 7.218186048874031e-09
vWf O 0 1.0790985470521264e-05
. O 0 1.353657353320159e-06

Defective O 1 0.9977625608444214
thrombosis B-Disease 1 0.999552309513092
in O 0 1.1394904504413716e-05
mutant O 0 6.145876977825537e-05
mice O 0 4.165345671935938e-06
was O 0 3.3344457506245817e-07
also O 0 2.187350967020052e-09
evident O 0 1.1293893820152334e-08
in O 0 3.3119434972306294e-10
an O 0 8.769217990645117e-11
in O 0 6.884564585085684e-10
vivo O 0 1.287295532392818e-07
model O 0 1.1525011700541654e-07
of O 0 8.386650733882561e-06
vascular B-Disease 1 0.9999997615814209
injury I-Disease 1 0.9999935626983643
. O 0 0.0014968827599659562

In O 0 1.3387391106789437e-07
this O 0 2.757586603507889e-09
model O 0 2.9141490998085828e-08
, O 0 4.324512303810479e-09
the O 0 1.662434812033098e-08
exteriorized O 0 4.792502295458689e-06
mesentery O 0 1.5424995581270196e-05
was O 0 1.1750063322324422e-06
superfused O 0 1.5299046935979277e-06
with O 0 1.9058745692746015e-08
ferric O 0 0.003804862964898348
chloride O 0 7.237831596285105e-06
and O 0 8.544763829831936e-08
the O 0 1.6091227905690175e-07
accumulation O 0 3.004192330990918e-05
of O 0 1.3244631190900691e-05
fluorescently O 0 7.210662442957982e-05
labeled O 0 4.906798380943656e-07
platelets O 0 6.388926294675912e-07
was O 0 6.365924321016792e-08
observed O 0 1.3361377781961892e-08
by O 0 2.480220029354996e-09
intravital O 0 2.7553435302252183e-06
microscopy O 0 1.0603960618027486e-05
. O 0 2.6119480480701895e-06

We O 0 1.6924149122132803e-06
conclude O 0 1.9217627595935483e-06
that O 0 3.5566429801292543e-09
these O 0 1.4607072218453254e-09
mice O 0 3.974146522978117e-08
very O 0 2.71345168556536e-09
closely O 0 7.98051686956569e-08
mimic O 0 1.8434942830936052e-05
severe O 0 0.0001930651196744293
human O 0 0.0009197990293614566
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 4.127890349536756e-07
will O 0 8.616130919847365e-09
be O 0 1.1092695650916085e-09
very O 0 3.522722391569033e-10
useful O 0 3.4595057374353644e-10
for O 0 6.425224241546346e-11
investigating O 0 2.5512312262776504e-09
the O 0 5.510588096946378e-10
role O 0 1.2204858457209866e-08
of O 0 7.414493552460044e-08
vWf O 0 1.066394133886206e-06
in O 0 1.144451555745718e-08
normal O 0 4.05142543513648e-07
physiology O 0 8.416379841946764e-07
and O 0 3.0716604815239634e-09
in O 0 8.915888471960898e-09
disease O 0 2.2089906792643887e-07
models O 0 2.5793861269107765e-08
. O 0 1.5853990120717754e-08
. O 0 1.8950333924294682e-07

Oral O 1 0.8295544385910034
contraceptives O 0 0.056588370352983475
and O 0 2.5930699365517285e-08
the O 0 4.613706039435783e-08
risk O 0 7.04738158674445e-06
of O 0 0.02914443425834179
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9762909412384033

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 1 0.7243102788925171
Study O 0 1.7366418205710943e-06
Group O 0 5.299638132783002e-07
. O 0 8.65405525019014e-07

BACKGROUND O 0 6.487444625236094e-05
Women O 0 4.057525870848622e-08
with O 0 3.1452227489126017e-09
mutations O 0 9.724475447114855e-09
in O 0 2.7121271894969823e-09
either O 0 2.102488849686779e-08
the O 0 3.392984382344366e-08
BRCA1 O 0 3.647035029530343e-08
or O 0 9.450631388574493e-09
the O 0 1.9313404209242435e-08
BRCA2 O 0 8.679138296940891e-09
gene O 0 4.279473220236696e-09
have O 0 4.2256789734018696e-10
a O 0 1.2326716314348118e-09
high O 0 8.894236458445448e-08
lifetime O 0 4.675870357573331e-08
risk O 0 2.3031602722767275e-06
of O 0 0.41341882944107056
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00039205601206049323

Oral O 1 0.99601811170578
contraceptives O 1 0.9998252987861633
protect O 0 0.0012298192596063018
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.5177312889136374e-05
general O 0 9.777854756976012e-07
, O 0 8.138333562612843e-09
but O 0 7.287127012922667e-10
it O 0 8.585069460886885e-11
is O 0 1.006082508969719e-10
not O 0 5.0295562853408526e-11
known O 0 4.93004914670081e-10
whether O 0 6.885247372245829e-10
they O 0 2.8614086100553493e-10
also O 0 4.597809910578121e-10
protect O 0 2.466755466556947e-09
against O 0 5.2671087047428955e-08
hereditary B-Disease 1 0.9908060431480408
forms I-Disease 0 0.03572375699877739
of I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0016964045353233814

METHODS O 0 1.3682032658834942e-05
We O 0 1.0979020004242557e-07
enrolled O 0 8.161651976479334e-07
207 O 0 1.9746842383483454e-07
women O 0 1.4467444131582852e-08
with O 0 5.26884718965448e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1236908903811127e-05
161 O 0 6.96074266670621e-07
of O 0 5.150104129825195e-07
their O 0 2.861597181436082e-08
sisters O 0 3.3596083426346013e-07
as O 0 6.314369915827456e-09
controls O 0 1.265423748009198e-07
in O 0 5.028113037042203e-09
a O 0 1.715916297939657e-08
case O 0 7.563645709751654e-08
- O 0 5.6703353124021305e-08
control O 0 1.6025694549171021e-06
study O 0 1.315819844194266e-07
. O 0 3.0739715839445125e-07

All O 0 1.3523910524781968e-07
the O 0 6.238450822593222e-08
patients O 0 1.030358642850615e-08
carried O 0 7.954006342458797e-10
a O 0 3.5965208589061604e-10
pathogenic O 0 1.6732913943329208e-09
mutation O 0 4.864449953956296e-10
in O 0 1.107666958155562e-09
either O 0 1.3702570633711275e-08
BRCA1 O 0 2.0453290616728736e-08
( O 0 6.329865520626754e-09
179 O 0 3.471837572988079e-08
women O 0 4.6536601239210995e-09
) O 0 1.99088390218094e-09
or O 0 2.3470711596473848e-08
BRCA2 O 0 5.53822161464268e-08
( O 0 1.6939821989581105e-08
28 O 0 2.572940047684824e-07
women O 0 1.677267214006406e-08
) O 0 4.2669398681027815e-08
. O 0 6.180866876093205e-07

The O 0 9.282301789426128e-07
control O 0 1.2886549484392162e-05
women O 0 1.6542017533538456e-08
were O 0 8.442423649057673e-09
enrolled O 0 1.99286809277055e-08
regardless O 0 1.1756476681057393e-08
of O 0 5.217332788021167e-09
whether O 0 1.7612503677710833e-09
or O 0 9.221636787515308e-10
not O 0 1.2610391897371898e-10
they O 0 1.5993227575616942e-10
had O 0 3.3084852635312245e-09
either O 0 1.0913437265003267e-08
mutation O 0 1.004940486382111e-08
. O 0 3.556549543759502e-08

Lifetime O 0 2.5709118744998705e-06
histories O 0 1.7407541008651606e-06
of O 0 1.5816499399079476e-06
oral O 0 0.0008977788966149092
- O 0 2.0447887436603196e-06
contraceptive O 0 2.1534202687689685e-07
use O 0 2.446718827542327e-09
were O 0 1.7242947070172931e-09
obtained O 0 1.156775786270714e-09
by O 0 1.4373746637375007e-10
interview O 0 1.028407048409008e-08
or O 0 9.96993460011808e-11
by O 0 9.166668292481805e-12
written O 0 1.9888779859145167e-11
questionnaire O 0 1.7721606127008016e-10
and O 0 7.264170515108859e-11
were O 0 1.0134266759109778e-09
compared O 0 1.830636264799068e-08
between O 0 6.595467283432299e-08
patients O 0 2.8657591855107967e-08
and O 0 3.8403267232922644e-09
control O 0 5.206567038840149e-06
women O 0 3.490180366938489e-09
, O 0 5.253367740820636e-10
after O 0 2.47726039681595e-09
adjustment O 0 2.4307562185299503e-08
for O 0 9.587228788632274e-10
year O 0 9.919050025786191e-10
of O 0 8.291933362158943e-09
birth O 0 1.8340996277288468e-08
and O 0 1.6684417403212137e-08
parity O 0 1.538861579319928e-05
. O 0 1.4865584034851054e-06

RESULTS O 0 1.1801407708844636e-06
The O 0 1.0444511389096078e-07
adjusted O 0 4.0010411339608254e-07
odds O 0 8.255308330262778e-07
ratio O 0 7.072644621075597e-07
for O 0 9.449763638258446e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 9.416714306098584e-07
with O 0 1.2131373683388347e-09
any O 0 4.206381465365894e-09
past O 0 1.7839159038857133e-09
use O 0 3.1751736795371244e-09
of O 0 2.6059213453777375e-08
oral O 0 0.00012902962043881416
contraceptives O 0 0.00013303838204592466
was O 0 2.435714122839272e-06
0 O 0 6.214923473635281e-07
. O 0 4.277847551747982e-07

5 O 0 4.071980583830737e-06
( O 0 7.313520455909384e-08
95 O 0 2.37701769378873e-07
percent O 0 1.021136384338206e-07
confidence O 0 3.732432958258869e-07
interval O 0 2.3740770416225132e-07
, O 0 6.981655698012901e-09
0 O 0 3.233397993795961e-09
. O 0 2.5764335109812464e-10
3 O 0 3.218790123327153e-09
to O 0 7.018582937057261e-10
0 O 0 8.932978801112768e-09
. O 0 1.2790964953879325e-09
8 O 0 4.264897413008839e-08
) O 0 2.5303359407757853e-08
. O 0 2.584893081802875e-07

The O 0 5.997275138724945e-07
risk O 0 4.1967672359533026e-07
decreased O 0 6.560237864050578e-08
with O 0 7.321078188127217e-10
increasing O 0 3.0274553974862783e-09
duration O 0 1.0426910890259933e-08
of O 0 1.6629255750189031e-09
use O 0 7.067211260647355e-10
( O 0 1.900467561100072e-10
P O 0 3.0916581295059586e-08
for O 0 8.617803137767055e-10
trend O 0 9.398931410942168e-09
, O 0 8.238707494001574e-10
< O 0 1.6923094037224473e-08
0 O 0 3.742974818976563e-09
. O 0 3.748802657188577e-10
001 O 0 1.7044669675669866e-08
) O 0 2.9375230026218446e-10
; O 0 2.0441374981583493e-10
use O 0 4.4880307803474295e-10
for O 0 1.6271328728834078e-09
six O 0 7.530275070166681e-09
or O 0 2.6648085960090384e-09
more O 0 2.2985925662855067e-10
years O 0 3.732836706404896e-09
was O 0 2.6054939539221778e-08
associated O 0 2.8880686731014293e-09
with O 0 3.3265806775872875e-10
a O 0 4.111151419294856e-09
60 O 0 8.704568621453745e-09
percent O 0 7.1118377853451875e-09
reduction O 0 6.365171145716886e-08
in O 0 2.322179426528237e-08
risk O 0 5.44922897915967e-07
. O 0 3.11798174834621e-07

Oral O 0 0.0028011573012918234
- O 0 2.12817558349343e-05
contraceptive O 0 3.4373256312392186e-06
use O 0 2.3682874328301295e-08
protected O 0 7.512840238632634e-05
against O 1 0.9999940395355225
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 6.674078179003118e-08
for O 0 6.538150465473791e-09
carriers O 0 5.385187407114245e-09
of O 0 1.290703988132691e-08
the O 0 1.944788508012607e-08
BRCA1 O 0 1.4872525433418105e-08
mutation O 0 1.196993060226248e-09
( O 0 1.5059860025701255e-09
odds O 0 7.237820653926974e-08
ratio O 0 2.3702622087284908e-08
, O 0 1.621852985245198e-09
0 O 0 2.122820808025949e-09
. O 0 1.6351930920421864e-10
5 O 0 1.2061694976139847e-09
; O 0 2.3927762549114107e-10
95 O 0 7.625756026641284e-09
percent O 0 7.2650649940442236e-09
confidence O 0 5.7303513045781074e-08
interval O 0 7.135536606028836e-08
, O 0 2.2702721924616753e-09
0 O 0 1.799756566001065e-09
. O 0 2.64097993474266e-10
3 O 0 2.857864833671897e-09
to O 0 1.1996237336830973e-09
0 O 0 7.722536388143908e-09
. O 0 4.320742097441155e-10
9 O 0 1.773251057102243e-08
) O 0 4.6195480774002817e-10
and O 0 2.8640731453144497e-10
for O 0 6.011608433276194e-10
carriers O 0 2.887776906490558e-09
of O 0 9.509578013933151e-09
the O 0 1.5973794731394264e-08
BRCA2 O 0 9.147504087536618e-09
mutation O 0 9.596267114275747e-10
( O 0 1.3201878479307538e-09
odds O 0 6.410886044250219e-08
ratio O 0 1.8418226943595073e-08
, O 0 2.051012026882404e-09
0 O 0 3.3070342020380394e-09
. O 0 2.6237936823214625e-10
4 O 0 6.639616856318753e-09
; O 0 4.127082564586715e-10
95 O 0 1.0044614029425247e-08
percent O 0 1.47052556798144e-08
confidence O 0 8.787044691871415e-08
interval O 0 5.9251444639585316e-08
, O 0 4.601883318855471e-09
0 O 0 2.4048105728979863e-09
. O 0 2.3714402663799206e-10
2 O 0 5.966079630326249e-09
to O 0 9.914415954881406e-10
1 O 0 3.4379468161205295e-08
. O 0 2.7862046003690466e-09
1 O 0 1.5800925723397086e-07
) O 0 2.3716143715546423e-08
. O 0 2.934827705303178e-07

CONCLUSIONS O 0 2.903300446632784e-05
Oral O 0 0.0007537495694123209
- O 0 7.791672032908536e-06
contraceptive O 0 8.555099952900491e-07
use O 0 9.030867609283177e-09
may O 0 1.6973225047678397e-09
reduce O 0 1.996801390902192e-09
the O 0 3.41728623176607e-09
risk O 0 1.387280235576327e-06
of O 1 0.7298001050949097
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.422162298098556e-07
women O 0 3.5329115188886817e-09
with O 0 6.032490063034857e-10
pathogenic O 0 1.1278839906481153e-07
mutations O 0 4.008646303788055e-09
in O 0 1.987234377054392e-09
the O 0 5.6318992136539237e-08
BRCA1 O 0 5.794747721665772e-07
or O 0 1.615351038708468e-06
BRCA2 O 0 1.9564282411010936e-05
gene O 0 7.148626173147932e-05

A O 0 2.2422667825594544e-05
Japanese O 0 2.5142033337033354e-05
family O 0 4.043400565478805e-07
with O 0 1.4896549771492573e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.715447943226536e-08
a O 0 8.132890627621236e-08
codon O 0 7.0894401460464e-08
291 O 0 5.220899268465473e-08
deletion O 0 3.5561842537390476e-07
: O 0 2.7063811192107323e-09
a O 0 1.078147882083158e-08
clinical O 0 5.281938229018124e-07
, O 0 1.5343019299507432e-08
biochemical O 0 1.2661672371905297e-05
, O 0 7.918487199276569e-08
pathological O 0 0.031495966017246246
, O 0 2.445311153564944e-08
and O 0 2.400549803383001e-08
genetic O 0 8.587502975387906e-07
report O 0 8.932897088698155e-08
. O 0 3.845852347694745e-07

We O 0 8.117112315630948e-07
report O 0 2.7878538588765878e-08
a O 0 9.406930345789988e-09
Japanese O 0 2.554724574110878e-07
family O 0 2.993247960603185e-08
with O 0 6.027601671121374e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0009602408390492201
ALD B-Disease 1 1.0
) O 0 4.310885159952704e-08
with O 0 6.192510948466179e-09
a O 0 3.274547921705562e-08
three O 0 8.387499583761837e-09
base O 0 1.6346699283076305e-07
pair O 0 7.066502689667686e-07
deletion O 0 7.006242981333344e-07
( O 0 1.8857017280993205e-08
delGAG O 0 2.507907765902928e-07
291 O 0 1.1355063556095502e-08
) O 0 2.7286064518960984e-09
in O 0 1.0697617014443495e-08
the O 0 7.173842391239305e-07
ALD B-Disease 1 1.0
gene O 0 4.601996624842286e-05
. O 0 1.0029835721070413e-05

A O 0 1.649436967454676e-06
variety O 0 2.6399206376481743e-07
of O 0 1.3537679421915527e-07
phenotypes O 0 4.0060731976154784e-07
were O 0 3.848893470603798e-08
observed O 0 6.46040376750534e-08
within O 0 1.9581060328732747e-08
this O 0 3.9724774580918165e-09
family O 0 4.3445631092708936e-08
. O 0 1.36679645379445e-07

While O 0 1.445592147319985e-06
the O 0 5.486900818141294e-07
proband O 0 7.430830737575889e-05
( O 0 1.348391123201509e-07
patient O 0 3.438918270148861e-07
1 O 0 5.632258535115398e-07
) O 0 3.3689744327602966e-09
was O 0 6.698896015677747e-08
classified O 0 2.026105327956884e-08
as O 0 2.941325849548093e-09
having O 0 4.440452006093665e-09
a O 0 1.3056735692629218e-09
rare O 0 1.516342162943829e-09
intermediate O 0 3.479055976640666e-08
type O 0 4.263295494411068e-08
of O 0 1.0943833217424981e-07
adult O 0 3.1363815651275218e-06
cerebral O 0 0.0007112811435945332
and O 0 7.95061652070217e-08
cerebello O 1 0.7865851521492004
- O 0 0.0002798775094561279
brain O 0 0.0002526210737414658
stem O 0 6.095925897398047e-08
forms O 0 2.3093877032920318e-08
, O 0 3.5689426969298665e-09
his O 0 3.0084727598023164e-08
younger O 0 1.6735114058974432e-06
brother O 0 2.1881130578549346e-06
( O 0 3.187973263152344e-08
patient O 0 3.1596132998856774e-07
2 O 0 4.5651108848687727e-07
) O 0 3.049838381841141e-09
and O 0 5.230138455658562e-08
nephew O 0 6.582678179256618e-05
( O 0 5.832471217104285e-08
patient O 0 1.0227292932540877e-06
3 O 0 8.25370250367996e-07
) O 0 1.403768834506991e-08
had O 0 1.3271800014535984e-07
a O 0 4.857816406911297e-07
childhood O 0 0.24170108139514923
ALD B-Disease 1 1.0
type O 1 0.8267673254013062
. O 0 1.7375597963109612e-05

Another O 0 2.3654136384720914e-05
nephew O 0 0.0015478500863537192
( O 0 6.469491040661524e-07
patient O 0 2.938075112979277e-06
4 O 0 1.1020745205314597e-06
) O 0 9.533950517948142e-09
of O 0 1.9603750445185142e-07
patient O 0 3.5360658330318984e-06
1 O 0 3.239244506403338e-06
was O 0 3.365746010786097e-07
classified O 0 6.452251710697965e-08
as O 0 4.891461458100821e-09
having O 0 1.007054972745891e-08
an O 0 9.733679640078208e-09
adolescent O 0 2.932689312729053e-06
form O 0 8.660618391331809e-07
. O 0 5.818032605020562e-06

The O 0 1.2814704177799285e-06
tau O 0 3.473985088930931e-06
level O 0 3.0013311516086105e-06
in O 0 2.5439243600544614e-08
the O 0 6.166864352508128e-08
cerebrospinal O 0 0.00024627489619888365
fluid O 0 0.04489533603191376
( O 0 1.2273558240849525e-06
CSF O 1 0.6512980461120605
) O 0 2.2146897649122366e-08
in O 0 1.7061518420291577e-08
patient O 0 1.416819515043244e-07
1 O 0 2.836827661667485e-07
was O 0 8.480386526343864e-08
as O 0 2.049901359768569e-09
high O 0 1.797630311273224e-08
as O 0 2.319582859122704e-10
that O 0 2.769533213875519e-11
of O 0 7.035796389942561e-09
patients O 0 6.957079534686272e-08
with O 0 1.000346969703969e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9932588338851929
( O 0 5.50456391579246e-08
AD B-Disease 0 3.49526914078524e-07
) O 0 2.8146109443127898e-08
. O 0 2.1846527431534923e-07

His O 0 4.977754997526063e-06
brain O 0 6.037430284777656e-05
magnetic O 0 1.3199515706219245e-05
resonance O 0 1.0947608643618878e-05
image O 0 2.254636228826712e-06
( O 0 4.172136769398094e-08
MRI O 0 0.00019198936934117228
) O 0 2.9075811980305843e-08
showed O 0 4.940027338307118e-07
abnormalities B-Disease 0 0.0015064073959365487
in I-Disease 0 2.1820515172521482e-08
the I-Disease 0 8.942237883502457e-08
bilateral I-Disease 1 0.9988303780555725
cerebellar I-Disease 1 0.9999963045120239
hemispheres I-Disease 0 0.003542227204889059
and O 0 6.623699846386444e-07
brain O 0 0.017442641779780388
stem O 0 6.470071411968092e-07
, O 0 1.2744306721046428e-09
but O 0 1.0200604250165668e-10
not O 0 7.524366546496353e-11
in O 0 2.548175837002731e-10
the O 0 1.975286245681218e-08
cerebral O 0 0.0006159202312119305
white O 0 3.3093705553710606e-08
matter O 0 6.379342920581621e-08
, O 0 2.9148355951136296e-10
where O 0 1.5566468947181278e-10
marked O 0 4.37942709874406e-10
reductions O 0 6.469661695263085e-09
of O 0 4.333834180414442e-09
the O 0 1.513545733189403e-08
cerebral O 0 1.2780561519321054e-05
blood O 0 2.6569333400061623e-08
flow O 0 3.352719701865681e-08
and O 0 3.424522221351367e-09
oxygen O 0 1.4295299877176149e-07
metabolism O 0 5.858214535692241e-07
were O 0 3.486374522410074e-09
clearly O 0 1.135503691074291e-09
demonstrated O 0 2.628657291836589e-10
by O 0 4.351622534537469e-11
positron O 0 2.4185887070871104e-08
emission O 0 5.3370996511148405e-08
tomography O 0 1.3391608035817626e-06
( O 0 4.866877389986257e-08
PET O 0 2.482939009951224e-07
) O 0 2.2913896557952285e-08
. O 0 2.3118541037092655e-07

In O 0 3.843897502520122e-06
patients O 0 2.108721446347772e-06
2 O 0 2.767879777820781e-06
and O 0 3.004733883926747e-08
3 O 0 2.541400760946999e-07
, O 0 9.805078970970271e-10
the O 0 2.4948141330582985e-09
autopsy O 0 9.925208388494866e-08
findings O 0 8.301459963888647e-09
showed O 0 7.591800255113412e-08
massive O 0 1.6415873460573494e-06
demyelination B-Disease 1 1.0
of I-Disease 0 4.834743958781473e-05
the I-Disease 0 1.9013536075362936e-05
cerebral I-Disease 1 0.9831021428108215
white I-Disease 0 3.4351293720646936e-07
matter I-Disease 0 1.1861170179372493e-07
with O 0 6.620543002711088e-10
sparing O 0 9.33486443699394e-09
of O 0 2.6423279564369295e-08
the O 0 1.5287393750895717e-07
U O 1 0.9701606035232544
- O 0 0.0005855801282450557
fibers O 0 1.349100216430088e-06
, O 0 4.10746769929915e-09
compatible O 0 3.8419912584686244e-08
with O 0 4.63671767647611e-10
the O 0 2.43037479030761e-09
findings O 0 4.62442617532588e-09
of O 0 1.156410647240591e-07
childhood O 0 0.011763322167098522
ALD B-Disease 1 1.0
. O 0 3.5491440939949825e-05

Oleic O 0 0.0009387893369421363
and O 0 1.9396040897845523e-06
erucic O 0 0.0017295238794758916
acids O 0 1.969062395801302e-06
( O 0 9.566687708684185e-08
Lorenzos O 0 3.880245458276477e-06
Oil O 0 1.404984146802235e-07
) O 0 3.960899663812967e-10
were O 0 9.59709089976002e-10
administered O 0 2.1718942200266156e-09
to O 0 5.78584014032657e-10
patients O 0 8.082566615996711e-09
1 O 0 6.254463613686312e-08
and O 0 3.7403200536800796e-09
4 O 0 4.306093615014106e-08
, O 0 2.3462273790464394e-10
but O 0 7.274929963996257e-11
sufficient O 0 2.3980866181716465e-09
effectiveness O 0 9.340456408324371e-09
was O 0 9.107254506091067e-09
not O 0 4.872714454151605e-10
obtained O 0 2.4972816703439094e-08
. O 0 4.499082706388435e-08

The O 0 1.246897909368272e-06
findings O 0 1.1276667777337934e-07
in O 0 8.243080884540177e-09
this O 0 1.179798259087761e-09
family O 0 2.0716810489318505e-09
suggest O 0 3.40441808077685e-09
that O 0 1.1771857100217886e-10
delGAG291 O 0 1.927263326706452e-08
is O 0 4.0687128666228034e-10
part O 0 7.472382712592207e-10
of O 0 9.107514742368039e-09
the O 0 9.359627739513598e-09
cause O 0 5.1790447486155244e-08
of O 0 2.3324162157223327e-07
Japanese O 0 0.00023013494501356035
ALD B-Disease 1 0.9999995231628418
with O 0 4.071783266113016e-08
phenotypic O 0 2.8818696591770276e-05
variations O 0 2.2450312826549634e-05
. O 0 1.4917773114575539e-06

Moreover O 0 9.085792953555938e-06
, O 0 2.5498216871255863e-08
although O 0 1.9779622384419326e-09
the O 0 9.989165050683368e-10
scale O 0 3.116316804607777e-08
of O 0 3.116302993433351e-09
the O 0 1.014983874725317e-09
study O 0 3.620873045839801e-10
is O 0 4.975446790678184e-11
limited O 0 1.7551594899689604e-10
, O 0 1.364496987621422e-10
there O 0 1.3749314187183614e-10
is O 0 7.180170347176329e-11
a O 0 3.297861150830528e-10
possibility O 0 4.429928424087848e-09
that O 0 3.998961162210435e-10
PET O 0 1.7902157978255673e-08
can O 0 5.989313489607184e-10
detect O 0 9.507295573030206e-08
an O 0 1.3526254782902924e-08
insidious B-Disease 0 1.9019864339497872e-05
lesion I-Disease 0 2.0533150745905004e-05
which O 0 3.930122449702367e-09
is O 0 7.669644364050043e-10
undetectable O 0 2.9156556280440782e-08
by O 0 2.3749527344740784e-10
computed O 0 2.0080260298982466e-07
tomogram O 0 4.395399628265295e-06
( O 0 4.588738278243909e-08
CT O 0 3.96269497286994e-05
) O 0 3.805226356234925e-09
or O 0 3.6000367131805433e-09
MRI O 0 5.401043836172903e-06
analysis O 0 3.4590474484730294e-08
, O 0 1.4039394091724944e-09
and O 0 2.7799818003160226e-10
that O 0 3.322292788099368e-11
the O 0 4.744873383089043e-10
higher O 0 8.00212696105973e-09
level O 0 5.4475052024827164e-08
of O 0 5.511200829033669e-09
tau O 0 2.347568006655365e-08
reflects O 0 1.5436150135883508e-09
the O 0 1.382597231147642e-10
process O 0 1.2862647613687272e-09
of O 0 2.2828743340141955e-08
neuronal B-Disease 0 5.595307084149681e-05
degeneration I-Disease 1 0.9099630117416382
in O 0 7.788432412780821e-06
ALD B-Disease 1 1.0
. O 0 9.568561654305086e-05

Lorenzos O 0 0.0005370380240492523
Oil O 0 3.7037793845229317e-06
should O 0 7.715027727783763e-09
be O 0 4.102548301077036e-10
given O 0 1.100376387230817e-10
in O 0 7.131961687889543e-11
the O 0 3.8302297444836597e-10
early O 0 1.3067356086082782e-08
stage O 0 7.807194890574465e-08
. O 0 9.590014116156453e-09
. O 0 1.7173005062431912e-07

Nonsense O 0 2.2384210751624778e-05
mutation O 0 1.9326694200572092e-07
in O 0 7.943052793280003e-08
exon O 0 4.803309820999857e-06
4 O 0 8.873223009686626e-07
of O 0 2.2768197993627837e-07
human O 0 1.337241002374867e-07
complement O 0 1.9502733721310506e-06
C9 O 0 0.0006503626354970038
gene O 0 1.542498040407736e-07
is O 0 3.7027558796864923e-09
the O 0 2.802813314772834e-09
major O 0 4.541345433040078e-08
cause O 0 8.150919938998413e-08
of O 0 1.6237147804076812e-07
Japanese O 0 0.00016826065257191658
complement B-Disease 0 0.0008092699572443962
C9 I-Disease 1 0.9999263286590576
deficiency I-Disease 1 0.9994908571243286
. O 0 1.8461649233358912e-05

Deficiency B-Disease 1 0.9993380904197693
of I-Disease 0 2.4883747755666263e-05
the I-Disease 0 1.6737986925363657e-06
ninth I-Disease 0 5.816490102006355e-06
component I-Disease 0 4.934719981974922e-06
of I-Disease 0 1.1897598142240895e-06
human I-Disease 0 1.982142663337072e-07
complement I-Disease 0 1.1897801641680417e-06
( O 0 2.671775689577771e-07
C9 O 0 0.00010437921446282417
) O 0 1.2281592631779858e-08
is O 0 9.731281336300412e-10
the O 0 1.137014260521596e-09
most O 0 1.995495546580628e-09
common O 0 5.337425363904913e-07
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 4.6246927354332e-07
Japan O 0 1.8558739611762576e-07
but O 0 5.135002978384762e-10
is O 0 1.1066781518964675e-10
rare O 0 2.1222530677267315e-10
in O 0 1.1379899106378488e-10
other O 0 2.5691362925961414e-10
countries O 0 2.737259530150027e-09
. O 0 1.196350467580487e-07

We O 0 1.892992429475271e-07
studied O 0 5.689021804755612e-07
the O 0 6.354202941594167e-09
molecular O 0 1.2551809902561217e-07
basis O 0 1.346188867046294e-07
of O 0 1.127415657720121e-06
C9 B-Disease 1 0.9994137287139893
deficiency I-Disease 1 0.8517024517059326
in O 0 6.653690576285953e-08
four O 0 6.109520711561345e-08
Japanese O 0 1.4527232451655436e-05
C9 B-Disease 1 0.9999545812606812
- I-Disease 1 0.9953470826148987
deficient I-Disease 1 0.9979267120361328
patients O 0 3.96797368011903e-05
who O 0 9.473046134189644e-07
had O 0 9.060277079697698e-05
suffered O 1 0.9999285936355591
from O 1 0.9165186882019043
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.92005279334262e-06

Direct O 0 1.1625355256228431e-07
sequencing O 0 9.696548630699908e-08
of O 0 1.6954926707057894e-07
amplified O 0 1.2995990346098552e-06
C9 O 0 2.7611156838247553e-05
cDNA O 0 6.078835212974809e-07
and O 0 8.497383241490297e-09
DNA O 0 5.1428688863097705e-08
revealed O 0 5.924511370380969e-08
a O 0 1.4547079096871585e-08
nonsense O 0 8.425874398199085e-08
substitution O 0 3.2940047134388806e-08
( O 0 5.977812467250487e-09
CGA O 0 2.5353417640872067e-06
- O 0 2.991909582306107e-07
- O 0 1.4416558258290024e-07
> O 0 4.760814675819347e-08
TGA O 0 2.1322023258107947e-07
) O 0 1.4564951467122e-09
at O 0 3.990583863355823e-08
codon O 0 1.330096388585389e-08
95 O 0 4.3278316042005827e-08
in O 0 8.887500513310442e-09
exon O 0 2.0625631691473245e-07
4 O 0 2.921757413787418e-08
in O 0 2.50867149276246e-09
the O 0 7.778237609556982e-09
four O 0 1.3260780917789816e-07
C9 B-Disease 0 0.008520357310771942
- I-Disease 0 7.645818550372496e-05
deficient I-Disease 0 1.5470221114810556e-05
individuals O 0 7.241894195431087e-08
. O 0 2.1272414869599743e-06

An O 0 2.2787966713622154e-07
allele O 0 1.6207272324209043e-07
- O 0 5.224734778153106e-08
specific O 0 8.34027957807848e-09
polymerase O 0 8.319412927448866e-07
chain O 0 6.681440112288328e-08
reaction O 0 2.735730308955908e-09
system O 0 8.757826464034224e-09
designed O 0 1.4306559492638371e-08
to O 0 9.738316819607462e-10
detect O 0 6.747226848347054e-07
exclusively O 0 8.463580769557666e-08
only O 0 1.2883764055615643e-09
one O 0 4.4397721610245355e-10
of O 0 3.4991389785687943e-09
the O 0 3.3736491378277833e-09
normal O 0 3.7738661973207854e-08
and O 0 1.0892884372282197e-09
mutant O 0 9.054772931449406e-09
alleles O 0 1.3992691449971062e-09
indicated O 0 7.475836838466421e-09
that O 0 1.3552013677919916e-10
all O 0 3.511345381124187e-10
the O 0 1.3332197568161064e-09
four O 0 1.0329102018147296e-09
patients O 0 5.565833904874751e-10
were O 0 7.869020435258278e-10
homozygous O 0 8.444770438487126e-10
for O 0 4.2298234359527953e-10
the O 0 2.063608173230591e-09
mutation O 0 1.6674420733053807e-09
in O 0 4.9311896788140075e-09
exon O 0 6.732610131621186e-07
4 O 0 6.333248592227392e-08
and O 0 1.5168858391589879e-09
that O 0 1.5112307238940303e-10
the O 0 1.2636931501219806e-09
parents O 0 2.80243217520848e-10
of O 0 3.6053346974540545e-09
patient O 0 6.916949502056013e-08
2 O 0 8.193971439141023e-07
were O 0 2.1073351774703042e-07
heterozygous O 0 3.3919627639988903e-07
. O 0 3.008231885814894e-07

The O 0 5.523557433662063e-07
common O 0 1.0568715680392415e-07
mutation O 0 8.858999756000685e-09
at O 0 9.631482100758149e-08
codon O 0 2.668243048731256e-08
95 O 0 5.643630629492691e-08
in O 0 4.123144492496067e-08
exon O 0 3.986350293416763e-06
4 O 0 3.697892054788099e-07
might O 0 8.487372582521857e-09
be O 0 2.4746344973181067e-09
responsible O 0 5.411081804851392e-09
for O 0 2.064938886547907e-09
most O 0 1.4361321021283402e-08
Japanese O 0 2.753611079242546e-05
C9 B-Disease 1 0.999921441078186
deficiency I-Disease 1 0.7808892726898193
. O 0 1.665630122715811e-07
. O 0 5.622871412924724e-07

BRCA1 O 0 7.923742373350251e-07
required O 0 5.0097163750706386e-08
for O 0 1.5130405373042777e-08
transcription O 0 5.1312272262293845e-06
- O 0 6.271346137509681e-06
coupled O 0 4.974509465682786e-06
repair O 0 0.0004911517607979476
of O 0 7.638709575985558e-06
oxidative O 0 0.0001891462889034301
DNA O 0 2.551711440901272e-05
damage O 0 0.00027022245922125876
. O 0 3.79046878151712e-06

The O 0 2.7550820959731936e-05
breast B-Disease 1 0.9999994039535522
and I-Disease 1 0.9999836683273315
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9992591738700867
gene O 0 3.0051032808842137e-06
BRCA1 O 0 5.336926847121504e-07
encodes O 0 9.386751997908505e-08
a O 0 1.8172396210047737e-07
zinc O 0 0.00043069335515610874
finger O 0 8.738942415220663e-05
protein O 0 1.075280920304067e-06
of O 0 3.2630455848448037e-07
unknown O 0 3.149353688058909e-06
function O 0 6.177381692396011e-06
. O 0 2.556138497311622e-06

Association O 0 2.266813226015074e-06
of O 0 7.003384325798834e-07
the O 0 3.184725301252911e-07
BRCA1 O 0 2.9533867973441374e-07
protein O 0 6.474540015233288e-08
with O 0 2.0633130759506457e-09
the O 0 5.449011908353896e-08
DNA O 0 3.3788041946536396e-06
repair O 0 0.00020685649360530078
protein O 0 4.607691607816378e-06
Rad51 O 0 4.380227437650319e-06
and O 0 2.722627900908492e-09
changes O 0 7.134826063293076e-09
in O 0 1.3799975606687553e-09
the O 0 9.253950938870048e-10
phosphorylation O 0 2.2818460454487877e-09
and O 0 1.3423008260460279e-09
cellular O 0 2.3330301246460294e-07
localization O 0 1.6527152411072166e-06
of O 0 4.877312775874998e-08
the O 0 1.2793949011324912e-08
protein O 0 2.7375740785373637e-08
after O 0 9.080196150534903e-09
exposure O 0 1.515932979145873e-07
to O 0 4.365742878320589e-09
DNA O 0 1.3472423461280414e-06
- O 0 4.591680067278503e-07
damaging O 0 1.0708686204452533e-07
agents O 0 1.0342493084181115e-08
are O 0 8.859784433878914e-11
consistent O 0 1.6367978084019796e-09
with O 0 1.187772519228858e-10
a O 0 7.038732374731183e-10
role O 0 1.1098711283352714e-08
for O 0 5.271859837563397e-09
BRCA1 O 0 3.2583056253088216e-08
in O 0 2.128490095287816e-08
DNA O 0 1.527628683106741e-06
repair O 0 9.023099119076505e-05
. O 0 3.565203542166273e-06

Here O 0 2.7326786948833615e-06
, O 0 1.985439546103862e-08
it O 0 8.112679972249737e-10
is O 0 3.7791131335396244e-10
shown O 0 1.3232533957463488e-09
that O 0 5.623113086272724e-10
mouse O 0 4.038478351731101e-08
embryonic O 0 1.6975182859368942e-07
stem O 0 1.4481599919236032e-07
cells O 0 4.6111285456618134e-08
deficient B-Disease 0 8.324976761286962e-07
in I-Disease 0 1.1809020428188433e-08
BRCA1 I-Disease 0 1.2198667853624556e-08
are O 0 5.21606646763928e-10
defective O 0 3.812049342855062e-08
in O 0 7.306249494298811e-10
the O 0 8.874469492603509e-10
ability O 0 8.267813655926659e-10
to O 0 2.49081921754879e-10
carry O 0 1.2312664221525438e-09
out O 0 6.545982644823312e-10
transcription O 0 2.765966939932696e-07
- O 0 5.17566263624758e-07
coupled O 0 4.463057905468304e-07
repair O 0 1.135517049988266e-05
of O 0 1.042422582031577e-06
oxidative O 0 1.2585706826939713e-05
DNA O 0 3.303208131910651e-06
damage O 0 1.6748952475609258e-05
, O 0 9.660806377098652e-09
and O 0 4.330380942718648e-09
are O 0 3.4876783683301937e-09
hypersensitive O 0 5.018458182348695e-07
to O 0 1.2315277686525405e-08
ionizing O 0 0.0014920911053195596
radiation O 0 0.05731586739420891
and O 0 3.4079668864706036e-08
hydrogen O 0 4.2866932403740066e-07
peroxide O 0 1.4305435342976125e-06
. O 0 3.6345568332762923e-07

These O 0 1.4793936031765043e-07
results O 0 1.2960342132828373e-07
suggest O 0 8.303284459998395e-08
that O 0 3.513919821784839e-09
BRCA1 O 0 2.225496231744728e-08
participates O 0 1.658542458926604e-08
, O 0 2.343670146842669e-09
directly O 0 2.8618685199433003e-09
or O 0 1.5064226532857106e-09
indirectly O 0 6.312479428061124e-09
, O 0 4.028196665117889e-10
in O 0 1.592881826439907e-09
transcription O 0 1.4548961644322844e-06
- O 0 2.0414531718415674e-06
coupled O 0 3.729910304173245e-06
repair O 0 0.0002459140378050506
of O 0 4.604528839990962e-06
oxidative O 0 3.302381082903594e-05
DNA O 0 9.922963727149181e-06
damage O 0 1.9549026546883397e-05
. O 0 7.643204469331977e-08
. O 0 2.9444211691043165e-07

Truncation O 0 0.00012211682042106986
mutations O 0 1.4015183751325822e-06
in O 0 8.001290296988373e-08
the O 0 6.000638563818939e-08
transactivation O 0 4.4124721171101555e-05
region O 0 7.997138595783326e-07
of O 0 8.429810236521007e-07
PAX6 O 0 7.291035581147298e-05
result O 0 9.041901449791112e-08
in O 0 2.4907171436439057e-08
dominant O 0 5.3254734666552395e-06
- O 0 2.9537727641582023e-07
negative O 0 1.7528929419086126e-08
mutants O 0 3.108551993591391e-07
. O 0 4.3475392885738984e-07

PAX6 O 0 0.0002791553270071745
is O 0 1.272271390462265e-07
a O 0 2.9667381440390272e-08
transcription O 0 1.2026558238176221e-07
factor O 0 1.1481574802019168e-08
with O 0 1.1792470333560345e-09
two O 0 4.010328957804177e-09
DNA O 0 2.9983787896981084e-08
- O 0 2.2931253340630064e-08
binding O 0 1.1799113686095097e-08
domains O 0 2.7982454753328057e-07
( O 0 1.8909167565084317e-08
paired O 0 1.7986529599056666e-07
box O 0 2.4632881832076237e-06
and O 0 4.918023321920373e-08
homeobox O 0 2.4657578023834503e-07
) O 0 1.460010778941978e-09
and O 0 4.220928051523742e-09
a O 0 6.360207294164866e-08
proline O 0 4.27297709393315e-06
- O 0 4.342477495811181e-06
serine O 0 4.211250598018523e-06
- O 0 3.486381501716096e-06
threonine O 0 1.2582482895595604e-06
( O 0 7.777335753189618e-08
PST O 0 0.000326825596857816
) O 0 7.697892812075224e-08
- O 0 2.760907023002801e-07
rich O 0 6.196317769990856e-08
transactivation O 0 6.249370471778093e-06
domain O 0 4.54572364105843e-06
. O 0 1.3154676707927138e-06

PAX6 O 0 0.020130114629864693
regulates O 0 4.376274227979593e-05
eye O 0 7.797789294272661e-05
development O 0 4.052124893405562e-07
in O 0 4.3414150496801085e-08
animals O 0 1.2119630632412282e-08
ranging O 0 3.3388784004273475e-07
from O 0 1.1159250412617894e-08
jellyfish O 0 6.158517251719786e-09
to O 0 3.779814239379675e-09
Drosophila O 0 8.688582653348931e-08
to O 0 3.458334774109062e-08
humans O 0 1.7006340158332023e-06
. O 0 7.430334676428174e-07

Heterozygous O 0 3.7280683500284795e-06
mutations O 0 1.8486404940176726e-07
in O 0 1.7051238643261968e-08
the O 0 3.668243309107311e-08
human O 0 1.6434626104455674e-07
PAX6 O 0 1.8957589418278076e-05
gene O 0 2.313690927735479e-08
result O 0 5.987146334263116e-09
in O 0 1.1287815127047907e-09
various O 0 1.984325592729874e-09
phenotypes O 0 3.243622614945707e-08
, O 0 2.148106359456392e-09
including O 0 1.513309122458395e-08
aniridia B-Disease 1 1.0
, O 0 1.5826971093702014e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.4496897569624707e-06
autosomal B-Disease 0 0.01862841099500656
dominant I-Disease 1 0.997929573059082
keratitis I-Disease 1 0.999981164932251
, O 0 2.134789383489988e-06
and O 0 4.888926923740655e-06
familial B-Disease 1 0.9999954700469971
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.12425974011421204

It O 0 1.3406784660219273e-07
is O 0 1.645045699660841e-08
believed O 0 7.89099807718685e-09
that O 0 9.137974404938021e-11
the O 0 6.496491122831571e-10
mutated O 0 1.4689577332305248e-09
allele O 0 4.528187602659273e-09
of O 0 2.802883969366121e-08
PAX6 O 0 4.689487468567677e-06
produces O 0 7.1694215009188156e-09
an O 0 3.070799392546064e-09
inactive O 0 4.138268536735268e-07
protein O 0 3.811715600932075e-07
and O 0 2.7671719138311346e-08
aniridia B-Disease 1 1.0
is O 0 3.202459808449021e-08
caused O 0 3.292434058721483e-08
due O 0 1.0179685006050931e-07
to O 0 1.5496542715709438e-08
genetic O 0 1.891178385449166e-06
haploinsufficiency O 0 5.010337918065488e-05
. O 0 2.766064426396042e-06

However O 0 3.3686939104882185e-07
, O 0 1.9679832874430758e-08
several O 0 4.5501264978042855e-09
truncation O 0 7.886899311415618e-07
mutations O 0 3.131582104742847e-08
have O 0 1.8050129169111528e-09
been O 0 2.7149014147909156e-09
found O 0 5.034664907199726e-10
to O 0 7.89302234682765e-11
occur O 0 1.3451122438112861e-09
in O 0 1.3294970679922358e-09
the O 0 9.180469717762207e-09
C O 0 0.00025771508808247745
- O 0 1.171881876871339e-06
terminal O 0 1.3045586229054607e-06
half O 0 5.426088911519855e-09
of O 0 1.0590565757695458e-08
PAX6 O 0 4.372839157440467e-06
in O 0 5.84481840704143e-09
patients O 0 2.0656953925168864e-09
with O 0 1.9832964159860467e-09
Aniridia B-Disease 1 0.9999910593032837
resulting O 0 1.011249537441472e-07
in O 0 5.670440561544865e-09
mutant O 0 9.627511232679353e-09
proteins O 0 8.854129651680864e-10
that O 0 3.2507105340862097e-10
retain O 0 1.3959988720557703e-08
the O 0 4.739267644993106e-09
DNA O 0 1.8868385964765366e-08
- O 0 3.7080567505398676e-09
binding O 0 2.132438670088277e-09
domains O 0 3.568903750306163e-08
but O 0 3.0701141628952655e-09
have O 0 5.770400268723108e-10
lost O 0 2.6779302331192412e-08
most O 0 2.659247544389842e-10
of O 0 3.254273517327988e-09
the O 0 1.2277892480483388e-08
transactivation O 0 4.511062343226513e-06
domain O 0 1.7197094166476745e-06
. O 0 7.623082183272345e-07

It O 0 6.465803181754382e-08
is O 0 9.736910833169077e-09
not O 0 1.0708615105770036e-09
clear O 0 4.956404175970874e-09
whether O 0 3.0544200502191643e-09
such O 0 3.7185530210592788e-09
mutants O 0 1.6759808829647227e-07
really O 0 9.882554508067187e-08
behave O 0 2.037903179541445e-08
as O 0 1.017729367447373e-08
loss O 0 1.033167293940096e-07
- O 0 1.4743554288543237e-07
of O 0 2.541744947848201e-07
- O 0 4.102815296391782e-07
function O 0 1.4265216918829537e-07
mutants O 0 6.837851174168463e-08
as O 0 6.359756277163342e-09
predicted O 0 3.416714378090546e-08
by O 0 7.111729427577984e-09
haploinsufficiency O 0 1.7510104953544214e-05
. O 0 1.366639025945915e-06

Contrary O 0 2.5456972707615932e-06
to O 0 1.9471563916795276e-08
this O 0 2.721117109416582e-09
theory O 0 7.43626173971279e-08
, O 0 8.415201868672284e-10
our O 0 6.482541170527156e-10
data O 0 4.383415408426572e-09
showed O 0 3.7920249162937125e-09
that O 0 3.7437563465969603e-11
these O 0 7.991990402800297e-11
mutants O 0 3.3306584157344332e-09
are O 0 2.2861749993108305e-10
dominant O 0 3.6903067268667655e-08
- O 0 3.663193082203975e-09
negative O 0 3.525659764136435e-10
in O 0 5.877234254825225e-10
transient O 0 3.484621302618507e-08
transfection O 0 1.509887539441479e-07
assays O 0 1.750006717315955e-08
when O 0 2.1068311539806928e-09
they O 0 4.0798642242378946e-10
are O 0 1.4026432793023957e-10
coexpressed O 0 3.0715739285369636e-08
with O 0 7.262899726079297e-10
wild O 0 3.997539010924811e-08
- O 0 4.213200668345962e-07
type O 0 3.8074063013482373e-06
PAX6 O 0 0.0014242063043639064
. O 0 2.722686986089684e-06

We O 0 9.604768820281606e-07
found O 0 2.8904398874374237e-08
that O 0 4.3331052634876244e-10
the O 0 2.7199287266910233e-09
dominant O 0 3.8242114897002466e-07
- O 0 1.829644702411315e-08
negative O 0 1.2203478227945652e-09
effects O 0 1.1594751470056508e-07
result O 0 2.198472515146932e-09
from O 0 1.2539427274305126e-09
the O 0 4.872101611042012e-10
enhanced O 0 5.606366482169278e-09
DNA O 0 1.4097837341964237e-09
binding O 0 7.154418724120148e-10
ability O 0 1.0243306203250313e-09
of O 0 4.9705288773793654e-09
these O 0 4.222747929105708e-09
mutants O 0 4.4187413550389465e-07
. O 0 2.996709724811808e-07

Kinetic O 0 9.261846571462229e-06
studies O 0 1.1635537333631873e-07
of O 0 2.502459928166445e-08
binding O 0 2.0688428747916987e-08
and O 0 1.0016567131287957e-08
dissociation O 0 1.1246091702332706e-07
revealed O 0 4.090114202881523e-08
that O 0 4.157928723547144e-10
various O 0 2.0239916409536818e-09
truncation O 0 1.8923243771951093e-07
mutants O 0 3.5615052240700606e-08
have O 0 2.0484240970120027e-09
3 O 0 3.1997061000765825e-08
- O 0 1.909356761586878e-08
5 O 0 2.7902478549890475e-08
- O 0 1.2927142911678402e-08
fold O 0 9.256797994794397e-09
higher O 0 8.97781582409607e-09
affinity O 0 1.6160446314472665e-09
to O 0 3.3148758737944206e-10
various O 0 1.1074767769514438e-09
DNA O 0 5.004700209809698e-09
- O 0 5.688756687938223e-10
binding O 0 2.1527028770673695e-10
sites O 0 1.1480052325429924e-10
when O 0 8.123142436478048e-11
compared O 0 3.8986885941838523e-10
with O 0 1.1589660481314823e-10
the O 0 3.6287428617498563e-09
wild O 0 1.412589245575191e-08
- O 0 2.183755043461133e-07
type O 0 9.486209364695242e-07
PAX6 O 0 0.00019521161448210478
. O 0 2.2631259071204113e-06

These O 0 9.582410598341085e-08
results O 0 3.3174533342616996e-08
provide O 0 3.134049819664142e-08
a O 0 1.2789752368291829e-08
new O 0 6.42643227521944e-09
insight O 0 3.835621242842535e-08
into O 0 1.959674422735702e-09
the O 0 7.825793346682985e-10
role O 0 1.4146870341846807e-08
of O 0 2.1821598750193516e-08
mutant O 0 2.522431543638959e-07
PAX6 O 0 1.934570900630206e-05
in O 0 7.849001804061118e-08
causing O 0 2.217243945779046e-06
aniridia B-Disease 1 0.9999518394470215
. O 0 1.5641641937236272e-07
. O 0 8.538765996490838e-07

Reversal O 0 0.00014001592353451997
of O 0 9.328503074357286e-05
severe O 1 0.9999876022338867
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 0.00047972117317840457
excellent O 0 0.00036199422902427614
neuropsychologic O 0 6.286683492362499e-05
outcome O 0 3.266582382366323e-07
in O 0 8.202710510829547e-09
very B-Disease 0 1.6550663062275817e-08
- I-Disease 0 1.8152529435155884e-07
long I-Disease 0 1.0953856843798349e-07
- I-Disease 0 6.901424853822391e-07
chain I-Disease 0 1.9177224430677597e-07
acyl I-Disease 0 4.639925066385331e-08
- I-Disease 0 8.952836338949055e-08
coenzyme I-Disease 0 6.679274378029731e-08
A I-Disease 0 1.0901622772507835e-05
dehydrogenase I-Disease 0 0.00029390054987743497
deficiency I-Disease 1 0.8059914708137512
. O 0 1.364794388791779e-05

Very B-Disease 0 5.667276127496734e-06
- I-Disease 0 3.1908359233057126e-05
long I-Disease 0 1.613463496141776e-06
- I-Disease 0 7.224869023048086e-07
chain I-Disease 0 8.216838409680349e-08
acyl I-Disease 0 1.2995572618024198e-08
- I-Disease 0 2.1278729889218084e-08
coenzyme I-Disease 0 8.473624468763319e-09
A I-Disease 0 6.47021920485713e-08
dehydrogenase I-Disease 0 1.4870984443859925e-07
( I-Disease 0 5.14140765517368e-08
VLCAD I-Disease 0 0.002188872080296278
) I-Disease 0 3.3744268534974253e-07
deficiency I-Disease 0 0.0309514869004488
is O 0 2.5659215197038066e-08
a O 0 2.3049965136578976e-07
disorder O 1 0.9935848116874695
of O 0 1.7617370758671314e-05
fatty O 0 6.787179154343903e-05
acid O 0 1.996960236283485e-06
beta O 0 3.13700388687721e-06
oxidation O 0 4.813425675820326e-07
that O 0 5.422912341401798e-09
reportedly O 0 6.511718453339199e-08
has O 0 6.161121612890952e-10
high O 0 1.5804264563712422e-08
rates O 0 7.32374916267986e-09
of O 0 6.873939639717719e-09
morbidity O 0 7.107649935278459e-07
and O 0 1.016941553189099e-08
mortality O 0 7.380991974059725e-06
. O 0 7.725809609837597e-07

We O 0 1.8159784076487995e-07
describe O 0 7.264125656547549e-08
the O 0 7.620987396705914e-09
outcome O 0 4.8310852207578137e-08
of O 0 1.4678661841571738e-08
a O 0 8.829731612536307e-09
5 O 0 3.123415837080756e-08
- O 0 8.608131984999545e-09
year O 0 3.279371663111874e-09
- O 0 1.0001451045127396e-07
old O 0 2.648050099196553e-07
girl O 0 1.2767114299094828e-07
with O 0 6.3801098804106e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 0.00010465788363944739
was O 0 1.1646838174783625e-05
first O 0 3.227459899335372e-08
seen O 0 8.812725127427257e-08
at O 0 1.3045071511896822e-07
5 O 0 1.1185098180988007e-08
months O 0 3.850286312001572e-09
of O 0 5.267397185093614e-09
age O 0 8.940413920299761e-08
with O 0 5.293021132501963e-08
severe O 1 0.9999408721923828
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999991655349731
hepatomegaly B-Disease 1 1.0
, O 1 0.9999872446060181
encephalopathy B-Disease 1 0.9999779462814331
, O 0 7.953920544423454e-07
and O 0 8.430884008703288e-06
hypotonia B-Disease 1 0.9986962676048279
. O 0 7.87739991210401e-05

Biochemical O 0 0.001069139107130468
studies O 0 1.6579388102400117e-05
indicated O 1 0.8376540541648865
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.0768062566057779e-05
by O 0 9.06503760944588e-09
a O 0 6.230341398349992e-08
stable O 0 3.939554517273791e-06
yet O 0 4.9806576640776257e-08
inactive O 0 9.450595825910568e-07
enzyme O 0 3.515095272632607e-07
. O 0 4.447065578006004e-07

Molecular O 0 7.604436541441828e-05
genetic O 0 2.2426786472351523e-06
analysis O 0 4.4650840891335974e-07
of O 0 1.6096703348011943e-06
her O 0 4.755804923206597e-07
VLCAD O 0 0.02641572803258896
gene O 0 2.8232361160007713e-07
revealed O 0 9.303225851908792e-07
a O 0 6.156663800993556e-08
T1372C O 0 8.090325991361169e-07
( O 0 2.5020495897365436e-08
F458L O 0 4.171771763594734e-07
) O 0 2.104173901784634e-08
missense O 0 4.032706328871427e-07
mutation O 0 1.9589764477245808e-08
and O 0 1.564163554235165e-08
a O 0 5.32922626916843e-07
1668 O 0 0.0004193259810563177
ACAG O 0 0.011672803200781345
1669 O 0 0.00025367390480823815
splice O 0 2.3316706574405544e-05
site O 0 1.7809898054110818e-06
mutation O 0 4.7253701040972373e-07
. O 0 1.4069742064748425e-06

After O 0 9.889207603919203e-07
initial O 0 3.123731744381075e-07
treatment O 0 9.990027365347487e-07
with O 0 7.278548963540743e-08
intravenous O 0 0.0004739044525194913
glucose O 0 0.0002851819444913417
and O 0 4.82922395406149e-08
carnitine O 0 1.3535897778638173e-05
, O 0 7.231470089408276e-09
the O 0 1.6518747258942312e-08
patient O 0 8.974514997817096e-08
has O 0 1.3656172859199955e-09
thrived O 0 2.557380973655654e-08
on O 0 4.630533290139738e-09
a O 0 2.493719897245228e-09
low O 0 4.1040948417503387e-07
- O 0 1.261387438944439e-07
fat O 0 4.811580467389831e-08
diet O 0 3.49020701229108e-09
supplemented O 0 8.180957022929647e-10
with O 0 3.530551961894446e-10
medium O 0 6.112528581070364e-07
- O 0 1.200702968162659e-07
chain O 0 5.85097836847126e-08
triglyceride O 0 1.327764920233676e-07
oil O 0 7.09910139562453e-08
and O 0 3.2784457371093367e-09
carnitine O 0 5.729252734454349e-07
and O 0 6.536504226772877e-09
avoidance O 0 5.658975624101004e-06
of O 0 1.1362405984982615e-06
fasting O 0 2.9990392249601427e-06
. O 0 4.043242256557278e-07

Her O 0 4.713228190666996e-05
ventricular O 1 0.9856465458869934
hypertrophy O 1 0.6118136048316956
resolved O 0 0.00014086079318076372
significantly O 0 4.446154093784571e-07
over O 0 3.848614582580012e-08
1 O 0 3.618101374058824e-08
year O 0 4.640725859150763e-10
, O 0 2.973981338971754e-10
and O 0 9.373130049894485e-10
cognitively O 0 1.924491698446218e-06
, O 0 3.405794757327385e-09
she O 0 1.0967582397825026e-09
is O 0 1.2998757625837243e-10
in O 0 6.724541756764069e-11
the O 0 3.714142049471292e-10
superior O 0 2.4065101911219244e-07
range O 0 2.267560006430358e-08
for O 0 3.231838130446363e-09
age O 0 3.8375867461581947e-07
. O 0 2.793829878555698e-07

Clinical O 0 2.245063296868466e-05
recognition O 0 7.85886550147552e-06
of O 1 0.9999243021011353
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 3.167129762005061e-06
important O 0 1.1689836298955925e-07
because O 0 2.46328091257908e-09
it O 0 1.9342581702996853e-10
is O 0 1.4238027423729704e-10
one O 0 7.671088764205081e-11
of O 0 9.6726748832765e-10
the O 0 9.87342763103527e-10
few O 0 1.4730119346495485e-09
directly O 0 2.7678053626800647e-08
treatable O 0 0.005720724351704121
causes O 0 1.3854871383500722e-07
of O 0 3.987437594332732e-06
cardiomyopathy B-Disease 1 1.0
in O 0 8.523586984665599e-06
children O 0 9.435972714300078e-08
. O 0 3.922246349929992e-08
. O 0 5.0506122306615e-07

Cloning O 0 3.931841547455406e-06
of O 0 1.3086915373605734e-07
a O 0 1.2714303387895143e-08
novel O 0 5.159372484797586e-09
member O 0 2.4905304485400848e-09
of O 0 4.590206437171673e-09
the O 0 1.1362733864928032e-08
low O 0 3.8095599848020356e-06
- O 0 1.035619732192572e-07
density O 0 3.917357105365227e-08
lipoprotein O 0 1.0831361578311771e-05
receptor O 0 9.912199629980023e-07
family O 0 5.070399424766947e-07
. O 0 6.800099754400435e-07

A O 0 3.048240159841953e-06
gene O 0 1.1479981054662858e-07
encoding O 0 2.308881903445581e-07
a O 0 1.3499519013748795e-07
novel O 0 8.142917806708283e-08
transmembrane O 0 3.4153339356635115e-07
protein O 0 8.932897088698155e-08
was O 0 1.4630445299701478e-08
identified O 0 2.0781308618378347e-10
by O 0 9.950476206888048e-12
DNA O 0 4.3553363693327185e-10
sequence O 0 2.33570773833236e-10
analysis O 0 7.279847835661712e-10
within O 0 4.773730855056613e-10
the O 0 3.4032103801706626e-09
insulin B-Disease 0 0.0002564424939919263
- I-Disease 0 0.42693543434143066
dependent I-Disease 1 0.9999734163284302
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.387118562794058e-06
IDDM B-Disease 0 0.0002901533734984696
) O 0 2.4927416575337702e-08
locus O 0 8.166746567894734e-08
IDDM4 O 0 5.204353328736033e-06
on O 0 5.267320375423878e-07
chromosome O 0 3.677066615637159e-06
11q13 O 0 9.102808689931408e-06
. O 0 1.3164892607164802e-06

Based O 0 9.036140795615211e-07
on O 0 1.5154587629240268e-07
its O 0 8.125445205564574e-09
chromosomal O 0 2.453003844493651e-06
position O 0 1.8652351627679309e-06
, O 0 6.3594409738243485e-09
this O 0 3.346180832419776e-10
gene O 0 1.2869568744022786e-09
is O 0 3.7997480162310637e-10
a O 0 8.264298134719184e-10
candidate O 0 1.4263258352187336e-09
for O 0 2.418139910531636e-09
conferring O 0 2.122301339113619e-06
susceptibility O 0 4.084091051481664e-05
to O 0 2.729344942054013e-06
diabetes B-Disease 1 0.999992847442627
. O 0 3.0247148970374838e-05

The O 0 4.3833424001604726e-07
gene O 0 5.7728946956103755e-08
, O 0 1.154726358976177e-08
termed O 0 1.1616987194429385e-07
low O 0 9.817322279559448e-07
- O 0 7.774088572887194e-08
density O 0 1.6739434727242042e-08
lipoprotein O 0 2.3229041801187122e-07
receptor O 0 5.226169719207974e-08
related O 0 1.303206573766147e-07
protein O 0 8.98461962606234e-08
5 O 0 4.889263394147747e-08
( O 0 1.9998354083838876e-09
LRP5 O 0 2.897851629768411e-07
) O 0 8.818062946502891e-10
, O 0 6.616655001678851e-10
encodes O 0 5.795615098946882e-10
a O 0 2.9031077541930017e-09
protein O 0 1.9647877991246787e-08
of O 0 5.094065613775456e-08
1615 O 0 4.2904907786578406e-06
amino O 0 4.1935102501611254e-08
acids O 0 2.6814722886570053e-08
that O 0 3.6125399893727206e-10
contains O 0 8.549874142005365e-10
conserved O 0 1.6914123435185502e-08
modules O 0 4.715528945098413e-08
which O 0 1.1012582512570646e-10
are O 0 1.7783222810985322e-11
characteristic O 0 6.475015523754735e-10
of O 0 1.977916941342528e-09
the O 0 1.7339778501934688e-09
low O 0 1.7620953940422623e-07
- O 0 2.3467130461085617e-08
density O 0 8.160950137892087e-09
lipoprotein O 0 1.727774360915646e-06
( O 0 4.710692635967462e-08
LDL O 0 1.959686869668076e-06
) O 0 6.698730459220315e-08
receptor O 0 2.623156376557745e-07
family O 0 1.4864674824366375e-07
. O 0 3.010447642282088e-07

These O 0 8.059755174372185e-08
modules O 0 1.8699656720855273e-06
include O 0 4.905020745127331e-08
a O 0 4.064280290094757e-08
putative O 0 1.2304951724217972e-07
signal O 0 2.3921359115774976e-07
peptide O 0 1.7087440795648945e-08
for O 0 3.1987767989960503e-09
protein O 0 1.006486627375125e-08
export O 0 3.3147401268252e-08
, O 0 3.854114360990479e-09
four O 0 5.129024760464063e-09
epidermal O 0 1.9453491972853953e-07
growth O 0 2.8705514409921307e-08
factor O 0 6.288135523391247e-08
( O 0 1.841808483504792e-08
EGF O 0 3.958721492836048e-07
) O 0 7.346232067106939e-09
repeats O 0 6.256647111513303e-08
with O 0 4.105243256447011e-09
associated O 0 1.3379667507251725e-07
spacer O 0 2.491031864337856e-06
domains O 0 1.0012461189035093e-06
, O 0 3.4360983391934496e-08
three O 0 5.054741691878917e-08
LDL O 0 3.420670509513002e-06
- O 0 3.615770538090146e-06
receptor O 0 9.907958542498818e-08
( O 0 2.604217108626017e-08
LDLR O 0 3.87334739571088e-06
) O 0 2.6118713858380715e-09
repeats O 0 6.244424533008441e-09
, O 0 2.611725558043787e-10
a O 0 9.061040251445718e-10
single O 0 2.7796385193568085e-09
transmembrane O 0 2.702096821849409e-07
spanning O 0 6.710661750730651e-07
domain O 0 3.0431783670792356e-07
, O 0 8.476339630192342e-09
and O 0 6.636552196681578e-09
a O 0 3.7812945663517894e-08
cytoplasmic O 0 8.56870371990226e-07
domain O 0 3.820303845714079e-06
. O 0 1.3939177279098658e-06

The O 0 1.0529997780395206e-06
encoded O 0 2.7833331728288613e-07
protein O 0 1.4520612978685676e-07
has O 0 1.3331383774684014e-09
a O 0 1.0961831442557468e-09
unique O 0 1.5701379085797385e-09
organization O 0 3.0163542774630514e-09
of O 0 1.702981080597965e-07
EGF O 0 2.0110255718464032e-05
and O 0 3.8989975337244687e-07
LDLR O 0 0.002674236660823226
repeats O 0 3.783488295994175e-07
; O 0 4.20248413846025e-09
therefore O 0 1.530913884550955e-08
, O 0 8.321942246425351e-09
LRP5 O 0 6.594589194719447e-06
likely O 0 2.0965222446989173e-08
represents O 0 7.173497795776029e-09
a O 0 9.973173398236668e-10
new O 0 4.5931378145347423e-10
category O 0 1.4755659805132382e-08
of O 0 1.8366026921512457e-08
the O 0 1.0573937458957516e-07
LDLR O 0 0.000687577819917351
family O 0 4.863852041125938e-07
. O 0 6.126248877080798e-07

Both O 0 1.0865852573260781e-06
human O 0 2.684507478534215e-07
and O 0 1.035542638305742e-07
mouse O 0 5.639761866405024e-07
LRP5 O 0 4.2089814087376e-05
cDNAs O 0 1.5862343616390717e-06
have O 0 1.285328066202851e-09
been O 0 8.102257753606068e-10
isolated O 0 1.6474185349224513e-09
and O 0 1.3944646826136164e-10
the O 0 5.598744801105227e-10
encoded O 0 3.1949294321265143e-09
mature O 0 6.4570748747883044e-09
proteins O 0 5.623498888773781e-10
are O 0 1.2612461075534043e-10
95 O 0 3.585755248280975e-09
% O 0 6.787855277856636e-10
identical O 0 2.3369075563550723e-09
, O 0 2.8179278355189297e-10
indicating O 0 1.513914660300486e-09
a O 0 4.540778031358883e-10
high O 0 1.173053831848847e-08
degree O 0 1.1206478234271344e-07
of O 0 1.0559201513160588e-08
evolutionary O 0 2.922370434532695e-08
conservation O 0 7.573746962918904e-09
. O 0 6.641807548390943e-09
. O 0 1.257084534245223e-07

The O 0 4.310139047447592e-06
APC B-Disease 0 4.453055680642137e-06
variants O 0 7.985173624547315e-07
I1307K O 0 1.218336478814308e-06
and O 0 7.679294533602388e-09
E1317Q O 0 2.8632410931095365e-07
are O 0 6.748263614575478e-10
associated O 0 3.7264612728904467e-07
with O 0 0.42107126116752625
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00150475581176579
but O 0 1.934197335629051e-08
not O 0 1.6246239908923599e-09
always O 0 3.1085916063489094e-09
with O 0 6.97110036362858e-10
a O 0 2.2369567531654866e-08
family O 0 6.6114602681466295e-09
history O 0 1.5339396952640527e-07
. O 0 2.1692088125746523e-07

Classical O 1 0.9999924898147583
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0004155056376475841
FAP B-Disease 0 1.4439744518313091e-05
) O 0 8.798918571528702e-08
is O 0 1.5079354653835253e-08
a O 0 2.0621889973426732e-08
high O 0 0.017065847292542458
- O 1 0.9972092509269714
penetrance O 1 0.9999450445175171
autosomal B-Disease 1 0.9999980926513672
dominant I-Disease 1 1.0
disease I-Disease 1 0.999972939491272
that O 0 2.4406887177974568e-08
predisposes O 0 1.148054479926941e-06
to O 0 1.0652904336438951e-08
hundreds O 0 2.786567421253494e-08
or O 0 8.445161903125609e-09
thousands O 0 2.3131658366537522e-08
of O 1 0.9887319803237915
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 8.873714136825583e-07
that O 0 1.811821692676574e-09
results O 0 3.933159575808531e-09
from O 0 4.765381866889129e-09
truncating O 0 9.646778664773592e-08
mutations O 0 6.467181901115282e-09
in O 0 1.7638053240176532e-09
the O 0 2.026093781637428e-08
APC B-Disease 0 1.1761072755689383e-06
gene O 0 1.9815104224107927e-06
. O 0 2.1416697109089e-06

A O 0 7.535539225500543e-06
variant O 0 6.476234830188332e-06
of O 0 1.5452984598596231e-06
FAP B-Disease 0 2.9350083423196338e-05
is O 0 8.068634997471236e-06
attenuated B-Disease 1 0.9987689852714539
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999986886978149
coli I-Disease 1 0.9964731335639954
, O 0 6.162961341260598e-08
which O 0 2.0958015323202517e-09
results O 0 9.6902219581807e-09
from O 0 1.549196895211935e-07
germ O 1 0.9998679161071777
- O 0 6.718846634612419e-06
line O 0 4.742172734495398e-07
mutations O 0 2.375112551078473e-09
in O 0 1.3980340218822107e-09
the O 0 3.168875384318426e-09
5 O 0 8.599581491353092e-09
and O 0 3.522823144308518e-10
3 O 0 7.280017921829085e-09
regions O 0 1.0521199467206088e-09
of O 0 8.18214740405665e-09
the O 0 3.318586294653869e-08
APC B-Disease 0 1.198270297209092e-06
gene O 0 7.945383799778938e-07
. O 0 9.813784345169552e-07

Attenuated B-Disease 1 0.9999792575836182
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999997615814209
patients O 0 3.968862984038424e-06
have O 0 2.1376267422823503e-09
" O 0 1.1278631362188207e-08
multiple O 0 5.288631541588984e-07
" O 1 0.871558427810669
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 4.736274377137306e-07
typically O 0 6.525119111699951e-09
fewer O 0 6.596543311587766e-10
than O 0 1.2868039966917877e-10
100 O 0 7.501599896819755e-10
) O 0 4.261256625337495e-11
without O 0 2.3270188553858873e-10
the O 0 1.4372932843897956e-09
florid O 0 1.0471798361777473e-07
phenotype O 0 1.0713913312088152e-08
of O 0 3.1721668847239926e-08
classical O 0 1.3888348803448025e-05
FAP B-Disease 0 1.016626447380986e-05
. O 0 1.982005642275908e-06

Another O 0 4.401128137487831e-07
group O 0 1.5081073456713057e-07
of O 0 5.366343316381972e-07
patients O 0 2.459757126871409e-07
with O 0 2.8692484832504306e-08
multiple O 0 0.001006560167297721
adenomas B-Disease 1 0.9979615211486816
has O 0 3.669054748911549e-08
no O 0 6.206759550764218e-09
mutations O 0 2.4104314100270585e-09
in O 0 1.2461771614624695e-09
the O 0 6.630934912266184e-09
APC B-Disease 0 6.353308634743371e-08
gene O 0 1.8498745646411408e-08
, O 0 2.910964358449064e-09
and O 0 1.0748046896935648e-09
their O 0 2.4347546201397563e-09
phenotype O 0 1.3566561207767336e-08
probably O 0 1.1303548319574475e-08
results O 0 1.388001380497883e-09
from O 0 1.3396255216235886e-09
variation O 0 1.4176555040990024e-08
at O 0 1.1031159630192633e-07
a O 0 3.5642693241300094e-09
locus O 0 5.935412161761633e-09
, O 0 7.524815215376179e-10
or O 0 1.3272927201768425e-09
loci O 0 1.1249690956560698e-08
, O 0 3.1082239004831536e-09
elsewhere O 0 5.8391358415121886e-09
in O 0 3.0359439406879574e-09
the O 0 2.1163453212125205e-08
genome O 0 9.130042144533945e-08
. O 0 6.062300599296577e-07

Recently O 0 8.368634553335141e-06
, O 0 3.660547776007661e-08
however O 0 1.1956155177017536e-08
, O 0 2.0008197321175203e-09
a O 0 6.486181369780297e-09
missense O 0 4.922077323499252e-08
variant O 0 1.262226021481183e-07
of O 0 2.6329764750698814e-06
APC B-Disease 0 8.771722605160903e-06
( O 0 2.534969496537087e-07
I1307K O 0 2.930072469098377e-06
) O 0 1.243921765592404e-08
was O 0 1.1602472227423277e-07
described O 0 5.4780415759125844e-09
that O 0 7.353471997983974e-11
confers O 0 9.431070369103622e-10
an O 0 5.020269269739863e-11
increased O 0 2.9705700121951395e-09
risk O 0 3.8844157757012e-07
of O 1 0.9861460328102112
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.809881935827434e-06
including O 0 1.0612306766688562e-07
multiple O 0 9.529147064313293e-06
adenomas B-Disease 1 0.9965000152587891
, O 0 2.560549319241545e-07
in O 0 4.285524255465134e-07
Ashkenazim O 0 0.0003788610629271716
. O 0 4.439931217348203e-06

We O 0 2.474485540915339e-07
have O 0 5.4530433502009146e-09
studied O 0 1.8789650368944422e-07
a O 0 1.882042743872603e-09
set O 0 2.2974189217706e-09
of O 0 3.30247074131762e-09
164 O 0 3.537093462568919e-08
patients O 0 4.679767240389765e-09
with O 0 1.2513654112922268e-08
multiple O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998524188995361
/ I-Disease 1 0.9999995231628418
or I-Disease 1 0.7943751811981201
carcinoma I-Disease 1 1.0
and O 0 1.1680153022552986e-07
analyzed O 0 4.1328024735776125e-07
codons O 0 6.877129266058546e-08
1263 O 0 2.2425504084822023e-06
- O 0 6.576467512786621e-07
1377 O 0 5.49438072994235e-06
( O 0 8.410203378161896e-08
exon O 0 1.7753885686033755e-06
15G O 0 1.6364323300877004e-06
) O 0 4.226954342101408e-09
of O 0 1.9192112787891347e-08
the O 0 3.506864487690109e-08
APC B-Disease 0 2.6940506359096617e-07
gene O 0 1.2434098550784256e-07
for O 0 3.1285856039175997e-07
germ O 1 0.9997807145118713
- O 0 3.335318615427241e-05
line O 0 5.206477908359375e-06
variants O 0 8.997737381832849e-07
. O 0 3.920115716482542e-07

Three O 0 2.6095358407474123e-06
patients O 0 1.2063914311966073e-07
with O 0 5.27463583921417e-09
the O 0 1.6098402610964513e-08
I1307K O 0 4.9069200258600176e-08
allele O 0 2.198401238828751e-09
were O 0 1.5348396997794111e-09
detected O 0 1.4159692085513598e-08
, O 0 1.3992791647599034e-10
each O 0 1.0293911556491508e-10
of O 0 1.2176397667928995e-08
Ashkenazi O 0 1.3408936183623155e-06
descent O 0 3.620197503551026e-06
. O 0 1.8122550500265788e-06

Four O 0 1.7573474906384945e-05
patients O 0 1.3298904377734289e-05
had O 0 2.0594156922015827e-06
a O 0 1.0906341003646958e-06
germ O 1 0.9992105960845947
- O 0 7.891595487308223e-06
line O 0 1.0433395800646394e-06
E1317Q O 0 5.626229153676832e-07
missense O 0 2.4828014488775807e-07
variant O 0 1.381506535835797e-07
of O 0 1.5014772714039282e-07
APC O 0 3.0280523333203746e-07
that O 0 4.884143312011702e-09
was O 0 8.7513683411089e-08
not O 0 2.1402610239640296e-10
present O 0 4.848795254197569e-10
in O 0 9.562738378932067e-10
controls O 0 4.470912884357858e-08
; O 0 6.193062729309418e-10
one O 0 5.150324056124589e-10
of O 0 5.12041342659586e-09
these O 0 1.3785033114999123e-09
individuals O 0 7.845760707780869e-10
had O 0 2.0758786689611952e-08
an O 0 5.661899837861029e-10
unusually O 0 7.0835168841654195e-09
large O 0 6.295774457321102e-10
number O 0 6.530145313377034e-10
of O 0 4.564462585676665e-08
metaplastic B-Disease 0 6.564695468114223e-06
polyps I-Disease 0 1.734668671815598e-06
of I-Disease 0 2.4334474346687784e-07
the I-Disease 0 3.718881487202452e-07
colorectum I-Disease 0 0.00010870290134334937
. O 0 2.3693662569712615e-06

There O 0 7.035288831502839e-07
is O 0 1.6690338000557858e-08
increasing O 0 7.226478970778771e-09
evidence O 0 1.606784927332683e-08
that O 0 1.6447615491799183e-10
there O 0 1.0519353166316137e-09
exist O 0 2.0773521569594777e-08
germ O 0 5.266221342026256e-05
- O 0 2.7414928993607646e-08
line O 0 1.1821121859156847e-08
variants O 0 4.718261337188778e-09
of O 0 5.562589056040679e-09
the O 0 6.642732586215061e-09
APC B-Disease 0 4.960094912576096e-08
gene O 0 9.28705645719674e-09
that O 0 8.070115686820145e-10
predispose O 0 2.2885943806727482e-08
to O 0 7.930677226042349e-10
the O 0 3.741818410674114e-09
development O 0 2.8565965592974862e-08
of O 0 2.286584276589565e-06
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
, O 0 7.064844567139517e-07
but O 0 2.233617291125256e-09
without O 0 3.1701326008715114e-09
the O 0 4.969827660517012e-09
florid O 0 2.076156562225151e-07
phenotype O 0 1.7483909875437575e-09
of O 0 4.299263611784454e-09
classical O 0 4.3820568862429354e-06
FAP B-Disease 0 9.05462158584669e-08
, O 0 2.990718117601432e-09
and O 0 6.799452112460358e-10
possibly O 0 3.871598153182276e-09
with O 0 6.488070636301302e-10
importance O 0 4.3571953938226216e-06
for O 1 0.5792444348335266
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 5.434142076410353e-05
in O 0 9.510357834585648e-09
the O 0 2.6740447633955e-09
general O 0 6.065790980613883e-09
population O 0 1.699187318626727e-10
. O 0 2.504239704492761e-09
. O 0 6.735603363949849e-08

Genomic O 0 6.530527116410667e-06
structure O 0 4.185466423223261e-06
of O 0 6.929757887519372e-07
the O 0 2.7635858259600354e-06
human O 1 0.9999610185623169
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999339580535889
CLD B-Disease 1 0.9999970197677612
) O 0 1.8723676475929096e-06
gene O 0 3.144188895021216e-06
. O 0 1.2216676168463891e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.999982476234436
CLD B-Disease 1 0.9999998807907104
) O 0 6.656958930761903e-07
is O 0 3.032843309824784e-08
caused O 0 9.400903167033903e-09
by O 0 3.3175073799185384e-10
mutations O 0 3.636364098724698e-09
in O 0 5.0364827863802475e-09
a O 0 5.071697284364518e-09
gene O 0 3.601554610099811e-09
which O 0 6.798298590737772e-10
encodes O 0 5.190899265983262e-09
an O 0 1.3532215348277532e-08
intestinal O 0 0.030448205769062042
anion O 0 0.00022611484746448696
transporter O 0 0.1829756498336792
. O 0 9.245758519682568e-06

We O 0 1.067096150109137e-06
report O 0 6.300897581468234e-08
here O 0 9.402338463360138e-09
the O 0 1.2989618269898529e-09
complete O 0 8.49177794748357e-09
genomic O 0 1.7495461079874985e-08
organization O 0 1.8167426452109225e-09
of O 0 1.0660301974496633e-08
the O 0 2.6643020234473624e-08
human O 0 3.753665396288852e-07
CLD B-Disease 0 0.00011764740338549018
gene O 0 5.5449756786174476e-08
which O 0 3.618279009742764e-09
spans O 0 8.695578657125225e-08
approximately O 0 9.478558382625124e-09
39kb O 0 5.864066565663961e-07
, O 0 2.3160562356849823e-09
and O 0 2.7233135746485004e-09
comprises O 0 1.0502301961423655e-07
21 O 0 1.6203438235606882e-06
exons O 0 8.548904588678852e-06
. O 0 1.5400006532217958e-06

All O 0 2.854428885257221e-06
exon O 0 0.0002492470375727862
/ O 0 3.9036582165863365e-05
intron O 0 1.576721842866391e-05
boundaries O 0 6.36776960050156e-08
conform O 0 1.366359896337599e-07
to O 0 3.2618064693679116e-08
the O 0 5.44668921520497e-07
GT O 0 0.00014914067287463695
/ O 0 0.001668520737439394
AG O 0 0.010338598862290382
rule O 0 4.809553047380177e-06
. O 0 2.3001925910648424e-06

An O 0 6.981658629001686e-08
analysis O 0 1.377239158273369e-07
of O 0 1.188583240718799e-07
the O 0 1.450080873155457e-07
putative O 0 2.0828688320762012e-06
promoter O 0 2.210980892414227e-05
region O 0 1.6043571804402745e-07
sequence O 0 6.824040355013494e-08
shows O 0 1.247755108124693e-07
a O 0 1.2631521428829728e-07
putative O 0 3.32853142026579e-06
TATA O 0 6.881436274852604e-05
box O 0 1.1627394997049123e-05
and O 0 6.271067576335554e-08
predicts O 0 1.7808103791594476e-07
multiple O 0 4.22197707905525e-08
transcription O 0 5.702112275685067e-07
factor O 0 5.0545292396009245e-08
binding O 0 6.225055670938673e-08
sites O 0 2.788455617519503e-07
. O 0 6.409835009435483e-07

The O 0 7.496171292586951e-07
genomic O 0 2.42864416577504e-06
structure O 0 1.557691689413332e-06
was O 0 1.9103117665508762e-07
determined O 0 1.232453605837236e-08
using O 0 2.9141864477111312e-09
DNA O 0 5.600552466233921e-09
from O 0 3.2371727520796867e-10
several O 0 1.1515931264138857e-10
sources O 0 9.451995852671757e-10
including O 0 1.599118337747285e-10
multiple O 0 6.3805085659396354e-09
large O 0 7.979146232628409e-08
- O 0 4.028159139579657e-07
insert O 0 1.525725821238666e-07
libaries O 0 1.041249220179452e-06
and O 0 2.6754529702799346e-09
genomic O 0 4.2305860148417196e-08
DNA O 0 8.62932481027201e-08
from O 0 6.354036230504789e-08
Finnish O 0 0.09609285742044449
CLD B-Disease 1 0.9999395608901978
patients O 0 2.9044329039606964e-06
and O 0 1.5182028789695323e-07
controls O 0 7.157077197916806e-05
. O 0 3.4479533042031107e-06

Exon O 0 0.00011013387120328844
- O 0 6.273519943533756e-07
specific O 0 1.839038965556483e-08
primers O 0 3.3894502848852426e-07
developed O 0 1.4211234855565635e-08
in O 0 7.99393051753583e-10
this O 0 6.62796900696705e-11
study O 0 2.34654073949514e-10
will O 0 3.4872955217979396e-11
facilitate O 0 7.353588293845803e-10
mutation O 0 2.691307454671943e-10
screening O 0 9.625596986140295e-10
studies O 0 1.5087892046850016e-09
of O 0 3.434379891587014e-09
patients O 0 2.851592073582765e-09
with O 0 1.8137027435471964e-09
the O 0 1.229912527378474e-06
disease O 0 0.19772808253765106
. O 0 8.350612574758998e-07

Genomic O 0 3.546921107044909e-06
sequencing O 0 1.2365386510282406e-06
of O 0 2.574005520727951e-06
a O 0 1.3804999070998747e-05
BAC O 1 0.9999207258224487
clone O 0 0.002039100509136915
H O 1 0.9999995231628418
_ O 0 1.0321327863493934e-06
RG364P16 O 0 1.63706306466338e-06
revealed O 0 1.033039254139112e-07
the O 0 2.7857900430916516e-09
presence O 0 8.339070767249268e-09
of O 0 2.166896706512489e-08
another O 0 9.313948723388421e-09
, O 0 9.246206023050263e-10
highly O 0 9.576707427072506e-09
homologous O 0 9.352151053576563e-09
gene O 0 7.114985489664605e-09
3 O 0 8.368104431610845e-08
of O 0 1.622182423943741e-07
the O 0 8.971620104603062e-07
CLD B-Disease 0 0.08872760832309723
gene O 0 1.315739552865125e-07
, O 0 5.352224885513124e-09
with O 0 6.172978794793949e-10
a O 0 2.4252577723871127e-09
similar O 0 1.1752434581069338e-09
genomic O 0 2.9503059550961552e-08
structure O 0 3.317381356282567e-07
, O 0 2.0533292843794015e-09
recently O 0 2.9576796567454267e-09
identified O 0 5.446865736224993e-10
as O 0 5.534879221613664e-10
the O 0 2.0432358383004612e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.7219876099261455e-05
( O 0 1.5159545228016214e-06
PDS B-Disease 0 7.250890485011041e-05
) O 0 5.280658399442473e-08
. O 0 1.1879044592433274e-07
. O 0 1.1693766737153055e-06

The O 0 1.6887759102246491e-06
APCI1307K O 0 0.00014925631694495678
allele O 0 6.834362693552976e-07
and O 0 2.3801571558124124e-07
cancer B-Disease 0 5.406323180068284e-05
risk O 0 2.4606015358585864e-07
in O 0 1.1426325663421721e-08
a O 0 8.107672755386375e-09
community O 0 2.6113384787862515e-09
- O 0 4.820359222890147e-09
based O 0 4.167106382180208e-10
study O 0 1.6634997823672393e-09
of O 0 1.5837036571042518e-08
Ashkenazi O 0 2.0871277683909284e-06
Jews O 0 5.158332783139485e-07
. O 0 5.500134534486278e-07

Mutations O 0 2.298092113051098e-06
in O 0 1.0571135078407679e-07
APC O 0 2.871225888156914e-07
are O 0 4.519050467166608e-09
classically O 0 3.906578513124259e-06
associated O 0 2.1266614567139186e-06
with O 0 0.00018427043687552214
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.3477407693862915
FAP B-Disease 0 1.974474434973672e-05
) O 0 4.8844814415360815e-08
, O 0 7.215240405145096e-09
a O 0 2.454193648304681e-08
highly O 0 0.00013011987903155386
penetrant O 1 0.9999986886978149
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9584110975265503
by O 0 2.2528020338086208e-07
multiple O 1 0.9825310111045837
intestinal O 1 1.0
polyps B-Disease 1 0.7019414901733398
and O 0 3.5884497151528194e-07
, O 0 2.9347932084533568e-08
without O 0 9.683704149665573e-08
surgical O 0 0.23349162936210632
intervention O 0 1.3731785657000728e-05
, O 0 3.995814346069437e-09
the O 0 3.61051655239919e-09
development O 0 9.704058356874157e-07
of O 1 0.9999978542327881
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.007596232928335667
CRC B-Disease 0 0.00048826372949406505
) O 0 2.248061008458535e-07
. O 0 5.801648512715474e-07

APC B-Disease 0 6.349149043671787e-05
is O 0 1.1977024314546725e-06
a O 0 2.068047933789785e-06
tumour O 1 0.9999998807907104
- O 0 0.00017064236453734338
suppressor O 0 4.706091203843243e-06
gene O 0 1.0865669963777691e-07
, O 0 5.923966206466957e-09
and O 0 3.008162607898157e-08
somatic O 0 1.0245196790492628e-05
loss O 0 2.3484033590648323e-05
occurs O 0 8.129809430101886e-06
in O 0 7.929344064905308e-06
tumours B-Disease 1 1.0
. O 0 7.493820885429159e-05

The O 0 8.635071935714222e-06
germline O 0 7.474323501810431e-05
T O 0 2.9006299882894382e-05
- O 0 2.4339627202607517e-07
to O 0 1.3789563269028804e-08
- O 0 1.1545825628900275e-07
A O 0 1.0789711524239465e-07
transversion O 0 5.189590979171044e-07
responsible O 0 1.7515095152020876e-08
for O 0 2.4570261381029468e-09
the O 0 2.03250358765672e-08
APC O 0 9.529990308010383e-08
I1307K O 0 2.5002015036079683e-07
allele O 0 8.238742132959942e-09
converts O 0 8.765046466407966e-09
the O 0 1.772039848191298e-09
wild O 0 2.4971660295136644e-09
- O 0 1.7908501348529171e-09
type O 0 1.1987751902253763e-09
sequence O 0 6.525849860494759e-10
to O 0 7.052318173883521e-10
a O 0 6.10497821185163e-08
homopolymer O 0 0.010572738945484161
tract O 0 0.013425671495497227
( O 0 2.7487166676110064e-07
A8 O 0 3.6384376471687574e-06
) O 0 5.2478625889307295e-09
that O 0 9.464443673223855e-10
is O 0 3.670467041416714e-09
genetically O 0 4.3340932620594685e-08
unstable O 0 6.293574188021012e-06
and O 0 2.0870265515782194e-08
prone O 0 1.041675204760395e-06
to O 0 2.533837495377611e-08
somatic O 0 1.3649503671331331e-05
mutation O 0 5.651256742567057e-07
. O 0 8.137651548167923e-07

The O 0 8.967933808889939e-07
I1307K O 0 1.3452305438477197e-06
allele O 0 8.302160381390422e-08
was O 0 2.4032786427596875e-07
found O 0 1.4917269197667338e-08
in O 0 1.1004173572359832e-08
6 O 0 1.985327799047809e-06
. O 0 5.263107141217915e-07

1 O 0 8.899206477508415e-06
% O 0 3.21236484523979e-07
of O 0 5.68159407521307e-07
unselected O 0 0.0005742558278143406
Ashkenazi O 0 5.52434994460782e-06
Jews O 0 5.047573381489201e-08
and O 0 1.885614331342822e-09
higher O 0 4.280202148265744e-08
proportions O 0 5.583170192835496e-08
of O 0 8.583361932323896e-08
Ashkenazim O 0 2.1056066543678753e-06
with O 0 2.2197010451918686e-08
family O 0 1.3756647376794717e-08
or O 0 4.9638972932086745e-09
personal O 0 6.997603207992142e-08
histories O 0 3.722152825957892e-07
of O 0 5.664433956553694e-06
CRC B-Disease 0 0.0037642226088792086
( O 0 4.111389557692746e-07
ref O 0 6.200388270372059e-06
. O 0 1.4020134386782956e-08
2 O 0 3.953786347210553e-07
) O 0 3.407122051157785e-08
. O 0 4.769521524394804e-07

To O 0 2.1086701451622503e-07
evaluate O 0 8.363571168956696e-07
the O 0 6.913480632420033e-08
role O 0 3.814643037003407e-07
of O 0 2.8102482474423596e-07
I1307K O 0 5.077631612948608e-06
in O 0 1.0664374627822326e-07
cancer B-Disease 0 2.2692531729262555e-06
, O 0 6.868802415738173e-09
we O 0 1.338282729079765e-08
genotyped O 0 1.5485779840673786e-06
5 O 0 1.7291557696808013e-07
, O 0 1.9755274749400087e-08
081 O 0 6.139044216979528e-06
Ashkenazi O 0 1.118080945161637e-06
volunteers O 0 5.599166996717031e-08
in O 0 6.088137993742748e-09
a O 0 1.5327428215528016e-08
community O 0 8.041141974501897e-09
survey O 0 1.2929614001677692e-07
. O 0 3.2191977084039536e-07

Risk O 0 8.070020157902036e-06
of O 0 4.203730895824265e-06
developing O 1 0.9998352527618408
colorectal B-Disease 1 1.0
, I-Disease 0 0.00012107248767279088
breast I-Disease 1 0.9268326759338379
and I-Disease 0 4.048802679790242e-07
other I-Disease 0 1.019085971165623e-06
cancers I-Disease 1 0.9997758269309998
were O 0 1.8986006011800782e-07
compared O 0 1.5343317727456451e-07
between O 0 3.0956562113715336e-07
genotyped O 0 2.2311630800686544e-06
I1307K O 0 4.1261106531464975e-08
carriers O 0 7.019707592981206e-10
and O 0 1.690991374703188e-10
non O 0 1.778650648986968e-08
- O 0 1.4569349282567146e-08
carriers O 0 1.3468323123433379e-09
and O 0 2.0367973974089182e-10
their O 0 7.542485386258235e-11
first O 0 2.5463404718095717e-09
- O 0 2.049323910569001e-08
degree O 0 6.349002319439023e-07
relatives O 0 3.888896316084356e-08
. O 0 1.211430742387165e-07

Sperm O 0 1.5491157228098018e-06
DNA O 0 2.8278225272515556e-07
analysis O 0 5.382047874036289e-08
in O 0 2.0423703617211686e-08
a O 0 6.718922236359504e-07
Friedreich B-Disease 1 0.7230403423309326
ataxia I-Disease 1 0.9951038360595703
premutation O 0 0.11837813258171082
carrier O 0 5.290886838338338e-05
suggests O 0 1.6067197066149674e-06
both O 0 7.729716600124448e-08
meiotic O 0 1.2871331819042098e-05
and O 0 3.16254293863949e-08
mitotic O 0 3.6577776540980267e-07
expansion O 0 1.3171657542443427e-07
in O 0 5.822675674949096e-09
the O 0 3.231562217820283e-08
FRDA B-Disease 0 4.813779378309846e-05
gene O 0 4.084010924998438e-07
. O 0 7.118082407941984e-07

Friedreich B-Disease 1 0.9999946355819702
ataxia I-Disease 1 0.9999901056289673
is O 0 4.162033746979432e-06
usually O 0 1.4732520980942354e-07
caused O 0 1.0139007855514137e-08
by O 0 1.243182778942753e-10
an O 0 3.204656262578709e-10
expansion O 0 7.719742001199847e-08
of O 0 8.350994562533742e-07
a O 0 1.1257095593464328e-06
GAA O 0 3.862690573441796e-05
trinucleotide O 0 9.566207154421136e-05
repeat O 0 4.831651381209667e-07
in O 0 9.044402560220988e-08
intron O 0 3.665180656753364e-06
1 O 0 4.782926907864749e-07
of O 0 9.923505217557249e-08
the O 0 1.8728482586993778e-07
FRDA B-Disease 0 0.0008765807142481208
gene O 0 2.748142605923931e-06
. O 0 1.4992123169577098e-06

Occasionally O 0 4.782603809871944e-06
, O 0 3.692052885639896e-08
a O 0 1.2250898073773442e-08
fully O 0 2.4872562676137022e-08
expanded O 0 5.5012652211416935e-09
allele O 0 2.562345002843358e-09
has O 0 6.117759632218167e-10
been O 0 3.8540978741785636e-10
found O 0 1.905741814356432e-10
to O 0 1.643400693307484e-10
arise O 0 8.607294432749768e-09
from O 0 3.227519806969781e-09
a O 0 2.143464961079644e-09
premutation O 0 1.7884738667817146e-07
of O 0 3.408447923902713e-08
100 O 0 3.887220501042066e-08
or O 0 1.9344296831036445e-08
less O 0 1.2469318733110413e-07
triplet O 0 5.460890406538965e-06
repeats O 0 1.3941037195763784e-06
. O 0 3.7842241340513283e-07

We O 0 6.213454071257729e-07
have O 0 6.170251420911654e-09
examined O 0 1.308343371420051e-07
the O 0 6.173429323297341e-09
sperm O 0 5.2699697938862755e-09
DNA O 0 1.358043810739673e-08
of O 0 6.416241316031801e-09
a O 0 1.452351483521852e-08
premutation O 0 5.001810222893255e-06
carrier O 0 2.0410052457009442e-06
. O 0 1.0286873930454021e-06

This O 0 3.906173162704363e-07
mans O 0 5.380587936087977e-06
leucocyte O 0 3.889419076585909e-06
DNA O 0 3.623637212513131e-07
showed O 0 6.522421358567954e-08
one O 0 1.2035381580233206e-09
normal O 0 3.36348460194813e-09
allele O 0 4.0610681484309907e-10
and O 0 7.902979659579756e-11
one O 0 7.254450512528265e-11
allele O 0 2.7786511980210093e-10
of O 0 1.3654715136368623e-09
approximately O 0 3.007094129259258e-09
100 O 0 1.8687657643567945e-08
repeats O 0 1.1027184143586055e-07
. O 0 9.57698489401082e-08

His O 0 1.2900561614515027e-06
sperm O 0 1.4721116770033404e-07
showed O 0 4.362681949032776e-08
an O 0 1.5395799912720776e-10
expanded O 0 9.493443808850088e-10
allele O 0 9.18514153624983e-10
in O 0 4.645198115049709e-10
a O 0 2.318062630735085e-09
tight O 0 7.198486429160766e-08
range O 0 4.3119541714986553e-08
centering O 0 4.12351432999003e-08
on O 0 8.031147302745012e-09
a O 0 1.063004351209429e-09
size O 0 2.2132233823413117e-09
of O 0 6.59730181595819e-09
approximately O 0 2.51310741106181e-08
320 O 0 2.0251208354693517e-07
trinucleotide O 0 1.3106642654747702e-05
repeats O 0 1.0046348961623153e-06
. O 0 4.531222543846525e-07

His O 0 2.1958745492156595e-05
affected O 0 8.995532880362589e-06
son O 0 1.7049071175279096e-05
has O 0 3.1836528080475546e-08
repeat O 0 5.8947765779748806e-08
sizes O 0 2.493692896621269e-08
of O 0 1.0189727817078165e-07
1040 O 0 1.1826634818135062e-06
and O 0 5.5653089248153265e-08
540 O 0 1.4962299701437587e-06
. O 0 7.829995070096629e-07

These O 0 3.570224293980573e-08
data O 0 1.9663647776724247e-07
suggest O 0 2.5614912857463423e-08
that O 0 4.228468131195484e-10
expansion O 0 1.4797201686178596e-08
occurs O 0 1.4715095808526257e-09
in O 0 3.099939471784552e-10
two O 0 2.851090474820239e-10
stages O 0 2.4544792864844567e-08
, O 0 5.471481046015469e-10
the O 0 8.882140578592157e-10
first O 0 1.3239601637238252e-09
during O 0 1.1198397764644596e-08
meiosis O 0 1.4195089548252326e-08
followed O 0 5.942488723320594e-10
by O 0 1.9936570450074242e-10
a O 0 2.6907236438944437e-09
second O 0 2.101181983960032e-08
mitotic O 0 4.7628537913624314e-07
expansion O 0 1.5782296713950927e-06
. O 0 1.4368823713084566e-06

We O 0 6.485960852842254e-07
also O 0 2.7414040815187946e-08
show O 0 7.4290142926258795e-09
that O 0 7.614498614971765e-11
in O 0 3.0710906040454233e-10
all O 0 2.5539026449195035e-10
informative O 0 2.9500626386180784e-09
carrier O 0 7.446520733367379e-09
father O 0 3.925253011516361e-09
to O 0 5.761074950427769e-10
affected O 0 8.482905933249185e-09
child O 0 4.7949153980653136e-08
transmissions O 0 2.96909405506085e-07
, O 0 8.248157157275671e-10
with O 0 1.1554521922585437e-10
the O 0 7.713214511539945e-10
notable O 0 2.8035884724886273e-09
exception O 0 2.6124491459000865e-09
of O 0 2.5522934876676118e-08
the O 0 3.9735553514219646e-08
premutation O 0 2.159908490284579e-06
carrier O 0 7.092157972010682e-08
, O 0 1.0422909202389974e-09
the O 0 1.068708899154558e-09
expansion O 0 9.932495714792822e-09
size O 0 1.1938038113612492e-08
decreases O 0 2.5794550495561452e-08
. O 0 6.513976913424813e-09
. O 0 1.2909752911127725e-07

The O 0 1.3953089137430652e-06
R496H O 0 6.107550689193886e-06
mutation O 0 5.52107266571511e-08
of O 0 1.1345315442667925e-07
arylsulfatase O 0 3.223147359676659e-05
A O 0 8.441741101705702e-07
does O 0 1.2644581381948683e-08
not O 0 1.639782709617066e-08
cause O 0 6.7617725107993465e-06
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999998807907104
. O 0 1.4306580851553008e-05

Deficiency B-Disease 1 0.997918426990509
of I-Disease 0 0.00010358242434449494
arylsulfatase I-Disease 1 0.89415043592453
A I-Disease 0 9.301031241193414e-05
( O 0 3.68311020793044e-07
ARSA O 0 0.00012544082710519433
) O 0 8.32443447507103e-09
enzyme O 0 7.801241252991531e-08
activity O 0 6.122837703514961e-07
causes O 0 1.6307260011672042e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 9.686965495347977e-05
MLD B-Disease 1 0.9999995231628418
) O 0 1.4657562132924795e-06
. O 0 1.2578259429574246e-06

A O 0 9.046556783687265e-07
number O 0 6.599217527991641e-08
of O 0 7.924618898869085e-07
ARSA O 0 0.002504338277503848
gene O 0 5.354142444957688e-07
mutations O 0 1.8887799058120436e-07
responsible O 0 2.812186323808419e-07
for O 0 1.0942752624032437e-06
MLD B-Disease 1 1.0
have O 0 1.644581999471484e-07
been O 0 8.137840268318541e-08
identified O 0 2.302111994367806e-07
. O 0 1.6491603105350805e-07

Recently O 0 6.392707746272208e-06
, O 0 3.254113423167837e-08
the O 0 1.4769541145653875e-08
R496H O 0 3.377939776783023e-07
mutation O 0 9.683422952377896e-09
of O 0 1.125312962813041e-07
ARSA O 0 0.0004957253695465624
was O 0 9.553701829645433e-07
proposed O 0 1.6813510583801872e-08
to O 0 7.824211278872895e-10
be O 0 1.7642763916470017e-09
a O 0 6.501787996882058e-09
cause O 0 3.486303157274051e-08
of O 0 5.028642590332311e-06
MLD B-Disease 1 1.0
( O 0 4.185303907888738e-07
Draghia O 0 3.088704943365883e-06
et O 0 9.337625215266598e-07
al O 0 2.543066557336715e-07
. O 0 4.049421686858068e-09
, O 0 3.4513349955744843e-09
1997 O 0 3.3845687141820235e-08
) O 0 8.797726991360832e-08
. O 0 8.959034971667279e-07

We O 0 1.0454291441419628e-06
have O 0 1.8165424719995826e-08
investigated O 0 6.921476369825541e-08
the O 0 2.4921034125213737e-09
R496H O 0 6.142670372355497e-08
mutation O 0 6.101643079681196e-10
and O 0 1.78409204076857e-10
found O 0 3.0236738113309514e-10
this O 0 2.7317748757527127e-11
mutation O 0 1.8944526503084091e-10
at O 0 7.645476252093886e-09
a O 0 7.487105935233274e-10
relatively O 0 1.215008316179933e-09
high O 0 9.503100528718278e-10
frequency O 0 1.6945664871315103e-09
in O 0 3.3049500636206375e-11
an O 0 1.6689294043970015e-11
African O 0 1.8761601994210508e-10
American O 0 4.778139550687399e-10
population O 0 4.4485009426109556e-11
( O 0 2.4103749551862563e-10
f O 0 6.162537857790085e-08
= O 0 2.3274647986681885e-08
0 O 0 7.730848849973881e-09
. O 0 3.506900880800856e-10
09 O 0 1.6226644916628175e-08
, O 0 2.9430431425225834e-09
n O 0 6.818601860913986e-08
= O 0 1.0695826091478011e-07
61 O 0 1.9083415736531606e-07
subjects O 0 1.253518576049828e-06
) O 0 7.72690071926263e-08
. O 0 6.11333916822332e-07

The O 0 3.635787834355142e-06
ARSA O 0 0.0003474999684840441
enzyme O 0 1.3733659898207407e-07
activity O 0 5.2824919549721017e-08
in O 0 4.039886647433377e-09
subjects O 0 5.3245834408244264e-08
with O 0 7.788060751856563e-10
and O 0 2.1501638247656274e-09
without O 0 3.864589093183213e-09
the O 0 4.443731160819198e-09
R496H O 0 7.577015992410452e-08
mutation O 0 6.77673028803838e-10
was O 0 1.5009426590495423e-08
determined O 0 1.3459957592942828e-08
and O 0 1.141533978454845e-09
found O 0 2.3547555016989463e-09
to O 0 5.04897457176412e-10
be O 0 6.247701023198715e-09
normal O 0 5.531865667762759e-07
. O 0 1.717757527330832e-07

It O 0 1.3851673941189802e-07
is O 0 1.1622191209426092e-08
therefore O 0 1.4543529047728043e-08
concluded O 0 1.8030524628898092e-08
that O 0 6.245907263613404e-11
the O 0 6.100630556282738e-10
R496H O 0 6.964661025676833e-08
mutation O 0 2.5872091136136532e-09
of O 0 2.360827977554436e-08
ARSA O 0 5.15227802679874e-05
does O 0 4.292536548433645e-09
not O 0 3.8067485275128377e-10
negatively O 0 1.312685182774942e-09
influence O 0 5.177343442852589e-09
the O 0 6.721390111152914e-10
activity O 0 4.4703818424807196e-09
of O 0 1.6657804025044243e-08
ARSA O 0 6.52625021757558e-05
and O 0 8.378354898752605e-09
is O 0 1.5170189548996404e-09
not O 0 5.987554341224666e-10
a O 0 1.2110249691943409e-08
cause O 0 4.093010375072481e-07
of O 0 0.00010401644976809621
MLD B-Disease 1 1.0

Down O 0 5.330088970367797e-05
- O 0 3.126490810245741e-06
regulation O 0 6.581266802641039e-07
of O 0 1.1357862916838712e-07
transmembrane O 0 7.436966370732989e-06
carbonic O 1 0.5683593153953552
anhydrases O 0 0.003168604802340269
in O 0 9.134183528658468e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9994995594024658
lines O 0 1.063918091404048e-07
by O 0 1.1193395099695636e-09
wild O 0 1.4027865979926446e-08
- O 0 5.6009721305372295e-08
type O 0 3.2835309866641182e-06
von B-Disease 1 0.9975595474243164
Hippel I-Disease 1 0.9997592568397522
- I-Disease 1 0.9947393536567688
Lindau I-Disease 1 0.699442982673645
transgenes O 0 0.0007202920969575644
. O 0 5.573956514126621e-06

To O 0 4.230086005918565e-07
discover O 0 3.1849623383095604e-07
genes O 0 6.334710889177586e-08
involved O 0 7.679825131390317e-08
in O 0 5.2735121158775655e-08
von B-Disease 1 0.9416264295578003
Hippel I-Disease 1 0.9999327659606934
- I-Disease 1 0.9999964237213135
Lindau I-Disease 1 0.9999951124191284
( O 0 1.1379159332136624e-05
VHL B-Disease 0 0.16274920105934143
) O 0 2.161416659873794e-06
- O 0 0.0001439707266399637
mediated O 0 0.00043003694736398757
carcinogenesis O 1 0.9980296492576599
, O 0 3.9913295779570035e-08
we O 0 1.638428948069759e-08
used O 0 4.704497769125737e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.999984622001648
lines O 0 2.1922360247117467e-05
stably O 0 3.1037445296533406e-05
transfected O 0 6.19827403625095e-07
with O 0 6.3975447162079035e-09
wild O 0 5.1528648015164435e-08
- O 0 1.881222431165952e-07
type O 0 2.1457565253513167e-06
VHL O 0 0.0571204274892807
- O 0 1.6057536413427442e-05
expressing O 0 4.143129785916244e-07
transgenes O 0 3.218027268303558e-05
. O 0 1.136351102104527e-06

Large O 0 8.30889121061773e-07
- O 0 5.725232199438324e-07
scale O 0 7.993722306309792e-07
RNA O 0 1.6596649743405578e-07
differential O 0 2.3805476700999861e-07
display O 0 4.127409169996099e-08
technology O 0 9.206109297110743e-08
applied O 0 1.0287640961337274e-08
to O 0 2.965490353279421e-10
these O 0 5.865923857761857e-10
cell O 0 6.022814602602011e-08
lines O 0 1.0031474539928809e-09
identified O 0 4.627008776125763e-10
several O 0 1.7156723264299956e-10
differentially O 0 1.2375958924337738e-08
expressed O 0 2.476149008057149e-10
genes O 0 2.8604590918135386e-10
, O 0 1.1895771867553862e-10
including O 0 1.195425008981843e-10
an O 0 8.999980205537383e-10
alpha O 0 4.802073362952797e-06
carbonic O 0 0.003991349600255489
anhydrase O 0 0.00022944655211176723
gene O 0 2.9476211693690857e-07
, O 0 3.666627534926192e-08
termed O 0 5.2172636060277e-06
CA12 O 0 0.0009493020479567349
. O 0 7.180507054727059e-06

The O 0 5.182384938962059e-07
deduced O 0 7.797304419909779e-07
protein O 0 4.425176314271084e-08
sequence O 0 4.966984601395552e-09
was O 0 2.5721691443436612e-08
classified O 0 7.490022824185871e-09
as O 0 8.345749646920808e-10
a O 0 3.382037538912641e-09
one O 0 2.4358415284808643e-09
- O 0 1.4110092649843864e-07
pass O 0 1.9546214957699704e-07
transmembrane O 0 1.717578697935096e-06
CA O 0 4.104156232642708e-06
possessing O 0 1.1831406254714238e-06
an O 0 3.487671706992046e-09
apparently O 0 6.130147056637725e-08
intact O 0 7.648220901046443e-08
catalytic O 0 8.771739601343143e-08
domain O 0 5.213346909727079e-08
in O 0 5.8056643936765795e-09
the O 0 1.7971400367855495e-08
extracellular O 0 3.21692532452289e-05
CA O 0 0.0004914589808322489
module O 0 0.001319619594141841
. O 0 4.583198006002931e-06

Reintroduced O 0 2.160244548576884e-05
wild O 0 2.789652171486523e-06
- O 0 4.236854692862835e-06
type O 0 9.115075044974219e-06
VHL B-Disease 0 0.0003127490926999599
strongly O 0 1.7239428018456238e-07
inhibited O 0 4.723522550875714e-08
the O 0 7.443183402955356e-09
overexpression O 0 1.9589801780739435e-08
of O 0 4.570288147931478e-09
the O 0 4.159501187928072e-09
CA12 O 0 3.0890348625689512e-06
gene O 0 2.0644506104616767e-09
in O 0 7.282097147509603e-10
the O 0 4.5260377667943885e-09
parental O 0 1.196933226310648e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999963045120239
lines O 0 0.00021613399439956993
. O 0 4.43457383880741e-06

Similar O 0 1.5506512340834888e-07
results O 0 4.074945536558516e-08
were O 0 1.8354015196564433e-08
obtained O 0 2.540922494631559e-08
with O 0 5.730698138251e-09
CA9 O 0 7.128537981770933e-05
, O 0 1.8111938615561485e-08
encoding O 0 2.4714125856917235e-07
another O 0 2.160111165494527e-07
transmembrane O 0 2.64002164840349e-06
CA O 0 9.56937697083049e-07
with O 0 6.370853178339075e-09
an O 0 1.5856350898957317e-08
intact O 0 3.7525630887103034e-06
catalytic O 0 4.5284591578820255e-06
domain O 0 3.542347258189693e-06
. O 0 8.484073532599723e-07

Although O 0 5.549879347199749e-07
both O 0 6.71575790534007e-08
domains O 0 1.5623886611138005e-06
of O 0 7.243883146657026e-07
the O 0 1.0366379683546256e-06
VHL B-Disease 0 0.00039711353019811213
protein O 0 1.6078296027899341e-07
contribute O 0 1.5572306111266698e-08
to O 0 3.329350128922215e-09
regulation O 0 6.305869533207442e-07
of O 0 1.5530503105765092e-07
CA12 O 0 3.501046376186423e-05
expression O 0 3.244853985506779e-08
, O 0 8.667751516533428e-10
the O 0 1.189360054887345e-09
elongin O 0 5.177671980050036e-08
binding O 0 4.554450150351386e-09
domain O 0 4.3319523967966234e-08
alone O 0 1.2872275689801427e-08
could O 0 4.637179973343564e-09
effectively O 0 1.6606244912509283e-07
regulate O 0 1.2448424513422651e-06
CA9 O 0 0.0005984993185847998
expression O 0 1.858966470535961e-06
. O 0 1.8991814840774168e-06

We O 0 2.6506572794460226e-06
mapped O 0 8.344804882653989e-06
CA12 O 0 0.00048436701763421297
and O 0 5.491057208928396e-07
CA9 O 0 0.0005939752445556223
loci O 0 3.5657370744957007e-07
to O 0 6.20705762344187e-08
chromosome O 0 1.888104065983498e-06
bands O 0 4.536066171567654e-06
15q22 O 0 1.638292451389134e-05
and O 0 3.239641159780149e-07
17q21 O 0 3.93452137359418e-05
. O 0 1.040837219079549e-06

2 O 0 1.9357941710040905e-05
respectively O 0 1.8868475990529987e-06
, O 0 5.6618731036905956e-08
regions O 0 1.0738057198977913e-07
prone O 0 3.8375247868316364e-07
to O 0 3.706812190529263e-09
amplification O 0 1.7484006775703165e-06
in O 0 1.149785777698753e-08
some O 0 7.392518153181982e-09
human O 0 1.5856975323913503e-06
cancers B-Disease 1 0.9986281394958496
. O 0 9.44956536841346e-06

Additional O 0 2.8556141273838875e-07
experiments O 0 9.668769962445367e-07
are O 0 1.9378856297436187e-09
needed O 0 1.2155328299456869e-08
to O 0 5.441694317376289e-10
define O 0 3.6328028585330685e-08
the O 0 9.347906448908816e-09
role O 0 2.3834803641875624e-07
of O 0 1.1065842500102008e-06
CA O 0 5.545819294638932e-05
IX O 0 0.0019295718520879745
and O 0 2.003719856702446e-07
CA O 0 3.3471849292254774e-06
XII O 0 1.3981506526761223e-05
enzymes O 0 5.447470918795716e-09
in O 0 1.1220541162870745e-09
the O 0 1.9126580319550612e-09
regulation O 0 5.903147837216238e-08
of O 0 1.9480332014154556e-08
pH O 0 8.358348964065954e-07
in O 0 1.0407201322948367e-08
the O 0 7.15305814580347e-09
extracellular O 0 4.0865120354283135e-07
microenvironment O 0 4.466221241727908e-07
and O 0 8.972316778432798e-10
its O 0 1.3255968545067276e-10
potential O 0 2.6257924723438464e-09
impact O 0 1.1361433571721591e-08
on O 0 2.726241632444726e-07
cancer B-Disease 0 6.855375886516413e-06
cell O 0 3.2793220725579886e-06
growth O 0 4.1444931753176206e-07
. O 0 3.586605714644975e-07

A O 0 2.4698626930330647e-06
gene O 0 1.5721830948223214e-07
encoding O 0 6.39782172129344e-07
a O 0 2.9482791319423995e-07
transmembrane O 0 2.983517788379686e-06
protein O 0 4.0220058394879743e-07
is O 0 2.2183159753552673e-09
mutated O 0 3.3287088641031914e-09
in O 0 1.313286257520474e-09
patients O 0 6.534349950015894e-08
with O 0 0.00018453734810464084
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 7.387344339804258e-06
. O 0 4.4621187953453045e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9969416260719299
WFS B-Disease 1 0.9999831914901733
; O 0 1.6835878341225907e-05
OMIM O 0 0.06932683289051056
222300 O 0 2.2858841475681402e-05
) O 0 2.4943778598185418e-08
is O 0 5.803029612394539e-09
an O 0 7.104302568450294e-08
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.999997615814209
defined O 0 2.324657998542534e-06
by O 0 4.714755519330538e-08
young O 0 1.193229991258704e-06
- O 0 4.706813706434332e-05
onset O 1 0.9999613761901855
non O 1 0.9999614953994751
- O 1 0.9999890327453613
immune O 1 0.9998737573623657
insulin B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999988079071045
dependent I-Disease 1 0.9999998807907104
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999874830245972
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.10166104882955551

Linkage O 0 5.40891669515986e-05
to O 0 2.3042515806537267e-07
markers O 0 2.1076921257190406e-06
on O 0 3.83678161597345e-06
chromosome O 0 1.2970932402822655e-05
4p O 0 0.000929894158616662
was O 0 1.6164328826562269e-06
confirmed O 0 7.431483339814804e-08
in O 0 9.76275948971761e-09
five O 0 2.6850701217995265e-08
families O 0 1.5788447882414403e-08
. O 0 3.945575031139015e-07

On O 0 3.9610478097529267e-07
the O 0 1.5786008944473906e-08
basis O 0 5.50029213286507e-08
of O 0 1.1226460827629126e-07
meiotic O 0 0.00012570185936056077
recombinants O 0 0.0008444330887869
and O 0 1.7784558394851047e-06
disease O 1 0.6001327037811279
- O 0 1.8192473589806468e-06
associated O 0 1.196053176499845e-06
haplotypes O 0 2.304537929376238e-06
, O 0 5.3121670617883865e-08
the O 0 3.6587823615263915e-07
WFS B-Disease 0 0.0007985701085999608
gene O 0 8.621871927516622e-08
was O 0 2.2034593882835907e-07
localized O 0 2.0806878353596403e-07
to O 0 2.087066341971422e-08
a O 0 1.5696288073741016e-06
BAC O 1 0.7547155022621155
/ O 0 7.285663741640747e-05
P1 O 0 0.00010471080167917535
contig O 0 5.412568043539068e-06
of O 0 5.332927699441825e-08
less O 0 2.3306633067932125e-08
than O 0 3.148601823710351e-09
250 O 0 2.659833775453535e-08
kb O 0 7.277532859006897e-06
. O 0 8.458092111141013e-07

Mutations O 0 4.989014996681362e-07
in O 0 4.990223700929164e-08
a O 0 4.126905395196445e-08
novel O 0 1.5244626894173052e-08
gene O 0 1.0332831479331617e-08
( O 0 9.66664881474344e-09
WFS1 O 0 3.6438548249861924e-06
) O 0 5.992858653769417e-09
encoding O 0 2.596539729893266e-07
a O 0 9.183765570242031e-08
putative O 0 3.374220796104055e-07
transmembrane O 0 6.283249831540161e-07
protein O 0 1.840435999156398e-07
were O 0 7.628113252167168e-09
found O 0 1.0759388935355219e-09
in O 0 2.79148509862992e-10
all O 0 2.4485943828089773e-10
affected O 0 4.769544204030751e-10
individuals O 0 9.116665061759122e-11
in O 0 6.454611956030476e-09
six O 0 2.3546539296148694e-07
WFS B-Disease 0 0.0002817650674842298
families O 0 1.530031656926667e-09
, O 0 1.5381776963252491e-09
and O 0 3.692091354867699e-10
these O 0 2.571195201195309e-10
mutations O 0 1.926277359842743e-09
were O 0 2.736314730356071e-09
associated O 0 9.624280039588484e-09
with O 0 1.9638763948393034e-09
the O 0 6.487254040621337e-07
disease O 0 0.011226098984479904
phenotype O 0 8.951143399826833e-07
. O 0 6.506529643957037e-07

WFS1 O 0 0.0006911129457876086
appears O 0 2.097588662763883e-07
to O 0 2.5667621361691317e-09
function O 0 3.1413993184514766e-08
in O 0 9.114658361397687e-09
survival O 0 8.028951583582966e-07
of O 0 1.9220233582473156e-07
islet O 0 5.458776286104694e-06
beta O 0 3.157120227115229e-05
- O 0 3.903934157278854e-06
cells O 0 4.1270077133503946e-08
and O 0 9.891942376327734e-09
neurons O 0 1.6976818528746662e-07
. O 0 1.1685941991856907e-08
. O 0 1.0501060643264282e-07

Stable O 0 0.00038441683864220977
interaction O 0 4.572636953525944e-06
between O 0 2.3297172901948215e-07
the O 0 1.0371630665417797e-08
products O 0 1.039046093609386e-08
of O 0 4.581940604708734e-09
the O 0 1.1120791398866459e-08
BRCA1 O 0 8.511564431046281e-08
and O 0 3.6639846712205326e-08
BRCA2 O 0 1.3581323798916856e-07
tumor B-Disease 0 1.714953214104753e-06
suppressor O 0 9.02873296126927e-07
genes O 0 2.0817070733869514e-08
in O 0 1.29339010612739e-08
mitotic O 0 8.959786441664619e-07
and O 0 1.716445865440619e-07
meiotic O 0 0.0009717784123495221
cells O 0 1.170849191112211e-05
. O 0 1.8234718481835444e-06

BRCA1 O 0 3.19505634251982e-05
and O 0 3.9686364061708446e-07
BRCA2 O 0 2.1766297209069307e-07
account O 0 6.645026306983937e-09
for O 0 6.732912560813986e-10
most O 0 4.898489391891303e-10
cases O 0 1.5566418154477901e-09
of O 0 9.994810312718982e-09
familial O 0 1.6335384316334967e-06
, O 0 3.5961473798806765e-08
early O 0 5.914005214435747e-06
onset O 1 0.999954104423523
breast B-Disease 1 0.9998576641082764
and I-Disease 0 0.23355482518672943
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.051281969921547e-06
encode O 0 4.9553669612123485e-08
products O 0 4.8680192321626237e-08
that O 0 1.9849755172884898e-10
each O 0 3.1349436935279584e-10
interact O 0 7.55000595376032e-09
with O 0 7.911101995716763e-09
hRAD51 O 0 3.882148121192586e-06
. O 0 6.520835427181737e-07

Results O 0 8.103406798909418e-07
presented O 0 1.537690764052968e-06
here O 0 1.2850740915837378e-07
show O 0 4.429913857961765e-08
that O 0 1.706450314387098e-09
BRCA1 O 0 2.831297152283696e-08
and O 0 9.099059283812494e-09
BRCA2 O 0 6.331292468075844e-08
coexist O 0 5.600534436212001e-08
in O 0 4.833598854503407e-09
a O 0 6.030916654964358e-09
biochemical O 0 5.969599783384183e-07
complex O 0 2.11026440410933e-06
and O 0 2.316963154669338e-08
colocalize O 0 3.15160104946699e-06
in O 0 6.76653257869475e-08
subnuclear O 0 8.846675882523414e-06
foci O 0 9.983837117033545e-06
in O 0 3.575894780283306e-08
somatic O 0 2.555177900376293e-07
cells O 0 1.398893534343415e-08
and O 0 1.758021728193171e-09
on O 0 6.300546750992453e-09
the O 0 9.107631870897137e-10
axial O 0 8.382862404232583e-09
elements O 0 3.4397178438894116e-08
of O 0 3.238022117102446e-08
developing O 0 3.4280211025361496e-07
synaptonemal O 0 7.534640644735191e-06
complexes O 0 3.5966045288660098e-06
. O 0 7.452191539414343e-07

Like O 0 1.564701051393058e-05
BRCA1 O 0 1.4831251974101178e-05
and O 0 2.5908211682690307e-06
RAD51 O 0 0.02529861591756344
, O 0 9.376915954817377e-07
BRCA2 O 0 9.739493407323607e-07
relocates O 0 3.3121304454653e-07
to O 0 5.6665296455093994e-08
PCNA O 0 4.778242146130651e-05
+ O 0 1.4807343973188836e-07
replication O 0 1.6155031090647753e-08
sites O 0 5.598264074535564e-10
following O 0 5.42143052673083e-10
exposure O 0 1.9223149649860716e-07
of O 0 4.624005001119258e-08
S O 0 2.056326593447011e-06
phase O 0 1.7919190895554493e-06
cells O 0 1.3174039636965063e-08
to O 0 6.194353474597847e-09
hydroxyurea O 0 1.1423173873481574e-06
or O 0 3.6693137417387334e-08
UV O 0 6.912466051289812e-05
irradiation O 0 7.041650860628579e-06
. O 0 2.3084282929630717e-07

Thus O 0 3.8575440157728735e-06
, O 0 3.6066091979591874e-07
BRCA1 O 0 2.0226946162438253e-07
and O 0 1.824393258686996e-08
BRCA2 O 0 3.3358734441435445e-08
participate O 0 1.0493128144162256e-08
, O 0 2.394859421883666e-09
together O 0 3.938895432042955e-09
, O 0 1.5978296463714514e-09
in O 0 2.2087067730325316e-09
a O 0 7.454464601153177e-09
pathway O 0 1.8557017256171093e-08
( O 0 6.838735355785275e-09
s O 0 2.6573539813057323e-08
) O 0 3.6037170469960245e-10
associated O 0 1.6041628025931232e-09
with O 0 3.040555307531889e-10
the O 0 2.4568012069181577e-09
activation O 0 4.284661869746742e-08
of O 0 9.98658222783888e-08
double O 0 5.630663508782163e-07
- O 0 4.324846486269962e-06
strand O 0 2.2521082598814246e-07
break O 0 3.494532734293898e-07
repair O 0 6.00021485297475e-06
and O 0 2.302746793247934e-07
/ O 0 0.00014961525448597968
or O 0 4.819769401365193e-07
homologous O 0 4.483946213440504e-06
recombination O 0 4.582328074320685e-06
. O 0 2.0952925297024194e-06

Dysfunction O 1 0.9993128776550293
of O 0 2.5639346858952194e-05
this O 0 2.2373329500169348e-07
pathway O 0 4.111172074772185e-06
may O 0 6.612964398300392e-08
be O 0 3.4992591047000587e-09
a O 0 1.2925952530551399e-09
general O 0 1.993597065208519e-09
phenomenon O 0 7.488552000722848e-09
in O 0 1.9233685477626494e-10
the O 0 2.8079805147740444e-10
majority O 0 1.3297575540693884e-10
of O 0 1.3026735246057797e-09
cases O 0 3.010686810966945e-09
of O 0 1.7075899449991994e-07
hereditary B-Disease 1 0.9999998807907104
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999241828918457
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6162411813857034e-05
. O 0 4.5250703806232195e-06

A O 0 3.837066742562456e-06
novel O 0 2.2921203424175474e-07
Arg362Ser O 0 7.639224577360437e-07
mutation O 0 2.361340012413393e-09
in O 0 2.418601097176065e-09
the O 0 5.211812759142731e-09
sterol O 0 1.4230649014734809e-07
27 O 0 2.6412882903059653e-07
- O 0 1.981532165018507e-07
hydroxylase O 0 5.170576855562103e-07
gene O 0 2.9507054577493363e-08
( O 0 1.9832253173035497e-08
CYP27 O 0 6.529431175295031e-06
) O 0 3.806039039488951e-09
: O 0 3.352415844926071e-10
its O 0 1.2097400858834817e-10
effects O 0 3.107727408746541e-08
on O 0 1.6141756375986915e-08
pre O 0 1.588341689284789e-07
- O 0 1.0315069687294454e-08
mRNA O 0 4.494414618250175e-09
splicing O 0 5.388721913135441e-09
and O 0 5.113305889814512e-10
enzyme O 0 7.307173088832997e-09
activity O 0 3.711674523287911e-08
. O 0 1.4209682319688e-07

A O 0 1.1246471331105568e-05
novel O 0 4.142426632824936e-07
C O 0 4.546399850369198e-06
to O 0 1.3821214395193238e-08
A O 0 7.701006410343325e-08
mutation O 0 2.2286554823836013e-09
in O 0 2.0209558471151468e-09
the O 0 5.423253846004172e-09
sterol O 0 2.106443162119831e-07
27 O 0 4.664753419092449e-07
- O 0 5.369849986891495e-07
hydroxylase O 0 1.017507997858047e-06
gene O 0 1.0274094819351376e-07
( O 0 3.828699490782128e-08
CYP27 O 0 1.4629891666118056e-05
) O 0 9.33495325483591e-09
was O 0 2.7661798185363295e-08
identified O 0 1.8220103203958615e-09
by O 0 1.459163900818794e-10
sequencing O 0 1.0332121824774276e-08
amplified O 0 2.1670150829322665e-07
CYP27 O 0 4.242175691615557e-06
gene O 0 3.431853912161387e-08
products O 0 1.724170672900982e-08
from O 0 3.281329874482708e-09
a O 0 7.487995112853696e-09
patient O 0 4.5657944980348475e-08
with O 0 7.638162458079023e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 8.242931471613701e-06
CTX B-Disease 0 0.00905784871429205
) O 0 2.1979563769036758e-07
. O 0 8.357623073607101e-07

The O 0 6.302070119090786e-07
mutation O 0 7.232438292703591e-08
changed O 0 9.829972924535468e-08
the O 0 4.034297873545256e-08
adrenodoxin O 0 1.3504416074283654e-06
cofactor O 0 8.16126544123108e-08
binding O 0 1.9888393154587902e-08
residue O 0 2.7693374704540474e-07
362Arg O 0 1.63927055041313e-07
to O 0 1.9180513177730063e-08
362Ser O 0 3.8766575016779825e-06
( O 0 1.3182275893086626e-07
CGT O 0 1.0749204193416517e-05
362Arg O 0 2.3482925826101564e-06
to O 0 6.716449263421964e-08
AGT O 0 0.00029597460525110364
362Ser O 0 1.498946403444279e-06
) O 0 5.843280082018509e-09
, O 0 8.582977661930613e-10
and O 0 1.1858987125634712e-09
was O 0 1.423153008772715e-07
responsible O 0 6.467887203598366e-08
for O 0 6.563879395571348e-08
deficiency O 0 0.019473347812891006
in O 0 9.012493507043473e-08
the O 0 1.142567640499692e-07
sterol O 0 1.0014714462158736e-06
27 O 0 3.9299413856497267e-07
- O 0 5.008541492657059e-08
hydroxylase O 0 1.284949178170791e-07
activity O 0 7.960567316445122e-09
, O 0 3.344081678235966e-10
as O 0 3.2202993049956774e-10
confirmed O 0 1.9571182174882296e-10
by O 0 2.915406804859799e-11
expression O 0 6.246458905678764e-10
of O 0 6.582821399092609e-09
mutant O 0 2.0178521964453466e-08
cDNA O 0 6.566133947671915e-08
into O 0 6.706822830437886e-08
COS O 0 0.00011644690675893798
- O 0 2.7227390546613606e-06
1 O 0 1.8196845985585242e-06
cells O 0 1.3646655361299054e-07
. O 0 2.8910113769597956e-07

Quantitative O 0 8.148623237502761e-06
analysis O 0 1.0411657740405644e-06
showed O 0 1.0306381881264315e-07
that O 0 4.1704459330382804e-10
the O 0 8.823245467581842e-10
expression O 0 1.6924668333473392e-09
of O 0 7.669355817085943e-09
CYP27 O 0 6.066817377359257e-07
gene O 0 9.8490515743066e-10
mRNA O 0 9.211586160517982e-09
in O 0 8.027008502331512e-10
the O 0 1.762130774629611e-09
patient O 0 2.1647569070637473e-08
represented O 0 4.93770500042956e-08
52 O 0 1.9746248653973453e-06
. O 0 1.7223075019501266e-06

5 O 0 4.161362994636875e-06
% O 0 1.8284522695921623e-07
of O 0 5.891112664357934e-08
the O 0 2.931072984324601e-08
normal O 0 1.5607162140440778e-06
level O 0 1.3448428944684565e-05
. O 0 5.186810199120373e-07

As O 0 3.6477453591032827e-07
the O 0 6.286384746090334e-08
mutation O 0 3.40881207705479e-08
occurred O 0 1.4733520004028833e-07
at O 0 6.957929343798241e-08
the O 0 4.635906325489714e-09
penultimate O 0 4.625707461514139e-08
nucleotide O 0 8.126855632895058e-09
of O 0 4.416558496700418e-08
exon O 0 3.9204783774948737e-07
6 O 0 2.03590488467853e-07
( O 0 1.1268654453999716e-08
- O 0 2.7502919053290498e-08
2 O 0 5.092171662113287e-08
position O 0 7.970461268769213e-08
of O 0 3.6524409097182797e-07
exon O 0 6.044702786311973e-06
6 O 0 1.1696326509991195e-05
- O 0 5.20485946253757e-06
intron O 0 1.699603490123991e-05
6 O 0 7.055767810015823e-07
splice O 0 4.6878099624336755e-07
site O 0 4.1568068098740696e-08
) O 0 1.2237300062167833e-09
of O 0 8.552586194809919e-09
the O 0 1.509935820820374e-08
gene O 0 2.8694564946363244e-08
, O 0 7.411633973219978e-09
we O 0 6.96092605778631e-09
hypothesized O 0 1.3063617743114264e-08
that O 0 1.179406156071039e-10
the O 0 1.334260257834785e-09
mutation O 0 2.5875053211166232e-09
may O 0 6.969893995290022e-09
partially O 0 1.96496774407251e-08
affect O 0 4.238256856581302e-09
the O 0 1.0442150477629752e-09
normal O 0 1.2106831093205983e-08
splicing O 0 7.3183867854709206e-09
efficiency O 0 2.0580511517209743e-08
in O 0 4.071416093154312e-09
exon O 0 3.49580602687638e-07
6 O 0 5.1193218553180486e-08
and O 0 1.3442914559291808e-09
cause O 0 6.3689333806848936e-09
alternative O 0 1.0594122024087937e-08
splicing O 0 3.678205828805403e-08
elsewhere O 0 6.661002416308293e-09
, O 0 3.1580249526541593e-10
which O 0 1.0564710217764173e-10
resulted O 0 3.146770843898139e-09
in O 0 9.734788530835203e-10
decreased O 0 1.1942552191612776e-07
transcript O 0 2.6223409577141865e-07
in O 0 2.129739717915413e-09
the O 0 9.093854558273051e-09
patient O 0 2.3390454373384273e-07
. O 0 1.9887450264377549e-07

Transfection O 0 0.00011711885599652305
of O 0 3.817655851889867e-06
constructed O 0 1.6329591744579375e-05
minigenes O 0 1.8745740817394108e-05
, O 0 1.0578432352303935e-08
with O 0 1.1393088694688913e-09
or O 0 3.5110392371251464e-09
without O 0 3.2113702808089784e-09
the O 0 1.8169816762281243e-09
mutation O 0 4.389973107254974e-10
, O 0 8.317098121324307e-10
into O 0 1.7180974865027565e-08
COS O 0 0.001116391853429377
- O 0 3.4600350318214623e-06
1 O 0 5.40750875188678e-07
cells O 0 5.337565056606763e-09
confirmed O 0 2.7848656714013487e-09
that O 0 3.3610957766994076e-11
the O 0 6.641208694091461e-10
mutant O 0 1.2571740093392236e-08
minigene O 0 2.137267358648387e-07
was O 0 4.0225270225846543e-08
responsible O 0 1.0485806001270248e-08
for O 0 6.762901350043649e-10
a O 0 8.300173881536921e-10
mRNA O 0 2.662766229732938e-09
species O 0 6.762884696698279e-11
alternatively O 0 4.822391375114421e-09
spliced O 0 3.327700781596832e-08
at O 0 3.5849364365958536e-08
an O 0 2.0543009515705535e-09
activated O 0 5.554311428568326e-07
cryptic O 0 7.275391453731572e-07
5 O 0 1.0560695784533891e-07
splice O 0 7.440374929501559e-07
site O 0 8.002420059938231e-08
88 O 0 4.2466828631404496e-07
bp O 0 7.761832989672257e-07
upstream O 0 1.8338134566420194e-07
from O 0 2.9734456674646026e-08
the O 0 2.0265188638290965e-08
3 O 0 6.57993695085679e-08
end O 0 6.400696150876684e-08
of O 0 1.9282602181647235e-07
exon O 0 7.53255744712078e-06
6 O 0 6.738122010574443e-06
. O 0 1.6691983546479605e-06

Our O 0 1.196555103888386e-06
data O 0 4.286930277430656e-07
suggest O 0 6.314926537243082e-08
that O 0 8.810884799537178e-10
the O 0 3.4951568306240688e-09
C O 0 3.1191476068670454e-07
to O 0 1.598073451347659e-09
A O 0 2.3103392976508985e-08
mutation O 0 1.2335018562126265e-09
at O 0 2.9711269888821334e-08
the O 0 7.271774737915848e-09
penultimate O 0 2.3534147430837038e-07
nucleotide O 0 5.4911623692532885e-08
of O 0 8.497176651189875e-08
exon O 0 8.5492115431407e-07
6 O 0 2.040751070353508e-07
of O 0 3.485704880290541e-08
the O 0 4.487641191985858e-08
CYP27 O 0 1.4352839571074583e-05
gene O 0 1.3556937794589885e-08
not O 0 1.627567414175246e-09
only O 0 1.5221142124488551e-09
causes O 0 3.140776172472215e-08
the O 0 7.514180566658979e-08
deficiency B-Disease 0 7.29225212126039e-05
in I-Disease 0 1.697893203811418e-08
the I-Disease 0 1.652924375150633e-08
sterol I-Disease 0 1.0892438240261981e-07
27 I-Disease 0 4.4911178775919325e-08
- I-Disease 0 1.901024226924619e-08
hydroxylase I-Disease 0 1.2473637411858363e-07
activity I-Disease 0 6.862751700253966e-09
, O 0 5.681285442094008e-10
but O 0 1.05283459728156e-09
also O 0 2.554054967518482e-09
partially O 0 1.676342975542866e-08
leads O 0 1.01419050935192e-09
to O 0 1.815127631532576e-10
alternative O 0 3.930797465301339e-09
pre O 0 1.4818857607679092e-07
- O 0 1.0556744811651697e-08
mRNA O 0 1.0174071363167059e-08
splicing O 0 2.67337796344691e-08
of O 0 4.978290224499915e-09
the O 0 1.1028757462838712e-08
gene O 0 9.972268344426993e-08
. O 0 5.183640610084694e-07

To O 0 4.1696318930917187e-07
our O 0 2.8690442377410363e-07
knowledge O 0 1.8619863340063603e-06
, O 0 5.012878112609087e-09
this O 0 2.7245486422522447e-10
is O 0 1.3812924415379513e-10
the O 0 3.321046215809531e-10
first O 0 2.4929200370671367e-10
report O 0 1.6280818360137062e-10
regarding O 0 5.506228251128675e-10
effects O 0 1.3226862272119888e-08
on O 0 2.448863156701009e-08
pre O 0 1.3668773135577794e-07
- O 0 8.944367912988582e-09
mRNA O 0 4.347577853280882e-09
splicing O 0 8.90178508683448e-09
of O 0 2.9821622948844606e-09
a O 0 2.3359940648504107e-09
mutation O 0 9.321231564385357e-10
at O 0 4.650104656889198e-08
the O 0 2.3043408958756117e-08
- O 0 1.1155466950185655e-07
2 O 0 1.7495702309133776e-07
position O 0 9.142588908161997e-08
of O 0 1.0224012214621325e-07
a O 0 1.0124036720071672e-07
5 O 0 3.75471785218906e-07
splice O 0 4.27936953428798e-07
site O 0 3.054130672808242e-07
. O 0 3.095700549238245e-07

ATM O 0 0.0014011352322995663
germline O 0 5.804912871099077e-05
mutations O 0 1.1206686849618563e-06
in O 0 4.0334870732294803e-07
classical O 1 0.9999986886978149
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00047204599832184613
in O 0 4.899111161194014e-08
the O 0 4.244439466560834e-08
Dutch O 0 3.175921301590279e-05
population O 0 1.1268460831104221e-08
. O 0 2.449968690143578e-07

Germline O 0 0.0002098344557452947
mutations O 0 5.122365109855309e-07
in O 0 3.301074258388326e-08
the O 0 2.2679190081476008e-08
ATM O 0 2.352387582504889e-06
gene O 0 2.2090356210924256e-09
are O 0 2.7378415506928988e-11
responsible O 0 2.0909052267370498e-10
for O 0 5.291320159805935e-10
the O 0 1.7446714991820045e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.999964714050293
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.9426794299070025e-06
. O 0 1.6529074855498038e-06

In O 0 2.0828238689318823e-07
our O 0 3.318326946555317e-08
study O 0 6.876745839434761e-09
, O 0 7.751160824298609e-10
we O 0 3.86329773727212e-10
have O 0 2.0646533094303976e-11
determined O 0 3.649021362850391e-10
the O 0 3.5528036068654956e-10
ATM O 0 5.1341462636855795e-08
mutation O 0 5.26118926202912e-10
spectrum O 0 1.363795920639177e-08
in O 0 1.2336877075469488e-09
19 O 0 3.349095578641936e-08
classical O 0 5.82041684538126e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 4.2525553567429597e-07
, O 0 4.0185965666239554e-10
including O 0 1.8829322823155081e-10
some O 0 6.164739552172449e-11
immigrant O 0 7.536881119207806e-10
populations O 0 1.1762969764905762e-10
, O 0 1.2287484918438452e-10
as O 0 1.1827311352519132e-10
well O 0 2.7561916637885986e-10
as O 0 8.246631155728323e-10
12 O 0 3.3547842281933526e-09
of O 0 5.569627425927592e-09
Dutch O 0 6.430259986700548e-07
ethnic O 0 1.1200661731436412e-08
origin O 0 5.79899364083758e-08
. O 0 1.0692745888718491e-07

Both O 0 7.496028047171421e-07
the O 0 1.5055738344926795e-07
protein O 0 1.5060835778513137e-07
truncation O 0 3.474182790341729e-07
test O 0 3.694060168868418e-08
( O 0 6.37403774206291e-09
PTT O 0 2.438291062389908e-07
) O 0 1.4689325311678658e-09
and O 0 3.9216141445308494e-10
the O 0 1.4157606198494932e-09
restriction O 0 2.6554425325286957e-09
endonuclease O 0 1.0368109926162106e-08
fingerprinting O 0 1.4479694243618724e-07
( O 0 7.807488877631386e-09
REF O 0 4.7322066620836267e-07
) O 0 5.740716235713705e-10
method O 0 9.094565101008811e-09
were O 0 4.962493749260943e-10
used O 0 8.024652053961745e-10
and O 0 1.5417397913886077e-10
compared O 0 2.4186381786250877e-09
for O 0 4.1628009372907115e-10
their O 0 1.704003604885429e-10
detection O 0 1.9733130685040123e-08
efficiency O 0 7.727988027284027e-09
, O 0 2.488292905056255e-10
identifying O 0 2.002274346324384e-09
76 O 0 2.129289811136914e-08
% O 0 2.89407942055675e-09
and O 0 2.8426752063381855e-09
60 O 0 1.7655631623370027e-08
% O 0 3.339576837291247e-09
of O 0 1.1723559900644887e-08
the O 0 1.653892489628106e-08
mutations O 0 1.7175796784840713e-08
, O 0 1.567137708491373e-08
respectively O 0 6.171277959765575e-07
. O 0 7.150898113650328e-07

Most O 0 3.351361499426275e-07
patients O 0 2.0577142834099504e-07
were O 0 4.230255257198223e-08
found O 0 6.162864440995008e-09
to O 0 1.6301273664254268e-09
be O 0 1.4406588810800258e-08
compound O 0 2.253600086987717e-06
heterozygote O 0 3.855907925753854e-05
. O 0 1.9551748664525803e-06

Seventeen O 0 3.921995812561363e-06
mutations O 0 1.0321529941847984e-07
were O 0 1.5585380097604684e-08
distinct O 0 6.900698679146444e-09
, O 0 3.1281299772700777e-09
of O 0 1.3169944246271825e-08
which O 0 1.3447505331498633e-09
10 O 0 7.959549463976145e-09
were O 0 2.060312365159689e-09
not O 0 3.8686140402255376e-10
reported O 0 5.4328199716735526e-09
previously O 0 3.7988755252627016e-08
. O 0 5.381011192184815e-08

Mutations O 0 2.321118245163234e-06
are O 0 2.999328430064452e-08
small O 0 1.4672307813157204e-08
deletions O 0 1.3789437502964574e-07
or O 0 7.964261072856971e-08
point O 0 7.964935321069788e-06
mutations O 0 7.942401225591311e-08
frequently O 0 2.2827611800835257e-08
affecting O 0 3.88414456153896e-08
splice O 0 8.058192975113343e-07
sites O 0 1.8950605351619743e-07
. O 0 5.187720830690523e-07

Moreover O 0 1.1951537089771591e-05
, O 0 2.939118530775886e-07
a O 0 5.705288685931009e-07
16 O 0 3.820205165538937e-06
. O 0 2.4970827325887512e-06

7 O 0 0.00011667276703519747
- O 0 9.361419870401733e-06
kb O 0 1.6172089090105146e-05
genomic O 0 1.0155149539059494e-06
deletion O 0 6.677566375401511e-07
of O 0 2.586513119240408e-07
the O 0 5.6433290041013606e-08
3 O 0 2.5389081770299526e-07
end O 0 3.2318830278654787e-08
of O 0 1.0447216425291117e-08
the O 0 5.8702354088779884e-09
gene O 0 5.048206297431079e-09
, O 0 7.729782924847939e-10
most O 0 3.26877247491808e-10
likely O 0 1.5412936482661621e-09
a O 0 5.349273246579855e-10
result O 0 3.3875964255969393e-09
of O 0 2.6849422241070897e-08
recombination O 0 2.3026053952435177e-08
between O 0 2.6825414778386403e-08
two O 0 4.319862689783349e-09
LINE O 0 5.880811499991978e-07
elements O 0 2.897580770877539e-07
, O 0 7.607771301820776e-09
was O 0 7.556363357252849e-08
identified O 0 1.1332566174360181e-07
. O 0 2.375778080931923e-07

The O 0 3.0741006185053266e-07
most O 0 4.989735735705381e-09
frequently O 0 3.0516538185310083e-09
found O 0 4.476873316505703e-10
mutation O 0 1.3968498580041455e-10
, O 0 1.731802062865384e-10
identified O 0 1.3693471911935262e-09
in O 0 6.946823671860614e-10
three O 0 2.0307548975750933e-09
unrelated O 0 5.640929501282699e-08
Turkish O 0 6.901457254571142e-07
A B-Disease 1 0.999994158744812
- I-Disease 1 0.9829390048980713
T I-Disease 1 0.9999850988388062
individuals O 0 6.997467050240402e-09
, O 0 1.0272425576829392e-08
was O 0 8.547682028847703e-08
previously O 0 1.727574350240957e-08
described O 0 1.0019657326054698e-09
to O 0 6.883155850845313e-11
be O 0 4.3714654118787166e-10
a O 0 1.0296979935375816e-09
Turkish O 0 1.42471208164352e-07
A B-Disease 1 0.9999908208847046
- I-Disease 1 0.999890923500061
T I-Disease 1 0.9999996423721313
founder O 0 4.353995245764963e-05
mutation O 0 2.1599566935037728e-07
. O 0 7.049728196761862e-07

The O 0 1.6393283885918208e-07
presence O 0 4.965376732002369e-08
of O 0 1.192928067439425e-07
a O 0 6.675784192111678e-08
founder O 0 3.6911097822667216e-07
mutation O 0 3.706974727180068e-09
among O 0 6.495536886141906e-10
relatively O 0 1.2547545225061185e-08
small O 0 1.2262579840438548e-09
ethnic O 0 1.317139397549738e-09
population O 0 5.503442840337769e-11
groups O 0 1.1610015726581935e-10
in O 0 8.024589881472366e-10
Western O 0 1.4738164466621129e-08
Europe O 0 1.5320853918865396e-08
could O 0 1.1270216981884573e-09
indicate O 0 1.0692124963185279e-09
a O 0 5.503886235658229e-10
high O 0 4.279408383212058e-09
carrier O 0 1.1970843205588722e-09
frequency O 0 1.1923929399415556e-08
in O 0 2.506450880179756e-10
such O 0 2.6817967291314915e-10
communities O 0 4.0537027068410225e-09
. O 0 1.2504376911692816e-07

In O 0 5.138907681612181e-07
patients O 0 9.963712699345706e-08
of O 0 4.886195625886103e-08
Dutch O 0 2.0352932551759295e-05
ethnic O 0 1.909750046991121e-08
origin O 0 1.118497117147399e-08
, O 0 7.560811421392089e-10
however O 0 5.433998251369587e-10
, O 0 2.7427088378217945e-10
no O 0 6.251559825365405e-10
significant O 0 9.378927856573682e-09
founder O 0 9.92587132486733e-08
effect O 0 3.495858535984553e-08
could O 0 9.99292382175554e-09
be O 0 8.79669936892924e-09
identified O 0 1.1139265154724853e-07
. O 0 2.8733484214171767e-07

The O 0 4.06618823944882e-07
observed O 0 5.997206358188123e-07
genetic O 0 9.881499352104584e-08
heterogeneity O 0 1.6029379423798673e-07
including O 0 4.030635381013781e-09
the O 0 8.366840553719612e-09
relative O 0 1.201313921228575e-06
high O 0 2.488125801392016e-06
percentage O 0 1.523280417359274e-07
of O 0 8.918954108594335e-08
splice O 0 1.5921285694275866e-06
- O 0 3.450672636517993e-07
site O 0 5.136232417157771e-08
mutations O 0 1.2813486272023056e-08
had O 0 2.5580737528230202e-08
no O 0 9.706314862967247e-09
reflection O 0 4.893452043575053e-08
on O 0 7.928809253598956e-08
the O 0 1.9567917064478024e-08
phenotype O 0 8.163880949041413e-08
. O 0 1.7822459597027773e-07

All O 0 3.562844312909874e-07
patients O 0 2.6956004717249016e-07
manifested O 0 1.973835139779112e-07
classical O 0 0.00033008723403327167
A B-Disease 1 0.9999980926513672
- I-Disease 1 0.9996542930603027
T I-Disease 1 0.9999618530273438
and O 0 1.2157554074576638e-08
increased O 0 6.991026424429947e-08
cellular O 0 3.989012782312784e-07
radioresistant O 0 2.849120619430323e-07
DNA O 0 6.314276390639861e-08
synthesis O 0 1.522727046676664e-07
. O 0 1.24766344811178e-07

Determination O 0 6.768934326828457e-06
of O 0 6.450497949117562e-07
the O 0 4.799582242753786e-08
genomic O 0 2.4038953938543273e-07
structure O 0 2.1658478033259598e-07
of O 0 5.502979050220347e-08
the O 0 1.4775148216017442e-08
COL4A4 O 0 2.1873223886359483e-05
gene O 0 4.023629873728396e-09
and O 0 4.5677672755317644e-10
of O 0 1.3730668158018489e-08
novel O 0 1.5791766827533138e-07
mutations O 0 4.341786279837834e-06
causing O 0 0.00014905561693012714
autosomal B-Disease 1 0.9999974966049194
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.01420147530734539

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.5925512545654783e-06
a O 0 3.5718771869142074e-06
progressive O 1 0.9998759031295776
hematuric B-Disease 1 0.9999994039535522
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.5041379332542419
by O 0 2.9191810426709708e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999872446060181
abnormalities I-Disease 1 0.999983549118042
and O 0 7.853838468463437e-08
associated O 0 3.992514621131704e-07
with O 0 1.951983108483546e-08
mutations O 0 1.3496854478489695e-07
in O 0 5.12092377391582e-08
either O 0 1.0038488795771627e-07
the O 0 1.0869401023683167e-07
COL4A3 O 0 0.0003140242479275912
or O 0 1.5665072794490698e-08
the O 0 1.0732770228116806e-08
COL4A4 O 0 4.719583102996694e-06
gene O 0 3.98712796112477e-09
, O 0 4.179651624802716e-10
which O 0 5.474547551398423e-11
encode O 0 1.1280927303403132e-09
the O 0 4.626534266805038e-09
alpha3 O 0 8.133330311466125e-07
and O 0 2.2729164328438856e-08
alpha4 O 0 1.7921476683113724e-05
type O 0 0.0003882248420268297
IV O 1 0.9999998807907104
collagen O 0 0.39906591176986694
chains O 0 2.725276499404572e-05
, O 0 9.796824684826788e-08
respectively O 0 1.9731264728761744e-06
. O 0 1.1809897841885686e-06

To O 0 4.6495639338672845e-08
date O 0 2.0059684402440325e-07
, O 0 3.4672629212195716e-09
mutation O 0 5.714126949385445e-10
screening O 0 5.6378501867015984e-09
in O 0 7.896595599632406e-10
the O 0 2.201615556529646e-09
two O 0 3.0098830094971163e-09
genes O 0 7.570078786045542e-09
has O 0 1.257806525600813e-09
been O 0 2.3108581714836873e-09
hampered O 0 5.436378103240713e-08
by O 0 5.666805358295335e-10
the O 0 3.4053790898269654e-09
lack O 0 2.265255893973972e-08
of O 0 1.7329602641780184e-08
genomic O 0 1.9786354243933602e-07
structure O 0 1.1688191534631187e-06
information O 0 5.579859134741127e-07
. O 0 8.034198231143819e-07

We O 0 7.017142706899904e-07
report O 0 6.600551927249398e-08
here O 0 1.5512540585405077e-08
the O 0 1.0257031890503754e-09
complete O 0 4.0584295923906666e-09
characterization O 0 2.5832511241219436e-08
of O 0 1.0028342600776341e-08
the O 0 1.0735861977195782e-08
48 O 0 1.1593944293508684e-07
exons O 0 9.369222908617303e-08
of O 0 6.695651677546266e-08
the O 0 5.0977689625142375e-08
COL4A4 O 0 1.937648448802065e-05
gene O 0 1.608072608405564e-08
, O 0 1.1807033128974354e-09
a O 0 2.079483918393521e-09
comprehensive O 0 2.150837730141575e-08
gene O 0 5.186841622872862e-09
screen O 0 3.4492578038225474e-07
, O 0 4.1090975066993e-09
and O 0 9.795732003325952e-10
the O 0 9.839118408905279e-10
subsequent O 0 1.3307757118496966e-09
detection O 0 7.452207029245983e-08
of O 0 5.814196679665429e-09
10 O 0 2.715264013630758e-09
novel O 0 4.803084596716189e-10
mutations O 0 7.724447748103103e-10
in O 0 1.170451846554954e-09
eight O 0 6.35946761917694e-08
patients O 0 3.856973762594862e-06
diagnosed O 0 0.4770594835281372
with O 0 3.407040276215412e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00046817923430353403

Furthermore O 0 1.119654825743055e-05
, O 0 1.219010101749518e-07
we O 0 1.784668945958856e-08
identified O 0 1.6506715994069054e-08
a O 0 5.724624330127881e-09
glycine O 0 2.5827930016930623e-08
to O 0 1.7484310665949465e-09
alanine O 0 4.4906464324867557e-08
substitution O 0 6.37238670719853e-08
in O 0 9.862120009529463e-09
the O 0 3.0027113240294057e-08
collagenous O 0 6.380775630532298e-06
domain O 0 8.460821021571974e-08
that O 0 1.712809005738336e-09
is O 0 2.7485651532543898e-09
apparently O 0 1.3009759491922068e-08
silent O 0 2.3384201242038216e-08
in O 0 8.330768297426516e-10
the O 0 1.0034115760504392e-09
heterozygous O 0 2.9920133037819596e-09
carriers O 0 2.078524241611035e-09
, O 0 1.11044229367252e-09
in O 0 4.9357065101673925e-09
11 O 0 2.0372451103867206e-07
. O 0 5.93594620568183e-07

5 O 0 1.81502582563553e-06
% O 0 3.0757892233168604e-08
of O 0 3.5158524980261063e-08
all O 0 2.476476135271355e-09
control O 0 1.7958831222131266e-07
individuals O 0 2.6707505651479835e-10
, O 0 9.356500019208625e-10
and O 0 7.611685726160999e-10
in O 0 6.913777328421133e-10
one O 0 3.942704218662385e-10
control O 0 1.847057440329536e-08
individual O 0 1.6812244651998043e-10
homozygous O 0 2.3473563093290295e-09
for O 0 6.554003451064716e-10
this O 0 8.128788753225535e-10
glycine O 0 1.8433922832628014e-07
substitution O 0 3.3348305805702694e-07
. O 0 4.5493564471144055e-07

There O 0 1.1869922218465945e-06
has O 0 1.874720645389516e-08
been O 0 3.3930669385284773e-09
no O 0 4.868924152745535e-10
previous O 0 1.0236315128864248e-09
finding O 0 9.929976840794552e-09
of O 0 6.751768921731127e-09
a O 0 4.062642666724514e-09
glycine O 0 2.151346478740379e-08
substitution O 0 1.3941948928675174e-08
that O 0 4.413547860515621e-10
is O 0 3.076455201700412e-10
not O 0 1.1096668722787584e-10
associated O 0 2.6272704012342274e-09
with O 0 1.8908717647203588e-10
any O 0 5.129914715240602e-09
obvious O 0 4.6364398542664276e-08
phenotype O 0 7.866263196376622e-09
in O 0 1.0256463456315146e-09
homozygous O 0 2.3262977322247025e-08
individuals O 0 4.527669350551378e-09
. O 0 3.9194986811708077e-07

Founder O 0 0.014152219519019127
BRCA1 O 0 1.0694070624595042e-05
and O 0 1.1852123549260796e-07
BRCA2 O 0 1.7719654010761587e-07
mutations O 0 5.704296590636204e-09
in O 0 1.845362751495827e-09
French O 0 4.120944083751965e-07
Canadian O 0 2.939304795290809e-05
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.1619350920664147e-05
. O 0 1.1226508831896354e-05

We O 0 5.543600423152384e-07
have O 0 3.295096417943455e-09
identified O 0 4.432599176595886e-09
four O 0 1.9546338159148746e-10
mutations O 0 1.0145207590683825e-10
in O 0 4.8074814962273393e-11
each O 0 3.6432544481268536e-11
of O 0 6.357403492529556e-09
the O 0 5.308657478053647e-07
breast B-Disease 1 0.9999951124191284
cancer I-Disease 1 0.9997391104698181
- O 0 0.005460598040372133
susceptibility O 0 0.0001179623868665658
genes O 0 3.9381544070238306e-07
, O 0 3.8257212509051897e-08
BRCA1 O 0 3.591472363950743e-08
and O 0 6.400742602608034e-09
BRCA2 O 0 1.5462322977555232e-08
, O 0 6.053397783034598e-10
in O 0 6.703056998347279e-10
French O 0 4.208048665077513e-07
Canadian O 0 5.053616769146174e-05
breast B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999961853027344
and O 1 0.9980999827384949
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.4767641093603743e-07
from O 0 5.273522560855781e-07
Quebec O 0 1.1786373761424329e-05
. O 0 1.4686091844851035e-06

To O 0 2.8975117061236233e-07
identify O 0 5.239171969151357e-06
founder O 0 6.918673170730472e-05
effects O 0 0.13655979931354523
, O 0 9.718286264615017e-08
we O 0 1.5395139385532275e-08
examined O 0 4.836995159962498e-08
independently O 0 1.1420812739970643e-08
ascertained O 0 5.727521568132943e-08
French O 0 8.942323859173484e-08
Canadian O 0 3.639905514774e-07
cancer B-Disease 0 2.1255004867271055e-07
families O 0 7.37195374189703e-11
for O 0 1.6670215208236527e-10
the O 0 5.186324703032597e-10
distribution O 0 3.837002271467327e-09
of O 0 3.4945704108224618e-09
these O 0 1.1001753952299964e-09
eight O 0 4.738998882203305e-08
mutations O 0 6.74675106893119e-08
. O 0 2.637409295402904e-07

Mutations O 0 9.417469186701055e-07
were O 0 1.0000649552921459e-07
found O 0 2.056858328103317e-08
in O 0 4.753979432337019e-09
41 O 0 1.4868716391447379e-07
of O 0 1.8924436062661698e-07
97 O 0 4.300974069337826e-06
families O 0 2.585622027595491e-08
. O 0 5.79534457756381e-07

Six O 0 9.734609420775087e-07
of O 0 4.072832382462366e-07
eight O 0 8.9940847658454e-08
mutations O 0 1.2293591922230007e-08
were O 0 1.0490226465265096e-08
observed O 0 2.9987276661813667e-08
at O 0 1.9403020701247442e-07
least O 0 1.4803074321889653e-08
twice O 0 3.1881958761914575e-07
. O 0 2.5599729269742966e-07

The O 0 9.084458724828437e-06
BRCA1 O 0 6.259563178900862e-06
C4446T O 0 6.523935098812217e-06
mutation O 0 5.153837889793067e-08
was O 0 1.003757006401429e-07
the O 0 6.759087511909456e-09
most O 0 6.057139789739097e-10
common O 0 2.206693938688886e-09
mutation O 0 5.975084316212076e-10
found O 0 1.1418759271464296e-09
, O 0 2.000177662386804e-10
followed O 0 6.170530197913138e-10
by O 0 8.471422452416277e-10
the O 0 6.142541053577588e-08
BRCA2 O 0 4.283297414531262e-07
8765delAG O 0 1.4002490615894203e-06
mutation O 0 3.933042194148584e-07
. O 0 7.322829560507671e-07

Together O 0 2.14673286791367e-06
, O 0 4.93442868787497e-08
these O 0 2.03451167024582e-09
mutations O 0 4.065534131569848e-09
were O 0 6.248034978284522e-09
found O 0 1.9639025961026846e-09
in O 0 1.4309090579089911e-09
28 O 0 4.749414017624076e-08
of O 0 1.0171707742756553e-07
41 O 0 3.0172336096256913e-07
families O 0 1.3703922441266059e-09
identified O 0 4.954059829032076e-09
to O 0 1.0328629063138806e-09
have O 0 1.9625694402947147e-09
a O 0 1.4975798379168737e-08
mutation O 0 2.7727192986048976e-08
. O 0 1.6856192530667613e-07

The O 0 5.2776681513933e-07
odds O 0 4.4932480705028865e-06
of O 0 4.066203018737724e-08
detection O 0 7.260288157340256e-07
of O 0 1.4118135105434249e-08
any O 0 3.5613065829664947e-09
of O 0 2.7767361743258334e-08
the O 0 1.1702827151793826e-08
four O 0 1.1266547694788187e-08
BRCA1 O 0 1.534231763855587e-08
mutations O 0 1.1509619035621199e-08
was O 0 5.735019499297778e-07
18 O 0 2.3869727101555327e-06
. O 0 1.6493205521328491e-06

7x O 0 0.010067402385175228
greater O 0 9.519772902422119e-06
if O 0 1.4394770175840677e-07
one O 0 5.140669667724751e-09
or O 0 5.854288165352273e-10
more O 0 7.828879905469321e-11
cases O 0 1.5427200628082005e-09
of O 0 3.1273109925678e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.94911876860715e-06
also O 0 2.218882855231641e-09
present O 0 1.347017386521543e-09
in O 0 1.0423684138061162e-09
the O 0 8.467500478559487e-09
family O 0 3.7399292551754115e-08
. O 0 8.991202804509157e-08

The O 0 2.9600528250739444e-07
odds O 0 6.21997571670363e-07
of O 0 1.4725744179600042e-08
detection O 0 2.3994152797968127e-07
of O 0 7.803349966195583e-09
any O 0 3.2109168657257214e-09
of O 0 1.2054709230824301e-08
the O 0 7.688483627532605e-09
four O 0 3.778093926598558e-08
BRCA2 O 0 3.820208860361163e-08
mutations O 0 2.0828947455697744e-08
was O 0 9.042718147611595e-07
5 O 0 2.0082550236111274e-06
. O 0 1.3473310218614643e-06

3x O 0 0.0005941502749919891
greater O 0 1.4092154287936864e-06
if O 0 6.61037873328496e-08
there O 0 7.395888790284744e-09
were O 0 4.995973412746935e-09
at O 0 1.161250828829452e-08
least O 0 8.018159747269493e-11
five O 0 1.6760887122657664e-10
cases O 0 6.599853441535686e-10
of O 0 5.457478735593213e-08
breast B-Disease 1 0.8826950192451477
cancer I-Disease 0 0.004025107249617577
in O 0 1.3005026744394854e-07
the O 0 9.313957889389712e-07
family O 0 4.952395897817041e-07
. O 0 4.6608980142082146e-07

Interestingly O 0 3.6921555874869227e-06
, O 0 6.287008602612332e-08
the O 0 1.0478228062993367e-08
presence O 0 2.526400955105146e-08
of O 0 2.481958745192969e-07
a O 0 2.4208375180023722e-06
breast B-Disease 1 0.9278450608253479
cancer I-Disease 0 0.00037114828592166305
case O 0 5.26351357166277e-07
< O 0 3.1558337809656223e-07
36 O 0 2.6110360096254226e-08
years O 0 2.761623374425426e-09
of O 0 1.1731523308355918e-08
age O 0 1.3306778612331982e-07
was O 0 5.350288034833284e-08
strongly O 0 9.019330282633575e-10
predictive O 0 8.699457154648371e-09
of O 0 1.8031686144226455e-09
the O 0 5.857694329591823e-10
presence O 0 2.6840600853006435e-09
of O 0 2.3543782479151787e-09
any O 0 1.5636346661906941e-09
of O 0 8.735754342126256e-09
the O 0 8.684138741443803e-09
eight O 0 2.7519394762975935e-08
mutations O 0 7.738726992556622e-09
screened O 0 2.415735309568845e-07
. O 0 2.3216352929011919e-07

Carriers O 0 7.697245223425853e-07
of O 0 1.1278119416147092e-07
the O 0 5.759319687825837e-09
same O 0 1.3778672647291046e-09
mutation O 0 2.0075006934572315e-10
, O 0 7.912964727907479e-11
from O 0 1.1182037240597964e-10
different O 0 1.6730257457187037e-10
families O 0 3.582306326577189e-11
, O 0 5.465637317736416e-11
shared O 0 5.248400603008463e-10
similar O 0 6.648572803413799e-10
haplotypes O 0 1.7718987166404077e-08
, O 0 1.1741008165699895e-09
indicating O 0 5.118069967835481e-09
that O 0 2.7036864413965134e-10
the O 0 1.3474130700075193e-09
mutant O 0 5.9317226686061986e-09
alleles O 0 1.2299214979805129e-09
were O 0 9.30109589347694e-09
likely O 0 2.302187329661365e-09
to O 0 1.8710964722057355e-10
be O 0 4.621636962021114e-10
identical O 0 7.602486418178955e-10
by O 0 1.1326284354851168e-10
descent O 0 1.4216874788530731e-08
for O 0 2.2488098050388317e-09
a O 0 3.2924201143202936e-09
mutation O 0 6.999932855578095e-10
in O 0 1.0954932516682447e-09
the O 0 9.884473683996475e-09
founder O 0 3.483465604858793e-07
population O 0 5.032190664167047e-09
. O 0 2.696636727250734e-07

The O 0 3.8860715534383417e-08
identification O 0 5.092870836165275e-08
of O 0 6.642202521334184e-08
common O 0 4.6626499283775047e-07
BRCA1 O 0 2.3428539464021014e-07
and O 0 5.926161250613404e-08
BRCA2 O 0 7.767329890384644e-08
mutations O 0 6.499903282275454e-09
will O 0 5.754441367855634e-10
facilitate O 0 1.2728814446916203e-08
carrier O 0 2.1924728699218576e-08
detection O 0 2.1177733344757144e-07
in O 0 1.914848057893437e-09
French O 0 8.824110295790888e-07
Canadian O 0 9.218580999004189e-06
breast B-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999774694442749
and O 1 0.9969231486320496
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.165559857938206e-06
. O 0 2.996809371325071e-06

Are O 0 2.965981025226938e-07
Dp71 O 0 4.282883310224861e-05
and O 0 2.5839983663900057e-07
Dp140 O 0 6.775138172088191e-05
brain O 0 0.00017050867609214038
dystrophin O 0 2.4456621758872643e-06
isoforms O 0 8.269429940810369e-08
related O 0 2.0854349358501167e-08
to O 0 5.0891588720958225e-09
cognitive B-Disease 1 0.8145119547843933
impairment I-Disease 1 0.9999998807907104
in O 1 0.9999978542327881
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.999327540397644

Molecular O 0 8.752086614549626e-06
study O 0 1.184229390105429e-07
and O 0 1.1776226216397845e-08
neuropsychological O 0 3.982638361321733e-07
analysis O 0 1.3750010019464298e-08
were O 0 2.92790347522498e-09
performed O 0 8.895963077293345e-09
concurrently O 0 2.0833676117604227e-08
on O 0 3.117915881034605e-08
49 O 0 1.5694403145971592e-06
patients O 0 1.3315325304574799e-05
with O 1 0.999830961227417
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999926090240479
DMD B-Disease 1 1.0
) O 0 6.710380517915837e-08
in O 0 4.093210215216914e-09
order O 0 1.1314198467005099e-09
to O 0 3.784754176727745e-10
find O 0 1.9304482457016547e-09
a O 0 2.548604882690597e-09
molecular O 0 5.4801237325818875e-08
explanation O 0 4.680454690486613e-09
for O 0 4.1059303179658e-10
the O 0 4.513958984375677e-09
cognitive B-Disease 0 4.093437746632844e-05
impairment I-Disease 0 9.758987289387733e-05
observed O 0 3.6767752931154973e-07
in O 0 2.8031193366473417e-08
most O 0 3.4173959306826873e-07
DMD B-Disease 1 0.9999997615814209
patients O 0 3.943162937503075e-06
. O 0 1.4622489743487677e-06

Complete O 0 1.4394279332918813e-06
analysis O 0 2.622431054533081e-07
of O 0 1.948514949390301e-07
the O 0 1.3051742087100138e-07
dystrophin O 0 3.0099590730969794e-06
gene O 0 7.34484757458631e-08
was O 0 3.0401150752368267e-07
performed O 0 7.034618221268829e-08
to O 0 4.114257823317757e-09
define O 0 1.0861857191457602e-07
the O 0 5.54868897495453e-08
localization O 0 1.368087214359548e-05
of O 0 2.3958665451573324e-07
deletions O 0 1.168751779800914e-07
and O 0 2.185487879557968e-08
duplications O 0 2.3159352622315055e-06
in O 0 1.5200319225527892e-08
relation O 0 8.132239059932544e-08
to O 0 3.426612993351341e-09
the O 0 3.53676981035278e-08
different O 0 1.7109999816966592e-06
DMD B-Disease 1 1.0
promoters O 0 9.295870404457673e-05
. O 0 2.556133495090762e-06

Qualitative O 0 9.447889169678092e-06
analysis O 0 6.082105414861871e-07
of O 0 1.745728610558217e-07
the O 0 1.2447137009985454e-07
Dp71 O 0 9.493625839240849e-06
transcript O 0 6.0764705267502e-07
and O 0 1.7178213296276112e-09
testing O 0 2.569897405990673e-09
for O 0 2.443397151274951e-10
the O 0 6.571189148374401e-10
specific O 0 7.460420059501871e-10
first O 0 4.136683440236766e-09
exon O 0 1.5290717669813603e-07
of O 0 2.0501447650644877e-08
Dp140 O 0 2.3352249911567924e-07
were O 0 1.3020483358161528e-08
also O 0 1.5786361107217317e-09
carried O 0 3.979089946426484e-09
out O 0 7.427541248716807e-09
. O 0 6.900319959868284e-08

Neuropsychological O 0 5.2528048399835825e-05
analysis O 0 6.652383603977796e-07
assessed O 0 1.6860821006048354e-06
verbal O 0 5.175123078515753e-06
and O 0 4.22397476995684e-07
visuospatial O 0 0.0006614228477701545
intelligence O 0 7.392403858830221e-06
, O 0 1.7614731007142836e-08
verbal O 0 2.913752723543439e-07
memory O 0 0.00011763865040848032
, O 0 1.1510084618748806e-07
and O 0 5.039252570782082e-08
reading O 0 1.2704804248642176e-05
skills O 0 0.00020553886133711785
. O 0 2.4291168756462866e-06

Comparison O 0 1.816315943869995e-06
of O 0 5.645896408168483e-07
molecular O 0 2.9796506169077475e-06
and O 0 3.876447607353839e-08
psychometric O 0 1.266396702703787e-05
findings O 0 5.205338382552327e-08
demonstrated O 0 5.272405445566619e-08
that O 0 6.919265715943368e-10
deletions O 0 1.616813172233833e-08
and O 0 5.422798210474866e-09
duplications O 0 4.120908556615177e-07
that O 0 1.405402350052043e-09
were O 0 5.201811870136908e-09
localized O 0 2.431065126984322e-07
in O 0 6.956983877870471e-09
the O 0 1.2644219893331865e-08
distal O 0 5.504668365574616e-07
part O 0 4.882581094989291e-08
of O 0 1.6899652166557644e-07
the O 0 1.336974548848957e-07
gene O 0 6.991092504904373e-08
seemed O 0 1.6563713245432155e-07
to O 0 9.271582945835632e-10
be O 0 1.0584845222538775e-09
preferentially O 0 7.485338571200373e-09
associated O 0 2.1271830519253854e-08
with O 0 2.3409414851016663e-08
cognitive B-Disease 1 0.9895819425582886
impairment I-Disease 1 0.9999332427978516
. O 0 7.683466537855566e-05

Two O 0 4.0236017184724915e-07
altered O 0 8.725182283342292e-07
Dp71 O 0 6.479892363131512e-06
transcripts O 0 9.202823889609135e-07
and O 0 2.6597766211722274e-09
two O 0 1.211243771948034e-09
deleted O 0 2.6590120327796285e-08
Dp140 O 0 4.227972638659594e-08
DNA O 0 4.112171048120672e-09
sequences O 0 2.772369001036168e-09
were O 0 1.2177785446709777e-09
found O 0 7.762508413833302e-10
in O 0 2.5908769574201074e-10
four O 0 2.1452728482529437e-09
patients O 0 3.320929309325038e-08
with O 0 8.812489227238984e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.017469899728894234

These O 0 7.737608598290535e-08
findings O 0 8.066106715887145e-08
suggest O 0 1.8442307236909983e-08
that O 0 2.835287837843481e-10
some O 0 1.2914980196399029e-10
sequences O 0 5.15231146636097e-09
located O 0 6.98681112965005e-09
in O 0 1.8349666230932371e-09
the O 0 4.867218184045896e-09
distal O 0 2.2728215753886616e-07
part O 0 1.2928376591503365e-08
of O 0 1.9054276378938084e-08
the O 0 4.30051860789149e-09
gene O 0 1.1225658180791243e-09
and O 0 6.838079547044629e-10
, O 0 5.813284853495304e-10
in O 0 4.234343986553313e-10
particular O 0 2.8465436674451894e-09
, O 0 1.057879006616247e-09
some O 0 9.542642231963328e-10
DMD B-Disease 1 0.9990136623382568
isoforms O 0 3.946944104882277e-08
expressed O 0 7.038829963335047e-09
in O 0 4.215408910823726e-09
the O 0 4.4985078773152054e-08
brain O 0 3.139568434562534e-05
may O 0 4.73176164916822e-09
be O 0 2.556290734645472e-10
related O 0 7.793350964568901e-10
to O 0 7.139066421357754e-11
the O 0 3.097382128558479e-09
cognitive B-Disease 0 0.00016496411990374327
impairment I-Disease 0 0.0034441847819834948
associated O 0 4.796013854502235e-06
with O 0 1.9264234651927836e-06
DMD B-Disease 1 1.0
. O 0 7.339721719290537e-07
. O 0 1.0583144103293307e-06

I1307K O 0 5.794642129330896e-05
APC O 0 2.693888745852746e-06
and O 0 3.343377130704539e-08
hMLH1 O 0 2.553207139044389e-07
mutations O 0 7.362854326231627e-09
in O 0 1.082577694155873e-09
a O 0 2.85360535201562e-09
non O 0 2.6221960069960915e-07
- O 0 2.2458711157469224e-07
Jewish O 0 6.307593114485144e-09
family O 0 6.847477029836568e-10
with O 0 1.2623729839233988e-09
hereditary B-Disease 1 0.9999998807907104
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.98673415184021

We O 0 3.4462394182810385e-07
describe O 0 1.504422755260748e-07
a O 0 1.1508169528440249e-08
French O 0 3.4707124996202765e-07
Canadian O 0 8.673794695823744e-07
hereditary B-Disease 1 0.9999996423721313
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999791383743286
HNPCC B-Disease 1 0.9999973773956299
) O 0 1.0258796692141914e-06
kindred O 0 1.8028786143986508e-05
which O 0 1.5301431233183393e-08
carries O 0 2.1864844157448715e-08
a O 0 2.9476217022761375e-09
novel O 0 5.830388616345772e-09
truncating O 0 2.690058522603067e-07
mutation O 0 3.99252506610992e-08
in O 0 4.097219274967756e-08
hMLH1 O 0 4.8083466026582755e-06
. O 0 1.8502926195651526e-06

Interestingly O 0 1.5189912119240034e-05
, O 0 2.2379964548235876e-07
the O 0 1.6148568704466015e-07
I1307K O 0 4.601109139912296e-06
APC O 0 4.0369928910877206e-07
polymorphism O 0 2.859189009996044e-07
, O 0 4.743653914118795e-09
associated O 0 5.737359032309541e-09
with O 0 3.2227570612164413e-10
an O 0 6.880861991298559e-10
increased O 0 1.5820572230040852e-07
risk O 0 0.0001620033144718036
of O 1 0.9999910593032837
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.7276193981815595e-06
is O 0 1.5791970398026933e-08
also O 0 7.818781178059453e-10
present O 0 1.3696292988640835e-09
in O 0 2.56188070757446e-09
this O 0 2.6090631877195847e-09
family O 0 2.800885212650428e-08
. O 0 1.4278595017458429e-07

The O 0 2.6624786642059917e-06
I1307K O 0 1.4328496035886928e-05
polymorphism O 0 1.41269913456199e-06
has O 0 1.3640144125304232e-08
previously O 0 6.239272209995761e-08
only O 0 1.0778717918213943e-09
been O 0 1.2232794777133904e-09
identified O 0 1.280360928390678e-09
in O 0 2.690137279603988e-10
individuals O 0 6.132745700160314e-11
of O 0 9.619985696929234e-09
self O 0 4.231474122207146e-07
- O 0 7.023556918284157e-07
reported O 0 5.3772353680869855e-08
Ashkenazi O 0 1.0502682812330022e-07
Jewish O 0 1.1501104069111534e-08
origins O 0 1.3880648452868627e-07
. O 0 1.0672410866163773e-07

In O 0 2.866659372102731e-07
addition O 0 3.129790826505996e-08
, O 0 3.4730276432526352e-09
in O 0 1.5864236591056624e-09
this O 0 5.161269189812856e-10
family O 0 1.5969491284906212e-09
, O 0 1.4751544430424701e-09
there O 0 1.7127013141049474e-09
appears O 0 5.9340536928687015e-09
to O 0 3.5211369930898684e-10
be O 0 3.1619804552462938e-09
no O 0 5.6779088097869135e-09
relationship O 0 1.0135488892615285e-08
between O 0 9.38094935065692e-09
the O 0 3.736027487377669e-09
I1307K O 0 3.2158951057681406e-08
polymorphism O 0 3.075764309912188e-09
and O 0 8.60390370061026e-11
the O 0 3.7924932638766506e-10
presence O 0 1.4076665388884635e-09
or O 0 2.28687402348271e-09
absence O 0 2.421439262434433e-07
of O 0 1.830369569688628e-06
cancer B-Disease 0 0.00018496523262001574
. O 0 1.12374721084052e-07
. O 0 6.647620693911449e-07

Identification O 0 5.980825790175004e-07
of O 0 1.9635670867046429e-07
a O 0 3.9867266821147496e-08
novel O 0 1.38719737918791e-08
mutation O 0 3.4795191172776185e-09
of O 0 1.381694403335132e-08
the O 0 7.029574788930404e-08
CPO O 0 1.2289122423680965e-05
gene O 0 5.907686784212274e-08
in O 0 1.1443817449219296e-08
a O 0 2.7360758991790135e-08
Japanese O 0 7.193283181550214e-06
hereditary B-Disease 1 0.9999914169311523
coproporphyria I-Disease 1 0.9979992508888245
family O 0 3.928187197743682e-06
. O 0 2.7206053800910013e-06

Hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.999997615814209
( O 0 0.004876225255429745
HCP B-Disease 1 0.9999589920043945
) O 0 1.845270958256151e-07
is O 0 8.129227069275657e-09
an O 0 3.053745700754007e-08
autosomal B-Disease 1 0.9999994039535522
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999979734420776
characterized O 0 2.961017116831499e-06
by O 0 6.614513381464349e-09
a O 0 1.0026124073192477e-06
deficiency B-Disease 1 0.9986428618431091
of I-Disease 1 0.6916276216506958
coproporphyrinogen I-Disease 1 0.9900557994842529
oxidase I-Disease 0 5.668863991559192e-07
( O 0 9.67331104106961e-08
CPO O 0 1.7656560657997034e-06
) O 0 1.3697181167060535e-09
caused O 0 1.7482443270822046e-09
by O 0 1.4327872221997495e-10
a O 0 1.5776848716342329e-09
mutation O 0 1.6457039064832202e-09
in O 0 2.855173208970996e-09
the O 0 4.297733013913785e-08
CPO O 0 5.524162406800315e-05
gene O 0 6.031241355231032e-07
. O 0 7.223779903142713e-07

Only O 0 2.0829392610721698e-07
11 O 0 3.041089655653195e-07
mutations O 0 1.0687583262836142e-08
of O 0 2.0622833218908454e-08
the O 0 1.795529769310633e-08
gene O 0 1.2902116708346512e-08
have O 0 1.1209952965884895e-09
been O 0 3.0581450705113866e-09
reported O 0 1.615000932986277e-08
in O 0 5.085221843614818e-08
HCP B-Disease 1 0.9997246861457825
patients O 0 3.9945047319633886e-05
. O 0 7.2775051194184925e-06

We O 0 2.597047625840787e-07
report O 0 9.668086775604934e-09
another O 0 3.956220684386835e-09
mutation O 0 3.8183983752659856e-10
in O 0 6.591248657983328e-10
a O 0 6.747906677873061e-09
Japanese O 0 2.0983120521123055e-06
family O 0 2.2696569601521333e-07
. O 0 5.462632657327049e-07

Polymerase O 0 0.00010220361582469195
chain O 0 2.3282700567506254e-06
reaction O 0 5.6247497326467055e-08
- O 0 8.478138369127919e-08
single O 0 4.319277824293977e-09
strand O 0 1.653110359711718e-08
conformational O 0 4.661353525392542e-09
polymorphism O 0 7.785986078090446e-09
and O 0 9.771174980244268e-10
direct O 0 1.3585871316834641e-09
sequence O 0 6.896892501551122e-10
analyses O 0 4.713350598706256e-09
demonstrated O 0 1.3105294627280273e-08
a O 0 7.292248138668356e-09
C O 0 2.36558605593018e-07
to O 0 2.0794519439704118e-09
T O 0 1.1542456945790036e-07
substitution O 0 1.1653022546909142e-08
in O 0 5.443513639846742e-09
exon O 0 1.0066348465898045e-07
1 O 0 2.594336301342537e-08
of O 0 6.393872986620863e-09
the O 0 1.1255272269750094e-08
CPO O 0 5.815441568302049e-07
gene O 0 8.216334279609327e-09
at O 0 4.412929399677523e-08
nucleotide O 0 2.5503958056560805e-08
position O 0 7.805051183140677e-08
85 O 0 7.911769017709958e-08
, O 0 7.236022891987659e-09
which O 0 9.055148852965544e-10
lies O 0 1.8978035143391025e-08
in O 0 1.6504189126465008e-09
the O 0 8.00896771124826e-09
putative O 0 1.5870364222791977e-07
presequence O 0 2.9591919314952975e-07
for O 0 7.895048170780683e-09
targeting O 0 4.404268594271343e-08
to O 0 2.6793813390213472e-08
mitochondria O 0 3.487731646600878e-06
. O 0 1.2658597370318603e-06

This O 0 1.6970513883052263e-08
mutation O 0 3.0167683906512366e-09
changes O 0 3.0704305764572837e-09
the O 0 2.9336499896004398e-09
codon O 0 6.181913203562317e-09
for O 0 2.993691516905983e-09
glutamine O 0 2.1215022627529834e-08
to O 0 4.026885047636597e-09
a O 0 1.3594639192149316e-08
termination O 0 6.165806354374581e-08
codon O 0 4.488232008270643e-08
at O 0 1.6624893817152042e-07
amino O 0 9.727336447440393e-08
acid O 0 1.9982793730832782e-07
position O 0 1.2946682090841932e-06
29 O 0 9.801618944038637e-06
. O 0 1.6053581930464134e-06

MaeI O 0 5.084815711597912e-05
restriction O 0 7.951008456075215e-07
analysis O 0 2.957688138849335e-07
showed O 0 8.284001040692601e-08
two O 0 7.175409710846736e-10
other O 0 5.399408697925878e-10
carriers O 0 5.201782116159848e-09
in O 0 2.2706532210037267e-09
the O 0 1.7817743724890533e-08
family O 0 4.980049439495815e-08
. O 0 1.0713568343589941e-07

The O 0 7.900849595898762e-06
C O 1 0.922415018081665
- O 0 0.0003021380689460784
T O 0 2.7378409868106246e-06
mutation O 0 2.74093769903061e-09
is O 0 6.789603324008908e-10
located O 0 2.537477783448594e-09
within O 0 1.6812315983827375e-09
a O 0 1.3045882152340482e-09
recently O 0 1.6825661974806394e-09
proposed O 0 2.2156521062299817e-09
putative O 0 3.199496889649822e-09
alternative O 0 8.236146209483763e-10
translation O 0 3.374511559073312e-09
initiation O 0 9.62257296066582e-09
codon O 0 1.635316237980078e-08
( O 0 1.4384952784496363e-08
TIC O 0 4.7670118874520995e-06
- O 0 6.538969614666712e-07
1 O 0 2.4284975097543793e-07
) O 0 1.437874486143187e-09
, O 0 1.3029718415324965e-09
supporting O 0 8.796062545002314e-09
that O 0 5.660520940864444e-09
TIC O 0 4.304297544877045e-05
- O 0 1.2023180033793324e-06
1 O 0 2.910769865138718e-07
is O 0 8.965302944474729e-10
the O 0 2.789224629040632e-09
real O 0 5.054317853137036e-07
TIC O 0 4.87282159156166e-06
rather O 0 3.7609527936410814e-08
than O 0 1.4739401699159771e-08
TIC O 0 6.505501005449332e-06
- O 0 2.240499412664576e-07
2 O 0 1.2219980760619364e-07
. O 0 5.744596354162468e-09
. O 0 5.6668756798217146e-08

Human B-Disease 0 7.609383487761079e-07
complement I-Disease 0 7.395436114165932e-06
factor I-Disease 0 0.0009143400238826871
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999693632125854
associated O 0 0.0004085053224116564
with O 1 0.6913507580757141
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.999962568283081

This O 0 3.2531705329574834e-08
study O 0 1.7690554798832636e-08
reports O 0 8.203164370002014e-09
on O 0 1.0254415094834712e-08
six O 0 1.8601375995075387e-09
cases O 0 1.5485426274608471e-09
of O 0 5.176466899570187e-08
deficiency B-Disease 0 0.00040377379627898335
in I-Disease 0 1.0880431666748791e-08
the I-Disease 0 8.815411511875482e-09
human I-Disease 0 3.4102867196850184e-09
complement I-Disease 0 2.090169815005538e-08
regulatory I-Disease 0 3.065189559947612e-07
protein I-Disease 0 2.985052560688928e-07
Factor I-Disease 0 4.788371938957425e-07
H I-Disease 1 0.9990798234939575
( O 0 8.833458053914e-08
FH O 0 9.681771189207211e-07
) O 0 6.608078528813621e-10
in O 0 2.0160191571694241e-10
the O 0 1.2317168118780586e-10
context O 0 2.09160044839507e-09
of O 0 5.518984824703921e-09
an O 0 4.9975675153746124e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.2506153881549835

Five O 0 1.1079569048888516e-06
of O 0 2.744311302649294e-07
the O 0 8.105213389342225e-09
cases O 0 1.8313931482438761e-09
were O 0 4.506851003505119e-10
observed O 0 7.838342197530324e-10
in O 0 6.999034685151173e-11
children O 0 3.172803339501762e-11
presenting O 0 5.463558494511744e-09
with O 0 3.6661731428466737e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
HUS B-Disease 1 1.0
) O 0 7.325833576032892e-05
. O 0 2.2709897166350856e-05

Two O 0 1.6119440715556266e-07
of O 0 2.0413779111549957e-07
the O 0 6.054188617099499e-08
children O 0 1.8956979985773614e-08
exhibited O 0 1.2030681091346196e-06
a O 0 5.307811647980998e-07
homozygous O 0 8.580637768318411e-06
deficiency O 0 0.032331570982933044
characterized O 0 2.0440721471004508e-07
by O 0 2.351474570616574e-09
the O 0 2.7095021337686376e-08
absence O 0 5.577900878961373e-07
of O 0 1.1417191103646473e-07
the O 0 3.1284773882589434e-08
150 O 0 1.4059740927052644e-08
- O 0 9.111459142729927e-09
kD O 0 8.570324183665434e-08
form O 0 1.942689120681962e-09
of O 0 3.3879274496939615e-08
Factor O 0 3.051941348530818e-07
H O 1 0.9989266991615295
and O 0 5.08419129019444e-09
the O 0 3.206706011837923e-09
presence O 0 2.022945810864485e-09
, O 0 2.2550453171454876e-10
upon O 0 2.3927408943080763e-09
immunoblotting O 0 4.160502697914126e-08
, O 0 5.139343395299534e-10
of O 0 2.91324186996178e-09
the O 0 7.298607052064199e-09
42 O 0 1.3928583086908475e-07
- O 0 1.0953397122648312e-07
kD O 0 1.3768533335678512e-06
Factor O 0 4.292969038033334e-07
H O 1 0.9560376405715942
- O 0 1.7045829281414626e-06
like O 0 3.6567310957025256e-08
protein O 0 5.994175467094465e-08
1 O 0 3.263362771122047e-07
( O 0 1.5277052511919464e-08
FHL O 0 3.4389615848340327e-06
- O 0 3.141190063615795e-07
1 O 0 1.4743231702141202e-07
) O 0 1.043124253641281e-09
and O 0 1.5002005193665013e-09
other O 0 3.959632621786113e-09
FH O 0 5.347219939721981e-06
- O 0 2.782086028219055e-07
related O 0 2.296135050983139e-07
protein O 0 2.7432332672105986e-07
( O 0 1.058232701467432e-08
FHR O 0 5.6900212257460225e-06
) O 0 1.7926623741004732e-08
bands O 0 2.2836009065940743e-06
. O 0 8.432930371782277e-07

Southern O 0 4.592407549353084e-06
blot O 0 2.3861714453232707e-06
and O 0 7.310045013753097e-09
PCR O 0 5.72434295520452e-08
analysis O 0 4.001969866607169e-09
of O 0 5.95425708738162e-09
DNA O 0 1.0796114224831399e-07
of O 0 4.7023352323094514e-08
one O 0 8.198925094404785e-09
patient O 0 1.5333679925788601e-07
with O 0 1.3493443873358046e-07
homozygous O 0 9.019846038427204e-05
deficiency O 1 0.9997567534446716
ruled O 0 1.011663789540762e-05
out O 0 4.0071101992111835e-09
the O 0 1.432039375970362e-09
presence O 0 6.871605950919957e-09
of O 0 8.678807006390343e-09
a O 0 3.0932432171226765e-09
large O 0 1.7116594808186392e-09
deletion O 0 5.161698268807413e-08
of O 0 3.023751915520734e-08
the O 0 7.58710996251466e-08
FH O 0 3.6790167996514356e-06
gene O 0 6.6889476180165275e-09
as O 0 2.2461092985537334e-09
the O 0 7.107471056144732e-09
underlying O 0 0.00039875818765722215
defect O 0 4.651737526728539e-06
for O 0 1.5786947926699213e-07
the O 0 2.897110789490398e-05
deficiency O 1 0.9999963045120239
. O 0 4.202972922939807e-05

The O 0 2.7371936539566377e-07
other O 0 2.764792483844758e-08
four O 0 8.789253769236893e-09
children O 0 1.5609885606338025e-09
presented O 0 1.7054263778959466e-08
with O 0 3.152443284193396e-08
heterozygous O 0 1.1754135812225286e-05
deficiency O 1 0.8574070334434509
and O 0 1.1558670820477346e-07
exhibited O 0 2.2683097995468415e-06
a O 0 2.311913149810607e-08
normal O 0 4.0009953750086424e-07
immunoblotting O 0 7.147468181756267e-07
pattern O 0 4.154706090275795e-08
of O 0 5.206824749137695e-09
proteins O 0 1.179060404865595e-09
of O 0 1.8773256726944965e-08
the O 0 2.07654082373665e-07
FH O 0 0.0003754371136892587
family O 0 2.7855955408995214e-07
. O 0 4.773062300955644e-07

Factor B-Disease 1 0.9883719086647034
H I-Disease 1 1.0
deficiency I-Disease 1 0.99996018409729
is O 0 1.0624174962003963e-07
the O 0 3.976133200467302e-08
only O 0 1.2071785704392823e-07
complement B-Disease 1 0.9999995231628418
deficiency I-Disease 1 1.0
associated O 0 0.00031101645436137915
with O 0 9.116013643506449e-06
HUS B-Disease 1 1.0
. O 0 7.99802437541075e-05

These O 0 2.256121689470092e-07
observations O 0 6.833925567661936e-07
suggest O 0 7.482744024400745e-08
a O 0 1.2215151556915771e-08
role O 0 2.4357870387348157e-08
for O 0 6.874126512457224e-08
FH O 0 0.00031353719532489777
and O 0 5.230123747423931e-07
/ O 0 0.0004123132093809545
or O 0 3.477849190858251e-07
FH O 0 1.20290542326984e-05
receptors O 0 4.163074862617577e-08
in O 0 5.095219801631856e-09
the O 0 2.8503647442335023e-08
pathogenesis O 0 0.002168178791180253
of O 0 1.0996463061019313e-05
idiopathic O 1 0.9999768733978271
HUS B-Disease 1 1.0
. O 0 1.6341693935828516e-06
. O 0 3.316484253446106e-06

Further O 0 6.359552457979589e-07
evidence O 0 3.433727329138492e-07
for O 0 5.684735349120729e-09
a O 0 6.638008365200676e-09
major O 0 3.624836253379726e-08
ancient O 0 6.934637440281222e-06
mutation O 0 0.00014489097520709038
underlying O 1 0.9999995231628418
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.2146392691647634e-05
linkage O 0 0.00013238779501989484
disequilibrium O 0 3.9606355130672455e-05
studies O 0 3.493838818258155e-08
in O 0 8.490493863533288e-10
the O 0 2.1432853269942598e-09
Japanese O 0 9.335472839211434e-08
population O 0 1.1525825849290072e-09
. O 0 5.541666325825645e-08

The O 1 0.9999362230300903
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.07824787497520447
DM B-Disease 1 1.0
) O 0 9.183397509104907e-08
mutation O 0 7.910649912901135e-09
is O 0 1.7009911257304111e-09
an O 0 3.44529071938382e-09
unstable O 0 0.024727052077651024
( O 0 6.996949082349602e-07
CTG O 0 0.00016529380809515715
) O 0 2.2232518048781458e-08
n O 0 2.2063589710796805e-07
repeat O 0 7.831489767795574e-08
, O 0 1.8410559743387012e-09
present O 0 2.5829787198006215e-09
at O 0 1.9052023958465725e-08
a O 0 1.033625629531798e-09
copy O 0 2.580300195731411e-09
number O 0 2.97719932040863e-10
of O 0 2.780110364142274e-09
5 O 0 4.6396596786735245e-08
- O 0 2.9287427594226756e-08
37 O 0 2.0143721357612776e-08
repeats O 0 7.409683977499526e-09
on O 0 8.233056014717022e-09
normal O 0 1.3308829593938754e-08
chromosomes O 0 1.3532543974292821e-09
but O 0 1.3400797138629628e-10
amplified O 0 1.6904053712352152e-09
to O 0 3.4306332774569626e-10
50 O 0 5.47142109397214e-09
- O 0 3.4034570717267343e-09
3000 O 0 1.399576121663415e-09
copies O 0 1.9626407166128956e-09
on O 0 1.059713738982282e-07
DM B-Disease 1 0.9989495873451233
chromosomes O 0 2.0457737264223397e-06
. O 0 5.252622372609039e-07

Previous O 0 6.551391038556176e-07
findings O 0 2.12710048685949e-07
in O 0 2.9567448933676133e-08
Caucasian O 0 4.585697581660497e-07
populations O 0 1.1040839353881893e-08
of O 0 7.334711540352146e-07
a O 0 4.41335178038571e-05
DM B-Disease 1 1.0
founder O 1 0.9981921315193176
chromosome O 0 2.6599191187415272e-05
raise O 0 2.0875665995845338e-07
a O 0 4.003605269531363e-08
question O 0 2.117605113483023e-08
about O 0 3.2272964856083775e-10
the O 0 7.755656672436828e-10
molecular O 0 2.0244597109808637e-08
events O 0 8.89692541861109e-10
involved O 0 1.9377968119016487e-09
in O 0 1.1620788775701385e-09
the O 0 3.8491556608732935e-09
expansion O 0 2.7461516083349125e-07
mutation O 0 6.319348955230453e-08
. O 0 3.21121319757367e-07

To O 0 2.898545403695607e-07
investigate O 0 2.411896502962918e-06
whether O 0 2.1553597662204993e-07
a O 0 2.9596913009299897e-07
founder O 0 2.676353233255213e-06
chromosome O 0 4.2444074210834515e-07
for O 0 9.161249892031265e-08
the O 0 2.6972818432113854e-06
DM B-Disease 1 0.9999998807907104
mutation O 0 3.065744635932788e-08
exists O 0 5.079180187550492e-09
in O 0 4.299958722420172e-10
the O 0 6.665357710211595e-10
Japanese O 0 8.931650086196896e-09
population O 0 4.407236381398505e-11
, O 0 2.5699056771522066e-10
we O 0 1.5022993959945552e-09
genotyped O 0 4.58133087022361e-08
families O 0 1.163684149041444e-10
using O 0 2.0512742615608204e-09
polymorphic O 0 1.4154021954482232e-08
markers O 0 1.052249345434575e-07
near O 0 1.0837826494025649e-06
the O 0 2.3444675889550126e-07
( O 0 1.447962603151609e-07
CTG O 0 2.961535756185185e-05
) O 0 2.1439445774262822e-08
n O 0 5.567160883401812e-07
repeat O 0 2.5945101356228406e-07
region O 0 1.6922714962674945e-07
and O 0 4.842579670594205e-08
constructed O 0 1.1804822861449793e-05
haplotypes O 0 1.930994949361775e-05
. O 0 5.4157694648893084e-06

Six O 0 5.782282528343785e-07
different O 0 3.4268371251755525e-08
haplotypes O 0 4.68247066010008e-07
were O 0 5.4415757233527984e-08
found O 0 2.9418545821613407e-08
and O 0 2.4496339179336246e-08
DM B-Disease 1 0.9999985694885254
alleles O 0 1.1514311637483843e-07
were O 0 1.3182238944864366e-07
always O 0 9.061618300165719e-08
haplotype O 0 7.205134693322179e-07
A O 0 1.4875156466587214e-06
. O 0 9.71557710727211e-07

To O 0 1.539842173770012e-07
find O 0 2.7671877234070053e-08
an O 0 7.627264930754052e-10
origin O 0 4.724511448728208e-09
of O 0 3.416297289504655e-08
the O 0 1.192582175235657e-07
( O 0 5.941032910072863e-08
CTG O 0 1.2415000128385145e-05
) O 0 1.4332724340704317e-08
n O 0 2.2408626421110966e-07
repeat O 0 9.931191868872702e-08
mutation O 0 4.5301398188257735e-09
and O 0 1.332792654018533e-09
to O 0 6.285408304940177e-10
investigate O 0 2.0369471442904796e-08
the O 0 5.126628455087712e-09
mechanism O 0 3.4188599329354474e-07
of O 0 2.1249608295192957e-08
the O 0 3.4729679132539104e-09
expansion O 0 9.271233558649783e-09
mutation O 0 1.353083339816763e-10
in O 0 4.998265343281183e-11
the O 0 1.2978071395330915e-10
Japanese O 0 4.7813148995601296e-09
population O 0 1.8431131620921803e-11
we O 0 7.336618118580773e-11
have O 0 3.0708140891233526e-11
studied O 0 9.688374547067724e-09
90 O 0 7.583576433489725e-09
Japanese O 0 1.496021582170215e-07
DM B-Disease 1 0.9950727820396423
families O 0 2.310184044063135e-09
comprising O 0 6.250418405073788e-09
190 O 0 2.2524200282703077e-09
affected O 0 1.672273652886247e-09
and O 0 2.232927176493149e-09
130 O 0 5.265400915277496e-08
unaffected O 0 9.193797154694039e-07
members O 0 1.8160528725275071e-07
. O 0 1.368655603073421e-06

The O 0 6.008541504343157e-07
results O 0 3.925592864106875e-07
suggest O 0 1.8657264888588543e-07
that O 0 1.2408168936772768e-09
a O 0 6.953535081066775e-09
few O 0 6.890978898610456e-09
common O 0 1.0826690655107996e-08
ancestral O 0 5.560216109756766e-08
mutations O 0 4.74686689955206e-09
in O 0 2.162845014197501e-09
both O 0 8.69477911891181e-09
Caucasian O 0 3.527180751916603e-07
and O 0 3.936799775061672e-09
Japanese O 0 1.1759890128359984e-07
populations O 0 2.4956317568047837e-10
have O 0 2.428417016087092e-11
originated O 0 8.193758865848721e-11
by O 0 3.3671253719252947e-12
expansion O 0 4.812180653956943e-10
of O 0 1.0266093530830744e-09
an O 0 6.791676110395883e-10
ancestral O 0 2.369245244437934e-08
n O 0 1.8166730342272785e-07
= O 0 6.787874440306041e-08
5 O 0 1.962518147990977e-08
repeat O 0 6.420281639663017e-09
to O 0 1.92270199761424e-09
n O 0 6.707206523515197e-08
= O 0 1.441888315412143e-07
19 O 0 2.3647311309105135e-07
- O 0 1.6467728869429266e-07
37 O 0 8.902977555180769e-08
copies O 0 1.3166231838113163e-07
. O 0 1.7534188145873486e-07

These O 0 5.247034451372201e-08
data O 0 5.354330667728391e-08
support O 0 5.695479643463841e-09
multistep O 0 2.0864540317688807e-07
models O 0 3.232154099919171e-08
of O 0 2.1506474467969383e-07
triplet O 0 5.678074558090884e-06
repeat O 0 3.978568940965488e-07
expansion O 0 1.4203598652784422e-07
that O 0 9.950751334031338e-10
have O 0 1.8548364233428316e-10
been O 0 1.7094986537458112e-10
proposed O 0 1.6700224536592145e-10
for O 0 3.1339511541439435e-10
both O 0 1.670928995167742e-08
DM B-Disease 1 0.9999998807907104
and O 0 8.796466772764688e-07
Friedreichs B-Disease 0 0.16549809277057648
ataxia I-Disease 0 0.00047920472570694983
. O 0 9.351904139975886e-08
. O 0 5.589146780948795e-07

The O 0 1.291147668780468e-07
molecular O 0 1.2261765505172662e-06
basis O 0 2.252091917398502e-06
of O 0 0.06919454783201218
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.15814054627117e-07
the O 0 3.456936781276454e-08
western O 0 4.8864009727367375e-08
Cape O 0 8.358820480225404e-08
, O 0 1.0648266712820487e-09
South O 0 2.775079011030357e-08
Africa O 0 4.406402709378199e-08
. O 0 1.0690033747096095e-07

Deficiency B-Disease 1 0.9998328685760498
of I-Disease 0 3.817694232566282e-05
the I-Disease 0 2.668121624083142e-06
sixth I-Disease 0 6.088656391511904e-06
component I-Disease 0 2.513319259378477e-06
of I-Disease 0 9.618004241929157e-07
human I-Disease 0 3.019634675638372e-07
complement I-Disease 0 2.3186203179648146e-06
( O 0 6.310868343462062e-07
C6 O 0 0.00010605088755255565
) O 0 9.936229616869241e-09
has O 0 1.179195296963087e-09
been O 0 2.8378849270538353e-10
reported O 0 1.7368302629439114e-10
in O 0 4.5201235115976957e-11
a O 0 4.2082552720312805e-11
number O 0 6.001431296365212e-11
of O 0 1.6617714981848053e-09
families O 0 4.9087942044501176e-11
from O 0 4.801545827604059e-10
the O 0 1.3883031391159761e-09
western O 0 2.057729275861675e-08
Cape O 0 1.3345044180823606e-07
, O 0 3.939549131359854e-09
South O 0 3.487327404627649e-08
Africa O 0 3.6216778909192726e-08
. O 0 1.502071569348118e-07

Meningococcal B-Disease 1 0.9999969005584717
disease I-Disease 1 0.7439881563186646
is O 0 2.3114854030836796e-08
endemic O 0 6.838174471113234e-09
in O 0 1.3245210483958658e-09
the O 0 7.986466599163577e-09
Cape O 0 4.159940374393045e-07
and O 0 7.244222444136028e-10
almost O 0 1.7026140497478082e-09
all O 0 3.2204588995554673e-10
pedigrees O 0 1.0880473411134517e-08
of O 0 6.888419079587038e-08
total O 0 0.0003463742323219776
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.433256880380213e-06
C6Q0 O 0 0.004923317115753889
) O 0 3.5715306268002678e-09
have O 0 1.6090283272429673e-10
been O 0 2.4086332928163756e-10
ascertained O 0 7.217387576474721e-09
because O 0 4.303979395103852e-10
of O 0 3.226204370321284e-08
recurrent O 0 0.2269914150238037
disease O 0 0.4942370653152466
. O 0 2.045725068455795e-06

We O 0 3.7379189166131255e-07
have O 0 2.111320673847672e-09
sequenced O 0 5.1522723865105036e-09
the O 0 2.8648177163859145e-09
expressed O 0 2.047634950486099e-09
exons O 0 2.7357106802128328e-08
of O 0 2.3685132077844173e-08
the O 0 7.780229083209633e-08
C6 O 0 1.5517163774347864e-05
gene O 0 1.4256738012363712e-08
from O 0 2.2422739220928634e-09
selected O 0 3.0738993572754225e-09
cases O 0 9.145231794072117e-10
and O 0 7.496837040044113e-10
have O 0 4.0228145814502625e-10
found O 0 1.8865569106907287e-09
three O 0 2.5349236043581413e-09
molecular O 0 2.588292772998102e-05
defects O 0 0.4354555010795593
leading O 0 5.0705230023595504e-06
to O 0 2.929200704215873e-08
total O 0 3.137033672828693e-06
deficiency O 1 0.9999926090240479
879delG O 0 0.00015343505947384983
, O 0 3.819968341645108e-08
which O 0 1.0871319400251878e-09
is O 0 3.7845809819359033e-10
the O 0 2.0206396555977335e-09
common O 0 1.2151201822518942e-08
defect O 0 7.313465033575994e-08
in O 0 3.496563483196269e-09
the O 0 9.953033952569967e-09
Cape O 0 2.5864761710181483e-07
and O 0 2.151181233145394e-09
hitherto O 0 1.8599918405470817e-07
unreported O 0 4.6419966537314394e-08
, O 0 5.280914594507635e-10
and O 0 5.848272421893341e-10
1195delC O 0 4.039765144625562e-08
and O 0 2.9123083944426753e-09
1936delG O 0 1.3695927236767602e-07
, O 0 1.089155543532172e-09
which O 0 1.6786706746874103e-10
have O 0 5.729140425958512e-11
been O 0 1.1384372611278337e-10
previously O 0 6.117747974876409e-10
reported O 0 2.811946786529518e-10
in O 0 1.672205846015018e-10
African O 0 1.8175198235326206e-08
- O 0 2.2309239966489258e-07
Americans O 0 2.6490193150152663e-08
. O 0 2.054490693126354e-07

We O 0 1.7039213844327605e-06
also O 0 6.25426110900662e-08
show O 0 1.0381428161565509e-08
that O 0 1.8998733142261415e-10
the O 0 2.512986263525363e-09
879delG O 0 8.773413640028593e-08
and O 0 1.735209487208067e-08
1195delC O 0 2.3463649085897487e-06
defects O 0 8.681724466441665e-06
are O 0 3.2632612168015385e-09
associated O 0 1.619722951318181e-07
with O 0 1.3939839504928386e-07
characteristic O 1 0.9999990463256836
C6 O 1 1.0
/ O 1 0.9999982118606567
C7 O 1 0.5038552284240723
region O 0 1.757684771064305e-07
DNA O 0 2.8244954819456325e-08
marker O 0 1.596246335111573e-08
haplotypes O 0 4.626969030141481e-08
, O 0 7.4820666329245e-10
although O 0 7.565571502610169e-10
small O 0 1.0870759847847467e-09
variations O 0 2.649443686664199e-08
were O 0 2.2523222398262988e-08
observed O 0 2.025416421247428e-07
. O 0 2.2034529933989688e-07

The O 0 3.039137709492934e-06
1936delG O 0 4.60435840068385e-05
defect O 0 2.0998350009904243e-05
was O 0 8.239569524448598e-07
observed O 0 5.946791858946199e-08
only O 0 1.7482509884203523e-09
once O 0 7.280295477585241e-09
in O 0 7.172372140651362e-10
the O 0 1.732252230546294e-09
Cape O 0 4.8889830850384897e-08
, O 0 1.700266871740297e-10
but O 0 2.8260000242696925e-11
its O 0 5.848470319147481e-11
associated O 0 3.947220772460014e-09
haplotype O 0 3.4707049678672774e-08
could O 0 6.7159859895582485e-09
be O 0 8.842169663125787e-09
deduced O 0 4.128453383600572e-07
. O 0 1.7459616685755464e-07

The O 0 7.766379326312745e-07
data O 0 9.777799050425529e-07
from O 0 4.959678889804309e-08
the O 0 2.566166124040592e-08
haplotypes O 0 2.447014821882476e-07
indicate O 0 2.7455012485688712e-08
that O 0 2.0241991416369842e-10
these O 0 1.0224758539845169e-10
three O 0 5.726674690009759e-10
molecular O 0 1.1866798104165355e-06
defects O 0 2.381324748057523e-06
account O 0 2.4845192569955543e-09
for O 0 3.791562175337049e-09
the O 0 1.4356561450767913e-07
defects O 0 8.111214992823079e-05
in O 0 1.0557509533271059e-08
all O 0 1.9337242918027187e-09
the O 0 9.469468764677913e-09
38 O 0 1.137621552516066e-07
unrelated O 0 1.0676728123826251e-07
C6Q0 O 0 1.7281698774240795e-06
individuals O 0 2.346800254127146e-10
we O 0 1.2338406962797421e-09
have O 0 1.1203726835162797e-10
studied O 0 2.0677145329273117e-08
from O 0 1.7628972726058123e-09
the O 0 1.2798097692723331e-08
Cape O 0 8.234392794292944e-07
. O 0 2.3957386474648956e-07

We O 0 1.112772793021577e-06
have O 0 6.02184790921001e-09
also O 0 1.5447930712397806e-09
observed O 0 5.076632891842792e-09
the O 0 1.9816703833441807e-09
879delG O 0 7.68597985256747e-08
defect O 0 8.191785383360184e-08
in O 0 6.509605299243049e-09
two O 0 7.830683301790486e-08
Dutch O 1 0.9999984502792358
C6 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
kindreds O 0 0.00031756237149238586
, O 0 1.5747575687896642e-08
but O 0 7.836428728147382e-10
the O 0 1.2199941057389196e-09
879delG O 0 5.50148868683209e-08
defect O 0 4.642111406383265e-08
in O 0 2.572015711521658e-09
the O 0 2.0648533549660897e-08
Cape O 0 1.4654864344265661e-06
probably O 0 1.5313577961251212e-08
did O 0 8.926093197914042e-10
not O 0 1.1390279691658733e-10
come O 0 2.6317176216039684e-10
from O 0 4.164643629955833e-10
The O 0 1.5072073589195156e-09
Netherlands O 0 2.719920644267404e-07
. O 0 6.5393219728093754e-09
. O 0 7.752706210339966e-08

Complement B-Disease 1 0.9999979734420776
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.4993738659541123e-06
seven O 0 6.460822277176703e-08
further O 0 7.724352002469459e-08
molecular O 0 0.00010308638593414798
defects O 0 0.00016327326011378318
and O 0 1.72354255312257e-08
their O 0 1.2765039691942093e-08
associated O 0 2.110948798872414e-06
marker O 0 3.523442956065992e-06
haplotypes O 0 1.8923848983831704e-05
. O 0 6.161648343550041e-06

Seven O 0 5.713598056900082e-07
further O 0 4.545106691011824e-08
molecular O 0 6.457046310970327e-07
bases O 0 3.87214385000334e-07
of O 1 0.9922928810119629
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.583887687203969e-07
described O 0 1.415606789123558e-06
. O 0 3.1087506613403093e-07

All O 0 2.2448126912877342e-08
these O 0 1.4494119238150915e-09
new O 0 4.15681267185164e-09
molecular O 0 7.136706585697539e-07
defects O 0 6.228381153050577e-07
involve O 0 2.1843751696337677e-08
single O 0 1.4194818653834318e-08
- O 0 7.878834651364741e-08
nucleotide O 0 2.6145542619815387e-08
events O 0 3.4898741674282974e-09
, O 0 9.026179248472488e-10
deletions O 0 7.741354224322095e-09
and O 0 2.2203732186198977e-09
substitutions O 0 3.563421202557038e-08
, O 0 4.951866139357719e-10
some O 0 1.757169271199288e-10
of O 0 6.320889145428055e-09
which O 0 1.0096566915862581e-09
alter O 0 2.0727529914665865e-08
splice O 0 6.153388198981702e-08
sites O 0 9.710166892773486e-09
, O 0 1.5772757544496585e-09
and O 0 1.63505664563246e-09
others O 0 2.813505339815947e-08
codons O 0 1.4868206790197291e-06
. O 0 1.1382719549146714e-06

They O 0 3.6758915911150325e-08
are O 0 5.922381474121607e-10
distributed O 0 2.019675399145271e-10
along O 0 1.031471019707908e-09
the O 0 4.063766656514645e-09
C7 O 0 2.4385451524722157e-06
gene O 0 5.191077789845622e-09
, O 0 1.6825597581870966e-09
but O 0 2.205464283422387e-10
predominantly O 0 7.551443359510301e-10
towards O 0 6.527944851342227e-09
the O 0 1.076329425586664e-08
3 O 0 1.7961366438612458e-07
end O 0 1.9786088500950427e-07
. O 0 1.810320640061036e-07

All O 0 1.4559994099272444e-07
were O 0 6.029205223967438e-08
found O 0 7.48593897981209e-09
in O 0 2.9939426493541532e-09
compound O 0 1.1962386281538784e-07
heterozygous O 0 7.053239414744894e-08
individuals O 0 1.5264470576425992e-08
. O 0 5.613356393041613e-07

The O 0 0.0009124520001932979
C6 O 1 0.9999964237213135
/ O 1 0.9996863603591919
C7 O 0 0.01595604419708252
marker O 0 2.4301643861690536e-06
haplotypes O 0 1.2718884363493999e-06
associated O 0 4.4520643882606237e-07
with O 0 4.83133391071533e-08
most O 0 8.826855264487676e-06
C7 B-Disease 1 0.9999990463256836
defects I-Disease 1 0.8860209584236145
are O 0 2.5321899244090673e-08
tabulated O 0 3.0569387945433846e-06
. O 0 6.50017852876772e-08
. O 0 2.494150237453141e-07

A O 0 2.1417559764813632e-05
genome O 0 6.619279702135827e-07
- O 0 3.4198967568954686e-07
wide O 0 5.6338009812861856e-08
search O 0 2.029207024634161e-08
for O 0 4.720286828074904e-09
chromosomal O 0 1.035755303746555e-05
loci O 0 1.049063598657085e-06
linked O 0 6.452426532632671e-06
to O 0 8.008024110495171e-08
mental O 1 0.9999977350234985
health O 0 0.000738028553314507
wellness O 0 0.00014459286467172205
in O 0 4.4341913252310405e-08
relatives O 0 2.67355648730927e-08
at O 0 2.246595158794662e-07
high O 0 3.5112934710923582e-06
risk O 0 2.7214462079427904e-06
for O 0 1.490478462073952e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 2.776768894818815e-07
the O 0 3.6374865430843784e-07
Old O 0 2.5687625111459056e-06
Order O 0 8.738541623642959e-08
Amish O 0 4.984991619494394e-07
. O 0 1.870053409902539e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999741315841675
BPAD B-Disease 1 1.0
; O 1 0.9999539852142334
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 7.507933332817629e-07
is O 0 1.7481218250736674e-08
characterized O 0 1.2801320004030003e-08
by O 0 4.898331185110294e-10
episodes O 0 1.3186173930535006e-07
of O 0 1.3604181958726258e-06
mania B-Disease 0 0.32075485587120056
and O 0 1.7167009218610474e-06
/ O 1 0.96695876121521
or O 0 4.014053047285415e-06
hypomania B-Disease 1 0.9865919947624207
interspersed O 0 5.006597803003388e-07
with O 0 3.504722956293449e-09
periods O 0 2.5537759938742965e-05
of O 0 1.0159818884858396e-05
depression B-Disease 1 0.9994389414787292
. O 0 5.584945029113442e-06

Compelling O 0 3.095059355473495e-06
evidence O 0 4.2219733131787507e-07
supports O 0 2.3582535035870933e-08
a O 0 4.841090195384368e-09
significant O 0 4.845506218487117e-09
genetic O 0 1.4717657315088672e-08
component O 0 1.4008125504005875e-07
in O 0 5.088828913812904e-09
the O 0 1.2792411574480411e-08
susceptibility O 0 4.0458499483975174e-07
to O 0 4.8966544596851236e-08
develop O 0 9.310961468145251e-05
BPAD B-Disease 1 1.0
. O 0 3.8405240047723055e-05

To O 0 6.387135442764702e-08
date O 0 1.5901483152447327e-07
, O 0 1.604352650730334e-09
however O 0 1.662256554624264e-09
, O 0 1.074808797518756e-09
linkage O 0 3.836770190446259e-08
studies O 0 4.4586649927680355e-09
have O 0 2.744932892095875e-10
attempted O 0 4.982317669544045e-09
only O 0 1.1928490140089565e-10
to O 0 4.622342508753263e-10
identify O 0 4.794668484464637e-08
chromosomal O 0 2.6979538233717903e-05
loci O 0 3.417024743157526e-07
that O 0 1.9011148211234286e-08
cause O 0 1.2515388903011626e-07
or O 0 3.6156573290924143e-09
increase O 0 1.6672194735889434e-09
the O 0 5.150896598138388e-09
risk O 0 7.775985721991674e-08
of O 0 1.018933986074444e-07
developing O 0 2.459148527123034e-05
BPAD B-Disease 1 0.9999998807907104
. O 0 6.889114956720732e-06

To O 0 3.502663616927748e-07
determine O 0 9.20174386465078e-07
whether O 0 7.176456051638525e-08
there O 0 1.0813606010628973e-08
could O 0 3.2158444795982177e-09
be O 0 1.01612285252628e-09
protective O 0 1.0032666253323441e-08
alleles O 0 2.7444516104147e-10
that O 0 8.180718602535109e-11
prevent O 0 1.3717548208447283e-09
or O 0 4.2332456984262024e-10
reduce O 0 3.731697617581631e-09
the O 0 3.5702909517709713e-09
risk O 0 3.5454423397141e-08
of O 0 4.155617361334407e-08
developing O 0 4.628320766641991e-06
BPAD B-Disease 1 1.0
, O 0 4.310455548051095e-09
similar O 0 6.140884467598084e-10
to O 0 1.7934469187519397e-10
what O 0 5.220266441341437e-10
is O 0 1.5323321778115684e-10
observed O 0 9.496485819937561e-10
in O 0 3.188395658604293e-10
other O 0 7.4255015469759655e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.844930394185212e-08
we O 0 1.758468570756122e-08
used O 0 4.233399693021056e-07
mental O 1 0.970515251159668
health O 0 7.572220056317747e-06
wellness O 0 1.8617163732415065e-05
( O 0 8.759363900878725e-09
absence O 0 1.248877765647194e-07
of O 0 9.273289691691389e-08
any O 0 1.300197823184135e-06
psychiatric B-Disease 1 0.9999926090240479
disorder I-Disease 0 0.16462010145187378
) O 0 1.8618308006423945e-09
as O 0 2.2159307722091626e-09
the O 0 3.1571594227841615e-09
phenotype O 0 6.0837268556213075e-09
in O 0 2.0207784334758117e-09
our O 0 4.509725037848966e-09
genome O 0 8.951774432830462e-09
- O 0 1.9878191537259227e-08
wide O 0 2.8186510903083217e-08
linkage O 0 1.0640378178550236e-07
scan O 0 2.2222964446427795e-07
of O 0 1.7889187020614372e-08
several O 0 1.903544877279728e-09
large O 0 1.4254561975235447e-08
multigeneration O 0 1.4527428220389993e-06
Old O 0 1.3249643870949512e-07
Order O 0 1.1673042976667602e-08
Amish O 0 1.1571509617169795e-07
pedigrees O 0 2.9100888809807657e-08
exhibiting O 0 9.350243246331047e-09
an O 0 4.807172437892859e-10
extremely O 0 6.675427499658326e-08
high O 0 1.2564869393827394e-06
incidence O 0 0.0001907513360492885
of O 0 3.184115485055372e-05
BPAD B-Disease 1 1.0
. O 0 3.238302087993361e-05

We O 0 2.9345917482714867e-06
have O 0 4.1262524064222816e-08
found O 0 1.830873763708496e-08
strong O 0 2.658797626509113e-09
evidence O 0 8.615309354809142e-09
for O 0 8.314481880766778e-10
a O 0 3.2644191794162225e-09
locus O 0 1.2053283704460682e-08
on O 0 1.0755233859072177e-07
chromosome O 0 3.1961994295670593e-07
4p O 0 2.1864108930458315e-05
at O 0 9.41107600738178e-07
D4S2949 O 0 2.0355106755687302e-07
( O 0 3.3398506182891197e-09
maximum O 0 3.8327474527477534e-08
GENEHUNTER O 0 2.6824498036148725e-06
- O 0 1.3996840664276533e-07
PLUS O 0 2.1174442110805103e-07
nonparametric O 0 2.602936604034767e-07
linkage O 0 1.2072442245880666e-07
score O 0 8.14649112612642e-08
= O 0 3.919883084790854e-08
4 O 0 5.6791026992186744e-08
. O 0 1.55616075581122e-09
05 O 0 6.791202622480341e-08
, O 0 3.5828431332873834e-09
P O 0 2.955925424430461e-07
= O 0 2.893893125133218e-08
5 O 0 7.992119854804969e-09
. O 0 4.4762329953762503e-10
22 O 0 3.967752348899012e-09
x O 0 1.6147113868214547e-08
10 O 0 3.170231366311782e-08
( O 0 5.700478755699123e-09
- O 0 3.1667561017911794e-08
4 O 0 1.6854995621429225e-08
) O 0 6.502540728092754e-10
; O 0 1.1724985427008505e-09
SIBPAL O 0 6.437585966523329e-07
Pempirical O 0 2.14478134807905e-07
value O 0 2.8220723535810066e-08
< O 0 7.366509890971429e-08
3 O 0 2.185917225006051e-08
x O 0 3.602380616030132e-08
10 O 0 1.9395653083620346e-08
( O 0 1.448991704400271e-09
- O 0 1.2788435199695414e-08
5 O 0 5.764110966310909e-09
) O 0 2.9905511400585283e-10
) O 0 1.5817548659757819e-10
and O 0 4.2210468453873773e-10
suggestive O 0 5.932494673288602e-08
evidence O 0 7.984578331843295e-09
for O 0 1.0427403385193657e-09
a O 0 2.4348847382782424e-09
locus O 0 1.7500466853448415e-08
on O 0 2.711454385462275e-07
chromosome O 0 1.1214576716156444e-06
4q O 0 1.7863941366158542e-06
at O 0 6.838046147095156e-07
D4S397 O 0 6.478907152995816e-07
( O 0 4.171784695472525e-09
maximum O 0 4.758708627150554e-08
GENEHUNTER O 0 1.7450290670240065e-06
- O 0 7.433808235646211e-08
PLUS O 0 1.21618029425008e-07
nonparametric O 0 5.268324443363781e-08
linkage O 0 2.690812195282888e-08
score O 0 4.390630792272532e-08
= O 0 2.4119502839425877e-08
3 O 0 2.0509935083623532e-08
. O 0 5.857169194101175e-10
29 O 0 2.2058365800603497e-08
, O 0 4.162445499389378e-09
P O 0 4.0106988308252767e-07
= O 0 2.0590722016322616e-08
2 O 0 2.8809070684587823e-08
. O 0 4.444974666117929e-10
57 O 0 1.0453435450585857e-08
x O 0 5.928806956490007e-08
10 O 0 5.1154959379573484e-08
( O 0 4.085613181104009e-09
- O 0 3.314999474923752e-08
3 O 0 1.863497800513869e-08
) O 0 7.828077630556152e-10
; O 0 1.5524551644219287e-09
SIBPAL O 0 8.70078622483561e-07
Pempirical O 0 5.476147748595395e-07
value O 0 5.561021865219118e-08
< O 0 1.3855584768407425e-07
1 O 0 4.381578833090316e-08
x O 0 5.4414510231026725e-08
10 O 0 5.190783625153017e-08
( O 0 4.120123797690667e-09
- O 0 2.562923206994583e-08
3 O 0 3.8837296045812764e-08
) O 0 1.41735467806825e-09
) O 0 6.475447955622826e-10
that O 0 3.1460489768875277e-10
are O 0 3.272066229076387e-10
linked O 0 9.522504029746415e-08
to O 0 1.384688808059309e-08
mental O 1 0.9999009370803833
health O 0 0.0008045443100854754
wellness O 0 0.00028882912010885775
. O 0 1.9995445654785726e-06

These O 0 9.424605451613388e-08
findings O 0 5.697568639106976e-08
are O 0 1.267043026054182e-09
consistent O 0 8.277616814211797e-09
with O 0 5.465702335172296e-10
the O 0 2.9060049921980635e-09
hypothesis O 0 3.3750522376863046e-09
that O 0 1.799785667722098e-11
certain O 0 3.1251048970837303e-10
alleles O 0 1.07044295649672e-09
could O 0 1.609554045600703e-09
prevent O 0 1.7800827478708925e-08
or O 0 1.5919038309775146e-09
modify O 0 1.1789845544285527e-08
the O 0 5.259285895675703e-09
clinical O 0 5.445821216198965e-07
manifestations O 0 2.0564796159305843e-06
of O 0 8.123314728436526e-06
BPAD B-Disease 1 1.0
and O 0 8.209648427737193e-08
perhaps O 0 1.4179394547397806e-08
other O 0 2.3183632791301534e-09
related O 0 5.7682332226249855e-06
affective B-Disease 1 0.9995648264884949
disorders I-Disease 1 0.9999994039535522
. O 0 4.7526573325740173e-05

Segregation O 0 0.08487355709075928
distortion O 1 0.9998151659965515
in O 1 0.9268543124198914
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0012872465886175632

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9993017911911011
DM B-Disease 1 1.0
) O 0 1.1206334420421626e-06
is O 0 3.3432367985142264e-08
an O 0 5.176249828764412e-08
autosomal B-Disease 1 0.9999403953552246
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999984502792358
which O 0 9.015244728516336e-08
, O 0 6.0938889490103065e-09
in O 0 4.072938430965678e-09
the O 0 1.820746753367075e-08
typical O 0 5.805588898510905e-07
pedigree O 0 9.92168835978191e-08
, O 0 2.2154744705460416e-09
shows O 0 7.972783322429677e-09
a O 0 6.6874550341822214e-09
three O 0 6.049961420728778e-09
generation O 0 9.579009656590642e-07
anticipation O 0 1.1245806490478572e-06
cascade O 0 9.594794391887262e-06
. O 0 1.059226178767858e-06

This O 0 3.552073746249107e-09
results O 0 4.041499224172185e-08
in O 0 6.769629976588476e-07
infertility B-Disease 1 0.9999998807907104
and O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9920920133590698
CDM B-Disease 1 0.9921104311943054
) O 0 3.38034951141708e-08
with O 0 3.1812779077711184e-09
the O 0 4.297733013913785e-08
disappearance O 0 1.0735574278442073e-06
of O 0 2.7561843580770073e-06
DM B-Disease 1 1.0
in O 0 2.1872774880193901e-07
that O 0 3.0095861802692525e-08
pedigree O 0 6.67703204726422e-07
. O 0 5.106468847770884e-07

The O 0 5.695124016824593e-08
concept O 0 7.161361281760037e-08
of O 0 7.569244075966708e-08
segregation O 0 1.1838441423606128e-05
distortion O 0 2.957299329864327e-05
, O 0 5.6870015363585935e-09
where O 0 1.5190689817146108e-09
there O 0 3.5256531027982874e-10
is O 0 1.887945355605325e-10
preferential O 0 7.392673584405429e-09
transmission O 0 6.781429817692697e-08
of O 0 3.6850225093587596e-09
the O 0 1.9163717279724324e-09
larger O 0 3.245867352674736e-09
allele O 0 4.831128386229011e-09
at O 0 5.943753222936721e-08
the O 0 3.621781274887326e-08
DM B-Disease 1 0.9986773133277893
locus O 0 1.1851976466914493e-07
, O 0 8.498485470909145e-09
has O 0 1.2894311174349582e-09
been O 0 1.6258639989885637e-09
put O 0 3.058623354590395e-09
forward O 0 2.0974260550588042e-08
to O 0 3.6582217255443084e-09
explain O 0 6.35040109386864e-08
partially O 0 1.2301737228881393e-07
the O 0 1.527606308115992e-08
maintenance O 0 4.405232175486162e-06
of O 0 3.982447651651455e-06
DM B-Disease 1 1.0
in O 0 5.240483602619861e-08
the O 0 2.0587696880625117e-08
population O 0 1.2374984370566722e-09
. O 0 9.120208233071025e-08

In O 0 5.135463538863405e-07
a O 0 9.901177122628724e-08
survey O 0 5.1931305478092327e-08
of O 0 4.1414585894017364e-07
DM B-Disease 1 0.9999995231628418
in O 0 2.721028522501001e-07
Northern O 0 2.969156298604503e-07
Ireland O 0 1.5573620260056487e-07
, O 0 1.0684811257988258e-08
59 O 0 2.042653335365685e-07
pedigrees O 0 2.7372877298148524e-07
were O 0 1.3709987456422823e-07
ascertained O 0 7.060264124447713e-06
. O 0 1.3019163134231349e-06

Sibships O 0 4.984123006579466e-05
where O 0 4.675852594004937e-08
the O 0 4.845422729715665e-09
status O 0 8.147217123166683e-09
of O 0 2.1745147904539408e-08
all O 0 1.2668546212069032e-09
the O 0 5.181788775843188e-09
members O 0 9.508376308531297e-10
had O 0 6.895080950641841e-09
been O 0 5.817921144846139e-10
identified O 0 7.087134767935765e-10
were O 0 6.972709076791261e-10
examined O 0 5.290071047880929e-09
to O 0 2.1972179631291056e-10
determine O 0 1.024382001446611e-08
the O 0 1.0619713997073177e-08
transmission O 0 6.818366955485544e-07
of O 0 2.9355769370909002e-08
the O 0 7.449947503346266e-08
DM B-Disease 1 0.9999991655349731
expansion O 0 1.3029224419369712e-06
from O 0 4.838037881427226e-08
affected O 0 4.217370896952843e-09
parents O 0 7.755834308120768e-10
to O 0 4.182530433105569e-10
their O 0 3.863704911566401e-09
offspring O 0 1.122881627679817e-07
. O 0 4.483081568196212e-07

Where O 0 1.0541029951127712e-06
the O 0 3.0882139867571823e-07
transmitting O 0 0.00018450251081958413
parent O 0 3.6111867984800483e-07
was O 0 1.0358869531046366e-06
male O 0 2.045195088840046e-07
, O 0 7.020169334737147e-08
58 O 0 3.104409643128747e-06
. O 0 2.316443442396121e-06

3 O 0 3.784198952416773e-06
% O 0 6.724653900391786e-08
of O 0 1.0962300223127386e-07
the O 0 5.635638444800861e-08
offspring O 0 1.6043932404841144e-08
were O 0 9.504536713222933e-09
affected O 0 1.4814930393569625e-09
, O 0 3.9546643737509157e-10
and O 0 1.3443524071732327e-10
in O 0 4.791930185987781e-10
the O 0 6.894078086183697e-10
case O 0 2.403265364492313e-09
of O 0 8.098858805816178e-10
a O 0 2.4350332861189372e-09
female O 0 3.072277365845366e-08
transmitting O 0 2.6859781428356655e-05
parent O 0 7.964914061631134e-08
, O 0 4.900915229200109e-08
68 O 0 3.7885135952819837e-06
. O 0 2.586922619229881e-06

7 O 0 2.7406849767430685e-05
% O 0 5.901582653677906e-07
were O 0 3.5337666304258164e-07
affected O 0 3.4607111842888116e-07
. O 0 6.350558692247432e-07

Studies O 0 2.3022380446491297e-06
on O 0 1.4502458043352817e-06
meiotic O 0 4.831527257920243e-05
drive O 0 9.184823284158483e-07
in O 0 2.657813240602991e-07
DM B-Disease 1 0.9999990463256836
have O 0 7.000404256274351e-09
shown O 0 5.767102351228459e-09
increased O 0 2.2580421976670095e-09
transmission O 0 3.3417705935789854e-08
of O 0 1.1136791489008147e-09
the O 0 8.858049294069303e-10
larger O 0 1.787342163162009e-09
allele O 0 1.0822865936788162e-09
at O 0 2.6174484801799736e-08
the O 0 2.4357499128768723e-08
DM B-Disease 0 0.11256743222475052
locus O 0 3.2686696016526184e-08
in O 0 1.4290823635576544e-08
non O 0 2.4138569187925896e-06
- O 0 6.365262379404157e-05
DM O 1 0.9999969005584717
heterozygotes O 0 2.105919338646345e-05
for O 0 4.1971233599724656e-07
CTGn O 0 0.00015018112026154995
. O 0 2.1837602162122494e-06

This O 0 7.39157712814631e-08
study O 0 8.492121850167678e-08
provides O 0 6.374402339304197e-09
further O 0 1.9759938130192722e-09
evidence O 0 1.0834250829816483e-08
that O 0 6.688625764361689e-10
the O 0 3.75889506187832e-08
DM B-Disease 1 0.999996542930603
expansion O 0 1.583678567840252e-06
tends O 0 5.076655185121126e-08
to O 0 5.600400143634943e-10
be O 0 4.2892303042663116e-09
transmitted O 0 5.705463834715374e-08
preferentially O 0 7.461195394853348e-08
. O 0 1.424686075779391e-07

Diagnosis O 1 0.9995332956314087
of O 1 0.6783967614173889
hemochromatosis B-Disease 1 1.0
. O 0 0.0032013878226280212

If O 0 0.00021257679327391088
untreated O 1 0.9999996423721313
, O 0 0.08893322944641113
hemochromatosis B-Disease 1 1.0
can O 0 0.0006274472107179463
cause O 0 0.33140861988067627
serious O 1 0.9425883889198303
illness O 0 0.0043453313410282135
and O 0 5.599078534146429e-09
early B-Disease 0 3.672626291972847e-07
death I-Disease 0 7.980241889526951e-08
, O 0 7.640106880479891e-10
but O 0 4.126232411305608e-10
the O 0 1.327009879759089e-08
disease O 0 1.0901151199504966e-06
is O 0 1.0093332836191848e-09
still O 0 1.3631606954334075e-09
substantially O 0 2.4006597598713597e-08
under O 0 4.536307187663624e-07
- O 0 9.895060065900907e-05
diagnosed O 0 0.000657003722153604
. O 0 1.386458961860626e-06

The O 0 8.928823831411137e-07
cornerstone O 0 5.247788067208603e-05
of O 0 2.041078062120505e-07
screening O 0 8.636010306872777e-08
and O 0 1.6652014211970823e-09
case O 0 3.0683111607032743e-09
detection O 0 1.514700898042065e-08
is O 0 1.9384020777390987e-10
the O 0 6.974624766620252e-10
measurement O 0 2.441001356601191e-07
of O 0 1.7378400229972613e-07
serum O 0 2.520096700209251e-07
transferrin O 0 6.160399266263994e-07
saturation O 0 3.907782968326501e-07
and O 0 7.88732634759981e-09
the O 0 3.14057260197842e-08
serum O 0 6.469157938226999e-07
ferritin O 0 8.175634320650715e-06
level O 0 4.31864327765652e-06
. O 0 8.44511532704928e-07

Once O 0 1.5534695876340265e-06
the O 0 6.819915654432407e-08
diagnosis O 0 1.1127878678962588e-05
is O 0 1.101649971246843e-08
suspected O 0 2.683575814899086e-07
, O 0 5.995430818472869e-09
physicians O 0 3.635402023860479e-08
must O 0 9.161927216894128e-09
use O 0 2.8624048908909572e-08
serum O 0 1.5451201988980756e-06
ferritin O 0 2.9787626772304066e-05
levels O 0 7.8802468124195e-06
and O 0 4.959225066158979e-07
hepatic O 1 0.9993900060653687
iron O 1 0.9998899698257446
stores O 0 1.1048833812310477e-06
on O 0 7.201452376648376e-07
liver O 0 1.55301484028314e-06
biopsy O 0 3.170893876358605e-07
specimens O 0 5.6356999067475044e-09
to O 0 1.5698803368380254e-09
assess O 0 2.79654074120117e-07
patients O 0 1.816778194552171e-08
for O 0 2.950327093742544e-09
the O 0 1.4178691998267823e-08
presence O 0 3.4598136267049995e-07
of O 0 1.9953648006776348e-05
iron B-Disease 1 0.9999996423721313
overload I-Disease 1 0.9934511184692383
. O 0 7.19926765668788e-06

Liver O 1 0.5661096572875977
biopsy O 0 0.003615688532590866
is O 0 3.3575483371350856e-07
also O 0 7.91934429145158e-09
used O 0 5.649281487052349e-09
to O 0 1.0547279716277558e-09
establish O 0 2.8165068499674817e-08
the O 0 1.1860191939661036e-08
presence O 0 2.9068047524560825e-08
or O 0 2.3382684233297368e-08
absence O 0 1.1511526736285305e-06
of O 0 1.6613290426903404e-05
cirrhosis B-Disease 1 0.9999998807907104
, O 0 9.21598228842413e-08
which O 0 3.3849740788127747e-09
can O 0 4.09067357765025e-09
affect O 0 1.3321532321697305e-07
prognosis O 0 8.328936019097455e-06
and O 0 1.4614080612318503e-07
management O 0 1.540679659228772e-05
. O 0 2.7720377602236113e-06

A O 0 5.68190944250091e-06
DNA O 0 7.086694608915423e-07
- O 0 6.017257447865632e-08
based O 0 2.209380900453084e-09
test O 0 8.837291454177887e-10
for O 0 8.836701370640299e-10
the O 0 1.255597137372888e-08
HFE O 0 4.20979722548509e-06
gene O 0 1.1646934083842098e-08
is O 0 8.989274880022435e-10
commercially O 0 1.9465726808221007e-09
available O 0 7.665709733650772e-10
, O 0 6.263432134057112e-11
but O 0 1.791791194583059e-11
its O 0 1.8980903654375325e-11
place O 0 9.292703828656101e-10
in O 0 1.1532548527259934e-10
the O 0 3.745886656414399e-10
diagnosis O 0 1.1023311117241974e-06
of O 0 1.5920146552161896e-06
hemochromatosis B-Disease 1 1.0
is O 0 1.8025372128249728e-07
still O 0 3.995305775106317e-08
being O 0 2.256127551447662e-08
evaluated O 0 3.9517848904324637e-07
. O 0 1.7277267261306406e-07

Currently O 0 1.7463227095504408e-06
, O 0 1.4869404374451278e-08
the O 0 3.9455425593359905e-09
most O 0 4.352637417159855e-10
useful O 0 2.9702358350647273e-09
role O 0 3.3252376407943984e-09
for O 0 3.6234223954600964e-10
this O 0 8.239960797018497e-11
test O 0 3.9185635292149357e-10
is O 0 4.562244679262584e-11
in O 0 2.6061559160739378e-11
the O 0 1.1948163292085923e-10
detection O 0 3.539638839811232e-07
of O 0 6.414261974896363e-07
hemochromatosis B-Disease 1 1.0
in O 0 7.082520170342832e-08
the O 0 3.744326093624295e-08
family O 0 2.5742536990946974e-09
members O 0 3.2730959609317267e-10
of O 0 2.0531345512608823e-08
patients O 0 7.030805715402266e-09
with O 0 2.628563366968706e-09
a O 0 8.140417406821143e-08
proven O 0 2.2633164917351678e-05
case O 0 4.3004799721302334e-08
of O 0 2.6673221853457107e-08
the O 0 3.515071966830874e-07
disease O 0 0.0004146331921219826
. O 0 8.645541811347357e-07

It O 0 7.584982597563794e-08
is O 0 2.1912020642389507e-08
crucial O 0 1.0326388064640923e-06
to O 0 3.106080441739323e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 0.9999997615814209
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.0004409507382661104
because O 0 6.995053922764782e-07
phlebotomy O 1 0.9995643496513367
therapy O 1 0.6493998169898987
can O 0 1.703326972801733e-07
avert O 0 0.14382487535476685
serious O 1 0.9999992847442627
chronic O 1 1.0
disease O 1 0.999998927116394
and O 0 9.89100357173811e-08
can O 0 1.5246314433170483e-08
even O 0 5.616556109089288e-09
lead O 0 1.0379250348080404e-08
to O 0 1.5670563735525889e-09
normal O 0 1.5520583929173881e-06
life O 0 2.1079401335555303e-07
expectancy O 0 9.457342287078063e-08
. O 0 8.358306935463133e-09
. O 0 1.251833765536503e-07

Prevalence O 0 0.00023181944561656564
of O 0 3.0409437385969795e-06
the O 0 6.104757517277903e-07
I1307K O 0 9.580046935298014e-06
APC B-Disease 0 2.4755499339335074e-07
gene O 0 1.1804899280321024e-08
variant O 0 1.203788979609044e-08
in O 0 2.3747170896371017e-10
Israeli O 0 1.5903924843740924e-09
Jews O 0 7.536766211124757e-10
of O 0 2.744509064456224e-10
differing O 0 2.1613591472124938e-10
ethnic O 0 1.2596257370489639e-10
origin O 0 4.585076485152939e-10
and O 0 2.2682368483462056e-10
risk O 0 4.3239285929530524e-08
for O 0 8.751443601795472e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.012446258217096329

BACKGROUND O 0 6.602040957659483e-05
& O 0 7.768062459945213e-06
AIMS O 0 1.633250406030129e-07
Israeli O 0 3.024951666930065e-08
Jews O 0 7.00857993862769e-09
of O 0 3.437460094346534e-09
European O 0 1.8261445688949607e-08
birth O 0 3.376380419695124e-08
, O 0 3.8502130372819465e-09
i O 0 1.0617567269832762e-08
. O 0 4.561107047607038e-10
e O 0 1.903385227208787e-09
. O 0 3.610115262286939e-10
, O 0 1.8704695570193053e-09
Ashkenazim O 0 2.817348558892263e-07
, O 0 1.1571554825451358e-09
have O 0 8.366018294791999e-11
the O 0 2.0635333441987314e-09
highest O 1 0.9045407772064209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.005216565914452076
of O 0 2.2757360440550656e-08
any O 0 1.5774983541660959e-09
Israeli O 0 2.3575250196472552e-08
ethnic O 0 2.920119257510123e-08
group O 0 8.310477284112494e-08
. O 0 2.2259870036123175e-07

The O 0 3.2862972147995606e-06
I1307K O 0 1.7767537428881042e-05
APC B-Disease 0 4.0626724739922793e-07
gene O 0 4.598594927074373e-08
variant O 0 8.231207715425626e-08
was O 0 1.4629041800162668e-07
found O 0 5.682935455553206e-09
in O 0 9.55510426337014e-09
6 O 0 1.9172778138454305e-06
. O 0 6.219584065547679e-07

1 O 0 8.297588465211447e-06
% O 0 7.359600573408898e-08
of O 0 9.677334134039484e-08
American O 0 3.5985966206908415e-08
Jews O 0 1.2526405690493903e-08
, O 0 1.1939785826697857e-09
28 O 0 7.786253419794775e-09
% O 0 1.5047370016674222e-09
of O 0 2.7112493583558717e-08
their O 0 1.5340874597313814e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.686369432718493e-05
, O 0 4.5443151464041875e-09
but O 0 3.073311605206186e-10
not O 0 1.1258330379071424e-10
in O 0 7.044386740595598e-10
non O 0 1.4082117161251517e-07
- O 0 2.3080497157934587e-07
Jews O 0 7.117404265954974e-08
. O 0 2.1642723879722325e-07

We O 0 4.121517918065365e-07
assessed O 0 8.443311116934638e-07
the O 0 2.5877831433263054e-08
I1307K O 0 4.819631271857361e-07
prevalence O 0 4.89765383804297e-08
in O 0 2.96287855361399e-10
Israeli O 0 2.6573678812980006e-09
Jews O 0 6.933982832357799e-10
of O 0 2.9829347325538436e-10
differing O 0 1.456372245023374e-10
ethnic O 0 2.6750840431688516e-10
origin O 0 2.820998712405043e-10
and O 0 4.2587480764133545e-10
risk O 0 4.761659155860798e-08
for O 0 3.469644298093044e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.023624800145626068

METHODS O 0 4.515504315349972e-06
DNA O 0 1.8832975001714658e-07
samples O 0 1.8405373225505173e-08
from O 0 3.1290667834582564e-09
500 O 0 1.1619415429819924e-09
unrelated O 0 4.741039560940408e-09
Jews O 0 8.863287881410997e-10
of O 0 3.053668429231493e-09
European O 0 7.0280981034898105e-09
or O 0 2.4573680867945313e-09
non O 0 1.3999398973396637e-08
- O 0 2.762819528712157e-09
European O 0 9.112046117643047e-10
origin O 0 6.324841206328813e-10
, O 0 8.982346116903628e-11
with O 0 4.905836500923577e-11
or O 0 4.985509227672935e-10
without O 0 2.193852211007652e-09
a O 0 3.5748017879200233e-09
personal O 0 3.131504655584649e-08
and O 0 4.33433271496142e-08
/ O 0 3.417978223296814e-05
or O 0 1.2993892539725493e-07
family O 0 3.773050760713659e-09
history O 0 1.0344741951939795e-08
of O 0 6.102742844404929e-08
neoplasia B-Disease 0 1.4354852282849606e-05
, O 0 3.1219011820127207e-09
were O 0 2.276247190735603e-09
examined O 0 7.99306487664353e-09
for O 0 7.765470488863002e-10
the O 0 2.4352098115798526e-09
I1307K O 0 3.6602056496803925e-08
variant O 0 3.3333402704727177e-09
by O 0 1.0551379214795986e-10
the O 0 1.2304893770576086e-09
allele O 0 1.6114154455237895e-09
- O 0 8.363405523681422e-10
specific O 0 7.944818136706999e-10
oligonucleotide O 0 3.4024890283035347e-07
( O 0 1.9086794367240145e-08
ASO O 0 6.757904884580057e-06
) O 0 1.6440012018392736e-08
method O 0 4.07199337359998e-07
. O 0 4.71874102458969e-07

RESULTS O 0 1.4397876384464325e-06
In O 0 7.548728575557107e-08
persons O 0 1.628456303137682e-08
at O 0 3.055890260839078e-07
average O 0 2.7955321613148953e-08
risk O 0 2.552627620389103e-07
for O 0 1.551620152895339e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.973125886768685e-07
I1307K O 0 2.052713625744218e-06
was O 0 2.1052341026006616e-07
found O 0 1.207058542007644e-08
in O 0 1.301881891180301e-08
5 O 0 2.4765819262029254e-07
. O 0 4.0088056607601175e-07

0 O 0 3.6750825529452413e-06
% O 0 1.2977606900221872e-07
of O 0 6.585034384443134e-08
120 O 0 8.69367227096518e-08
European O 0 1.403671632260739e-07
and O 0 1.1373232666755939e-07
1 O 0 8.105137567326892e-06
. O 0 9.106621519094915e-07

6 O 0 4.999702468921896e-06
% O 0 1.0484049539627449e-07
of O 0 9.64953912330202e-08
188 O 0 4.607049319815815e-08
non O 0 1.6822019688333967e-07
- O 0 4.2807570821423724e-08
European O 0 1.5110652284988646e-08
Jews O 0 8.10555356167697e-09
( O 0 2.4935964404448896e-09
P O 0 3.1310690928876284e-07
= O 0 2.36618333815386e-08
0 O 0 9.381522225737626e-09
. O 0 4.847297008225837e-10
08 O 0 3.0790705096706006e-08
) O 0 1.7487588266362764e-08
. O 0 3.4298261653020745e-07

It O 0 2.811408705838403e-07
occurred O 0 1.3863848380424315e-06
in O 0 4.6341057213794556e-08
15 O 0 6.459546852966014e-07
. O 0 7.346122288254264e-07

4 O 0 2.893738837883575e-06
% O 0 4.0772935250288356e-08
of O 0 8.901788817183842e-08
52 O 0 2.7186786155652953e-07
Ashkenazi O 0 5.882690743419516e-07
Israelis O 0 6.156299292570111e-08
with O 0 9.592871208496945e-08
familial O 0 0.0014717640588060021
cancer B-Disease 1 0.6095717549324036
( O 0 3.00323279134318e-07
P O 0 7.06542341504246e-05
= O 0 2.6174166123382747e-07
0 O 0 1.5690250876332357e-08
. O 0 1.0467915423362228e-09
02 O 0 1.876702526715235e-08
) O 0 6.898286941670051e-10
and O 0 1.6265835345308233e-09
was O 0 1.8546472801972413e-08
not O 0 2.2731219684324344e-10
detected O 0 6.344853531459194e-09
in O 0 4.0415643054458883e-10
51 O 0 1.1349477802014007e-08
non O 0 7.1498142517612e-08
- O 0 1.5715288625983703e-08
European O 0 4.606695469533406e-09
Jews O 0 2.363268469807167e-09
at O 0 2.3832864570749734e-08
increased O 0 5.5015728861462776e-08
cancer B-Disease 0 2.202857558586402e-06
risk O 0 1.7515236550025293e-07
. O 0 3.2193881338571373e-07

Colorectal B-Disease 1 0.9999988079071045
neoplasia I-Disease 1 0.9995642304420471
occurred O 0 0.000886314723175019
personally O 0 4.924819222651422e-06
or O 0 3.9645012606115415e-08
in O 0 3.210782306695137e-09
the O 0 2.1310235798210897e-09
families O 0 2.958981670797556e-10
of O 0 9.174938142564315e-09
13 O 0 3.184570118719421e-08
of O 0 3.981901031124835e-08
20 O 0 5.832360017166138e-08
Ashkenazi O 0 1.0822812868127585e-07
I1307K O 0 1.3182929592403525e-07
carriers O 0 2.2518316100672564e-09
, O 0 7.250829936467085e-10
8 O 0 1.3179945135277649e-08
of O 0 2.8104750526836142e-08
whom O 0 6.463003643375487e-08
also O 0 1.1961811097194186e-08
had O 0 5.072212161394418e-08
a O 0 1.02568806781278e-08
personal O 0 1.305194103906615e-07
or O 0 4.954837606874207e-08
family O 0 4.593963875976215e-09
history O 0 2.446594216110043e-08
of O 0 7.719696668573306e-07
noncolonic O 0 0.0006720763049088418
neoplasia B-Disease 0 0.4157724678516388
. O 0 2.0741210391861387e-05

CONCLUSIONS O 0 1.9675197108881548e-05
The O 0 1.960767349373782e-06
I1307K O 0 1.6627365766908042e-05
APC O 0 2.1699299850297393e-06
variant O 0 9.787950148165692e-07
may O 0 3.0628282132738605e-08
represent O 0 3.6245508816534766e-09
a O 0 9.557655999969938e-09
susceptibility O 0 3.517986044698773e-07
gene O 0 5.621810927891602e-08
for O 0 5.500469910657557e-07
colorectal B-Disease 1 1.0
, I-Disease 0 3.6319515857030638e-06
or I-Disease 0 3.2080939149636833e-07
other I-Disease 0 2.3182275654676232e-08
, I-Disease 0 9.872871231664249e-08
cancers I-Disease 1 0.5343853235244751
in O 0 6.000913543857678e-08
Ashkenazi O 0 3.025759497177205e-06
Jews O 0 4.654346241750318e-08
, O 0 1.492568624250623e-09
and O 0 9.661206279432122e-10
partially O 0 2.4500172557395672e-08
explains O 0 3.443812346404229e-09
the O 0 1.1049997583612026e-09
higher O 0 8.530319206556669e-08
incidence O 0 3.485037450445816e-05
of O 0 0.059006210416555405
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.4789999625008932e-07
European O 0 1.1966791646500496e-07
Israelis O 0 2.2900032092820766e-07
. O 0 2.598705179934768e-07

Systematic O 0 1.1856244555019657e-06
analysis O 0 2.3043833152769366e-07
of O 0 1.4621161881223088e-07
coproporphyrinogen O 0 3.2905227271839976e-05
oxidase O 0 4.100498244952178e-06
gene O 0 8.49717889650492e-06
defects O 0 0.0018553996924310923
in O 0 8.783925977695617e-07
hereditary B-Disease 1 0.9999971389770508
coproporphyria I-Disease 1 0.9989562034606934
and O 0 2.385072775723529e-06
mutation O 0 4.245723346230079e-07
update O 0 2.2692163383908337e-06
. O 0 2.548624252085574e-06

Hereditary B-Disease 1 0.9999992847442627
coproporphyria I-Disease 1 0.999941349029541
( O 0 0.00011816638289019465
HC B-Disease 1 1.0
) O 0 2.2236476979742292e-06
is O 0 6.328394874799415e-08
an O 0 3.650341398042656e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.04748247563838959
autosomal O 1 0.9999995231628418
dominant O 1 0.9999986886978149
inheritance O 0 0.0002878823142964393
caused O 0 3.539169313171442e-07
by O 0 1.5637002803714495e-09
deficient B-Disease 0 3.5706650578504195e-06
activity I-Disease 0 2.151507061398661e-07
of I-Disease 0 5.630147938973096e-07
coproporphyrinogen I-Disease 0 0.00012577103916555643
III I-Disease 1 0.9998847246170044
oxidase I-Disease 0 1.7497400222055148e-06
( O 0 1.5318316570755997e-07
CPO O 0 1.804233579605352e-05
) O 0 2.755546120170038e-07
. O 0 6.957383789085725e-07

Clinical O 0 0.0016872341511771083
manifestations O 0 0.11383786797523499
of O 0 0.00012246970436535776
the O 0 0.0009273963514715433
disease O 1 0.9989689588546753
are O 0 1.5268364350617958e-09
characterized O 0 1.241584612898805e-08
by O 0 1.2818808237113899e-09
acute O 1 0.9904823303222656
attacks O 0 1.361813588118821e-06
of O 1 0.9232370257377625
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.1093428586027585e-06
precipitated O 0 2.7855000439558353e-07
by O 0 9.562756142500461e-10
drugs O 0 1.389790753592024e-07
, O 0 1.0098532010616168e-09
fasting O 0 1.996372134271951e-08
, O 0 2.6153308407828035e-09
cyclical O 0 4.332496246206574e-06
hormonal O 0 2.074694748444017e-05
changes O 0 1.2947987215738976e-07
, O 0 7.819981817647204e-08
or O 0 1.012039228953654e-05
infectious B-Disease 1 0.9999997615814209
diseases I-Disease 1 0.9999903440475464
. O 0 1.0046693205367774e-05

Skin O 1 0.9999903440475464
photosensitivity O 1 0.999972939491272
may O 0 9.428878001926932e-06
also O 0 3.485525112978394e-08
be O 0 8.669343465328438e-09
present O 0 4.3260488524765606e-08
. O 0 2.2563538948361384e-07

The O 0 2.4032128749240655e-06
seven O 0 1.0216062946710736e-06
exons O 0 7.208653869383852e-07
, O 0 2.1705700348206847e-08
the O 0 1.28052079162444e-07
exon O 0 7.805459972587414e-06
/ O 0 4.103612354811048e-06
intron O 0 3.3175217595271533e-06
boundaries O 0 1.101339108799948e-08
and O 0 2.7682685033170173e-09
part O 0 2.807025012430131e-08
of O 0 1.0919895743199959e-07
3 O 0 8.208800181819242e-07
noncoding O 0 1.3438316273095552e-06
sequence O 0 2.3684320282768567e-08
of O 0 3.666998082962891e-08
the O 0 4.8824880138909066e-08
CPO O 0 2.170319248762098e-06
gene O 0 9.453371418999268e-09
were O 0 3.1811686618254953e-09
systematically O 0 3.4676133076061433e-09
analyzed O 0 1.2259352422105962e-09
by O 0 7.689546221989474e-11
an O 0 3.6918448853562325e-10
exon O 0 1.1234343588739648e-07
- O 0 3.172094409364945e-08
by O 0 1.0485605272947396e-08
- O 0 4.665363576350501e-06
exon O 0 8.219617484428454e-06
denaturing O 0 3.860270953737199e-05
gradient O 0 1.4369999917107634e-05
gel O 0 9.515278361504897e-05
electrophoresis O 0 2.669996138138231e-05
( O 0 1.9218163060941151e-07
DGGE O 0 9.86032682703808e-06
) O 0 2.091624429212402e-09
strategy O 0 8.26662027719749e-09
followed O 0 3.5733208059163246e-10
by O 0 1.7527767431912977e-11
direct O 0 2.3529314607806384e-10
sequencing O 0 3.902097311936359e-09
in O 0 2.1959623008882545e-09
seven O 0 1.4072861098668454e-08
unrelated O 0 3.260814764871611e-07
heterozygous O 0 1.8028484305432357e-07
HC B-Disease 1 0.9999966621398926
patients O 0 1.7184601119879517e-06
from O 0 9.718416293935661e-08
France O 0 2.9546544055847335e-07
, O 0 4.24217105887692e-09
Holland O 0 1.0308799858194106e-07
, O 0 1.3495581319133976e-09
and O 0 3.3682099331855397e-09
Czech O 0 5.489263912750175e-06
Republic O 0 9.778277672012337e-06
. O 0 3.387015340194921e-06

Seven O 0 1.3023907285969472e-06
novel O 0 7.700447923753018e-08
mutations O 0 9.08535913168862e-09
and O 0 1.6112402523305036e-09
two O 0 1.8695920367406416e-09
new O 0 1.0362317226508821e-08
polymorphisms O 0 1.633194273154004e-07
were O 0 9.178582160984661e-08
detected O 0 5.421753485279623e-06
. O 0 3.9857769706941326e-07

Among O 0 8.867117884392428e-08
these O 0 5.7777818085469335e-09
mutations O 0 1.464711463228241e-08
two O 0 5.1660093980387956e-09
are O 0 1.5110009909946598e-09
missense O 0 1.346332680896012e-07
( O 0 3.9051877287477055e-09
G197W O 0 1.288081534767116e-07
, O 0 2.9956563896149646e-09
W427R O 0 1.0146692375201383e-07
) O 0 9.762940456070623e-10
, O 0 1.062337551260839e-09
two O 0 3.8188208151268555e-10
are O 0 5.574822270482116e-10
nonsense O 0 9.259238709091733e-08
( O 0 1.1779253128452183e-09
Q306X O 0 4.7768871525022405e-08
, O 0 1.3416942001853727e-09
Q385X O 0 4.5739007248357666e-08
) O 0 7.487920283821836e-10
, O 0 7.476460006650143e-10
two O 0 7.608666474645531e-10
are O 0 3.7399899843748585e-10
small O 0 3.057421871233146e-09
deletions O 0 2.9156391079254718e-08
( O 0 1.1176845227112153e-08
662de14bp O 0 3.143716469367064e-07
; O 0 5.0757034131265755e-09
1168del3bp O 0 6.494545914392802e-07
removing O 0 3.2264881610899465e-07
a O 0 2.563485423934253e-08
glycine O 0 1.2730858145459933e-07
at O 0 3.670353692086792e-07
position O 0 1.86111861921745e-07
390 O 0 6.168099986325615e-08
) O 0 1.7258379170215221e-09
, O 0 7.234804977329645e-10
and O 0 4.4894174489051863e-10
one O 0 4.039699408320274e-10
is O 0 1.6223687671068632e-10
a O 0 7.121893075279218e-10
splicing O 0 5.385896173493165e-09
mutation O 0 7.792935186046179e-10
( O 0 2.583658620380902e-09
IVS1 O 0 2.007313014473766e-06
- O 0 6.528881044687296e-07
15c O 0 2.9251752948766807e-06
- O 0 4.262661832399317e-07
- O 0 2.1577453424015403e-07
> O 0 1.034652257203561e-07
g O 0 9.51357250755791e-08
) O 0 1.043761077568206e-09
which O 0 1.2834269202954829e-09
creates O 0 8.219656955077426e-09
a O 0 1.8873809182196055e-09
new O 0 3.7160219346077383e-09
acceptor O 0 8.325435452150032e-09
splice O 0 9.125060387304984e-07
site O 0 3.120766223219107e-07
. O 0 6.677209967165254e-07

The O 0 7.992807127266133e-07
pathological O 0 3.895146073773503e-05
significance O 0 7.751876864858787e-07
of O 0 6.450073186670124e-08
the O 0 2.7071981989479355e-08
point O 0 6.146374289528467e-07
mutations O 0 7.009355762477298e-09
G197W O 0 1.220556100633985e-07
, O 0 4.269738340667573e-09
W427R O 0 1.7326570400655328e-07
, O 0 3.1464886252052793e-09
and O 0 1.4688260607798043e-09
the O 0 8.972286913433436e-09
in O 0 1.732547083577174e-08
- O 0 7.997949325044829e-08
frame O 0 5.686993631570658e-07
deletion O 0 1.660227013644544e-07
390delGly O 0 9.492709551750522e-08
were O 0 2.8754598702107614e-09
assessed O 0 5.561442861790056e-09
by O 0 3.04408200035855e-11
their O 0 4.124624947143829e-11
respective O 0 2.4060355929833577e-09
expression O 0 3.204914555965388e-09
in O 0 1.2966400175784543e-09
a O 0 7.73196506820284e-10
prokaryotic O 0 7.863888984438461e-10
system O 0 5.681125792023067e-09
using O 0 3.3554239387001417e-09
site O 0 1.1236481967102918e-08
- O 0 2.0793777366634458e-08
directed O 0 2.619905536960232e-08
mutagenesis O 0 9.776813385542482e-06
. O 0 1.4019381069374504e-06

These O 0 6.600312474347447e-08
mutations O 0 3.5305959045217605e-08
resulted O 0 3.384801416927985e-08
in O 0 2.6040916090153132e-09
the O 0 5.84067239017827e-09
absence O 0 8.152972696962024e-08
or O 0 3.945730409071757e-09
a O 0 3.483370480950043e-09
dramatic O 0 6.233289440160661e-08
decrease O 0 1.648866287951023e-07
of O 0 7.755721185276343e-07
CPO O 0 9.730952297104523e-05
activity O 0 1.7986220655075158e-06
. O 0 4.940757776239479e-07

The O 0 3.8465270790766226e-07
two O 0 4.314109247616216e-08
polymorphisms O 0 7.577521898838313e-08
were O 0 1.228093715610612e-08
localized O 0 7.753223485451599e-08
in O 0 8.260740536059075e-09
noncoding O 0 4.3917572156715323e-07
part O 0 5.536317626564369e-09
of O 0 1.247561876027703e-08
the O 0 1.2651842240529731e-08
gene O 0 3.5918474861063032e-09
1 O 0 4.766457095684018e-08
) O 0 1.28393129461557e-09
a O 0 1.4475779686051737e-08
C O 0 7.467455361620523e-06
/ O 0 1.1352821047694306e-06
G O 0 3.4747827726278047e-07
polymorphism O 0 1.6319884110771454e-08
in O 0 1.7920597228382462e-09
the O 0 1.6319697593303317e-08
promotor O 0 1.980652814381756e-05
region O 0 3.1405937761519453e-07
, O 0 1.271587990459011e-08
142 O 0 1.1209172612325347e-07
bp O 0 3.7990821510902606e-07
upstream O 0 5.023523641511929e-08
from O 0 4.256695440574276e-09
the O 0 3.903035672436772e-09
transcriptional O 0 4.139669229630272e-08
initiation O 0 3.408779392088945e-08
site O 0 3.467806664048112e-08
( O 0 1.214128619864141e-08
- O 0 1.550796326910131e-07
142C O 0 7.8556041671618e-07
/ O 0 4.507887183535786e-07
G O 0 5.434931154013611e-07
) O 0 3.289771122183538e-09
, O 0 2.3611823607438964e-09
and O 0 4.144027787589266e-09
2 O 0 1.829942135600504e-07
) O 0 2.4558921563055947e-09
a O 0 1.661566173538631e-08
6 O 0 1.1301278846076457e-07
bp O 0 5.995319440899038e-08
deletion O 0 3.34705205773389e-08
polymorphism O 0 3.771275558506204e-08
in O 0 4.743400339179971e-09
the O 0 8.42723668625922e-09
3 O 0 1.4332361786273395e-07
noncoding O 0 7.45204999930138e-07
part O 0 7.699562765139945e-09
of O 0 3.852889207678345e-08
the O 0 8.121729422327917e-08
CPO O 0 4.78982474305667e-06
gene O 0 5.20140801540947e-08
, O 0 1.0826154195342497e-08
574 O 0 2.5702303219077294e-07
bp O 0 5.798130473522178e-07
downstream O 0 1.4095324729623826e-07
of O 0 4.688677179842671e-08
the O 0 1.3648003616140159e-08
last O 0 3.1648482945456635e-08
base O 0 4.924124397120977e-08
of O 0 1.0806409989072563e-08
the O 0 4.024888866638321e-09
normal O 0 3.384375446557897e-08
termination O 0 1.0520682991455033e-08
codon O 0 1.3823745703689383e-08
( O 0 4.143774656739652e-09
+ O 0 8.605754686641376e-08
574 O 0 8.984463306660473e-07
delATTCTT O 0 3.906816800736124e-06
) O 0 2.647345525019773e-07
. O 0 1.3250493111627293e-06

Five O 0 4.143179012316978e-06
intragenic O 0 6.316862709354609e-05
dimorphisms O 0 3.878692223224789e-05
are O 0 1.865062415618013e-08
now O 0 6.55293197482365e-09
well O 0 1.7745764857579616e-09
characterized O 0 1.6541195080321813e-08
and O 0 1.0665380800745083e-09
the O 0 4.177294510299134e-09
high O 0 1.9769699122207385e-07
degree O 0 4.5645845148101216e-07
of O 0 2.5701240247144597e-08
allelic O 0 1.4956791005715786e-07
heterogeneity O 0 3.26196897049158e-07
in O 0 4.5542613236193574e-08
HC B-Disease 1 0.9999986886978149
is O 0 1.0643483960848243e-07
demonstrated O 0 2.2154461376544532e-08
with O 0 5.970846594927082e-10
seven O 0 6.644401695510282e-10
new O 0 1.2189910192361708e-10
different O 0 5.7596653141311904e-11
mutations O 0 1.6590218088197162e-10
making O 0 2.2428803259089136e-10
a O 0 4.411713216967428e-10
total O 0 6.798363538784713e-10
of O 0 3.486848498823747e-08
nineteen O 0 6.775559313609847e-07
CPO O 0 4.279772474546917e-05
gene B-Disease 0 1.2250287682036287e-06
defects I-Disease 0 7.200832897069631e-06
reported O 0 4.072024140100439e-08
so O 0 4.732195080237034e-09
far O 0 1.8429471282388477e-08
. O 0 5.93971538620508e-09
. O 0 1.0769500846663504e-07

Coincidence O 0 1.3891330127080437e-05
of O 0 4.064148981797189e-07
two O 0 1.2849879382770268e-08
novel O 0 2.862535986025705e-08
arylsulfatase O 0 3.4993649933312554e-07
A O 0 4.4225014761423154e-08
alleles O 0 2.3765216461413274e-09
and O 0 4.0558529867951165e-09
mutation O 0 1.1322925708157072e-08
459 O 0 1.4445639351379214e-07
+ O 0 5.535464993045025e-07
1G O 0 6.296864285104675e-06
> O 0 4.861644811171573e-07
A O 0 1.0089914326272265e-07
within O 0 3.794964698045078e-08
a O 0 2.907819585118432e-08
family O 0 7.723759409827835e-09
with O 0 3.464250042384265e-08
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999996423721313
: O 0 1.018111905892738e-08
molecular O 0 2.439748669758046e-08
basis O 0 1.9611858803614268e-08
of O 0 2.266734000500037e-08
phenotypic O 0 1.3340021723706741e-05
heterogeneity O 0 4.094904943485744e-05
. O 0 7.245427696034312e-06

In O 0 1.2498469459387707e-06
a O 0 4.6846858481330855e-07
family O 0 2.8261336382229274e-08
with O 0 9.634822717430325e-09
three O 0 1.2323012299475522e-07
siblings O 0 6.244188739401579e-07
, O 0 3.0667546280227498e-09
one O 0 7.319527761673328e-10
developed O 0 3.925839209273363e-08
classical O 0 0.00014652738173026592
late O 1 0.6703792214393616
infantile O 1 0.9999847412109375
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.9925691706012003e-05
MLD B-Disease 1 0.9999995231628418
) O 0 1.110744136667563e-07
, O 0 2.3590905229298187e-08
fatal O 0 3.310684064672387e-07
at O 0 4.160388868967857e-07
age O 0 5.312329562912055e-07
5 O 0 8.136024831628674e-08
years O 0 7.153003078741449e-09
, O 0 1.4166789963354631e-09
with O 0 1.7870352975180026e-09
deficient O 0 2.1200085029704496e-05
arylsulfatase O 0 1.9575516489567235e-05
A O 0 1.6630300478936988e-06
( O 0 1.746132483049223e-08
ARSA O 0 4.141677891311701e-06
) O 0 6.537573260523288e-10
activity O 0 2.8268656304675233e-09
and O 0 2.713543556520648e-10
increased O 0 1.880780509111446e-08
galactosylsulfatide O 0 7.124600415409077e-06
( O 0 1.0489529955748367e-07
GS O 0 0.03000025264918804
) O 0 5.0949111596310104e-08
excretion O 0 5.253744461697352e-07
. O 0 2.812653008277266e-07

The O 0 5.579997264248959e-07
two O 0 3.5641416928910985e-08
other O 0 1.2340014343692474e-08
siblings O 0 2.2834345259070687e-07
, O 0 1.179632391767882e-08
apparently O 0 1.1839854607842426e-07
healthy O 0 4.8773966199178176e-08
at O 0 1.7426858676117263e-06
12 O 0 2.0461726535359048e-07
( O 0 7.051703221350181e-09
1 O 0 1.885896381281782e-07
/ O 0 1.33974424443295e-07
2 O 0 4.6965535460685714e-08
) O 0 2.7616328668322865e-10
and O 0 5.088583443502159e-10
15 O 0 5.219233933928535e-09
years O 0 1.7935917195899265e-09
, O 0 1.770694285641028e-10
respectively O 0 3.5615441706937645e-09
, O 0 2.97633639956274e-10
and O 0 1.9158372110972266e-10
their O 0 8.954502694891175e-10
father O 0 8.240789384217351e-08
, O 0 5.534966263098795e-09
apparently O 0 3.3797562082327204e-08
healthy O 0 3.1394089550218496e-09
as O 0 9.907346054660593e-10
well O 0 1.7326883261503667e-09
, O 0 9.998886163486986e-10
presented O 0 6.938805086065258e-08
ARSA O 0 7.486192771466449e-05
and O 0 1.0376720638305414e-07
GS O 0 0.0695459172129631
values O 0 3.004206661216813e-08
within O 0 8.920906680032203e-09
the O 0 1.917560110697991e-09
range O 0 1.1230636687287188e-07
of O 0 5.495206210071046e-07
MLD B-Disease 1 0.9999998807907104
patients O 0 1.7471773389843293e-05
. O 0 2.322643922525458e-06

Mutation O 0 2.0943924994298868e-07
screening O 0 1.039345818298898e-07
and O 0 2.5004596171385174e-09
sequence O 0 1.0563189434265041e-08
analysis O 0 1.0418362172970319e-08
disclosed O 0 8.064814949193533e-08
the O 0 1.3134823895200043e-08
involvement O 0 1.4839604034477816e-07
of O 0 1.970514951210589e-08
three O 0 2.4199300341365415e-09
different O 0 1.0918808968085614e-08
ARSA O 0 0.00011924670252483338
mutations O 0 1.5937517972020032e-08
being O 0 1.207058542007644e-08
the O 0 1.3573956403334364e-09
molecular O 0 2.707528601320064e-08
basis O 0 2.180304292664914e-08
of O 0 9.602353401305663e-08
intrafamilial O 0 5.659061571350321e-06
phenotypic O 0 4.2908632167382166e-05
heterogeneity O 0 7.090051076374948e-05
. O 0 1.2940341548528522e-05

The O 0 1.7822217159846332e-06
late O 0 0.0006769367610104382
infantile O 0 0.4863343834877014
patient O 0 0.000113847287138924
inherited O 0 0.19864825904369354
from O 0 1.8382589814791572e-06
his O 0 6.12513304076856e-07
mother O 0 1.0813940320986148e-07
the O 0 1.925753068121594e-08
frequent O 0 2.502851259578165e-08
0 O 0 3.062886477778193e-08
- O 0 3.0572774534221026e-08
type O 0 1.86256016831976e-07
mutation O 0 4.241129758497664e-08
459 O 0 2.9980648719174496e-07
+ O 0 1.1342572179273702e-06
1G O 0 8.559175512345973e-06
> O 0 2.970158732296113e-07
A O 0 1.3573010448908462e-07
, O 0 3.951153182413236e-09
and O 0 4.182556523346648e-09
from O 0 1.9300845366387875e-08
his O 0 5.790604618027828e-08
father O 0 9.564297442921088e-08
a O 0 1.2586615305565374e-08
novel O 0 2.495851969541718e-09
, O 0 1.436700480805797e-10
single O 0 1.9999336908771426e-10
basepair O 0 5.556505300319259e-08
microdeletion O 0 1.1410344313844689e-07
of O 0 1.7003950247840294e-08
guanine O 0 6.093787163763409e-08
at O 0 6.983136557892067e-08
nucleotide O 0 1.4364773370800776e-08
7 O 0 2.5548212434500783e-08
in O 0 3.60086072070942e-09
exon O 0 3.7459085433511063e-07
1 O 0 3.4222196632072155e-07
( O 0 1.7687586506553998e-08
7delG O 0 4.342049066963227e-07
) O 0 6.759193382777084e-08
. O 0 6.686577194159327e-07

The O 0 1.1442276672823937e-06
two O 0 6.256229312384676e-07
clinically O 0 0.0006852248916402459
unaffected O 0 4.747063940158114e-06
siblings O 0 1.544102303796535e-07
carried O 0 7.398964552152165e-09
the O 0 7.392659373550714e-09
maternal O 0 5.8013281289959195e-08
mutation O 0 5.214875198333857e-09
459 O 0 4.6609287096543994e-08
+ O 0 2.970411117075855e-07
1G O 0 3.672321554404334e-06
> O 0 2.545861548242101e-07
A O 0 8.682751229116548e-08
and O 0 4.298452260798058e-09
, O 0 1.3926579889300683e-09
on O 0 5.703067351703339e-09
their O 0 6.720287659689461e-10
paternal O 0 7.440812854753176e-09
allele O 0 3.0782763005277047e-09
, O 0 7.067521012871225e-10
a O 0 1.0051969256963389e-09
novel O 0 1.0641708625414026e-09
cytosine O 0 1.0928768112705711e-08
to O 0 1.6008129266609217e-09
thymidine O 0 3.2823962214934e-07
transition O 0 1.2068647947671707e-06
at O 0 2.0811730792047456e-06
nucleotide O 0 3.846076026547962e-07
2435 O 0 1.0129178917850368e-05
in O 0 5.7365408423493136e-08
exon O 0 8.692575192981167e-07
8 O 0 6.903058391571903e-08
, O 0 1.049718645340647e-09
resulting O 0 1.7993206924415972e-09
in O 0 6.602195457006133e-10
substitution O 0 7.213933006511297e-09
of O 0 1.3185502467649712e-08
alanine O 0 3.317573771255411e-08
464 O 0 5.657544477344345e-08
by O 0 1.2479593358705188e-08
valine O 0 1.1806973816419486e-05
( O 0 3.032733957297751e-07
A464V O 0 8.833481842884794e-06
) O 0 2.7605963737187267e-07
. O 0 1.704118062662019e-06

The O 0 5.118842182127992e-06
fathers O 0 1.4628515145886922e-06
genotype O 0 5.116750116940239e-07
thus O 0 1.174705559492395e-07
was O 0 1.017998101815465e-06
7delG O 0 1.1324121260258835e-05
/ O 0 1.7970935004996136e-05
A464V O 0 2.6924481062451378e-05
. O 0 1.4042127531865845e-06

Mutation O 0 7.495406748603273e-07
A464V O 0 5.98162932874402e-06
was O 0 3.67522233091222e-07
not O 0 1.7111306815920102e-09
found O 0 1.7965327003821585e-09
in O 0 2.175571500728779e-09
18 O 0 1.6721412521292223e-07
unrelated O 0 1.3592492905445397e-05
MLD B-Disease 1 1.0
patients O 0 7.717282528574287e-07
and O 0 3.4072389354378174e-08
50 O 0 3.087486675212858e-07
controls O 0 5.5413561312889215e-06
. O 0 8.68235190409905e-07

A464V O 0 5.0586600991664454e-05
, O 0 1.5926677576771908e-07
although O 0 3.7645271788733226e-08
clearly O 0 3.0629192337983113e-07
modifying O 0 2.889822781071416e-06
ARSA O 0 0.08251691609621048
and O 0 1.124340542446589e-06
GS O 1 0.999957799911499
levels O 0 3.1067465897649527e-05
, O 0 3.324484509903414e-08
apparently O 0 3.622078637022241e-08
bears O 0 1.0023026852934436e-08
little O 0 3.4491041134288025e-09
significance O 0 2.9166888904086363e-09
for O 0 2.0279911083775914e-09
clinical O 0 3.118814504432521e-07
manifestation O 0 3.3022756724676583e-06
of O 0 2.8795979233109392e-05
MLD B-Disease 1 1.0
, O 0 6.383676236509928e-07
mimicking O 0 2.270699042128399e-06
the O 0 1.1795979304451976e-07
frequent O 0 7.916053732515138e-07
ARSA O 0 0.00040732434717938304
pseudodeficiency O 0 5.1950180932180956e-05
allele O 0 3.0431310733547434e-06
. O 0 2.9771169920422835e-06

Our O 0 6.344166081362346e-07
results O 0 3.7952684550646154e-08
demonstrate O 0 2.5846112805538723e-08
that O 0 3.2968675012234883e-10
in O 0 2.563619594386779e-10
certain O 0 1.9136432438671136e-09
genetic O 0 7.325764528332002e-08
conditions O 0 4.702174464910058e-06
MLD B-Disease 1 1.0
- O 0 0.05760486051440239
like O 0 2.998739319082233e-06
ARSA O 1 0.9429948925971985
and O 0 2.0528918867057655e-06
GS O 1 0.9999672174453735
values O 0 1.3071473858872196e-07
need O 0 9.220128660558657e-09
not O 0 1.2819094397098496e-10
be O 0 1.1256247323121471e-10
paralleled O 0 1.2936557380882618e-09
by O 0 3.527697856053891e-10
clinical O 0 6.5447920860606246e-06
disease O 0 1.596680340298917e-05
, O 0 3.4077571875457124e-09
a O 0 3.992089325777215e-09
finding O 0 9.525116695385805e-09
with O 0 1.0896707980379006e-09
serious O 0 5.206241553423752e-07
diagnostic O 0 1.3446302773445495e-06
and O 0 6.526203577550405e-08
prognostic O 0 0.0007477022591046989
implications O 0 1.5024318599898834e-05
. O 0 1.6628778212179895e-06

Moreover O 0 1.9267896277597174e-05
, O 0 1.30712990653592e-07
further O 0 2.6384961415715225e-07
ARSA O 0 7.478601764887571e-05
alleles O 0 9.919474308617282e-08
functionally O 0 4.654976635265484e-07
similar O 0 5.215671006197908e-09
to O 0 7.466516294130088e-09
A464V O 0 9.787520411919104e-07
might O 0 1.2737192633949235e-08
exist O 0 3.797555159223975e-09
which O 0 2.916347996428925e-10
, O 0 2.1691440310611654e-10
together O 0 6.195650104068307e-10
with O 0 1.1355015816505443e-09
0 O 0 7.419077263648433e-08
- O 0 4.939947118032251e-08
type O 0 2.2279388645074505e-07
mutations O 0 2.8583023947703623e-08
, O 0 7.179972172366433e-09
may O 0 2.3717619512808596e-07
cause O 0 4.859076398133766e-06
pathological O 1 0.9995707869529724
ARSA O 1 0.9996111989021301
and O 0 5.49315473108436e-06
GS O 1 0.9999849796295166
levels O 0 9.965904609998688e-06
, O 0 1.4539692783088753e-09
but O 0 7.644038874099479e-11
not O 0 4.842821629824634e-11
clinical O 0 1.4159017069914626e-08
outbreak O 0 1.7984629341327718e-09
of O 0 3.834185857698458e-09
the O 0 4.5320263097892166e-08
disease O 0 4.365072982182028e-06
. O 0 1.5199217884287464e-08
. O 0 1.8973969417857006e-07

Human O 0 0.03589705377817154
MLH1 O 1 0.9999992847442627
deficiency O 1 0.9999990463256836
predisposes O 0 0.0004924869281239808
to O 0 5.520547347259708e-06
hematological B-Disease 1 0.9999997615814209
malignancy I-Disease 1 0.999998927116394
and O 0 3.713057958520949e-05
neurofibromatosis B-Disease 1 0.9999960660934448
type I-Disease 1 0.6201085448265076
1 I-Disease 0 0.0014459270751103759
. O 0 2.029383267654339e-06

Heterozygous O 0 0.0001364178315270692
germ O 1 0.9991788268089294
- O 0 1.4542867575073615e-05
line O 0 2.833337191532337e-07
mutations O 0 1.7162165022455156e-09
in O 0 8.314227639694138e-10
the O 0 3.482799160181571e-09
DNA O 0 1.2411107945808908e-06
mismatch O 0 0.15800921618938446
repair O 0 0.001704650348983705
genes O 0 2.1799492344598548e-07
lead O 0 3.605883591717429e-07
to O 0 4.912904500997683e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.813774585723877

The O 0 6.438012405851623e-06
disease O 0 0.0003312937915325165
susceptibility O 0 3.174054199917009e-06
of O 0 3.3940597177206655e-07
individuals O 0 9.893187602472153e-09
who O 0 1.3555651889873843e-07
constitutionally O 0 1.0766558489194722e-06
lack O 0 2.2605949823173432e-07
both O 0 5.899508881412885e-09
wild O 0 7.332499052381536e-09
- O 0 9.204296880227503e-09
type O 0 1.0202715117202388e-08
alleles O 0 2.360970752235403e-09
is O 0 3.0188811450670983e-09
unknown O 0 3.9161324139058706e-07
. O 0 3.968345367866277e-07

We O 0 5.680618642145419e-07
have O 0 5.691939364282916e-09
identified O 0 1.3850981694929487e-08
three O 0 1.7506535110456412e-09
offspring O 0 1.208324662549387e-09
in O 0 4.901012928826276e-10
a O 0 6.603976743235762e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.05429874360561371
who O 0 2.019001385633601e-06
developed O 0 0.014186042360961437
hematological B-Disease 1 0.9999943971633911
malignancy I-Disease 1 0.9999302625656128
at O 0 1.850707849371247e-05
a O 0 2.8859888701049385e-08
very O 0 5.445539130732868e-09
early O 0 2.1305126551851572e-08
age O 0 3.003427551107052e-08
, O 0 1.8035435367380614e-09
and O 0 9.071328688214919e-10
at O 0 4.343502268966404e-08
least O 0 3.3557551182283873e-10
two O 0 2.1561835650274475e-10
of O 0 2.6053383894719673e-09
them O 0 7.294357895482051e-10
displayed O 0 6.153305776024354e-08
signs O 0 7.719093986224834e-08
of O 0 2.997412877903116e-07
neurofibromatosis B-Disease 0 0.00475780013948679
type I-Disease 0 2.3166170649346896e-05
1 I-Disease 0 3.447733251960017e-05
( O 0 2.0389126120790024e-07
NF1 B-Disease 0 4.0891729440772906e-05
) O 0 1.4933104353076487e-07
. O 0 1.0047815521829762e-06

DNA O 0 2.8221649017723394e-07
sequence O 0 2.489942829697611e-08
analysis O 0 3.897084432935571e-09
and O 0 4.409727860643642e-10
allele O 0 1.4729332198371026e-09
- O 0 1.005898808692507e-09
specific O 0 1.5048166879250147e-10
amplification O 0 2.9094728404288617e-08
in O 0 3.957956629108139e-09
two O 0 9.949314261348263e-09
siblings O 0 1.3604955029222765e-07
revealed O 0 3.2165061725208943e-07
a O 0 1.317590374583233e-07
homozygous O 0 3.0727116495654627e-07
MLH1 O 0 3.360681876074523e-05
mutation O 0 4.519328555829816e-08
( O 0 1.3768747919584712e-08
C676T O 0 8.34671141092258e-07
- O 0 5.876197519683046e-07
- O 0 4.2880506612164027e-07
> O 0 3.475369396710448e-07
Arg226Stop O 0 3.216777486159117e-06
) O 0 5.205725273071948e-08
. O 0 2.5874680886772694e-07

Thus O 0 2.2770116174797295e-06
, O 0 8.356142444654324e-08
a O 0 2.1159119967251172e-07
homozygous O 0 4.587960575008765e-06
germ O 1 0.9999434947967529
- O 0 0.0015557047445327044
line O 0 3.8212561776163056e-05
MLH1 O 0 0.10725797712802887
mutation O 0 1.931790478693074e-07
and O 0 5.7718814616691816e-08
consequent O 0 0.2536119520664215
mismatch O 1 1.0
repair O 1 0.9999998807907104
deficiency O 1 0.9999867677688599
results O 0 4.945343903273169e-07
in O 0 5.235428446326296e-08
a O 0 7.498002219108457e-08
mutator O 0 1.5240609172906261e-05
phenotype O 0 4.919702689676342e-08
characterized O 0 8.72639986937429e-08
by O 0 4.4246277752790775e-08
leukemia B-Disease 1 1.0
and O 0 0.13126243650913239
/ O 1 1.0
or O 1 0.9999876022338867
lymphoma B-Disease 1 1.0
associated O 1 0.5878802537918091
with O 0 4.9456411943538114e-06
neurofibromatosis B-Disease 1 0.9999991655349731
type I-Disease 1 0.9408912062644958
1 I-Disease 0 0.0007984038675203919
. O 0 1.1429327173573256e-07
. O 0 5.182078552934399e-07

Missense O 0 0.00015254503523465246
mutations O 0 7.072401899677061e-07
in O 0 2.8200707546943704e-08
the O 0 1.9444323484663073e-08
most O 0 2.330200032929497e-09
ancient O 0 5.229130906059254e-08
residues O 0 5.299330041452777e-07
of O 0 1.5737387570879946e-07
the O 0 2.2973901536715857e-07
PAX6 O 0 0.00012606987729668617
paired O 0 8.820659900266037e-07
domain O 0 1.5483210518141277e-06
underlie O 0 2.85543637801311e-06
a O 0 2.760713968541495e-08
spectrum O 0 5.156097813596716e-06
of O 0 9.139045687334146e-06
human O 1 0.9999792575836182
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9982351064682007

Mutations O 0 2.7674204829963855e-06
of O 0 5.143398880136374e-07
the O 0 2.3723093534044892e-07
human O 0 1.0840503819053993e-06
PAX6 O 0 0.31656724214553833
gene O 0 0.0002791840524878353
underlie O 1 0.9999809265136719
aniridia B-Disease 1 1.0
( O 1 0.9933950304985046
congenital B-Disease 1 1.0
absence I-Disease 0 0.13058631122112274
of I-Disease 0 0.001622122130356729
the I-Disease 0 1.3636494259117171e-05
iris I-Disease 0 6.87226201989688e-05
) O 0 3.117250102491198e-08
, O 0 6.328150892187523e-09
a O 0 2.4264343423396895e-08
rare O 0 5.725631240238727e-07
dominant O 1 0.9992688298225403
malformation B-Disease 1 1.0
of I-Disease 1 0.9943535327911377
the I-Disease 1 0.9555901288986206
eye I-Disease 1 0.9999929666519165
. O 0 5.575360046350397e-05

The O 0 9.893188916976214e-07
spectrum O 0 1.5562050975859165e-05
of O 0 1.2288410289329477e-06
PAX6 O 0 0.0016536626499146223
mutations O 0 2.6988749368683784e-07
in O 0 1.0357460666909901e-07
aniridia B-Disease 1 0.9999996423721313
patients O 0 6.484587515842577e-07
is O 0 4.709737488894916e-09
highly O 0 2.2987702408272526e-08
biased O 0 1.5507335859865634e-08
, O 0 3.729347386460802e-10
with O 0 4.615224036275123e-10
92 O 0 6.382288120221347e-08
% O 0 1.0652863480231645e-08
of O 0 2.3951896466201106e-08
all O 0 3.733449105425279e-09
reported O 0 2.5038350059958248e-08
mutations O 0 4.5930788061809835e-09
leading O 0 1.363327761794153e-08
to O 0 2.1422796869785543e-09
premature O 0 7.918139743878783e-08
truncation O 0 1.3607451592179132e-06
of O 0 3.363089433605637e-07
the O 0 2.9770643550364184e-07
protein O 0 2.2800594479122083e-07
( O 0 9.854448812518513e-09
nonsense O 0 6.452743406271111e-08
, O 0 1.698702067898239e-09
splicing O 0 1.0857752030801748e-08
, O 0 1.7174018873689079e-09
insertions O 0 1.4468438003234496e-08
and O 0 3.558027206196357e-09
deletions O 0 4.3013741901631874e-08
) O 0 3.0854183652451184e-09
and O 0 9.897755504084671e-09
just O 0 1.1461166593562666e-07
2 O 0 2.4146757482412795e-07
% O 0 3.946332594040314e-09
leading O 0 7.425699610763559e-09
to O 0 2.1043963793765386e-10
substitution O 0 1.208717215206434e-08
of O 0 9.434134362606983e-09
one O 0 8.856613220586951e-10
amino O 0 1.577185382295454e-09
acid O 0 3.3558207324091427e-09
by O 0 6.571252431086805e-10
another O 0 1.4763203992629315e-08
( O 0 3.765216760598378e-08
missense O 0 3.988830314938241e-07
) O 0 1.0116333726273297e-07
. O 0 9.364699735670001e-07

The O 0 3.410184774566005e-07
extraordinary O 0 6.493647788374801e-07
conservation O 0 4.414891208170957e-08
of O 0 1.0928146565447605e-07
the O 0 2.414579114429216e-07
PAX6 O 0 0.00023072902695275843
protein O 0 6.386939617186727e-07
at O 0 1.510486669076272e-07
the O 0 6.8525234375726995e-09
amino O 0 6.225934612302808e-08
acid O 0 1.5622529758729797e-07
level O 0 2.8750007459166227e-06
amongst O 0 2.293027705491113e-07
vertebrates O 0 1.7983544466915191e-06
predicts O 0 2.3070660404300725e-07
that O 0 2.322147141242681e-09
pathological O 0 8.998713019536808e-05
missense O 0 2.9026605261606164e-06
mutations O 0 3.434014672620833e-08
should O 0 7.209627561621801e-09
in O 0 3.0993794197797797e-09
fact O 0 1.2182688191586521e-09
be O 0 4.3539158389727106e-10
common O 0 1.5196428559960395e-09
even O 0 5.872528574535352e-10
though O 0 3.025525663336026e-10
they O 0 7.079970637535737e-11
are O 0 8.721278560441803e-11
hardly O 0 2.9763833619966817e-09
ever O 0 1.6933516810979654e-09
seen O 0 2.525994746704896e-09
in O 0 8.428811426597349e-09
aniridia B-Disease 1 0.9997996687889099
patients O 0 1.0981863169945427e-06
. O 0 4.0936501477517595e-07

This O 0 8.34935605098508e-08
indicates O 0 2.392535236594995e-07
that O 0 2.0152435276088454e-09
there O 0 2.6305044809049605e-09
is O 0 5.949803982829849e-10
a O 0 1.754256739872062e-09
heavy O 0 5.161668923392426e-07
ascertainment O 0 6.271217716857791e-05
bias O 0 7.072921448525449e-08
in O 0 4.3783576764155896e-10
the O 0 1.778085734205348e-10
selection O 0 1.8861465722608273e-09
of O 0 3.6279605986067054e-09
patients O 0 2.1834576369172964e-09
for O 0 5.37409539091982e-09
PAX6 O 0 1.843313111749012e-05
mutation O 0 2.279706734498177e-08
analysis O 0 1.966827412047678e-08
and O 0 3.2514442249720332e-09
that O 0 1.0066223410376551e-09
the O 0 2.7702876437274426e-08
missing O 0 8.150286703312304e-06
PAX6 O 0 0.11875411868095398
missense O 0 3.617648690124042e-05
mutations O 0 6.645573193964083e-07
frequently O 0 1.0319875798359135e-07
may O 0 7.122999789999085e-08
underlie O 0 1.2941274007971515e-06
phenotypes O 0 1.8728162842762686e-07
distinct O 0 2.0276711865108155e-08
from O 0 1.588222033888087e-07
textbook O 0 2.6365283702034503e-05
aniridia B-Disease 1 0.9999538660049438
. O 0 4.343264208728215e-06

Here O 0 2.175180270569399e-06
we O 0 4.765502481518524e-08
present O 0 1.3513876240267564e-08
four O 0 1.3136026488780317e-08
novel O 0 3.514511348612359e-08
PAX6 O 0 1.9689539840328507e-05
missense O 0 2.0557934021780966e-06
mutations O 0 7.749350316998971e-08
, O 0 6.0247660194079344e-09
two O 0 4.100187744882078e-09
in O 0 1.057625365064041e-08
association O 0 1.3830733891495584e-08
with O 0 1.0934481764479642e-08
atypical O 0 0.0001070473954314366
phenotypes O 0 1.3778600987279788e-05
ectopia B-Disease 0 0.0003397018008399755
pupillae I-Disease 0 4.994838309357874e-05
( O 0 3.151649607957552e-08
displaced B-Disease 0 1.1179232650704307e-08
pupils I-Disease 0 4.1755200186344155e-08
) O 0 3.232548806408886e-08
and O 0 2.467571903252974e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.8611939549446106
( O 0 1.5761420399940107e-06
searching B-Disease 0 3.5278139876027126e-06
gaze I-Disease 0 2.357549237785861e-05
) O 0 1.125703263937794e-08
, O 0 2.625026418456855e-09
and O 0 1.5158159172301566e-09
two O 0 2.8054338852001592e-09
in O 0 6.610502367720983e-09
association O 0 2.3532649162660846e-09
with O 0 9.704200776283756e-10
more O 0 7.2019310515258894e-09
recognizable O 0 9.334489732282236e-06
aniridia B-Disease 1 0.9999991655349731
phenotypes O 0 5.030618194723502e-05
. O 0 5.120458354213042e-06

Strikingly O 0 1.3603398656414356e-05
, O 0 8.715936417047487e-08
all O 0 8.686159347348621e-09
four O 0 1.187569775851216e-08
mutations O 0 4.693873290051442e-09
are O 0 9.170314507755961e-10
located O 0 1.2317627806623932e-08
within O 0 9.394665489992349e-09
the O 0 2.0839994618881974e-08
PAX6 O 0 8.148747838276904e-06
paired O 0 1.5572787503970176e-07
domain O 0 5.679525116875084e-08
and O 0 2.2556014833696736e-09
affect O 0 1.2860644105217034e-08
amino O 0 1.8216844921425945e-08
acids O 0 9.058608085865671e-09
which O 0 1.9478640922443446e-10
are O 0 6.697482152207002e-11
highly O 0 1.1289666979052981e-09
conserved O 0 4.849565193865146e-09
in O 0 4.887980575851714e-10
all O 0 1.023777951303373e-09
known O 0 8.564062348170864e-09
paired O 0 8.228067827076302e-08
domain O 0 2.683601678654668e-07
proteins O 0 1.7896836368436198e-07
. O 0 6.500580980173254e-07

Our O 0 1.6426271258751513e-06
results O 0 1.3134466314568272e-07
support O 0 1.2862630072163483e-08
the O 0 2.5577907791785037e-08
hypothesis O 0 6.892898252175428e-09
that O 0 3.4053888181562186e-11
the O 0 1.7352672077031173e-10
under O 0 2.416102207192239e-09
- O 0 4.879115333977779e-09
representation O 0 1.8055570372155216e-09
of O 0 3.2875959732336923e-08
missense O 0 8.958573403106129e-07
mutations O 0 3.1113572163121717e-08
is O 0 1.851578335099191e-09
caused O 0 4.1973811093498625e-09
by O 0 1.6330277130549575e-09
ascertainment O 0 0.004190899431705475
bias O 0 2.9073564746795455e-06
and O 0 1.709278762973554e-08
suggest O 0 1.2727308096316392e-08
that O 0 1.368816310298726e-10
a O 0 4.925452823378862e-10
substantial O 0 1.0588242282949523e-08
burden O 0 7.690672987337166e-08
of O 0 3.8921359646337805e-07
PAX6 B-Disease 1 0.9757441282272339
- I-Disease 0 0.0003959034220315516
related I-Disease 0 0.0006523734191432595
disease I-Disease 0 0.00028317864052951336
remains O 0 2.248848005592663e-07
to O 0 1.0848452136613673e-09
be O 0 1.163330232145654e-08
uncovered O 0 1.5813483287274721e-06
. O 0 1.2444059116489825e-08
. O 0 2.0194470096157602e-07

The O 0 4.7121756097112666e-07
chromosomal O 0 7.232731604744913e-06
order O 0 7.752912978276072e-08
of O 0 2.5312201046290284e-07
genes O 0 1.4546156990036252e-07
controlling O 0 1.2131737094023265e-05
the O 0 3.452068142451026e-07
major O 0 6.524494438053807e-06
histocompatibility O 0 0.07190823554992676
complex O 0 9.45181236602366e-05
, O 0 2.0680142043261185e-08
properdin O 0 3.7301910538189986e-07
factor O 0 6.944207342485242e-08
B O 0 4.202328454994131e-06
, O 0 1.522579751167541e-08
and O 0 4.432415323663008e-08
deficiency B-Disease 0 0.034488797187805176
of I-Disease 0 2.260244400531519e-06
the I-Disease 0 5.16586965204624e-07
second I-Disease 0 5.403663294600847e-07
component I-Disease 0 2.8396259494911646e-06
of I-Disease 0 5.743788165091246e-07
complement I-Disease 0 3.299109266663436e-06
. O 0 1.8548544176155701e-06

The O 0 1.272177087230375e-06
relationship O 0 4.3667242266565154e-07
of O 0 1.0800953731404661e-07
the O 0 1.1291955814840549e-08
genes O 0 3.5788201291353516e-09
coding O 0 9.032524417307286e-08
for O 0 4.798746733314374e-09
HLA O 0 6.40789110661899e-08
to O 0 1.0792665650072308e-09
those O 0 1.1631565710601421e-09
coding O 0 7.287829362212506e-08
for O 0 6.2048894911015395e-09
properdin O 0 5.573784847001662e-07
Factor O 0 7.620917585882125e-08
B O 0 9.485313512413995e-07
allotypes O 0 4.091827747743082e-07
and O 0 4.556918398179732e-09
for O 0 3.31678293719051e-08
deficiency B-Disease 0 0.0033862541895359755
of I-Disease 0 1.891762735795055e-06
the I-Disease 0 3.956804164317873e-07
second I-Disease 0 1.8478526442322618e-07
component I-Disease 0 7.977478162501939e-07
of I-Disease 0 3.649909672276408e-07
complement I-Disease 0 4.1887540191964945e-07
( O 0 5.819159198949819e-08
C2 O 0 4.7249326939891034e-07
) O 0 9.562975966659337e-10
was O 0 7.20385440189375e-09
studied O 0 1.5670421404934132e-08
in O 0 4.0506553666830314e-10
families O 0 9.684059804060396e-11
of O 0 8.647280225204668e-09
patients O 0 1.3584433133928542e-07
with O 0 7.712316119068419e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.922915518283844

Patients O 0 1.7516098296255223e-06
were O 0 2.1088343515884844e-08
selected O 0 5.988494145015011e-09
because O 0 4.600581859914854e-10
they O 0 1.9531133654826505e-10
were O 0 1.1107049724401463e-09
heterozygous O 0 1.748958089464736e-09
or O 0 2.006667276788221e-09
homozygous O 0 2.154061036208077e-07
for O 0 1.800216296032886e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0003700659435708076

12 O 0 5.481197604240151e-06
families O 0 1.273563832171476e-08
with O 0 1.0315738485644488e-08
15 O 0 2.5300423089902324e-07
matings O 0 1.6987471553875366e-06
informative O 0 9.878613127511926e-07
for O 0 5.587187843048014e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.641476021381095e-05
found O 0 3.5777063089881267e-07
. O 0 2.7524129109224305e-07

Of O 0 7.505938810936641e-06
57 O 0 4.749332674691686e-06
informative O 0 6.444201972044539e-07
meioses O 0 4.296132374292938e-06
, O 0 8.58273629944506e-09
two O 0 1.3280979649366031e-09
crossovers O 0 6.171287036949025e-09
were O 0 2.9384099597962177e-09
noted O 0 6.065131508137256e-09
between O 0 1.3672735121872392e-07
the O 0 2.9394115699687973e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.250168489898897e-08
and O 0 4.39500169591156e-09
the O 0 3.732923659072185e-08
HLA O 0 1.903290126392676e-06
- O 0 2.484047627149266e-06
B O 0 5.415573468781076e-06
gene O 0 3.321193542404899e-09
, O 0 3.3801011989353924e-10
with O 0 2.489308759123787e-10
a O 0 5.717836870644533e-09
recombinant O 0 9.064605954733906e-09
fraction O 0 4.916100593277406e-08
of O 0 6.816989639446547e-08
0 O 0 5.498089308275667e-07
. O 0 3.9492567793786293e-07

035 O 0 0.016076453030109406
. O 0 0.0001344424526905641

A O 0 1.4487675798591226e-05
lod O 0 6.026609844411723e-05
score O 0 4.4450814584706677e-07
of O 0 1.0046935727814343e-07
13 O 0 2.9252424482706374e-08
was O 0 5.600381491888129e-09
calculated O 0 2.9798823408810904e-09
for O 0 3.780052271196155e-09
linkage O 0 1.4789092347200494e-05
between O 1 0.9994818568229675
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 9.749383934831712e-06
HLA O 0 6.586546078324318e-05
- O 0 4.357058514870005e-06
B O 0 8.2612441474339e-06
at O 0 8.247204874578529e-08
a O 0 5.445629502887073e-10
maximum O 0 1.1105185659943118e-09
likelihood O 0 6.858273393639536e-10
value O 0 9.385240362647096e-10
of O 0 1.3001217880059812e-09
the O 0 7.005315216801478e-10
recombinant O 0 2.5978803552817453e-09
fraction O 0 3.901978296028119e-09
of O 0 1.5213197812613544e-08
0 O 0 1.9364460968063213e-07
. O 0 2.686448965505406e-07

04 O 0 0.007146814838051796
. O 0 0.00026099939714185894

18 O 0 6.09376866123057e-06
families O 0 1.2492048284684643e-08
with O 0 1.3729883008295474e-08
21 O 0 3.4918744518108724e-07
informative O 0 3.321879304962749e-08
matings O 0 9.767494191237347e-08
for O 0 2.5783370993792687e-09
both O 0 7.036466964649435e-09
properdin O 0 8.592770086579549e-07
Factor O 0 9.676632828359288e-08
B O 0 7.145382596718264e-07
allotype O 0 4.3835976271111576e-07
and O 0 8.923271899163865e-09
HLA O 0 7.566760586996679e-07
- O 0 1.3866017525288044e-06
B O 0 1.0898463187913876e-05
were O 0 4.8333983926340807e-08
found O 0 7.074783781035876e-08
. O 0 1.1872531757717297e-07

Of O 0 4.3384584387240466e-06
72 O 0 4.391687525640009e-06
informative O 0 7.298205559891358e-07
meioses O 0 5.661577688442776e-06
, O 0 1.5831780331154732e-08
three O 0 6.7967849126659985e-09
recombinants O 0 7.784094009366527e-07
were O 0 1.6698107785373395e-08
found O 0 2.7547739644973035e-09
, O 0 3.725593722414544e-10
giving O 0 7.574841309754277e-10
a O 0 1.3141281396400473e-09
recombinant O 0 5.356984189575087e-09
fraction O 0 2.146927791102371e-08
of O 0 6.141416974969616e-08
0 O 0 5.251184802546049e-07
. O 0 3.139045645639271e-07

042 O 0 0.008092203177511692
. O 0 0.00010145553824258968

A O 0 9.605770173948258e-06
lod O 0 3.085182106588036e-05
score O 0 5.648912519973237e-07
of O 0 3.338082592563296e-07
16 O 0 6.44601470867201e-07
between O 0 3.4962326367349306e-07
HLA O 0 3.887468210450606e-06
- O 0 1.4192158914738684e-06
B O 0 2.1421171823021723e-06
and O 0 4.908162765104862e-09
Factor O 0 3.3362994145136327e-08
B O 0 6.167383048705233e-07
allotypes O 0 6.341383596009109e-07
was O 0 8.687124619655151e-08
calculated O 0 1.5369879591276003e-08
at O 0 1.8301545168242228e-08
a O 0 8.622373370847924e-10
maximum O 0 2.882554417382721e-09
likelihood O 0 1.225937573678948e-09
value O 0 5.776280564973035e-10
of O 0 5.678468806280534e-10
the O 0 3.8156097725838833e-10
recombinant O 0 5.946448666804827e-09
fraction O 0 9.856536031804808e-09
of O 0 2.1403694816513053e-08
0 O 0 4.5552954475169827e-07
. O 0 5.075600029158522e-07

04 O 0 0.004806770011782646
. O 0 0.00013574969489127398

A O 0 3.2929542612691876e-06
crossover O 0 1.4221967603589292e-06
was O 0 6.530723908326763e-07
shown O 0 1.097376056691246e-08
to O 0 1.3821734867747182e-09
have O 0 4.842879985922366e-10
occurred O 0 5.25126697681344e-09
between O 0 8.731669276507148e-10
genes O 0 7.176405303344069e-11
for O 0 1.8945611746090663e-10
Factor O 0 5.044433315504193e-09
B O 0 1.1745218131409274e-07
and O 0 4.870152725544585e-09
HLA O 0 6.765241664652422e-07
- O 0 2.89827380584029e-06
D O 0 5.815700569655746e-05
, O 0 5.8768341304471505e-09
in O 0 3.6640177558666664e-09
which O 0 4.708300860301051e-09
HLA O 0 1.6627066088403808e-06
- O 0 6.740152912243502e-06
D O 0 0.00013415100693237036
segregared O 0 6.014658083586255e-06
with O 0 2.8046596156627857e-08
HLA O 0 1.8740949599305168e-05
- O 0 2.144353175026481e-06
A O 0 7.358968332482618e-07
and O 0 1.1126566334951349e-07
B O 0 0.00030379369854927063
. O 0 9.121424113800458e-07

These O 0 3.697493156096243e-08
studies O 0 5.977233286103001e-08
suggest O 0 5.134417779828482e-09
that O 0 3.970912834661e-11
the O 0 1.1952357159561444e-10
genes O 0 8.006270646454539e-11
for O 0 3.594394781814003e-10
Factor O 0 2.437925061826718e-08
B O 0 4.473372609936632e-05
and O 0 9.711088750918861e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.6263083324474792e-08
located O 0 1.7151114306557247e-08
outside O 0 7.951613589796125e-09
those O 0 3.835412820674122e-10
for O 0 1.6634585930930257e-09
HLA O 0 2.7263328661319974e-07
, O 0 1.5235317452066965e-09
that O 0 5.345323142447178e-11
the O 0 2.948390420698388e-10
order O 0 4.561124811175432e-10
of O 0 4.1888155166702745e-09
genese O 0 1.8635587650805974e-07
is O 0 1.909894908891374e-09
HLA O 0 4.3683023420726386e-08
- O 0 8.748381219447765e-08
A O 0 1.4588152907890617e-07
, O 0 5.935774094467661e-09
- O 0 3.187006569760342e-08
B O 0 1.0741862297436455e-06
, O 0 7.219508102451755e-09
- O 0 3.121754232893181e-08
D O 0 3.721872587902908e-07
, O 0 1.7069354818488591e-09
Factor O 0 1.6367797783800597e-08
B O 0 7.801962965459097e-06
allotype O 0 0.00016892717394512147
, O 0 1.0834388376679271e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 8.576289012296456e-09
that O 0 8.832770626021613e-11
the O 0 9.83530923370779e-10
genes O 0 3.969478079568489e-09
coding O 0 1.2370080639811931e-06
for O 0 2.053022853942821e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.3463186121498438e-07
Factor O 0 1.1360050677922118e-07
B O 0 9.014923421091225e-07
allotypes O 0 1.5672041797643033e-07
are O 0 1.9035222009744501e-10
approximately O 0 5.576842876386934e-10
3 O 0 6.019045706295856e-09
- O 0 5.005368119981313e-09
- O 0 7.379360233983334e-09
5 O 0 7.750662334160552e-09
centimorgans O 0 2.548081212694342e-08
from O 0 1.899671309146811e-09
the O 0 2.823066669321861e-09
HLA O 0 3.528381853357132e-07
- O 0 1.1869860827573575e-07
A O 0 9.916352894379088e-08
and O 0 1.1005285571741297e-08
HLA O 0 1.3532650200431817e-06
- O 0 8.256788532889914e-07
B O 0 9.999654366765753e-07
loci O 0 6.562900445317155e-09
, O 0 6.499428217843217e-10
and O 0 1.1494689228230826e-10
that O 0 1.0046519866024894e-10
the O 0 1.1834808688604426e-09
apparent O 0 2.3563156759109916e-08
lack O 0 3.087215105779251e-08
of O 0 4.4806451882095644e-08
recombinants O 0 4.387939043226652e-07
between O 0 6.000429930708151e-09
the O 0 1.3386626251943312e-09
Factor O 0 1.8853132388585436e-08
B O 0 2.0602092263288796e-06
gene O 0 4.958648105457542e-07
and O 0 1.2437041732482612e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 6.748977739334805e-06
suggests O 0 8.038768584128775e-08
that O 0 1.976588476226837e-10
these O 0 1.7172831212608486e-10
two O 0 9.72691927003666e-10
genes O 0 4.527461960890378e-09
lie O 0 1.2486181333315471e-07
in O 0 8.527777595190855e-09
close O 0 2.425791763016605e-07
proximity O 0 2.096386708672071e-07
to O 0 5.578463024846769e-09
one O 0 1.5489952431835263e-08
another O 0 7.852655414808396e-08
. O 0 6.562714816027437e-07

Distribution O 0 2.938596253443393e-06
of O 0 1.6298115497193066e-06
emerin O 0 0.00014237739378586411
and O 0 4.992494382349832e-07
lamins O 0 0.0005033250199630857
in O 0 2.966155498995704e-08
the O 0 3.6244145462660526e-08
heart O 0 2.003388544835616e-06
and O 0 6.943263741732153e-09
implications O 0 1.7361985271691083e-07
for O 0 2.826708680458978e-07
Emery B-Disease 1 0.9969469904899597
- I-Disease 1 0.9999995231628418
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.038568709045648575

Emerin O 0 0.0001889406266855076
is O 0 1.4976103557273746e-07
a O 0 1.5123056584798178e-07
nuclear O 0 8.669760063639842e-06
membrane O 0 3.177702296852658e-07
protein O 0 1.5110652284988646e-08
which O 0 2.6057098145848556e-10
is O 0 3.479457555410903e-10
missing O 0 7.904254140100875e-09
or O 0 6.243507932879311e-09
defective O 0 4.752876066049794e-06
in O 0 5.836232617184578e-07
Emery B-Disease 1 0.99981290102005
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.998708963394165
EDMD B-Disease 1 1.0
) O 0 8.158593118423596e-06
. O 0 3.61127354153723e-06

It O 0 1.2625861245396663e-07
is O 0 3.050258712278264e-08
one O 0 2.8860533962671298e-09
member O 0 2.047659286574799e-08
of O 0 1.6226341870151373e-07
a O 0 2.008156201327438e-07
family O 0 3.946424698142437e-08
of O 0 6.258568419070798e-07
lamina O 0 0.05673752725124359
- O 0 2.1452291548484936e-05
associated O 0 4.811791427528078e-07
proteins O 0 6.405774133355635e-09
which O 0 1.2450129815988475e-09
includes O 0 6.283337405932343e-09
LAP1 O 0 4.982262453268049e-06
, O 0 9.621692775851898e-09
LAP2 O 0 6.891796147101559e-06
and O 0 6.454158807400745e-08
lamin O 0 1.237582546309568e-05
B O 0 1.918816997203976e-05
receptor O 0 3.823361964805372e-07
( O 0 4.3421650275377033e-07
LBR O 0 4.761635136674158e-05
) O 0 4.0971966086544853e-07
. O 0 1.5399904214064009e-06

A O 0 2.753657099674456e-06
panel O 0 1.6253831063295365e-06
of O 0 2.379884875836069e-07
16 O 0 1.7204264679548942e-07
monoclonal O 0 1.4148866966934293e-08
antibodies O 0 3.795150860241847e-09
( O 0 9.435142445113343e-09
mAbs O 0 2.8792160833290836e-07
) O 0 4.861576918813171e-09
has O 0 1.721767506346339e-09
been O 0 1.244115588328043e-09
mapped O 0 1.9783923388416724e-09
to O 0 2.203462828864744e-10
six O 0 4.472597292526359e-10
specific O 0 1.4747625343147774e-10
sites O 0 2.535812115844749e-10
throughout O 0 1.1472172517512647e-10
the O 0 4.3512429770409256e-10
emerin O 0 1.9532343742412195e-08
molecule O 0 1.9192141209600777e-09
using O 0 2.6457256385725714e-09
phage O 0 1.0794812155268119e-08
- O 0 4.372301631860864e-09
displayed O 0 5.082659182420457e-09
peptide O 0 4.724619362406202e-09
libraries O 0 4.828401678480532e-09
and O 0 9.070221795859368e-10
has O 0 3.3075181482544735e-10
been O 0 3.551096361409378e-10
used O 0 1.767087448589777e-10
to O 0 2.9719005034678503e-10
localize O 0 2.2352173800754827e-07
emerin O 0 8.633696779725142e-06
in O 0 2.078977168196161e-08
human O 0 5.421312110343024e-08
and O 0 4.219304514663236e-07
rabbit O 0 5.229278485785471e-06
heart O 0 0.00015015290409792215
. O 0 5.103293005959131e-06

Several O 0 4.060042613218684e-07
mAbs O 0 2.5478295810899e-06
against O 0 5.806674963082514e-08
different O 0 8.835493225944901e-09
emerin O 0 2.3830832560634008e-06
epitopes O 0 6.977018642828625e-07
did O 0 1.522120918195924e-08
not O 0 1.0239907810571935e-09
recognize O 0 1.2688285089268447e-08
intercalated O 0 2.490998269877309e-07
discs O 0 1.1350297427270561e-05
in O 0 1.8195143169918992e-08
the O 0 5.524295687564518e-08
heart O 0 6.418290922738379e-06
, O 0 3.0013698193442906e-09
though O 0 7.403210267042937e-10
they O 0 1.753754086397663e-10
recognized O 0 2.0568533543041667e-09
cardiomyocyte O 0 1.7582831901563623e-07
nuclei O 0 2.4257078123923748e-08
strongly O 0 6.456569501267495e-09
, O 0 8.326273004399809e-10
both O 0 1.3432868151141975e-09
at O 0 1.495386783290087e-07
the O 0 1.7314404132662276e-08
rim O 0 2.2764746177017514e-07
and O 0 1.1533655142059729e-09
in O 0 4.378736040422382e-09
intranuclear O 0 1.2245510561115225e-06
spots O 0 9.24101257737675e-08
or O 0 4.431037936569737e-08
channels O 0 9.427146210327919e-07
. O 0 3.43068961683457e-07

A O 0 3.575646042008884e-05
polyclonal O 0 2.30411569646094e-05
rabbit O 0 1.5007901765784482e-06
antiserum O 0 3.6940857626177603e-06
against O 0 5.886529379495187e-07
emerin O 0 9.511405551165808e-06
did O 0 2.883991356839033e-08
recognize O 0 1.9506693149651255e-08
both O 0 3.6059898178564254e-08
nuclear O 0 4.326554062572541e-06
membrane O 0 8.727781874995344e-08
and O 0 1.2963580209301995e-09
intercalated O 0 7.434885418433623e-08
discs O 0 2.5751961629794096e-07
but O 0 5.511050504836135e-10
, O 0 4.539355349941765e-11
after O 0 4.327463942743748e-10
affinity O 0 1.2341324628906136e-09
purification O 0 5.199840558134383e-08
against O 0 1.905115176725758e-08
a O 0 1.2297531881699797e-08
pure O 0 7.602841378684388e-07
- O 0 6.756331316637443e-08
emerin O 0 3.538322346230416e-07
band O 0 1.1393620269473104e-07
on O 0 4.758753746614275e-08
a O 0 1.0448053089362475e-08
western O 0 1.3955250288688603e-08
blot O 0 1.1788905140974748e-07
, O 0 2.523846909241456e-09
it O 0 2.8308244637287316e-10
stained O 0 1.939883986779023e-07
only O 0 2.84846657372384e-09
the O 0 2.259124443071414e-08
nuclear O 0 4.224017629894661e-06
membrane O 0 1.2363569794615614e-06
. O 0 1.4219972399587277e-07

These O 0 5.270092984233088e-08
results O 0 3.557926930852773e-08
would O 0 3.637418588553487e-09
not O 0 4.444084822363692e-10
be O 0 3.444125817875232e-10
expected O 0 2.171579138732227e-09
if O 0 9.677805223873293e-10
immunostaining O 0 9.892701058333842e-08
at O 0 6.127341123374208e-08
intercalated O 0 1.817485753008441e-07
discs O 0 1.2073852531102602e-06
were O 0 5.107849698759992e-09
due O 0 3.270445469993888e-09
to O 0 1.587482229004067e-10
a O 0 7.289573944468941e-10
product O 0 8.868039635956393e-10
of O 0 4.419531407506838e-09
the O 0 9.09640451851601e-09
emerin O 0 3.63656084800823e-07
gene O 0 2.479784821929343e-09
and O 0 1.4893409838734328e-09
, O 0 4.703119560467428e-10
therefore O 0 5.47506440184975e-09
, O 0 7.538606405788073e-10
cast O 0 2.3683268679519642e-09
some O 0 2.8384802841507906e-10
doubt O 0 2.6162290112097253e-09
upon O 0 5.226533095203933e-10
the O 0 9.889769003734727e-10
hypothesis O 0 5.251187040755667e-09
that O 0 1.0731884270143155e-09
cardiac B-Disease 1 0.8616594672203064
defects I-Disease 0 0.11418614536523819
in O 0 1.0809814739332069e-05
EDMD B-Disease 1 1.0
are O 0 9.234405240476917e-08
caused O 0 4.8972054855767055e-08
by O 0 1.5386266705164076e-09
absence O 0 2.39027059478758e-07
of O 0 3.146184610614e-07
emerin O 0 1.796637661755085e-05
from O 0 3.775248842430301e-07
intercalated O 0 1.1411031664465554e-05
discs O 0 0.0005194791592657566
. O 0 4.021977474621963e-06

Although O 0 2.7426758606452495e-06
emerin O 0 1.0906093848461751e-05
was O 0 4.139934333124984e-07
abundant O 0 2.38099193694552e-08
in O 0 4.580148704746989e-09
the O 0 4.490789962119379e-09
membranes O 0 5.4799460968979474e-08
of O 0 5.0387718886213406e-08
cardiomyocyte O 0 1.7850521771833883e-06
nuclei O 0 2.0379776799472893e-07
, O 0 1.3011041133381696e-09
it O 0 1.9013668417500185e-10
was O 0 1.3678964627672485e-08
absent O 0 7.0956871489613604e-09
from O 0 3.3662686527158314e-10
many O 0 6.992683515560927e-11
non O 0 7.46681934060689e-08
- O 0 7.153428214223823e-07
myocyte O 0 1.2583210263983347e-05
cells O 0 8.879113444493214e-09
in O 0 3.298517015082325e-09
the O 0 6.52428724379206e-08
heart O 0 5.2620704082073644e-05
. O 0 1.7074447669074289e-06

This O 0 2.5588008156773867e-08
distribution O 0 8.376376570140565e-08
of O 0 8.98222154432915e-08
emerin O 0 2.516607537472737e-06
was O 0 3.5079345650501637e-08
similar O 0 3.188310726542909e-10
to O 0 2.0645479770209363e-10
that O 0 2.457170023006938e-10
of O 0 4.035021561321628e-08
lamin O 0 2.2190674826561008e-06
A O 0 8.939782958350406e-08
, O 0 1.6352655896056945e-09
a O 0 1.7733042811940436e-09
candidate O 0 1.5741500325461288e-09
gene O 0 9.83671588627999e-10
for O 0 6.971406230071864e-10
an O 0 1.2053922304744447e-09
autosomal O 0 2.5792982683015e-07
form O 0 1.0968079777740058e-06
of O 1 0.5895712375640869
EDMD B-Disease 1 1.0
. O 0 0.0006096726865507662

In O 0 8.751232485337823e-07
contrast O 0 1.6155729554157006e-06
, O 0 6.179199090183829e-07
lamin O 0 0.00014883250696584582
B1 O 0 0.002344880485907197
was O 0 6.51650361760403e-06
absent O 0 1.4899760572006926e-06
from O 0 5.223817822752608e-08
cardiomyocyte O 0 2.2014651221979875e-06
nuclei O 0 4.856227633354138e-07
, O 0 5.794115409685219e-09
showing O 0 6.39398507473743e-08
that O 0 1.2821455896983025e-08
lamin O 0 2.330639290448744e-05
B1 O 0 1.524648268969031e-05
is O 0 1.0741735279040654e-09
not O 0 1.2334964993865327e-10
essential O 0 1.3801449982864256e-09
for O 0 4.3397382909482474e-10
localization O 0 5.809311005577911e-07
of O 0 3.8193924467577745e-08
emerin O 0 3.5160073252882285e-07
to O 0 2.482870575803986e-09
the O 0 3.5426506173052985e-08
nuclear O 0 1.6855252397363074e-05
lamina O 0 8.162666927091777e-05
. O 0 1.3039914392720675e-06

Lamin O 1 0.9147201180458069
B1 O 1 0.8340070247650146
is O 0 3.503896550682839e-07
also O 0 2.030252232998464e-08
almost O 0 1.9296576780902797e-08
completely O 0 3.1456568194698775e-07
absent O 0 1.490170689066872e-06
from O 0 5.699698704120237e-07
skeletal O 1 0.9345152378082275
muscle O 0 0.0005790405557490885
nuclei O 0 0.016956808045506477
. O 0 3.344322612974793e-05

In O 0 3.36040079673694e-06
EDMD B-Disease 1 0.9999932050704956
, O 0 2.8484569369879864e-08
the O 0 1.934967741590299e-09
additional O 0 2.1761152879662404e-09
absence O 0 7.729436646286558e-08
of O 0 3.376174788627395e-07
lamin O 0 0.0018051277147606015
B1 O 1 0.9944483041763306
from O 0 4.464625817490742e-06
heart O 1 0.9999076128005981
and O 0 0.002599631901830435
skeletal O 1 1.0
muscle O 1 0.9999659061431885
nuclei O 1 0.9993845224380493
which O 0 7.821635676918959e-07
already O 0 3.3094974583036674e-07
lack O 0 3.148835503452574e-07
emerin O 0 2.3002146463113604e-06
may O 0 1.5603098812988492e-09
offer O 0 9.238074194506396e-11
an O 0 3.539936399565846e-11
alternative O 0 2.1191475241266744e-09
explanation O 0 3.990140662324393e-09
of O 0 4.52958692775951e-09
why O 0 5.1052388982952834e-09
these O 0 4.007986997844881e-10
tissues O 0 1.7702907584293825e-08
are O 0 5.945198222612191e-10
particularly O 0 3.0290785435482803e-09
affected O 0 1.7686698772223508e-09
. O 0 4.430672273514347e-09
. O 0 1.565444591733467e-07

Genetic O 0 3.502420668155537e-06
mapping O 0 4.736604751087725e-06
of O 0 2.152060233129305e-06
the O 0 2.1125902094354387e-06
copper B-Disease 1 0.9972149133682251
toxicosis I-Disease 1 0.7862784266471863
locus O 0 1.0805708825500915e-06
in O 0 7.450770453942823e-07
Bedlington O 0 0.0002643459592945874
terriers O 0 2.2846639694762416e-05
to O 0 1.2309600094795314e-07
dog O 0 2.436843260511523e-06
chromosome O 0 4.599770591084962e-07
10 O 0 8.442330567959289e-08
, O 0 2.376458141384319e-09
in O 0 2.663340215036669e-09
a O 0 1.1222987872372414e-08
region O 0 7.274677216173586e-08
syntenic O 0 3.874234266731946e-07
to O 0 1.9765140635286116e-09
human O 0 3.40848025359719e-08
chromosome O 0 7.374156894002226e-07
region O 0 6.159800136629201e-07
2p13 O 0 9.10970447876025e-06
- O 0 3.5089501579932403e-06
p16 O 0 5.5814093684602994e-06
. O 0 6.76042361646978e-07

Abnormal O 1 0.9999856948852539
hepatic B-Disease 1 0.9999995231628418
copper I-Disease 1 0.9999599456787109
accumulation I-Disease 0 0.009391787461936474
is O 0 2.6228454075294394e-08
recognized O 0 1.448243569512897e-08
as O 0 2.7637749866471495e-08
an O 0 1.4919211821506906e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.05334826558828354
man O 0 0.00105968804564327
, O 0 9.031904113498967e-08
mouse O 0 1.0944579571514623e-06
, O 0 2.6847175149669056e-07
rat O 0 4.301105218473822e-05
and O 0 7.396130854431249e-07
dog O 0 0.00026659551076591015
. O 0 9.320577191829216e-06

The O 0 1.674724785516446e-06
major O 0 7.504607310693245e-06
cause O 0 3.694803308462724e-05
of O 0 0.0013828270602971315
hepatic B-Disease 1 0.9999998807907104
copper I-Disease 1 0.9999998807907104
accumulation I-Disease 1 0.9999886751174927
in O 0 5.2336148655740544e-05
man O 0 1.0451556590851396e-05
is O 0 1.2009177652316794e-08
a O 0 2.351027283964413e-08
dysfunctional O 0 2.9535713110817596e-06
ATP7B O 0 0.0003527917433530092
gene O 0 2.0088516805572e-07
, O 0 5.0245205329702e-08
causing O 0 1.955074185389094e-05
Wilson B-Disease 0 0.0981137678027153
disease I-Disease 1 0.9972079396247864
( O 0 2.0953104922227794e-06
WD B-Disease 0 0.0018875468522310257
) O 0 1.1452549415480462e-06
. O 0 2.4786475023574894e-06

Mutations O 0 8.754788609621755e-07
in O 0 6.748255998445529e-08
the O 0 6.206028047017753e-08
ATP7B O 0 0.00012259413779247552
genes O 0 1.1651556164338217e-08
have O 0 4.30611407642445e-10
also O 0 3.2313371423065007e-10
been O 0 6.482863135204298e-10
demonstrated O 0 4.326154101619295e-09
in O 0 4.278200016472056e-09
mouse O 0 5.157309246328623e-08
and O 0 8.374300364266674e-08
rat O 0 8.28659631224582e-06
. O 0 4.4775356400350574e-07

The O 0 7.941332114569377e-06
ATP7B O 0 0.0009449219796806574
gene O 0 7.115632456589083e-07
has O 0 2.3962497763818646e-08
been O 0 6.584139899956654e-09
excluded O 0 1.045570829916187e-08
in O 0 6.610587077737762e-10
the O 0 1.231052815242606e-09
much O 0 1.6898386689945255e-08
rarer O 0 7.860265327508387e-07
human O 0 4.224039287237247e-07
copper B-Disease 1 0.9998865127563477
overload I-Disease 1 0.9999744892120361
disease O 1 0.8140975832939148
non B-Disease 0 1.8903308500739513e-06
- I-Disease 0 3.626364843967167e-07
Indian I-Disease 0 3.6277203463441765e-08
childhood I-Disease 0 0.00012782803969457746
cirrhosis I-Disease 1 0.9997217059135437
, O 0 3.171827955839035e-08
indicating O 0 5.020693265578302e-07
genetic O 0 1.1129448012070497e-06
heterogeneity O 0 1.4130834642855916e-05
. O 0 5.795433025923558e-06

By O 0 4.6529347486057304e-08
investigating O 0 1.5868123455220484e-06
the O 0 1.3341836790914385e-07
common O 0 3.462890526861884e-05
autosomal O 1 0.9824596643447876
recessive O 1 0.9989166259765625
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 1.2212342880957294e-05
CT B-Disease 1 0.9991698265075684
) O 0 2.5124746727556158e-08
in O 0 1.227659680580473e-07
Bedlington O 0 0.00969571154564619
terriers O 0 9.046964260051027e-05
, O 0 1.023069806649346e-08
we O 0 2.105473351221576e-09
have O 0 2.3118798542220986e-10
identified O 0 6.036932620467894e-10
a O 0 1.6098140875886457e-10
new O 0 1.1442321395938038e-10
locus O 0 1.517736825107363e-09
involved O 0 3.0269009521077805e-09
in O 0 3.9576864452328664e-08
progressive O 1 0.9999983310699463
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0003617568872869015

We O 0 5.464050332193437e-07
examined O 0 1.4637474805567763e-06
whether O 0 5.406173997357655e-08
the O 0 5.6822123895017285e-08
WD B-Disease 0 1.5503155736951157e-05
gene O 0 1.1749531836358074e-07
ATP7B O 0 2.0934805434080772e-05
was O 0 3.0772599757256103e-07
also O 0 3.022516459338931e-09
causative O 0 6.272778563243264e-08
for O 0 2.6380424955618764e-08
CT B-Disease 0 0.0005619957228191197
by O 0 6.374159422506409e-09
investigating O 0 5.011847861169372e-07
the O 0 1.072708428750957e-07
chromosomal O 0 0.0009754582424648106
co O 0 0.0008452968904748559
- O 0 1.7946751540875994e-05
localization O 0 0.000998499570414424
of O 0 1.891178385449166e-06
ATP7B O 0 0.00012247342965565622
and O 0 2.180304292664914e-08
C04107 O 0 1.4432460204716335e-07
, O 0 5.175928574630007e-10
using O 0 5.163031668864448e-10
fluorescence O 0 9.489791175099072e-09
in O 0 7.94114107804944e-09
situ O 0 1.036035087054188e-06
hybridization O 0 1.3519849062504363e-07
( O 0 2.3920760483520098e-08
FISH O 0 4.543061038475571e-07
) O 0 1.9738664036594855e-08
. O 0 2.0005504097753146e-07

C04107 O 0 7.37874725018628e-05
is O 0 1.082607496982746e-07
an O 0 1.5228236449615906e-08
anonymous O 0 1.6915664957650733e-07
microsatellite O 0 2.609284365462372e-06
marker O 0 1.5928058019198943e-06
closely O 0 8.930237527238205e-07
linked O 0 2.8606693831534358e-06
to O 0 2.696037597615941e-07
CT B-Disease 1 0.9999680519104004
. O 0 2.2795540644438006e-05

However O 0 3.57904491465888e-06
, O 0 1.1892039992744685e-06
BAC O 0 0.0008858478395268321
clones O 0 1.0413732525194064e-06
containing O 0 8.53214245921663e-08
ATP7B O 0 7.45949728298001e-06
and O 0 1.069306865275621e-08
C04107 O 0 3.8915160871511034e-07
mapped O 0 4.1920465321254596e-08
to O 0 4.5469423781696605e-09
the O 0 1.1779004438494667e-07
canine O 0 1.8240896679344587e-05
chromosome O 0 1.9123526726616547e-06
regions O 0 2.160554117836e-07
CFA22q11 O 0 6.098418907640735e-06
and O 0 2.2503169105902998e-08
CFA10q26 O 0 2.132077270289301e-06
, O 0 4.218843496772706e-09
respectively O 0 1.3443588464667755e-08
, O 0 7.171264138072786e-10
demonstrating O 0 2.114678920861479e-08
that O 0 3.5681260168729523e-09
WD B-Disease 0 1.5413378378070774e-06
cannot O 0 1.6565380178690248e-08
be O 0 4.783212048664609e-09
homologous O 0 7.21483033316872e-08
to O 0 4.184226298775684e-08
CT B-Disease 0 0.09619982540607452
. O 0 3.1592624054610496e-06

The O 0 5.244501153356396e-06
copper O 0 0.0011617999989539385
transport O 0 4.717355295724701e-06
genes O 0 1.7101990579249104e-07
CTR1 O 0 2.7855003281729296e-05
and O 0 2.4744519322439373e-08
CTR2 O 0 3.252616443205625e-05
were O 0 2.6881703973913318e-08
also O 0 1.6041230566088416e-09
excluded O 0 3.435545847807475e-09
as O 0 9.393263944446062e-10
candidate O 0 1.0434226815903003e-09
genes O 0 7.044816396906128e-10
for O 0 2.703192558684009e-09
CT B-Disease 0 0.0006207112455740571
since O 0 2.390579822986183e-08
they O 0 8.032522424983313e-10
both O 0 1.1849716763379092e-09
mapped O 0 1.8707771332060474e-08
to O 0 1.0571614694754317e-08
canine O 0 1.998438165173866e-05
chromosome O 0 2.4188566385419108e-05
region O 0 6.862374902993906e-06
CFA11q22 O 0 0.00036803330294787884
. O 0 2.043498170678504e-06

2 O 0 0.0001835182192735374
- O 0 4.593482299242169e-05
22 O 0 7.3484875429130625e-06
. O 0 1.6761181313995621e-06

5 O 0 0.0002158477291231975
. O 0 2.8608537832042202e-05

A O 0 2.1142409423191566e-06
transcribed O 0 3.387159495105152e-07
sequence O 0 3.0661833960721196e-08
identified O 0 1.110425973394058e-08
from O 0 3.836738926565886e-09
the O 0 4.852424240198161e-09
C04107 O 0 2.694407896797202e-07
- O 0 6.949069586426049e-08
containing O 0 3.7918823636573507e-08
BAC O 0 6.842873699497432e-05
was O 0 2.441038589040545e-07
found O 0 3.3295912693631635e-09
to O 0 8.397164075191199e-10
be O 0 1.6176329165062953e-09
homologous O 0 5.619856580096894e-09
to O 0 6.952656228520482e-10
a O 0 4.149516730223013e-09
gene O 0 5.1519672972233366e-09
expressed O 0 2.49492826398523e-09
from O 0 1.0500395219992242e-08
human O 0 9.03817376496363e-09
chromosome O 0 1.8952050595544279e-07
2p13 O 0 8.114449769891507e-07
- O 0 8.251107175283323e-08
p16 O 0 6.817236908318591e-08
, O 0 2.860471637333717e-09
a O 0 2.556365119588122e-09
region O 0 2.6811449060915038e-08
devoid O 0 5.257398356661724e-07
of O 0 1.1245357534050981e-08
any O 0 4.52958692775951e-09
positional O 0 2.113378286594525e-06
candidate O 0 2.103271441455945e-07
genes O 0 1.5663658814446535e-07
. O 0 3.828309331765922e-07

Molecular O 0 3.534070174282533e-06
analysis O 0 1.9590014233017428e-07
of O 0 1.1818589484846598e-07
the O 0 5.285686555112079e-08
APC B-Disease 0 2.901543325606326e-07
gene O 0 2.220594552682087e-08
in O 0 6.87923851216965e-09
205 O 0 2.2591891024603683e-08
families O 0 6.728265167232905e-10
: O 0 1.634729240862498e-09
extended O 0 3.352418787017086e-08
genotype O 0 8.994493896352651e-07
- O 0 7.541100330854533e-07
phenotype O 0 5.173220074539131e-08
correlations O 0 2.377711467715926e-07
in O 0 6.970332755429354e-09
FAP B-Disease 0 4.6179494006537425e-08
and O 0 8.929822437053758e-10
evidence O 0 5.9620757220102405e-09
for O 0 2.5577975848456447e-10
the O 0 1.4753569477221617e-09
role O 0 3.782939117513706e-08
of O 0 1.468346937372189e-07
APC B-Disease 0 3.017179039943585e-07
amino O 0 8.6131109355847e-08
acid O 0 1.0723811527668659e-07
changes O 0 1.628526860031343e-07
in O 0 0.001000923803076148
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999109506607056
. O 0 0.00011550138151505962

BACKGROUND O 0 0.0014581331051886082
/ O 0 6.534968269988894e-05
AIMS O 0 7.210537660284899e-07
The O 0 2.5943560189034542e-08
development O 0 2.0283660262521153e-07
of O 1 0.7352883815765381
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.054162789339898e-07
a O 0 1.4366801082132952e-08
variable O 0 6.279120334795607e-09
range O 0 1.1023773005547355e-08
of O 0 5.908281419664263e-09
extracolonic O 0 1.6758432366259512e-06
manifestations O 0 2.5577875931048766e-05
in O 0 6.809699243603973e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.6020185285015032e-05
FAP B-Disease 0 1.5174298368947348e-06
) O 0 1.1060167004472987e-08
is O 0 1.9546608776011e-09
the O 0 5.755473320157023e-10
result O 0 1.9832697706334557e-09
of O 0 7.728106155013847e-09
the O 0 1.6250369938575204e-08
dominant O 0 6.603437668672996e-06
inheritance O 0 1.907185719574045e-06
of O 0 0.00042712080175988376
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999878406524658
( O 0 1.5985733625711873e-06
APC B-Disease 0 6.6866045926872175e-06
) O 0 3.335524070280371e-07
gene O 0 2.8325180210231338e-06
mutations O 0 6.0427778407756705e-06
. O 0 3.845947503577918e-06

In O 0 1.0908738090620318e-07
this O 0 2.2991200054889305e-09
study O 0 1.9187016420119107e-09
, O 0 1.9045280630347605e-10
direct O 0 5.201025721213171e-10
mutation O 0 3.1827937507777904e-10
analysis O 0 1.6177007511330999e-09
of O 0 5.354185095285402e-09
the O 0 1.800529858542177e-08
APC B-Disease 0 1.8967257631175016e-07
gene O 0 2.0894162844342645e-08
was O 0 8.380308003097525e-08
performed O 0 5.275806103099967e-08
to O 0 2.316895564291599e-09
determine O 0 1.1584648973439471e-07
genotype O 0 7.250932867464144e-07
- O 0 3.540523039191612e-07
phenotype O 0 3.9153025710447764e-08
correlations O 0 1.149874009342966e-07
for O 0 2.3412363603370068e-08
nine O 0 3.96796650647957e-07
extracolonic O 0 1.4102469322097022e-05
manifestations O 0 3.739419980774983e-06
and O 0 8.122562178414228e-09
to O 0 7.114737687885508e-10
investigate O 0 8.534644990731977e-09
the O 0 1.2910922331244024e-09
incidence O 0 9.31055694763927e-07
of O 0 8.889674063539132e-08
APC B-Disease 0 2.430896017813211e-07
mutations O 0 1.67312634857808e-08
in O 0 1.1743612304826456e-08
non O 0 0.035500094294548035
- O 1 0.9999945163726807
FAP O 1 0.999998927116394
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.011882304213941097

METHODS O 0 3.946015567635186e-05
The O 0 5.96749373471539e-07
APC B-Disease 0 4.307088090627076e-07
gene O 0 6.137997132782402e-08
was O 0 2.073443710060019e-07
analysed O 0 1.9017139152310847e-07
in O 0 3.5005809362331775e-09
190 O 0 1.0874705580476984e-08
unrelated O 0 4.48714487788493e-08
FAP B-Disease 0 2.903779261487216e-08
and O 0 7.601678397861633e-09
15 O 0 4.3458436493892805e-07
non O 1 0.630163311958313
- O 1 0.9999988079071045
FAP O 1 0.9999994039535522
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.259424248535652e-06
using O 0 3.858924060295976e-07
denaturing O 0 4.150461245444603e-05
gradient O 0 7.971797458594665e-06
gel O 0 1.4635402294516098e-05
electrophoresis O 0 2.8329770884738537e-06
, O 0 1.5714030965341408e-08
the O 0 1.4309425644398743e-08
protein O 0 4.29190016859593e-08
truncation O 0 1.3332120829545602e-07
test O 0 5.933442182026738e-09
, O 0 7.476431695963015e-10
and O 0 8.015136887529195e-10
direct O 0 2.4457683878154057e-08
sequencing O 0 3.4783468549903773e-07
. O 0 5.3239335784383e-07

RESULTS O 0 9.566580956743564e-06
Chain O 0 3.756812930078013e-06
terminating O 0 5.913233280807617e-07
signals O 0 2.94717438009684e-07
were O 0 7.444844740689405e-09
only O 0 3.7822212028970625e-10
identified O 0 1.4984818941243816e-09
in O 0 9.037894321828333e-10
patients O 0 2.4461774827955196e-09
belonging O 0 5.89632564995668e-09
to O 0 7.54251827661534e-10
the O 0 2.8442279642604262e-08
FAP B-Disease 0 5.192546268517617e-07
group O 0 1.5974015354913718e-07
( O 0 8.058341194328023e-08
105 O 0 2.277756721014157e-06
patients O 0 7.034838631625462e-07
) O 0 6.442942179774036e-08
. O 0 6.811802677475498e-07

Amino O 0 1.8375001218373654e-06
acid O 0 3.214522337202652e-07
changes O 0 3.271526338721742e-08
were O 0 1.0487865687025533e-08
identified O 0 6.496755133866827e-09
in O 0 1.913168734546389e-09
four O 0 2.8076447833313978e-09
patients O 0 5.914336131951359e-09
, O 0 8.61698101761732e-10
three O 0 2.605750726303313e-09
of O 0 7.296229114217567e-07
whom O 0 3.998225963641744e-07
belonged O 0 3.7299955693015363e-06
to O 0 1.5470782432913666e-09
the O 0 2.1657481141801327e-08
non O 0 9.750025128596462e-06
- O 0 3.300669959571678e-06
FAP O 0 2.388388509189099e-07
group O 0 2.470731601533771e-07
of O 1 0.9999942779541016
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9989232420921326
. O 0 2.102915277646389e-05

Genotype O 0 0.0003872667730320245
- O 0 0.00022224527492653579
phenotype O 0 1.561128556204494e-06
correlations O 0 4.586560862662736e-06
identified O 0 8.206845336644619e-08
significant O 0 3.9883236269133704e-08
differences O 0 3.289409278295352e-07
in O 0 4.660179797610908e-09
the O 0 2.3478399224785562e-09
nature O 0 5.663393309873754e-09
of O 0 4.432464173476092e-09
certain O 0 1.5017388221849615e-08
extracolonic O 0 1.3886530041418155e-06
manifestations O 0 5.848774549122027e-07
in O 0 8.994424760544462e-09
FAP B-Disease 0 1.5189937130344333e-07
patients O 0 1.3365685447297437e-08
belonging O 0 2.364148876665695e-08
to O 0 2.709800384081973e-09
three O 0 6.297437238345083e-08
mutation O 0 4.971755060978467e-07
subgroups O 0 3.107161683146842e-05
. O 0 5.251387392490869e-06

CONCLUSIONS O 0 1.2447887456801254e-05
Extended O 0 2.7297433007333893e-06
genotype O 0 4.585861006489722e-06
- O 0 2.5453086891502608e-06
phenotype O 0 6.503328364715344e-08
correlations O 0 4.457672559965431e-07
made O 0 1.2577783259359876e-08
in O 0 1.7460882739683825e-09
this O 0 1.3301761081496721e-10
study O 0 1.6850905115717296e-09
may O 0 8.266284323710238e-10
have O 0 8.105962429061364e-11
the O 0 3.839094042668023e-10
potential O 0 1.5284360443956757e-09
to O 0 1.076252489906615e-10
determine O 0 3.8448413341996e-09
the O 0 3.7216163484288245e-10
most O 0 2.1160324881197567e-10
appropriate O 0 2.2795185738999635e-09
surveillance O 0 4.611902326701056e-08
and O 0 1.2318842612657477e-09
prophylactic O 0 1.3731397530136746e-06
treatment O 0 3.8315383221743105e-07
regimens O 0 4.562764956972387e-07
for O 0 2.568701473748547e-09
those O 0 2.0643089460037345e-09
patients O 0 3.3051865688804583e-09
with O 0 6.22148887963192e-10
mutations O 0 1.552491468714834e-08
associated O 0 9.153110624993133e-08
with O 0 8.597465850357366e-09
life O 0 1.0012270195147721e-06
threatening O 0 1.7075587948056636e-06
conditions O 0 5.667276127496734e-06
. O 0 1.653440335758205e-06

This O 0 6.069380731332785e-08
study O 0 5.35531121670374e-08
also O 0 3.3938243326758766e-09
provided O 0 3.9432177523224254e-09
evidence O 0 5.365195399065215e-09
for O 0 4.056485147785338e-10
the O 0 4.1021435137622575e-09
pathological O 0 4.966692358721048e-06
nature O 0 1.3551663791133706e-08
of O 0 1.5740546643883135e-08
amino O 0 7.671652646479288e-09
acid O 0 7.0774124338868205e-09
changes O 0 2.7852269379735617e-09
in O 0 3.0253022309523203e-09
APC O 0 3.0138597395534816e-08
associated O 0 1.8208439200861903e-08
with O 0 6.910033656382097e-10
both O 0 5.595769181354626e-09
FAP B-Disease 0 7.373623134299123e-08
and O 0 3.666655246092887e-08
non O 1 0.9999719858169556
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8902629613876343
. O 0 5.837167691424838e-07
. O 0 2.2637627807853278e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
and O 0 0.051077283918857574
cancer B-Disease 1 0.9995157718658447
risk O 0 1.2049593351548538e-05
of O 0 2.4041664801188745e-06
the O 0 8.032888217712753e-06
APC O 0 5.1527153118513525e-05
I1307K O 0 3.47403074556496e-05
polymorphism O 0 6.5287708821415436e-06
. O 0 2.123540525644785e-06

Germ O 1 0.9999642372131348
- O 0 0.0002644715132191777
line O 0 2.1151324745005695e-06
and O 0 1.4806830428426565e-08
somatic O 0 3.215497201836115e-07
truncating O 0 7.131570214369276e-07
mutations O 0 2.23363549878286e-08
of O 0 2.6786404205836334e-08
the O 0 2.8228743786939958e-08
APC B-Disease 0 2.45609555804549e-07
gene O 0 1.5033206679504474e-08
are O 0 1.0652573267933008e-09
thought O 0 5.94415805466042e-09
to O 0 1.063973908976834e-09
initiate O 0 1.1395590263418853e-05
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9985257983207703
formation O 1 0.5284212231636047
in O 0 0.09254135191440582
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.06794682890176773
sporadic O 1 0.9999997615814209
colorectal O 1 1.0
carcinogenesis O 1 0.9999997615814209
, O 0 1.942491962836357e-06
respectively O 0 1.772126961441245e-05
. O 0 2.9485984214261407e-06

Recently O 0 3.2547395676374435e-06
, O 0 2.947066413128141e-08
an O 0 2.463286996601255e-08
isoleucine O 0 3.210036811651662e-05
- O 0 3.158279650961049e-05
- O 0 1.4632011698267888e-05
> O 0 9.864039611784392e-07
lysine O 0 2.6957675913763524e-07
polymorphism O 0 2.7120872658770168e-08
at O 0 9.647146725910716e-08
codon O 0 5.038531725176654e-08
1307 O 0 1.2119119219278218e-06
( O 0 6.4548091316396494e-09
I1307K O 0 1.19178864110836e-07
) O 0 2.209937344233026e-09
of O 0 1.5421266041926174e-08
the O 0 3.2572184949231087e-08
APC B-Disease 0 2.5617947585487855e-07
gene O 0 4.0240845322614405e-08
has O 0 1.8382209088230184e-09
been O 0 8.143127283588569e-10
identified O 0 1.3869003723243623e-09
in O 0 1.4184391439187038e-09
6 O 0 2.209348437531844e-08
% O 0 3.435611350965928e-09
- O 0 2.9307097193509435e-08
7 O 0 4.620469340466116e-08
% O 0 3.039988483166667e-09
of O 0 6.34812158395448e-09
the O 0 1.4222353961201861e-08
Ashkenazi O 0 1.3270989995817217e-07
Jewish O 0 1.5968373290320415e-08
population O 0 1.7480776826062083e-09
. O 0 7.481545338805518e-08

To O 0 3.9341563251582556e-07
assess O 0 2.1125499642948853e-06
the O 0 8.312174060165489e-08
risk O 0 2.6975524747285817e-07
of O 0 3.855440056099724e-08
this O 0 2.559380263278399e-09
common O 0 2.781618313463241e-08
APC B-Disease 0 1.0600250277548184e-07
allelic O 0 8.781345854913525e-07
variant O 0 2.146045062545454e-06
in O 0 1.1165008118041442e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9999983310699463
, O 0 6.121676392467634e-07
we O 0 1.9969395026464554e-08
have O 0 2.7991575723973483e-10
analyzed O 0 6.817819198090547e-09
a O 0 5.550895854078419e-10
large O 0 5.174961570375558e-10
cohort O 0 1.2061839527177654e-08
of O 0 6.813646091785586e-09
unselected O 0 7.82603910920443e-06
Ashkenazi O 0 2.0239063758253906e-07
Jewish O 0 8.031515008610768e-09
subjects O 0 1.1219952966712299e-07
with O 0 9.263880329513086e-09
adenomatous B-Disease 0 1.6106983821373433e-05
polyps I-Disease 0 5.225250333751319e-06
and O 0 2.153781153424461e-08
. O 0 9.155677105354698e-08
or O 1 0.9999662637710571
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 9.829129510308121e-08
for O 0 1.2122705506101283e-08
the O 0 2.0870251660198846e-07
APC O 0 6.653870059381006e-06
I1307K O 0 1.4285080396803096e-05
polymorphism O 0 3.4446993595338427e-06
. O 0 2.185353878303431e-06

The O 0 1.1979572036580066e-06
APC O 0 1.5697157778049586e-06
I1307K O 0 1.606489945515932e-06
allele O 0 2.6010550158162005e-08
was O 0 5.461945917772937e-08
identified O 0 6.389033302411917e-09
in O 0 1.7675906294201127e-09
48 O 0 1.2607904054107166e-08
( O 0 9.746308204938714e-10
10 O 0 2.7108446598589353e-09
. O 0 2.594700010405404e-10
1 O 0 9.293577463154179e-09
% O 0 1.4355315824943204e-09
) O 0 6.42157660379894e-10
of O 0 2.219883121767907e-08
476 O 0 9.754654684002162e-07
patients O 0 1.277307205782563e-06
. O 0 6.488781991720316e-07

Compared O 0 3.094593807873025e-07
with O 0 4.469495440417859e-09
the O 0 3.031765949401688e-09
frequency O 0 1.7938798890781982e-08
in O 0 3.436809170587196e-10
two O 0 1.0014894469279056e-10
separate O 0 1.404380639558056e-10
population O 0 2.158108067251696e-11
control O 0 5.186743035068275e-09
groups O 0 1.2639576885131731e-10
, O 0 4.510282147762723e-10
the O 0 3.0404874173939334e-09
APC O 0 4.7727432672672876e-08
I1307K O 0 1.9102206749721518e-07
allele O 0 3.493850542213295e-09
is O 0 3.38175210057301e-10
associated O 0 5.878288411587107e-10
with O 0 8.425605352302412e-11
an O 0 3.1761712704359013e-10
estimated O 0 4.895278848948692e-09
relative O 0 1.844674386575207e-07
risk O 0 2.8478223157435423e-07
of O 0 5.572679810939007e-07
1 O 0 1.560863347549457e-05
. O 0 8.433863172285783e-07

5 O 0 0.000106685227365233
- O 0 4.592058758134954e-05
1 O 0 2.7916166800423525e-05
. O 0 3.4608999612828484e-06

7 O 0 5.665169010171667e-05
for O 0 3.309010571683757e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9996875524520874
( O 0 1.0911626304732636e-06
both O 0 4.8782345629661e-07
P O 0 0.0001486334076616913
= O 0 6.523827096316381e-07
. O 0 1.81726687031869e-08
01 O 0 9.84777898338507e-07
) O 0 6.8030779232231e-08
. O 0 5.386858674683026e-07

Furthermore O 0 2.2604706373385852e-06
, O 0 4.226787098104978e-08
compared O 0 2.9456165506758225e-08
with O 0 7.954298553158878e-09
noncarriers O 0 5.87742533753044e-06
, O 0 1.6799054591842832e-08
APC O 0 1.4332498210478661e-07
I1307K O 0 2.3764850709540042e-07
carriers O 0 4.29255297973441e-09
had O 0 9.711940140988418e-10
increased O 0 1.101251867474673e-10
numbers O 0 1.2567219487280568e-10
of O 0 6.44233688618101e-09
adenomas B-Disease 0 0.009200993925333023
and O 0 0.0009557164157740772
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999978542327881
per O 0 8.597274245403241e-06
patient O 0 5.284096914692782e-06
( O 0 3.480954546830617e-08
P O 0 7.085639936121879e-06
= O 0 7.496000620221821e-08
. O 0 2.0314445681179905e-09
03 O 0 4.954837606874207e-08
) O 0 1.1398522126171429e-09
, O 0 5.371080247229543e-10
as O 0 7.977069560460848e-10
well O 0 1.075058930766204e-09
as O 0 1.6886361198231725e-09
a O 0 5.84825299299041e-09
younger O 0 3.63382817170077e-08
age O 0 5.358076009542856e-07
at O 0 1.062920182448579e-05
diagnosis O 0 6.465513433795422e-05
. O 0 1.1595629985095002e-06

We O 0 1.130563873630308e-06
conclude O 0 1.4031633099875762e-06
that O 0 4.514355111950863e-09
the O 0 1.9761905889481568e-08
APC O 0 1.4791891089771525e-07
I1307K O 0 9.630193744669668e-07
variant O 0 1.4349676291658398e-07
leads O 0 1.207947519787922e-08
to O 0 3.6952352289176815e-09
increased O 0 8.890502840586123e-07
adenoma B-Disease 1 1.0
formation O 0 2.3592408979311585e-05
and O 0 7.148423719627317e-08
directly O 0 1.5299388422818083e-08
contributes O 0 1.2669850724122966e-09
to O 0 5.030057481647532e-10
3 O 0 1.7788337913771102e-08
% O 0 1.886420131214095e-09
- O 0 8.079268809524365e-09
4 O 0 9.310894277803072e-09
% O 0 4.923837448878032e-10
of O 0 1.4781454948931128e-09
all O 0 3.4949234617442926e-09
Ashkenazi O 0 1.2637471627385821e-05
Jewish O 0 0.0002713397843763232
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.035774741671048e-05

The O 0 3.674149979815411e-07
estimated O 0 5.1716313009819714e-08
relative O 0 7.358182187999773e-07
risk O 0 1.3813642851800978e-07
for O 0 8.810300933248527e-09
carriers O 0 1.79864905192062e-08
may O 0 4.4172052682256435e-09
justify O 0 1.0127367833234757e-09
specific O 0 2.388070852177293e-10
clinical O 0 2.6163886612806664e-09
screening O 0 1.6801833258028864e-09
for O 0 4.937210640321155e-10
the O 0 5.268251168644156e-09
360 O 0 4.761604799341512e-08
, O 0 1.7887232806046427e-09
000 O 0 6.106513072978714e-09
Americans O 0 7.557581227501942e-10
expected O 0 3.6685632309740868e-09
to O 0 6.988073453229049e-10
harbor O 0 1.5956581478349108e-07
this O 0 1.1757474160933867e-10
allele O 0 4.748104687202215e-10
, O 0 1.590934745054895e-10
and O 0 6.481375852684934e-11
genetic O 0 2.2434878954591397e-10
testing O 0 3.6914013512578947e-10
in O 0 9.759509866924532e-11
the O 0 4.803084596716189e-10
setting O 0 8.95338025941328e-09
of O 0 1.294841478483022e-08
long O 0 1.4596885478113109e-08
- O 0 2.5756254018460822e-08
term O 0 1.921159586970589e-08
- O 0 6.429349497238945e-09
outcome O 0 2.100411622407705e-09
studies O 0 6.203312308272757e-10
may O 0 3.4276637084218464e-10
impact O 0 1.3890766314972325e-09
significantly O 0 5.733325281198631e-08
on O 0 7.370750972768292e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 3.667379860416986e-05
in O 0 1.6814946102172712e-09
this O 0 3.742615661828097e-10
population O 0 8.18973111549326e-10
. O 0 8.339058865658444e-08

Localization O 0 0.00018455831741448492
of O 0 3.2286411624227185e-06
human O 0 3.611255863233964e-07
BRCA1 O 0 8.802594919643525e-08
and O 0 2.2916770703318434e-09
its O 0 7.606823504424653e-10
loss O 0 4.28591242496168e-08
in O 0 9.322196348193756e-09
high O 0 3.620080178734497e-06
- O 0 3.235923600186652e-07
grade O 0 1.1663844816212077e-05
, O 0 9.351972529714203e-09
non B-Disease 0 0.000618148420471698
- I-Disease 1 0.9997442364692688
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.017799468711018562

Although O 0 5.050824256613851e-07
the O 0 8.88343691940463e-08
link O 0 5.5907781870701e-07
between O 0 7.977411797810419e-08
the O 0 1.3779144580894354e-07
BRCA1 O 0 9.297460792367929e-07
tumour B-Disease 1 0.9999994039535522
- O 0 1.1121226634713821e-05
suppressor O 0 1.1719824897227227e-06
gene O 0 8.04600901460617e-08
and O 0 3.283398370967916e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 0.0002361783554079011
established O 0 9.771208624442806e-07
, O 0 3.427122807764249e-09
the O 0 3.861789554804318e-09
role O 0 1.3599442638678738e-07
, O 0 1.7957070275187448e-09
if O 0 3.527623748666997e-10
any O 0 8.479892898982655e-10
, O 0 2.9676971990966194e-10
of O 0 3.5809506471196073e-09
BRCA1 O 0 3.155232963791832e-09
in O 0 7.605623686401941e-09
non B-Disease 0 0.014217679388821125
- I-Disease 1 0.9973716735839844
familial I-Disease 1 0.9920549392700195
cancers I-Disease 1 0.9999995231628418
is O 0 1.5091806062628166e-06
unclear O 0 5.319047886587214e-06
. O 0 7.820949576853309e-07

BRCA1 O 0 2.512568789825309e-05
mutations O 0 1.8917037891696964e-07
are O 0 4.1903498448903065e-09
rare O 0 1.9602660827899854e-08
in O 0 1.118763748308993e-08
sporadic B-Disease 0 0.00011932790948776528
cancers I-Disease 1 0.9987024068832397
, O 0 5.232593025539245e-08
but O 0 1.510569447304988e-08
loss O 0 8.440405281362473e-07
of O 0 4.176482889306499e-06
BRCA1 O 0 2.0303517089814704e-07
resulting O 0 3.829663342003187e-08
from O 0 8.402423645748058e-09
reduced O 0 1.5818468313000267e-08
expression O 0 6.8930297025815435e-09
or O 0 3.5422094146753125e-09
incorrect O 0 1.497694057661647e-08
subcellular O 0 9.537988034935552e-07
localization O 0 1.7931396314452286e-06
is O 0 3.61269325566127e-09
postulated O 0 8.792339301066932e-09
to O 0 2.3116769609643484e-10
be O 0 1.41364711603309e-10
important O 0 1.2645394731336523e-09
in O 0 7.48363648828132e-10
non B-Disease 0 3.2502109661436407e-06
- I-Disease 0 0.038762111216783524
familial I-Disease 1 0.9968699812889099
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9994864463806152

Epigenetic O 0 0.002652151044458151
loss O 0 0.00031415570992976427
, O 0 5.768204687228717e-07
however O 0 1.8612179530919093e-07
, O 0 1.0443629960832368e-08
has O 0 3.2330876864605784e-10
not O 0 8.6544986455106e-11
received O 0 2.452923142381991e-10
general O 0 2.510806451638814e-09
acceptance O 0 2.9229820786014216e-09
due O 0 1.1733245486311716e-08
to O 0 6.704745092456221e-10
controversy O 0 2.7282889281110556e-09
regarding O 0 3.125881553600607e-09
the O 0 3.9980174726395035e-09
subcellular O 0 7.390004270746431e-07
localization O 0 2.073229552479461e-06
of O 0 1.6561122606617573e-07
BRCA1 O 0 5.2079400347793126e-08
proteins O 0 5.2483932755365e-09
, O 0 1.5847300138815967e-09
reports O 0 2.4673201259872712e-09
of O 0 6.4636056507083595e-09
which O 0 6.517863471167118e-10
have O 0 4.1644368509174967e-10
ranged O 0 7.541633806340542e-08
from O 0 8.129998341210865e-10
exclusively O 0 2.3782311675546453e-09
nuclear O 0 2.7497149446276126e-08
, O 0 4.664319278036011e-11
to O 0 8.330160172764778e-11
conditionally O 0 2.1332818178620983e-08
nuclear O 0 2.179431675131127e-07
, O 0 3.485548516479753e-10
to O 0 4.577195011901125e-10
the O 0 4.217904248093873e-08
ER O 0 0.0006105792126618326
/ O 0 3.375438609509729e-06
golgi O 0 5.641613824991509e-06
, O 0 5.3090749574380425e-09
to O 0 2.637462692689496e-09
cytoplasmic O 0 3.9924157135828864e-07
invaginations O 0 1.6409314866905333e-06
into O 0 6.664816964985221e-08
the O 0 1.7144630248822068e-07
nucleus O 0 5.199620318308007e-06
. O 0 1.1259929806328728e-06

In O 0 4.827055022360582e-07
an O 0 6.47756621674489e-08
attempt O 0 1.7193046630836761e-07
to O 0 1.6050512030574282e-08
resolve O 0 7.93980859725707e-07
this O 0 1.6597379026705994e-09
issue O 0 1.3346503457967174e-08
, O 0 4.437283318559082e-10
we O 0 3.8975878080549364e-10
have O 0 1.3889962791058252e-10
comprehensively O 0 1.6984373019113264e-08
characterized O 0 1.3092702921824184e-08
19 O 0 8.013463315137415e-08
anti O 0 1.1458284916443517e-06
- O 0 3.910238774551544e-06
BRCA1 O 0 1.2408203531322215e-07
antibodies O 0 1.1574919511758708e-07
. O 0 3.997997168880829e-07

These O 0 1.5397687036511343e-07
reagents O 0 1.4686218037240906e-06
detect O 0 2.763525117188692e-06
a O 0 4.590655464653537e-07
220 O 0 9.536188372294419e-07
- O 0 3.662235030787997e-06
kD O 0 6.7125511122867465e-06
protein O 0 1.815254506709607e-07
localized O 0 1.895693060305348e-07
in O 0 4.034480749481872e-09
discrete O 0 2.2964263735048007e-07
nuclear O 0 3.874584308505291e-06
foci O 0 5.675312308994762e-07
in O 0 2.180535974005693e-09
all O 0 1.4902901135371849e-09
epithelial O 0 3.030900188605301e-06
cell O 0 4.395374617160996e-06
lines O 0 1.540744776207248e-08
, O 0 1.5509389605927737e-10
including O 0 4.699575104072373e-11
those O 0 1.770930624367395e-10
derived O 0 2.3054345099637885e-09
from O 0 5.2133067640625086e-08
breast B-Disease 0 0.0018040945287793875
malignancies I-Disease 0 0.0010889604454860091
. O 0 5.228660029388266e-06

Immunohistochemical O 0 6.086990106268786e-05
staining O 0 1.0363827641413081e-05
of O 0 5.800818598800106e-06
human O 0 2.2352501218847465e-06
breast O 0 3.4601802326506004e-05
specimens O 0 1.0953564810733951e-07
also O 0 1.6252478474143572e-08
revealed O 0 5.173383215151262e-07
BRCA1 O 0 4.1738363165677583e-07
nuclear O 0 1.3792629033559933e-05
foci O 0 1.1357054063410033e-05
in O 0 2.7364727372969355e-08
benign O 0 0.3033333718776703
breast O 1 0.9153879880905151
, O 0 2.1027030925324652e-06
invasive B-Disease 1 0.9999908208847046
lobular I-Disease 1 1.0
cancers I-Disease 1 0.999998927116394
and O 0 3.5504069728631293e-06
low B-Disease 1 0.999982476234436
- I-Disease 1 0.999943733215332
grade I-Disease 1 0.9999998807907104
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00015154671564232558

Conversely O 0 1.919279748108238e-05
, O 0 4.373071362806513e-07
BRCA1 O 0 1.622940573042797e-07
expression O 0 3.105985513229825e-08
was O 0 1.2200254673189193e-07
reduced O 0 3.014699245795782e-08
or O 0 2.339186178090813e-09
undetectable O 0 2.128752356611585e-07
in O 0 3.295314576767794e-10
the O 0 3.2010946671157114e-10
majority O 0 2.296383916355893e-10
of O 0 6.652254302963456e-09
high O 0 7.022792487987317e-06
- O 0 2.6629409148881678e-06
grade O 0 0.19604772329330444
, O 0 2.1286375613271957e-06
ductal B-Disease 1 0.9999998807907104
carcinomas I-Disease 1 1.0
, O 0 2.257311706443943e-07
suggesting O 0 8.142265528476855e-08
that O 0 6.296411170225724e-10
absence O 0 1.8635445542258822e-07
of O 0 1.1860688573506195e-06
BRCA1 O 0 6.273950816648721e-07
may O 0 4.804537212521609e-08
contribute O 0 1.3870386617043096e-08
to O 0 1.4082358612554913e-09
the O 0 3.1630921881742324e-08
pathogenesis O 0 8.471524779452011e-05
of O 0 2.0229851571684776e-08
a O 0 1.280597849984133e-09
significant O 0 4.175773060666188e-09
percentage O 0 5.958270321571035e-08
of O 0 1.179804982598398e-07
sporadic B-Disease 1 0.897143542766571
breast I-Disease 1 0.9999908208847046
cancers I-Disease 1 0.9996877908706665
. O 0 5.018438855586282e-07
. O 0 1.712583411972446e-06

